

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: U.S. Patent No. 7,138,501
Inventor(s): Ruben et al.
Issued: November 21, 2006
Applicant: Human Genome Sciences Inc.
Docket No.: PF523P1
FDA Approval: BLA 125370 (BENLYSTA[®] (belimumab))

Mail Stop Hatch-Waxman PTE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 U.S.C. § 156

Dear Sir:

Pursuant to 35 U.S.C. § 156, Human Genome Sciences Inc. (hereinafter "HGS") hereby requests an extension of the term of U.S. Patent No. 7,138,501 (the '501 Patent). HGS is the assignee of the entire right, title and interest in the above-captioned patent by virtue of an assignment to HGS recorded on March 8, 2002 at reel 012660, frame 0444, and a chain of title recorded on March 13, 2003 at reel 013847, frame 0919 and at reel 013847, frame 0928. By the Power of Attorney enclosed herein (Attachment A), Applicant appoints the Practitioners at Customer Number 24633, including Kevin Shaw, as attorneys for HGS with regard to this application for extension of term of the '501 Patent and to transact all business in the U.S. Patent and Trademark Office in connection therewith.

HGS hereby provides the following information as required by 37 C.F.R. § 1.740.

1. Identification of the Approved Product [§ 1.740(a)(1)]:

The approved product BENLYSTA[®] (belimumab) is a recombinant fully human IgG₁λ monoclonal antibody that specifically binds to soluble human B Lymphocyte

Stimulator (BLyS). Belimumab is produced by NS0 mouse myeloma cells in serum-free cell culture production medium and has an approximate molecular weight of 147 kDa. BENLYSTA is supplied as a sterile, white to off-white, preservative-free, lyophilized powder for intravenous infusion.

2. Federal Statute Governing Regulatory Approval of the Approved Product [§ 1.740(a)(2)]:

The approved product was subject to regulatory review under, *inter alia*, the Public Health Service Act (42 U.S.C. § 201 *et seq.*) and the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355 *et seq.*).

3. Date of Approval for Commercial Marketing [§ 1.740(a)(3)]:

The approved product BENLYSTA received approval for commercial marketing or use under § 351 of the Public Health Service Act on March 9, 2011. A copy of the FDA approval letter (as released by the FDA with confidential commercial information redacted) is attached (Attachment B).

4. Identification of Active Ingredient and Certifications Related to Commercial Marketing of Approved Product [§ 1.740(a)(4)]:

The active ingredient of BENLYSTA is belimumab, which has not been approved for commercial marketing or use under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, or the Virus-Serum-Toxin Act prior to the approval granted on March 9, 2011 to the present Applicant. A copy of the package insert describing the approved product is attached (Attachment C).

5. Statement Regarding Timeliness of Submission of Patent Term Extension Request [§ 1.740(a)(5)]:

This application for extension of patent term under 35 U.S.C. § 156 is being submitted within the permitted sixty (60) day period pursuant to 37 C.F.R. § 1.720(f). The last day on which this application may be submitted is May 7, 2011.

**6. Complete Identification of the Patent for Which Extension is Being Sought
[§ 1.740(a)(6)]:**

Listed Inventors: Steven M. Ruben, Gil H. Choi, Tristan Vaughan, David Hilbert

Patent No.: 7,138,501

Issue Date: November 21, 2006

Expiration Date: July 9, 2023¹ (without extension under 35 U.S.C. §156)

7. Copy of the Patent for Which an Extension is Being Sought [§ 1.740(a)(7)]:

A copy of the '501 Patent is attached (Attachment D).

8. Copies of Disclaimers, Certificates of Correction, Receipt of Maintenance Fee Payment, or Reexamination Certificate [§ 1.740(a)(8)]:

No disclaimer or reexamination certificate has been issued on this patent. A copy of the certificate of correction issued on March 6, 2007 is provided as Attachment E. A copy of the Maintenance Fee Statement indicating the timely payment of relevant maintenance fees to date is provided as Attachment F.

**9. Statement Regarding Patent Claims Relative to Approved Product
[§ 1.740(a)(9)]:**

¹ Includes patent term adjustment under 35 U.S.C. 154(b) of 754 days as listed on the face of the '501 Patent. A Petition for Reconsideration of Patent Term Adjustment is pending before the United States Patent and Trademark Office, and a Complaint filed in the United States District Court for the District of Columbia is also pending, in each case seeking correction of the patent term adjustment for the '501 Patent from 754 days to 1,135 days. Including the requested patent term adjustment correction, the '501 Patent would expire July 24, 2024.

The statements below are made solely to comply with the requirements of 37 C.F.R. § 1.740(a)(9). Applicant notes that, as the M.P.E.P. acknowledges, § 1.740(a)(9) does not require an applicant to show whether or how the listed claims would be infringed, and that this question cannot be answered without specific knowledge concerning acts performed by third parties. As such, these comments are not an assertion or an admission of Applicant as to the scope of the listed claims, or whether or how any of the listed claims would be infringed, literally or under the doctrine of equivalents, by the manufacture, use, sale, offer for sale or the importation of any product.

At least claims 1-2, 4-10, 14-24, and 29-36 of the '501 Patent claim the approved product, namely, the active pharmaceutical ingredient in BENLYSTA.

Claim 1 reads as follows:

An isolated antibody that immunospecifically binds B Lymphocyte Stimulator protein wherein said antibody comprises a first amino acid sequence at least 85% identical to amino acid residues 1-123 of SEQ ID NO:327 and a second amino acid sequence at least 85% identical to amino acid residues 141-249 of SEQ ID NO:327 and wherein said B Lymphocyte Stimulator protein is selected from the group consisting of:

- (a) a protein whose amino acid sequence consists of amino acid residues 1-285 of SEQ ID NO:3228;
- (b) a protein whose amino acid sequence consists of amino acid residues 134-285 of SEQ ID NO:3228; and
- (c) a trimer of the protein of (b).

Claim 1 of the '501 Patent reads on the active ingredient in BENLYSTA as the active ingredient (belimumab) meets all the limitations of the claim. The active ingredient (belimumab) is a recombinant fully human IgG₁λ monoclonal antibody that specifically binds to soluble human B Lymphocyte Stimulator (BLyS). *See* Attachment C. Soluble human BLyS is a protein, predominantly found as a trimer, whose amino acid sequence consists of amino acid residues 134-285 of SEQ ID NO:3228. The amino acid sequence of belimumab comprises amino acid residues 1-123 of SEQ ID NO: 327 of the '501 Patent and amino acid residues 141-249 of SEQ

ID NO: 327 of the '501 Patent. *See* Sequence listing of the '501 Patent (Attachment D).

Accordingly, belimumab meets all of the limitations of claim 1 of the '501 Patent.

10. **Relevant Dates Under 35 U.S.C. § 156 for Determination of Applicable Regulatory Review Period [37 C.F.R. § 1.740(a)(10)]:**

The relevant dates and information pursuant to 35 U.S.C. § 156(g) are as follows:

Investigational New Drug Application (BB-IND No. 9970) for BENLYSTA was filed on August 15, 2001 and became effective on October 23, 2001. A copy of the letter from the FDA reflecting the effective date of this IND is provided as Attachment G.

Original Biologics Licensing Application for BENLYSTA (BLA 125370) was submitted on June 10, 2010.

Biologics License No. 1820 for BENLYSTA was issued on March 9, 2011. A copy of the approval letter (as released by the FDA with confidential commercial information redacted) is provided as Attachment B.

11. Summary of Significant Events During Regulatory Review Period [§ 1.740(a)(11)]:

A summary of the significant activities undertaken by Applicant during the regulatory review period with respect to the approved product is provided below. Further, a description of various clinical trials conducted by Applicant during the regulatory review is annexed hereto as Attachment H. Applicant reserves the right to supplement the chronology with materials from which it was derived or other evidence related to Applicant's conduct in obtaining the approval of BENLYSTA as provided by 21 C.F.R. § 60.32.

On August 15, 2001, HGS submitted to the FDA an investigational new drug application for a recombinant human monoclonal antibody (belimumab) that specifically binds human B Lymphocyte Stimulator Protein. The antibody was developed as a potential new therapeutic for the treatment of autoimmune disease.

On September 13, 2001, FDA placed BB-IND 9970 on clinical hold.

On October 23, 2001, FDA communicated to HGS via telephone that the clinical hold was removed, thus making BB-IND 9970 effective, as confirmed by a communication mailed to HGS on October 30, 2001 (Attachment G).

From approximately October 23, 2001 until approximately April 20, 2010, a series of Phase I, II, and III clinical trials were conducted.

On January 20, 2003, HGS submitted to the FDA a request for Fast Track Designation.

On March 6, 2003, representatives from HGS and CBER participated in an end-of-Phase I meeting.

On March 13, 2006, representatives from HGS and CBER participated in an end-of-Phase II meeting.

On January 22, 2010, representatives from HGS and CBER participated in a Pre-BLA meeting.

On June 10, 2010, HGS submitted a biologics licensing application for BENLYSTA (BLA 125370).

On March 9, 2011, FDA approved BLA 125370, issuing marketing authorization for BENLYSTA (Attachment B).

12. Statement Concerning Eligibility for and Duration of Extension Sought Under 35 U.S.C. § 156 [37 C.F.R. § 1.740(a)(1)]:

Applicant is of the opinion that U.S. Patent No. 7,138,501 is eligible for extension based upon meeting the requirements under 35 U.S.C. § 156 as follows:

- (a) 35 U.S.C. § 156(a): U.S. Patent No. 7,138,501 claims a product.
- (b) 35 U.S.C. § 156(a)(1): U.S. Patent No. 7,138,501 has not expired before the submission of this application.
- (c) 35 U.S.C. § 156(a)(2): The term of U.S. Patent No. 7,138,501 has never been extended under 35 U.S.C. § 156(e)(1).
- (d) 35 U.S.C. § 156(a)(3): The application for patent term extension is submitted by the owner of record of the patent in accordance with the requirements of paragraphs (1) through (4) of 35 U.S.C. § 156(d) and the rules of the Patent and Trademark Office.
- (e) 35 U.S.C. § 156(a)(4): The product BENLYSTA has been subject to a regulatory review period before its commercial marketing or use.
- (f) 35 U.S.C. § 156(a)(5)(A): The commercial marketing or use of the product BENLYSTA after the regulatory review period is the first permitted commercial marketing or use under the provisions of § 351(a) of the Public Service Act.
- (g) 35 U.S.C. § 156(c)(4): No other patent has been extended for the same regulatory review period for the product BENLYSTA.

- (h) 35 U.S.C. § 156(d)(1): This application is submitted within the permitted 60 day period beginning on the date the product first received permission for commercial marketing or use.

Applicant respectfully submits that the term of U.S. Patent No. 7,138,501 should be extended from July 9, 2023² up to and including March 9, 2025, or 610 days. This extension was calculated per 37 C.F.R. § 1.775 as follows:

- (a) The regulatory review period under 35 U.S.C. § 156(g)(1)(B) began on October 23, 2001 and ended on March 9, 2011, which is a total of 3426 days, which is the sum of (1) and (2) below:
- (1) The period of review under 35 U.S.C. § 156(g)(1)(B)(i), the “Testing Period,” began on October 23, 2001 and ended on June 10, 2010, which is 3153 days; and
- (2) The period of review under 35 U.S.C. § 156(g)(1)(B)(ii), the “Approval Period,” began on June 10, 2010 and ended on March 9, 2011, which is 273 days.
- (b) The regulatory review period upon which the period of extension is calculated is the entire regulatory review period as determined in (a) less 2504 days, which is the sum of (1) – (3) below:
- (1) The number of days in the regulatory review period which were on or before the date on which the patent issued (November 21, 2006), which is 1856 days; and
- (2) The number of days during which Applicant did not act with due diligence, which is zero days; and

² As noted *supra*, Applicant is seeking corrected patent term adjustment for the ‘501 Patent from 754 days to 1,135 days; the corrected expiration date would be July 24, 2024.

- (3) One half the number of days determined in subparagraph (a)(1) above after the patent issued, which is 648 days;
- (c) The number of days as determined in (a) minus (b) above (922 days) when added to the original term of the patent (July 9, 2023³) would result in the date of January 16, 2026.
- (d) Fourteen years when added to the date of issuance of the Biologics License (March 9, 2011) would result in the date of March 9, 2025.
- (e) The earlier date as determined in (c) and (d) above is March 9, 2025.
- (f) Since U.S. Patent No. 7,138,501 issued after September 24, 1984, the period of extension may not exceed five years from the original expiration date of July 9, 2023. Five years added to July 9, 2023 would result in a date of July 9, 2028.
- (g) The earlier date as determined in (e) and (f) above is March 9, 2025.

13. Statement Pursuant to 37 C.F.R. § 1.740(a)(13):

Applicant acknowledges a duty to disclose to the Director of the United States Patent and Trademark Office and the Secretary of Health and Human Services any information which is material to the determination of entitlement to the extension sought.

14. Applicable Fee [§ 1.740(a)(14)]:

The transmittal document filed herewith authorizes the U.S. Patent and Trademark Office to charge the prescribed fee pursuant to 37 C.F.R. §1.20(j) for receiving and

³ As noted *supra*, Applicant is seeking corrected patent term adjustment for the '501 Patent from 754 days to 1,135 days; the corrected expiration date would be July 24, 2024.

acting upon the application for extension to the deposit account associated with the undersigned attorney.

15. Name and Address for Correspondence [§ 1.740(a)(15)]:

Please address all correspondence to:

Kevin Shaw
Hogan Lovells US LLP
Columbia Square
555 Thirteenth Street, NW
Washington, District of Columbia 20004
Phone: 202-637-6466
Fax: 202-637-5910
Email: kevin.shaw@hoganlovells.com


The correspondence address for U.S. Patent No. 7,138,501 is unchanged for all other purposes. A Power of Attorney granted to the undersigned, a copy of which is included as Attachment A, accompanies this communication.

Two additional copies of this application are enclosed, in compliance with 37 C.F.R. § 1.740(b).

If this application for extension of patent term is held to be informal, Applicant may seek to have that holding reviewed by filing a petition with the required fee, as necessary, pursuant to 37 C.F.R. §§ 1.181, 1.182, or 1.183, as appropriate, within such time as may be set in any notice that the application has been held to be informal, or if no time is set, within one month of the date on which the application was held informal.

Respectfully submitted,

Date: April 8, 2011


Kevin G. Shaw (Reg. No. 43,110)

HOGAN LOVELLS US LLP
555 Thirteenth Street, N.W.
Washington, D.C. 20004
Telephone: 202-637-6466
Facsimile: 202-637-5910
e-mail: kevin.shaw@hoganlovells.com
Customer No. 24633

Index of Attachments

<u>Attachment A:</u>	Power of Attorney
<u>Attachment B:</u>	FDA Approval Letter (as released by FDA in redacted form)
<u>Attachment C:</u>	Package Insert for BENLYSTA
<u>Attachment D:</u>	U.S. Patent No. 7,138,501
<u>Attachment E:</u>	Certificate of Correction
<u>Attachment F:</u>	Maintenance Fee Statement
<u>Attachment G:</u>	FDA Letter Regarding Effective Date of IND
<u>Attachment H:</u>	Summary of Clinical Trials

U.S. Patent No. 7,138,501

Application for Patent Term Extension

Attachment A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent No. 7,138,501

Patentee: Ruben et al.

Issued: November 21, 2006

Docket No.: PF523P1

POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Statement Under 37 C.F.R. § 3.73

Human Genome Sciences, Inc. ("HGS"), organized and existing under the laws of the State of Delaware, having its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850, states that it is the assignee of record of the entire right, title and interest for the above-identified application by virtue of assignments directed to U.S. Application No. 09/880,748, filed June 15, 2001, that matured into the above-identified patent, and all continuation and divisional applications thereof, as listed in the chain of title below:

1. From: Steven M. Ruben, Steven C. Barash, Gil H. Choi, Tristan Vaughan, and David Hilbert
To: Human Genome Sciences, Inc.
The document was recorded in the U.S. Patent and Trademark Office on March 8, 2002, at Reel 012660, Frame 0444.
2. From: Tristan Vaughan
To: Cambridge Antibody Technology, Ltd.
The document was recorded in the U.S. Patent and Trademark Office on March 13, 2003, at Reel 013847, Frame 0919.
3. From: Cambridge Antibody Technology, Ltd.
To: Human Genome Sciences, Inc.
The document was recorded in the U.S. Patent and Trademark Office on March 13, 2003, at Reel 013847, Frame 0928.


The undersigned, whose title is supplied below, is empowered to sign this document on behalf of HGS. The undersigned has reviewed all the documents in the chain of title of the above-captioned application, and, to the best of the undersigned's knowledge and belief, HGS has title in the application as described above.

Power of Attorney or Authorization of Agent

HGS hereby appoints the Practitioners at **Customer Number 24633** as its attorneys or agents for the purpose of prosecuting an Application for Extension of Patent Term Under 35 U.S.C. §156 in connection with U.S. Patent 7,138,501, and to transact all business in the U.S. Patent and Trademark Office only in connection therewith. The correspondence address for the instant patent is unchanged for all other purposes. Please direct all communications for this Application for Extension of Patent Term to Kevin Shaw.

On behalf of Human Genome Sciences, Inc.:

For: Human Genome Sciences, Inc.

Signature: 

Name: James H. Davis

Title: Executive Vice President and General Counsel

Date: 7 Apr 2011

Attachment B



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

Our STN: BL 125370/0

BLA APPROVAL
March 9, 2011

Human Genome Sciences, Inc.
14200 Shady Grove Road
Rockville, MD 20850

Attention: Diana J. Daly
Executive Director, Regulatory Affairs

Dear Ms. Daly:

Please refer to your Biologics License Application (BLA) dated June 9, 2010, received June 9, 2010, submitted under section 351 of the Public Health Service Act for Benlysta (belimumab) for injection.

We acknowledge receipt of your amendments dated July 20, August 10 and 27, September 15, 24, 27, and 30, October 6, 13, 19, 25, 26, and 27, November 3, 8, 10, 23, and 30, and December 1, 9, and 21, 2010, and January 28, February 8, 11, 14, 17, 23, and 25, and March 3 and 4, 2011.

We are issuing Department of Health and Human Services U.S. License No. 1820 to Human Genome Sciences, Rockville, Maryland, under the provisions of section 351(a) of the Public Health Service Act controlling the manufacture and sale of biological products. The license authorizes you to introduce, or deliver for introduction into interstate commerce, those products for which your company has demonstrated compliance with establishment and product standards.

Under this license, you are authorized to manufacture the product belimumab. Belimumab is indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.

Under this license, you are approved to manufacture belimumab drug substance at Human Genome Sciences, Inc., in Rockville, Maryland. The final formulated product will be manufactured, filled, labeled, and packaged at Hospira, Inc., in McPherson, Kansas. You may label your product with the proprietary name Benlysta and will market it as 120 mg in a 5-mL vial and 400 mg in a 20-mL vial.

Results of ongoing stability studies should be submitted throughout the dating period, as the data become available, including the results of stability studies from the first three production lots.

The dating period for the 120-mg vial of belimumab shall be 36 months from the date of manufacture when stored at 2° to 8°C. The dating period for the 400-mg vial of belimumab shall be 36 months from the date of manufacture when stored at 2° to 8°C. The dating period for drug

substance shall be 36 months when stored at -40° and/or -80°C. Belimumab drug product stability may be extended by inclusion of additional data for pilot lots and commercial lots in the Benlysta annual report.

We have approved the stability protocols in your license application for the purpose of extending the expiration dating period of your drug substance and drug product under 21 CFR 601.12.

You are not currently required to submit samples of future lots of belimumab to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of belimumab, or in the manufacturing facilities, will require the submission of information to your biologics license application for our review and written approval, consistent with 21 CFR 601.12.

We are approving this application for use as recommended in the enclosed agreed-upon labeling text and with the minor editorial revision listed below.

- Replace "US License No. 0000" on the carton and container and the "US License No. XXXX" in the package insert and medication guide with "U.S. License No. 1820".

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 601.14(b)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to, except with the revisions listed, the enclosed labeling (text for the package insert and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. For administrative purposes, designate this submission "Product Correspondence – Final SPL for approved BLA STN 125370."

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE-CONTAINER LABELS

Submit final printed carton and container labels that are identical to the enclosed carton and immediate-container labels, except with the revisions listed above, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes,

designate this submission "Product Correspondence -- Final Printed Carton and Container Labels for approved BLA STN 125370." Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with final printed labeling (FPL) that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 to 4 years 11 months because necessary studies are impossible or highly impracticable. This is because too few children have the disease condition to study.

We are deferring submission of your pediatric study for ages 5 to 16 years for this application because this product is ready for approval for use in adults and the pediatric study has not been completed.

Your deferred pediatric study required by section 505B(a) of the Federal Food, Drug, and Cosmetic Act (FDCA) is a required postmarketing study. The status of this postmarketing study must be reported annually according to 21 CFR 601.28 and section 505B(a)(3)(B) of the Federal Food, Drug, and Cosmetic Act. This required study is listed below.

1. Phase 2, multicenter study to evaluate the safety, efficacy, and pharmacokinetics of belimumab plus background standard therapy in 100 pediatric subjects ages 5 years to 17 years of age with active systemic lupus erythematosus (SLE).

Final Protocol Submission: August 2011
Study Completion Date: March 2016
Final Report Submission: October 2016

Submit final reports to this BLA. For administrative purposes, all submissions related to this required pediatric postmarketing study must be clearly designated "Required Pediatric Assessment(s)."

POSTMARKETING REQUIREMENTS UNDER 505(o)

Section 505(o)(3) of the FDCA authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to identify unexpected serious risks related to immunogenicity and negative pregnancy outcomes related to Benlysta (belimumab).

Furthermore, the new pharmacovigilance system that FDA is required to establish under section 505(k)(3) of the FDCA is not yet sufficient to assess these serious risks.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following:

2. Develop improved immunogenicity assays that are less sensitive to product interference that are capable of detecting human anti-human antibodies (HAHA) in the presence of belimumab at ranges that would be expected to occur in patients receiving both high and low doses.

The timetable you submitted on February 11, 2011, states that you will conduct these studies according to the following schedule:

Final Protocol Submission: March 2012
Final Report Submission: January 2013

3. Conduct a pregnancy registry to evaluate pregnancy outcomes for women exposed to Benlysta (belimumab) during pregnancy.

The timetable you submitted on February 23, 2011, states that you will conduct this study according to the following schedule:

Final Protocol Submission: July 2011
Study Completion Date: October 2018
Final Report Submission: April 2019

Finally, we have determined that only a clinical trial (rather than a nonclinical or observational study) will be sufficient to identify unexpected serious risks related to the potential for Benlysta (belimumab) to interfere with host responses to vaccinations, and to assess a signal of serious risks of mortality, infection, and malignancy with Benlysta (belimumab).

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following:

4. Conduct a randomized clinical trial to evaluate the effects of Benlysta (belimumab) treatment on host response to therapeutic vaccines. B cell-dependent antigens (e.g., pneumococcal polysaccharide vaccine) and T cell-dependent antigens (e.g., tetanus toxoid) will be evaluated.

The timetable you submitted on February 14, 2011, states that you will conduct this trial according to the following schedule:

Final Protocol Submission: December 2011
Trial Completion Date: March 2014
Final Report Submission: September 2014

5. Conduct a randomized, placebo-controlled clinical trial with Benlysta (belimumab) in 5000 patients with active, autoantibody-positive systemic lupus erythematosus to evaluate Benlysta's long term safety profile including adverse events of special interest (e.g., mortality, malignancy, serious and opportunistic infections and depression/suicidality).

The timetable you submitted on February 23, 2011, states that you will conduct this trial according to the following schedule:

Final Protocol Submission: September 2011
Trial Completion Date: May 2022

Interim Report Submission: May 2019 (1 year data)
May 2020 (2 year data)

Final Report Submission: May 2023 (5 year data)

Submit the protocols to your IND 9970, with a cross-reference letter to this BLA. Submit all final reports to your BLA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate: **"Required Postmarketing Protocol Under 505(o)," "Required Postmarketing Final Report Under 505(o)," "Required Postmarketing Correspondence Under 505(o)."**

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 601.70, requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 601.70 to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 601.70. We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

**POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS
UNDER SECTION 506B**

We remind you of your postmarketing commitments:

6. Conduct a randomized, controlled clinical trial in patients with lupus nephritis to evaluate the efficacy and safety of Benlysta (belimumab).

The timetable you submitted on February 23, 2011, states that you will conduct this trial according to the following schedule:

Final Protocol Submission: January 2012
Trial Completion: January 2017
Final Report Submission: October 2017

7. Conduct a randomized, controlled clinical trial to evaluate the efficacy and safety of Benlysta (belimumab) in African-American patients with SLE.

The timetable you submitted on November 30, 2010, states that you will conduct this trial according to the following schedule:

Final Protocol Submission: November 2011
Trial Completion Date: July 2017
Final Report Submission: January 2018

8. Submit a final report for the long-term, open-label, continuation trial LBSL99.

The timetable you submitted on February 23, 2011, states that you will conduct this trial according to the following schedule:

Trial Completion Date: May 2016
Final Report Submission: December 2016

9. Submit a final report for the long-term, open-label, continuation trial C1066.

The timetable you submitted on February 23, 2011, states that you will conduct this trial according to the following schedule:

Trial Completion Date: May 2015
Final Report Submission: December 2015

10. Submit a final report for the long-term, open-label, continuation trial C1074.

The timetable you submitted on February 23, 2011, states that you will conduct this trial according to the following schedule:

Trial Completion Date: March 2015
Final Report Submission: October 2015

Submit clinical protocols to your IND 9970 for this product and all final reports to this BLA. In addition, under 21 CFR 601.70, you should include a status summary of each commitment in your annual progress report of postmarketing studies/trials to this BLA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled "Postmarketing Commitment Protocol," "Postmarketing Commitment Final Report," or "Postmarketing Commitment Correspondence."

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitments:

11. Submit data supporting microbial control for the UF/DF membrane lifetime studies in a CBE-0 supplement by June 2012.

The timetable you submitted on December 21, 2010, states that you will conduct this study according to the following schedule:

Final Protocol Submission: September 2010
Study Completion Date: December 2011
Final Report Submission: June 2012

12. Qualify the capper and validate the integrity of the belimumab drug product container closure in a helium leak test using 5 mL vials prepared at minimum and maximum sealing forces. Information and summary validation data of the helium leak test and the integrity of the belimumab drug product container closure should be submitted in a Changes Being Effected (CBE-0) supplement. Include the preparation of the positive controls and sensitivity (breach size) of the helium leak test.

The timetable you submitted on December 21, 2010, states that you will conduct this study according to the following schedule:

Final Protocol Submission: March 2011
Study Completion Date: April 2011
Final Report Submission: June 2011

13. Provide quantitative data to demonstrate removal of soluble contaminants by the vial washing process. The quantitative qualification data should be submitted in a Changes Being Effected (CBE-0) supplement.

The timetable you submitted on December 21, 2010, states that you will conduct this study according to the following schedule:

Final Protocol Submission: March 2011
Study Completion Date: April 2011
Final Report Submission: June 2011

Submit nonclinical and chemistry, manufacturing, and controls protocols and all final reports to this BLA. In addition, under 21 CFR 601.70, you should include a status summary of each commitment in your annual progress report of postmarketing studies to this BLA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled "Postmarketing Commitment Protocol," "Postmarketing Commitment Final Report," or "Postmarketing Commitment Correspondence."

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

We acknowledge receipt of your submissions dated November 23, 2010, and February 23, 2011, of a proposed risk evaluation and mitigation strategy (REMS). We have determined that at this time, a REMS is not necessary for Benlysta (belimumab) to ensure that its benefits outweigh its risks. We will notify you if we become aware of new safety information and make a determination that a REMS is necessary.

REPORTING REQUIREMENTS

You must submit adverse experience reports under the adverse experience reporting requirements for licensed biological products (21 CFR 600.80). You should submit postmarketing adverse experience reports to:

Food and Drug Administration
Center for Drug Evaluation and Research
Central Document Room
5901-B Ammendale Road
Beltsville, MD 20705-1266

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements for licensed biological products (21 CFR 600.81).

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding, and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA-3486 to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
5901-B Ammendale Road
Beltsville, MD 20705-1266

Biological product deviations sent by courier or overnight mail should be addressed to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
10903 New Hampshire Avenue, Bldg. 51, Room 4206
Silver Spring, MD 20903

MEDWATCH-TO-MANUFACTURER PROGRAM

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at <http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm>.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the

proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and the package insert at the time of initial dissemination or publication accompanied by a Form FDA 2253. For instructions on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence to support that claim.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this BLA and to the following address:

MedWatch Program
Office of Special Health Issues
Food and Drug Administration
10903 New Hampshire Ave
Building 32, Mail Stop 5353
Silver Spring, MD 20993

POST-ACTION FEEDBACK MEETING

New molecular entities and new biologics qualify for a post-action feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

If you have any questions, call Philantha M. Bowen, Regulatory Project Manager, at (301) 796-2466.

Sincerely,

A handwritten signature in black ink, appearing to read 'CJ Rosebraugh', with a long horizontal flourish extending to the right.

/Curtis J. Rosebraugh, M.D., M.P.H./

Curtis J. Rosebraugh, M.D., M.P.H.

Director

Office of Drug Evaluation II

Center for Drug Evaluation and Research

Enclosures:

Content of Labeling

Carton and Container Labeling

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use BENLYSTA safely and effectively. See full prescribing information for BENLYSTA.

BENLYSTA® (belimumab)
for injection, for intravenous use only
Initial U.S. Approval: 2011

INDICATIONS AND USAGE

BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. (1, 14)

Limitations of Use: The efficacy of BENLYSTA has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus (1). BENLYSTA has not been studied in combination with other biologics or intravenous cyclophosphamide (1). Use of BENLYSTA is not recommended in these situations.

DOSAGE AND ADMINISTRATION

- Recommended dosage regimen is 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. Reconstitute, dilute and administer as an intravenous infusion only, over a period of 1 hour. (2.1)
- Consider administering premedication for prophylaxis against infusion reactions and hypersensitivity reactions (2.2)

DOSAGE FORMS AND STRENGTHS

Single-use vials of belimumab lyophilized powder:

- 120 mg per vial (3)
- 400 mg per vial (3)

CONTRAINDICATIONS

Previous anaphylaxis to belimumab. (4)

WARNINGS AND PRECAUTIONS

- Mortality:** There were more deaths reported with BENLYSTA than with placebo during the controlled period of clinical trials. (5.1)
- Serious Infections:** Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA. Use with caution in patients with chronic infections. Consider interrupting BENLYSTA therapy if patients develop a new infection during BENLYSTA treatment. (5.2)
- Hypersensitivity Reactions, Including Anaphylaxis:** Serious reactions have been reported. BENLYSTA should be administered by healthcare providers prepared to manage anaphylaxis. Monitor patients during and for an appropriate period of time after administration of BENLYSTA. (2.2, 5.4)
- Depression:** Depression and suicidality have been reported in BENLYSTA studies. Patients should be instructed to contact their healthcare provider if they experience new or worsening depression, suicidal thoughts or other mood changes. (5.6)
- Immunization:** Live vaccines should not be given concurrently with BENLYSTA. (5.7)

ADVERSE REACTIONS

Common adverse reactions (≥5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Haman Genome Sciences, Inc. at 1-877-423-6597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

- Pregnancy:** Registry available. (8.1)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: March 2011

FULL PRESCRIBING INFORMATION: CONTENTS*

1	INDICATIONS AND USAGE
2	DOSAGE AND ADMINISTRATION
2.1	Dosage Schedule
2.2	Premedication Recommendations
2.3	Preparation of Solutions
2.4	Administration Instructions
3	DOSAGE FORMS AND STRENGTHS
4	CONTRAINDICATIONS
5	WARNINGS AND PRECAUTIONS
5.1	Mortality
5.2	Serious Infections
5.3	Malignancy
5.4	Hypersensitivity Reactions, Including Anaphylaxis
5.5	Infusion Reactions
5.6	Depression
5.7	Immunization
5.8	Concomitant Use with Other Biologic Therapies or Intravenous Cyclophosphamide
6	ADVERSE REACTIONS
6.1	Clinical Trials Experience
6.2	Immunogenicity

7	DRUG INTERACTIONS
8	USE IN SPECIFIC POPULATIONS
8.1	Pregnancy
8.3	Nursing Mothers
8.4	Pediatric Use
8.5	Geriatric Use
8.6	Race
10	OVERDOSAGE
11	DESCRIPTION
12	CLINICAL PHARMACOLOGY
12.1	Mechanism of Action
12.2	Pharmacodynamics
12.3	Pharmacokinetics
13	NONCLINICAL TOXICOLOGY
13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility
14	CLINICAL STUDIES
16	HOW SUPPLIED/STORAGE AND HANDLING
17	PATIENT COUNSELING INFORMATION
17.1	Advice for the Patient

* Sections or subsections omitted from the full prescribing information are not listed

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

BENLYSTA® (belimumab) is indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.

Limitations of Use

The efficacy of BENLYSTA has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. BENLYSTA has not been studied in combination with other biologics or intravenous cyclophosphamide. Use of BENLYSTA is not recommended in these situations.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage Schedule

BENLYSTA is for intravenous infusion **only** and must be reconstituted and diluted prior to administration [see *Dosage and Administration* 2.3]]. Do not administer as an intravenous push or bolus.

The recommended dosage regimen is 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. Reconstitute, dilute and administer as an intravenous infusion only, over a period of 1 hour. The infusion rate may be slowed or interrupted if the patient develops an infusion reaction. The infusion must be discontinued immediately if the patient experiences a serious hypersensitivity reaction [see *Contraindications* (4), *Warnings and Precautions* (5.4)].

2.2 Premedication Recommendations

Prior to dosing with BENLYSTA, consider administering premedication for prophylaxis against infusion reactions and hypersensitivity reactions. [see *Warnings and Precautions* (5.4, 5.5) and *Adverse Reactions* (6.1)].

2.3 Preparation of Solutions

BENLYSTA is provided as a lyophilized powder in a single-use vial for intravenous infusion only and should be reconstituted and diluted by a healthcare professional using aseptic technique as follows:

Reconstitution Instructions

1. Remove BENLYSTA from the refrigerator and allow to stand 10 to 15 minutes for the vial to reach room temperature.
2. Reconstitute the BENLYSTA powder with Sterile Water for Injection, USP, as follows. The reconstituted solution will contain a concentration of 80 mg/mL belimumab.
 - Reconstitute the 120 mg vial with 1.5 mL Sterile Water for Injection, USP.
 - Reconstitute the 400 mg vial with 4.8 mL Sterile Water for Injection, USP.
3. The stream of sterile water should be directed toward the side of the vial to minimize foaming. Gently swirl the vial for 60 seconds. Allow the vial to sit at room temperature during reconstitution, gently swirling the vial for 60 seconds every 5 minutes until the powder is dissolved. *Do not shake*. Reconstitution is typically complete within 10 to 15 minutes after the sterile water has been added, but it may take up to 30 minutes. Protect

the reconstituted solution from sunlight.

4. If a mechanical reconstitution device (swirler) is used to reconstitute BENLYSTA, it should not exceed 500 rpm and the vial swirled for no longer than 30 minutes.
5. Once reconstitution is complete, the solution should be opalescent and colorless to pale yellow, and without particles. Small air bubbles, however, are expected and acceptable.

Dilution Instructions

6. Dextrose intravenous solutions are incompatible with BENLYSTA. BENLYSTA should only be diluted in 0.9% Sodium Chloride Injection, USP. Dilute the reconstituted product to 250 mL in 0.9% Sodium Chloride Injection, USP (normal saline) for intravenous infusion. From a 250-mL infusion bag or bottle of normal saline, withdraw and discard a volume equal to the volume of the reconstituted solution of BENLYSTA required for the patient's dose. Then add the required volume of the reconstituted solution of BENLYSTA into the infusion bag or bottle. Gently invert the bag or bottle to mix the solution. Any unused solution in the vials must be discarded.
7. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard the solution if any particulate matter or discoloration is observed.
8. The reconstituted solution of BENLYSTA, if not used immediately, should be stored protected from direct sunlight and refrigerated at 2° to 8°C (36° to 46°F). Solutions of BENLYSTA diluted in normal saline may be stored at 2° to 8°C (36° to 46°F) or room temperature. The total time from reconstitution of BENLYSTA to completion of infusion should not exceed 8 hours.
9. No incompatibilities between BENLYSTA and polyvinylchloride or polyolefin bags have been observed.

2.4 Administration Instructions

1. The diluted solution of BENLYSTA should be administered by intravenous infusion only, over a period of 1 hour.
2. BENLYSTA should be administered by healthcare providers prepared to manage anaphylaxis. *[see Warnings and Precautions (5.4)]*
3. BENLYSTA should not be infused concomitantly in the same intravenous line with other agents. No physical or biochemical compatibility studies have been conducted to evaluate the coadministration of BENLYSTA with other agents.

3 DOSAGE FORMS AND STRENGTHS

Single-use vials of belimumab lyophilized powder for injection:

- 120 mg per vial
- 400 mg per vial

4 CONTRAINDICATIONS

BENLYSTA is contraindicated in patients who have had anaphylaxis with belimumab.

5 WARNINGS AND PRECAUTIONS

5.1 Mortality

There were more deaths reported with BENLYSTA than with placebo during the controlled period of the clinical trials. Out of 2133 patients in 3 clinical trials, a total of 14 deaths occurred

89 during the placebo-controlled, double-blind treatment periods: 3/675 (0.4%), 5/673 (0.7%),
90 0/111 (0%), and 6/674 (0.9%) deaths in the placebo, BENLYSTA 1 mg/kg, BENLYSTA 4
91 mg/kg, and BENLYSTA 10 mg/kg groups, respectively. No single cause of death
92 predominated. Etiologies included infection, cardiovascular disease and suicide.
93

94 **5.2 Serious Infections**

95 Serious and sometimes fatal infections have been reported in patients receiving
96 immunosuppressive agents, including BENLYSTA. Physicians should exercise caution when
97 considering the use of BENLYSTA in patients with chronic infections. Patients receiving any
98 therapy for chronic infection should not begin therapy with BENLYSTA. Consider interrupting
99 BENLYSTA therapy in patients who develop a new infection while undergoing treatment with
100 BENLYSTA and monitor these patients closely.
101

102 In the controlled clinical trials, the overall incidence of infections was 71% in patients treated
103 with BENLYSTA compared with 67% in patients who received placebo. The most frequent
104 infections (>5% of patients receiving BENLYSTA) were upper respiratory tract infection,
105 urinary tract infection, nasopharyngitis, sinusitis, bronchitis, and influenza. Serious infections
106 occurred in 6.0% of patients treated with BENLYSTA and in 5.2% of patients who received
107 placebo. The most frequent serious infections included pneumonia, urinary tract infection,
108 cellulitis, and bronchitis. Infections leading to discontinuation of treatment occurred in 0.7% of
109 patients receiving BENLYSTA and 1.0% of patients receiving placebo. Infections resulting in
110 death occurred in 0.3% (4/1458) of patients treated with BENLYSTA and in 0.1% (1/675) of
111 patients receiving placebo.
112

113 **5.3 Malignancy**

114 The impact of treatment with BENLYSTA on the development of malignancies is not known. In
115 the controlled clinical trials, malignancies (including non-melanoma skin cancers) were reported
116 in 0.4% of patients receiving BENLYSTA and 0.4% of patients receiving placebo. In the
117 controlled clinical trials, malignancies, excluding non-melanoma skin cancers, were observed in
118 0.2% (3/1458) and 0.3% (2/675) of patients receiving BENLYSTA and placebo, respectively. As
119 with other immunomodulating agents, the mechanism of action of BENLYSTA could increase
120 the risk for the development of malignancies.
121

122 **5.4 Hypersensitivity Reactions, Including Anaphylaxis**

123 In the controlled clinical trials, hypersensitivity reactions (occurring on the same day of infusion)
124 were reported in 13% (191/1458) of patients receiving BENLYSTA and 11% (76/675) of
125 patients receiving placebo. Anaphylaxis was observed in 0.6% (9/1458) of patients receiving
126 BENLYSTA and 0.4% (3/675) of patients receiving placebo. Manifestations included
127 hypotension, angioedema, urticaria or other rash, pruritus, and dyspnea. Due to overlap in signs
128 and symptoms, it was not possible to distinguish between hypersensitivity reactions and infusion
129 reactions in all cases [see *Warnings and Precautions* (5.5)]. Some patients (13%) received
130 premedication, which may have mitigated or masked a hypersensitivity response; however, there
131 is insufficient evidence to determine whether premedication diminishes the frequency or severity
132 of hypersensitivity reactions.
133

BENLYSTA should be administered by healthcare providers prepared to manage anaphylaxis. In the event of a serious reaction, administration of BENLYSTA must be discontinued immediately and appropriate medical therapy administered. Patients should be monitored during and for an appropriate period of time after administration of BENLYSTA. Patients should be informed of the signs and symptoms of a hypersensitivity reaction and instructed to seek immediate medical care should a reaction occur.

5.5 Infusion Reactions

In the controlled clinical trials, adverse events associated with the infusion (occurring on the same day of the infusion) were reported in 17% (251/1458) of patients receiving BENLYSTA and 15% (99/675) of patients receiving placebo. Serious infusion reactions (excluding hypersensitivity reactions) were reported in 0.5% of patients receiving BENLYSTA and 0.4% of patients receiving placebo and included bradycardia, myalgia, headache, rash, urticaria, and hypotension. The most common infusion reactions ($\geq 3\%$ of patients receiving BENLYSTA) were headache, nausea, and skin reactions. Due to overlap in signs and symptoms, it was not possible to distinguish between hypersensitivity reactions and infusion reactions in all cases [see *Warnings and Precautions* (5.4)]. Some patients (13%) received premedication, which may have mitigated or masked an infusion reaction; however there is insufficient evidence to determine whether premedication diminishes the frequency or severity of infusion reactions [see *Adverse Reactions* (6.1)].

BENLYSTA should be administered by healthcare providers prepared to manage infusion reactions. The infusion rate may be slowed or interrupted if the patient develops an infusion reaction. Healthcare providers should be aware of the risk of hypersensitivity reactions, which may present as infusion reactions, and monitor patients closely.

5.6 Depression

In the controlled clinical trials, psychiatric events were reported more frequently with BENLYSTA (16%) than with placebo (12%), related primarily to depression-related events (6.3% BENLYSTA and 4.7% placebo), insomnia (6.0% BENLYSTA and 5.3% placebo), and anxiety (3.9% BENLYSTA and 2.8% placebo). Serious psychiatric events were reported in 0.8% of patients receiving BENLYSTA (0.6% and 1.2% with 1 and 10 mg/kg, respectively) and 0.4% of patients receiving placebo. Serious depression was reported in 0.4% (6/1458) of patients receiving BENLYSTA and 0.1% (1/675) of patients receiving placebo. Two suicides (0.1%) were reported in patients receiving BENLYSTA. The majority of patients who reported serious depression or suicidal behavior had a history of depression or other serious psychiatric disorders and most were receiving psychoactive medications. It is unknown if BENLYSTA treatment is associated with increased risk for these events.

Patients receiving BENLYSTA should be instructed to contact their healthcare provider if they experience new or worsening depression, suicidal thoughts, or other mood changes.

5.7 Immunization

Live vaccines should not be given for 30 days before or concurrently with BENLYSTA as clinical safety has not been established. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving BENLYSTA or the effect of

BENLYSTA on new immunizations. Because of its mechanism of action, BENLYSTA may interfere with the response to immunizations.

5.8 Concomitant Use with Other Biologic Therapies or Intravenous Cyclophosphamide

BENLYSTA has not been studied in combination with other biologic therapies, including B-cell targeted therapies, or intravenous cyclophosphamide. Therefore, use of BENLYSTA is not recommended in combination with biologic therapies or intravenous cyclophosphamide.

6 ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:

- **Mortality** [see *Warnings and Precautions* (5.1)]
- **Serious Infections** [see *Warnings and Precautions* (5.2)]
- **Malignancy** [see *Warnings and Precautions* (5.3)]
- **Hypersensitivity Reactions, Including Anaphylaxis** [see *Warnings and Precautions* (5.4)]
- **Infusion reactions** [see *Warnings and Precautions* (5.5)]
- **Depression** [see *Warnings and Precautions* (5.6)]

6.1 Clinical Trials Experience

The data described below reflect exposure to BENLYSTA plus standard of care compared with placebo plus standard of care in 2133 patients in 3 controlled studies. Patients received BENLYSTA at doses of 1 mg/kg (N=673), 4 mg/kg (N=111; Trial 1 only), or 10 mg/kg (N=674) or placebo (N=675) intravenously over a 1-hour period on Days 0, 14, 28, and then every 28 days. In two of the studies (Trial 1 and Trial 3), treatment was given for 48 weeks, while in the other study (Trial 2) treatment was given for 72 weeks [see *Clinical Studies* (14)]. Because there was no apparent dose-related increase in the majority of adverse events observed with BENLYSTA, the safety data summarized below are presented for the 3 doses pooled, unless otherwise indicated; the adverse reaction table displays the results for the recommended dose of 10 mg/kg compared with placebo.

The population had a mean age of 39 (range 18-75), 94% were female, and 52% were Caucasian. In these trials, 93% of patients treated with BENLYSTA reported an adverse reaction compared with 92% treated with placebo.

The most common serious adverse reactions were serious infections (6.0% and 5.2% in the groups receiving BENLYSTA and placebo, respectively) [see *Warnings and Precautions* (5.2)].

The most commonly-reported adverse reactions, occurring in $\geq 5\%$ of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.

The proportion of patients who discontinued treatment due to any adverse reaction during the controlled clinical trials was 6.2% for patients receiving BENLYSTA and 7.1% for patients receiving placebo. The most common adverse reactions resulting in discontinuation of treatment ($\geq 1\%$ of patients receiving BENLYSTA or placebo) were infusion reactions (1.6% BENLYSTA and 0.9% placebo), lupus nephritis (0.7% BENLYSTA and 1.2% placebo), and infections (0.7% BENLYSTA and 1.0% placebo).

Table 1 lists adverse reactions, regardless of causality, occurring in at least 3% of patients with SLE who received BENLYSTA 10 mg/kg and at an incidence at least 1% greater than that observed with placebo in the 3 controlled studies.

Table 1 Incidence of Adverse Reactions Occurring in at Least 3% of Patients Treated With BENLYSTA 10 mg/kg Plus Standard of Care and at Least 1% More Frequently Than in Patients Receiving Placebo plus Standard of Care in 3 Controlled SLE Studies

Preferred Term	BENLYSTA 10 mg/kg + Standard of Care (n = 674) %	Placebo + Standard of Care (n = 675) %
Nausea	15	12
Diarrhea	12	9
Pyrexia	10	8
Nasopharyngitis	9	7
Bronchitis	9	5
Insomnia	7	5
Pain in extremity	6	4
Depression	5	4
Migraine	5	4
Pharyngitis	5	3
Cystitis	4	3
Leukopenia	4	2
Gastroenteritis viral	3	1

6.2 Immunogenicity

In Trials 2 and 3, anti-belimumab antibodies were detected in 4 of 563 (0.7%) patients receiving BENLYSTA 10 mg/kg and in 27 of 559 (4.8%) patients receiving BENLYSTA 1 mg/kg. The reported frequency for the group receiving 10 mg/kg may underestimate the actual frequency due to lower assay sensitivity in the presence of high drug concentrations. Neutralizing antibodies were detected in 3 patients receiving BENLYSTA 1 mg/kg. Three patients with anti-belimumab antibodies experienced mild infusion reactions of nausea, erythematous rash, pruritus, eyelid edema, headache, and dyspnea; none of the reactions was life-threatening. The clinical relevance of the presence of anti-belimumab antibodies is not known.

The data reflect the percentage of patients whose test results were positive for antibodies to belimumab in specific assays. The observed incidence of antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology,

sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to belimumab with the incidence of antibodies to other products may be misleading.

7 DRUG INTERACTIONS

Formal drug interaction studies have not been performed with BENLYSTA. In clinical trials of patients with SLE, BENLYSTA was administered concomitantly with other drugs, including corticosteroids, antimalarials, immunomodulatory and immunosuppressive agents (including azathioprine, methotrexate, and mycophenolate), angiotensin pathway antihypertensives, HMG-CoA reductase inhibitors (statins), and NSAIDs without evidence of a clinically meaningful effect of these concomitant medications on belimumab pharmacokinetics. The effect of belimumab on the pharmacokinetics of other drugs has not been evaluated [see *Pharmacokinetics 12.3*].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C. There are no adequate and well-controlled clinical studies using BENLYSTA in pregnant women. Immunoglobulin G (IgG) antibodies, including BENLYSTA, can cross the placenta. Because animal reproduction studies are not always predictive of human response, BENLYSTA should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. Women of childbearing potential should use adequate contraception during treatment with BENLYSTA and for at least 4 months after the final treatment.

Nonclinical reproductive studies have been performed in pregnant cynomolgus monkeys receiving belimumab at doses of 0, 5 and 150 mg/kg by intravenous infusion (the high dose was approximately 9 times the anticipated maximum human exposure) every 2 weeks from gestation day 20 to 150. Belimumab was shown to cross the placenta. Belimumab was not associated with direct or indirect teratogenicity under the conditions tested. Fetal deaths were observed in 14%, 24% and 15% of pregnant females in the 0, 5 and 150 mg/kg groups, respectively. Infant deaths occurred with an incidence of 0%, 8% and 5%. The cause of fetal and infant deaths is not known. The relevance of these findings to humans is not known. Other treatment-related findings were limited to the expected reversible reduction of B cells in both dams and infants and reversible reduction of IgM in infant monkeys. B-cell numbers recovered after the cessation of belimumab treatment by about 1 year post-partum in adult monkeys and by 3 months of age in infant monkeys. IgM levels in infants exposed to belimumab in utero recovered by 6 months of age.

Pregnancy Registry: To monitor maternal-fetal outcomes of pregnant women exposed to BENLYSTA, a pregnancy registry has been established. Healthcare professionals are encouraged to register patients and pregnant women are encouraged to enroll themselves by calling 1-877-681-6296.

8.3 Nursing Mothers

It is not known whether BENLYSTA is excreted in human milk or absorbed systemically after ingestion. However, belimumab was excreted into the milk of cynomolgus monkeys. Because

maternal antibodies are excreted in human breast milk, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of breastfeeding to the infant and the importance of the drug to the mother.

8.4 Pediatric Use

Safety and effectiveness of BENLYSTA have not been established in children.

8.5 Geriatric Use

Clinical studies of BENLYSTA did not include sufficient numbers of subjects aged 65 or over to determine whether they respond differently from younger subjects. Use with caution in elderly patients.

8.6 Race

In Trial 2 and Trial 3, response rates for the primary endpoint were lower for black subjects in the BENLYSTA group relative to black subjects in the placebo group [see *Clinical Studies (14)*]. Use with caution in black/African-American patients.

10 OVERDOSAGE

There is no clinical experience with overdosage of BENLYSTA. Two doses of up to 20 mg/kg have been given by intravenous infusion to humans with no increase in incidence or severity of adverse reactions compared with doses of 1, 4, or 10 mg/kg.

11 DESCRIPTION

BENLYSTA (belimumab) is a human IgG1 λ monoclonal antibody specific for soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B). Belimumab has a molecular weight of approximately 147 kDa. Belimumab is produced by recombinant DNA technology in a mammalian cell expression system.

BENLYSTA is supplied as a sterile, white to off-white, preservative-free, lyophilized powder for intravenous infusion. Upon reconstitution with Sterile Water for Injection, USP, [see *Dosage and Administration (2.3)*] each single-use vial delivers 80 mg/mL belimumab in 0.16 mg/mL citric acid, 0.4 mg/mL polysorbate 80, 2.7 mg/mL sodium citrate, and 80 mg/mL sucrose, with a pH of 6.5.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

BENLYSTA is a BLyS-specific inhibitor that blocks the binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells. BENLYSTA does not bind B cells directly, but by binding BLyS, BENLYSTA inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.

12.2 Pharmacodynamics

In Trial 1 and Trial 2 in which B cells were measured, treatment with BENLYSTA significantly reduced circulating CD19+, CD20+, naïve, and activated B cells, plasmacytoid cells, and the SLE B-cell subset at Week 52. Reductions in naïve and the SLE B-cell subset were observed as early as Week 8 and were sustained to Week 52. Memory cells increased initially and slowly.

declined toward baseline levels by Week 52. The clinical relevance of these effects on B cells has not been established.

Treatment with BENLYSTA led to reductions in IgG and anti-dsDNA, and increases in complement (C3 and C4). These changes were observed as early as Week 8 and were sustained through Week 52. The clinical relevance of normalizing these biomarkers has not been definitively established.

12.3 Pharmacokinetics

The pharmacokinetic parameters displayed in Table 2 are based on population parameter estimates which are specific to the 563 patients who received belimumab 10 mg/kg in Trials 2 and 3 [see *Clinical Studies* (14)].

Table 2. Population Pharmacokinetic Parameters in Patients with SLE after Intravenous Infusion of BENLYSTA 10 mg/kg¹

Pharmacokinetic Parameter	Population Estimates (n = 563)
Peak concentration (C_{max} , $\mu\text{g/mL}$)	313
Area under the curve ($AUC_{0-\infty}$, $\text{day} \cdot \mu\text{g/mL}$)	3,083
Distribution half-life ($t_{1/2}$, days)	1.75
Terminal half-life ($t_{1/2}$, days)	19.4
Systemic clearance (CL, mL/day)	215
Volume of distribution (V_{ss} , L)	5.29

Intravenous infusions were administered at 2-week intervals for the first 3 doses and at 4-week intervals thereafter.

Drug Interactions: No formal drug interaction studies have been conducted with belimumab. Concomitant use of mycophenolate, azathioprine, methotrexate, antimalarials, NSAIDs, aspirin, and HMG-CoA reductase inhibitors did not significantly influence belimumab pharmacokinetics. Coadministration of steroids and angiotensin-converting enzyme (ACE) inhibitors resulted in an increase of systemic clearance of belimumab that was not clinically significant because the magnitude was well within the range of normal variability of clearance. The effect of belimumab on the pharmacokinetics of other drugs has not been evaluated.

Special Populations:

The following information is based on the population pharmacokinetic analysis.

Age: Age did not significantly influence belimumab pharmacokinetics in the study population, where the majority of subjects (70%) were between 18 and 45 years of age. No pharmacokinetic data are available in pediatric patients. Limited pharmacokinetic data are available for elderly patients as only 1.4% of the subjects included in the pharmacokinetic analysis were 65 years of age or older [see *Use in Specific Populations* (8.5)].

Gender: Gender did not significantly influence belimumab pharmacokinetics in the largely (94%) female study population.

Race: Race did not significantly influence belimumab pharmacokinetics. The racial distribution was 53% white/Caucasian, 16% Asian, 16% Alaska native/American Indian, and 14% black/African American.

Renal Impairment: No formal studies were conducted to examine the effects of renal impairment on the pharmacokinetics of belimumab. Belimumab has been studied in a limited number of patients with SLE and renal impairment (261 subjects with moderate renal impairment, creatinine clearance ≥ 30 and < 60 mL/min; 14 subjects with severe renal impairment, creatinine clearance ≥ 15 and < 30 mL/min). Although increases in creatinine clearance and proteinuria (> 2 g/day) increased belimumab clearance, these effects were within the expected range of variability. Therefore, dosage adjustment in patients with renal impairment is not recommended.

Hepatic Impairment: No formal studies were conducted to examine the effects of hepatic impairment on the pharmacokinetics of belimumab. Belimumab has not been studied in patients with severe hepatic impairment. Baseline ALT and AST levels did not significantly influence belimumab pharmacokinetics.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal studies have not been performed to evaluate the carcinogenic potential of belimumab. The mutagenic potential of belimumab was not evaluated.

Effects on male and female fertility have not been directly evaluated in animal studies.

14 CLINICAL STUDIES

The safety and effectiveness of BENLYSTA were evaluated in three randomized, double-blind, placebo-controlled studies involving 2133 patients with SLE according to the American College of Rheumatology criteria (Trial 1, 2, and 3). Patients with severe active lupus nephritis and severe active CNS lupus were excluded. Patients were on a stable standard of care SLE treatment regimen comprising any of the following (alone or in combination): corticosteroids, antimalarials, NSAIDs, and immunosuppressives. Use of other biologics and intravenous cyclophosphamide were not permitted.

Trial 1: BENLYSTA 1 mg/kg, 4 mg/kg, 10 mg/kg

Trial 1 enrolled 449 patients and evaluated doses of 1, 4, and 10 mg/kg BENLYSTA plus standard of care compared with placebo plus standard of care over 52 weeks in patients with SLE. Patients had to have a SELENA-SLEDAI score of ≥ 4 at baseline and a history of autoantibodies (anti-nuclear antibody (ANA) and/or anti-double-stranded DNA (anti-dsDNA), but 28% of the population was autoantibody negative at baseline. The co-primary endpoints were percent change in SELENA-SLEDAI score at Week 24 and time to first flare over 52 weeks. No significant differences between any of the BENLYSTA groups and the placebo group were observed. Exploratory analysis of this study identified a subgroup of patients (72%), who were autoantibody positive, in whom BENLYSTA appeared to offer benefit. The results of

this study informed the design of Trials 2 and 3 and led to the selection of a target population and indication that is limited to autoantibody-positive SLE patients.

Trials 2 and 3: BENLYSTA 1 mg/kg and 10 mg/kg

Trials 2 and 3 were randomized, double-blind, placebo-controlled trials in patients with SLE that were similar in design except duration - Trial 2 was 76 weeks duration and Trial 3 was 52 weeks duration. Eligible patients had active SLE disease, defined as a SELENA-SLEDAI score ≥ 6 , and positive autoantibody test results at screening. Patients were excluded from the study if they had ever received treatment with a B-cell targeted agent or if they were currently receiving other biologic agents. Intravenous cyclophosphamide was not permitted within the previous 6 months or during study. Trial 2 was conducted primarily in North America and Europe. Trial 3 was conducted in South America, Eastern Europe, Asia, and Australia.

Baseline concomitant medications included corticosteroids (Trial 2: 76%, Trial 3: 96%), immunosuppressives (Trial 2: 56%, Trial 3: 42%; including azathioprine, methotrexate and mycophenolate), and antimalarials (Trial 2: 63%, Trial 3: 67%). Most patients (>70%) were receiving 2 or more classes of SLE medications.

In Trial 2 and Trial 3, more than 50% of patients had 3 or more active organ systems at baseline. The most common active organ systems at baseline based on SELENA SLEDAI were mucocutaneous (82% in both studies); immunology (Trial 2: 74%, Trial 3: 85%); and musculoskeletal (Trial 2: 73%, Trial 3: 59%). Less than 16% of patients had some degree of renal activity and less than 7% of patients had activity in the vascular, cardio-respiratory, or CNS systems.

At screening, patients were stratified by disease severity based on their SELENA-SLEDAI score (≤ 9 vs ≥ 10), proteinuria level (< 2 g/24 hr vs ≥ 2 g/24 hr), and race (African or Indigenous-American descent vs. other), and then randomly assigned to receive BENLYSTA 1 mg/kg, BENLYSTA 10 mg/kg, or placebo in addition to standard of care. The patients were administered study medication intravenously over a 1-hour period on Days 0, 14, 28, and then every 28 days for 48 weeks in Trial 3 and for 72 weeks in Trial 2.

The primary efficacy endpoint was a composite endpoint (SLE Responder Index or SRI) that defined response as meeting each of the following criteria at Week 52 compared with baseline:

- ≥ 4 -point reduction in the SELENA-SLEDAI score, and
- no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores, and
- no worsening (< 0.30 -point increase) in Physician's Global Assessment (PGA) score.

The SRI uses the SELENA-SLEDAI score as an objective measure of reduction in global disease activity; the BILAG index to ensure no significant worsening in any specific organ system; and the PGA to ensure that improvements in disease activity are not accompanied by worsening of the patient's condition overall.

In both Trials 2 and 3, the proportion of SLE patients achieving an SRI response, as defined for the primary endpoint, was significantly higher in the BENLYSTA 10 mg/kg group than in the

placebo group in both studies. The effect on the SRI was not consistently significantly different for the BENLYSTA 1mg/kg group relative to placebo in both trials. The 1 mg/kg dose is not recommended. The trends in comparisons between the treatment groups for the rates of response for the individual components of the endpoint were generally consistent with that of the SRI (Table 3). At Week 76 in Trial 2, the SRI response rate with BENLYSTA 10 mg/kg was not significantly different from that of placebo (39% and 32%, respectively).

Table 3. Clinical Response Rate in Patients with SLE After 52 Weeks of Treatment

Response ¹	Trial 2			Trial 3		
	Placebo + Standard of Care (n = 275)	BENLYSTA 1 mg/kg + Standard of Care ² (n = 271)	BENLYSTA 10 mg/kg + Standard of Care (n = 273)	Placebo + Standard of Care (n = 287)	BENLYSTA 1 mg/kg + Standard of Care ² (n = 288)	BENLYSTA 10 mg/kg + Standard of Care (n = 290)
SLE Responder Index	34%	41% (p = 0.104)	43% (p = 0.021)	44%	51% (p = 0.013)	58% (p < 0.001)
Odds Ratio (95% CI) vs. placebo		1.3 (0.9, 1.9)	1.5 (1.1, 2.2)		1.6 (1.1, 2.2)	1.8 (1.3, 2.6)
Components of SLE Responder Index						
Percent of patients with reduction in SELENA- SLEDAI ≥4	36%	43%	47%	46%	53%	58%
Percent of patients with no worsening by BILAG index	65%	75%	69%	73%	79%	81%
Percent of patients with no worsening by PGA	63%	73%	69%	69%	79%	80%

¹Patients dropping out of the study early or experiencing certain increases in background medication were considered as failures in these analyses. In both studies, a higher proportion of placebo patients were considered as failures for this reason as compared to the BENLYSTA groups.

²The 1 mg/kg dose is not recommended.

The reduction in disease activity seen in the SRI was related primarily to improvement in the most commonly involved organ systems namely, mucocutaneous, musculoskeletal, and immunology.

Effect in Black/African-American Patients

Exploratory sub-group analyses of SRI response rate in patients of black race were performed. In Trial 2 and Trial 3 combined, the SRI response rate in black patients (N=148) in the BENLYSTA groups was less than that in the placebo group (22/50 or 44% for placebo, 15/48 or 31% for BENLYSTA 1 mg/kg, and 18/50 or 36% for BENLYSTA 10 mg/kg). In Trial 1, black patients (N=106) in the BENLYSTA groups did not appear to have a different response than the

rest of the study population. Although no definitive conclusions can be drawn from these subgroup analyses, caution should be used when considering BENLYSTA treatment in black/African-American SLE patients.

Effect on Concomitant Steroid Treatment:

In Trial 2 and Trial 3, 46% and 69% of patients, respectively, were receiving prednisone at doses > 7.5 mg/day at baseline. The proportion of patients able to reduce their average prednisone dose by at least 25% to ≤7.5 mg/day during Weeks 40 through 52 was not consistently significantly different for BENLYSTA relative to placebo in both trials. In Trial 2, 17% of patients receiving BENLYSTA 10 mg/kg and 19% of patients receiving BENLYSTA 1 mg/kg achieved this level of steroid reduction compared with 13% of patients receiving placebo. In Trial 3, 19%, 21%, and 12% of patients receiving BENLYSTA 10 mg/kg, BENLYSTA 1 mg/kg, and placebo, respectively, achieved this level of steroid reduction.

Effect on Severe SLE Flares:

The probability of experiencing a severe SLE flare, as defined by a modification of the SELENA Trial flare criteria which excluded severe flares triggered only by an increase of the SELENA-SLEDAI score to >12, was calculated for both Trials 2 and 3. The proportion of patients having at least 1 severe flare over 52 weeks was not consistently significantly different for BENLYSTA relative to placebo in both trials. In Trial 2, 18% of patients receiving BENLYSTA 10 mg/kg and 16% of patients receiving BENLYSTA 1 mg/kg had a severe flare compared with 24% of patients receiving placebo. In Trial 3, 14%, 18%, and 23% of patients receiving BENLYSTA 10 mg/kg, BENLYSTA 1 mg/kg and placebo, respectively, had a severe flare.

16 HOW SUPPLIED/STORAGE AND HANDLING

BENLYSTA is a sterile, preservative-free lyophilized powder for reconstitution, dilution, and intravenous infusion provided in single-use glass vials with a latex-free rubber stopper and a flip-off seal. Each 5-mL vial contains 120 mg of belimumab. Each 20-mL vial contains 400 mg of belimumab.

BENLYSTA is supplied as follows:

120 mg belimumab in a 5-mL single-use vial	NDC 49401-101-01
400 mg belimumab in a 20-mL single-use vial	NDC 49401-102-01

Store vials of BENLYSTA refrigerated between 2° to 8°C (36° to 46°F). Vials should be protected from light and stored in the original carton until use. *Do not freeze.* Avoid exposure to heat. Do not use beyond the expiration date.

17 PATIENT COUNSELING INFORMATION

See Medication Guide.

17.1 Advice for the Patient

Patients should be given the Medication Guide for BENLYSTA and provided an opportunity to read it prior to each treatment session. It is important that the patient's overall health be assessed at each infusion visit and any questions resulting from the patient's reading of the Medication Guide be discussed.

Mortality: Patients should be advised that more patients receiving BENLYSTA in the main clinical trials died than did patients receiving placebo treatment [see *Warnings and Precautions* (5.1)].

Serious Infections: Patients should be advised that BENLYSTA may decrease their ability to fight infections. Patients should be asked if they have a history of chronic infections and if they are currently on any therapy for an infection [see *Warnings and Precautions* (5.2)]. Patients should be instructed to tell their healthcare provider if they develop signs or symptoms of an infection.

Hypersensitivity/Anaphylactic and Infusion Reactions: Educate patients on the signs and symptoms of anaphylaxis, including wheezing, difficulty breathing, peri-oral or lingual edema, and rash. Patients should be instructed to immediately tell their healthcare provider if they experience symptoms of an allergic reaction during or after the administration of BENLYSTA [see *Warnings and Precautions* (5.4, 5.5)].

Depression: Patients should be instructed to contact their healthcare provider if they experience new or worsening depression, suicidal thoughts or other mood changes. [see *Warnings and Precautions* (5.6)].

Immunizations: Patients should be informed that they should not receive live vaccines while taking BENLYSTA. Response to vaccinations could be impaired by BENLYSTA [see *Warnings and Precautions* (5.7)].

Pregnancy and Nursing Mothers: Patients should be informed that BENLYSTA has not been studied in pregnant women or nursing mothers so the effects of BENLYSTA on pregnant women or nursing infants are not known. Patients should be instructed to tell their healthcare provider if they are pregnant, become pregnant, or are thinking about becoming pregnant [see *Use in Specific Populations* (8.1)]. Patients should be instructed to tell their healthcare provider if they plan to breastfeed their infant [see *Use in Specific Populations* (8.3)].

566 BENLYSTA is a registered trademark of Human Genome Sciences, Inc., used under license by
567 GlaxoSmithKline.

568
569 Manufactured by:
570 Human Genome Sciences, Inc.
571 Rockville, Maryland 20850
572 US License No. XXXX

573
574 Marketed by:

**HUMAN
GENOME
SCIENCES**

575 Human Genome Sciences, Inc.
576 Rockville, MD 20850
577

 **GlaxoSmithKline**

GlaxoSmithKline
Research Triangle Park, NC 27709

578 ©2011, Human Genome Sciences, Inc. All rights reserved.

MEDICATION GUIDE

BENLYSTA[®] (ben-LIST-ah) (belimumab)

Injection for intravenous use

Read this Medication Guide before you start receiving BENLYSTA and before each treatment. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.

What is the most important information I should know about BENLYSTA?

BENLYSTA can cause serious side effects. Some of these side effects may cause death. It is not known if BENLYSTA causes these serious side effects. Tell your healthcare provider right away if you have any of the symptoms listed below while receiving BENLYSTA.

1. Infections. Symptoms of an infection can include:

- fever
- chills
- pain or burning with urination
- urinating often
- bloody diarrhea
- coughing up mucus

2. Heart Problems. Symptoms of heart problems can include:

- chest discomfort or pain
- shortness of breath
- cold sweats
- nausea
- dizziness
- discomfort in other areas of the upper body

3. Mental health problems and suicide. Symptoms of mental health problems can include:

- thoughts of suicide or dying
- attempt to commit suicide
- trouble sleeping (insomnia)
- new or worse anxiety
- new or worse depression
- acting on dangerous impulses
- other unusual changes in your behavior or mood
- thoughts of hurting yourself or others

37 **What is BENLYSTA?**

38 BENLYSTA is a prescription medicine used to treat adults with active systemic lupus
39 erythematosus (SLE or lupus) who are receiving other lupus medicines.

40 BENLYSTA contains *belimumab* which is in a group of medicines called *monoclonal*
41 *antibodies*. Lupus is a disease of the immune system (the body system that fights infection).
42 People with active lupus often have high levels of a certain protein in their blood. BENLYSTA
43 binds to and limits the activity of the protein. When given together with other medicines for
44 lupus, BENLYSTA decreases lupus disease activity more than other lupus medicines alone.

- 45 • It is not known if BENLYSTA is safe and effective in people with severe active lupus
46 nephritis or severe active central nervous system lupus.
- 47 • It is not known if BENLYSTA is safe and effective in children.

48 **Who should not receive BENLYSTA?**

49 **Do not receive BENLYSTA if you:**

- 50 • are allergic to belimumab or any of the ingredients in BENLYSTA. See the end of this
51 Medication Guide for a complete list of ingredients in BENLYSTA.

52 **What should I tell my healthcare provider before receiving BENLYSTA?**

53 Before you receive BENLYSTA, tell your healthcare provider if you:

- 54 • think you have an infection or have infections that keep coming back. You should not
55 receive BENLYSTA if you have an infection unless your healthcare provider tells you to.
56 See **"What is the most important information I should know about BENLYSTA."**
- 57 • have or have had mental health problems such as depression or thoughts of suicide
- 58 • have recently received a vaccination or if you think you may need a vaccination. If you
59 are receiving BENLYSTA, you should not receive live vaccines.
- 60 • are receiving other biologic medicines, monoclonal antibodies or IV infusions of
61 cyclophosphamide (Cytosan®)
- 62 • have or have had any type of cancer
- 63 • have any other medical conditions
- 64 • are pregnant or plan to become pregnant. It is not known if BENLYSTA will harm your
65 unborn baby. Tell your healthcare provider if you become pregnant during your treatment
66 with BENLYSTA.
- 67 • If you become pregnant while receiving BENLYSTA, talk to your healthcare provider
68 about enrolling in the BENLYSTA Pregnancy Registry. You can enroll in this
69 registry by calling 1-877-681-6296. The purpose of this registry is to monitor the
70 health of you and your baby.

71 • are breastfeeding or plan to breastfeed. It is not known if BENLYSTA passes into your
72 breast milk. You and your healthcare provider should decide if you will receive
73 BENLYSTA or breastfeed. You should not do both.

74 **Tell your healthcare provider about all the medicines you take, including prescription and**
75 **non-prescription medicines, vitamins, and herbal supplements.**

76 Know the medicines you take. Keep a list of your medicines with you to show to your
77 healthcare provider and pharmacist when you get a new medicine.

78 **How will I receive BENLYSTA?**

79 • You will be given BENLYSTA by a healthcare provider through a needle placed in a
80 vein (IV infusion). It takes about 1 hour to give you the full dose of BENLYSTA.
81 • Your healthcare provider will tell you how often you should receive BENLYSTA.
82 • Your healthcare provider may give you medicines before you receive BENLYSTA to
83 help reduce your chance of having a reaction. A healthcare provider will watch you
84 closely while you are receiving BENLYSTA and after your infusion for signs of a
85 reaction.

86 **What are the possible side effects of BENLYSTA?**

87 **BENLYSTA can cause serious side effects.**

88 • See "What is the most important information I should know about BENLYSTA?"

89 **1. Cancer.** BENLYSTA may reduce the activity of your immune system. Medicines that affect
90 the immune system may increase your risk of certain cancers.

91 **2. Allergic (hypersensitivity) and infusion reactions.** Serious allergic or infusion reactions
92 can happen on the day of or the day after receiving BENLYSTA. Symptoms of an allergic or
93 infusion reaction may include:

94 • itching
95 • swelling of the face, lips, mouth, tongue, or throat
96 • trouble breathing
97 • anxiousness
98 • low blood pressure
99 • dizziness or fainting
100 • headache
101 • nausea
102 • skin rash, redness, or swelling

103 Your healthcare provider will watch you closely while you are receiving BENLYSTA and
104 after your infusion for signs of a reaction.

105 **The most common side effects of BENLYSTA include:**

- 106 • nausea
- 107 • diarrhea
- 108 • fever
- 109 • stuffy or runny nose
- 110 • sore throat
- 111 • cough (bronchitis)
- 112 • trouble sleeping
- 113 • leg or arm pain
- 114 • headache (migraine)
- 115 • urinary tract infection
- 116 • decreased white blood cell count (leukopenia)
- 117 • vomiting
- 118 • stomach pain

119
120 Tell your healthcare provider if you have any side effect that bothers you or that does not go
121 away.

122 These are not all the possible side effects of BENLYSTA. For more information, ask your
123 healthcare provider.

124 Call your doctor for medical advice about side effects. You may report side effects to FDA at
125 1-800-FDA-1088.

126 **General information about the safe and effective use of BENLYSTA**

127 Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.
128 Do not use BENLYSTA for a condition for which it was not prescribed.

129 This Medication Guide summarizes the most important information about BENLYSTA. For
130 more information about BENLYSTA, talk with your healthcare provider.

131 You can ask your healthcare provider or pharmacist for information about BENLYSTA that is
132 written for healthcare professionals.

133 For more information about BENLYSTA, go to www.BENLYSTA.com or call 1-877-423-6597.

134 **What are the ingredients in BENLYSTA?**

135 **Active ingredient:** belimumab.


136 **Inactive ingredients:** citric acid, polysorbate 80, sodium citrate, sucrose.

137 RX Only
138
139 BENLYSTA is a registered trademark of Human Genome Sciences, Inc., used under license by
140 GlaxoSmithKline.

141 Manufactured by
142 Human Genome Sciences, Inc.
143 Rockville, Maryland 20850
144 US License No. XXXX


145 Marketed by
**HUMAN
GENOME
SCIENCES**

146 Human Genome Sciences, Inc.
147 Rockville, MD 20850

 **GlaxoSmithKline**
GlaxoSmithKline
Research Triangle Park, NC 27709


148 This Medication Guide has been approved by the U.S. Food and Drug Administration.
149 Issued: March 2011
150 ©2011, Human Genome Sciences, Inc. All rights reserved.

PMS 526 PMS 123 PMS Warm Gray 7 B



Human Genome Sciences
Printed Side // T080410G_A

PMS 526 PMS 123 PMS Warm Gray 7 Black



Benlysta[®]
(belimumab)

For Injection

120 mg/vial

For intravenous infusion after dilution only
Single-use vial; Discard unused portion

NDC 40401-101-01

See prescribing information for
reconstitution, dilutions, and dosage
information.

REFRIGERATE: Store at 2° to 8°C (36°
to 46°F). Protect from light by storing
in original package until use.

Do Not Freeze

Human Genome Sciences
Rockville, MD 20850 USA

US License No. 0000

Rx only

80039 Rev. 001



Benlysta[®]
(belimumab)

For Injection

300 mg/vial

For intravenous infusion after dilution only
Single-use vial; Discard unused portion

NDC 40401-102-01

See prescribing information for
reconstitution, dilutions, and dosage
information.

REFRIGERATE: Store at 2° to 8°C (36°
to 46°F). Protect from light by storing
in original package until use.

Do Not Freeze

Human Genome Sciences
Rockville, MD 20850 USA

US License No. 0000

Rx only

80035 Rev. 001



U.S. Patent No. 7,138,501

Application for Patent Term Extension

Attachment C

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use BENLYSTA safely and effectively. See full prescribing information for BENLYSTA.

BENLYSTA® (belimumab)
for injection, for intravenous use only
Initial U.S. Approval: 2011

INDICATIONS AND USAGE

BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. (1, 14)

Limitations of Use: The efficacy of BENLYSTA has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus (1). BENLYSTA has not been studied in combination with other biologics or intravenous cyclophosphamide (1). Use of BENLYSTA is not recommended in these situations.

DOSAGE AND ADMINISTRATION

- Recommended dosage regimen is 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. Reconstitute, dilute and administer as an intravenous infusion only, over a period of 1 hour. (2.1)
- Consider administering premedication for prophylaxis against infusion reactions and hypersensitivity reactions (2.2)

DOSAGE FORMS AND STRENGTHS

Single-use vials of belimumab lyophilized powder:

- 120 mg per vial (3)
- 400 mg per vial (3)

CONTRAINDICATIONS

Previous anaphylaxis to belimumab. (4)

WARNINGS AND PRECAUTIONS

- Mortality:** There were more deaths reported with BENLYSTA than with placebo during the controlled period of clinical trials. (5.1)
- Serious Infections:** Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA. Use with caution in patients with chronic infections. Consider interrupting BENLYSTA therapy if patients develop a new infection during BENLYSTA treatment. (5.2)
- Hypersensitivity Reactions, Including Anaphylaxis:** Serious reactions have been reported. BENLYSTA should be administered by healthcare providers prepared to manage anaphylaxis. Monitor patients during and for an appropriate period of time after administration of BENLYSTA. (2.2, 5.4)
- Depression:** Depression and suicidality have been reported in BENLYSTA studies. Patients should be instructed to contact their healthcare provider if they experience new or worsening depression, suicidal thoughts or other mood changes. (5.6)
- Immunization:** Live vaccines should not be given concurrently with BENLYSTA. (5.7)

ADVERSE REACTIONS

Common adverse reactions (≥5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Human Genome Sciences, Inc. at 1-877-423-6597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

- Pregnancy:** Registry available. (8.1)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: March 2011

FULL PRESCRIBING INFORMATION: CONTENTS*

1	INDICATIONS AND USAGE
2	DOSAGE AND ADMINISTRATION
2.1	Dosage Schedule
2.2	Premedication Recommendations
2.3	Preparation of Solutions
2.4	Administration Instructions
3	DOSAGE FORMS AND STRENGTHS
4	CONTRAINDICATIONS
5	WARNINGS AND PRECAUTIONS
5.1	Mortality
5.2	Serious Infections
5.3	Malignancy
5.4	Hypersensitivity Reactions, Including Anaphylaxis
5.5	Infusion Reactions
5.6	Depression
5.7	Immunization
5.8	Concomitant Use with Other Biologic Therapies or Intravenous Cyclophosphamide
6	ADVERSE REACTIONS
6.1	Clinical Trials Experience
6.2	Immunogenicity

7	DRUG INTERACTIONS
8	USE IN SPECIFIC POPULATIONS
8.1	Pregnancy
8.3	Nursing Mothers
8.4	Pediatric Use
8.5	Geriatric Use
8.6	Race
10	OVERDOSAGE
11	DESCRIPTION
12	CLINICAL PHARMACOLOGY
12.1	Mechanism of Action
12.2	Pharmacodynamics
12.3	Pharmacokinetics
13	NONCLINICAL TOXICOLOGY
13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility
14	CLINICAL STUDIES
16	HOW SUPPLIED/STORAGE AND HANDLING
17	PATIENT COUNSELING INFORMATION
17.1	Advice for the Patient

* Sections or subsections omitted from the full prescribing information are not listed

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

BENLYSTA® (belimumab) is indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.

Limitations of Use

The efficacy of BENLYSTA has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. BENLYSTA has not been studied in combination with other biologics or intravenous cyclophosphamide. Use of BENLYSTA is not recommended in these situations.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage Schedule

BENLYSTA is for intravenous infusion **only** and must be reconstituted and diluted prior to administration [see *Dosage and Administration* 2.3)]. Do not administer as an intravenous push or bolus.

The recommended dosage regimen is 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. Reconstitute, dilute and administer as an intravenous infusion only, over a period of 1 hour. The infusion rate may be slowed or interrupted if the patient develops an infusion reaction. The infusion must be discontinued immediately if the patient experiences a serious hypersensitivity reaction [see *Contraindications* (4), *Warnings and Precautions* (5.4)].

2.2 Premedication Recommendations

Prior to dosing with BENLYSTA, consider administering premedication for prophylaxis against infusion reactions and hypersensitivity reactions. [see *Warnings and Precautions* (5.4, 5.5) and *Adverse Reactions* (6.1)].

2.3 Preparation of Solutions

BENLYSTA is provided as a lyophilized powder in a single-use vial for intravenous infusion only and should be reconstituted and diluted by a healthcare professional using aseptic technique as follows:

Reconstitution Instructions

1. Remove BENLYSTA from the refrigerator and allow to stand 10 to 15 minutes for the vial to reach room temperature.
2. Reconstitute the BENLYSTA powder with Sterile Water for Injection, USP, as follows. The reconstituted solution will contain a concentration of 80 mg/mL belimumab.
 - Reconstitute the 120 mg vial with 1.5 mL Sterile Water for Injection, USP.
 - Reconstitute the 400 mg vial with 4.8 mL Sterile Water for Injection, USP.
3. The stream of sterile water should be directed toward the side of the vial to minimize foaming. Gently swirl the vial for 60 seconds. Allow the vial to sit at room temperature during reconstitution, gently swirling the vial for 60 seconds every 5 minutes until the powder is dissolved. *Do not shake*. Reconstitution is typically complete within 10 to 15 minutes after the sterile water has been added, but it may take up to 30 minutes. Protect

the reconstituted solution from sunlight.

4. If a mechanical reconstitution device (swirler) is used to reconstitute BENLYSTA, it should not exceed 500 rpm and the vial swirled for no longer than 30 minutes.
5. Once reconstitution is complete, the solution should be opalescent and colorless to pale yellow, and without particles. Small air bubbles, however, are expected and acceptable.

Dilution Instructions

6. Dextrose intravenous solutions are incompatible with BENLYSTA. BENLYSTA should only be diluted in 0.9% Sodium Chloride Injection, USP. Dilute the reconstituted product to 250 mL in 0.9% Sodium Chloride Injection, USP (normal saline) for intravenous infusion. From a 250-mL infusion bag or bottle of normal saline, withdraw and discard a volume equal to the volume of the reconstituted solution of BENLYSTA required for the patient's dose. Then add the required volume of the reconstituted solution of BENLYSTA into the infusion bag or bottle. Gently invert the bag or bottle to mix the solution. Any unused solution in the vials must be discarded.
7. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard the solution if any particulate matter or discoloration is observed.
8. The reconstituted solution of BENLYSTA, if not used immediately, should be stored protected from direct sunlight and refrigerated at 2° to 8°C (36° to 46°F). Solutions of BENLYSTA diluted in normal saline may be stored at 2° to 8°C (36° to 46°F) or room temperature. The total time from reconstitution of BENLYSTA to completion of infusion should not exceed 8 hours.
9. No incompatibilities between BENLYSTA and polyvinylchloride or polyolefin bags have been observed.

2.4 Administration Instructions

1. The diluted solution of BENLYSTA should be administered by intravenous infusion only, over a period of 1 hour.
2. BENLYSTA should be administered by healthcare providers prepared to manage anaphylaxis. *[see Warnings and Precautions (5.4)]*
3. BENLYSTA should not be infused concomitantly in the same intravenous line with other agents. No physical or biochemical compatibility studies have been conducted to evaluate the coadministration of BENLYSTA with other agents.

3 DOSAGE FORMS AND STRENGTHS

Single-use vials of belimumab lyophilized powder for injection:

- 120 mg per vial
- 400 mg per vial

4 CONTRAINDICATIONS

BENLYSTA is contraindicated in patients who have had anaphylaxis with belimumab.

5 WARNINGS AND PRECAUTIONS

5.1 Mortality

There were more deaths reported with BENLYSTA than with placebo during the controlled period of the clinical trials. Out of 2133 patients in 3 clinical trials, a total of 14 deaths occurred

during the placebo-controlled, double-blind treatment periods: 3/675 (0.4%), 5/673 (0.7%), 0/111 (0%), and 6/674 (0.9%) deaths in the placebo, BENLYSTA 1 mg/kg, BENLYSTA 4 mg/kg, and BENLYSTA 10 mg/kg groups, respectively. No single cause of death predominated. Etiologies included infection, cardiovascular disease and suicide.

5.2 Serious Infections

Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA. Physicians should exercise caution when considering the use of BENLYSTA in patients with chronic infections. Patients receiving any therapy for chronic infection should not begin therapy with BENLYSTA. Consider interrupting BENLYSTA therapy in patients who develop a new infection while undergoing treatment with BENLYSTA and monitor these patients closely.

In the controlled clinical trials, the overall incidence of infections was 71% in patients treated with BENLYSTA compared with 67% in patients who received placebo. The most frequent infections (>5% of patients receiving BENLYSTA) were upper respiratory tract infection, urinary tract infection, nasopharyngitis, sinusitis, bronchitis, and influenza. Serious infections occurred in 6.0% of patients treated with BENLYSTA and in 5.2% of patients who received placebo. The most frequent serious infections included pneumonia, urinary tract infection, cellulitis, and bronchitis. Infections leading to discontinuation of treatment occurred in 0.7% of patients receiving BENLYSTA and 1.0% of patients receiving placebo. Infections resulting in death occurred in 0.3% (4/1458) of patients treated with BENLYSTA and in 0.1% (1/675) of patients receiving placebo.

5.3 Malignancy

The impact of treatment with BENLYSTA on the development of malignancies is not known. In the controlled clinical trials, malignancies (including non-melanoma skin cancers) were reported in 0.4% of patients receiving BENLYSTA and 0.4% of patients receiving placebo. In the controlled clinical trials, malignancies, excluding non-melanoma skin cancers, were observed in 0.2% (3/1458) and 0.3% (2/675) of patients receiving BENLYSTA and placebo, respectively. As with other immunomodulating agents, the mechanism of action of BENLYSTA could increase the risk for the development of malignancies.

5.4 Hypersensitivity Reactions, Including Anaphylaxis

In the controlled clinical trials, hypersensitivity reactions (occurring on the same day of infusion) were reported in 13% (191/1458) of patients receiving BENLYSTA and 11% (76/675) of patients receiving placebo. Anaphylaxis was observed in 0.6% (9/1458) of patients receiving BENLYSTA and 0.4% (3/675) of patients receiving placebo. Manifestations included hypotension, angioedema, urticaria or other rash, pruritus, and dyspnea. Due to overlap in signs and symptoms, it was not possible to distinguish between hypersensitivity reactions and infusion reactions in all cases [see *Warnings and Precautions* (5.5)]. Some patients (13%) received premedication, which may have mitigated or masked a hypersensitivity response; however, there is insufficient evidence to determine whether premedication diminishes the frequency or severity of hypersensitivity reactions.

BENLYSTA should be administered by healthcare providers prepared to manage anaphylaxis. In the event of a serious reaction, administration of BENLYSTA must be discontinued immediately and appropriate medical therapy administered. Patients should be monitored during and for an appropriate period of time after administration of BENLYSTA. Patients should be informed of the signs and symptoms of a hypersensitivity reaction and instructed to seek immediate medical care should a reaction occur.

5.5 Infusion Reactions

In the controlled clinical trials, adverse events associated with the infusion (occurring on the same day of the infusion) were reported in 17% (251/1458) of patients receiving BENLYSTA and 15% (99/675) of patients receiving placebo. Serious infusion reactions (excluding hypersensitivity reactions) were reported in 0.5% of patients receiving BENLYSTA and 0.4% of patients receiving placebo and included bradycardia, myalgia, headache, rash, urticaria, and hypotension. The most common infusion reactions ($\geq 3\%$ of patients receiving BENLYSTA) were headache, nausea, and skin reactions. Due to overlap in signs and symptoms, it was not possible to distinguish between hypersensitivity reactions and infusion reactions in all cases [see *Warnings and Precautions* (5.4)]. Some patients (13%) received premedication, which may have mitigated or masked an infusion reaction; however there is insufficient evidence to determine whether premedication diminishes the frequency or severity of infusion reactions [see *Adverse Reactions* (6.1)].

BENLYSTA should be administered by healthcare providers prepared to manage infusion reactions. The infusion rate may be slowed or interrupted if the patient develops an infusion reaction. Healthcare providers should be aware of the risk of hypersensitivity reactions, which may present as infusion reactions, and monitor patients closely.

5.6 Depression

In the controlled clinical trials, psychiatric events were reported more frequently with BENLYSTA (16%) than with placebo (12%), related primarily to depression-related events (6.3% BENLYSTA and 4.7% placebo), insomnia (6.0% BENLYSTA and 5.3% placebo), and anxiety (3.9% BENLYSTA and 2.8% placebo). Serious psychiatric events were reported in 0.8% of patients receiving BENLYSTA (0.6% and 1.2% with 1 and 10 mg/kg, respectively) and 0.4% of patients receiving placebo. Serious depression was reported in 0.4% (6/1458) of patients receiving BENLYSTA and 0.1% (1/675) of patients receiving placebo. Two suicides (0.1%) were reported in patients receiving BENLYSTA. The majority of patients who reported serious depression or suicidal behavior had a history of depression or other serious psychiatric disorders and most were receiving psychoactive medications. It is unknown if BENLYSTA treatment is associated with increased risk for these events.

Patients receiving BENLYSTA should be instructed to contact their healthcare provider if they experience new or worsening depression, suicidal thoughts, or other mood changes.

5.7 Immunization

Live vaccines should not be given for 30 days before or concurrently with BENLYSTA as clinical safety has not been established. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving BENLYSTA or the effect of

BENLYSTA on new immunizations. Because of its mechanism of action, BENLYSTA may interfere with the response to immunizations.

5.8 Concomitant Use with Other Biologic Therapies or Intravenous Cyclophosphamide

BENLYSTA has not been studied in combination with other biologic therapies, including B-cell targeted therapies, or intravenous cyclophosphamide. Therefore, use of BENLYSTA is not recommended in combination with biologic therapies or intravenous cyclophosphamide.

6 ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:

- **Mortality** [see *Warnings and Precautions (5.1)*]
- **Serious Infections** [see *Warnings and Precautions (5.2)*]
- **Malignancy** [see *Warnings and Precautions (5.3)*]
- **Hypersensitivity Reactions, Including Anaphylaxis** [see *Warnings and Precautions (5.4)*]
- **Infusion reactions** [see *Warnings and Precautions (5.5)*]
- **Depression** [see *Warnings and Precautions (5.6)*]

6.1 Clinical Trials Experience

The data described below reflect exposure to BENLYSTA plus standard of care compared with placebo plus standard of care in 2133 patients in 3 controlled studies. Patients received BENLYSTA at doses of 1 mg/kg (N=673), 4 mg/kg (N=111; Trial 1 only), or 10 mg/kg (N=674) or placebo (N=675) intravenously over a 1-hour period on Days 0, 14, 28, and then every 28 days. In two of the studies (Trial 1 and Trial 3), treatment was given for 48 weeks, while in the other study (Trial 2) treatment was given for 72 weeks [see *Clinical Studies (14)*]. Because there was no apparent dose-related increase in the majority of adverse events observed with BENLYSTA, the safety data summarized below are presented for the 3 doses pooled, unless otherwise indicated; the adverse reaction table displays the results for the recommended dose of 10 mg/kg compared with placebo.

The population had a mean age of 39 (range 18-75), 94% were female, and 52% were Caucasian. In these trials, 93% of patients treated with BENLYSTA reported an adverse reaction compared with 92% treated with placebo.

The most common serious adverse reactions were serious infections (6.0% and 5.2% in the groups receiving BENLYSTA and placebo, respectively) [see *Warnings and Precautions (5.2)*].

The most commonly-reported adverse reactions, occurring in $\geq 5\%$ of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.

The proportion of patients who discontinued treatment due to any adverse reaction during the controlled clinical trials was 6.2% for patients receiving BENLYSTA and 7.1% for patients receiving placebo. The most common adverse reactions resulting in discontinuation of treatment ($\geq 1\%$ of patients receiving BENLYSTA or placebo) were infusion reactions (1.6% BENLYSTA and 0.9% placebo), lupus nephritis (0.7% BENLYSTA and 1.2% placebo), and infections (0.7% BENLYSTA and 1.0% placebo).

Table 1 lists adverse reactions, regardless of causality, occurring in at least 3% of patients with SLE who received BENLYSTA 10 mg/kg and at an incidence at least 1% greater than that observed with placebo in the 3 controlled studies.

Table 1 Incidence of Adverse Reactions Occurring in at Least 3% of Patients Treated With BENLYSTA 10 mg/kg Plus Standard of Care and at Least 1% More Frequently Than in Patients Receiving Placebo plus Standard of Care in 3 Controlled SLE Studies

Preferred Term	BENLYSTA 10 mg/kg + Standard of Care (n = 674) %	Placebo + Standard of Care (n = 675) %
Nausea	15	12
Diarrhea	12	9
Pyrexia	10	8
Nasopharyngitis	9	7
Bronchitis	9	5
Insomnia	7	5
Pain in extremity	6	4
Depression	5	4
Migraine	5	4
Pharyngitis	5	3
Cystitis	4	3
Leukopenia	4	2
Gastroenteritis viral	3	1

6.2 Immunogenicity

In Trials 2 and 3, anti-belimumab antibodies were detected in 4 of 563 (0.7%) patients receiving BENLYSTA 10 mg/kg and in 27 of 559 (4.8%) patients receiving BENLYSTA 1 mg/kg. The reported frequency for the group receiving 10 mg/kg may underestimate the actual frequency due to lower assay sensitivity in the presence of high drug concentrations. Neutralizing antibodies were detected in 3 patients receiving BENLYSTA 1 mg/kg. Three patients with anti-belimumab antibodies experienced mild infusion reactions of nausea, erythematous rash, pruritus, eyelid edema, headache, and dyspnea; none of the reactions was life-threatening. The clinical relevance of the presence of anti-belimumab antibodies is not known.

The data reflect the percentage of patients whose test results were positive for antibodies to belimumab in specific assays. The observed incidence of antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology,

sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to belimumab with the incidence of antibodies to other products may be misleading.

7 DRUG INTERACTIONS

Formal drug interaction studies have not been performed with BENLYSTA. In clinical trials of patients with SLE, BENLYSTA was administered concomitantly with other drugs, including corticosteroids, antimalarials, immunomodulatory and immunosuppressive agents (including azathioprine, methotrexate, and mycophenolate), angiotensin pathway antihypertensives, HMG-CoA reductase inhibitors (statins), and NSAIDs without evidence of a clinically meaningful effect of these concomitant medications on belimumab pharmacokinetics. The effect of belimumab on the pharmacokinetics of other drugs has not been evaluated [see *Pharmacokinetics 12.3*].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C. There are no adequate and well-controlled clinical studies using BENLYSTA in pregnant women. Immunoglobulin G (IgG) antibodies, including BENLYSTA, can cross the placenta. Because animal reproduction studies are not always predictive of human response, BENLYSTA should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. Women of childbearing potential should use adequate contraception during treatment with BENLYSTA and for at least 4 months after the final treatment.

Nonclinical reproductive studies have been performed in pregnant cynomolgus monkeys receiving belimumab at doses of 0, 5 and 150 mg/kg by intravenous infusion (the high dose was approximately 9 times the anticipated maximum human exposure) every 2 weeks from gestation day 20 to 150. Belimumab was shown to cross the placenta. Belimumab was not associated with direct or indirect teratogenicity under the conditions tested. Fetal deaths were observed in 14%, 24% and 15% of pregnant females in the 0, 5 and 150 mg/kg groups, respectively. Infant deaths occurred with an incidence of 0%, 8% and 5%. The cause of fetal and infant deaths is not known. The relevance of these findings to humans is not known. Other treatment-related findings were limited to the expected reversible reduction of B cells in both dams and infants and reversible reduction of IgM in infant monkeys. B-cell numbers recovered after the cessation of belimumab treatment by about 1 year post-partum in adult monkeys and by 3 months of age in infant monkeys. IgM levels in infants exposed to belimumab in utero recovered by 6 months of age.

Pregnancy Registry: To monitor maternal-fetal outcomes of pregnant women exposed to BENLYSTA, a pregnancy registry has been established. Healthcare professionals are encouraged to register patients and pregnant women are encouraged to enroll themselves by calling 1-877-681-6296.

8.3 Nursing Mothers

It is not known whether BENLYSTA is excreted in human milk or absorbed systemically after ingestion. However, belimumab was excreted into the milk of cynomolgus monkeys. Because

maternal antibodies are excreted in human breast milk, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of breastfeeding to the infant and the importance of the drug to the mother.

8.4 Pediatric Use

Safety and effectiveness of BENLYSTA have not been established in children.

8.5 Geriatric Use

Clinical studies of BENLYSTA did not include sufficient numbers of subjects aged 65 or over to determine whether they respond differently from younger subjects. Use with caution in elderly patients.

8.6 Race

In Trial 2 and Trial 3, response rates for the primary endpoint were lower for black subjects in the BENLYSTA group relative to black subjects in the placebo group [*see Clinical Studies (14)*]. Use with caution in black/African-American patients.

10 OVERDOSAGE

There is no clinical experience with overdosage of BENLYSTA. Two doses of up to 20 mg/kg have been given by intravenous infusion to humans with no increase in incidence or severity of adverse reactions compared with doses of 1, 4, or 10 mg/kg.

11 DESCRIPTION

BENLYSTA (belimumab) is a human IgG1 λ monoclonal antibody specific for soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B). Belimumab has a molecular weight of approximately 147 kDa. Belimumab is produced by recombinant DNA technology in a mammalian cell expression system.

BENLYSTA is supplied as a sterile, white to off-white, preservative-free, lyophilized powder for intravenous infusion. Upon reconstitution with Sterile Water for Injection, USP, [*see Dosage and Administration (2.3)*] each single-use vial delivers 80 mg/mL belimumab in 0.16 mg/mL citric acid, 0.4 mg/mL polysorbate 80, 2.7 mg/mL sodium citrate, and 80 mg/mL sucrose, with a pH of 6.5.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

BENLYSTA is a BLyS-specific inhibitor that blocks the binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells. BENLYSTA does not bind B cells directly, but by binding BLyS, BENLYSTA inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.

12.2 Pharmacodynamics

In Trial 1 and Trial 2 in which B cells were measured, treatment with BENLYSTA significantly reduced circulating CD19+, CD20+, naïve, and activated B cells, plasmacytoid cells, and the SLE B-cell subset at Week 52. Reductions in naïve and the SLE B-cell subset were observed as early as Week 8 and were sustained to Week 52. Memory cells increased initially and slowly

declined toward baseline levels by Week 52. The clinical relevance of these effects on B cells has not been established.

Treatment with BENLYSTA led to reductions in IgG and anti-dsDNA, and increases in complement (C3 and C4). These changes were observed as early as Week 8 and were sustained through Week 52. The clinical relevance of normalizing these biomarkers has not been definitively established.

12.3 Pharmacokinetics

The pharmacokinetic parameters displayed in Table 2 are based on population parameter estimates which are specific to the 563 patients who received belimumab 10 mg/kg in Trials 2 and 3 [see *Clinical Studies* (14)].

Table 2. Population Pharmacokinetic Parameters in Patients with SLE after Intravenous Infusion of BENLYSTA 10 mg/kg¹

Pharmacokinetic Parameter	Population Estimates (n = 563)
Peak concentration (C _{max} , µg/mL)	313
Area under the curve (AUC _{0-∞} , day•µg/mL)	3,083
Distribution half-life (t _{1/2} , days)	1.75
Terminal half-life (t _{1/2} , days)	19.4
Systemic clearance (CL, mL/day)	215
Volume of distribution (V _{ss} , L)	5.29

¹ Intravenous infusions were administered at 2-week intervals for the first 3 doses and at 4-week intervals thereafter.

Drug Interactions: No formal drug interaction studies have been conducted with belimumab. Concomitant use of mycophenolate, azathioprine, methotrexate, antimalarials, NSAIDs, aspirin, and HMG-CoA reductase inhibitors did not significantly influence belimumab pharmacokinetics. Coadministration of steroids and angiotensin-converting enzyme (ACE) inhibitors resulted in an increase of systemic clearance of belimumab that was not clinically significant because the magnitude was well within the range of normal variability of clearance. The effect of belimumab on the pharmacokinetics of other drugs has not been evaluated.

Special Populations:

The following information is based on the population pharmacokinetic analysis.

Age: Age did not significantly influence belimumab pharmacokinetics in the study population, where the majority of subjects (70%) were between 18 and 45 years of age. No pharmacokinetic data are available in pediatric patients. Limited pharmacokinetic data are available for elderly patients as only 1.4% of the subjects included in the pharmacokinetic analysis were 65 years of age or older [see *Use in Specific Populations* (8.5)].

Gender: Gender did not significantly influence belimumab pharmacokinetics in the largely (94%) female study population.

Race: Race did not significantly influence belimumab pharmacokinetics. The racial distribution was 53% white/Caucasian, 16% Asian, 16% Alaska native/American Indian, and 14% black/African American.

Renal Impairment: No formal studies were conducted to examine the effects of renal impairment on the pharmacokinetics of belimumab. Belimumab has been studied in a limited number of patients with SLE and renal impairment (261 subjects with moderate renal impairment, creatinine clearance ≥ 30 and < 60 mL/min; 14 subjects with severe renal impairment, creatinine clearance ≥ 15 and < 30 mL/min). Although increases in creatinine clearance and proteinuria (> 2 g/day) increased belimumab clearance, these effects were within the expected range of variability. Therefore, dosage adjustment in patients with renal impairment is not recommended.

Hepatic Impairment: No formal studies were conducted to examine the effects of hepatic impairment on the pharmacokinetics of belimumab. Belimumab has not been studied in patients with severe hepatic impairment. Baseline ALT and AST levels did not significantly influence belimumab pharmacokinetics.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal studies have not been performed to evaluate the carcinogenic potential of belimumab. The mutagenic potential of belimumab was not evaluated.

Effects on male and female fertility have not been directly evaluated in animal studies.

14 CLINICAL STUDIES

The safety and effectiveness of BENLYSTA were evaluated in three randomized, double-blind, placebo-controlled studies involving 2133 patients with SLE according to the American College of Rheumatology criteria (Trial 1, 2, and 3). Patients with severe active lupus nephritis and severe active CNS lupus were excluded. Patients were on a stable standard of care SLE treatment regimen comprising any of the following (alone or in combination): corticosteroids, antimalarials, NSAIDs, and immunosuppressives. Use of other biologics and intravenous cyclophosphamide were not permitted.

Trial 1: BENLYSTA 1 mg/kg, 4 mg/kg, 10 mg/kg

Trial 1 enrolled 449 patients and evaluated doses of 1, 4, and 10 mg/kg BENLYSTA plus standard of care compared with placebo plus standard of care over 52 weeks in patients with SLE. Patients had to have a SELENA-SLEDAI score of ≥ 4 at baseline and a history of autoantibodies (anti-nuclear antibody (ANA) and/or anti-double-stranded DNA (anti-dsDNA)), but 28% of the population was autoantibody negative at baseline. The co-primary endpoints were percent change in SELENA-SLEDAI score at Week 24 and time to first flare over 52 weeks. No significant differences between any of the BENLYSTA groups and the placebo group were observed. Exploratory analysis of this study identified a subgroup of patients (72%), who were autoantibody positive, in whom BENLYSTA appeared to offer benefit. The results of

this study informed the design of Trials 2 and 3 and led to the selection of a target population and indication that is limited to autoantibody-positive SLE patients.

Trials 2 and 3: BENLYSTA 1 mg/kg and 10 mg/kg

Trials 2 and 3 were randomized, double-blind, placebo-controlled trials in patients with SLE that were similar in design except duration - Trial 2 was 76 weeks duration and Trial 3 was 52 weeks duration. Eligible patients had active SLE disease, defined as a SELENA-SLEDAI score ≥ 6 , and positive autoantibody test results at screening. Patients were excluded from the study if they had ever received treatment with a B-cell targeted agent or if they were currently receiving other biologic agents. Intravenous cyclophosphamide was not permitted within the previous 6 months or during study. Trial 2 was conducted primarily in North America and Europe. Trial 3 was conducted in South America, Eastern Europe, Asia, and Australia.

Baseline concomitant medications included corticosteroids (Trial 2: 76%, Trial 3: 96%), immunosuppressives (Trial 2: 56%, Trial 3: 42%; including azathioprine, methotrexate and mycophenolate), and antimalarials (Trial 2: 63%, Trial 3: 67%). Most patients (>70%) were receiving 2 or more classes of SLE medications.

In Trial 2 and Trial 3, more than 50% of patients had 3 or more active organ systems at baseline. The most common active organ systems at baseline based on SELENA SLEDAI were mucocutaneous (82% in both studies); immunology (Trial 2: 74%, Trial 3: 85%); and musculoskeletal (Trial 2: 73%, Trial 3: 59%). Less than 16% of patients had some degree of renal activity and less than 7% of patients had activity in the vascular, cardio-respiratory, or CNS systems.

At screening, patients were stratified by disease severity based on their SELENA-SLEDAI score (≤ 9 vs ≥ 10), proteinuria level (< 2 g/24 hr vs ≥ 2 g/24 hr), and race (African or Indigenous-American descent vs. other), and then randomly assigned to receive BENLYSTA 1 mg/kg, BENLYSTA 10 mg/kg, or placebo in addition to standard of care. The patients were administered study medication intravenously over a 1-hour period on Days 0, 14, 28, and then every 28 days for 48 weeks in Trial 3 and for 72 weeks in Trial 2.

The primary efficacy endpoint was a composite endpoint (SLE Responder Index or SRI) that defined response as meeting each of the following criteria at Week 52 compared with baseline:

- ≥ 4 -point reduction in the SELENA-SLEDAI score, and
- no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores, and
- no worsening (< 0.30 -point increase) in Physician's Global Assessment (PGA) score.

The SRI uses the SELENA-SLEDAI score as an objective measure of reduction in global disease activity; the BILAG index to ensure no significant worsening in any specific organ system; and the PGA to ensure that improvements in disease activity are not accompanied by worsening of the patient's condition overall.

In both Trials 2 and 3, the proportion of SLE patients achieving an SRI response, as defined for the primary endpoint, was significantly higher in the BENLYSTA 10 mg/kg group than in the

placebo group in both studies. The effect on the SRI was not consistently significantly different for the BENLYSTA 1mg/kg group relative to placebo in both trials. The 1 mg/kg dose is not recommended. The trends in comparisons between the treatment groups for the rates of response for the individual components of the endpoint were generally consistent with that of the SRI (Table 3). At Week 76 in Trial 2, the SRI response rate with BENLYSTA 10 mg/kg was not significantly different from that of placebo (39% and 32%, respectively).

Table 3. Clinical Response Rate in Patients with SLE After 52 Weeks of Treatment

Response ¹	Trial 2			Trial 3		
	Placebo + Standard of Care (n = 275)	BENLYSTA 1 mg/kg + Standard of Care ² (n = 271)	BENLYSTA 10 mg/kg + Standard of Care (n = 273)	Placebo + Standard of Care (n = 287)	BENLYSTA 1 mg/kg + Standard of Care ² (n = 288)	BENLYSTA 10 mg/kg + Standard of Care (n = 290)
SLE Responder Index	34%	41%	43%	44%	51%	58%
		(p = 0.104)	(p = 0.021)		(p = 0.013)	(p < 0.001)
Odds Ratio (95% CI) vs. placebo		1.3 (0.9, 1.9)	1.5 (1.1, 2.2)		1.6 (1.1, 2.2)	1.8 (1.3, 2.6)
Components of SLE Responder Index						
Percent of patients with reduction in SELENA-SLEDAI ≥ 4	36%	43%	47%	46%	53%	58%
Percent of patients with no worsening by BILAG index	65%	75%	69%	73%	79%	81%
Percent of patients with no worsening by PGA	63%	73%	69%	69%	79%	80%

¹Patients dropping out of the study early or experiencing certain increases in background medication were considered as failures in these analyses. In both studies, a higher proportion of placebo patients were considered as failures for this reason as compared to the BENLYSTA groups.

²The 1 mg/kg dose is not recommended.

The reduction in disease activity seen in the SRI was related primarily to improvement in the most commonly involved organ systems namely, mucocutaneous, musculoskeletal, and immunology.

Effect in Black/African-American Patients

Exploratory sub-group analyses of SRI response rate in patients of black race were performed. In Trial 2 and Trial 3 combined, the SRI response rate in black patients (N=148) in the BENLYSTA groups was less than that in the placebo group (22/50 or 44% for placebo, 15/48 or 31% for BENLYSTA 1 mg/kg, and 18/50 or 36% for BENLYSTA 10 mg/kg). In Trial 1, black patients (N=106) in the BENLYSTA groups did not appear to have a different response than the

rest of the study population. Although no definitive conclusions can be drawn from these subgroup analyses, caution should be used when considering BENLYSTA treatment in black/African-American SLE patients.

Effect on Concomitant Steroid Treatment:

In Trial 2 and Trial 3, 46% and 69% of patients, respectively, were receiving prednisone at doses > 7.5 mg/day at baseline. The proportion of patients able to reduce their average prednisone dose by at least 25% to ≤7.5 mg/day during Weeks 40 through 52 was not consistently significantly different for BENLYSTA relative to placebo in both trials. In Trial 2, 17% of patients receiving BENLYSTA 10 mg/kg and 19% of patients receiving BENLYSTA 1 mg/kg achieved this level of steroid reduction compared with 13% of patients receiving placebo. In Trial 3, 19%, 21%, and 12% of patients receiving BENLYSTA 10 mg/kg, BENLYSTA 1 mg/kg, and placebo, respectively, achieved this level of steroid reduction.

Effect on Severe SLE Flares:

The probability of experiencing a severe SLE flare, as defined by a modification of the SELENA Trial flare criteria which excluded severe flares triggered only by an increase of the SELENA-SLEDAI score to >12, was calculated for both Trials 2 and 3. The proportion of patients having at least 1 severe flare over 52 weeks was not consistently significantly different for BENLYSTA relative to placebo in both trials. In Trial 2, 18% of patients receiving BENLYSTA 10 mg/kg and 16% of patients receiving BENLYSTA 1 mg/kg had a severe flare compared with 24% of patients receiving placebo. In Trial 3, 14%, 18%, and 23% of patients receiving BENLYSTA 10 mg/kg, BENLYSTA 1 mg/kg and placebo, respectively, had a severe flare.

16 HOW SUPPLIED/STORAGE AND HANDLING

BENLYSTA is a sterile, preservative-free lyophilized powder for reconstitution, dilution, and intravenous infusion provided in single-use glass vials with a latex-free rubber stopper and a flip-off seal. Each 5-mL vial contains 120 mg of belimumab. Each 20-mL vial contains 400 mg of belimumab.

BENLYSTA is supplied as follows:

120 mg belimumab in a 5-mL single-use vial	NDC 49401-101-01
400 mg belimumab in a 20-mL single-use vial	NDC 49401-102-01

Store vials of BENLYSTA refrigerated between 2° to 8°C (36° to 46°F). Vials should be protected from light and stored in the original carton until use. *Do not freeze.* Avoid exposure to heat. Do not use beyond the expiration date.

17 PATIENT COUNSELING INFORMATION

See Medication Guide.

17.1 Advice for the Patient

Patients should be given the Medication Guide for BENLYSTA and provided an opportunity to read it prior to each treatment session. It is important that the patient's overall health be assessed at each infusion visit and any questions resulting from the patient's reading of the Medication Guide be discussed.

Mortality: Patients should be advised that more patients receiving BENLYSTA in the main clinical trials died than did patients receiving placebo treatment [see *Warnings and Precautions (5.1)*].

Serious Infections: Patients should be advised that BENLYSTA may decrease their ability to fight infections. Patients should be asked if they have a history of chronic infections and if they are currently on any therapy for an infection [see *Warnings and Precautions (5.2)*]. Patients should be instructed to tell their healthcare provider if they develop signs or symptoms of an infection.

Hypersensitivity/Anaphylactic and Infusion Reactions: Educate patients on the signs and symptoms of anaphylaxis, including wheezing, difficulty breathing, peri-oral or lingual edema, and rash. Patients should be instructed to immediately tell their healthcare provider if they experience symptoms of an allergic reaction during or after the administration of BENLYSTA [see *Warnings and Precautions (5.4, 5.5)*].

Depression: Patients should be instructed to contact their healthcare provider if they experience new or worsening depression, suicidal thoughts or other mood changes. [see *Warnings and Precautions (5.6)*].

Immunizations: Patients should be informed that they should not receive live vaccines while taking BENLYSTA. Response to vaccinations could be impaired by BENLYSTA [see *Warnings and Precautions (5.7)*].

Pregnancy and Nursing Mothers: Patients should be informed that BENLYSTA has not been studied in pregnant women or nursing mothers so the effects of BENLYSTA on pregnant women or nursing infants are not known. Patients should be instructed to tell their healthcare provider if they are pregnant, become pregnant, or are thinking about becoming pregnant [see *Use in Specific Populations (8.1)*]. Patients should be instructed to tell their healthcare provider if they plan to breastfeed their infant [see *Use in Specific Populations (8.3)*].


566 BENLYSTA is a registered trademark of Human Genome Sciences, Inc., used under license by
567 GlaxoSmithKline.

568
569 Manufactured by:
570 Human Genome Sciences, Inc.
571 Rockville, Maryland 20850
572 U.S. License No. 1820

573
574 Marketed by:

**HUMAN
GENOME
SCIENCES**

575 Human Genome Sciences, Inc.
576 Rockville, MD 20850
577



578 ©2011, Human Genome Sciences, Inc. All rights reserved.

MEDICATION GUIDE

BENLYSTA[®] (ben-LIST-ah) (belimumab)

Injection for intravenous use

Read this Medication Guide before you start receiving BENLYSTA and before each treatment. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.

What is the most important information I should know about BENLYSTA?

BENLYSTA can cause serious side effects. Some of these side effects may cause death. It is not known if BENLYSTA causes these serious side effects. Tell your healthcare provider right away if you have any of the symptoms listed below while receiving BENLYSTA.

1. Infections. Symptoms of an infection can include:

- fever
- chills
- pain or burning with urination
- urinating often
- bloody diarrhea
- coughing up mucus

2. Heart Problems. Symptoms of heart problems can include:

- chest discomfort or pain
- shortness of breath
- cold sweats
- nausea
- dizziness
- discomfort in other areas of the upper body

3. Mental health problems and suicide. Symptoms of mental health problems can include:

- thoughts of suicide or dying
- attempt to commit suicide
- trouble sleeping (insomnia)
- new or worse anxiety
- new or worse depression
- acting on dangerous impulses
- other unusual changes in your behavior or mood
- thoughts of hurting yourself or others

37 **What is BENLYSTA?**

38 BENLYSTA is a prescription medicine used to treat adults with active systemic lupus
39 erythematosus (SLE or lupus) who are receiving other lupus medicines.

40 BENLYSTA contains *belimumab* which is in a group of medicines called *monoclonal*
41 *antibodies*. Lupus is a disease of the immune system (the body system that fights infection).
42 People with active lupus often have high levels of a certain protein in their blood. BENLYSTA
43 binds to and limits the activity of the protein. When given together with other medicines for
44 lupus, BENLYSTA decreases lupus disease activity more than other lupus medicines alone.

- 45 • It is not known if BENLYSTA is safe and effective in people with severe active lupus
46 nephritis or severe active central nervous system lupus.
47 • It is not known if BENLYSTA is safe and effective in children.

48 **Who should not receive BENLYSTA?**

49 **Do not receive BENLYSTA if you:**

- 50 • are allergic to belimumab or any of the ingredients in BENLYSTA. See the end of this
51 Medication Guide for a complete list of ingredients in BENLYSTA.

52 **What should I tell my healthcare provider before receiving BENLYSTA?**

53 Before you receive BENLYSTA, tell your healthcare provider if you:

- 54 • think you have an infection or have infections that keep coming back. You should not
55 receive BENLYSTA if you have an infection unless your healthcare provider tells you to.
56 **See “What is the most important information I should know about BENLYSTA.”**
57 • have or have had mental health problems such as depression or thoughts of suicide
58 • have recently received a vaccination or if you think you may need a vaccination. If you
59 are receiving BENLYSTA, you should not receive live vaccines.
60 • are receiving other biologic medicines, monoclonal antibodies or IV infusions of
61 cyclophosphamide (Cytosan[®])
62 • have or have had any type of cancer
63 • have any other medical conditions
64 • are pregnant or plan to become pregnant. It is not known if BENLYSTA will harm your
65 unborn baby. Tell your healthcare provider if you become pregnant during your treatment
66 with BENLYSTA.
67 • If you become pregnant while receiving BENLYSTA, talk to your healthcare provider
68 about enrolling in the BENLYSTA Pregnancy Registry. You can enroll in this
69 registry by calling 1-877-681-6296. The purpose of this registry is to monitor the
70 health of you and your baby.

- 71 • are breastfeeding or plan to breastfeed. It is not known if BENLYSTA passes into your
72 breast milk. You and your healthcare provider should decide if you will receive
73 BENLYSTA or breastfeed. You should not do both.
- 74 **Tell your healthcare provider about all the medicines you take**, including prescription and
75 non-prescription medicines, vitamins, and herbal supplements.
- 76 Know the medicines you take. Keep a list of your medicines with you to show to your
77 healthcare provider and pharmacist when you get a new medicine.
- 78 **How will I receive BENLYSTA?**
- 79 • You will be given BENLYSTA by a healthcare provider through a needle placed in a
80 vein (IV infusion). It takes about 1 hour to give you the full dose of BENLYSTA.
81 • Your healthcare provider will tell you how often you should receive BENLYSTA.
82 • Your healthcare provider may give you medicines before you receive BENLYSTA to
83 help reduce your chance of having a reaction. A healthcare provider will watch you
84 closely while you are receiving BENLYSTA and after your infusion for signs of a
85 reaction.
- 86 **What are the possible side effects of BENLYSTA?**
- 87 **BENLYSTA can cause serious side effects.**
- 88 • See “What is the most important information I should know about BENLYSTA?”
- 89 **1. Cancer.** BENLYSTA may reduce the activity of your immune system. Medicines that affect
90 the immune system may increase your risk of certain cancers.
- 91 **2. Allergic (hypersensitivity) and infusion reactions.** Serious allergic or infusion reactions
92 can happen on the day of or the day after receiving BENLYSTA. Symptoms of an allergic or
93 infusion reaction may include:
- 94 • itching
95 • swelling of the face, lips, mouth, tongue, or throat
96 • trouble breathing
97 • anxiousness
98 • low blood pressure
99 • dizziness or fainting
100 • headache
101 • nausea
102 • skin rash, redness, or swelling

Your healthcare provider will watch you closely while you are receiving BENLYSTA and after your infusion for signs of a reaction.

The most common side effects of BENLYSTA include:

- nausea
- diarrhea
- fever
- stuffy or runny nose
- sore throat
- cough (bronchitis)
- trouble sleeping
- leg or arm pain
- headache (migraine)
- urinary tract infection
- decreased white blood cell count (leukopenia)
- vomiting
- stomach pain

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of BENLYSTA. For more information, ask your healthcare provider.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of BENLYSTA

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BENLYSTA for a condition for which it was not prescribed.

This Medication Guide summarizes the most important information about BENLYSTA. For more information about BENLYSTA, talk with your healthcare provider.

You can ask your healthcare provider or pharmacist for information about BENLYSTA that is written for healthcare professionals.

For more information about BENLYSTA, go to www.BENLYSTA.com or call 1-877-423-6597.

What are the ingredients in BENLYSTA?

Active ingredient: belimumab.


Inactive ingredients: citric acid, polysorbate 80, sodium citrate, sucrose.

137 RX Only
138
139 BENLYSTA is a registered trademark of Human Genome Sciences, Inc., used under license by
140 GlaxoSmithKline.

141 Manufactured by
142 Human Genome Sciences, Inc.
143 Rockville, Maryland 20850
144 U.S. License No. 1820

145 Marketed by
**HUMAN
GENOME
SCIENCES**

146 Human Genome Sciences, Inc.
147 Rockville, MD 20850



148 This Medication Guide has been approved by the U.S. Food and Drug Administration.

149 Issued: March 2011

150 ©2011, Human Genome Sciences, Inc. All rights reserved.

U.S. Patent No. 7,138,501

Application for Patent Term Extension

Attachment D



US007138501B2

(12) **United States Patent**
Ruben et al.

(10) **Patent No.:** **US 7,138,501 B2**
(45) **Date of Patent:** **Nov. 21, 2006**

(54) **ANTIBODIES THAT
IMMUNOSPECIFICALLY BIND BLYS**

(75) Inventors: **Steven M. Ruben**, Olney, MD (US);
Gil H. Choi, Rockville, MD (US);
Tristan Vaughan, Great Shelford (GB);
David Hilbert, Bethesda, MD (US)

(73) Assignee: **Human Genome Sciences, Inc.**,
Rockville, MD (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 754 days.

WO	WO00/26244	A2	5/2000
WO	WO00/39295	A1	7/2000
WO	WO00/40716	A2	7/2000
WO	WO00/43032	A2	7/2000
WO	WO00/45836	A1	8/2000
WO	WO00/47740	A2	8/2000
WO	WO00/50597	A2	8/2000
WO	WO00/60079	A2	10/2000
WO	WO00/67034	A1	11/2000
WO	WO00/68378	A1	11/2000
WO	WO00/77256	A1	12/2000
WO	WO01/40466	A2	6/2001
WO	WO01/87977	A2	11/2001

(21) Appl. No.: **09/880,748**

(22) Filed: **Jun. 15, 2001**

(65) **Prior Publication Data**

US 2003/0059937 A1 Mar. 27, 2003

Related U.S. Application Data

(60) Provisional application No. 60/293,499, filed on May
25, 2001, provisional application No. 60/277,379,
filed on Mar. 21, 2001, provisional application No.
60/276,248, filed on Mar. 16, 2001, provisional appli-
cation No. 60/240,816, filed on Oct. 17, 2000, pro-
visional application No. 60/212,210, filed on Jun. 16,
2000.

(51) **Int. Cl.**

C07K 16/00 (2006.01)

C12P 21/08 (2006.01)

(52) **U.S. Cl.** **530/388.23**; 530/387.1;
530/387.3; 530/387.9; 530/388.15; 530/391.1;
530/391.3; 530/391.7

(58) **Field of Classification Search** 530/387.1,
530/387.3, 387.9, 388.1, 388.15, 388.23,
530/389.1, 389.2, 391.1, 391.3, 391.7; 435/326,
435/328, 331, 335

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,297,367	B1	10/2001	Tribouley
6,403,770	B1	6/2002	Yu et al.
6,562,579	B1	5/2003	Yu et al.
2001/0010925	A1	8/2001	Wiley
2002/0055624	A1	5/2002	Wiley
2003/0012783	A1	1/2003	Kindsvogel

FOREIGN PATENT DOCUMENTS

EP	0869180	A1	10/1998
EP	0921194	A2	6/1999
WO	WO97/33902	A1	9/1997
WO	WO98/18921	A1	5/1998
WO	WO98/27114	A2	6/1998
WO	WO98/55620	A1	12/1998
WO	WO98/55621	A1	12/1998
WO	WO99/11791	A2	3/1999
WO	WO99/12964	A2	3/1999
WO	WO99/33980	A2	7/1999

OTHER PUBLICATIONS

Kennell, D.E., Prog. Nucl. Acid Res. Med. Biol, 11:259-301 1971.*
Kabat et al Sequences of Proteins of Immunological Interest Forth
Edition, 1987, pp. 44, 53, 54, 63, 69, 70, and 76.*
Ashkenazi, et al., Response, Nature Immunology, (2000) 1:179.
Baumgarth, Nicole, Secreted IgM versus BLYS in Germinal Center
Formation, Nature Immunology, (2000) 1:179.
Batten et al., BFF Mediates Survival of Peripheral Immature B
Lymphocytes. The Journal of Experimental Medicine, (2000)
192:1453-65.
Cheema et al., Elevated Serum B Lymphocyte Stimulator Levels in
Patients with Systemic Immune-Based Rheumatic Diseases, Arthri-
tis and Rheumatism (2001) 44:1313-1319.
Cyster, Jason G., B Cells on the Front Line, Nature Immunology,
(2000) 1:9-10.
Do et al., Attenuation of Apoptosis Underlies B Lymphocyte
Stimulator Enhancement of Humoral Immune Response, The Jour-
nal of Experimental Medicine, (2000) 192: 953-964.
Dorner and Putterman, B cells, BAFF/zTNF4, TACI, and Systemic
Lupus Erythematosus, Arthritis Research (2001) 3:197-9.

(Continued)

Primary Examiner—Patricia A. Duffy

(74) *Attorney, Agent, or Firm*—Human Genome Sciences,
Inc.

(57) **ABSTRACT**

The present invention relates to antibodies and related
molecules that immunospecifically bind to B Lymphocyte
Stimulator. The present invention also relates to methods
and compositions for detecting or diagnosing a disease or
disorder associated with aberrant B Lymphocyte Stimulator
expression or inappropriate function of B Lymphocyte
Stimulator comprising antibodies or fragments or variants
thereof or related molecules that immunospecifically bind to
B Lymphocyte Stimulator. The present invention further
relates to methods and compositions for preventing, treating
or ameliorating a disease or disorder associated with aber-
rant B Lymphocyte Stimulator expression or inappropriate B
Lymphocyte Stimulator function comprising administering
to an animal an effective amount of one or more antibodies
or fragments or variants thereof or related molecules that
immunospecifically bind to B Lymphocyte Stimulator.

37 Claims, 16 Drawing Sheets

OTHER PUBLICATIONS

Gross et al., TACI and BCMA are receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease, *Nature*, (2000) 404:995-999.

Hatzoglou et al., TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, TRAF3 and Activates NF- κ B, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase, *The Journal of Immunology*, (2000) 165:1322-1330.

Hu et al., Characterization of TNFRSF19, a Novel Member of the Tumor Necrosis Factor Receptor Superfamily, *Genomics*, 62:1023-107 (1999).

Khare et al., Severe B Cell Hyperplasia and autoimmune disease in TALL-1 transgenic mice, *The Proceedings of the National Academy of Sciences*, (2000) 97:3370-3375.

Laabi et al., Lymphocyte Survival-Ignorance is BLyS, *Science*, (2001) 289:883.

Mackay et al., Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations, *The Journal of Experimental Medicine*, (1999) 190:1697-1710.

Marsters, et al., Interaction of the TNF Homologues BLyS and APRIL with the TNF Receptor Homologues BCMA and TACI, *Current Biology*, (2000) 10:785-788.

Moore et al., BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator, *Science*, (1999) 285:260-263.

Mukhopadhyay et al., Identification and Characterization of a Novel Cytokine, THANK, A TNF Homologue That Activates Apoptosis, Nuclear Factor- κ B, c-Jun NH2 Terminal Kinase (1999) *The Journal of Biological Chemistry* 274:15978-81.

Nardelli et al., Synthesis and Release of B-Lymphocyte Stimulator from Myeloid Cells, *Blood*, (2001) 97:198-204.

Parry et al., Pharmacokinetics and Immunological Effects of Exogenously Administered Recombinant Human B Lymphocyte Stimulator (BLyS) in Mice, *The Journal of Pharmacology and Experimental Therapeutics*, (2001) 296:396-404.

Schneider et al., BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth, *The Journal of Experimental Medicine*, (1999) 189:1747-1756.

Shu et al., TALL-1 is a Novel Member of the TNF Family that is Down-Regulated by Mitogens, *Journal of Leukocyte Biology*, (1999) 65:680-683.

Thompson et al., BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population, *The Journal of Experimental Medicine*, (2000) 192:129-135.

Tribouley et al., Characterization of a New Member of the TNF Family Expressed on Antigen Presenting Cells, (1999) *Biological Chemistry* 380:1443-7.

Ware, Carl, APRIL and BAFF Connect Autoimmunity and Cancer. *The Journal of Experimental Medicine* (2000) 192:F35-F37.

Xia et al., TACI Is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation, *The Journal of Experimental Medicine*, (2000) 192:137-143.

Yan et al., Identification of a receptor for BLyS Demonstrates a Crucial Role in Humoral Immunity, *Nature Immunology*, (2000) 1:37-41.

Yu et al., APRIL and TALL-1 and Receptors BCMA and TACI: System for Regulating Humoral Immunity, *Nature Immunology*, (2000) 1:252-256.

Zhang et al., Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus, *The Journal of Immunology*, (2001) 166:6-10.

Kanakaraj et al., BLyS Binds to B Cells With High Affinity and Induces Activation of the Transcription Factors NF- κ B and Elk-1, *Cytokine* (2001) 13:25-31.

Wu et al., Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI Is a High Affinity Receptor for TNF Family Members APRIL and BLyS, *The Journal of Biological Chemistry* (2000) 275:35478-35485.

* cited by examiner





FIG. 2







FIG. 3












FIG. 8










FIG. 11
Scfvs to soluble BLyS only








FIG. 14
Plate I079 Sensorgram - 8 Clones






FIG. 15
I082C03 Sensorgram



P388 Competition ELISA

**FIG. 16**

1

ANTIBODIES THAT IMMUNOSPECIFICALLY BIND BLYS

INTRODUCTION

The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator (BLyS™) protein. The present invention also relates to methods and compositions for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor expression or inappropriate function of B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor, comprising antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor expression or inappropriate B Lymphocyte Stimulator function or B Lymphocyte Stimulator receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to B Lymphocyte Stimulator.

BACKGROUND OF THE INVENTION

B Lymphocyte Stimulator (BLyS™) protein is a member of the tumor necrosis factor ("TNF") superfamily that induces both in vivo and in vitro B cell proliferation and differentiation (Moore et al., Science 285: 260-263 (1999)). B Lymphocyte Stimulator is distinguishable from other B cell growth and differentiation factors such as IL-2, IL-4, IL-5, IL-6, IL-7, IL-13, IL-15, CD40L, or CD27L (CD70) by its monocyte-specific gene and protein expression pattern and its specific receptor distribution and biological activity on B lymphocytes. B Lymphocyte Stimulator expression is not detected on natural killer ("NK") cells, T cells or B cells, but is restricted to cells of myeloid origin. B Lymphocyte Stimulator expression on resting monocytes is upregulated by interferon-gamma (IFN-gamma). The gene encoding B Lymphocyte Stimulator has been mapped to chromosome 13q34.

B Lymphocyte Stimulator is expressed as a 285 amino acid type II membrane-bound polypeptide and a soluble 152 amino acid polypeptide (Moore et al., 1999 supra). The membrane-bound form of B Lymphocyte Stimulator has a predicted transmembrane spanning domain between amino acid residues 47 and 73. The NH₂-terminus of the soluble form of B Lymphocyte Stimulator begins at Ala¹³⁴ of the membrane-bound form of B Lymphocyte Stimulator. Soluble recombinant B Lymphocyte Stimulator has been shown to induce in vitro proliferation of murine splenic B cells and to bind to a cell-surface receptor on these cells (Moore et al., 1999 supra). Soluble B Lymphocyte Stimulator administration to mice has been shown to result in an increase in the proportion of CD45R^{dull}, Ly6D^{bright} (also known as ThB) B cells and an increase in serum IgM and IgA levels (Moore et al., 1999 supra). Thus, B Lymphocyte Stimulator displays a B cell tropism in both its receptor distribution and biological activity.

Based upon its expression pattern and biological activity, B Lymphocyte Stimulator has been suggested to be involved in the exchange of signals between B cells and monocytes or their differentiated progeny. The restricted expression patterns of B Lymphocyte Stimulator receptor and ligand

2

suggest that B Lymphocyte Stimulator may function as a regulator of T cell-independent responses in a manner analogous to that of CD40 and CD40L in T cell-dependent antigen activation. As such, antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator may find medical utility in, for example, the treatment of B cell disorders associated with autoimmunity, neoplasia, or immunodeficiency syndromes.

SUMMARY OF THE INVENTION

The present invention encompasses antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to a polypeptide or polypeptide fragment of B Lymphocyte Stimulator. In particular, the invention encompasses antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to a polypeptide or polypeptide fragment of human B Lymphocyte Stimulator (SEQ ID NOS:3228 and/or 3229) or B Lymphocyte Stimulator expressed on human monocytes; murine B Lymphocyte Stimulator (SEQ ID NOS:3230 and/or 3231) or B Lymphocyte Stimulator expressed on murine monocytes; rat B Lymphocyte Stimulator (either the soluble forms as given in SEQ ID NOS:3232, 3233, 3234 and/or 3235 or in a membrane associated form, e.g., on the surface of rat monocytes); or monkey B Lymphocyte Stimulator (e.g., the monkey B Lymphocyte Stimulator polypeptides of SEQ ID NOS:3236 and/or 3237, the soluble form of monkey B Lymphocyte Stimulator, or B Lymphocyte Stimulator expressed on monkey monocytes), preferably human B Lymphocyte Stimulator. The present invention also encompasses methods and compositions for detecting, diagnosing, or prognosing diseases or disorders associated with aberrant B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor expression or inappropriate function of B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor in an animal, preferably a mammal, and most preferably a human, comprising, or alternatively consisting of, use of antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to B Lymphocyte Stimulator. Diseases and disorders which can be detected, diagnosed, or prognosed with the antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) of the invention include, but are not limited to, immune disorders (e.g., lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, Hashimoto's disease, and immunodeficiency syndrome), inflammatory disorders (e.g., asthma, allergic disorders, and rheumatoid arthritis), infectious diseases (e.g., AIDS), and proliferative disorders (e.g., leukemia, carcinoma, and lymphoma). The present invention further encompasses methods and compositions for preventing, treating or ameliorating diseases or disorders associated with aberrant B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor expression or inappropriate function of B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor in an animal, preferably a mammal, and most preferably a human, comprising, or alternatively consisting of, administering to said animal an effective amount of one or more antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to B Lymphocyte Stimulator. Diseases and disorders which can be prevented, treated or ameliorated by administering an effective amount of an antibody of the invention include, but are not limited to,

immune disorders (e.g., lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, Hashimoto's disease, and immunodeficiency syndrome), inflammatory disorders (e.g., asthma, allergic disorders, and rheumatoid arthritis), infectious diseases (e.g., AIDS), and proliferative disorders (e.g., leukemia, carcinoma, and lymphoma).

Using phage display technology, the present inventors have identified single chain antibody molecules ("scFvs") that immunospecifically bind to B Lymphocyte Stimulator, including scFvs that immunospecifically bind to soluble B Lymphocyte Stimulator, scFvs that immunospecifically bind the membrane-bound form of B Lymphocyte Stimulator, and scFvs that immunospecifically bind to both the soluble form and the membrane-bound form of B Lymphocyte Stimulator. Molecules comprising, or alternatively consisting of, fragments or variants of these scFvs (e.g., including VH domains, VH CDRs, VL domains, or VL CDRs having an amino acid sequence of any one of those referred to in Table 1), that immunospecifically bind the soluble form of B Lymphocyte Stimulator, the membrane-bound form of B Lymphocyte Stimulator, and/or both the soluble form and membrane-bound form of B Lymphocyte Stimulator, are also encompassed by the invention, as are nucleic acid molecules that encode these scFvs, and/or molecules.

In particular, the invention relates to scFvs comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-2128, preferably SEQ ID NOS:834-872, 1570-1595, and 1886-1908, and most preferably SEQ ID NOS:1-46, 321-329, 1563-1569, and 1881-1885, as referred to in Table 1 below. In specific embodiments, the present invention relates to scFvs that immunospecifically bind the soluble form of B Lymphocyte Stimulator, said scFvs comprising, or alternatively consisting of, an amino acid sequence of SEQ ID NOS: 1563-1569, preferably SEQ ID NOS:1570-1595, and most preferably SEQ ID NOS: 1563-1569, as referred to in Table 1, below. In other embodiments, the present invention also relates to scFvs that immunospecifically bind the membrane-bound form of B Lymphocyte Stimulator, said scFvs comprising, or alternatively consisting of, an amino acid sequence of SEQ ID NOS: 1881-2128, preferably SEQ ID NOS:1886-1908, and most preferably SEQ ID NOS: 1881-1885, as referred to in Table 1 below. The present invention further relates to scFvs that immunospecifically bind both the membrane-bound form and soluble form of B Lymphocyte Stimulator, said scFvs comprising, or alternatively consisting of, an amino acid sequence of SEQ ID NOS: 1-1562, preferably SEQ ID NOS: 834-872, and most preferably SEQ ID NOS: 1-46, and 321-329, as referred to in Table 1 below. Molecules comprising, or alternatively consisting of, fragments or variants of these scFvs (e.g., including VH domains, VH CDRs, VL domains, or VL CDRs having an amino acid sequence of any one of those referred to in Table 1), that immunospecifically bind the soluble form of B Lymphocyte Stimulator, the membrane-bound form of B Lymphocyte Stimulator, and/or both the soluble form and membrane-bound form of B Lymphocyte Stimulator, are also encompassed by the invention, as are nucleic acid molecules that encode these scFvs, and/or molecules.

The present invention provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to a polypeptide or polypeptide fragment of B Lymphocyte Stimulator, said antibodies comprising, or alternatively consisting of, a polypeptide having the amino acid sequence of any one of the variable heavy ("VH") domains referred to in

Table 1, below, or any one of the variable light ("VL") domains referred to in Table 1. In a preferred embodiment, antibodies of the present invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VH domain contained in SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908, as referred to in Table 1 below. In another preferred embodiment, antibodies (including molecules comprising or alternatively consisting of, antibody fragments or variants thereof) of the present invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VL domain contained in SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908, as referred to in Table 1 below. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies (e.g., including VH domains, VH CDRs, VL domains, or VL CDRs having an amino acid sequence of any one of those referred to in Table 1), that immunospecifically bind the soluble form of B Lymphocyte Stimulator, the membrane-bound form of B Lymphocyte Stimulator, and/or both the soluble form and membrane-bound form of B Lymphocyte Stimulator, are also encompassed by the invention, as are nucleic acid molecules that encode these antibodies, and/or molecules.

The present invention also provides antibodies (including molecules comprising or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to a polypeptide or a polypeptide fragment of B Lymphocyte Stimulator, said antibodies comprising, or alternatively consisting of, a polypeptide having the amino acid sequence of any one of the VH domains referred to in Table 1, below, and any one of the VL domains referred to in Table 1. In a preferred embodiment, the antibodies of the invention comprise or alternatively consist of, a polypeptide having the amino acid sequence of a VH and VL domain contained in the same scFv referred to in Table 1. In another preferred embodiment, antibodies of the present invention, comprise, or alternatively consist of, a VH domain from an scFv of SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908, as disclosed in Table 1, and a VL domain from an scFv SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908, as disclosed in Table 1. In another preferred embodiment, antibodies of the present invention comprise, or alternatively consist of, the VH and VL domain from a single scFv of SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908, as disclosed in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies (e.g., including VH domains, VH CDRs, VL domains, or VL CDRs having an amino acid sequence of any one of those referred to in Table 1), that immunospecifically bind the soluble form of B Lymphocyte Stimulator, the membrane-bound form of B Lymphocyte Stimulator, and/or both the soluble form and membrane-bound form of B Lymphocyte Stimulator, are also encompassed by the invention, as are nucleic acid molecules that encode these antibodies, and/or molecules.

The present invention also provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to a polypeptide or a polypeptide fragment of B Lymphocyte Stimulator, said antibodies comprising, or alternatively consisting of, a polypeptide having the amino acid sequence of any one, two, three or more of the VH complementarity determining regions ("CDRs") (i.e., VH CDR1, VH CDR2, or VH CDR3) referred to in Table 1 and/or any one, two, three or more of the VL CDRs (i.e., VL CDR1, VL CDR2, or VL CDR3) referred to in Table 1. In one embodiment, antibodies of the present invention com-

5

prise, or alternatively consist of, a polypeptide having the amino acid sequence of any one of the VH CDR1s referred to in Table 1 and/or any one of the VL CDR1s referred to in Table 1. In another embodiment, antibodies of the present invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one of the VH CDR2s referred to in Table 1 and/or any one of the VL CDR2s referred to in Table 1. In a preferred embodiment, antibodies of the present invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one of the VH CDR3s referred to in Table 1 and/or any one of the VL CDR3s referred to in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies (e.g., including VH domains, VH CDRs, VL domains, or VL CDRs having an amino acid sequence of any one of those referred to in Table 1), that immunospecifically bind the soluble form of B Lymphocyte Stimulator, the membrane-bound form of B Lymphocyte Stimulator, and/or both the soluble form and membrane-bound form of B Lymphocyte Stimulator, are also encompassed by the invention, as are nucleic acid molecules that encode these antibodies, and/or molecules.

In another embodiment, antibodies of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) immunospecifically bind to a polypeptide or polypeptide fragment of B Lymphocyte Stimulator, and comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one of the VH CDR1s referred to in Table 1, any one of the VH CDR2s referred to in Table 1, and/or any one of the VH CDR3s referred to in Table 1. In another embodiment, antibodies of the present invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one of the VL CDR1s referred to in Table 1, any one of the VL CDR2s referred to in Table 1, and/or any one of the VL CDR3s referred to in Table 1. In a preferred embodiment, antibodies of the present invention comprise, or alternatively consist of, at least one, two, three, four, five, six, or more CDRs that correspond to the same scFv referred to in Table 1, more preferably where CDR1, CDR2, and CDR3 of the VL domain correspond to the same scFv or where CDR1, CDR2, and CDR3 of the VH domain correspond to the same scFv, and most preferably where all six CDRs correspond to the same scFv referred to in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies (e.g., including VH domains, VH CDRs, VL domains, or VL CDRs having an amino acid sequence of any one of those referred to in Table 1), that immunospecifically bind the soluble form of B Lymphocyte Stimulator, the membrane-bound form of B Lymphocyte Stimulator, and/or both the soluble form and membrane-bound form of B Lymphocyte Stimulator, are also encompassed by the invention, as are nucleic acid molecules that encode these antibodies, and/or molecules.

The present invention also provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that: immunospecifically bind to the soluble form of B Lymphocyte Stimulator (e.g., a polypeptide consisting of amino acids 134–285 of SEQ ID NO:3228); that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator (e.g., a polypeptide consisting of amino acids 1–285 of SEQ ID NO:3228 or a B Lymphocyte Stimulator polypeptide expressed on the surface of monocytes) and/or that immunospecifically bind to both the soluble form and membrane-bound form of B Lymphocyte Stimulator. In a preferred embodiment, antibodies of the present invention immuno-

6

specifically bind to the soluble form of B Lymphocyte Stimulator and comprise, or alternatively consist of, a VH domain, VH CDR1, VH CDR2, VH CDR3, VL domain, VL CDR1, VL CDR2, and/or VL CDR3 corresponding to one or more scFvs, that immunospecifically bind to the soluble form of B Lymphocyte Stimulator. In another preferred embodiment, antibodies of the present invention immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator and comprise, or alternatively consist of, a VH domain, VH CDR1, VH CDR2, VH CDR3, VL domain, VL CDR1, VL CDR2, and/or VL CDR3 corresponding to one or more scFvs, that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator. In yet another preferred embodiment, antibodies of the present invention immunospecifically bind to the soluble form and membrane-bound form of B Lymphocyte Stimulator and comprise, or alternatively consist of, a VH domain, VH CDR1, VH CDR2, VH CDR3, VL domain, VL CDR1, VL CDR2, and/or VL CDR3 corresponding to one or more scFvs, that immunospecifically binds to the soluble form and membrane-bound form of B Lymphocyte Stimulator. In another preferred embodiment, antibodies of the present invention comprise, or alternatively consist of, a VH domain and a VL domain corresponding to the same scFv disclosed in Table 1, which antibodies immunospecifically bind to the soluble form of B Lymphocyte Stimulator, the membrane-bound form of B Lymphocyte Stimulator, or both the soluble form and membrane-bound form of B Lymphocyte Stimulator. Nucleic acid molecules encoding these antibodies are also encompassed by the invention. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies (e.g., including VH domains, VH CDRs, VL domains, or VL CDRs having an amino acid sequence of any one of those referred to in Table 1), that immunospecifically bind the soluble form of B Lymphocyte Stimulator, the membrane-bound form of B Lymphocyte Stimulator, and/or both the soluble form and membrane-bound form of B Lymphocyte Stimulator, are also encompassed by the invention, as are nucleic acid molecules that encode these antibodies, and/or molecules.

A VH domain of an amino acid sequence disclosed herein may be combined with

a VL domain of an amino acid sequence disclosed herein, or other VL domains, to provide a VH/VL pairing representing an antigen-binding site of an antibody. Similarly, a VL domain of an amino acid sequence disclosed herein may be combined with a VH domain of an amino acid sequence disclosed herein, or other VH domains. Further, one or more CDRs disclosed herein may be taken from a VH or VL domain and incorporated into a suitable framework as discussed *infra*.

The present invention provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof (including derivatives)) comprising, or alternatively consisting of, of VH domains, VL domains and/or CDRs described herein, which antibodies, immunospecifically bind to B Lymphocyte Stimulator (e.g., soluble B Lymphocyte Stimulator and membrane-bound B Lymphocyte Stimulator) and can be routinely assayed for immunospecific binding to B Lymphocyte Stimulator using methods known in the art, such as, for example, the immunoassays disclosed *infra*. Antibodies and antibody fragments or variants (including derivatives) of the invention may include, for example, one or more amino acid sequence alterations (addition, deletion, substitution and/or insertion of an amino acid residue). These alterations may be made in one or more framework regions and/or one or more CDR's.

The antibodies of the invention (including antibody fragments, and variants and derivative thereof) can be routinely made by methods known in the art. Molecules comprising, or alternatively consisting of, fragments or variants of any of the VH domains, VH CDRs, VL domains, and VL CDRs whose sequences are specifically disclosed herein may be employed in accordance with the present invention. Nucleic acid molecules encoding these antibodies and molecules (including fragments, variants, and derivatives) are also encompassed by the invention.

The present invention also provides panels of antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants) wherein the panel members correspond to one, two, three, four, five, ten, fifteen, twenty, or more different antibodies of the invention (e.g., whole antibodies, Fabs, F(ab')₂ fragments, Fd fragments, disulfide-linked Fvs (sdFvs), antiidiotypic (anti-Id) antibodies, and scFvs). The present invention further provides mixtures of antibodies, wherein the mixture corresponds to one, two, three, four, five, ten, fifteen, twenty, or more different antibodies of the invention (e.g., whole antibodies, Fabs, F(ab')₂ fragments, Fd fragments, disulfide-linked Fvs (sdFvs), antiidiotypic (anti-Id) antibodies, and scFvs). The present invention also provides for compositions comprising, or alternatively consisting of, one, two, three, four, five, ten, fifteen, twenty, or more antibodies of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof). A composition of the invention may comprise, or alternatively consist of, one, two, three, four, five, ten, fifteen, twenty, or more amino acid sequences of one or more antibodies or fragments or variants thereof. Alternatively, a composition of the invention may comprise, or alternatively consist of, nucleic acid molecules encoding one or more antibodies of the invention.

The present invention also provides for fusion proteins comprising an antibody (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) of the invention, and a heterologous polypeptide (i.e., a polypeptide unrelated to an antibody or antibody domain). Nucleic acid molecules encoding these fusion proteins are also encompassed by the invention. A composition of the present invention may comprise, or alternatively consist of, one, two, three, four, five, ten, fifteen, twenty or more fusion proteins of the invention. Alternatively, a composition of the invention may comprise, or alternatively consist of, nucleic acid molecules encoding one, two, three, four, five, ten, fifteen, twenty or more fusion proteins of the invention.

The present invention also provides for a nucleic acid molecule, generally

isolated, encoding an antibody (including molecules such as scFvs, which comprise, or alternatively consist of, an antibody fragment or variant thereof) of the invention. The present invention also provides a host cell transformed with a nucleic acid molecule of the invention and progeny thereof. The present invention also provides a method for the production of an antibody (including a molecule comprising, or alternatively consisting of, an antibody fragment or variant thereof) of the invention. The present invention further provides a method of expressing an antibody (including a molecule comprising, or alternatively consisting of, an antibody fragment or variant thereof) of the invention from a nucleic acid molecule. These and other aspects of the invention are described in further detail below.

The present invention also encompasses methods and compositions for detecting, diagnosing and/or prognosing

diseases or disorders associated with aberrant B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor expression or inappropriate B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor function in an animal, preferably a mammal, and most preferably a human, comprising using antibodies (including molecules which comprise, or alternatively consist of, antibody fragments or variants thereof) that immunospecifically bind to B Lymphocyte Stimulator. Diseases and disorders which can be detected, diagnosed or prognosed with the antibodies of the invention include, but are not limited to, immune disorders (e.g., lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, Hashimoto's disease, and immunodeficiency syndrome), inflammatory disorders (e.g., asthma, allergic disorders, and rheumatoid arthritis), infectious diseases (e.g., AIDS), and proliferative disorders (e.g., leukemia, carcinoma, and lymphoma).

In specific embodiments, the present invention encompasses methods and compositions for detecting, diagnosing and/or prognosing diseases or disorders associated with hypergammaglobulinemia (e.g., AIDS, autoimmune diseases, and some immunodeficiencies). In other specific embodiments, the present invention encompasses methods and compositions for detecting, diagnosing and/or prognosing diseases or disorders associated with hypogammaglobulinemia (e.g., an immunodeficiency).

The present invention further encompasses methods and compositions for preventing, treating or ameliorating diseases or disorders associated with aberrant B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor expression or inappropriate B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor function in an animal, preferably a mammal, and most preferably a human, comprising administering to said animal an effective amount of one or more antibodies (including molecules which comprise, or alternatively consist of, antibody fragments or variants thereof) that immunospecifically bind to B Lymphocyte Stimulator. Diseases and disorders which can be prevented, treated or inhibited by administering an effective amount of one or more antibodies or molecules of the invention include, but are not limited to, immune disorders (e.g., lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, Hashimoto's disease, and immunodeficiency syndrome), inflammatory disorders (e.g., asthma, allergic disorders, and rheumatoid arthritis), infectious diseases (e.g., AIDS), and proliferative disorders (e.g., leukemia, carcinoma, and lymphoma).

In specific embodiments, the present invention encompasses methods and compositions (e.g., antagonistic anti-B Lymphocyte Stimulator antibodies) for preventing, treating or ameliorating diseases or disorders associated with hypergammaglobulinemia (e.g., AIDS, autoimmune diseases, and some immunodeficiency syndromes). In other specific embodiments, the present invention encompasses methods and compositions (e.g., agonistic anti-B Lymphocyte Stimulator antibodies) for preventing, treating or ameliorating diseases or disorders associated with hypogammaglobulinemia (e.g., an immunodeficiency syndrome).

Autoimmune disorders, diseases, or conditions that may be detected, diagnosed, prognosed, or monitored using the antibodies of the invention include, but are not limited to, autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, autoimmune neutropenia, autoimmunocytopenia, hemolytic anemia, antiphospholipid syndrome, dermatitis, gluten-sensitive enteropathy, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis (e.g., IgA nephropathy), Multiple Sclerosis, Neuritis, Uveitis Ophthalmia, Polyendocrinopathies, Purpura

(e.g., Henoch-Schoenlein purpura), Reiter's Disease, Stiff-Man Syndrome, Autoimmune Pulmonary Inflammation, myocarditis, IgA glomerulonephritis, dense deposit disease, rheumatic heart disease, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye, autoimmune thyroiditis, hypothyroidism (i.e., Hashimoto's thyroiditis, systemic lupus erythematosus, discoid lupus, Goodpasture's syndrome, Pemphigus, Receptor autoimmunities such as, for example, (a) Graves' Disease, (b) Myasthenia Gravis, and (c) insulin resistance, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, rheumatoid arthritis, scleroderma with anti-collagen antibodies, mixed connective tissue disease, polymyositis/dermatomyositis, pernicious anemia, idiopathic Addison's disease, infertility, glomerulonephritis such as primary glomerulonephritis and IgA nephropathy, bullous pemphigoid, Sjögren's syndrome, diabetes mellitus, and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis), chronic active hepatitis, primary biliary cirrhosis, other endocrine gland failure, vitiligo, vasculitis, post-MI, cardiomyopathy syndrome, urticaria, atopic dermatitis, asthma, inflammatory myopathies, and other inflammatory, granulomatous, degenerative, and atrophic disorders).

Immunodeficiencies that may be detected, diagnosed, prognosed, or monitored using the antibodies of the invention include, but are not limited to, severe combined immunodeficiency (SCID)-X linked, SCID-autosomal, adenosine deaminase deficiency (ADA deficiency), X-linked agammaglobulinemia (XLA), Bruton's disease, congenital agammaglobulinemia, X-linked infantile agammaglobulinemia, acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, transient hypogammaglobulinemia of infancy, unspecified hypogammaglobulinemia, agammaglobulinemia, common variable immunodeficiency (CVID) (acquired), Wiskott-Aldrich Syndrome (WAS), X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, selective IgA deficiency, IgG subclass deficiency (with or without IgA deficiency), antibody deficiency with normal or elevated Igs, immunodeficiency with thymoma, Ig heavy chain deletions, kappa chain deficiency, B cell lymphoproliferative disorder (BLPD), selective IgM immunodeficiency, recessive agammaglobulinemia (Swiss type), reticular dysgenesis, neonatal neutropenia, severe congenital leukopenia, thymic aplasia/aplasia or dysplasia with immunodeficiency, ataxia-telangiectasia, short limbed dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof syndrome-combined immunodeficiency with Igs, purine nucleoside phosphorylase deficiency (PNP), MHC Class II deficiency (Bare Lymphocyte Syndrome) and severe combined immunodeficiency.

Definitions

The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. As such, the term antibody encompasses not only whole antibody molecules, but also antibody fragments as well as variants (including derivatives) of antibodies and antibody fragments. Examples of molecules which are described by the term "antibody" in this application include, but are not limited to: single chain Fvs (scFvs), Fab fragments, Fab' fragments, F(ab')₂, disulfide linked Fvs (sdFvs), Fvs, and fragments comprising or alternatively consisting of, either a

VL or a VH domain. The term "single chain Fv" or "scFv" as used herein refers to a polypeptide comprising a VL domain of antibody linked to a VH domain of an antibody. Antibodies that immunospecifically bind to B Lymphocyte Stimulator may have cross-reactivity with other antigens. Preferably, antibodies that immunospecifically bind to B Lymphocyte Stimulator do not cross-react with other antigens. Antibodies that immunospecifically bind to B Lymphocyte Stimulator can be identified, for example, by immunoassays or other techniques known to those of skill in the art, e.g., the immunoassays described in the Examples below.

Antibodies of the invention include, but are not limited to, monoclonal, multispecific, human or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁ and IgA₂) or subclass of immunoglobulin molecule.

Preferably, an antibody of the invention comprises, or alternatively consists of, a VH domain, VH CDR, VL domain, or VL CDR having an amino acid sequence of any one of those referred to in Table 1, or a fragment or variant thereof.

An antibody of the invention "which binds the soluble form of B Lymphocyte Stimulator" is one which binds the 152 amino acid soluble form of the B Lymphocyte Stimulator protein (amino acids 134-285 of SEQ ID NO:3228). In specific embodiments of the invention, an antibody of the invention "which binds the soluble form of B Lymphocyte Stimulator" does not also bind the membrane-bound or membrane-associated form of B Lymphocyte Stimulator. Assays which measure binding to the soluble form of B Lymphocyte Stimulator include, but are not limited to, receptor binding inhibition assay or capture of soluble B Lymphocyte Stimulator from solution as described in Examples 8 and 9.

An antibody of the invention "which binds the membrane-bound form of B Lymphocyte Stimulator" is one which binds the membrane-associated (uncleaved) B Lymphocyte Stimulator protein. In specific embodiments of the invention, an antibody of the invention "which binds the membrane-bound form of B Lymphocyte Stimulator" does not also bind the soluble form of B Lymphocyte Stimulator. Binding to HIS-tagged B Lymphocyte Stimulator (as described herein) in an ELISA is an indicator that an antibody binds the membrane-bound form of B Lymphocyte Stimulator, but should not be relied upon as proof of specificity for the membrane-bound form of B Lymphocyte Stimulator. Assays that may be relied upon as proof of an antibody's specificity for membrane-bound B Lymphocyte Stimulator, include, but are not limited to, binding to plasma membranes expressing B Lymphocyte Stimulator as described in Example 2. An antibody of the invention "which binds the both the soluble form and the membrane-bound form of B Lymphocyte Stimulator" is one which binds both the membrane-bound form and the soluble form of B Lymphocyte Stimulator.

The term "variant" as used herein refers to a polypeptide that possesses a similar or identical function as a B Lymphocyte Stimulator polypeptide, a fragment of B Lymphocyte Stimulator, an anti-B Lymphocyte Stimulator antibody or antibody fragment thereof, but does not necessarily comprise a similar or identical amino acid sequence of a B Lymphocyte Stimulator polypeptide, a fragment of B Lym-

phocyte Stimulator, an anti-B Lymphocyte Stimulator antibody or antibody fragment thereof, or possess a similar or identical structure of a B Lymphocyte Stimulator polypeptide, a fragment of B Lymphocyte Stimulator, an anti-B Lymphocyte Stimulator antibody or antibody fragment thereof. A variant having a similar amino acid refers to a polypeptide that satisfies at least one of the following: (a) a polypeptide comprising, or alternatively consisting of, an amino acid sequence that is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the amino acid sequence of a B Lymphocyte Stimulator polypeptide, a fragment of B Lymphocyte Stimulator, an anti-B Lymphocyte Stimulator antibody or antibody fragment thereof (including a VH domain, VHCDR, VL domain, or VLCDR having an amino acid sequence of any one of those referred to in Table 1) described herein; (b) a polypeptide encoded by a nucleotide sequence, the complementary sequence of which hybridizes under stringent conditions to a nucleotide sequence encoding a B Lymphocyte Stimulator polypeptide (e.g., SEQ ID NO:3228), a fragment of B Lymphocyte Stimulator, an anti-B Lymphocyte Stimulator antibody or antibody fragment thereof (including a VH domain, VHCDR, VL domain, or VLCDR having an amino acid sequence of any one of those referred to in Table 1), described herein, of at least 5 amino acid residues, at least 10 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, at least 25 amino acid residues, at least 30 amino acid residues, at least 40 amino acid residues, at least 50 amino acid residues, at least 60 amino acid residues, at least 70 amino acid residues, at least 80 amino acid residues, at least 90 amino acid residues, at least 100 amino acid residues, at least 125 amino acid residues, or at least 150 amino acid residues; and (c) a polypeptide encoded by a nucleotide sequence that is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99%, identical to the nucleotide sequence encoding a B Lymphocyte Stimulator polypeptide, a fragment of B Lymphocyte Stimulator, an anti-B Lymphocyte Stimulator antibody or antibody fragment thereof (including a VH domain, VHCDR, VL domain, or VLCDR having an amino acid sequence of any one of those referred to in Table 1), described herein. A polypeptide with similar structure to a B Lymphocyte Stimulator polypeptide, a fragment of B Lymphocyte Stimulator, an anti-B Lymphocyte Stimulator antibody or antibody fragment thereof, described herein refers to a polypeptide that has a similar secondary, tertiary or quaternary structure of a B Lymphocyte Stimulator polypeptide, a fragment of B Lymphocyte Stimulator, an anti-B Lymphocyte Stimulator antibody, or antibody fragment thereof, described herein. The structure of a polypeptide can be determined by methods known to those skilled in the art, including but not limited to, X-ray crystallography, nuclear magnetic resonance, and crystallographic electron microscopy.

To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide at the corresponding position in the second

sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical overlapping positions / total number of positions × 100%). In one embodiment, the two sequences are the same length.

The determination of percent identity between two sequences can be accomplished using a mathematical algorithm known to those of skill in the art. An example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul *Proc. Natl. Acad. Sci. USA* 87:2264-2268(1990), modified as in Karlin and Altschul *Proc. Natl. Acad. Sci. USA* 90:5873-5877(1993). The BLASTn and BLASTx programs of Altschul, et al. *J. Mol. Biol.* 215:403-410(1990) have incorporated such an algorithm. BLAST nucleotide searches can be performed with the BLASTn program, score=100, wordlength=12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches can be performed with the BLASTx program, score=50, wordlength=3 to obtain amino acid sequences homologous to a protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. *Nucleic Acids Res.* 25:3389-3402(1997). Alternatively, PSI-BLAST can be used to perform an iterated search which detects distant relationships between molecules (Id.). When utilizing BLAST, Gapped BLAST, and PSI-BLAST programs, the default parameters of the respective programs (e.g., BLASTx and BLASTn) can be used. (See <http://www.ncbi.nlm.nih.gov>.)

Another example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). The ALIGN program (version 2.0) which is part of the GCG sequence alignment software package has incorporated such an algorithm. Other algorithms for sequence analysis known in the art include ADVANCE and ADAM as described in Torellis and Robotti *Comput. Appl. Biosci.*, 10: 3-5(1994); and FASTA described in Pearson and Lipman *Proc. Natl. Acad. Sci.* 85:2444-8 (1988). Within FASTA, ktup is a control option that sets the sensitivity and speed of the search.

The term "derivative" as used herein, refers to a variant polypeptide of the invention that comprises, or alternatively consists of, an amino acid sequence of a B Lymphocyte Stimulator polypeptide, a fragment of B Lymphocyte Stimulator, or an antibody of the invention that immunospecifically binds to B Lymphocyte Stimulator, which has been altered by the introduction of amino acid residue substitutions, deletions or additions. The term "derivative" as used herein also refers to a B Lymphocyte Stimulator polypeptide, a fragment of B Lymphocyte Stimulator, an antibody that immunospecifically binds to B Lymphocyte Stimulator which has been modified, e.g., by the covalent attachment of any type of molecule to the polypeptide. For example, but not by way of limitation, a B Lymphocyte Stimulator polypeptide, a fragment of B Lymphocyte Stimulator, or an anti-B Lymphocyte Stimulator antibody, may be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. A derivative of a B Lymphocyte Stimulator polypeptide, a fragment of B Lymphocyte Stimulator, or an anti-B Lymphocyte Stimulator antibody, may be modified by chemical modifications using techniques known to those of skill in the art, including, but not limited to, specific chemical cleavage, acetylation, formylation, meta-

bolic synthesis of tunicamycin, etc. Further, a derivative of a B Lymphocyte Stimulator polypeptide, a fragment of B Lymphocyte Stimulator, or an anti-B Lymphocyte Stimulator antibody, may contain one or more non-classical amino acids. A polypeptide derivative possesses a similar or identical function as a B Lymphocyte Stimulator polypeptide, a fragment of B Lymphocyte Stimulator, or an anti-B Lymphocyte Stimulator antibody, described herein.

The term "epitopes" as used herein refers to portions of B Lymphocyte Stimulator having antigenic or immunogenic activity in an animal, preferably a mammal. An epitope having immunogenic activity is a portion of B Lymphocyte Stimulator that elicits an antibody response in an animal. An epitope having antigenic activity is a portion of B Lymphocyte Stimulator to which an antibody immunospecifically binds as determined by any method known in the art, for example, by the immunoassays described herein. Antigenic epitopes need not necessarily be immunogenic.

The term "fragment" as used herein refers to a polypeptide comprising an amino acid sequence of at least 5 amino acid residues, at least 10 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, at least 25 amino acid residues, at least 30 amino acid residues, at least 35 amino acid residues, at least 40 amino acid residues, at least 45 amino acid residues, at least 50 amino acid residues, at least 60 amino acid residues, at least 70 amino acid residues, at least 80 amino acid residues, at least 90 amino acid residues, at least 100 amino acid residues, at least 125 amino acid residues, at least 150 amino acid residues, at least 175 amino acid residues, at least 200 amino acid residues, or at least 250 amino acid residues, of the amino acid sequence of B Lymphocyte Stimulator, or an anti-B Lymphocyte Stimulator antibody (including molecules such as scFv's, that comprise, or alternatively consist of, antibody fragments or variants thereof) that immunospecifically binds to B Lymphocyte Stimulator.

The term "fusion protein" as used herein refers to a polypeptide that comprises, or alternatively consists of, an amino acid sequence of an anti-B Lymphocyte Stimulator antibody of the invention and an amino acid sequence of a heterologous polypeptide (i.e., a polypeptide unrelated to an antibody or antibody domain).

The term "host cell" as used herein refers to the particular subject cell transfected with a nucleic acid molecule and the progeny or potential progeny of such a cell. Progeny may not be identical to the parent cell transfected with the nucleic acid molecule due to mutations or environmental influences that may occur in succeeding generations or integration of the nucleic acid molecule into the host cell genome.

DESCRIPTION OF THE FIGURES

FIG. 1. ELISA results for three scFvs, I006E07, I008D05 and I016F04, that immunospecifically bind to U937 membranes, but not to bind to or cross-react with TNF-alpha or BSA.

FIG. 2. The results for three scFvs, I016H07, I001C09 and I018D07, in a receptor inhibition assay.

FIG. 3. ELISA results for two scFvs (I022D01 and I031F02) demonstrating their ability to bind to human B Lymphocyte Stimulator and to cross-react with mouse B Lymphocyte Stimulator, but not to bind to or cross-react with other antigens of the TNF ligand family.

FIG. 4. ELISA results for three scFvs (I031F09, I050A12, and I051C04) binding to U937 plasma membranes when either B Lymphocyte Stimulator or TNF-alpha is used as a competitor.

FIG. 5. Kinetic analysis of scFv antibody I003C02. A dilution series of I003C02 from 3 nM to 825 nM is shown. Association and dissociation curves were generated using a BIAcore 2000 and BIAevaluation 3.0 software.

FIG. 6. Typical titration curves for two scFv antibodies (I007F11 and I050A07) are shown in FIG. 6. Unlabelled B Lymphocyte Stimulator competed for binding to its receptor with an IC_{50} value of 0.8 nM. The IC_{50} values for I007F11 and I050A07 are 7.9 nM and 17.1 nM, respectively. The assay was performed in triplicate and standard error bars are shown.

FIG. 7. ELISA results for three scFvs clones (I074B12, I075F12 and I075A02) that immunospecifically bind to immobilized B Lymphocyte Stimulator, but not to U937 plasma membranes, TNF-alpha or BSA. As a control, a phage antibody that recognizes TNF α , is also shown in FIG. 7.

FIG. 8. The results for two scFvs (I025B09 and I026C04) in a receptor inhibition assay.

FIG. 9. ELISA results for two scFvs clones (I067F05 and I078D02) demonstrating their ability to bind to immobilized human B Lymphocyte Stimulator and to cross-react with immobilized mouse B Lymphocyte Stimulator, but not to bind to or cross-react with other antigens of the TNF ligand family.

As a control, a phage antibody that recognizes TNF α , is also shown in FIG. 7.

FIG. 10. Kinetic analysis of scFV antibody I002A01. A dilution series of I002A01 from 3 nM to 1650 nM is shown. Association and dissociation curves were generated using a BIAcore 2000 and BIAevaluation 3.0 software.

FIG. 11. Typical titration curves for two scFvs, I0068C06 and I074B12, are shown in FIG. 11. Unlabelled B Lymphocyte Stimulator competed for binding to its receptor with an inhibitory constant 50 (IC_{50}) value of 0.66 nM. The IC_{50} values for I0068C06 and I074B12 are 61 nM and 13 nM, respectively. The assay was performed in triplicate and standard error bars are shown.

FIG. 12. ELISA results for three clones (I079C01, I081C10 and I082A02) demonstrating their ability to bind histidine-tagged B Lymphocyte Stimulator, U937 plasma membranes, but not to bind immobilized biotinylated B Lymphocyte Stimulator.

FIG. 13. ELISA results for three scFvs (I079B04, I079F08, and I080B01) binding to U937 plasma membranes when either histidine-tagged B Lymphocyte Stimulator or biotinylated B Lymphocyte Stimulator is used as a competitor.

FIG. 14. An example of the dissociation section of a typical sensorgram for 8 scFvs is shown in FIG. 14. An anti-TNF α antibody that does not recognize B Lymphocyte Stimulator was included as a control. Of the 8 scFvs exemplified, I079F06 was identified for further study due to the relatively high numbers of RU's bound to the surface.

FIG. 15. A typical example of the binding curves generated for the scFv antibody I082C03 is shown in FIG. 15. The off-rate for this clone was calculated as $2 \times 10^{-3} \text{ s}^{-1}$. The affinity of I082C03 was calculated as 20 nM, assuming 100% activity of the scFv.

FIG. 16. ELISA results for three scFvs (I079B04, I079F08, and I080B01) binding to P388 plasma membranes when either histidine-tagged B Lymphocyte Stimulator or biotinylated B Lymphocyte Stimulator is used as a competitor.

DETAILED DESCRIPTION OF THE
INVENTION

The present invention encompasses antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to B Lymphocyte Stimulator or a fragment or variant of B Lymphocyte Stimulator. In particular, the invention provides antibodies such as, for example, single chain Fvs (scFvs) having an amino acid sequence of any one of SEQ ID NOS:1-2128, as referred to in Table 1. In particular, the present invention encompasses antibodies that immunospecifically bind to a polypeptide, a polypeptide fragment or variant, or an epitope of human B Lymphocyte Stimulator (SEQ ID NOS:3228 and/or 3229) or B Lymphocyte Stimulator expressed on human monocytes; murine B Lymphocyte Stimulator (SEQ ID NOS:3230 and/or 3231) or B Lymphocyte Stimulator expressed on murine monocytes; rat B Lymphocyte Stimulator (either the soluble forms as given in SEQ ID NOS:3232, 3233, 3234 and/or 3235 or in a membrane associated form, e.g., on the surface of rat monocytes); or monkey B Lymphocyte Stimulator (e.g., the monkey B Lymphocyte Stimulator polypeptides of SEQ ID NOS:3236 and/or 3237, the soluble form of monkey B Lymphocyte Stimulator, or B Lymphocyte Stimulator expressed on monkey monocytes) (as determined by immunoassays known in the art for assaying specific antibody-antigen binding).

The polypeptide sequence shown in SEQ ID NO:3228 was obtained by sequencing and translating the cDNA of the HNEDU15 clone which was deposited on Oct. 22, 1996 at the American Type Culture Collection, 10801 University Boulevard, Manassas, Va. 20110-2209, and assigned ATCCTM Accession No. 97768. The deposited clone is contained in the pBluescript SK(-) plasmid (Stratagene, La Jolla, Calif.). The ATCCTM deposits were made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure.

The polypeptide sequence shown in SEQ ID NO:3229 was obtained by sequencing and translating the cDNA of the HDPMC52 clone, which was deposited on Dec. 10, 1998 at the American Type Culture Collection, and assigned ATCCTM Accession No. 203518. The deposited clone is contained in the pBluescript SK(-) plasmid (Stratagene, La Jolla, Calif.). The ATCCTM deposits were made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure.

The B Lymphocyte Stimulator polypeptides bound by the antibodies of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to antibodies that bind monomers and multimers of the B Lymphocyte Stimulator polypeptides of the invention, their preparation, and compositions (preferably, pharmaceutical compositions) containing them. In specific embodiments, the antibodies of the invention bind B Lymphocyte Stimulator monomers, dimers, trimers or tetramers. In additional embodiments, the antibodies of the invention bind at least dimers, at least trimers, or at least tetramers of B Lymphocyte Stimulator.

Multimeric B Lymphocyte Stimulator bound by the antibodies of the invention may be homomers or heteromers. A B Lymphocyte Stimulator homomer, refers to a multimer containing only B Lymphocyte Stimulator polypeptides (including B Lymphocyte Stimulator fragments, variants, and fusion proteins, as described herein). These homomers may contain B Lymphocyte Stimulator polypeptides having identical or different amino acid sequences.

In specific embodiments, the antibodies of the invention bind a B Lymphocyte Stimulator homodimer (e.g., containing two B Lymphocyte Stimulator polypeptides having identical or different amino acid sequences) or a B Lymphocyte Stimulator homotrimer (e.g., containing three B Lymphocyte Stimulator polypeptides having identical or different amino acid sequences). In a preferred embodiment, the antibodies of the invention bind homotrimers of B Lymphocyte Stimulator. In additional embodiments, the antibodies of the invention bind a homomeric B Lymphocyte Stimulator multimer which is at least a homodimer, at least a homotrimer, or at least a homotetramer.

Heteromeric B Lymphocyte Stimulator refers to a multimer containing heterologous polypeptides (i.e., polypeptides of a different protein) in addition to the B Lymphocyte Stimulator polypeptides of the invention. In a specific embodiment, the antibodies of the invention bind a B Lymphocyte Stimulator heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the antibodies of the invention bind a heteromeric B Lymphocyte Stimulator multimer which is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer. In highly preferred embodiments, the antibodies of the invention bind a heterotrimer comprising both B Lymphocyte Stimulator polypeptides and APRIL polypeptides (SEQ ID NO:3239; GenBank Accession No. AF046888; PCT International Publication Number WO97/33902; J. Exp. Med. 188(6):1185-1190) or fragments or variants thereof. In other highly preferred embodiments, the antibodies of the invention bind a heterotrimer comprising one B Lymphocyte Stimulator polypeptide (including fragments or variants) and two APRIL polypeptides (including fragments or variants). In still other highly preferred embodiments, the antibodies of the invention bind a heterotrimer comprising two B Lymphocyte Stimulator polypeptides (including fragments or variants) and one APRIL polypeptide (including fragments or variants). In a further nonexclusive embodiment, the heteromers bound by the antibodies of the invention contain CD40 ligand polypeptide sequence(s), or biologically active fragment(s) or variant(s) thereof.

In particularly preferred embodiments, the antibodies of the invention bind homomeric, especially homotrimeric, B Lymphocyte Stimulator polypeptides, wherein the individual protein components of the multimers consist of the mature form of B Lymphocyte Stimulator (e.g., amino acids residues 134-285 of SEQ ID NO:3228, or amino acids residues 134-266 of SEQ ID NO:3229) or fragments or variants thereof. In other specific embodiments, antibodies of the invention bind heteromeric, especially heterotrimeric, B Lymphocyte Stimulator polypeptides such as a heterotrimer containing two B Lymphocyte Stimulator polypeptides and one APRIL polypeptide or a heterotrimer containing one B Lymphocyte Stimulator polypeptide and two APRIL polypeptides, and wherein the individual protein components of the B Lymphocyte Stimulator heteromer consist of the mature extracellular soluble portion of either B Lymphocyte Stimulator (e.g., amino acids residues 134-285 of SEQ ID NO:3228, or amino acids residues 134-266 of SEQ ID NO:3229) or fragments or variants thereof, or the mature extracellular soluble portion APRIL (e.g., amino acid residues 105-250 of SEQ ID NO:3239) or fragments or variants thereof.

In specific embodiments, the antibodies of the invention bind conformational epitopes of a B Lymphocyte Stimulator monomeric protein. In specific embodiments, the antibodies of the invention bind conformational epitopes of a B Lym-

phocyte Stimulator multimeric, especially trimeric, protein. In other embodiments, antibodies of the invention bind conformational epitopes that arise from the juxtaposition of B Lymphocyte Stimulator with a heterologous polypeptide, such as might be present when B Lymphocyte Stimulator forms heterotrimers (e.g., with APRIL polypeptides (e.g., SEQ ID NO:3239)), or in fusion proteins between B Lymphocyte Stimulator and a heterologous polypeptide.

B Lymphocyte Stimulator multimers bound by the antibodies of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, B Lymphocyte Stimulator multimers, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, B Lymphocyte Stimulator heteromultimers, such as, for example, B Lymphocyte Stimulator heterotrimers or B Lymphocyte Stimulator heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, B Lymphocyte Stimulator multimers are formed by covalent associations with and/or between the B Lymphocyte Stimulator polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in SEQ ID NO:3228 or SEQ ID NO:3229). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a B Lymphocyte Stimulator fusion protein. In one example, covalent associations are between the heterologous sequence contained in a fusion protein (see, e.g., U.S. Pat. No. 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in a B Lymphocyte Stimulator-Fc fusion protein. In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another TNF family ligand/receptor member that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication No. WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from CD40L, or a soluble fragment thereof. In another embodiment, two or B Lymphocyte Stimulator polypeptides are joined through synthetic linkers (e.g., peptide, carbohydrate or soluble polymer linkers). Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple B Lymphocyte Stimulator polypeptides separated by peptide linkers may be produced using conventional recombinant DNA technology.

In one embodiment, antibodies of the invention immunospecifically bind a B Lymphocyte Stimulator polypeptide having the amino acid sequence of SEQ ID NO:3228 or as encoded by the cDNA clone contained in ATCC™ No. 97768, or a polypeptide comprising a portion (i.e., a fragment) of the above polypeptides. In another embodiment, the invention provides an antibody that binds an isolated B

Lymphocyte Stimulator polypeptide having the amino acid sequence of SEQ ID NO:3229 or the amino acid sequence encoded by the cDNA clone contained in ATCC™ No. 203518, or an antibody that binds polypeptide comprising a portion (i.e., fragment) of the above polypeptides.

Antibodies of the present invention immunospecifically bind to polypeptides comprising or alternatively, consisting of, the amino acid sequence of SEQ ID NO:3228, encoded by the cDNA contained in the plasmid having ATCC™ accession number 97768, or encoded by nucleic acids which hybridize (e.g., under stringent hybridization conditions) to the nucleotide sequence contained in the deposited clone. Antibodies of the present invention also bind to fragments of the amino acid sequence of SEQ ID NO:3228, encoded by the cDNA contained in the plasmid having ATCC™ accession number 97768, or encoded by nucleic acids which hybridize (e.g., under stringent hybridization conditions) to the nucleotide sequence contained in the deposited clone.

Additionally, antibodies of the present invention bind polypeptides comprising or alternatively, consisting of, the amino acid sequence of SEQ ID NO:3229, encoded by the cDNA contained in the plasmid having ATCC™ accession number 203518, or encoded by nucleic acids which hybridize (e.g., under stringent hybridization conditions) to the nucleotide sequence contained in the deposited clone. Antibodies of the present invention also bind to fragments of the amino acid sequence of SEQ ID NO:3229, encoded by the cDNA contained in the plasmid having ATCC™ accession number 203518, or encoded by nucleic acids which hybridize (e.g., under stringent hybridization conditions) to the nucleotide sequence contained in the deposited clone.

In addition, antibodies of the invention bind polypeptides or polypeptide fragments comprising or alternatively, consisting of, an amino acid sequence contained in SEQ ID NOS: 3230 through 3237.

In specific embodiments, the antibodies of the present invention immunospecifically bind polypeptide fragments including polypeptides comprising or alternatively, consisting of, an amino acid sequence contained in SEQ ID NO:3228, encoded by the cDNA contained in the deposited clone, or encoded by nucleic acids which hybridize (e.g., under stringent hybridization conditions) to the nucleotide sequence contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments that may be bound by the antibodies of the present invention, include, for example, fragments that comprise or alternatively, consist of from about amino acid residues: 1 to 50, 51 to 100, 101 to 150, 151 to 200, 201 to 250, and/or 251 to 285 of SEQ ID NO:3228. Moreover, polypeptide fragments can be at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 175 or 200 amino acids in length.

In specific embodiments, antibodies of the present invention bind polypeptide fragments comprising, or alternatively consisting of, amino acid residues: 1-46, 31-44, 47-72, 73-285, 73-83, 94-102, 148-152, 166-181, 185-209, 210-221, 226-237, 244-249, 253-265, and/or 277-285 of SEQ ID NO:3228.

It will be recognized by one of ordinary skill in the art that mutations targeted to regions of a B Lymphocyte Stimulator polypeptide of SEQ ID NO:3228 which encompass the nineteen amino acid residue insertion which is not found in the B Lymphocyte Stimulator polypeptide sequence of SEQ ID NO:3229 (i.e., amino acid residues Val-142 through Lys-160 of the sequence of SEQ ID NO:3229) may affect the

observed biological activities of the B Lymphocyte Stimulator polypeptide. More specifically, a partial, non-limiting and non-exclusive list of such residues of the B Lymphocyte Stimulator polypeptide sequence which may be targeted for mutation includes the following amino acid residues of the B Lymphocyte Stimulator polypeptide sequence as shown in SEQ ID NO:3228: V-142; T-143; Q-144; D-145; C-146; L-147; Q-148; L-149; I-150; A-151; D-152; S-153; E-154; T-155; P-156; T-157; I-158; Q-159; and K-160. Thus, in specific embodiments, antibodies of the present invention that bind B Lymphocyte Stimulator polypeptides which have one or more mutations in the region from V-142 through K-160 of SEQ ID NO:3228 are contemplated.

Polypeptide fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments that may be bound by antibodies of the present invention, include, for example, fragments that comprise or alternatively, consist of from about amino acid residues: 1 to 15, 16-30, 31-46, 47-55, 56-72, 73-104, 105-163, 163-188, 186-210 and 210-284 of the amino acid sequence disclosed in SEQ ID NO:3228. Additional representative examples of polypeptide fragments that may be bound by antibodies of the present invention, include, for example, fragments that comprise or alternatively, consist of from about amino acid residues: 1 to 143, 1-150, 47-143, 47-150, 73-143, 73-150, 100-150, 140-145, 142-148, 140-150, 140-200, 140-225, and 140-266 of the amino acid sequence disclosed in SEQ ID NO:3229. Moreover, polypeptide fragments that may be bound by antibodies of the present invention, can be at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 175 or 200 amino acids in length. In this context, "about" means the particularly recited ranges and ranges larger or smaller by several, a few, 5, 4, 3, 2 or 1 amino acid residues at either or both the amino- and carboxy-termini.

Additional preferred embodiments encompass antibodies that bind polypeptide fragments comprising, or alternatively consisting of, the predicted intracellular domain of B Lymphocyte Stimulator (e.g., amino acid residues 1-46 of SEQ ID NO:3228), the predicted transmembrane domain of B Lymphocyte Stimulator (e.g., amino acid residues 47-72 of SEQ ID NO:3228), the predicted extracellular domain of B Lymphocyte Stimulator (e.g., amino acid residues 73-285 of SEQ ID NO:3228), the mature soluble extracellular domain of B Lymphocyte Stimulator (e.g., amino acids residues 134-285 of SEQ ID NO:3228), the predicted TNF conserved domain of B Lymphocyte Stimulator (e.g., amino acids 191 to 284 of SEQ ID NO:3228), and a polypeptide comprising, or alternatively, consisting of the predicted intracellular domain fused to the predicted extracellular domain of B Lymphocyte Stimulator (amino acid residues 1-46 fused to amino acid residues 73-285 of SEQ ID NO:3228).

Further additional preferred embodiments encompass polypeptide fragments comprising, or alternatively consisting of, the predicted intracellular domain of B Lymphocyte Stimulator (amino acid residues 1-46 of SEQ ID NO:3229), the predicted transmembrane domain of B Lymphocyte Stimulator (amino acid residues 47-72 of SEQ ID NO:3229), the predicted extracellular domain of B Lymphocyte Stimulator (amino acid residues 73-266 of SEQ ID NO:3229), the predicted TNF conserved domain of B Lymphocyte Stimulator (amino acids 172 to 265 of SEQ ID NO:3229), and a polypeptide comprising, or alternatively, consisting of the predicted intracellular domain fused to the

predicted extracellular domain of B Lymphocyte Stimulator (amino acid residues 1-46 fused to amino acid residues 73-266 of SEQ ID NO:3229).

Certain additional embodiments of the invention encompass antibodies that bind polypeptide fragments comprising, or alternatively consisting of, the predicted beta-pleated sheet regions of the B Lymphocyte Stimulator polypeptides of SEQ ID NO:3228 and SEQ ID NO:3229. These polypeptide fragments comprising the beta-pleated sheets of B Lymphocyte Stimulator comprise, or alternatively consist of, amino acid residues Gln-144 to Ala-151, Phe-172 to Lys-173, Ala-177 to Glu-179, Asn-183 to Ile-185, Gly-191 to Lys-204, His-210 to Val-219, Leu-226 to Pro-237, Asn-242 to Ala-251, Gly-256 to Ile-263 and/or Val-276 to Leu-284 of SEQ ID NO:3228. In another, nonexclusive embodiment, these polypeptide fragments comprising the beta-pleated sheets of B Lymphocyte Stimulator comprise, or alternatively consist of, amino acid residues Phe-153 to Lys-154, Ala-158 to Glu-160, Asn-164 to Ile-166, Gly-172 to Lys-185, His-191 to Val-200, Leu-207 to Pro-218, Asn-223 to Ala-232, Gly-237 to Ile-244 and/or Val-257 to Leu-265 of SEQ ID NO:3229.

A partial, non-limiting, and exemplary list of polypeptides that may be bound by the antibodies of the invention includes polypeptides that comprise, or alternatively consist of, combinations of amino acid sequences of the invention includes, for example, [Met-1 to Lys-113] fused to [Leu-114 to Thr-141] fused to [Val-142 to Lys-160] fused to [Gly-161 to Gln-198] fused to [Val-199 to Ala-248] fused to [Gly-249 to Leu-285] of SEQ ID NO:3228; or [Met-1 to Lys-113] fused to [Val-142 to Lys-160] fused to [Gly-161 to Gln-198] fused to [Val-199 to Ala-248] fused to [Gly-249 to Leu-285] of SEQ ID NO:3228; or [Met-1 to Lys-113] fused to [Leu-114 to Thr-141] fused to [Val-142 to Lys-160] fused to [Gly-161 to Gln-198] fused to [Gly-249 to Leu-285] of SEQ ID NO:3228. Other combinations of amino acids sequences that may be bound by the antibodies of the invention may include the polypeptide fragments in an order other than that recited above (e.g., [Leu-114 to Thr-141] fused to [Val-199 to Ala-248] fused to [Gly-249 to Leu-285] fused to [Val-142 to Lys-160] of (SEQ ID NO:3228)). Other combinations of amino acids sequences that may be bound by the antibodies of the invention may also include heterologous polypeptide fragments as described herein and/or other polypeptides or polypeptide fragments of the present invention (e.g., [Met-1 to Lys-113] fused to [Leu-114 to Thr-141] fused to [Val-142 to Lys-160] fused to [Gly-161 to Gln-198] fused to [Gly-249 to Leu-285] of SEQ ID NO:3228 fused to a FLAG tag; or [Met-1 to Lys-113] of SEQ ID NO:3228 fused to [Leu-114 to Thr-141] of SEQ ID NO:3228 fused to [Glu-135 to Asn-165] of SEQ ID NO:39 fused to [Val-142 to Lys-160] of SEQ ID NO:3228 fused to [Gly-161 to Gln-198] of SEQ ID NO:3228 fused to [Val-199 to Ala-248] of SEQ ID NO:3228 fused to [Gly-249 to Leu-285] of SEQ ID NO:3228).

A partial, non-limiting, and exemplary list of polypeptides that may be bound by the antibodies of the invention includes polypeptides that comprise, or alternatively consist of, combinations of amino acid sequences includes, for example, [Met-1 to Lys-113] fused to [Leu-114 to Thr-141] fused to [Gly-142 to Gln-179] fused to [Val-180 to Ala-229] fused to [Gly-230 to Leu-266] of SEQ ID NO:3229; [Met-1 to Lys-113] fused to [Gly-142 to Gln-179] fused to [Val-180 to Ala-229] fused to [Gly-230 to Leu-266] of SEQ ID NO:3229; or [Met-1 to Lys-113] fused to [Leu-114 to Thr-141] fused to [Gly-142 to Gln-179] fused to [Gly-230 to Leu-266] of SEQ ID NO:3229. Other of amino acids

sequences that may be bound by the antibodies of the invention combinations may include the polypeptide fragments in an order other than that recited above (e.g., [Leu-114 to Thr-141] fused to [Val-180 to Ala-229] fused to [Gly-230 to Leu-266] fused to [Gly-142 to Gln-179] of SEQ ID NO:3229). Other combinations of amino acid sequences that may be bound by the antibodies of the invention may also include heterologous polypeptide fragments as described herein and/or other polypeptides or polypeptide fragments of the present invention (e.g., [Met-1 to Lys-113] fused to [Leu-114 to Thr-141] fused to [Gly-142 to Gln-179] fused to [Gly-230 to Leu-266] of SEQ ID NO:3229 fused to a FLAG tag (SEQ ID NO:3238) or, [Met-1 to Lys-113] of SEQ ID NO:3229 fused to [Leu-114 to Thr-141] of SEQ ID NO:3229 fused to [Glu-135 to Asn-165] of SEQ ID NO:39 fused to [Gly-142 to Gln-179] of SEQ ID NO:3229 fused to [Val-180 to Ala-229] of SEQ ID NO:3229 fused to [Gly-230 to Leu-266] of SEQ ID NO:3229.

Additional embodiments of the invention encompass antibodies that bind B Lymphocyte Stimulator polypeptide fragments comprising, or alternatively consisting of, functional regions of polypeptides of the invention, such as the Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions, Chou-Fasman alpha-regions, beta-regions, and coil-regions, Kyte-Doolittle hydrophilic regions and hydrophobic regions, Eisenberg alpha- and beta-amphipathic regions, Karplus-Schulz flexible regions, Emini surface-forming regions and Jameson-Wolf regions of high antigenic index set out in Tables 9 and 10 and as described herein. In a preferred embodiment, the polypeptide fragments bound by the antibodies of the invention are antigenic (i.e., containing four or more contiguous amino acids having an antigenic index of greater than or equal to 1.5, as identified using the default parameters of the Jameson-Wolf program) of a complete (i.e., full-length) B Lymphocyte Stimulator polypeptide (e.g., SEQ ID NOS:3228 and 3229).

The data representing the structural or functional attributes of the B Lymphocyte Stimulator polypeptide of SEQ ID NO:3228 (Table 9) or the B Lymphocyte Stimulator polypeptide of SEQ ID NO:3229 (Table 10), as described above, was generated using the various modules and algorithms of the DNA*STAR set on default parameters. Column I represents the results of a Garnier-Robson analysis of alpha helical regions; Column II represents the results of a Chou-Fasman analysis of alpha helical regions; Column III

represents the results of a Garnier Robson analysis of beta sheet regions; Column IV represents the results of a Chou-Fasman analysis of beta sheet regions; Column V represents the results of a Garnier Robson analysis of turn regions; Column VI represents the results of a Chou-Fasman analysis of turn regions; Column VII represents the results of a Garnier Robson analysis of coil regions; Column VIII represents a Kyte-Doolittle hydrophilicity plot; Column IX represents a Hopp-Woods hydrophobicity plot; Column X represents the results of an Eisenberg analysis of alpha amphipathic regions; Column XI represents the results of an Eisenberg analysis of beta amphipathic regions; Column XII represents the results of a Karplus-Schultz analysis of flexible regions; Column XIII represents the Jameson-Wolf antigenic index score; and Column XIV represents the Emini surface probability plot.

In a preferred embodiment, the data presented in columns VIII, IX, XIII, and XIV of Tables 9 and 10 can be used to determine regions of the B Lymphocyte Stimulator polypeptide of SEQ ID NO:3228 (Table 9) or the B Lymphocyte Stimulator polypeptide of SEQ ID NO:3229 (Table 10) which exhibit a high degree of potential for antigenicity. Regions of high antigenicity are determined from the data presented in columns VIII, IX, XIII, and/or XIV by choosing values which represent regions of the polypeptide which are likely to be exposed on the surface of the polypeptide in an environment in which antigen recognition may occur in the process of initiation of an immune response.

The above-mentioned preferred regions set out in Tables 9 and 10 include, but are not limited to, regions of the aforementioned types identified by analysis of the amino acid sequence set out in SEQ ID NO:2. As set out in Tables 9 and 10, such preferred regions include Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions, Chou-Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle hydrophilic regions, Eisenberg alpha- and beta-amphipathic regions, Karplus-Schulz flexible regions, Jameson-Wolf regions of high antigenic index and Emini surface-forming regions. Preferably, antibodies of the present invention bind B Lymphocyte Stimulator polypeptides or B Lymphocyte Stimulator polypeptide fragments and variants comprising regions of B Lymphocyte Stimulator that combine several structural features, such as several (e.g., 1, 2, 3, or 4) of the same or different region features set out above and in Tables 9 and 10.

TABLE 9

Res	Position	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII	XIII	XIV
Met	1	A	0.73	-0.71	.	.	.	0.95	1.39
Asp	2	A	T	.	1.12	-0.66	*	.	.	1.15	1.56
Asp	3	A	T	.	1.62	-1.09	*	.	.	1.15	2.12
Ser	4	A	T	.	2.01	-1.51	.	.	.	1.15	4.19
Thr	5	A	T	.	2.40	-2.13	.	.	F	1.30	4.35
Glu	6	A	A	2.70	-1.73	*	*	F	0.90	4.51
Arg	7	A	A	2.81	-1.34	*	*	F	0.90	4.51
Glu	8	A	A	2.00	-1.73	*	*	F	0.90	6.12
Gln	9	A	A	1.99	-1.53	*	*	F	0.90	2.91
Ser	10	A	.	.	B	.	.	.	2.00	-1.04	*	*	F	0.90	2.15
Arg	11	A	.	.	B	.	.	.	1.33	-0.66	*	*	F	0.90	1.66
Leu	12	A	.	.	B	.	.	.	0.41	-0.09	*	*	F	0.45	0.51
Thr	13	A	.	.	B	.	.	.	0.46	0.20	*	*	F	-0.15	0.32
Ser	14	A	A	0.50	-0.19	*	*	.	0.30	0.32
Cys	15	A	A	0.91	-0.19	*	*	.	0.30	0.78
Leu	16	A	A	0.80	-0.87	*	*	F	0.90	1.06
Lys	17	A	A	1.61	-1.36	.	*	F	0.90	1.37
Lys	18	A	A	1.32	-1.74	.	*	F	0.90	4.44
Arg	19	A	A	1.67	-1.70	.	*	F	0.90	5.33
Glu	20	A	A	1.52	-2.39	.	*	F	0.90	5.33

TABLE 9-continued

Res	Position	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII	XIII	XIV
Glu	21	A	A	2.38	-1.70	.	*	F	0.90	2.20
Met	22	A	A	2.33	-1.70	.	*	F	0.90	2.24
Lys	23	A	A	1.62	-1.70	*	*	F	0.90	2.24
Leu	24	A	A	0.66	-1.13	*	*	F	0.75	0.69
Lys	25	A	A	0.36	-0.49	.	*	F	0.45	0.52
Glu	26	A	A	.	B	.	.	.	-0.53	-0.71	*	*	.	0.60	0.35
Cys	27	A	A	.	B	.	.	.	-0.74	-0.03	*	*	.	0.30	0.30
Val	28	A	A	.	B	.	.	.	-1.00	-0.03	*	*	.	0.30	0.12
Ser	29	A	A	.	B	.	.	.	-0.08	0.40	*	*	.	-0.30	0.11
Ile	30	A	.	.	B	.	.	.	-0.08	0.40	*	*	.	-0.30	0.40
Leu	31	A	.	.	B	.	.	.	-0.08	-0.17	*	.	.	0.45	1.08
Pro	32	.	.	.	B	.	.	C	0.29	-0.81	*	.	F	1.10	1.39
Arg	33	T	.	.	0.93	-0.81	.	*	F	1.50	2.66
Lys	34	T	.	.	0.93	-1.07	.	.	F	1.84	4.98
Glu	35	C	0.97	-1.37	*	*	F	1.98	4.32
Ser	36	T	C	1.89	-1.16	*	*	F	2.52	1.64
Pro	37	T	C	1.80	-1.16	*	*	F	2.86	1.60
Ser	38	T	T	.	1.39	-0.77	*	.	F	3.40	1.24
Val	39	A	T	.	1.39	-0.39	.	*	F	2.36	1.24
Arg	40	A	1.39	-0.77	*	*	F	2.46	1.60
Ser	41	A	1.34	-1.20	*	*	F	2.46	2.00
Ser	42	T	T	.	1.60	-1.16	.	*	F	3.06	2.67
Lys	43	T	T	.	1.09	-1.80	.	*	F	3.06	2.72
Asp	44	T	T	.	1.13	-1.11	*	*	F	3.40	1.67
Gly	45	A	T	.	0.43	-0.81	*	*	F	2.66	1.03
Lys	46	A	A	0.14	-0.70	.	.	F	1.77	0.52
Leu	47	A	A	0.13	-0.20	*	.	.	0.98	0.31
Leu	48	A	A	-0.72	0.29	*	.	.	0.04	0.46
Ala	49	A	A	-1.53	0.54	.	*	.	-0.60	0.19
Ala	50	A	A	-2.00	1.23	.	.	.	-0.60	0.19
Thr	51	A	A	-2.63	1.23	.	.	.	-0.60	0.19
Leu	52	A	A	-2.63	1.04	.	.	.	-0.60	0.19
Leu	53	A	A	-2.63	1.23	.	.	.	-0.60	0.15
Leu	54	A	A	-2.34	1.41	.	.	.	-0.60	0.09
Ala	55	A	A	-2.42	1.31	.	.	.	-0.60	0.14
Leu	56	A	A	-2.78	1.20	.	.	.	-0.60	0.09
Leu	57	A	T	.	-2.78	1.09	.	.	.	-0.20	0.06
Ser	58	A	T	.	-2.28	1.09	.	.	.	-0.20	0.05
Cys	59	A	T	.	-2.32	1.07	.	.	.	-0.20	0.09
Cys	60	A	T	.	-2.59	1.03	.	.	.	-0.20	0.08
Leu	61	.	.	B	B	.	.	.	-2.08	0.99	.	.	.	-0.60	0.04
Thr	62	.	.	B	B	.	.	.	-1.97	0.99	.	.	.	-0.60	0.11
Val	63	.	.	B	B	.	.	.	-1.91	1.20	.	.	.	-0.60	0.17
Val	64	.	.	B	B	.	.	.	-1.24	1.39	.	.	.	-0.60	0.33
Ser	65	.	.	B	B	.	.	.	-1.43	1.10	.	.	.	-0.60	0.40
Phe	66	A	.	.	B	.	.	.	-1.21	1.26	.	.	.	-0.60	0.40
Tyr	67	A	.	.	B	.	.	.	-1.49	1.11	.	.	.	-0.60	0.54
Gln	68	A	.	.	B	.	.	.	-1.44	0.97	.	.	.	-0.60	0.41
Val	69	A	.	.	B	.	.	.	-0.59	1.27	.	.	.	-0.60	0.39
Ala	70	A	.	.	B	.	.	.	-0.63	0.89	.	.	.	-0.60	0.43
Ala	71	A	.	.	B	.	.	.	0.07	0.56	.	*	.	-0.60	0.25
Leu	72	A	T	.	-0.50	0.16	.	*	.	0.10	0.55
Gln	73	A	T	.	-1.09	0.20	.	.	F	0.25	0.45
Gly	74	A	T	.	-0.53	0.20	.	.	F	0.25	0.45
Asp	75	A	T	.	-0.76	0.09	.	*	F	0.25	0.73
Leu	76	A	A	-0.06	0.09	.	*	F	-0.15	0.35
Ala	77	A	A	0.17	-0.31	.	*	.	0.30	0.69
Ser	78	A	A	0.17	-0.24	.	*	.	0.30	0.42
Leu	79	A	A	-0.30	-0.24	.	*	.	0.30	0.88
Arg	80	A	A	-0.30	-0.24	.	*	.	0.30	0.72
Ala	81	A	A	0.17	-0.34	.	*	.	0.30	0.93
Glu	82	A	A	0.72	-0.30	.	*	.	0.45	1.11
Leu	83	A	A	0.99	-0.49	.	*	.	0.30	0.77
Gln	84	A	A	1.21	0.01	.	*	.	-0.15	1.04
Gly	85	A	A	1.10	0.01	*	*	.	-0.30	0.61
His	86	A	A	1.73	0.01	*	*	.	-0.15	1.27
His	87	A	A	0.92	-0.67	.	*	.	0.75	1.47
Ala	88	A	A	1.52	-0.39	.	*	.	0.45	1.22
Glu	89	A	A	0.93	-0.39	.	.	.	0.45	1.39
Lys	90	A	A	0.93	-0.39	*	.	F	0.60	1.03
Leu	91	A	T	.	0.38	-0.46	*	.	.	0.85	1.01
Pro	92	A	T	.	0.07	-0.46	.	.	.	0.70	0.59
Ala	93	A	T	.	0.07	-0.03	.	.	.	0.70	0.29
Gly	94	A	T	.	-0.14	0.47	.	.	.	-0.20	0.36
Ala	95	A	-0.14	0.21	.	*	.	-0.10	0.36
Gly	96	A	0.08	-0.21	.	.	F	0.65	0.71
Ala	97	A	-0.06	-0.21	.	.	F	0.65	0.72

TABLE 9-continued

Res	Position	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII	XIII	XIV
Pro	98	A	-0.28	-0.21	.	*	F	0.65	0.71
Lys	99	A	A	0.07	-0.03	.	.	F	0.45	0.59
Ala	100	A	A	0.66	-0.46	.	.	F	0.60	1.01
Gly	101	A	A	0.41	-0.96	.	.	F	0.90	1.13
Leu	102	A	A	0.79	-0.89	.	.	F	0.75	0.57
Glu	103	A	A	0.41	-0.46	*	.	F	0.45	0.88
Glu	104	A	A	-0.49	-0.46	*	.	F	0.45	0.89
Ala	105	A	A	-0.21	-0.24	.	.	.	0.30	0.81
Pro	106	A	A	-0.46	-0.44	.	.	.	0.30	0.67
Ala	107	A	A	0.01	0.06	.	.	.	-0.30	0.39
Val	108	A	A	-0.80	0.49	.	*	.	-0.60	0.38
Thr	109	A	A	-0.76	0.67	.	*	.	-0.60	0.20
Ala	110	A	A	-1.06	0.24	*	*	.	-0.30	0.40
Gly	111	A	A	-1.54	0.43	*	*	.	-0.60	0.38
Leu	112	A	A	-0.96	0.57	*	*	.	-0.60	0.23
Lys	113	.	A	B	-0.31	0.09	*	*	.	-0.30	0.39
Ile	114	.	A	B	-0.21	0.01	*	.	.	-0.30	0.61
Phe	115	.	A	B	-0.21	0.01	*	.	.	0.15	1.15
Glu	116	.	A	C	-0.08	-0.17	*	.	F	1.25	0.58
Pro	117	.	A	C	0.39	0.26	*	*	F	1.10	1.28
Pro	118	C	0.34	-0.00	.	.	F	2.20	1.47
Ala	119	T	C	0.89	-0.79	.	*	F	3.00	1.47
Pro	120	T	C	1.59	-0.36	.	*	F	2.25	0.94
Gly	121	T	T	.	1.29	-0.39	.	*	F	2.15	0.98
Glu	122	T	T	.	1.20	-0.43	.	.	F	2.00	1.30
Gly	123	C	1.41	-0.54	.	.	F	1.60	1.12
Asn	124	T	C	2.00	-0.57	.	.	F	1.50	1.97
Ser	125	T	C	1.91	-0.60	.	*	F	1.50	1.82
Ser	126	T	C	2.37	-0.21	.	*	F	1.54	2.47
Gln	127	T	C	2.37	-0.64	.	*	F	2.18	3.01
Asn	128	C	2.76	-0.64	.	.	F	2.32	3.61
Ser	129	T	C	2.87	-1.03	.	.	F	2.86	5.39
Arg	130	T	T	.	2.58	-1.41	*	.	F	3.40	6.09
Asn	131	T	T	.	2.02	-1.31	*	.	F	3.06	3.83
Lys	132	T	T	.	2.02	-1.07	*	.	F	2.72	2.12
Arg	133	T	.	.	1.68	-1.06	*	.	F	2.18	1.88
Ala	134	C	1.77	-0.63	*	.	F	1.64	1.15
Val	135	C	1.66	-0.60	*	.	F	1.49	0.89
Gln	136	C	1.66	-0.60	*	.	F	1.83	0.79
Gly	137	T	C	1.30	-0.60	*	.	F	2.52	1.35
Pro	138	T	C	0.33	-0.61	*	.	F	2.86	2.63
Glu	139	T	T	.	0.61	-0.61	*	.	F	3.40	1.13
Glu	140	A	T	.	1.47	-0.53	*	.	F	2.66	1.64
Thr	141	A	1.47	-0.56	.	.	F	2.12	1.84
Val	142	A	1.14	-0.99	.	.	F	1.78	1.77
Thr	143	A	T	.	0.54	-0.41	.	.	F	1.19	0.55
Gln	144	A	T	.	0.54	0.27	*	.	F	0.25	0.31
Asp	145	A	T	.	-0.27	0.19	*	.	F	0.25	0.73
Cys	146	A	T	.	-0.84	0.23	*	.	.	0.10	0.42
Leu	147	A	A	-0.58	0.43	*	.	.	-0.60	0.17
Gln	148	A	A	-0.27	0.53	*	.	.	-0.60	0.10
Leu	149	A	A	-0.57	0.53	*	*	.	-0.30	0.32
Ile	150	A	A	-0.57	0.34	*	.	.	0.30	0.52
Ala	151	.	A	C	-0.21	-0.34	.	*	.	1.40	0.52
Asp	152	T	T	.	0.39	-0.26	.	*	F	2.45	0.91
Ser	153	T	C	0.08	-0.51	.	.	F	3.00	2.00
Glu	154	T	C	-0.00	-0.71	.	.	F	2.70	2.86
Thr	155	T	C	0.89	-0.53	*	.	F	2.40	1.20
Pro	156	.	.	.	B	.	.	C	1.52	-0.13	*	.	F	1.56	1.55
Thr	157	.	.	.	B	T	.	.	1.18	-0.51	*	.	F	1.92	1.79
Ile	158	A	.	.	B	.	.	.	1.18	-0.09	.	.	F	1.08	1.23
Gln	159	T	T	.	0.93	-0.19	.	.	F	2.04	1.07
Lys	160	T	T	.	0.93	0.14	*	.	F	1.60	1.16
Gly	161	T	T	.	0.44	0.14	*	.	F	1.44	2.38
Ser	162	T	T	.	-0.10	0.24	*	.	F	1.28	1.19
Tyr	163	.	.	.	B	T	.	.	0.58	0.49	*	.	.	0.12	0.44
Thr	164	.	.	B	B	.	.	.	0.29	0.91	*	.	.	-0.44	0.69
Phe	165	.	.	B	B	.	.	.	-0.57	1.40	*	.	.	-0.60	0.54
Val	166	.	.	B	B	.	.	.	-1.03	1.70	.	.	.	-0.60	0.29
Pro	167	.	.	B	B	.	.	.	-1.03	1.63	.	.	.	-0.60	0.16
Trp	168	A	.	.	B	.	.	.	-1.49	1.53	.	*	.	-0.60	0.25
Leu	169	A	.	.	B	.	.	.	-1.13	1.53	*	.	.	-0.60	0.29
Leu	170	A	.	.	B	.	.	.	-0.32	0.89	*	.	.	-0.30	0.38
Ter	171	A	0.19	0.46	*	.	.	0.20	0.71
Phe	172	T	.	.	0.10	-0.03	*	.	.	1.80	0.85
Lys	173	T	T	.	-0.20	-0.33	*	.	F	2.60	1.38
Arg	174	T	C	-0.20	-0.51	.	.	F	3.00	1.04

TABLE 9-continued

Res	Position	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII	XIII	XIV
Gly	175	T	C	0.61	-0.21	.	.	F	2.25	0.99
Ser	176	A	T	.	0.91	-1.00	*	.	F	2.05	0.86
Ala	177	A	A	1.66	-1.00	*	.	F	1.35	0.76
Leu	178	A	A	1.61	-1.00	.	.	F	1.20	1.54
Glu	179	A	A	1.50	-1.43	.	.	F	0.90	1.98
Glu	180	A	A	1.89	-1.41	*	.	F	0.90	3.16
Lys	181	A	A	1.30	-1.91	*	.	F	0.90	7.66
Glu	182	A	A	1.08	-1.91	.	.	F	0.90	3.10
Asn	183	A	A	1.03	-1.23	*	*	F	0.90	1.48
Lys	184	A	A	1.08	-0.59	*	.	F	0.75	0.55
Ile	185	A	A	1.08	-0.59	*	*	.	0.60	0.63
Leu	186	A	A	0.72	-0.59	*	*	.	0.60	0.68
Val	187	A	A	0.38	-0.50	.	*	.	0.30	0.49
Lys	188	A	A	0.13	-0.07	*	*	F	0.45	0.69
Glu	189	A	T	.	-0.61	0.00	*	*	F	0.40	1.32
Thr	190	T	T	.	-0.42	0.10	.	*	F	0.80	1.54
Gly	191	T	T	.	-0.50	0.24	*	.	F	0.65	0.67
Tyr	192	T	T	.	0.11	0.93	*	*	.	0.20	0.27
Phe	193	.	.	B	B	.	.	.	-0.28	1.69	.	.	.	-0.60	0.29
Phe	194	.	.	B	B	.	.	.	-0.28	1.63	.	*	.	-0.60	0.29
Ile	195	.	.	B	B	.	.	.	-0.82	1.60	.	.	.	-0.60	0.32
Tyr	196	.	.	B	B	.	.	.	-1.29	1.49	.	.	.	-0.60	0.28
Gly	197	.	.	.	B	T	.	.	-1.29	1.39	.	.	.	-0.20	0.26
Gln	198	.	.	.	B	T	.	.	-0.90	1.36	.	.	.	-0.20	0.59
Val	199	.	.	.	B	.	.	C	-0.20	1.16	.	.	.	-0.40	0.54
Leu	200	.	.	.	B	.	.	C	0.73	0.40	.	.	.	-0.10	0.92
Tyr	201	T	T	.	0.67	-0.03	.	.	.	1.25	1.06
Thr	202	T	T	.	0.77	0.06	.	.	F	0.80	2.06
Asp	203	T	T	.	0.18	0.17	.	.	F	0.80	3.91
Lys	204	A	T	.	0.43	-0.01	.	.	F	1.00	2.52
Thr	205	A	A	0.90	-0.16	.	.	F	0.60	1.73
Tyr	206	A	A	1.11	-0.21	.	.	.	0.45	1.03
Ala	207	A	A	0.61	0.29	.	.	.	-0.30	0.70
Met	208	A	A	-0.28	0.97	.	.	.	-0.60	0.40
Gly	209	A	A	.	B	.	.	.	-0.32	1.17	*	.	.	-0.60	0.18
His	210	A	A	.	B	.	.	.	0.10	0.81	*	.	.	-0.60	0.31
Leu	211	A	A	.	B	.	.	.	0.39	0.31	.	.	.	-0.30	0.61
Ile	212	A	A	.	B	.	.	.	1.02	-0.30	.	.	.	0.45	1.22
Gln	213	A	A	.	B	.	.	.	0.77	-0.73	.	*	.	0.75	1.80
Arg	214	A	A	.	B	.	.	.	1.08	-0.59	.	*	F	0.90	1.62
Lys	215	A	A	.	B	.	.	.	0.26	-0.77	*	*	F	0.90	3.14
Lys	216	A	A	.	B	.	.	.	0.37	-0.81	.	*	F	0.90	1.35
Val	217	.	A	B	B	.	.	.	0.91	-0.43	*	*	.	0.30	0.60
His	218	.	A	B	B	.	.	.	0.91	-0.00	.	*	.	0.30	0.29
Val	219	.	A	B	B	.	.	.	0.80	-0.00	*	*	.	0.30	0.25
Phe	220	.	.	B	B	.	.	.	-0.06	-0.00	*	.	.	0.30	0.57
Gly	221	A	.	.	B	.	.	.	-0.40	0.04	.	*	.	-0.30	0.35
Asp	222	A	-0.36	-0.07	*	.	.	0.50	0.63
Glu	223	A	-1.18	-0.03	*	.	.	0.50	0.60
Leu	224	A	.	.	B	.	.	.	-0.63	-0.17	.	.	.	0.30	0.45
Ser	225	A	.	.	B	.	.	.	-0.74	-0.11	.	.	.	0.30	0.39
Leu	226	A	.	.	B	.	.	.	-1.10	0.57	.	*	.	-0.60	0.18
Val	227	A	.	.	B	.	.	.	-0.99	1.36	.	*	.	-0.60	0.19
Thr	228	A	.	.	B	.	.	.	-1.66	0.67	*	*	.	-0.60	0.28
Leu	229	A	.	.	B	.	.	.	-1.73	0.86	*	.	.	-0.60	0.18
Phe	230	A	.	.	B	.	.	.	-1.43	0.86	*	.	.	-0.60	0.17
Arg	231	A	.	.	B	.	.	.	-0.62	0.61	*	.	.	-0.60	0.21
Cys	232	.	.	.	B	T	.	.	-0.37	0.53	*	.	.	-0.20	0.41
Ile	233	.	.	.	B	T	.	.	-0.27	0.46	*	.	.	-0.20	0.46
Gln	234	.	.	.	B	T	.	.	0.54	0.10	*	.	.	0.10	0.37
Asn	235	.	.	.	B	.	.	C	0.93	0.10	*	.	.	0.05	1.19
Met	236	.	.	.	B	.	.	C	0.01	0.01	*	.	F	0.20	2.44
Pro	237	.	.	.	B	.	.	C	0.47	0.01	*	.	F	0.44	1.16
Glu	238	T	.	.	1.36	0.04	*	.	F	1.08	1.12
Thr	239	C	1.36	0.04	*	.	F	1.12	1.82
Leu	240	C	1.06	-0.17	*	.	F	1.96	1.89
Pro	241	T	.	.	0.99	-0.21	.	.	F	2.40	1.46
Asn	242	T	.	.	0.96	0.36	.	.	F	1.41	0.54
Asn	243	T	T	.	0.66	0.63	.	.	F	1.22	1.03
Ser	244	T	T	.	0.38	0.33	.	.	F	1.13	0.89
Cys	245	T	T	.	0.84	0.40	.	.	.	0.74	0.56
Tyr	246	T	T	.	0.17	0.43	.	.	.	0.20	0.35
Ser	247	A	-0.42	0.71	.	.	.	-0.40	0.18
Ala	248	A	A	-0.38	0.83	.	.	.	-0.60	0.34
Gly	249	A	A	-0.89	0.26	.	.	.	-0.30	0.43
Ile	250	A	A	-0.22	0.19	*	.	.	-0.30	0.27
Ala	251	A	A	0.02	-0.20	*	.	.	0.30	0.46

TABLE 9-continued

Res	Position	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII	XIII	XIV
Lys	252	A	A	-0.02	-0.70	.	.	.	0.60	0.80
Leu	253	A	A	0.57	-0.70	.	.	F	0.90	1.13
Glu	254	A	A	0.91	-1.39	.	.	F	0.90	1.87
Glu	255	A	A	0.99	-1.89	.	.	F	0.90	1.62
Gly	256	A	A	1.58	-1.20	.	*	F	0.90	1.62
Asp	257	A	A	0.72	-1.49	.	*	F	0.90	1.62
Glu	258	A	A	0.94	-0.80	*	*	F	0.75	0.77
Leu	259	A	A	0.06	-0.30	*	*	.	0.30	0.79
Gln	260	A	A	-0.16	-0.04	*	.	.	0.30	0.33
Leu	261	A	A	0.30	0.39	*	.	.	-0.30	0.30
Ala	262	A	A	0.30	0.39	*	.	.	-0.30	0.70
Ile	263	A	A	0.30	-0.30	.	*	.	0.30	0.70
Pro	264	A	T	.	0.52	-0.30	.	*	F	1.00	1.37
Arg	265	A	T	.	0.52	-0.49	.	*	F	1.00	1.37
Glu	266	A	T	.	0.44	-0.59	*	*	F	1.30	3.38
Asn	267	A	T	.	0.73	-0.59	*	*	F	1.30	1.53
Ala	268	A	0.81	-0.63	*	*	.	0.95	1.05
Gln	269	A	1.02	0.06	*	*	.	-0.10	0.50
Ile	270	A	0.57	0.06	.	*	.	0.15	0.52
Ser	271	C	0.57	0.09	.	*	.	0.60	0.51
Leu	272	C	-0.29	-0.41	.	*	F	1.60	0.49
Asp	273	T	T	.	-0.01	-0.17	.	*	F	2.25	0.52
Gly	274	T	T	.	-0.71	-0.37	.	*	F	2.50	0.56
Asp	275	T	T	.	-0.52	0.03	.	*	F	1.65	0.59
Val	276	A	T	.	-0.57	0.13	.	*	F	1.00	0.30
Thr	277	A	.	.	B	.	.	.	-0.34	0.56	.	*	.	-0.10	0.30
Phe	278	A	.	.	B	.	.	.	-1.16	0.63	.	*	.	-0.35	0.18
Phe	279	A	.	.	B	.	.	.	-0.77	1.31	.	*	.	-0.60	0.20
Gly	280	A	A	-1.58	0.67	.	*	.	-0.60	0.28
Ala	281	A	A	-1.53	0.87	.	*	.	-0.60	0.27
Leu	282	A	A	-1.61	0.77	*	.	.	-0.60	0.26
Lys	283	A	A	-1.30	0.41	*	.	.	-0.60	0.33
Leu	284	A	A	-0.99	0.41	.	.	.	-0.60	0.42
Leu	285	A	A	-1.03	0.34	*	.	.	-0.30	0.65

TABLE 10

Res	Position	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII	XIII	XIV
Met	1	A	0.73	-0.71	.	.	.	0.95	1.39
Asp	2	A	T	.	1.12	-0.66	*	.	.	1.15	1.56
Asp	3	A	T	.	1.62	-1.09	*	.	.	1.15	2.12
Ser	4	A	T	.	2.01	-1.51	.	.	.	1.15	4.19
Thr	5	A	T	.	2.40	-2.13	.	.	F	1.30	4.35
Glu	6	A	A	2.70	-1.73	*	*	F	0.90	4.51
Arg	7	A	A	2.81	-1.34	*	*	F	0.90	4.51
Glu	8	A	A	2.00	-1.73	*	*	F	0.90	6.12
Gln	9	A	A	1.99	-1.53	*	*	F	0.90	2.91
Ser	10	A	.	.	B	.	.	.	2.00	-1.04	*	*	F	0.90	2.15
Arg	11	A	.	.	B	.	.	.	1.33	-0.66	*	*	F	0.90	1.66
Leu	12	A	.	.	B	.	.	.	0.41	-0.09	*	*	F	0.45	0.51
Thr	13	A	.	.	B	.	.	.	0.46	0.20	*	*	F	-0.15	0.32
Ser	14	A	A	0.50	-0.19	*	*	.	0.30	0.32
Cys	15	A	A	0.91	-0.19	*	*	.	0.30	0.78
Leu	16	A	A	0.80	-0.87	*	*	F	0.90	1.06
Lys	17	A	A	1.61	-1.36	.	*	F	0.90	1.37
Lys	18	A	A	1.32	-1.74	.	*	F	0.90	4.44
Arg	19	A	A	1.67	-1.70	.	*	F	0.90	5.33
Glu	20	A	A	1.52	-2.39	.	*	F	0.90	5.33
Glu	21	A	A	2.38	-1.70	.	*	F	0.90	2.20
Met	22	A	A	2.33	-1.70	.	*	F	0.90	2.24
Lys	23	A	A	1.62	-1.70	*	*	F	0.90	2.24
Leu	24	A	A	0.66	-1.13	*	*	F	0.75	0.69
Lys	25	A	A	0.36	-0.49	.	*	F	0.45	0.52
Glu	26	A	A	.	B	.	.	.	-0.53	-0.71	*	*	.	0.60	0.35
Cys	27	A	A	.	B	.	.	.	-0.74	-0.03	*	*	.	0.30	0.30
Val	28	A	A	.	B	.	.	.	-1.00	-0.03	*	*	.	0.30	0.12
Ser	29	A	A	.	B	.	.	.	-0.08	0.40	*	*	.	-0.30	0.11
Ile	30	A	.	.	B	.	.	.	-0.08	0.40	*	*	.	-0.30	0.40
Leu	31	A	.	.	B	.	.	.	-0.08	-0.17	*	.	.	0.45	1.08
Pro	32	.	.	.	B	.	.	C	0.29	-0.81	*	.	F	1.10	1.39
Arg	33	T	.	.	0.93	-0.81	.	*	F	1.50	2.66
Lys	34	T	.	.	0.93	-1.07	.	.	F	1.84	4.98
Glu	35	C	0.97	-1.37	*	*	F	1.98	4.32

TABLE 10-continued

Res	Position	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII	XIII	XIV
Ser	36	T	C	1.89	-1.16	*	*	F	2.52	1.64
Pro	37	T	C	1.80	-1.16	*	*	F	2.86	1.60
Ser	38	T	T	.	1.39	-0.77	*	.	F	3.40	1.24
Val	39	A	T	.	1.39	-0.39	.	*	F	2.36	1.24
Arg	40	A	1.39	-0.77	*	*	F	2.46	1.60
Ser	41	A	1.34	-1.20	*	*	F	2.46	2.00
Ser	42	T	T	.	1.60	-1.16	.	*	F	3.06	2.67
Lys	43	T	T	.	1.09	-1.80	*	*	F	3.06	2.72
Asp	44	T	T	.	1.13	-1.11	*	*	F	3.40	1.67
Gly	45	A	T	.	0.43	-0.81	*	*	F	2.66	1.03
Lys	46	A	A	0.14	-0.70	.	.	F	1.77	0.52
Leu	47	A	A	0.13	-0.20	*	.	.	0.98	0.31
Leu	48	A	A	-0.72	0.29	*	.	.	0.04	0.46
Ala	49	A	A	-1.53	0.54	.	*	.	-0.60	0.19
Ala	50	A	A	-2.00	1.23	.	.	.	-0.60	0.19
Thr	51	A	A	-2.63	1.23	.	.	.	-0.60	0.19
Leu	52	A	A	-2.63	1.04	.	.	.	-0.60	0.19
Leu	53	A	A	-2.63	1.23	.	.	.	-0.60	0.15
Leu	54	A	A	-2.34	1.41	.	.	.	-0.60	0.09
Ala	55	A	A	-2.42	1.31	.	.	.	-0.60	0.14
Leu	56	A	A	-2.78	1.20	.	.	.	-0.60	0.09
Leu	57	A	T	.	-2.78	1.09	.	.	.	-0.20	0.06
Ser	58	A	T	.	-2.28	1.09	.	.	.	-0.20	0.05
Cys	59	A	T	.	-2.32	1.07	.	.	.	-0.20	0.09
Cys	60	A	T	.	-2.59	1.03	.	.	.	-0.20	0.08
Leu	61	.	.	B	B	.	.	.	-2.08	0.99	.	.	.	-0.60	0.04
Thr	62	.	.	B	B	.	.	.	-1.97	0.99	.	.	.	-0.60	0.11
Val	63	.	.	B	B	.	.	.	-1.91	1.20	.	.	.	-0.60	0.17
Val	64	.	.	B	B	.	.	.	-1.24	1.39	.	.	.	-0.60	0.33
Ser	65	.	.	B	B	.	.	.	-1.43	1.10	.	.	.	-0.60	0.40
Phe	66	A	.	.	B	.	.	.	-1.21	1.26	.	.	.	-0.60	0.40
Tyr	67	A	.	.	B	.	.	.	-1.49	1.11	.	.	.	-0.60	0.54
Gln	68	A	.	.	B	.	.	.	-1.44	0.97	.	.	.	-0.60	0.41
Val	69	A	.	.	B	.	.	.	-0.59	1.27	.	.	.	-0.60	0.39
Ala	70	A	.	.	B	.	.	.	-0.63	0.89	.	.	.	-0.60	0.43
Ala	71	A	.	.	B	.	.	.	0.07	0.56	.	*	.	-0.60	0.25
Leu	72	A	T	.	-0.50	0.16	.	.	.	0.10	0.55
Gln	73	A	T	.	-1.09	0.20	.	.	F	0.25	0.45
Gly	74	A	T	.	-0.53	0.20	.	.	F	0.25	0.45
Asp	75	A	T	.	-0.76	0.09	.	*	F	0.25	0.73
Leu	76	A	A	-0.06	0.09	.	*	F	-0.15	0.35
Ala	77	A	A	0.17	-0.31	.	*	.	0.30	0.69
Ser	78	A	A	0.17	-0.24	.	*	.	0.30	0.42
Leu	79	A	A	-0.30	-0.24	.	*	.	0.30	0.88
Arg	80	A	A	-0.30	-0.24	.	*	.	0.30	0.72
Ala	81	A	A	0.17	-0.34	.	*	.	0.30	0.93
Glu	82	A	A	0.72	-0.30	.	*	.	0.45	1.11
Leu	83	A	A	0.99	-0.49	.	*	.	0.30	0.77
Gln	84	A	A	1.21	0.01	.	*	.	-0.15	1.04
Gly	85	A	A	1.10	0.01	*	*	.	-0.30	0.61
His	86	A	A	1.73	0.01	*	*	.	-0.15	1.27
His	87	A	A	0.92	-0.67	.	*	.	0.75	1.47
Ala	88	A	A	1.52	-0.39	.	*	.	0.45	1.22
Glu	89	A	A	0.93	-0.39	.	.	.	0.45	1.39
Lys	90	A	A	0.93	-0.39	*	.	F	0.60	1.03
Leu	91	A	T	.	0.38	-0.46	*	.	.	0.85	1.01
Pro	92	A	T	.	0.07	-0.46	.	.	.	0.70	0.59
Ala	93	A	T	.	0.07	-0.03	.	.	.	0.70	0.29
Gly	94	A	T	.	-0.14	0.47	.	.	.	-0.20	0.36
Ala	95	A	-0.14	0.21	.	*	.	-0.10	0.36
Gly	96	A	0.08	-0.21	.	.	F	0.65	0.71
Ala	97	A	-0.06	-0.21	.	.	F	0.65	0.72
Pro	98	A	-0.28	-0.21	.	*	F	0.65	0.71
Lys	99	A	A	0.07	-0.03	.	.	F	0.45	0.59
Ala	100	A	A	0.66	-0.46	.	.	F	0.60	1.01
Gly	101	A	A	0.41	-0.96	.	.	F	0.90	1.13
Leu	102	A	A	0.79	-0.89	.	.	F	0.75	0.57
Glu	103	A	A	0.41	-0.46	*	.	F	0.45	0.88
Glu	104	A	A	-0.49	-0.46	*	.	F	0.45	0.89
Ala	105	A	A	-0.21	-0.24	.	.	.	0.30	0.81
Pro	106	A	A	-0.46	-0.44	.	.	.	0.30	0.67
Ala	107	A	A	0.01	0.06	.	.	.	-0.30	0.39
Val	108	A	A	-0.80	0.49	*	*	.	-0.60	0.38
Thr	109	A	A	-0.76	0.67	.	*	.	-0.60	0.20
Ala	110	A	A	-1.06	0.24	*	*	.	-0.30	0.40
Gly	111	A	A	-1.54	0.43	*	*	.	-0.60	0.38
Leu	112	A	A	-0.96	0.57	*	*	.	-0.60	0.23

TABLE 10-continued

Res	Position	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII	XIII	XIV
Lys	113	.	A	B	-0.31	0.09	*	*	.	-0.30	0.39
Ile	114	.	A	B	-0.21	0.01	*	.	.	-0.30	0.61
Phe	115	.	A	B	-0.21	0.01	*	.	.	0.15	1.15
Glu	116	.	A	C	-0.08	-0.17	*	.	F	1.25	0.58
Pro	117	.	A	C	0.39	0.26	*	*	F	1.10	1.28
Pro	118	C	0.34	0.00	*	.	F	2.20	1.47
Ala	119	T	C	0.89	-0.79	.	*	F	3.00	1.47
Pro	120	T	C	1.59	-0.36	.	*	F	2.25	0.94	
Gly	121	T	T	.	1.29	-0.39	.	*	F	2.15	0.98
Glu	122	T	T	.	1.20	-0.43	.	.	F	2.00	1.30
Gly	123	C	1.41	-0.54	.	.	F	1.60	1.12
Asn	124	T	C	2.00	-0.57	.	.	F	1.50	1.97
Ser	125	T	C	1.91	-0.60	.	*	F	1.50	1.82
Ser	126	T	C	2.37	-0.21	.	*	F	1.54	2.47
Gln	127	T	C	2.37	-0.64	.	*	F	2.18	3.01
Asn	128	C	2.76	-0.64	.	.	F	2.32	3.61
Ser	129	T	C	2.87	-1.03	.	.	F	2.86	5.39
Arg	130	T	T	.	2.58	-1.41	*	.	F	3.40	6.09
Asn	131	T	T	.	2.02	-1.31	*	.	F	3.06	3.83
Lys	132	T	T	.	2.02	-1.07	*	.	F	2.72	2.12
Arg	133	T	.	.	1.68	-1.06	*	.	F	2.18	1.88
Ala	134	C	1.77	-0.63	*	.	F	1.64	1.15
Val	135	C	1.66	-0.60	*	.	F	1.15	0.89
Gln	136	C	1.66	-0.60	*	.	F	1.49	0.79
Gly	137	T	C	1.30	-0.60	*	.	F	2.18	1.35
Pro	138	T	C	0.84	-0.61	*	.	F	2.52	2.63
Glu	139	T	C	1.13	-0.83	*	.	F	2.86	1.50
Glu	140	T	T	.	1.74	-0.84	.	.	F	3.40	2.03
Thr	141	T	.	.	1.43	-0.51	.	.	F	2.86	2.06
Gly	142	T	T	.	1.08	-0.46	.	.	F	2.42	1.72
Ser	143	T	T	.	0.43	0.33	.	.	F	1.33	0.86
Tyr	144	T	T	.	0.22	0.97	.	.	.	0.54	0.44
Thr	145	T	T	.	-0.07	0.91	.	.	.	0.20	0.69
Phe	146	.	.	B	B	.	.	.	-0.57	1.40	.	.	.	-0.60	0.54
Val	147	.	.	B	B	.	.	.	-1.03	1.70	.	.	.	-0.60	0.29
Pro	148	.	.	B	B	.	.	.	-1.03	1.63	.	.	.	-0.60	0.16
Trp	149	A	.	.	B	.	.	.	-1.49	1.53	.	*	.	-0.60	0.25
Leu	150	A	.	.	B	.	.	.	-1.13	1.53	*	.	.	-0.60	0.29
Leu	151	A	.	.	B	.	.	.	-0.32	0.89	*	.	.	-0.30	0.38
Ser	152	A	0.19	0.46	*	.	.	0.20	0.71
Phe	153	T	.	.	0.10	-0.03	*	.	.	1.80	0.85
Lys	154	T	T	.	-0.20	-0.33	*	.	F	2.60	1.38
Arg	155	T	C	.	-0.20	-0.51	.	.	F	3.00	1.04
Gly	156	T	C	.	0.61	-0.21	.	.	F	2.25	0.99
Ser	157	A	.	.	.	T	.	.	0.91	-1.00	*	.	F	2.05	0.86
Ala	158	A	A	1.66	-1.00	*	.	F	1.35	0.76
Leu	159	A	A	1.61	-1.00	.	.	F	1.20	1.54
Glu	160	A	A	1.50	-1.43	.	.	F	0.90	1.98
Glu	161	A	A	1.89	-1.41	*	.	F	0.90	3.16
Lys	162	A	A	1.30	-1.91	*	.	F	0.90	7.66
Glu	163	A	A	1.08	-1.91	.	.	F	0.90	3.10
Asn	164	A	A	1.03	-1.23	*	*	F	0.90	1.48
Lys	165	A	A	1.08	-0.59	*	.	F	0.75	0.55
Ile	166	A	A	1.08	-0.59	*	*	.	0.60	0.63
Leu	167	A	A	0.72	-0.59	*	*	.	0.76	0.68
Val	168	A	A	0.38	-0.50	.	*	.	0.92	0.49
Lys	169	A	A	0.13	-0.07	*	*	F	0.93	0.69
Glu	170	A	.	.	.	T	.	.	-0.61	0.00	*	*	F	1.64	1.32
Thr	171	T	T	.	-0.42	0.10	.	*	F	1.60	1.54
Gly	172	T	T	.	-0.50	0.24	*	.	F	1.29	0.67
Tyr	173	T	T	.	0.11	0.93	*	*	.	0.68	0.27
Phe	174	.	.	B	B	.	.	.	-0.28	1.69	.	.	.	-0.28	0.29
Phe	175	.	.	B	B	.	.	.	-0.28	1.63	.	*	.	-0.44	0.29
Ile	176	.	.	B	B	.	.	.	-0.82	1.60	.	.	.	-0.60	0.32
Tyr	177	.	.	B	B	.	.	.	-1.29	1.49	.	.	.	-0.60	0.28
Gly	178	.	.	.	B	T	.	.	-1.29	1.39	.	.	.	-0.20	0.26
Gln	179	.	.	.	B	T	.	.	-0.90	1.36	.	.	.	-0.20	0.59
Val	180	.	.	.	B	.	.	C	-0.20	1.16	.	.	.	-0.40	0.54
Leu	181	.	.	.	B	.	.	C	0.73	0.40	.	.	.	-0.10	0.92
Tyr	182	T	T	.	0.67	-0.03	.	.	.	1.25	1.06
Thr	183	T	T	.	0.77	0.06	.	.	F	0.80	2.06
Asp	184	T	T	.	0.18	0.17	.	.	F	0.80	3.91
Lys	185	A	.	.	.	T	.	.	0.43	-0.01	.	.	F	1.00	2.52
Thr	186	A	A	0.90	-0.16	.	.	F	0.60	1.73
Tyr	187	A	A	1.11	-0.21	.	.	.	0.45	1.03
Ala	188	A	A	0.61	0.29	.	.	.	-0.30	0.70
Met	189	A	A	-0.28	0.97	.	.	.	-0.60	0.40

TABLE 10-continued

Res	Position	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII	XIII	XIV
Gly	190	A	A	.	B	.	.	.	-0.32	1.17	*	.	.	-0.60	0.18
His	191	A	A	.	B	.	.	.	0.10	0.81	*	.	.	-0.60	0.31
Leu	192	A	A	.	B	.	.	.	0.39	0.31	.	.	.	-0.30	0.61
Ile	193	A	A	.	B	.	.	.	1.02	-0.30	.	.	.	0.45	1.22
Gln	194	A	A	.	B	.	.	.	0.77	-0.73	.	*	.	0.75	1.80
Arg	195	A	A	.	B	.	.	.	1.08	-0.59	*	*	F	0.90	1.62
Lys	196	A	A	.	B	.	.	.	0.26	-0.77	*	*	F	0.90	3.14
Lys	197	A	A	.	B	.	.	.	0.37	-0.81	.	*	F	0.90	1.35
Val	198	.	A	B	B	.	.	.	0.91	-0.43	*	*	.	0.30	0.60
His	199	.	A	B	B	.	.	.	0.91	0.00	*	*	.	0.30	0.29
Val	200	.	A	B	B	.	.	.	0.80	0.00	*	*	.	0.30	0.25
Phe	201	.	.	B	B	.	.	.	-0.06	0.00	*	.	.	0.30	0.57
Gly	202	A	.	.	B	.	.	.	-0.40	0.04	.	*	.	-0.30	0.35
Asp	203	A	-0.36	-0.07	*	.	.	0.50	0.63
Glu	204	A	-1.18	-0.03	*	.	.	0.50	0.60
Leu	205	A	.	.	B	.	.	.	-0.63	-0.17	.	.	.	0.30	0.45
Ser	206	A	.	.	B	.	.	.	-0.74	-0.11	.	.	.	0.30	0.39
Leu	207	A	.	.	B	.	.	.	-1.10	0.57	.	*	.	-0.60	0.18
Val	208	A	.	.	B	.	.	.	-0.99	1.36	.	*	.	-0.60	0.19
Thr	209	A	.	.	B	.	.	.	-1.66	0.67	*	*	.	-0.60	0.28
Leu	210	A	.	.	B	.	.	.	-1.73	0.86	*	.	.	-0.60	0.18
Phe	211	A	.	.	B	.	.	.	-1.43	0.86	*	.	.	-0.60	0.17
Arg	212	A	.	.	B	.	.	.	-0.62	0.61	*	.	.	-0.60	0.21
Cys	213	.	.	.	B	T	.	.	-0.37	0.53	*	.	.	-0.20	0.41
Ile	214	.	.	.	B	T	.	.	-0.27	0.46	*	.	.	-0.20	0.46
Gln	215	.	.	.	B	T	.	.	0.54	0.10	*	.	.	0.10	0.37
Asn	216	.	.	.	B	.	.	C	0.93	0.10	*	.	.	0.05	1.19
Met	217	.	.	.	B	.	.	C	0.01	0.01	*	.	F	0.20	2.44
Pro	218	.	.	.	B	.	.	C	0.47	0.01	*	.	F	0.44	1.16
Glu	219	T	.	.	1.36	0.04	*	.	F	1.08	1.12
Thr	220	C	1.36	0.04	*	.	F	1.12	1.82
Leu	221	C	1.06	-0.17	*	.	F	1.96	1.89
Pro	222	T	.	.	0.99	-0.21	.	.	F	2.40	1.46
Asn	223	T	.	.	0.96	0.36	.	.	F	1.41	0.54
Asn	224	T	T	.	0.66	0.63	.	.	F	1.22	1.03
Ser	225	T	T	.	0.38	0.33	.	.	F	1.13	0.89
Cys	226	T	T	.	0.84	0.40	.	.	.	0.74	0.56
Tyr	227	T	T	.	0.17	0.43	.	.	.	0.20	0.35
Ser	228	A	-0.42	0.71	.	.	.	-0.40	0.18
Ala	229	A	A	-0.38	0.83	.	.	.	-0.60	0.34
Gly	230	A	A	-0.89	0.26	.	.	.	-0.30	0.43
Ile	231	A	A	-0.22	0.19	*	.	.	-0.30	0.27
Ala	232	A	A	0.02	-0.20	*	.	.	0.30	0.46
Lys	233	A	A	-0.02	-0.70	.	.	.	0.60	0.80
Leu	234	A	A	0.57	-0.70	.	.	F	0.90	1.13
Glu	235	A	A	0.91	-1.39	.	.	F	0.90	1.87
Glu	236	A	A	0.99	-1.89	.	.	F	0.90	1.62
Gly	237	A	A	1.58	-1.20	.	*	F	0.90	1.62
Asp	238	A	A	0.72	-1.49	.	*	F	0.90	1.62
Glu	239	A	A	0.94	-0.80	*	*	F	0.75	0.77
Leu	240	A	A	0.06	-0.30	*	*	.	0.30	0.79
Gln	241	A	A	-0.16	-0.04	*	.	.	0.30	0.33
Leu	242	A	A	0.30	0.39	*	.	.	-0.30	0.30
Ala	243	A	A	0.30	0.39	*	.	.	-0.30	0.70
Ile	244	A	A	0.30	-0.30	.	*	.	0.30	0.70
Pro	245	A	T	.	0.52	-0.30	.	*	F	1.00	1.37
Arg	246	A	T	.	0.52	-0.49	.	*	F	1.00	1.37
Glu	247	A	T	.	0.44	-0.59	*	*	F	1.30	3.38
Asn	248	A	T	.	0.73	-0.59	*	*	F	1.30	1.53
Ala	249	A	0.81	-0.63	*	*	.	0.95	1.05
Gln	250	A	1.02	0.06	*	*	.	-0.10	0.50
Ile	251	A	0.57	0.06	*	*	.	0.15	0.52
Ser	252	C	0.57	0.09	.	*	.	0.60	0.51
Leu	253	C	-0.29	-0.41	.	*	F	1.60	0.49
Asp	254	T	T	.	-0.01	-0.17	.	*	F	2.25	0.52
Gly	255	T	T	.	-0.71	-0.37	.	*	F	2.50	0.56
Asp	256	T	T	.	-0.52	0.03	.	*	F	1.65	0.59
Val	257	A	T	.	-0.57	0.13	.	*	F	1.00	0.30
Thr	258	A	.	.	B	.	.	.	-0.34	0.56	.	*	.	-0.10	0.30
Phe	259	A	.	.	B	.	.	.	-1.16	0.63	.	*	.	-0.35	0.18
Phe	260	A	.	.	B	.	.	.	-0.77	1.31	.	*	.	-0.60	0.20
Gly	261	A	A	-1.58	0.67	.	*	.	-0.60	0.28
Ala	262	A	A	-1.53	0.87	.	*	.	-0.60	0.27
Leu	263	A	A	-1.61	0.77	*	.	.	-0.60	0.26
Lys	264	A	A	-1.30	0.41	*	.	.	-0.60	0.33

TABLE 10-continued

Res	Position	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII	XIII	XIV
Leu	265	A	A	-0.99	0.41	.	.	.	-0.60	0.42
Leu	266	A	A	-1.03	0.34	*	.	.	-0.30	0.65

In another embodiment, the invention provides antibodies that bind a polypeptide comprising, or alternatively consisting of, an epitope-bearing portion of a polypeptide of the invention. The epitope of this polypeptide portion may be an immunogenic or antigenic epitope of a polypeptide of the invention. An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response when the whole protein is the immunogen. On the other hand, a region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." The number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. See, for instance, Geysen et al., *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1983).

As to the selection of polypeptides bearing an antigenic epitope (i.e., that contain a region of a protein molecule to which an antibody can bind), it is well known in that art that relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See, for instance, Sutcliffe, J. G., Shinnick, T. M., Green, N. and Learner, R. A. (1983) "Antibodies that react with predetermined sites on proteins", *Science*, 219:660-666. Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact proteins (i.e., immunogenic epitopes) nor to the amino or carboxyl terminals. Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a polypeptide of the invention. See, for instance, Wilson et al., *Cell* 37:767-778 (1984) at 777.

In specific embodiments, antibodies of the present invention bind antigenic epitope-bearing peptides and polypeptides of B Lymphocyte Stimulator and preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids contained within the amino acid sequence of a B Lymphocyte Stimulator polypeptide. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof.

Non-limiting examples of antigenic polypeptides or peptides that can be used to generate B Lymphocyte Stimulator-specific antibodies and which may be bound by the antibodies of the invention include: a polypeptide comprising, or alternatively consisting of, amino acid residues from about Phe-115 to about Leu-147 in SEQ ID NO:3228; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Ile-150 to about Tyr-163 in SEQ ID NO:3228; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Ser-171 to about Phe-194 in SEQ ID NO:3228; a polypeptide

comprising, or alternatively consisting of, amino acid residues from about Glu-223 to about Tyr-246 in SEQ ID NO:3228; and a polypeptide comprising, or alternatively consisting of, amino acid residues from about Ser-271 to about Phe-278 in FIGS. 1A and 1B (SEQ ID NO:3228). In this context, "about" means the particularly recited ranges and ranges larger or smaller by several, a few, 5, 4, 3, 2 or 1 amino acid residues at either or both the amino- and carboxy-terminals. These polypeptide fragments have been determined to bear antigenic epitopes of the B Lymphocyte Stimulator polypeptide by the analysis of the Jameson-Wolf antigenic index, as disclosed Table 9, above.

Non-limiting examples of antigenic polypeptides or peptides that can be used to generate B Lymphocyte Stimulator-specific antibodies and which may be bound by the antibodies of the invention include: a polypeptide comprising, or alternatively consisting of, amino acid residues from about Pro-32 to about Leu-47 in SEQ ID NO:3229; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Glu-116 to about Ser-143 in SEQ ID NO:3229; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Phe-153 to about Tyr-173 in SEQ ID NO:3229; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Pro-218 to about Tyr-227 in SEQ ID NO:3229; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Ala-232 to about Gln-241 in SEQ ID NO:3229; a polypeptide comprising, or alternatively consisting of, amino acid residues from about Ile-244 to about Ala-249 in SEQ ID NO:3229; and a polypeptide comprising, or alternatively consisting of, amino acid residues from about Ser-252 to about Val-257 in SEQ ID NO:3229. In this context, "about" means the particularly recited ranges and ranges larger or smaller by several, a few, 5, 4, 3, 2 or 1 amino acid residues at either or both the amino- and carboxy-terminals. These polypeptide fragments have been determined to bear antigenic epitopes of the B Lymphocyte Stimulator polypeptide by the analysis of the Jameson-Wolf antigenic index, as disclosed in Table 10 generated by the Protean component of the DNA*STAR computer program (as set forth above).

B Lymphocyte Stimulator epitope-bearing peptides and polypeptides may be produced by any conventional means. See, e.g., Houghten, R. A. (1985) General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. *Proc. Natl. Acad. Sci. USA* 82:5131-5135; this "Simultaneous Multiple Peptide Synthesis (SMPS)" process is further described in U.S. Pat. No. 4,631,211 to Houghten et al. (1986).

The present invention encompasses antibodies that bind polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID NO:3228, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCCTM deposit No. 97768, or encoded by a polynucleotide that

hybridizes to cDNA sequence contained in ATCC™ deposit No. 97768 (e.g., under hybridization conditions described herein).

The present invention also encompasses antibodies that bind polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID NO:3229, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC™ deposit No. 203518, or encoded by a polynucleotide that hybridizes to the cDNA sequence contained in ATCC™ deposit No. 203518 (e.g., under hybridization conditions described herein).

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses antibodies that bind a polypeptide comprising an epitope. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described *infra*. (See, for example, Geysen et al., *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

B Lymphocyte Stimulator polypeptide fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, *Proc. Natl. Acad. Sci. USA* 82:5131-5135 (1985), further described in U.S. Pat. No. 4,631,211).

In the present invention, antibodies of the present invention bind antigenic epitopes preferably containing a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes that may be bound by antibodies of the present invention are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., *Cell* 37:767-778 (1984); Sutcliffe et al., *Science* 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., *supra*; Wilson et al., *supra*; Chow et al., *Proc. Natl. Acad. Sci. USA* 82:910-914; and Bittle et al., *J. Gen. Virol.* 66:2347-2354 (1985)). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immu-

nogenic epitopes of B Lymphocyte Stimulator may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing B Lymphocyte Stimulator polypeptides may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., *supra*; Wilson et al., *supra*, and Bittle et al., *J. Gen. Virol.*, 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemocyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimido-benzoyl-N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier-coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 micrograms of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the antibodies of the present invention may bind polypeptides comprising an immunogenic or antigenic epitope fused to other polypeptide sequences. For example, the B Lymphocyte Stimulator polypeptides may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof), or albumin (including but not limited to recombinant human albumin or fragments or variants thereof (see, e.g., U.S. Pat. No. 5,876,969, issued Mar. 2, 1999, EP Patent 0 413 622, and U.S. Pat. No. 5,766,883, issued Jun. 16, 1998, herein incorporated by reference in their entirety)), resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., *Nature*, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof

41

alone. See, e.g., Fountoulakis et al., *J. Biochem.*, 270: 3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:8972-897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix-binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni²⁺ nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

In another embodiment, the antibodies of the present invention bind B Lymphocyte Stimulator polypeptides and/or the epitope-bearing fragments thereof that are fused with a heterologous antigen (e.g., polypeptide, carbohydrate, phospholipid, or nucleic acid). In specific embodiments, the heterologous antigen is an immunogen.

In a more specific embodiment, the heterologous antigen is the gp120 protein of HIV, or a fragment thereof.

In another embodiment, antibodies of the present invention bind B Lymphocyte Stimulator polypeptides and/or the epitope-bearing fragments thereof that are fused with polypeptide sequences of another TNF ligand family member (or biologically active fragments or variants thereof). In a specific embodiment, the antibodies of the present invention bind B Lymphocyte Stimulator polypeptides of the present invention are fused with a CD40L polypeptide sequence. In a preferred embodiment, the CD40L polypeptide sequence is soluble.

In another embodiment, antibodies of the present invention bind mutant B Lymphocyte Stimulator polypeptides that have been generated by random mutagenesis of a polynucleotide encoding the B Lymphocyte Stimulator polypeptide, by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, antibodies of the present invention bind one or more components, motifs, sections, parts, domains, fragments, etc., of B Lymphocyte Stimulator recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are, for example, TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), AIM-II (International Publication No. WO 97/34911), APRIL (*J. Exp. Med.* 188(6): 1185-1190), endokine-alpha (International Publication No. WO 98/07880), OPG, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication

42

No. WO 98/06842), TR12, CAD, and v-FLIP. In further embodiments, the heterologous molecules are any member of the TNF family.

In another preferred embodiment, antibodies of the present invention bind B Lymphocyte Stimulator polypeptides of the invention (including biologically active fragments or variants thereof), that are fused with soluble APRIL polypeptides (e.g., amino acid residues 105 through 250 of SEQ ID NO:3239), or biologically active fragments or variants thereof.

To improve or alter the characteristics of B Lymphocyte Stimulator polypeptides, protein engineering may be employed. Recombinant DNA technology known to those skilled in the art can be used to create novel mutant proteins or "muteins including single or multiple amino acid substitutions, deletions, additions or fusion proteins. Such modified polypeptides can show, e.g., enhanced activity or increased stability. In addition, they may be purified in higher yields and show better solubility than the corresponding natural polypeptide, at least under certain purification and storage conditions. For instance, for many proteins, including the extracellular domain or the mature form(s) of a secreted protein, it is known in the art that one or more amino acids may be deleted from the N-terminus or C-terminus without substantial loss of biological function. For instance, Ron et al., *J. Biol. Chem.*, 268:2984-2988 (1993) reported modified KGF proteins that had heparin binding activity even if 3, 8, or 27 amino-terminal amino acid residues were missing. Accordingly, antibodies of the present invention may bind B Lymphocyte Stimulator polypeptide mutants or variants generated by protein engineering.

In the present case, since the protein of the invention is a member of the TNF polypeptide family, deletions of N-terminal amino acids up to the Gly (G) residue at position 191 in SEQ ID NO:3228 may retain some biological activity such as, for example, the ability to stimulate lymphocyte (e.g., B cell) proliferation, differentiation, and/or activation, and cytotoxicity to appropriate target cells. Polypeptides having further N-terminal deletions including the Gly (G) residue would not be expected to retain biological activities because it is known that this residue in TNF-related polypeptides is in the beginning of the conserved domain required for biological activities. However, even if deletion of one or more amino acids from the N-terminus of a protein results in modification or loss of one or more biological functions of the protein, other functional activities may still be retained. Thus, the ability of the shortened protein to induce and/or bind to antibodies which recognize the complete or extracellular domain of the protein generally will be retained when less than the majority of the residues of the complete or extracellular domain of the protein are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete protein retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art.

Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence of the B Lymphocyte Stimulator of SEQ ID NO:3228, up to the glycine residue at position 191 (Gly-191 residue from the amino terminus). In particular, the present invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, the amino acid sequence of residues n¹-285 of SEQ ID NO:3228, where n¹ is an integer in the range of the amino acid position of amino acid residues 2-190 of the amino acid sequence in SEQ ID

NO:3228. More in particular, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues 2-285, 3-285, 4-285, 5-285, 6-285, 7-285, 8-285, 9-285, 10-285, 11-285, 12-285, 13-285, 14-285, 15-285, 16-285, 17-285, 18-285, 19-285, 20-285, 21-285, 22-285, 23-285, 24-285, 25-285, 26-285, 27-285, 28-285, 29-285, 30-285, 31-285, 32-285, 33-285, 34-285, 35-285, 36-285, 37-285, 38-285, 39-285, 40-285, 41-285, 42-285, 43-285, 44-285, 45-285, 46-285, 47-285, 48-285, 49-285, 50-285, 51-285, 52-285, 53-285, 54-285, 55-285, 56-285, 57-285, 58-285, 59-285, 60-285, 61-285, 62-285, 63-285, 64-285, 65-285, 66-285, 67-285, 68-285, 69-285, 70-285, 71-285, 72-285, 73-285, 74-285, 75-285, 76-285, 77-285, 78-285, 79-285, 80-285, 81-285, 82-285, 83-285, 84-285, 85-285, 86-285, 87-285, 88-285, 89-285, 90-285, 91-285, 92-285, 93-285, 94-285, 95-285, 96-285, 97-285, 98-285, 99-285, 100-285, 101-285, 102-285, 103-285, 104-285, 105-285, 106-285, 107-285, 108-285, 109-285, 110-285, 111-285, 112-285, 113-285, 114-285, 115-285, 116-285, 117-285, 118-285, 119-285, 120-285, 121-285, 122-285, 123-285, 124-285, 125-285, 126-285, 127-285, 128-285, 129-285, 130-285, 131-285, 132-285, 133-285, 134-285, 135-285, 136-285, 137-285, 138-285, 139-285, 140-285, 141-285, 142-285, 143-285, 144-285, 145-285, 146-285, 147-285, 148-285, 149-285, 150-285, 151-285, 152-285, 153-285, 154-285, 155-285, 156-285, 157-285, 158-285, 159-285, 160-285, 161-285, 162-285, 163-285, 164-285, 165-285, 166-285, 167-285, 168-285, 169-285, 170-285, 171-285, 172-285, 173-285, 174-285, 175-285, 176-285, 177-285, 178-285, 179-285, 180-285, 181-285, 182-285, 183-285, 184-285, 185-285, 186-285, 187-285, 188-285, 189-285, and 190-285 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of B Lymphocyte Stimulator polypeptides described above.

Furthermore, since the predicted extracellular domain of the B Lymphocyte Stimulator polypeptides of the invention may itself elicit biological activity, deletions of N- and C-terminal amino acid residues from the predicted extracellular region of the polypeptide (spanning positions Gln-73 to Leu-285 of SEQ ID NO:3228) may retain some biological activity such as, for example, ligand binding, stimulation of lymphocyte (e.g., B cell) proliferation, differentiation, and/or activation, and modulation of cell replication or modulation of target cell activities. However, even if deletion of one or more amino acids from the N-terminus of the predicted extracellular domain of a B Lymphocyte Stimulator polypeptide results in modification or loss of one or more biological functions of the polypeptide, other functional activities may still be retained. Thus, the ability of the shortened polypeptides to induce and/or bind to antibodies which recognize the complete or mature or extracellular domains of the polypeptides generally will be retained when less than the majority of the residues of the complete or mature or extracellular domains of the polypeptides are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art.

Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues

deleted from the amino terminus of the amino acid sequence of B Lymphocyte Stimulator shown in SEQ ID NO:3228, up to the glycine residue at position number 280. In particular, the present invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, the amino acid sequence of residues n^2 -285 of SEQ ID NO:3228, where n^2 is an integer in the range of the amino acid position of amino acid residues 73-280 in SEQ ID NO:3228, and 73 is the position of the first residue from the N-terminus of the predicted extracellular domain of the B Lymphocyte Stimulator polypeptide (disclosed in SEQ ID NO:3228). More in particular, in certain embodiments, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues of Q-73 to L-285; G-74 to L-285; D-75 to L-285; L-76 to L-285; A-77 to L-285; S-78 to L-285; L-79 to L-285; R-80 to L-285; A-81 to L-285; E-82 to L-285; L-83 to L-285; Q-84 to L-285; G-85 to L-285; H-86 to L-285; H-87 to L-285; A-88 to L-285; E-89 to L-285; K-90 to L-285; L-91 to L-285; P-92 to L-285; A-93 to L-285; G-94 to L-285; A-95 to L-285; P-96 to L-285; A-97 to L-285; P-98 to L-285; K-99 to L-285; A-100 to L-285; G-101 to L-285; L-102 to L-285; E-103 to L-285; E-104 to L-285; A-105 to L-285; P-106 to L-285; A-107 to L-285; V-108 to L-285; T-109 to L-285; A-110 to L-285; G-111 to L-285; L-112 to L-285; K-113 to L-285; I-114 to L-285; F-115 to L-285; E-116 to L-285; P-117 to L-285; P-118 to L-285; A-119 to L-285; P-120 to L-285; G-121 to L-285; E-122 to L-285; G-123 to L-285; N-124 to L-285; S-125 to L-285; S-126 to L-285; Q-127 to L-285; N-128 to L-285; S-129 to L-285; R-130 to L-285; N-131 to L-285; K-132 to L-285; R-133 to L-285; A-134 to L-285; V-135 to L-285; Q-136 to L-285; G-137 to L-285; P-138 to L-285; E-139 to L-285; E-140 to L-285; T-141 to L-285; V-142 to L-285; T-143 to L-285; Q-144 to L-285; D-145 to L-285; C-146 to L-285; L-147 to L-285; Q-148 to L-285; L-149 to L-285; I-150 to L-285; A-151 to L-285; D-152 to L-285; S-153 to L-285; E-154 to L-285; T-155 to L-285; P-156 to L-285; T-157 to L-285; I-158 to L-285; Q-159 to L-285; K-160 to L-285; G-161 to L-285; S-162 to L-285; Y-163 to L-285; T-164 to L-285; F-165 to L-285; V-166 to L-285; P-167 to L-285; W-168 to L-285; L-169 to L-285; L-170 to L-285; S-171 to L-285; F-172 to L-285; K-173 to L-285; R-174 to L-285; G-175 to L-285; S-176 to L-285; A-177 to L-285; L-178 to L-285; E-179 to L-285; E-180 to L-285; K-181 to L-285; E-182 to L-285; N-183 to L-285; K-184 to L-285; I-185 to L-285; L-186 to L-285; V-187 to L-285; K-188 to L-285; E-189 to L-285; T-190 to L-285; G-191 to L-285; Y-192 to L-285; F-193 to L-285; F-194 to L-285; I-195 to L-285; Y-196 to L-285; G-197 to L-285; Q-198 to L-285; V-199 to L-285; L-200 to L-285; Y-201 to L-285; T-202 to L-285; D-203 to L-285; K-204 to L-285; T-205 to L-285; Y-206 to L-285; A-207 to L-285; M-208 to L-285; G-209 to L-285; H-210 to L-285; L-211 to L-285; I-212 to L-285; Q-213 to L-285; R-214 to L-285; K-215 to L-285; K-216 to L-285; V-217 to L-285; H-218 to L-285; V-219 to L-285; F-220 to L-285; G-221 to L-285; D-222 to L-285; E-223 to L-285; L-224 to L-285; S-225 to L-285; L-226 to L-285; V-227 to L-285; T-228 to L-285; L-229 to L-285; F-230 to L-285; R-231 to L-285; C-232 to L-285; I-233 to L-285; Q-234 to L-285; N-235 to L-285; M-236 to L-285; P-237 to L-285; E-238 to L-285; T-239 to L-285; L-240 to L-285; P-241 to L-285; N-242 to L-285; N-243 to L-285; S-244 to L-285; C-245 to L-285; Y-246 to L-285; S-247 to L-285; A-248 to L-285; G-249 to L-285; I-250 to L-285; A-251 to L-285; K-252 to L-285; L-253 to L-285; E-254 to L-285; E-255 to L-285; G-256 to L-285; D-257 to L-285;

E-258 to L-285; L-259 to L-285; Q-260 to L-285; L-261 to L-285; A-262 to L-285; I-263 to L-285; P-264 to L-285; R-265 to L-285; E-266 to L-285; N-267 to L-285; A-268 to L-285; Q-269 to L-285; I-270 to L-285; S-271 to L-285; L-272 to L-285; D-273 to L-285; G-274 to L-285; D-275 to L-285; V-276 to L-285; T-277 to L-285; F-278 to L-285; F-279 to L-285; and G-280 to L-285 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of B Lymphocyte Stimulator polypeptides described above.

Highly preferred embodiments of the invention are directed to antibodies that bind polypeptides comprising, or alternatively consisting of, a polypeptide having an amino acid sequence least 80%, 85%, 90% identical and more preferably at least 95%, 96%, 97%, 98%, 99% or 100% identical to B Lymphocyte Stimulator polypeptide having the amino acid sequence at positions 134–285 of SEQ ID NO:3228.

Preferred embodiments of the invention are directed to antibodies that bind polypeptides comprising, or alternatively consisting of, a polypeptide having an amino acid sequence at least 90% identical to a B Lymphocyte Stimulator polypeptide having the amino acid sequence at positions 134–285 of SEQ ID NO:3228. More preferred embodiments of the invention are directed to antibodies that bind polypeptides comprising, or alternatively consisting of, a polypeptide having an amino acid sequence at least 95% identical to a B Lymphocyte Stimulator polypeptide having the amino acid sequence at positions 134–285 of SEQ ID NO:3228. More preferred embodiments of the invention are directed to antibodies that bind polypeptides comprising, or alternatively consisting of, a polypeptide having an amino acid sequence at least 96% identical to a B Lymphocyte Stimulator polypeptide having the amino acid sequence at positions 134–285 of SEQ ID NO:3228.

Additionally, more preferred embodiments of the invention are directed to antibodies that bind polypeptides comprising, or alternatively consisting of, a polypeptide having an amino acid sequence at least 97% to a B Lymphocyte Stimulator polypeptide having the amino acid sequence at positions 134–285 of SEQ ID NO:3228. Additionally, more preferred embodiments of the invention are directed to antibodies that bind polypeptides comprising, or alternatively consisting of, a polypeptide having an amino acid sequence at least 98% to a B Lymphocyte Stimulator polypeptide having the amino acid sequence at positions 134–285 of SEQ ID NO:3228. Additionally, more preferred embodiments of the invention are directed to antibodies that bind polypeptides comprising, or alternatively consisting of, a polypeptide having an amino acid sequence at least 99% identical to B Lymphocyte Stimulator polypeptide having the amino acid sequence at positions 134–285 of SEQ ID NO:3228.

In specific embodiments, antibodies of the present invention bind polypeptides comprising, or alternatively consisting of, one of the following N-terminally deleted polypeptide fragments of B Lymphocyte Stimulator: amino acid residues Ala-71 through Leu-285, amino acid residues Ala-81 through Leu-285, amino acid residues Leu-112 through Leu-285, amino acid residues Ala-134 through Leu-285, amino acid residues Leu-147 through Leu-285, and amino acid residues Gly-161 through Leu-285 of SEQ ID NO:3228.

Similarly, many examples of biologically functional C-terminal deletion polypeptides are known. For instance, Interferon gamma shows up to ten times higher activities by deleting 8–10 amino acid residues from the carboxy terminus of the protein (Döbeli et al., *J. Biotechnology* 7:199–216 (1988)). Since the present protein is a member of the TNF polypeptide family, deletions of C-terminal amino acids up to the leucine residue at position 284 are expected to retain most if not all biological activity such as, for example, ligand binding, the ability to stimulate lymphocyte (e.g., B cell) proliferation, differentiation, and/or activation, and modulation of cell replication. Polypeptides having deletions of up to about 10 additional C-terminal residues (i.e., up to the glycine residue at position 274) also may retain some activity such as receptor binding, although such polypeptides would lack a portion of the conserved TNF domain which extends to about Leu-284 of SEQ ID NO:3228. However, even if deletion of one or more amino acids from the C-terminus of a protein results in modification or loss of one or more biological functions of the protein, other functional activities may still be retained. Thus, the ability of the shortened protein to induce and/or bind to antibodies which recognize the complete or mature protein generally will be retained when less than the majority of the residues of the complete or mature protein are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of a complete protein retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art.

Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of the B Lymphocyte Stimulator polypeptide of SEQ ID NO:3228, up to the glycine residue at position 274 (Gly-274). In particular, the present invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, the amino acid sequence of residues 1– m^1 of the amino acid sequence in SEQ ID NO:3228, where m^1 is any integer in the range of the amino acid position of amino acid residues 274–284 in SEQ ID NO:3228. More in particular, the invention provides antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues 1–274, 1–275, 1–276, 1–277, 1–278, 1–279, 1–280, 1–281, 1–282, 1–283 and 1–284 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of B Lymphocyte Stimulator polypeptides described above.

Also provided are antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively consisting of, B Lymphocyte Stimulator polypeptides with one or more amino acids deleted from both the amino and the carboxyl termini, which may be described generally as having residues n^1 – m^1 of SEQ ID NO:3228, where n^1 and m^1 are integers as defined above. Also included are antibodies that bind a polypeptide comprising, or alternatively consisting of, a portion of the complete B Lymphocyte Stimulator amino acid sequence encoded by the deposited cDNA clone contained in ATCCTM Accession No. 97768 where this portion excludes from 1 to 190 amino acids from the amino terminus or from 1 to 11 amino acids from the C-terminus of the complete amino acid sequence (or any combination of

these N-terminal and C-terminal deletions) encoded by the cDNA clone in the deposited plasmid.

Similarly, deletions of C-terminal amino acid residues of the predicted extracellular domain of B Lymphocyte Stimulator up to the leucine residue at position 79 of SEQ ID NO:3228 may retain some biological activity, such as, for example, ligand binding, stimulation of lymphocyte (e.g., B cell) proliferation, differentiation, and/or activation, and modulation of cell replication or modulation of target cell activities. Polypeptides having further C-terminal deletions including Leu-79 of SEQ ID NO:3228 would not be expected to retain biological activities.

However, even if deletion of one or more amino acids from the C-terminus of a polypeptide results in modification or loss of one or more biological functions of the polypeptide, other functional activities may still be retained. Thus, the ability of the shortened polypeptide to induce and/or bind to antibodies which recognize the complete, mature or extracellular forms of the polypeptide generally will be retained when less than the majority of the residues of the complete, mature or extracellular forms of the polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of the predicted extracellular domain retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art.

Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of the predicted extracellular domain of B Lymphocyte Stimulator polypeptide shown in SEQ ID NO:3228, up to the leucine residue at position 79 of SEQ ID NO:3228. In particular, the present invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, the amino acid sequence of residues 73-m² of the amino acid sequence in SEQ ID NO:3228, where m² is any integer in the range of the amino acid position of amino acid residues 79 to 285 in the amino acid sequence in SEQ ID NO:3228, and residue 78 is the position of the first residue at the C-terminus of the predicted extracellular domain of the B Lymphocyte Stimulator polypeptide (disclosed in SEQ ID NO:3228). More in particular, in certain embodiments, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues Q-73 to Leu-285; Q-73 to L-284; Q-73 to K-283; Q-73 to L-282; Q-73 to A-281; Q-73 to G-280; Q-73 to F-279; Q-73 to F-278; Q-73 to T-277; Q-73 to V-276; Q-73 to D-275; Q-73 to G-274; Q-73 to D-273; Q-73 to L-272; Q-73 to S-271; Q-73 to I-270; Q-73 to Q-269; Q-73 to A-268; Q-73 to N-267; Q-73 to E-266; Q-73 to R-265; Q-73 to P-264; Q-73 to I-263; Q-73 to A-262; Q-73 to L-261; Q-73 to Q-260; Q-73 to L-259; Q-73 to E-258; Q-73 to D-257; Q-73 to G-256; Q-73 to E-255; Q-73 to E-254; Q-73 to L-253; Q-73 to K-252; Q-73 to A-251; Q-73 to I-250; Q-73 to G-249; Q-73 to A-248; Q-73 to S-247; Q-73 to Y-246; Q-73 to C-245; Q-73 to S-244; Q-73 to N-243; Q-73 to N-242; Q-73 to P-241; Q-73 to L-240; Q-73 to T-239; Q-73 to E-238; Q-73 to P-237; Q-73 to M-236; Q-73 to N-235; Q-73 to Q-234; Q-73 to I-233; Q-73 to C-232; Q-73 to R-231; Q-73 to F-230; Q-73 to L-229; Q-73 to T-228; Q-73 to V-227; Q-73 to L-226; Q-73 to S-225; Q-73 to L-224; Q-73 to E-223; Q-73 to D-222; Q-73 to G-221; Q-73 to F-220; Q-73 to V-219; Q-73 to H-218; Q-73 to V-217; Q-73 to K-216; Q-73 to K-215; Q-73 to R-214; Q-73 to Q-213; Q-73 to I-212; Q-73 to L-211; Q-73 to H-210; Q-73 to G-209; Q-73 to M-208; Q-73 to A-207; Q-73 to Y-206; Q-73 to

T-205; Q-73 to K-204; Q-73 to D-203; Q-73 to T-202; Q-73 to Y-201; Q-73 to L-200; Q-73 to V-199; Q-73 to Q-198; Q-73 to G-197; Q-73 to Y-196; Q-73 to I-195; Q-73 to F-194; Q-73 to F-193; Q-73 to Y-192; Q-73 to G-191; Q-73 to T-190; Q-73 to E-189; Q-73 to K-188; Q-73 to V-187; Q-73 to L-186; Q-73 to I-185; Q-73 to K-184; Q-73 to N-183; Q-73 to E-182; Q-73 to K-181; Q-73 to E-180; Q-73 to E-179; Q-73 to L-178; Q-73 to A-177; Q-73 to S-176; Q-73 to G-175; Q-73 to R-174; Q-73 to K-173; Q-73 to F-172; Q-73 to S-171; Q-73 to L-170; Q-73 to L-169; Q-73 to W-168; Q-73 to P-167; Q-73 to V-166; Q-73 to F-165; Q-73 to T-164; Q-73 to Y-163; Q-73 to S-162; Q-73 to G-161; Q-73 to K-160; Q-73 to Q-159; Q-73 to I-158; Q-73 to T-157; Q-73 to P-156; Q-73 to T-155; Q-73 to E-154; Q-73 to S-153; Q-73 to D-152; Q-73 to A-151; Q-73 to I-150; Q-73 to L-149; Q-73 to Q-148; Q-73 to L-147; Q-73 to C-146; Q-73 to D-145; Q-73 to Q-144; Q-73 to T-143; Q-73 to V-142; Q-73 to T-141; Q-73 to E-140; Q-73 to E-139; Q-73 to P-138; Q-73 to G-137; Q-73 to Q-136; Q-73 to V-135; Q-73 to A-134; Q-73 to R-133; Q-73 to K-132; Q-73 to N-131; Q-73 to R-130; Q-73 to S-129; Q-73 to N-128; Q-73 to Q-127; Q-73 to S-126; Q-73 to S-125; Q-73 to N-124; Q-73 to G-123; Q-73 to E-122; Q-73 to G-121; Q-73 to P-120; Q-73 to A-119; Q-73 to P-118; Q-73 to P-117; Q-73 to E-116; Q-73 to F-115; Q-73 to I-114; Q-73 to K-113; Q-73 to L-112; Q-73 to G-111; Q-73 to A-110; Q-73 to T-109; Q-73 to V-108; Q-73 to A-107; Q-73 to P-106; Q-73 to A-105; Q-73 to E-104; Q-73 to E-103; Q-73 to L-102; Q-73 to G-101; Q-73 to A-100; Q-73 to K-99; Q-73 to P-98; Q-73 to A-97; Q-73 to G-96; Q-73 to A-95; Q-73 to G-94; Q-73 to A-93; Q-73 to P-92; Q-73 to L-91; Q-73 to K-90; Q-73 to E-89; Q-73 to A-88; Q-73 to H-87; Q-73 to H-86; Q-73 to G-85; Q-73 to Q-84; Q-73 to L-83; Q-73 to E-82; Q-73 to A-81; Q-73 to R-80; and Q-73 to L-79 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of B Lymphocyte Stimulator polypeptides described above.

The invention also provides antibodies that bind polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini of the predicted extracellular domain of B Lymphocyte Stimulator, which may be described generally as having residues n²-m² of SEQ ID NO:3228 where n² and m² are integers as defined above.

In another embodiment, antibodies of the present invention bind polypeptides consisting of a portion of the extracellular domain of the B Lymphocyte Stimulator amino acid sequence encoded by the cDNA plasmid contained in the deposit having ATCCTM accession no. 97768, where this portion excludes from 1 to about 206 amino acids from the amino terminus of the extracellular domain of the amino acid sequence encoded by the cDNA plasmid contained in the deposit having ATCCTM accession no. 97768, or from 1 to about 206 amino acids from the carboxy terminus of the extracellular domain of the amino acid sequence encoded by the cDNA plasmid contained in the deposit having ATCCTM accession no. 97768, or any combination of the above amino terminal and carboxy terminal deletions, of the entire extracellular domain of the amino acid sequence encoded by the cDNA plasmid contained in the deposit having ATCCTM accession no. 97768.

As mentioned above, even if deletion of one or more amino acids from the N-terminus of a polypeptide results in modification or loss of one or more functional activities

(e.g., biological activity) of the polypeptide, other functions or biological activities may still be retained. Thus, the ability of a shortened B Lymphocyte Stimulator mutein to induce and/or bind to antibodies which recognize the full-length or mature forms or the extracellular domain of the polypeptide generally will be retained when less than the majority of the residues of the full-length or mature or extracellular domain of the polypeptide are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a B Lymphocyte Stimulator mutein with a large number of deleted N-terminal amino acid residues may retain some functional (e.g., biological or immunogenic) activities. In fact, peptides composed of as few as six B Lymphocyte Stimulator amino acid residues may often evoke an immune response.

Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues deleted from the amino terminus of the predicted full-length amino acid sequence of the B Lymphocyte Stimulator shown in SEQ ID NO:3228, up to the glycine residue at position number 280 of the sequence shown SEQ ID NO:3228 and polynucleotides encoding such polypeptides. In particular, the present invention provides antibodies that bind polypeptides comprising the amino acid sequence of residues n^3 -285 of the sequence shown in SEQ ID NO:3228, where n^3 is an integer in the range of the amino acid position of amino acid residues 1 to 280 of the amino acid sequence in SEQ ID NO:3228.

More in particular, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues of D-2 to L-285; D-3 to L-285; S-4 to L-285; T-5 to L-285; E-6 to L-285; R-7 to L-285; E-8 to L-285; Q-9 to L-285; S-10 to L-285; R-11 to L-285; L-12 to L-285; T-13 to L-285; S-14 to L-285; C-15 to L-285; L-16 to L-285; K-17 to L-285; K-18 to L-285; R-19 to L-285; E-20 to L-285; E-21 to L-285; M-22 to L-285; K-23 to L-285; L-24 to L-285; K-25 to L-285; E-26 to L-285; C-27 to L-285; V-28 to L-285; S-29 to L-285; I-30 to L-285; L-31 to L-285; P-32 to L-285; R-33 to L-285; K-34 to L-285; E-35 to L-285; S-36 to L-285; P-37 to L-285; S-38 to L-285; V-39 to L-285; R-40 to L-285; S-41 to L-285; S-42 to L-285; K-43 to L-285; D-44 to L-285; G-45 to L-285; K-46 to L-285; L-47 to L-285; L-48 to L-285; A-49 to L-285; A-50 to L-285; T-51 to L-285; L-52 to L-285; L-53 to L-285; L-54 to L-285; A-55 to L-285; L-56 to L-285; L-57 to L-285; S-58 to L-285; C-59 to L-285; C-60 to L-285; L-61 to L-285; T-62 to L-285; V-63 to L-285; V-64 to L-285; S-65 to L-285; F-66 to L-285; Y-67 to L-285; Q-68 to L-285; V-69 to L-285; A-70 to L-285; A-71 to L-285; L-72 to L-285; Q-73 to L-285; G-74 to L-285; D-75 to L-285; L-76 to L-285; A-77 to L-285; S-78 to L-285; L-79 to L-285; R-80 to L-285; A-81 to L-285; E-82 to L-285; L-83 to L-285; Q-84 to L-285; G-85 to L-285; H-86 to L-285; H-87 to L-285; A-88 to L-285; E-89 to L-285; K-90 to L-285; L-91 to L-285; P-92 to L-285; A-93 to L-285; G-94 to L-285; A-95 to L-285; G-96 to L-285; A-97 to L-285; P-98 to L-285; K-99 to L-285; A-100 to L-285; G-101 to L-285; L-102 to L-285; E-103 to L-285; E-104 to L-285; A-105 to L-285; P-106 to L-285; A-107 to L-285; V-108 to L-285; T-109 to L-285; A-110 to L-285; G-111 to L-285; L-112 to L-285; K-113 to L-285; I-114 to L-285; F-115 to L-285; E-116 to L-285; P-117 to L-285; P-118 to L-285; A-119 to L-285; P-120 to L-285; G-121 to L-285; E-122 to L-285; G-123 to L-285;

N-124 to L-285; S-125 to L-285; S-126 to L-285; Q-127 to L-285; N-128 to L-285; S-129 to L-285; R-130 to L-285; N-131 to L-285; K-132 to L-285; R-133 to L-285; A-134 to L-285; V-135 to L-285; Q-136 to L-285; G-137 to L-285; P-138 to L-285; E-139 to L-285; E-140 to L-285; T-141 to L-285; V-142 to L-285; T-143 to L-285; Q-144 to L-285; D-145 to L-285; C-146 to L-285; L-147 to L-285; Q-148 to L-285; L-149 to L-285; I-150 to L-285; A-151 to L-285; D-152 to L-285; S-153 to L-285; E-154 to L-285; T-155 to L-285; P-156 to L-285; T-157 to L-285; I-158 to L-285; Q-159 to L-285; K-160 to L-285; G-161 to L-285; S-162 to L-285; Y-163 to L-285; T-164 to L-285; F-165 to L-285; V-166 to L-285; P-167 to L-285; W-168 to L-285; L-169 to L-285; L-170 to L-285; S-171 to L-285; F-172 to L-285; K-173 to L-285; R-174 to L-285; G-175 to L-285; S-176 to L-285; A-177 to L-285; L-178 to L-285; E-179 to L-285; E-180 to L-285; K-181 to L-285; E-182 to L-285; N-183 to L-285; K-184 to L-285; I-185 to L-285; L-186 to L-285; V-187 to L-285; K-188 to L-285; E-189 to L-285; T-190 to L-285; G-191 to L-285; Y-192 to L-285; F-193 to L-285; F-194 to L-285; I-195 to L-285; Y-196 to L-285; G-197 to L-285; Q-198 to L-285; V-199 to L-285; L-200 to L-285; Y-201 to L-285; T-202 to L-285; D-203 to L-285; K-204 to L-285; T-205 to L-285; Y-206 to L-285; A-207 to L-285; M-208 to L-285; G-209 to L-285; H-210 to L-285; L-211 to L-285; I-212 to L-285; Q-213 to L-285; R-214 to L-285; K-215 to L-285; K-216 to L-285; V-217 to L-285; H-218 to L-285; V-219 to L-285; F-220 to L-285; G-221 to L-285; D-222 to L-285; E-223 to L-285; L-224 to L-285; S-225 to L-285; L-226 to L-285; V-227 to L-285; T-228 to L-285; L-229 to L-285; F-230 to L-285; R-231 to L-285; C-232 to L-285; I-233 to L-285; Q-234 to L-285; N-235 to L-285; M-236 to L-285; P-237 to L-285; E-238 to L-285; T-239 to L-285; L-240 to L-285; P-241 to L-285; N-242 to L-285; N-243 to L-285; S-244 to L-285; C-245 to L-285; Y-246 to L-285; S-247 to L-285; A-248 to L-285; G-249 to L-285; I-250 to L-285; A-251 to L-285; K-252 to L-285; L-253 to L-285; E-254 to L-285; E-255 to L-285; G-256 to L-285; D-257 to L-285; E-258 to L-285; L-259 to L-285; Q-260 to L-285; L-261 to L-285; A-262 to L-285; I-263 to L-285; P-264 to L-285; R-265 to L-285; E-266 to L-285; N-267 to L-285; A-268 to L-285; Q-269 to L-285; I-270 to L-285; S-271 to L-285; L-272 to L-285; D-273 to L-285; G-274 to L-285; D-275 to L-285; V-276 to L-285; T-277 to L-285; F-278 to L-285; F-279 to L-285; and G-280 to L-285 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of B Lymphocyte Stimulator polypeptides described above.

Also as mentioned above, even if deletion of one or more amino acids from the C-terminus of a protein results in modification or loss of one or more functional activities (e.g., biological activity) of the protein, other functional activities may still be retained. Thus, the ability of a shortened B Lymphocyte Stimulator mutein to induce and/or bind to antibodies which recognize the complete or mature form or the extracellular domain of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature form or the extracellular domain of the polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a B

Lymphocyte Stimulator mutein with a large number of deleted C-terminal amino acid residues may retain some functional (e.g., biological or immunogenic) activities. In fact, peptides composed of as few as six B Lymphocyte Stimulator amino acid residues may often evoke an immune response.

Accordingly, the present invention further provides in another embodiment, antibodies that bind polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of the B Lymphocyte Stimulator shown in SEQ ID NO:3228, up to the glutamic acid residue at position number 6, and polynucleotides encoding such polypeptides. In particular, the present invention provides antibodies that bind polypeptides comprising the amino acid sequence of residues 1-m³ of SEQ ID NO:3228, where m³ is an integer in the range of the amino acid position of amino acid residues 6-284 of the amino acid sequence in SEQ ID NO:3228.

More in particular, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues M-1 to L-284; M-1 to K-283; M-1 to L-282; M-1 to A-281; M-1 to G-280; M-1 to F-279; M-1 to F-278; M-1 to T-277; M-1 to V-276; M-1 to D-275; M-1 to G-274; M-1 to D-273; M-1 to L-272; M-1 to S-271; M-1 to I-270; M-1 to Q-269; M-1 to A-268; M-1 to N-267; M-1 to E-266; M-1 to R-265; M-1 to P-264; M-1 to I-263; M-1 to A-262; M-1 to L-261; M-1 to Q-260; M-1 to L-259; M-1 to E-258; M-1 to D-257; M-1 to G-256; M-1 to E-255; M-1 to E-254; M-1 to L-253; M-1 to K-252; M-1 to A-251; M-1 to I-250; M-1 to G-249; M-1 to A-248; M-1 to S-247; M-1 to Y-246; M-1 to C-245; M-1 to S-244; M-1 to N-243; M-1 to N-242; M-1 to P-241; M-1 to L-240; M-1 to T-239; M-1 to E-238; M-1 to P-237; M-1 to M-236; M-1 to N-235; M-1 to Q-234; M-1 to I-233; M-1 to C-232; M-1 to R-231; M-1 to F-230; M-1 to L-229; M-1 to T-228; M-1 to V-227; M-1 to L-226; M-1 to S-225; M-1 to L-224; M-1 to E-223; M-1 to D-222; M-1 to G-221; M-1 to F-220; M-1 to V-219; M-1 to H-218; M-1 to V-217; M-1 to K-216; M-1 to K-215; M-1 to R-214; M-1 to Q-213; M-1 to I-212; M-1 to L-211; M-1 to H-210; M-1 to G-209; M-1 to M-208; M-1 to A-207; M-1 to Y-206; M-1 to T-205; M-1 to K-204; M-1 to D-203; M-1 to T-202; M-1 to Y-201; M-1 to L-200; M-1 to V-199; M-1 to Q-198; M-1 to G-197; M-1 to Y-196; M-1 to I-195; M-1 to F-194; M-1 to F-193; M-1 to Y-192; M-1 to G-191; M-1 to T-190; M-1 to E-189; M-1 to K-188; M-1 to V-187; M-1 to L-186; M-1 to I-185; M-1 to K-184; M-1 to N-183; M-1 to E-182; M-1 to K-181; M-1 to E-180; M-1 to E-179; M-1 to L-178; M-1 to A-177; M-1 to S-176; M-1 to G-175; M-1 to R-174; M-1 to K-173; M-1 to F-172; M-1 to S-171; M-1 to L-170; M-1 to L-169; M-1 to W-168; M-1 to P-167; M-1 to V-166; M-1 to F-165; M-1 to T-164; M-1 to Y-163; M-1 to S-162; M-1 to G-161; M-1 to K-160; M-1 to Q-159; M-1 to I-158; M-1 to T-157; M-1 to P-156; M-1 to T-155; M-1 to E-154; M-1 to S-153; M-1 to D-152; M-1 to A-151; M-1 to I-150; M-1 to L-149; M-1 to Q-148; M-1 to L-147; M-1 to C-146; M-1 to D-145; M-1 to Q-144; M-1 to T-143; M-1 to V-142; M-1 to T-141; M-1 to E-140; M-1 to E-139; M-1 to P-138; M-1 to G-137; M-1 to Q-136; M-1 to V-135; M-1 to A-134; M-1 to R-133; M-1 to K-132; M-1 to N-131; M-1 to R-130; M-1 to S-129; M-1 to N-128; M-1 to Q-127; M-1 to S-126; M-1 to S-125; M-1 to N-124; M-1 to G-123; M-1 to E-122; M-1 to G-121; M-1 to P-120; M-1 to A-119; M-1 to P-118; M-1 to P-117; M-1 to E-116; M-1 to F-115; M-1 to I-114; M-1 to K-113; M-1 to L-112; M-1 to G-111; M-1 to A-110; M-1 to T-109; M-1 to V-108; M-1 to A-107; M-1 to P-106; M-1 to A-105; M-1 to E-104; M-1 to E-103; M-1 to L-102; M-1

to G-101; M-1 to A-100; M-1 to K-99; M-1 to P-98; M-1 to A-97; M-1 to G-96; M-1 to A-95; M-1 to G-94; M-1 to A-93; M-1 to P-92; M-1 to L-91; M-1 to K-90; M-1 to E-89; M-1 to A-88; M-1 to H-87; M-1 to H-86; M-1 to G-85; M-1 to Q-84; M-1 to L-83; M-1 to E-82; M-1 to A-81; M-1 to R-80; M-1 to L-79; M-1 to S-78; M-1 to A-77; M-1 to L-76; M-1 to D-75; M-1 to G-74; M-1 to Q-73; M-1 to L-72; M-1 to A-71; M-1 to A-70; M-1 to V-69; M-1 to Q-68; M-1 to Y-67; M-1 to F-66; M-1 to S-65; M-1 to V-64; M-1 to V-63; M-1 to T-62; M-1 to L-61; M-1 to C-60; M-1 to C-59; M-1 to S-58; M-1 to L-57; M-1 to L-56; M-1 to A-55; M-1 to L-54; M-1 to L-53; M-1 to L-52; M-1 to T-51; M-1 to A-50; M-1 to A-49; M-1 to L-48; M-1 to L-47; M-1 to K-46; M-1 to G-45; M-1 to D-44; M-1 to K-43; M-1 to S-42; M-1 to S-41; M-1 to R-40; M-1 to V-39; M-1 to S-38; M-1 to P-37; M-1 to S-36; M-1 to E-35; M-1 to K-34; M-1 to R-33; M-1 to P-32; M-1 to L-31; M-1 to I-30; M-1 to S-29; M-1 to V-28; M-1 to C-27; M-1 to E-26; M-1 to K-25; M-1 to L-24; M-1 to K-23; M-1 to M-22; M-1 to E-21; M-1 to E-20; M-1 to R-19; M-1 to K-18; M-1 to K-17; M-1 to L-16; M-1 to C-15; M-1 to S-14; M-1 to T-13; M-1 to L-12; M-1 to R-11; M-1 to S-10; M-1 to Q-9; M-1 to E-8; M-1 to R-7; and M-1 to E-6 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of B Lymphocyte Stimulator polypeptides described above.

The invention also provides antibodies that bind polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini of a B Lymphocyte Stimulator polypeptide, which may be described generally as having residues n³-m³ of SEQ ID NO:3228, where n³ and m³ are integers as defined above.

Furthermore, since the predicted extracellular domain of the B Lymphocyte Stimulator polypeptide of SEQ ID NO:3229 may itself elicit functional activity (e.g., biological activity), deletions of N- and C-terminal amino acid residues from the predicted extracellular region of the polypeptide at positions Gln-73 to Leu-266 of SEQ ID NO:3229 may retain some functional activity, such as, for example, ligand binding, to stimulation of lymphocyte (e.g., B cell) proliferation, differentiation, and/or activation, modulation of cell replication, modulation of target cell activities and/or immunogenicity. However, even if deletion of one or more amino acids from the N-terminus of the predicted extracellular domain of a B Lymphocyte Stimulator polypeptide results in modification or loss of one or more functional activities of the polypeptide, other functional activities may still be retained. Thus, the ability of the shortened polypeptides to induce and/or bind to antibodies which recognize the complete or mature or extracellular domains of the polypeptides generally will be retained when less than the majority of the residues of the complete or mature or extracellular domains of the polypeptides are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art.

Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence of B Lymphocyte Stimulator shown in SEQ ID NO:3229, up to the glycine residue at position number 261. In particular, the present invention provides antibodies that bind polypeptides comprising the amino acid sequence of residues n⁴-266

of SEQ ID NO:3229, where n^4 is an integer in the range of the amino acid position of amino acid residues 73–261 of the amino acid sequence in SEQ ID NO:3229, and 261 is the position of the first residue from the N-terminus of the predicted extracellular domain B Lymphocyte Stimulator polypeptide (shown in SEQ ID NO:3229).

More in particular, in certain embodiments, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues of Q-73 to L-266; G-74 to L-266; D-75 to L-266; L-76 to L-266; A-77 to L-266; S-78 to L-266; L-79 to L-266; R-80 to L-266; A-81 to L-266; E-82 to L-266; L-83 to L-266; Q-84 to L-266; G-85 to L-266; H-86 to L-266; H-87 to L-266; A-88 to L-266; E-89 to L-266; K-90 to L-266; L-91 to L-266; P-92 to L-266; A-93 to L-266; G-94 to L-266; A-95 to L-266; G-96 to L-266; A-97 to L-266; P-98 to L-266; K-99 to L-266; A-100 to L-266; G-101 to L-266; L-102 to L-266; E-103 to L-266; E-104 to L-266; A-105 to L-266; P-106 to L-266; A-107 to L-266; V-108 to L-266; T-109 to L-266; A-110 to L-266; G-111 to L-266; L-112 to L-266; K-113 to L-266; I-114 to L-266; F-115 to L-266; E-116 to L-266; P-117 to L-266; P-118 to L-266; A-119 to L-266; P-120 to L-266; G-121 to L-266; E-122 to L-266; G-123 to L-266; N-124 to L-266; S-125 to L-266; S-126 to L-266; Q-127 to L-266; N-128 to L-266; S-129 to L-266; R-130 to L-266; N-131 to L-266; K-132 to L-266; R-133 to L-266; A-134 to L-266; V-135 to L-266; Q-136 to L-266; G-137 to L-266; P-138 to L-266; E-139 to L-266; E-140 to L-266; T-141 to L-266; G-142 to L-266; S-143 to L-266; Y-144 to L-266; T-145 to L-266; F-146 to L-266; V-147 to L-266; P-148 to L-266; W-149 to L-266; L-150 to L-266; L-151 to L-266; S-152 to L-266; F-153 to L-266; K-154 to L-266; R-155 to L-266; G-156 to L-266; S-157 to L-266; A-158 to L-266; L-159 to L-266; E-160 to L-266; E-161 to L-266; K-162 to L-266; E-163 to L-266; N-164 to L-266; K-165 to L-266; I-166 to L-266; L-167 to L-266; V-168 to L-266; K-169 to L-266; E-170 to L-266; T-171 to L-266; G-172 to L-266; Y-173 to L-266; F-174 to L-266; F-175 to L-266; I-176 to L-266; Y-177 to L-266; G-178 to L-266; Q-179 to L-266; V-180 to L-266; L-181 to L-266; Y-182 to L-266; T-183 to L-266; D-184 to L-266; K-185 to L-266; T-186 to L-266; Y-187 to L-266; A-188 to L-266; M-189 to L-266; G-190 to L-266; H-191 to L-266; L-192 to L-266; I-193 to L-266; Q-194 to L-266; R-195 to L-266; K-196 to L-266; K-197 to L-266; V-198 to L-266; H-199 to L-266; V-200 to L-266; F-201 to L-266; G-202 to L-266; D-203 to L-266; E-204 to L-266; L-205 to L-266; S-206 to L-266; L-207 to L-266; V-208 to L-266; T-209 to L-266; L-210 to L-266; F-211 to L-266; R-212 to L-266; C-213 to L-266; I-214 to L-266; Q-215 to L-266; N-216 to L-266; M-217 to L-266; P-218 to L-266; E-219 to L-266; T-220 to L-266; L-221 to L-266; P-222 to L-266; N-223 to L-266; N-224 to L-266; S-225 to L-266; C-226 to L-266; Y-227 to L-266; S-228 to L-266; A-229 to L-266; G-230 to L-266; I-231 to L-266; A-232 to L-266; K-233 to L-266; L-234 to L-266; E-235 to L-266; E-236 to L-266; G-237 to L-266; D-238 to L-266; E-239 to L-266; L-240 to L-266; Q-241 to L-266; L-242 to L-266; A-243 to L-266; I-244 to L-266; P-245 to L-266; R-246 to L-266; E-247 to L-266; N-248 to L-266; A-249 to L-266; Q-250 to L-266; I-251 to L-266; S-252 to L-266; L-253 to L-266; D-254 to L-266; G-255 to L-266; D-256 to L-266; V-257 to L-266; T-258 to L-266; F-259 to L-266; F-260 to L-266; and G-261 to L-266 of SEQ ID NO:3229. The present invention is also directed to antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid

residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of B Lymphocyte Stimulator polypeptides described above.

Similarly, deletions of C-terminal amino acid residues of the predicted extracellular domain of B Lymphocyte Stimulator up to the leucine residue at position 79 of SEQ ID NO:3229 may retain some functional activity, such as, for example, ligand binding, the ability to stimulate lymphocyte (e.g., B cell) proliferation, differentiation, and/or activation, modulation of cell replication, modulation of target cell activities and/or immunogenicity. Polypeptides having further C-terminal deletions including Leu-79 of SEQ ID NO:3229 would not be expected to retain biological activities.

However, even if deletion of one or more amino acids from the C-terminus of a polypeptide results in modification or loss of one or more functional activities (e.g., biological activity) of the polypeptide, other functional activities may still be retained. Thus, the ability of the shortened polypeptide to induce and/or bind to antibodies which recognize the complete, mature or extracellular forms of the polypeptide generally will be retained when less than the majority of the residues of the complete, mature or extracellular forms of the polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of the predicted extracellular domain retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art.

Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues from the carboxy terminus of the amino acid sequence of the predicted extracellular domain of B Lymphocyte Stimulator shown in SEQ ID NO:3229, up to the leucine residue at position 79 of SEQ ID NO:3229. In particular, the present invention provides antibodies that bind polypeptides having the amino acid sequence of residues 73– m^4 of the amino acid sequence in SEQ ID NO:3229, where m^4 is any integer in the range of the amino acid position of amino acid residues 79–265 of the amino acid sequence in SEQ ID NO:3229.

More in particular, in certain embodiments, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues Q-73 to L-265; Q-73 to K-264; Q-73 to L-263; Q-73 to A-262; Q-73 to G-261; Q-73 to F-260; Q-73 to F-259; Q-73 to T-258; Q-73 to V-257; Q-73 to D-256; Q-73 to G-255; Q-73 to D-254; Q-73 to L-253; Q-73 to S-252; Q-73 to I-251; Q-73 to Q-250; Q-73 to A-249; Q-73 to N-248; Q-73 to E-247; Q-73 to R-246; Q-73 to P-245; Q-73 to I-244; Q-73 to A-243; Q-73 to L-242; Q-73 to Q-241; Q-73 to L-240; Q-73 to E-239; Q-73 to D-238; Q-73 to G-237; Q-73 to E-236; Q-73 to E-235; Q-73 to L-234; Q-73 to K-233; Q-73 to A-232; Q-73 to I-231; Q-73 to G-230; Q-73 to A-229; Q-73 to S-228; Q-73 to Y-227; Q-73 to C-226; Q-73 to S-225; Q-73 to N-224; Q-73 to N-223; Q-73 to P-222; Q-73 to L-221; Q-73 to T-220; Q-73 to E-219; Q-73 to P-218; Q-73 to M-217; Q-73 to N-216; Q-73 to Q-215; Q-73 to I-214; Q-73 to C-213; Q-73 to R-212; Q-73 to F-211; Q-73 to L-210; Q-73 to T-209; Q-73 to V-208; Q-73 to L-207; Q-73 to S-206; Q-73 to L-205; Q-73 to E-204; Q-73 to D-203; Q-73 to G-202; Q-73 to F-201; Q-73 to V-200; Q-73 to H-199; Q-73 to V-198; Q-73 to K-197; Q-73 to K-196; Q-73 to R-195; Q-73 to Q-194; Q-73 to I-193; Q-73 to L-192; Q-73 to H-191; Q-73 to G-190; Q-73 to Q-7389; Q-73 to A-188; Q-73 to Y-187; Q-73 to T-186; Q-73 to K-185; Q-73 to D-184; Q-73 to T-183; Q-73 to Y-182; Q-73 to L-181; Q-73 to V-180; Q-73 to Q-179; Q-73 to G-178; Q-73 to Y-177;

Q-73 to I-176; Q-73 to F-175; Q-73 to F-174; Q-73 to Y-173; Q-73 to G-172; Q-73 to T-171; Q-73 to E-170; Q-73 to K-169; Q-73 to V-168; Q-73 to L-167; Q-73 to I-166; Q-73 to K-165; Q-73 to N-164; Q-73 to E-163; Q-73 to K-162; Q-73 to E-161; Q-73 to E-160; Q-73 to L-159; Q-73 to A-158; Q-73 to S-157; Q-73 to G-156; Q-73 to R-155; Q-73 to K-154; Q-73 to F-153; Q-73 to S-152; Q-73 to L-151; Q-73 to L-150; Q-73 to W-149; Q-73 to P-148; Q-73 to V-147; Q-73 to F-146; Q-73 to T-145; Q-73 to Y-144; Q-73 to S-143; Q-73 to G-142; Q-73 to T-141; Q-73 to E-140; Q-73 to E-139; Q-73 to P-138; Q-73 to G-137; Q-73 to Q-136; Q-73 to V-135; Q-73 to A-134; Q-73 to R-133; Q-73 to K-132; Q-73 to N-131; Q-73 to R-130; Q-73 to S-129; Q-73 to N-128; Q-73 to Q-127; Q-73 to S-126; Q-73 to S-125; Q-73 to N-124; Q-73 to G-123; Q-73 to E-122; Q-73 to G-121; Q-73 to P-120; Q-73 to A-119; Q-73 to P-118; Q-73 to P-117; Q-73 to E-116; Q-73 to F-115; Q-73 to I-114; Q-73 to K-113; Q-73 to L-112; Q-73 to G-111; Q-73 to A-110; Q-73 to T-109; Q-73 to V-108; Q-73 to A-107; Q-73 to P-106; Q-73 to A-105; Q-73 to E-104; Q-73 to E-103; Q-73 to L-102; Q-73 to G-101; Q-73 to A-100; Q-73 to K-99; Q-73 to P-98; Q-73 to A-97; Q-73 to G-96; Q-73 to A-95; Q-73 to G-94; Q-73 to A-93; Q-73 to P-92; Q-73 to L-91; Q-73 to K-90; Q-73 to E-89; Q-73 to A-88; Q-73 to H-87; Q-73 to H-86; Q-73 to G-85; Q-73 to Q-84; Q-73 to L-83; Q-73 to E-82; Q-73 to A-81; Q-73 to R-80; Q-73 to L-79; and Q-73 to S-78 of SEQ ID NO:3229. The present invention is also directed to antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of B Lymphocyte Stimulator polypeptides described above.

The invention also provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini of the predicted extracellular domain of B Lymphocyte Stimulator, which may be described generally as having residues n^4 - m^4 of SEQ ID NO:3229 where n^4 and m^4 are integers as defined above.

In another embodiment, antibodies of the present invention bind polypeptides consisting of a portion of the extracellular domain of the B Lymphocyte Stimulator amino acid sequence encoded by the cDNA clone contained in the deposit having ATCCTM Accession No. 203518, where this portion excludes from 1 to about 260 amino acids from the amino terminus of the extracellular domain of the amino acid sequence encoded by cDNA clone contained in the deposit having ATCCTM Accession No. 203518, or from 1 to about 187 amino acids from the carboxy terminus of the extracellular domain of the amino acid sequence encoded by cDNA clone contained in the deposit having ATCCTM Accession No. 203518, or any combination of the above amino terminal and carboxy terminal deletions, of the entire extracellular domain of the amino acid sequence encoded by the cDNA clone contained in the deposit having ATCCTM Accession No. 203518.

As mentioned above, even if deletion of one or more amino acids from the N-terminus of a polypeptide results in modification or loss of one or more functional activities (e.g., biological activity) of the polypeptide, other functional activities may still be retained. Thus, the ability of a shortened B Lymphocyte Stimulator polypeptide to induce and/or bind to antibodies which recognize the full-length or mature forms or the extracellular domain of the polypeptide generally will be retained when less than the majority of the residues of the full-length or mature or extracellular domain of the polypeptide are removed from the N-terminus.

Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a B Lymphocyte Stimulator mutein with a large number of deleted N-terminal amino acid residues may retain functional (e.g., immunogenic) activities. In fact, peptides composed of as few as six B Lymphocyte Stimulator amino acid residues may often evoke an immune response.

Accordingly, the present invention further provides antibodies that bind polypeptides having one or more residues deleted from the amino terminus of the predicted full-length amino acid sequence of the B Lymphocyte Stimulator polypeptide shown in SEQ ID NO:3229, up to the glycine residue at position number 261 of the sequence shown SEQ ID NO:3229 and polynucleotides encoding such polypeptides. In particular, the present invention provides antibodies that bind polypeptides comprising the amino acid sequence of residues n^5 -266 of the sequence shown in SEQ ID NO:3229, where n^5 is an integer in the range of the amino acid position of amino acid residues 1 to 261 of the amino acid sequence in SEQ ID NO:3229.

More in particular, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues of D-2 to L-266; D-3 to L-266; S-4 to L-266; T-5 to L-266; E-6 to L-266; R-7 to L-266; E-8 to L-266; Q-9 to L-266; S-10 to L-266; R-11 to L-266; L-12 to L-266; T-13 to L-266; S-14 to L-266; C-15 to L-266; L-16 to L-266; K-17 to L-266; K-18 to L-266; R-19 to L-266; E-20 to L-266; E-21 to L-266; M-22 to L-266; K-23 to L-266; L-24 to L-266; K-25 to L-266; E-26 to L-266; C-27 to L-266; V-28 to L-266; S-29 to L-266; I-30 to L-266; L-31 to L-266; P-32 to L-266; R-33 to L-266; K-34 to L-266; E-35 to L-266; S-36 to L-266; P-37 to L-266; S-38 to L-266; V-39 to L-266; R-40 to L-266; S-41 to L-266; S-42 to L-266; K-43 to L-266; D-44 to L-266; G-45 to L-266; K-46 to L-266; L-47 to L-266; L-48 to L-266; A-49 to L-266; A-50 to L-266; T-51 to L-266; L-52 to L-266; L-53 to L-266; L-54 to L-266; A-55 to L-266; L-56 to L-266; L-57 to L-266; S-58 to L-266; C-59 to L-266; C-60 to L-266; L-61 to L-266; T-62 to L-266; V-63 to L-266; V-64 to L-266; S-65 to L-266; F-66 to L-266; Y-67 to L-266; Q-68 to L-266; V-69 to L-266; A-70 to L-266; A-71 to L-266; L-72 to L-266; Q-73 to L-266; G-74 to L-266; D-75 to L-266; L-76 to L-266; A-77 to L-266; S-78 to L-266; L-79 to L-266; R-80 to L-266; A-81 to L-266; E-82 to L-266; L-83 to L-266; Q-84 to L-266; G-85 to L-266; H-86 to L-266; H-87 to L-266; A-88 to L-266; E-89 to L-266; K-90 to L-266; L-91 to L-266; P-92 to L-266; A-93 to L-266; G-94 to L-266; A-95 to L-266; G-96 to L-266; A-97 to L-266; P-98 to L-266; K-99 to L-266; A-100 to L-266; G-101 to L-266; L-102 to L-266; E-103 to L-266; E-104 to L-266; A-105 to L-266; P-106 to L-266; A-107 to L-266; V-108 to L-266; T-109 to L-266; A-110 to L-266; G-111 to L-266; L-112 to L-266; K-113 to L-266; I-114 to L-266; F-115 to L-266; E-116 to L-266; P-117 to L-266; P-118 to L-266; A-119 to L-266; P-120 to L-266; G-121 to L-266; E-122 to L-266; G-123 to L-266; N-124 to L-266; S-125 to L-266; S-126 to L-266; Q-127 to L-266; N-128 to L-266; S-129 to L-266; R-130 to L-266; N-131 to L-266; K-132 to L-266; R-133 to L-266; A-134 to L-266; V-135 to L-266; Q-136 to L-266; G-137 to L-266; P-138 to L-266; E-139 to L-266; E-140 to L-266; T-141 to L-266; G-142 to L-266; S-143 to L-266; Y-144 to L-266; T-145 to L-266; F-146 to L-266; V-147 to L-266; P-148 to L-266; W-149 to L-266; L-150 to L-266; L-151 to L-266;

S-152 to L-266; F-153 to L-266; K-154 to L-266; R-155 to L-266; G-156 to L-266; S-157 to L-266; A-158 to L-266; L-159 to L-266; E-160 to L-266; E-161 to L-266; K-162 to L-266; E-163 to L-266; N-164 to L-266; K-165 to L-266; I-166 to L-266; L-167 to L-266; V-168 to L-266; K-169 to L-266; E-170 to L-266; T-171 to L-266; G-172 to L-266; Y-173 to L-266; F-174 to L-266; F-175 to L-266; I-176 to L-266; Y-177 to L-266; G-178 to L-266; Q-179 to L-266; V-180 to L-266; L-181 to L-266; Y-182 to L-266; T-183 to L-266; D-184 to L-266; K-185 to L-266; T-186 to L-266; Y-187 to L-266; A-188 to L-266; M-189 to L-266; G-190 to L-266; H-191 to L-266; L-192 to L-266; I-193 to L-266; Q-194 to L-266; R-195 to L-266; K-196 to L-266; K-197 to L-266; V-198 to L-266; H-199 to L-266; V-200 to L-266; F-201 to L-266; G-202 to L-266; D-203 to L-266; E-204 to L-266; L-205 to L-266; S-206 to L-266; L-207 to L-266; V-208 to L-266; T-209 to L-266; L-210 to L-266; F-211 to L-266; R-212 to L-266; C-213 to L-266; I-214 to L-266; Q-215 to L-266; N-216 to L-266; M-217 to L-266; P-218 to L-266; E-219 to L-266; T-220 to L-266; L-221 to L-266; P-222 to L-266; N-223 to L-266; N-224 to L-266; S-225 to L-266; C-226 to L-266; Y-227 to L-266; S-228 to L-266; A-229 to L-266; G-230 to L-266; I-231 to L-266; A-232 to L-266; K-233 to L-266; L-234 to L-266; E-235 to L-266; E-236 to L-266; G-237 to L-266; D-238 to L-266; E-239 to L-266; L-240 to L-266; Q-241 to L-266; L-242 to L-266; A-243 to L-266; I-244 to L-266; P-245 to L-266; R-246 to L-266; E-247 to L-266; N-248 to L-266; A-249 to L-266; Q-250 to L-266; I-251 to L-266; S-252 to L-266; L-253 to L-266; D-254 to L-266; G-255 to L-266; D-256 to L-266; V-257 to L-266; T-258 to L-266; F-259 to L-266; F-260 to L-266; and G-261 to L-266 of SEQ ID NO:3229. The present invention is also directed to antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of B Lymphocyte Stimulator polypeptides described above.

Also as mentioned above, even if deletion of one or more amino acids from the C-terminus of a protein results in modification or loss of one or more functional activities (e.g., biological activities) of the protein, other functional activities may still be retained. Thus, the ability of a shortened B Lymphocyte Stimulator mutein to induce and/or bind to antibodies which recognize the complete or mature form or the extracellular domain of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature form or the extracellular domain of the polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a B Lymphocyte Stimulator mutein with a large number of deleted C-terminal amino acid residues may retain some functional (e.g., immunogenic) activities. In fact, peptides composed of as few as six B Lymphocyte Stimulator amino acid residues may often evoke an immune response.

Accordingly, the present invention further provides in another embodiment, antibodies that bind polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of the B Lymphocyte Stimulator shown in SEQ ID NO:3229, up to the glutamic acid residue at position number 6, and polynucleotides encoding such polypeptides. In particular, the present invention provides antibodies that bind polypeptides comprising the amino acid sequence of residues 1-m⁵ of SEQ ID NO:3229, where m⁵

is an integer in the range of the amino acid position of amino acid residues 6 to 265 in the amino acid sequence of SEQ ID NO:3229.

More in particular, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues M-1 to L-265; M-1 to K-264; M-1 to L-263; M-1 to A-262; M-1 to G-261; M-1 to F-260; M-1 to F-259; M-1 to T-258; M-1 to V-257; M-1 to D-256; M-1 to G-255; M-1 to D-254; M-1 to L-253; M-1 to S-252; M-1 to I-251; M-1 to Q-250; M-1 to A-249; M-1 to N-248; M-1 to E-247; M-1 to R-246; M-1 to P-245; M-1 to I-244; M-1 to A-243; M-1 to L-242; M-1 to Q-241; M-1 to L-240; M-1 to E-239; M-1 to D-238; M-1 to G-237; M-1 to E-236; M-1 to E-235; M-1 to L-234; M-1 to K-233; M-1 to A-232; M-1 to I-231; M-1 to G-230; M-1 to A-229; M-1 to S-228; M-1 to Y-227; M-1 to C-226; M-1 to S-225; M-1 to N-224; M-1 to N-223; M-1 to P-222; M-1 to L-221; M-1 to T-220; M-1 to E-219; M-1 to P-218; M-1 to M-217; M-1 to N-216; M-1 to Q-215; M-1 to I-214; M-1 to C-213; M-1 to R-212; M-1 to F-211; M-1 to L-210; M-1 to T-209; M-1 to V-208; M-1 to L-207; M-1 to S-206; M-1 to L-205; M-1 to E-204; M-1 to D-203; M-1 to G-202; M-1 to F-201; M-1 to V-200; M-1 to H-199; M-1 to V-198; M-1 to K-197; M-1 to K-196; M-1 to R-195; M-1 to Q-194; M-1 to I-193; M-1 to L-192; M-1 to H-191; M-1 to G-190; M-1 to M-189; M-1 to A-188; M-1 to Y-187; M-1 to T-186; M-1 to K-185; M-1 to D-184; M-1 to T-183; M-1 to Y-182; M-1 to L-181; M-1 to V-180; M-1 to Q-179; M-1 to G-178; M-1 to Y-177; M-1 to I-176; M-1 to F-175; M-1 to F-174; M-1 to Y-173; M-1 to G-172; M-1 to T-171; M-1 to E-170; M-1 to K-169; M-1 to V-168; M-1 to L-167; M-1 to I-166; M-1 to K-165; M-1 to N-164; M-1 to E-163; M-1 to K-162; M-1 to E-161; M-1 to E-160; M-1 to L-159; M-1 to A-158; M-1 to S-157; M-1 to G-156; M-1 to R-155; M-1 to K-154; M-1 to F-153; M-1 to S-152; M-1 to L-151; M-1 to L-150; M-1 to W-149; M-1 to P-148; M-1 to V-147; M-1 to F-146; M-1 to T-145; M-1 to Y-144; M-1 to S-143; M-1 to G-142; M-1 to T-141; M-1 to E-140; M-1 to E-139; M-1 to P-138; M-1 to G-137; M-1 to Q-136; M-1 to V-135; M-1 to A-134; M-1 to R-133; M-1 to K-132; M-1 to N-131; M-1 to R-130; M-1 to S-129; M-1 to N-128; M-1 to Q-127; M-1 to S-126; M-1 to S-125; M-1 to N-124; M-1 to G-123; M-1 to E-122; M-1 to G-121; M-1 to P-120; M-1 to A-119; M-1 to P-118; M-1 to P-117; M-1 to E-116; M-1 to F-115; M-1 to I-114; M-1 to K-113; M-1 to L-112; M-1 to G-111; M-1 to A-110; M-1 to T-109; M-1 to V-108; M-1 to A-107; M-1 to P-106; M-1 to A-105; M-1 to E-104; M-1 to E-103; M-1 to L-102; M-1 to G-101; M-1 to A-100; M-1 to K-99; M-1 to P-98; M-1 to A-97; M-1 to G-96; M-1 to A-95; M-1 to G-94; M-1 to A-93; M-1 to P-92; M-1 to L-91; M-1 to K-90; M-1 to E-89; M-1 to A-88; M-1 to H-87; M-1 to H-86; M-1 to G-85; M-1 to Q-84; M-1 to L-83; M-1 to E-82; M-1 to A-81; M-1 to R-80; M-1 to L-79; M-1 to S-78; M-1 to A-77; M-1 to L-76; M-1 to D-75; M-1 to G-74; M-1 to Q-73; M-1 to L-72; M-1 to A-71; M-1 to A-70; M-1 to V-69; M-1 to Q-68; M-1 to Y-67; M-1 to F-66; M-1 to S-65; M-1 to V-64; M-1 to V-63; M-1 to T-62; M-1 to L-61; M-1 to C-60; M-1 to C-59; M-1 to S-58; M-1 to L-57; M-1 to L-56; M-1 to A-55; M-1 to L-54; M-1 to L-53; M-1 to L-52; M-1 to T-51; M-1 to A-50; M-1 to A-49; M-1 to L-48; M-1 to L-47; M-1 to K-46; M-1 to G-45; M-1 to D-44; M-1 to K-43; M-1 to S-42; M-1 to S-41; M-1 to R-40; M-1 to V-39; M-1 to S-38; M-1 to P-37; M-1 to S-36; M-1 to E-35; M-1 to K-34; M-1 to R-33; M-1 to P-32; M-1 to L-31; M-1 to I-30; M-1 to S-29; M-1 to V-28; M-1 to C-27; M-1 to E-26; M-1 to K-25; M-1 to L-24; M-1 to K-23; M-1 to M-22; M-1 to E-21; M-1 to E-20; M-1 to R-19; M-1 to K-18; M-1 to K-17; M-1 to

L-16; M-1 to C-15; M-1 to S-14; M-1 to T-13; M-1 to L-12; M-1 to R-11; M-1 to S-10; M-1 to Q-9; M-1 to E-8; M-1 to R-7; and M-1 to E-6 of SEQ ID NO:3229. The present invention is also directed to antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of B Lymphocyte Stimulator polypeptides described above.

The invention also provides antibodies that bind polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini of a B Lymphocyte Stimulator polypeptide, which may be described generally as having residues n^5 - m^5 of SEQ ID NO:3229, where n^5 and m^5 are integers as defined above.

In additional embodiments, the present invention provides antibodies that bind polypeptides comprising the amino acid sequence of residues 134- m^6 of SEQ ID NO:3228, where m^6 is an integer from 140 to 285, corresponding to the position of the amino acid residue in SEQ ID NO:3228. For example, the invention provides antibodies that bind polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues A-134 to Leu-285; A-134 to L-284; A-134 to K-283; A-134 to L-282; A-134 to A-281; A-134 to G-280; A-134 to F-279; A-134 to F-278; A-134 to T-277; A-134 to V-276; A-134 to D-275; A-134 to G-274; A-134 to D-273; A-134 to L-272; A-134 to S-271; A-134 to I-270; A-134 to Q-269; A-134 to A-268; A-134 to N-267; A-134 to E-266; A-134 to R-265; A-134 to P-264; A-134 to I-263; A-134 to A-262; A-134 to L-261; A-134 to Q-260; A-134 to L-259; A-134 to E-258; A-134 to D-257; A-134 to G-256; A-134 to E-255; A-134 to E-254; A-134 to L-253; A-134 to K-252; A-134 to A-251; A-134 to I-250; A-134 to G-249; A-134 to A-248; A-134 to S-247; A-134 to Y-246; A-134 to C-245; A-134 to S-244; A-134 to N-243; A-134 to N-242; A-134 to P-241; A-134 to L-240; A-134 to T-239; A-134 to E-238; A-134 to P-237; A-134 to M-236; A-134 to N-235; A-134 to Q-234; A-134 to I-233; A-134 to C-232; A-134 to R-231; A-134 to F-230; A-134 to L-229; A-134 to T-228; A-134 to V-227; A-134 to L-226; A-134 to S-225; A-134 to L-224; A-134 to E-223; A-134 to D-222; A-134 to G-221; A-134 to F-220; A-134 to V-219; A-134 to H-218; A-134 to V-217; A-134 to K-216; A-134 to K-215; A-134 to R-214; A-134 to Q-213; A-134 to I-212; A-134 to L-211; A-134 to H-210; A-134 to G-209; A-134 to M-208; A-134 to A-207; A-134 to Y-206; A-134 to T-205; A-134 to K-204; A-134 to D-203; A-134 to T-202; A-134 to Y-201; A-134 to L-200; A-134 to V-199; A-134 to Q-198; A-134 to G-197; A-134 to Y-196; A-134 to I-195; A-134 to F-194; A-134 to F-193; A-134 to Y-192; A-134 to G-191; A-134 to T-190; A-134 to E-189; A-134 to K-188; A-134 to V-187; A-134 to L-186; A-134 to I-185; A-134 to K-184; A-134 to N-183; A-134 to E-182; A-134 to K-181; A-134 to E-180; A-134 to E-179; A-134 to L-178; A-134 to A-177; A-134 to S-176; A-134 to G-175; A-134 to R-174; A-134 to K-173; A-134 to F-172; A-134 to S-171; A-134 to L-170; A-134 to L-169; A-134 to W-168; A-134 to P-167; A-134 to V-166; A-134 to F-165; A-134 to T-164; A-134 to Y-163; A-134 to S-162; A-134 to G-161; A-134 to K-160; A-134 to Q-159; A-134 to I-158; A-134 to T-157; A-134 to P-156; A-134 to T-155; A-134 to E-154; A-134 to S-153; A-134 to D-152; A-134 to A-151; A-134 to I-150; A-134 to L-149; A-134 to Q-148; A-134 to L-147; A-134 to C-146; A-134 to D-145; A-134 to Q-144; A-134 to T-143; A-134 to V-142; A-134 to T-141; and A-134 to E-140 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind B Lymphocyte Stimulator polypeptides com-

prising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of B Lymphocyte Stimulator polypeptides described above.

In additional embodiments, antibodies of the present invention may bind polypeptide fragments comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues: M-1 to C-15; D-2 to L-16; D-3 to K-17; S-4 to K-18; T-5 to R-19; E-6 to E-20; R-7 to E-21; E-8 to M-22; Q-9 to K-23; S-10 to L-24; R-11 to K-25; L-12 to E-26; T-13 to C-27; S-14 to V-28; C-15 to S-29; L-16 to I-30; K-17 to L-31; K-18 to P-32; R-19 to R-33; E-20 to K-34; E-21 to E-35; M-22 to S-36; K-23 to P-37; L-24 to S-38; K-25 to V-39; E-26 to R-40; C-27 to S-41; V-28 to S-42; S-29 to K-43; I-30 to D-44; L-31 to G-45; P-32 to K-46; R-33 to L-47; K-34 to L-48; E-35 to A-49; S-36 to A-50; P-37 to T-51; S-38 to L-52; V-39 to L-53; R-40 to L-54; S-41 to A-55; S-42 to L-56; K-43 to L-57; D-44 to S-58; G-45 to C-59; K-46 to C-60; L-47 to L-61; L-48 to T-62; A-49 to V-63; A-50 to V-64; T-51 to S-65; L-52 to F-66; L-53 to Y-67; L-54 to Q-68; A-55 to V-69; L-56 to A-70; L-57 to A-71; S-58 to L-72; C-59 to Q-73; C-60 to G-74; L-61 to D-75; T-62 to L-76; V-63 to A-77; V-64 to S-78; S-65 to L-79; F-66 to R-80; Y-67 to A-81; Q-68 to E-82; V-69 to L-83; A-70 to Q-84; A-71 to G-85; L-72 to H-86; Q-73 to H-87; G-74 to A-88; D-75 to E-89; L-76 to K-90; A-77 to L-91; S-78 to P-92; L-79 to A-93; R-80 to G-94; A-81 to A-95; E-82 to G-96; L-83 to A-97; Q-84 to P-98; G-85 to K-99; H-86 to A-100; H-87 to G-101; A-88 to L-102; E-89 to E-103; K-90 to E-104; L-91 to A-105; P-92 to P-106; A-93 to A-107; G-94 to V-108; A-95 to T-109; G-96 to A-110; A-97 to G-111; P-98 to L-112; K-99 to K-113; A-100 to I-114; G-101 to F-115; L-102 to E-116; E-103 to P-117; E-104 to P-118; A-105 to A-119; P-106 to P-120; A-107 to G-121; V-108 to E-122; T-109 to G-123; A-110 to N-124; G-111 to S-125; L-112 to S-126; K-113 to Q-127; I-114 to N-128; F-115 to S-129; E-116 to R-130; P-117 to N-131; P-118 to K-132; A-119 to R-133; P-120 to A-134; G-121 to V-135; E-122 to Q-136; G-123 to G-137; N-124 to P-138; S-125 to E-139; S-126 to E-140; Q-127 to T-141; N-128 to V-142; S-129 to T-143; R-130 to Q-144; N-131 to D-145; K-132 to C-146; R-133 to L-147; A-134 to Q-148; V-135 to L-149; Q-136 to I-150; G-137 to A-151; P-138 to D-152; E-139 to S-153; E-140 to E-154; T-141 to T-155; V-142 to P-156; T-143 to T-157; Q-144 to I-158; D-145 to Q-159; C-146 to K-160; L-147 to G-161; Q-148 to S-162; L-149 to Y-163; I-150 to T-164; A-151 to F-165; D-152 to V-166; S-153 to P-167; E-154 to W-168; T-155 to L-169; P-156 to L-170; T-157 to S-171; I-158 to F-172; Q-159 to K-173; K-160 to R-174; G-161 to G-175; S-162 to S-176; Y-163 to A-177; T-164 to L-178; F-165 to E-179; V-166 to E-180; P-167 to K-181; W-168 to E-182; L-169 to N-183; L-170 to K-184; S-171 to I-185; F-172 to L-186; K-173 to V-187; R-174 to K-188; G-175 to E-189; S-176 to T-190; A-177 to G-191; L-178 to Y-192; E-179 to F-193; E-180 to F-194; K-181 to I-195; E-182 to Y-196; N-183 to G-197; K-184 to Q-198; I-185 to V-199; L-186 to L-200; V-187 to Y-201; K-188 to T-202; E-189 to D-203; T-190 to K-204; G-191 to T-205; Y-192 to Y-206; F-193 to A-207; F-194 to M-208; I-195 to G-209; Y-196 to H-210; G-197 to L-211; Q-198 to I-212; V-199 to Q-213; L-200 to R-214; Y-201 to K-215; T-202 to K-216; D-203 to V-217; K-204 to H-218; T-205 to V-219; Y-206 to F-220; A-207 to G-221; M-208 to D-222; G-209 to E-223; H-210 to L-224; L-211 to S-225; I-212 to L-226; Q-213 to V-227; R-214 to T-228; K-215 to L-229; K-216 to F-230; V-217 to

R-231; H-218 to C-232; V-219 to I-233; F-220 to Q-234; G-221 to N-235; D-222 to M-236; E-223 to P-237; L-224 to E-238; S-225 to T-239; L-226 to L-240; V-227 to P-241; T-228 to N-242; L-229 to N-243; F-230 to S-244; R-231 to C-245; C-232 to Y-246; I-233 to S-247; Q-234 to A-248; N-235 to G-249; M-236 to I-250; P-237 to A-251; E-238 to K-252; T-239 to L-253; L-240 to E-254; P-241 to E-255; N-242 to G-256; N-243 to D-257; S-244 to E-258; C-245 to L-259; Y-246 to Q-260; S-247 to L-261; A-248 to A-262; G-249 to I-263; I-250 to P-264; A-251 to R-265; K-252 to E-266; L-253 to N-267; E-254 to A-268; E-255 to Q-269; G-256 to I-270; D-257 to S-271; E-258 to L-272; L-259 to D-273; Q-260 to G-274; L-261 to D-275; A-262 to V-276; I-263 to T-277; P-264 to F-278; R-265 to F-279; E-266 to G-280; N-267 to A-281; A-268 to L-282; Q-269 to K-283; I-270 to L-284; and S-271 to L-285 of SEQ ID NO:3228. The present invention is also directed to antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of B Lymphocyte Stimulator polypeptides described above.

In additional embodiments, antibodies of the present invention may bind polypeptide fragments comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues: M-1 to C-15; D-2 to L-16; D-3 to K-17; S-4 to K-18; T-5 to R-19; E-6 to E-20; R-7 to E-21; E-8 to M-22; Q-9 to K-23; S-10 to L-24; R-11 to K-25; L-12 to E-26; T-13 to C-27; S-14 to V-28; C-15 to S-29; L-16 to I-30; K-17 to L-31; K-18 to P-32; R-19 to R-33; E-20 to K-34; E-21 to E-35; M-22 to S-36; K-23 to P-37; L-24 to S-38; K-25 to V-39; E-26 to R-40; C-27 to S-41; V-28 to S-42; S-29 to K-43; I-30 to D-44; L-31 to G-45; P-32 to K-46; R-33 to L-47; K-34 to L-48; E-35 to A-49; S-36 to A-50; P-37 to T-51; S-38 to L-52; V-39 to L-53; R-40 to L-54; S-41 to A-55; S-42 to L-56; K-43 to L-57; D-44 to S-58; G-45 to C-59; K-46 to C-60; L-47 to L-61; L-48 to T-62; A-49 to V-63; A-50 to V-64; T-51 to S-65; L-52 to F-66; L-53 to Y-67; L-54 to Q-68; A-55 to V-69; L-56 to A-70; L-57 to A-71; S-58 to L-72; C-59 to Q-73; C-60 to G-74; L-61 to D-75; T-62 to L-76; V-63 to A-77; V-64 to S-78; S-65 to L-79; F-66 to R-80; Y-67 to A-81; Q-68 to E-82; V-69 to L-83; A-70 to Q-84; A-71 to G-85; L-72 to H-86; Q-73 to H-87; G-74 to A-88; D-75 to E-89; L-76 to K-90; A-77 to L-91; S-78 to P-92; L-79 to A-93; R-80 to G-94; A-81 to A-95; E-82 to G-96; L-83 to A-97; Q-84 to P-98; G-85 to K-99; H-86 to A-100; H-87 to G-101; A-88 to L-102; E-89 to E-103; K-90 to E-104; L-91 to A-105; P-92 to P-106; A-93 to A-107; G-94 to V-108; A-95 to T-109; G-96 to A-110; A-97 to G-111; P-98 to L-112; K-99 to K-113; A-100 to I-114; G-101 to F-115; L-102 to E-116; E-103 to P-117; E-104 to P-118; A-105 to A-119; P-106 to P-120; A-107 to G-121; V-108 to E-122; T-109 to G-123; A-110 to N-124; G-111 to S-125; L-112 to S-126; K-113 to Q-127; I-114 to N-128; F-115 to S-129; E-116 to R-130; P-117 to N-131; P-118 to K-132; A-119 to R-133; P-120 to A-134; G-121 to V-135; E-122 to Q-136; G-123 to G-137; N-124 to P-138; S-125 to E-139; S-126 to E-140; Q-127 to T-141; N-128 to G-142; S-129 to S-143; R-130 to Y-144; N-131 to T-145; K-132 to F-146; R-133 to V-147; A-134 to P-148; V-135 to W-149; Q-136 to L-150; G-137 to L-151; P-138 to S-152; E-139 to F-153; E-140 to K-154; T-141 to R-155; G-142 to G-156; S-143 to S-157; Y-144 to A-158; T-145 to L-159; F-146 to E-160; V-147 to E-161; P-148 to K-162; W-149 to E-163; L-150 to N-164; L-151 to K-165; S-152 to I-166; F-153 to L-167; K-154 to V-168; R-155 to K-169; G-156 to E-170; S-157 to T-171;

A-158 to G-172; L-159 to Y-173; E-160 to F-174; E-161 to F-175; K-162 to I-176; E-163 to Y-177; N-164 to G-178; K-165 to Q-179; I-166 to V-180; L-167 to L-181; V-168 to Y-182; K-169 to T-183; E-170 to D-184; T-171 to K-185; G-172 to T-186; Y-173 to Y-187; F-174 to A-188; F-175 to M-189; I-176 to G-190; Y-177 to H-191; G-178 to L-192; Q-179 to I-193; V-180 to Q-194; L-181 to R-195; Y-182 to K-196; T-183 to K-197; D-184 to V-198; K-185 to H-199; T-186 to V-200; Y-187 to F-201; A-188 to G-202; M-189 to D-203; G-190 to E-204; H-191 to L-205; L-192 to S-206; I-193 to L-207; Q-194 to V-208; R-195 to T-209; K-196 to L-210; K-197 to F-211; V-198 to R-212; H-199 to C-213; V-200 to I-214; F-201 to Q-215; G-202 to N-216; D-203 to M-217; E-204 to P-218; L-205 to E-219; S-206 to T-220; L-207 to L-221; V-208 to P-222; T-209 to N-223; L-210 to N-224; F-211 to S-225; R-212 to C-226; C-213 to Y-227; I-214 to S-228; Q-215 to A-229; N-216 to G-230; M-217 to I-231; P-218 to A-232; E-219 to K-233; T-220 to L-234; L-221 to E-235; P-222 to E-236; N-223 to G-237; N-224 to D-238; S-225 to E-239; C-226 to L-240; Y-227 to Q-241; S-228 to L-242; A-229 to A-243; G-230 to I-244; I-231 to P-245; A-232 to R-246; K-233 to E-247; L-234 to N-248; E-235 to A-249; E-236 to Q-250; G-237 to I-251; D-238 to S-252; E-239 to L-253; L-240 to D-254; Q-241 to G-255; L-242 to D-256; A-243 to V-257; I-244 to T-258; P-245 to F-259; R-246 to F-260; E-247 to G-261; N-248 to A-262; A-249 to L-263; Q-250 to K-264; I-251 to L-265; and S-252 to L-266 of SEQ ID NO:3229. The present invention is also directed to antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of B Lymphocyte Stimulator polypeptides described above.

In additional embodiments, antibodies of the present invention may bind polypeptide fragments comprising, or alternatively consisting of, an amino acid sequence selected from the group consisting of residues: M-1 to F-15; D-2 to C-16; E-3 to S-17; S-4 to E-18; A-5 to K-19; K-6 to G-20; T-7 to E-21; L-8 to D-22; P-9 to M-23; P-10 to K-24; P-11 to V-25; C-12 to G-26; L-13 to Y-27; C-14 to D-28; F-15 to P-29; C-16 to I-30; S-17 to T-31; E-18 to P-32; K-19 to Q-33; G-20 to K-34; E-21 to E-35; D-22 to E-36; M-23 to G-37; K-24 to A-38; V-25 to W-39; G-26 to F-40; Y-27 to G-41; D-28 to I-42; P-29 to C-43; I-30 to R-44; T-31 to D-45; P-32 to G-46; Q-33 to R-47; K-34 to L-48; E-35 to L-49; E-36 to A-50; G-37 to A-51; A-38 to T-52; W-39 to L-53; F-40 to L-54; G-41 to L-55; I-42 to A-56; C-43 to L-57; R-44 to L-58; D-45 to S-59; G-46 to S-60; R-47 to S-61; L-48 to F-62; L-49 to T-63; A-50 to A-64; A-51 to M-65; T-52 to S-66; L-53 to L-67; L-54 to Y-68; L-55 to Q-69; A-56 to L-70; L-57 to A-71; L-58 to A-72; S-59 to L-73; S-60 to Q-74; S-61 to A-75; F-62 to D-76; T-63 to L-77; A-64 to M-78; M-65 to N-79; S-66 to L-80; L-67 to R-81; Y-68 to M-82; Q-69 to E-83; L-70 to L-84; A-71 to Q-85; A-72 to S-86; L-73 to Y-87; Q-74 to R-88; A-75 to G-89; D-76 to S-90; L-77 to A-91; M-78 to T-92; N-79 to P-93; L-80 to A-94; R-81 to A-95; M-82 to A-96; E-83 to G-97; L-84 to A-98; Q-85 to P-99; S-86 to E-100; Y-87 to L-101; R-88 to T-102; G-89 to A-103; S-90 to G-104; A-91 to V-105; T-92 to K-106; P-93 to L-107; A-94 to L-108; A-95 to T-109; A-96 to P-110; G-97 to A-111; A-98 to A-112; P-99 to P-113; E-100 to R-114; L-101 to P-115; T-102 to H-116; A-103 to N-117; G-104 to S-118; V-105 to S-119; K-106 to R-120; L-107 to G-121; L-108 to H-122; T-109 to R-123; P-110 to N-124; A-111 to R-125; A-112 to R-126; P-113 to A-127; R-114 to F-128; P-115 to Q-129;

H-116 to G-130; N-117 to P-131; S-118 to E-132; S-119 to E-133; R-120 to T-134; G-121 to E-135; H-122 to Q-136; R-123 to D-137; N-124 to V-138; R-125 to D-139; R-126 to L-140; A-127 to S-141; F-128 to A-142; Q-129 to P-143; G-130 to P-144; P-131 to A-145; E-132 to P-146; E-133 to C-147; T-134 to L-148; E-135 to P-149; Q-136 to G-150; D-137 to C-151; V-138 to R-152; D-139 to H-153; L-140 to S-154; S-141 to Q-155; A-142 to H-156; P-143 to D-157; P-144 to D-158; A-145 to N-159; P-146 to G-160; C-147 to M-161; L-148 to N-162; P-149 to L-163; G-150 to R-164; C-151 to N-165; R-152 to I-166; H-153 to I-167; S-154 to Q-168; Q-155 to D-169; H-156 to C-170; D-157 to L-171; D-158 to Q-172; N-159 to L-173; G-160 to I-174; M-161 to A-175; N-162 to D-176; L-163 to S-177; R-164 to D-178; N-165 to T-179; I-166 to P-180; I-167 to A-181; Q-168 to L-182; D-169 to E-183; C-170 to E-184; L-171 to K-185; Q-172 to E-186; L-173 to N-187; I-174 to K-188; A-175 to I-189; D-176 to V-190; S-177 to V-191; D-178 to R-192; T-179 to Q-193; P-180 to T-194; A-181 to G-195; L-182 to Y-196; E-183 to F-197; E-184 to F-198; K-185 to I-199; E-186 to Y-200; N-187 to S-201; K-188 to Q-202; I-189 to V-203; V-190 to L-204; V-191 to Y-205; R-192 to T-206; Q-193 to D-207; T-194 to P-208; G-195 to I-209; Y-196 to F-210; F-197 to A-211; F-198 to M-212; I-199 to G-213; Y-200 to H-214; S-201 to V-215; Q-202 to I-216; V-203 to Q-217; L-204 to R-218; Y-205 to K-219; T-206 to K-220; D-207 to V-221; P-208 to H-222; I-209 to V-223; F-210 to F-224; A-211 to G-225; M-212 to D-226; G-213 to E-227; H-214 to L-228; V-215 to S-229; I-216 to L-230; Q-217 to V-231; R-218 to T-232; K-219 to L-233; K-220 to F-234; V-221 to R-235; H-222 to C-236; V-223 to I-237; F-224 to Q-238; G-225 to N-239; D-226 to M-240; E-227 to P-241; L-228 to K-242; S-229 to T-243; L-230 to L-244; V-231 to P-245; T-232 to N-246; L-233 to N-247; F-234 to S-248; R-235 to C-249; C-236 to Y-250; I-237 to S-251; Q-238 to A-252; N-239 to G-253; M-240 to I-254; P-241 to A-255; K-242 to R-256; T-243 to L-257; L-244 to E-258; P-245 to E-259; N-246 to G-260; N-247 to D-261; S-248 to E-262; C-249 to I-263; Y-250 to Q-264; S-251 to L-265; A-252 to A-266; G-253 to I-267; I-254 to P-268; A-255 to R-269; R-256 to E-270; L-257 to N-271; E-258 to A-272; E-259 to Q-273; G-260 to I-274; D-261 to S-275; E-262 to R-276; I-263 to N-277; Q-264 to G-278; L-265 to D-279; A-266 to D-280; I-267 to T-281; P-268 to F-282; R-269 to F-283; E-270 to G-284; N-271 to A-285; A-272 to L-286; Q-273 to K-287; I-274 to L-288; and S-275 to L-289 of SEQ ID NO:38. The present invention is also directed to antibodies that bind B Lymphocyte Stimulator polypeptides comprising, or alternatively, consisting of, a contiguous sequence of amino acid residues at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of B Lymphocyte Stimulator polypeptides described above.

It will be recognized by one of ordinary skill in the art that some amino acid sequences of the B Lymphocyte Stimulator polypeptides can be varied without significant effect of the structure or function of the polypeptide. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the polypeptide which determine activity.

Thus, the invention further includes antibodies that bind variations of B Lymphocyte Stimulator polypeptides which show B Lymphocyte Stimulator polypeptide functional activity (e.g., biological activity) or which include regions of B Lymphocyte Stimulator polypeptide such as the polypeptide fragments described herein. Such mutants include deletions, insertions, inversions, repeats, and type substitutions selected according to general rules known in the art so as

have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990), wherein the authors indicate that there are two main approaches for studying the tolerance of an amino acid sequence to change. The first method relies on the process of evolution, in which mutations are either accepted or rejected by natural selection. The second approach uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene and selections or screens to identify sequences that maintain functionality.

As the authors state, these studies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at a certain position of the protein. For example, most buried amino acid residues require non-polar side chains, whereas few features of surface side chains are generally conserved. Other such phenotypically silent substitutions are described in Bowie, J. U. et al., *supra*, and the references cited therein. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gln, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe, Tyr.

Thus, antibodies of the present invention may bind fragments, derivatives or analogs of the polypeptide of SEQ ID NO:3228, or that encoded by the deposited cDNA plasmid, such as (i) polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) polypeptides in which one or more of the amino acid residues includes a substituent group, or (iii) polypeptides in which the extracellular domain of the polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) polypeptides in which the additional amino acids are fused to the extracellular domain of the polypeptide, such as an IgG Fc fusion region peptide or leader or secretory sequence or a sequence which is employed for purification of the extracellular domain of the polypeptide or a proprotein sequence.

Antibodies of the present invention may bind fragments, derivatives or analogs of the polypeptide of SEQ ID NO:3229, or that encoded by the deposited cDNA plasmid, such as (i) polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) polypeptides in which one or more of the amino acid residues includes a substituent group, or (iii) polypeptides in which the extracellular domain of the polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) polypeptides in which the additional amino acids are fused to the extracellular domain of the polypeptide, such as, a soluble biologically active fragment of another TNF ligand family member (e.g., CD40 Ligand), an IgG Fc fusion region peptide or leader or secretory sequence or a sequence which is employed for purification of the extra-

65

cellular domain of the polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

Thus, the antibodies of the invention may bind B Lymphocyte Stimulator polypeptides that include one or more amino acid substitutions, deletions or additions, either from natural mutations or human manipulation. As indicated, changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein (see Table 13).

TABLE 13

Conservative Amino Acid Substitutions.	
Aromatic	Phenylalanine
	Tryptophan
Hydrophobic	Tyrosine
	Leucine
	Isoleucine
Polar	Valine
	Glutamine
Basic	Asparagine
	Arginine
	Lysine
Acidic	Histidine
	Aspartic Acid
	Glutamic Acid
Small	Alanine
	Serine
	Threonine
	Methionine
	Glycine

In one embodiment of the invention, antibodies of the present invention bind polypeptides comprising, or alternatively consisting of, the amino acid sequence of a B Lymphocyte Stimulator polypeptide having an amino acid sequence which contains at least one conservative amino acid substitution, but not more than 50 conservative amino acid substitutions, even more preferably, not more than 40 conservative amino acid substitutions, still more preferably, not more than 30 conservative amino acid substitutions, and still even more preferably, not more than 20 conservative amino acid substitutions. In one embodiment of the invention, antibodies of the present invention bind polypeptides comprising, or alternatively consisting of, the amino acid sequence of a B Lymphocyte Stimulator polypeptide having an amino acid sequence which contains at least one conservative amino acid substitution, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 conservative amino acid substitutions.

For example, site directed changes at the amino acid level of B Lymphocyte Stimulator can be made by replacing a particular amino acid with a conservative substitution. Antibodies of the present invention may bind B Lymphocyte Stimulator amino acid sequences containing conservative substitution mutations of the polypeptide of SEQ ID NO:3228 including: M1 replaced with A, G, I, L, S, T, or V; D2 replaced with E; D3 replaced with E; S4 replaced with A, G, I, L, T, M, or V; T5 replaced with A, G, I, L, S, M, or V; E6 replaced with D; R7 replaced with H, or K; E8 replaced with D; Q9 replaced with N; S10 replaced with A, G, I, L, T, M, or V; R11 replaced with H, or K; L12 replaced with A, G, I, S, T, M, or V; T13 replaced with A, G, I, L, S, M, or V; S14 replaced with A, G, I, L, T, M, or V; L16 replaced with A, G, I, S, T, M, or V; K17 replaced with H, or R; K18 replaced with H, or R; R19 replaced with H, or K; E20 replaced with D; E21 replaced with D; M22 replaced with A, G, I, L, S, T, or V; K23 replaced with H, or R; L24

66

replaced with A, G, I, S, T, M, or V; K25 replaced with H, or R; E26 replaced with D; V28 replaced with A, G, I, L, S, T, or M; S29 replaced with A, G, I, L, T, M, or V; I30 replaced with A, G, L, S, T, M, or V; L31 replaced with A, G, I, S, T, M, or V; R33 replaced with H, or K; K34 replaced with H, or R; E35 replaced with D; S36 replaced with A, G, I, L, T, M, or V; S38 replaced with A, G, I, L, T, M, or V; V39 replaced with A, G, I, L, S, T, or M; R40 replaced with H, or K; S41 replaced with A, G, I, L, T, M, or V; S42 replaced with A, G, I, L, T, M, or V; K43 replaced with H, or R; D44 replaced with E; G45 replaced with A, I, L, S, T, M, or V; K46 replaced with H, or R; L47 replaced with A, G, I, S, T, M, or V; L48 replaced with A, G, I, S, T, M, or V; A49 replaced with G, I, L, S, T, M, or V; A50 replaced with G, I, L, S, T, M, or V; T51 replaced with A, G, I, L, S, M, or V; L52 replaced with A, G, I, S, T, M, or V; L53 replaced with A, G, I, S, T, M, or V; L54 replaced with A, G, I, S, T, M, or V; A55 replaced with G, I, L, S, T, M, or V; L56 replaced with A, G, I, S, T, M, or V; L57 replaced with A, G, I, S, T, M, or V; S58 replaced with A, G, I, L, T, M, or V; L61 replaced with A, G, I, S, T, M, or V; T62 replaced with A, G, I, L, S, M, or V; V63 replaced with A, G, I, L, S, T, or M; V64 replaced with A, G, I, L, S, T, or M; S65 replaced with A, G, I, L, T, M, or V; F66 replaced with W, or Y; Y67 replaced with F, or W; Q68 replaced with N; V69 replaced with A, G, I, L, S, T, or M; A70 replaced with G, I, L, S, T, M, or V; A71 replaced with G, I, L, S, T, M, or V; L72 replaced with A, G, I, S, T, M, or V; Q73 replaced with N; G74 replaced with A, I, L, S, T, M, or V; D75 replaced with E; L76 replaced with A, G, I, S, T, M, or V; A77 replaced with G, I, L, S, T, M, or V; S78 replaced with A, G, I, L, T, M, or V; L79 replaced with A, G, I, S, T, M, or V; R80 replaced with H, or K; A81 replaced with G, I, L, S, T, M, or V; E82 replaced with D; L83 replaced with A, G, I, S, T, M, or V; Q84 replaced with N; G85 replaced with A, I, L, S, T, M, or V; H86 replaced with K, or R; H87 replaced with K, or R; A88 replaced with G, I, L, S, T, M, or V; E89 replaced with D; K90 replaced with H, or R; L91 replaced with A, G, I, S, T, M, or V; A93 replaced with G, I, L, S, T, M, or V; G94 replaced with A, I, L, S, T, M, or V; A95 replaced with G, I, L, S, T, M, or V; G96 replaced with A, I, L, S, T, M, or V; A97 replaced with G, I, L, S, T, M, or V; K99 replaced with H, or R; A100 replaced with G, I, L, S, T, M, or V; G101 replaced with A, I, L, S, T, M, or V; L102 replaced with A, G, I, S, T, M, or V; E103 replaced with D; E104 replaced with D; A105 replaced with G, I, L, S, T, M, or V; A107 replaced with G, I, L, S, T, M, or V; V108 replaced with A, G, I, L, S, T, or M; T109 replaced with A, G, I, L, S, M, or V; A110 replaced with G, I, L, S, T, M, or V; G111 replaced with A, I, L, S, T, M, or V; L112 replaced with A, G, I, S, T, M, or V; K113 replaced with H, or R; I114 replaced with A, G, L, S, T, M, or V; F115 replaced with W, or Y; E116 replaced with D; A119 replaced with G, I, L, S, T, M, or V; G121 replaced with A, I, L, S, T, M, or V; E122 replaced with D; G123 replaced with A, I, L, S, T, M, or V; N124 replaced with Q; S125 replaced with A, G, I, L, T, M, or V; S126 replaced with A, G, I, L, T, M, or V; Q127 replaced with N; N128 replaced with Q; S129 replaced with A, G, I, L, T, M, or V; R130 replaced with H, or K; N131 replaced with Q; K132 replaced with H, or R; R133 replaced with H, or K; A134 replaced with G, I, L, S, T, M, or V; V135 replaced with A, G, I, L, S, T, or M; Q136 replaced with N; G137 replaced with A, I, L, S, T, M, or V; E139 replaced with D; E140 replaced with D; T141 replaced with A, G, I, L, S, M, or V; V142 replaced with A, G, I, L, S, T, or M; T143 replaced with A, G, I, L, S, M, or V; Q144 replaced with N; D145 replaced with E; L147 replaced with A, G, I,

67

S, T, M, or V; Q148 replaced with N; L149 replaced with A, G, I, S, T, M, or V; I150 replaced with A, G, L, S, T, M, or V; A151 replaced with G, I, L, S, T, M, or V; D152 replaced with E; S153 replaced with A, G, I, L, S, T, M, or V; E154 replaced with D; T155 replaced with A, G, I, L, S, M, or V; T157 replaced with A, G, I, L, S, M, or V; I158 replaced with A, G, L, S, T, M, or V; Q159 replaced with N; K160 replaced with H, or R; G161 replaced with A, I, L, S, T, M, or V; S162 replaced with A, G, I, L, S, T, M, or V; Y163 replaced with F, or W; T164 replaced with A, G, I, L, S, M, or V; F165 replaced with W, or Y; V166 replaced with A, G, I, L, S, T, or M; W168 replaced with F, or Y; L169 replaced with A, G, I, S, T, M, or V; L170 replaced with A, G, I, S, T, M, or V; S171 replaced with A, G, I, L, S, T, M, or V; F172 replaced with W, or Y; K173 replaced with H, or R; R174 replaced with H, or K; G175 replaced with A, I, L, S, T, M, or V; S176 replaced with A, G, I, L, S, T, M, or V; A177 replaced with G, I, L, S, T, M, or V; L178 replaced with A, G, I, S, T, M, or V; E179 replaced with D; E180 replaced with D; K181 replaced with H, or R; E182 replaced with D; N183 replaced with Q; K184 replaced with H, or R; I185 replaced with A, G, L, S, T, M, or V; L186 replaced with A, G, I, S, T, M, or V; V187 replaced with A, G, I, L, S, T, or M; K188 replaced with H, or R; E189 replaced with D; T190 replaced with A, G, I, L, S, M, or V; G191 replaced with A, I, L, S, T, M, or V; Y192 replaced with F, or W; F193 replaced with W, or Y; F194 replaced with W, or Y; I195 replaced with A, G, L, S, T, M, or V; Y196 replaced with F, or W; G197 replaced with A, I, L, S, T, M, or V; Q198 replaced with N; V199 replaced with A, G, I, L, S, T, or M; L200 replaced with A, G, I, S, T, M, or V; Y201 replaced with F, or W; T202 replaced with A, G, I, L, S, M, or V; D203 replaced with E; K204 replaced with H, or R; T205 replaced with A, G, I, L, S, M, or V; Y206 replaced with F, or W; A207 replaced with G, I, L, S, T, M, or V; M208 replaced with A, G, I, L, S, T, or V; G209 replaced with A, I, L, S, T, M, or V; H210 replaced with K, or R; L211 replaced with A, G, I, S, T, M, or V; I212 replaced with A, G, L, S, T, M, or V; Q213 replaced with N; R214 replaced with H, or K; K215 replaced with H, or R; K216 replaced with H, or R; V217 replaced with A, G, I, L, S, T, or M; H218 replaced with K, or R; V219 replaced with A, G, I, L, S, T, or M; F220 replaced with W, or Y; G221 replaced with A, I, L, S, T, M, or V; D222 replaced with E; E223 replaced with D; L224 replaced with A, G, I, S, T, M, or V; S225 replaced with A, G, I, L, S, T, M, or V; L226 replaced with A, G, I, S, T, M, or V; V227 replaced with A, G, I, L, S, T, or M; T228 replaced with A, G, I, L, S, M, or V; L229 replaced with A, G, I, S, T, M, or V; F230 replaced with W, or Y; R231 replaced with H, or K; I233 replaced with A, G, L, S, T, M, or V; Q234 replaced with N; N235 replaced with Q; M236 replaced with A, G, I, L, S, T, or V; E238 replaced with D; T239 replaced with A, G, I, L, S, M, or V; L240 replaced with A, G, I, S, T, M, or V; N242 replaced with Q; N243 replaced with Q; S244 replaced with A, G, I, L, S, T, M, or V; Y246 replaced with F, or W; S247 replaced with A, G, I, L, S, T, M, or V; A248 replaced with G, I, L, S, T, M, or V; G249 replaced with A, I, L, S, T, M, or V; I250 replaced with A, G, L, S, T, M, or V; A251 replaced with G, I, L, S, T, M, or V; K252 replaced with H, or R; L253 replaced with A, G, I, S, T, M, or V; E254 replaced with D; E255 replaced with D; G256 replaced with A, I, L, S, T, M, or V; D257 replaced with E; E258 replaced with D; L259 replaced with A, G, I, S, T, M, or V; Q260 replaced with N; L261 replaced with A, G, I, S, T, M, or V; A262 replaced with G, I, L, S, T, M, or V; I263 replaced with A, G, L, S, T, M, or V; R265 replaced with H, or K; E266 replaced with D; N267 replaced with Q; A268 replaced with G, I, L, S, T,

68

M, or V; Q269 replaced with N; I270 replaced with A, G, L, S, T, M, or V; S271 replaced with A, G, I, L, S, T, M, or V; L272 replaced with A, G, I, S, T, M, or V; D273 replaced with E; G274 replaced with A, I, L, S, T, M, or V; D275 replaced with E; V276 replaced with A, G, I, L, S, T, or M; T277 replaced with A, G, I, L, S, M, or V; F278 replaced with W, or Y; F279 replaced with W, or Y; G280 replaced with A, I, L, S, T, M, or V; A281 replaced with G, I, L, S, T, M, or V; L282 replaced with A, G, I, S, T, M, or V; K283 replaced with H, or R; L284 replaced with A, G, I, S, T, M, or V; and/or L285 replaced with A, G, I, S, T, M, or V.

In another embodiment, site directed changes at the amino acid level of B Lymphocyte Stimulator can be made by replacing a particular amino acid with a conservative substitution. Antibodies of the present invention may bind B Lymphocyte Stimulator amino acid sequences containing conservative substitution mutations of the polypeptide of SEQ ID NO:3229 including: M1 replaced with A, G, I, L, S, T, or V; D2 replaced with E; D3 replaced with E; S4 replaced with A, G, I, L, S, T, M, or V; T5 replaced with A, G, I, L, S, M, or V; E6 replaced with D; R7 replaced with H, or K; E8 replaced with D; Q9 replaced with N; S10 replaced with A, G, I, L, S, T, M, or V; R11 replaced with H, or K; L12 replaced with A, G, I, S, T, M, or V; T13 replaced with A, G, I, L, S, M, or V; S14 replaced with A, G, I, L, S, T, M, or V; L16 replaced with A, G, I, S, T, M, or V; K17 replaced with H, or R; K18 replaced with H, or R; R19 replaced with H, or K; E20 replaced with D; E21 replaced with D; M22 replaced with A, G, I, L, S, T, or V; K23 replaced with H, or R; L24 replaced with A, G, I, S, T, M, or V; K25 replaced with H, or R; E26 replaced with D; V28 replaced with A, G, I, L, S, T, or M; S29 replaced with A, G, I, L, S, T, M, or V; I30 replaced with A, G, L, S, T, M, or V; L31 replaced with A, G, I, S, T, M, or V; R33 replaced with H, or K; K34 replaced with H, or R; E35 replaced with D; S36 replaced with A, G, I, L, S, T, M, or V; S38 replaced with A, G, I, L, S, T, M, or V; V39 replaced with A, G, I, L, S, T, or M; R40 replaced with H, or K; S41 replaced with A, G, I, L, S, T, M, or V; S42 replaced with A, G, I, L, S, T, M, or V; K43 replaced with H, or R; D44 replaced with E; G45 replaced with A, I, L, S, T, M, or V; K46 replaced with H, or R; L47 replaced with A, G, I, S, T, M, or V; L48 replaced with A, G, I, S, T, M, or V; A49 replaced with G, I, L, S, T, M, or V; A50 replaced with G, I, L, S, T, M, or V; T51 replaced with A, G, I, L, S, M, or V; L52 replaced with A, G, I, S, T, M, or V; L53 replaced with A, G, I, S, T, M, or V; L54 replaced with A, G, I, S, T, M, or V; A55 replaced with G, I, L, S, T, M, or V; L56 replaced with A, G, I, S, T, M, or V; L57 replaced with A, G, I, S, T, M, or V; S58 replaced with A, G, I, L, S, T, M, or V; L61 replaced with A, G, I, S, T, M, or V; T62 replaced with A, G, I, L, S, M, or V; V63 replaced with A, G, I, L, S, T, or M; V64 replaced with A, G, I, L, S, T, or M; S65 replaced with A, G, I, L, S, T, M, or V; F66 replaced with W, or Y; Y67 replaced with F, or W; Q68 replaced with N; V69 replaced with A, G, I, L, S, T, or M; A70 replaced with G, I, L, S, T, M, or V; A71 replaced with G, I, L, S, T, M, or V; L72 replaced with A, G, I, S, T, M, or V; Q73 replaced with N; G74 replaced with A, I, L, S, T, M, or V; D75 replaced with E; L76 replaced with A, G, I, S, T, M, or V; A77 replaced with G, I, L, S, T, M, or V; S78 replaced with A, G, I, L, S, T, M, or V; L79 replaced with A, G, I, S, T, M, or V; R80 replaced with H, or K; A81 replaced with G, I, L, S, T, M, or V; E82 replaced with D; L83 replaced with A, G, I, S, T, M, or V; Q84 replaced with N; H85 replaced with A, I, L, S, T, M, or V; H86 replaced with K, or R; H87 replaced with K, or R; A88 replaced with G, I, L, S, T, M, or V; E89 replaced with D; K90 replaced with H, or R; L91 replaced

with A, G, I, S, T, M, or V; A93 replaced with G, I, L, S, T, M, or V; G94 replaced with A, I, L, S, T, M, or V; A95 replaced with G, I, L, S, T, M, or V; G96 replaced with A, I, L, S, T, M, or V; A97 replaced with G, I, L, S, T, M, or V; K99 replaced with H, or R; A100 replaced with G, I, L, S, T, M, or V; G101 replaced with A, I, L, S, T, M, or V; L102 replaced with A, G, I, S, T, M, or V; E103 replaced with D; E104 replaced with D; A105 replaced with G, I, L, S, T, M, or V; A107 replaced with G, I, L, S, T, M, or V; V108 replaced with A, G, I, L, S, T, or M; T109 replaced with A, G, I, L, S, M, or V; A110 replaced with G, I, L, S, T, M, or V; G111 replaced with A, I, L, S, T, M, or V; L112 replaced with A, G, I, S, T, M, or V; K113 replaced with H, or R; I114 replaced with A, G, L, S, T, M, or V; F115 replaced with W, or Y; E116 replaced with D; A119 replaced with G, I, L, S, T, M, or V; G121 replaced with A, I, L, S, T, M, or V; E122 replaced with D; G123 replaced with A, I, L, S, T, M, or V; N124 replaced with Q; S125 replaced with A, G, I, L, T, M, or V; S126 replaced with A, G, I, L, T, M, or V; Q127 replaced with N; N128 replaced with Q; S129 replaced with A, G, I, L, T, M, or V; R130 replaced with H, or K; N131 replaced with Q; K132 replaced with H, or R; R133 replaced with H, or K; A134 replaced with G, I, L, S, T, M, or V; V135 replaced with A, G, I, L, S, T, or M; Q136 replaced with N; G137 replaced with A, I, L, S, T, M, or V; E139 replaced with D; E140 replaced with D; T141 replaced with A, G, I, L, S, M, or V; G142 replaced with A, I, L, S, T, M, or V; S143 replaced with A, G, I, L, T, M, or V; Y144 replaced with F, or W; T145 replaced with A, G, I, L, S, M, or V; F146 replaced with W, or Y; V147 replaced with A, G, I, L, S, T, or M; W149 replaced with F, or Y; L150 replaced with A, G, I, S, T, M, or V; L151 replaced with A, G, I, S, T, M, or V; S152 replaced with A, G, I, L, T, M, or V; F153 replaced with W, or Y; K154 replaced with H, or R; R155 replaced with H, or K; G156 replaced with A, I, L, S, T, M, or V; S157 replaced with A, G, I, L, T, M, or V; A158 replaced with G, I, L, S, T, M, or V; L159 replaced with A, G, I, S, T, M, or V; E160 replaced with D; E161 replaced with D; K162 replaced with H, or R; E163 replaced with D; N164 replaced with Q; K165 replaced with H, or R; I166 replaced with A, G, L, S, T, M, or V; L167 replaced with A, G, I, S, T, M, or V; V168 replaced with A, G, I, L, S, T, or M; K169 replaced with H, or R; E170 replaced with D; T171 replaced with A, G, I, L, S, M, or V; G172 replaced with A, I, L, S, T, M, or V; Y173 replaced with F, or W; F174 replaced with W, or Y; F175 replaced with W, or Y; I176 replaced with A, G, L, S, T, M, or V; Y177 replaced with F, or W; G178 replaced with A, I, L, S, T, M, or V; Q179 replaced with N; V180 replaced with A, G, I, L, S, T, or M; L181 replaced with A, G, I, S, T, M, or V; Y182 replaced with F, or W; T183 replaced with A, G, I, L, S, M, or V; D184 replaced with E; K185 replaced with H, or R; T186 replaced with A, G, I, L, S, M, or V; Y187 replaced with F, or W; A188 replaced with G, I, L, S, T, M, or V; M189 replaced with A, G, I, L, S, T, or V; G190 replaced with A, I, L, S, T, M, or V; H191 replaced with K, or R; L192 replaced with A, G, I, S, T, M, or V; I193 replaced with A, G, L, S, T, M, or V; Q194 replaced with N; R195 replaced with H, or K; K196 replaced with H, or R; K197 replaced with H, or R; V198 replaced with A, G, I, L, S, T, or M; H199 replaced with K, or R; V200 replaced with A, G, I, L, S, T, or M; F201 replaced with W, or Y; G202 replaced with A, I, L, S, T, M, or V; D203 replaced with E; E204 replaced with D; L205 replaced with A, G, I, S, T, M, or V; S206 replaced with A, G, I, L, T, M, or V; L207 replaced with A, G, I, S, T, M, or V; V208 replaced with A, G, I, L, S, T, or M; T209 replaced with A, G, I, L, S, M, or V; L210 replaced with A, G, I, S, T, M, or V; F211 replaced

with W, or Y; R212 replaced with H, or K; I214 replaced with A, G, L, S, T, M, or V; Q215 replaced with N; N216 replaced with Q; M217 replaced with A, G, I, L, S, T, or V; E219 replaced with D; T220 replaced with A, G, I, L, S, M, or V; L221 replaced with A, G, I, S, T, M, or V; N223 replaced with Q; N224 replaced with Q; S225 replaced with A, G, I, L, T, M, or V; Y227 replaced with F, or W; S228 replaced with A, G, I, L, T, M, or V; A229 replaced with G, I, L, S, T, M, or V; G230 replaced with A, I, L, S, T, M, or V; I231 replaced with A, G, L, S, T, M, or V; A232 replaced with G, I, L, S, T, M, or V; K233 replaced with H, or R; L234 replaced with A, G, I, S, T, M, or V; E235 replaced with D; E236 replaced with D; G237 replaced with A, I, L, S, T, M, or V; D238 replaced with E; E239 replaced with D; L240 replaced with A, G, I, S, T, M, or V; Q241 replaced with N; L242 replaced with A, G, I, S, T, M, or V; A243 replaced with G, I, L, S, T, M, or V; I244 replaced with A, G, L, S, T, M, or V; R246 replaced with H, or K; E247 replaced with D; N248 replaced with Q; A249 replaced with G, I, L, S, T, M, or V; Q250 replaced with N; I251 replaced with A, G, L, S, T, M, or V; S252 replaced with A, G, I, L, T, M, or V; L253 replaced with A, G, I, S, T, M, or V; D254 replaced with E; G255 replaced with A, I, L, S, T, M, or V; D256 replaced with E; V257 replaced with A, G, I, L, S, T, or M; T258 replaced with A, G, I, L, S, M, or V; F259 replaced with W, or Y; F260 replaced with W, or Y; G261 replaced with A, I, L, S, T, M, or V; A262 replaced with G, I, L, S, T, M, or V; L263 replaced with A, G, I, S, T, M, or V; K264 replaced with H, or R; L265 replaced with A, G, I, S, T, M, or V; and/or L266 replaced with A, G, I, S, T, M, or V.

In another embodiment, site directed changes at the amino acid level of B Lymphocyte Stimulator can be made by replacing a particular amino acid with a conservative substitution. Antibodies of the present invention may bind B Lymphocyte Stimulator amino acid sequences containing conservative substitution mutations of the polypeptide of any one of SEQ ID NOS:3230-3237.

Amino acids in the B Lymphocyte Stimulator polypeptides that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, *Science* 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for functional activity, such ligand binding and the ability to stimulate lymphocyte (e.g., B cell) as, for example, proliferation, differentiation, and/or activation. Accordingly, antibodies of the present invention may bind amino acids in the B Lymphocyte Stimulator polypeptides that are essential for function. In preferred embodiments, antibodies of the present invention bind amino acids in the B Lymphocyte Stimulator polypeptides that are essential for function and inhibit B Lymphocyte Stimulator polypeptide function. In other preferred embodiments, antibodies of the present invention bind amino acids in the B Lymphocyte Stimulator polypeptides that are essential for function and enhance B Lymphocyte Stimulator polypeptide function.

Of special interest are substitutions of charged amino acids with other charged or neutral amino acids which may produce proteins with highly desirable improved characteristics, such as less aggregation. Aggregation may not only reduce activity but also be problematic when preparing pharmaceutical formulations, because aggregates can be immunogenic (Pinckard et al., *Clin. Exp. Immunol.* 2:331-340 (1967); Robbins et al., *Diabetes* 36: 838-845 (1987); Cleland et al., *Crit. Rev. Therapeutic Drug Carrier Systems* 10:307-377 (1993).

72

Y, P, or C; S58 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C59 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; C60 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; L61 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T62 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V63 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V64 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S65 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F66 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Y67 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Q68 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; V69 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A70 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A71 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L72 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q73 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G74 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D75 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L76 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A77 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S78 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L79 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R80 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A81 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E82 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L83 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q84 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G85 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H86 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H87 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A88 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E89 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K90 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L91 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P92 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A93 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G94 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A95 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G96 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A97 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P98 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; K99 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A100 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G101 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L102 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E103 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E104 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A105 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P106 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A107 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V108 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T109 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A110 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G111 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L112 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K113 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I114 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F115 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; E116 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P117 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; P118 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A119 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P120 replaced with D, E, H, K,

75

Q, F, W, Y, or C; N242 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N243 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; S244 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C245 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; Y246 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S247 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A248 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G249 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I250 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A251 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K252 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L253 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E254 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E255 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G256 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D257 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E258 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L259 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q260 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L261 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A262 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I263 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P264 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; R265 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E266 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N267 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; A268 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q269 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; I270 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S271 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L272 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D273 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G274 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D275 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V276 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T277 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F278 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; F279 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G280 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A281 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L282 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K283 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L284 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; and/or L285 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C.

In an additional embodiment, antibodies of the present invention bind B Lymphocyte Stimulator polypeptides comprising, or alternatively consisting of, a B Lymphocyte Stimulator amino acid sequence in which more than one amino acid (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 and 50) is replaced with the substituted amino acids as described above (either conservative or nonconservative).

In another embodiment of the invention, antibodies of the present invention bind B Lymphocyte Stimulator polypeptides with non-conservative substitutions of the sequence provided in SEQ ID NO:3229 including: M1 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D2 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D3 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S4 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T5 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E6 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R7 replaced with D, E, A, G, I, L, S, T, M, V, N,

76

Q, F, W, Y, P, or C; E8 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q9 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; S10 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R11 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L12 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T13 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S14 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C15 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; L16 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K17 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K18 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R19 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E20 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E21 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; M22 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K23 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L24 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K25 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E26 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C27 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; V28 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S29 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I30 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L31 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P32 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; R33 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K34 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E35 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S36 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P37 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; S38 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V39 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R40 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S41 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S42 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K43 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D44 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G45 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K46 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L47 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L48 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A49 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A50 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T51 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L52 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L53 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L54 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A55 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L56 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L57 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S58 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C59 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; C60 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; L61 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T62 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V63 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V64 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S65 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F66 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Y67 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Q68 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; V69 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A70

[illegible][illegible]

C; I193 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q194 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; R195 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K196 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K197 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V198 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H199 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V200 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F201 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G202 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D203 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E204 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L205 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S206 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L207 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V208 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T209 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L210 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F211 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; R212 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C213 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; I214 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q215 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N216 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; M217 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P218 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E219 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T220 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L221 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P222 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; N223 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N224 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; S225 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C226 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; Y227 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S228 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A229 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G230 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I231 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A232 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K233 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L234 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E235 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E236 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G237 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D238 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E239 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L240 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q241 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L242 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A243 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I244 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P245 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; R246 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E247 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N248 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; A249 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q250 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; I251 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S252 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L253

replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D254 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G255 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D256 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V257 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T258 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F259 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; F260 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G261 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A262 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K264 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L265 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; and/or L266 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C.

In another embodiment, site directed changes at the amino acid level of B Lymphocyte Stimulator can be made by replacing a particular amino acid with a non-conservative substitution. Antibodies of the present invention may bind B Lymphocyte Stimulator amino acid sequences containing non-conservative substitution mutations of the polypeptide of any one of SEQ ID NOS:3230-3237.

In an additional embodiment, antibodies of the present invention bind B Lymphocyte Stimulator polypeptides comprising, or alternatively consisting of, a B Lymphocyte Stimulator amino acid sequence in which more than one amino acid (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 and 50) is replaced with the substituted amino acids as described above (either conservative or nonconservative).

Replacement of amino acids can also change the selectivity of the binding of a ligand to cell surface receptors. For example, Ostade et al., *Nature* 361:266-268 (1993) describes certain mutations resulting in selective binding of TNF-alpha to only one of the two known types of TNF receptors. Since B Lymphocyte Stimulator is a member of the TNF polypeptide family, mutations similar to those in TNF-alpha are likely to have similar effects in B Lymphocyte Stimulator polypeptides.

Sites that are critical for ligand-receptor binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., *J. Mol. Biol.* 224:899-904 (1992) and de Vos et al., *Science* 255:306-312 (1992)).

Since B Lymphocyte Stimulator is a member of the TNF-related protein family, mutations may be made in sequences encoding amino acids in the TNF conserved domain, e.g., in positions Gly-191 through Leu-284 of SEQ ID NO:3228 or in positions Gly-172 through Leu-265 of SEQ ID NO:3229, may modulate rather than completely eliminate functional activities (e.g., biological activities) of B Lymphocyte Stimulator polypeptides or fragments or variants thereof. Accordingly, antibodies of the present invention may bind B Lymphocyte Stimulator polypeptides that have mutations in the TNF conserved domain. In preferred embodiments, antibodies of the present invention may bind B Lymphocyte Stimulator polypeptides that have mutations in the TNF conserved domain and act as antagonists of B Lymphocyte Stimulator. In other preferred embodiments, antibodies of the present invention may bind B Lymphocyte Stimulator polypeptides that have mutations in the TNF conserved domain and act as agonists of B Lymphocyte Stimulator.

Recombinant DNA technology known to those skilled in the art (see, for instance, DNA shuffling supra) can be used to create novel mutant proteins or muteins including single or multiple amino acid substitutions, deletions, additions or fusion proteins. Such modified polypeptides can show, e.g.,

enhanced activity or increased stability. In addition, they may be purified in higher yields and show better solubility than the corresponding natural polypeptide, at least under certain purification and storage conditions.

Thus, the invention also encompasses antibodies that bind B Lymphocyte Stimulator derivatives and analogs that have one or more amino acid residues deleted, added, or substituted to generate B Lymphocyte Stimulator polypeptides, e.g., that are better suited for expression, scale up, etc., in the host cells. For example, cysteine residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges; N-linked glycosylation sites can be altered or eliminated to achieve, for example, expression of a homogeneous product that is more easily recovered and purified from yeast hosts which are known to hyperglycosylate N-linked sites. To this end, a variety of amino acid substitutions at one or both of the first or third amino acid positions on any one or more of the glycosylation recognition sequences in the B Lymphocyte Stimulator polypeptides of the invention, and/or an amino acid deletion at the second position of any one or more such recognition sequences will prevent glycosylation of the B Lymphocyte Stimulator at the modified tripeptide sequence (see, e.g., Miyajimo et al., EMBO J 5(6):1193-1197). By way of non-limiting example, mutation of the serine at position 244 to alanine either singly or in combination with mutation of the asparagine at position 242 to glutamine abolishes glycosylation of the mature soluble form of B Lymphocyte Stimulator (e.g., amino acids 134-285 of SEQ ID NO:3228) when expressed in the yeast *Pichia pastoris*. A mutant B Lymphocyte Stimulator polypeptide in which only the asparagine at position 242 is mutated to glutamine, is still glycosylated when expressed in *Pichia pastoris*. In this mutant, the glycosylation event may be due to the activation or unmasking of an O-linked glycosylation site at serine 244. Similar mutations affecting glycosylation could also be made in the B Lymphocyte Stimulator polypeptide of SEQ ID NO:3229, i.e., asparagine-223 to glutamine and/or serine-224 to alanine of SEQ ID NO:3229. Additionally, one or more of the amino acid residues of the polypeptides of the invention (e.g., arginine and lysine residues) may be deleted or substituted with another residue to eliminate undesired processing by proteases such as, for example, furins or kexins. One possible result of such a mutation is that B Lymphocyte Stimulator polypeptide of the invention is not cleaved and released from the cell surface. Accordingly, antibodies of the invention may bind B Lymphocyte Stimulator derivatives and analogs that have one or more amino acid residues deleted, added, or substituted. In other embodiments, antibodies of the invention may bind B Lymphocyte Stimulator derivatives, variants or analogs that are unable to be cleaved from the cell surface.

In a specific embodiment, antibodies of the invention bind B Lymphocyte Stimulator polypeptides in which Lys-132 and/or Arg-133 of the B Lymphocyte Stimulator sequence shown in SEQ ID NO:3228 is mutated to another amino acid residue, or deleted altogether, to prevent or diminish release of the soluble form of B Lymphocyte Stimulator from cells expressing B Lymphocyte Stimulator. In a more specific embodiment, antibodies of the invention bind B Lymphocyte Stimulator polypeptides in which Lys-132 of the B Lymphocyte Stimulator sequence shown in SEQ ID NO:3228 is mutated to Ala-132. In another, nonexclusive specific embodiment, antibodies of the invention bind B Lymphocyte Stimulator polypeptides in which Arg-133 of the B Lymphocyte Stimulator sequence shown in SEQ ID NO:3228 is mutated to Ala-133. These mutated proteins,

and/or have uses such as, for example, in ex vivo therapy or gene therapy, to engineer cells expressing a B Lymphocyte Stimulator polypeptide that is retained on the surface of the engineered cells.

In a specific embodiment, antibodies of the invention bind B Lymphocyte Stimulator polypeptides in which Cys-146 of the B Lymphocyte Stimulator sequence shown in SEQ ID NO:3228 is mutated to another amino acid residue, or deleted altogether, for example, to aid preventing or diminishing oligomerization of the mutant B Lymphocyte Stimulator polypeptide when expressed in an expression system. In a specific embodiment, antibodies of the invention bind B Lymphocyte Stimulator polypeptides in which Cys-146 is replaced with a serine amino acid residue.

In another specific embodiment, antibodies of the invention bind B Lymphocyte Stimulator polypeptides in which Cys-232 of the B Lymphocyte Stimulator sequence shown in SEQ ID NO:3228 is mutated to another amino acid residue, or deleted altogether, for example, to aid preventing or diminishing oligomerization of the mutant B Lymphocyte Stimulator polypeptide when expressed in an expression system. In a specific embodiment, antibodies of the invention bind B Lymphocyte Stimulator polypeptides in which Cys-232 is replaced with a serine amino acid residue. Polypeptides encoding these polypeptides are also encompassed by the invention.

In yet another specific embodiment, antibodies of the invention bind B Lymphocyte Stimulator polypeptides in which Cys-245 of the B Lymphocyte Stimulator sequence shown in SEQ ID NO:3228 is mutated to another amino acid residue, or deleted altogether, for example, to aid preventing or diminishing oligomerization of the mutant B Lymphocyte Stimulator polypeptide when expressed in an expression system. In a specific embodiment, antibodies of the invention bind B Lymphocyte Stimulator polypeptides in which Cys-245 is replaced with a serine amino acid residue. Polypeptides encoding these polypeptides are also encompassed by the invention.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of the B Lymphocyte Stimulator polypeptides can be substantially purified by the one-step method described in Smith and Johnson, *Gene* 67:31-40 (1988).

The antibodies of the present invention bind B Lymphocyte Stimulator polypeptides including the complete polypeptide encoded by the deposited cDNA (ATCCTM Deposit No. 97768) including the intracellular, transmembrane and extracellular domains of the polypeptide encoded by the deposited cDNA, the mature soluble polypeptide encoded by the deposited cDNA, the extracellular domain minus the intracellular and transmembrane domains of the protein, the complete polypeptide of SEQ ID NO:3228, the mature soluble polypeptide of SEQ ID NO:3228, e.g., amino acids 134-285 of SEQ ID NO:3228, the extracellular domain of SEQ ID NO:3228, amino acid residues 73-285 of SEQ ID NO:3228 minus the intracellular and transmembrane domains, as well as polypeptides which have at least 80%, 85%, 90% similarity, more preferably at least 95% similarity, and still more preferably at least 96%, 97%, 98% or 99% similarity to those described above. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The antibodies of the present invention bind B Lymphocyte Stimulator polypeptides including the complete polypeptide encoded by the deposited cDNA including the intracellular, transmembrane and extracellular domains of

the polypeptide encoded by the deposited cDNA (ATCC™ Deposit No. 203518), the mature soluble polypeptide encoded by the deposited cDNA, the extracellular domain minus the intracellular and transmembrane domains of the protein, the complete polypeptide of SEQ ID NO:3229, the mature soluble of SEQ ID NO:3229, e.g., amino acid residues 134–266 of SEQ ID NO:3229, the extracellular domain of SEQ ID NO:3229, e.g., amino acid residues 73–266 of SEQ ID NO:3229 minus the intracellular and transmembrane domains, as well as polypeptides which have at least 80%, 85%, 90% similarity, more preferably at least 95% similarity, and still more preferably at least 96%, 97%, 98% or 99% similarity to those described above. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Further antibodies of the present invention bind polypeptides including polypeptides at least 80%, or at least 85% identical, more preferably at least 90% or 95% identical, still more preferably at least 96%, 97%, 98% or 99% identical to the polypeptide encoded by the deposited cDNA (ATCC™ Deposit No. 97768) or to the polypeptide of SEQ ID NO:3228, and also include antibodies that bind portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids.

Further antibodies of the present invention bind polypeptides including polypeptides at least 80%, or at least 85% identical, more preferably at least 90% or 95% identical, still more preferably at least 96%, 97%, 98% or 99% identical to the polypeptide encoded by the deposited cDNA (ATCC™ Deposit No. 203518) or to the polypeptide of SEQ ID NO:3229, and also include antibodies that bind portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids. Polynucleotides encoding these polypeptides are also encompassed by the invention.

By “% similarity” for two polypeptides is intended a similarity score produced by comparing the amino acid sequences of the two polypeptides using the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711) and the default settings for determining similarity. Bestfit uses the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics 2:482–489, 1981) to find the best segment of similarity between two sequences.

By a polypeptide having an amino acid sequence at least, for example, 95% “identical” to a reference amino acid sequence of a B Lymphocyte Stimulator polypeptide is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of the B Lymphocyte Stimulator polypeptide. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence of SEQ ID

NO:3228, the amino acid sequence encoded by the deposited cDNA clone HNEDU15 (ATCC™ Accession No. 97768), or fragments thereof, or, for instance, to the amino acid sequence of SEQ ID NO:3229, the amino acid sequence encoded by the deposited cDNA clone HDPMC52 (ATCC™ Accession No. 203518), or fragments thereof, can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed.

In a specific embodiment, the identity between a reference (query) sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, is determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237–245 (1990)). Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter. According to this embodiment, if the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction is made to the results to take into consideration the fact that the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. A determination of whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of this embodiment. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence. For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue

query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are made for the purposes of this embodiment.

Antibodies that Immunospecifically Bind B Lymphocyte Stimulator Polypeptides

The present invention also encompasses antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to B Lymphocyte Stimulator polypeptides, which antibodies comprise, or alternatively consist of, all or a portion of a heavy and/or light chain variable domain of the scFvs referred to in Table 1.

The present invention also encompasses methods and compositions for detecting, diagnosing and/or prognosing diseases or disorders associated with aberrant B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor expression or inappropriate B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor function in an animal, preferably a mammal, and most preferably a human, comprising using antibodies (including molecules which comprise, or alternatively consist of, antibody fragments or variants thereof) that immunospecifically bind to B Lymphocyte Stimulator. Diseases and disorders which can be detected, diagnosed or prognosed with the antibodies of the invention include, but are not limited to, immune disorders (e.g., lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, Hashimoto's disease, and immunodeficiency syndrome), inflammatory disorders (e.g., asthma, allergic disorders, and rheumatoid arthritis), infectious diseases (e.g., AIDS), and proliferative disorders (e.g., leukemia, carcinoma, and lymphoma).

The present invention further encompasses methods and compositions for preventing, treating or ameliorating diseases or disorders associated with aberrant B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor expression or inappropriate B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor function in an animal, preferably a mammal, and most preferably a human, comprising administering to said animal an effective amount of one or more antibodies (including molecules which comprise, or alternatively consist of, antibody fragments or variants thereof) that immunospecifically bind to B Lymphocyte Stimulator. Diseases and disorders which can be prevented, treated or inhibited by administering an effective amount of one or more antibodies or molecules of the invention include, but are not limited to, immune disorders (e.g., lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, Hashimoto's disease, and immunodeficiency syndrome), inflammatory disorders (e.g., asthma, allergic disorders, and rheumatoid arthritis), infectious diseases (e.g., AIDS), and proliferative disorders (e.g., leukemia, carcinoma, and lymphoma).

Anti-B Lymphocyte Stimulator Antibodies

The antibodies of the present invention were discovered, in part, using phage display technology. Single chain antibody molecules ("scFvs") displayed on the surface of phage particles were screened to identify those scFvs that immunospecifically bind to B Lymphocyte Stimulator, including the membrane-bound form and soluble form of B Lymphocyte Stimulator. The present invention encompasses the scFvs and portions thereof that were identified to immunospecifically bind to B Lymphocyte Stimulator, including

scFvs that immunospecifically bind to the soluble form of B Lymphocyte Stimulator, scFvs that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator, and scFvs that immunospecifically bind to both the soluble form and membrane-bound form of B Lymphocyte Stimulator. In particular, the present invention encompasses scFvs comprising, or alternatively consisting of, the amino acid sequence of SEQ ID NOS: 1-2128, as referred to in Table 1. Preferably, the scFvs of the present invention comprise, or alternatively consist of, the amino acid sequence of SEQ ID NOS: 1-46, 321-329, 834-872, 1563-1595, or 1881-1908. The scFvs include scFvs that bind to soluble B Lymphocyte Stimulator (e.g., scFvs comprising, or alternatively consisting of, an amino acid sequence of SEQ ID NOS: 1563-1880), scFvs that bind to the membrane-bound form of B Lymphocyte Stimulator (e.g., scFvs comprising, or alternatively consisting of, an amino acid sequence of SEQ ID NOS: 1881-2128), and scFvs that bind to both the soluble form and the membrane-bound form of B Lymphocyte Stimulator (e.g., scFvs comprising, or alternatively consisting of, an amino acid sequence of SEQ ID NOS: 1-1562). Molecules comprising, or alternatively consisting of, fragments or variants of these scFvs, that immunospecifically bind to B Lymphocyte Stimulator are also encompassed by the invention, as are nucleic acid molecules encoding these scFvs, molecules, fragments and/or variants.

In one embodiment of the present invention, scFvs that immunospecifically bind to B Lymphocyte Stimulator comprise a polypeptide having the amino acid sequence of any one of the VH domains referred to in Table 1 and/or any one of the VL domains referred to in Table 1. In preferred embodiments, scFvs of the present invention comprise the amino acid sequence of a VH domain and VL domain from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention comprise the amino acid sequence of a VH domain and VL domain from different scFvs referred to in Table 1. In another embodiment, scFvs that immunospecifically bind to B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs referred to in Table 1 and/or any one, two, three, or more of the VL CDRs referred to in Table 1. In preferred embodiments, scFvs of the present invention comprise the amino acid sequence of a VH CDR and VL CDR from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention comprise the amino acid sequence of a VH CDR and VL CDR from different scFvs referred to in Table 1. Molecules comprising, or alternatively consisting of, antibody fragments or variants of the scFvs referred to in Table 1 that immunospecifically bind to B Lymphocyte Stimulator are also encompassed by the invention, as are nucleic acid molecules encoding these scFvs, molecules, fragments and/or variants.

(Table 1 can be found at the end of the specification just prior to the claims.)

In another embodiment of the present invention, an scFv that immunospecifically binds to a soluble form of B Lymphocyte Stimulator, comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS:1563-1880 as referred to in Table 1. In a preferred embodiment, an scFv that immunospecifically binds to a soluble form of B Lymphocyte Stimulator comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS:1570-1595. In an even more preferred embodiment, an scFv that immunospecifically binds to a soluble form of B Lymphocyte Stimulator comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS:1563-1569.

In another embodiment of the present invention, an scFv that immunospecifically binds to a membrane-bound form of B Lymphocyte Stimulator comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS:1881-2128 as referred to in Table 1. In a preferred embodiment, an scFv that immunospecifically binds to a membrane-bound form of B Lymphocyte Stimulator comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS:1886-1908. In an even more preferred embodiment, an scFv that immunospecifically binds to a membrane-bound form of B Lymphocyte Stimulator comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS:1881-1885.

In another embodiment of the present invention, an scFv that immunospecifically binds to both the soluble form and membrane-bound form of B Lymphocyte Stimulator comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS:1-1562 as referred to in Table 1. In a preferred embodiment, an scFv that immunospecifically binds to both the soluble form and membrane-bound form of B Lymphocyte Stimulator comprises, or alternatively consists of, the amino acid sequence of SEQ ID NOS:834-872. In another preferred embodiment, an scFv that immunospecifically binds to both the soluble form and membrane-bound form of B Lymphocyte Stimulator comprises, or alternatively consists of, any one of the amino acid sequences of SEQ ID NOS:1-46 or 321-329. Molecules comprising, or alternatively consisting of, fragments or variants of these scFvs, that immunospecifically bind to the soluble form of B Lymphocyte Stimulator and/or the membrane-bound form of B Lymphocyte Stimulator are also encompassed by the invention, as are nucleic acid molecules encoding these scFvs, molecules, fragments and/or variants.

In another embodiment of the present invention, scFvs that immunospecifically bind to the soluble form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of any one of the VH domains contained in SEQ ID NOS:1563-1880 as disclosed in Table 1 and/or any one of the VL domains contained in SEQ ID NOS:1563-1880 as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the soluble form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH CDR and VL CDR from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the soluble form of B Lymphocyte Stimulator, comprise a polypeptide having amino acid sequence of a VH CDR and VL CDR from different scFvs referred to in Table 1. In another embodiment, scFvs that immunospecifically bind to the soluble form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs SEQ ID NOS:1563-1880 as disclosed in Table 1 and/or any one, two, three, or more of the VL CDRs contained in contained SEQ ID NOS:1563-1880, as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the soluble form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the soluble form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from different scFvs referred to in Table 1. In a preferred embodiment, scFvs that immunospecifically bind to the soluble form of B Lymphocyte Stimu-

lator, comprise a polypeptide having the amino acid sequence of any one of the VH CDR3s contained in SEQ ID NOS:1563-1880 as disclosed in Table 1 and/or any one of the VL CDR3s contained in SEQ ID NOS:1563-1880 as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the soluble form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH CDR and VL CDR from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the soluble form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH CDR and VL CDR from different scFvs referred to in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these scFvs, that immunospecifically bind to B Lymphocyte Stimulator, preferably the soluble form of B Lymphocyte Stimulator, are also encompassed by the invention, as are nucleic acid molecules encoding these scFvs, molecules, fragments and/or variants.

In another embodiment of the present invention, scFvs that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator comprise a polypeptide having the amino acid sequence of any one of the VH domains contained in SEQ ID NOS:1881-2128 as disclosed in Table 1 and/or any one of the VL domains contained in SEQ ID NOS:1881-2128 as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the soluble form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH CDR and VL CDR from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from different scFvs referred to in Table 1. In another embodiment, scFvs that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs contained in SEQ ID NOS:1881-2128 as disclosed in Table 1 and/or any one, two, three, or more of the VL CDRs contained in SEQ ID NOS:1881-2128 as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from different scFvs referred to in Table 1. In a preferred embodiment, scFvs that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of any one of the VH CDR3s contained in SEQ ID NOS:1881-2128 as disclosed in Table 1 and/or any one of the VL CDR3s contained in SEQ ID NOS:1881-2128 as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator, comprise a polypeptide having the

amino acid sequence of a VH CDR and VL CDR from different scFvs referred to in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these scFvs, that immunospecifically bind to B Lymphocyte Stimulator, preferably the membrane-bound form of B Lymphocyte Stimulator, are also encompassed by the invention, as are nucleic acid molecules encoding these scFvs, molecules, fragments and/or variants.

In another embodiment of the present invention, scFvs that immunospecifically bind to the soluble form and membrane-bound form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of any one of the VH domains contained in SEQ ID NOS:1-1562 as disclosed in Table 1 and/or any one of the VL domains contained in SEQ ID NOS:1-1562 as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the soluble and membrane-bound forms of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the soluble form and membrane-bound form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from different scFvs referred to in Table 1. In another embodiment, scFvs that immunospecifically bind to the soluble form and membrane-bound form of B Lymphocyte Stimulator comprise a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs contained in SEQ ID NOS:1-1562 as disclosed in Table 1 and/or any one, two, three, or more of the VL CDRs contained in SEQ ID NOS:1-1562 as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the soluble form and membrane-bound form of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the soluble and membrane-bound forms of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH domain and VL domain from different scFvs referred to in Table 1. In a preferred embodiment, scFvs that immunospecifically bind to the soluble and membrane-bound forms of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of any one of the VH CDR3s contained in SEQ ID NOS:1-1562 as disclosed in Table 1 and/or any one of the VL CDR3s contained in SEQ ID NOS:1-1562, as disclosed in Table 1. In preferred embodiments, scFvs of the present invention that immunospecifically bind to the soluble and membrane-bound forms of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH CDR and VL CDR from the same scFv referred to in Table 1. In alternative embodiments, scFvs of the present invention that immunospecifically bind to the soluble and membrane-bound forms of B Lymphocyte Stimulator, comprise a polypeptide having the amino acid sequence of a VH CDR and VL CDR from different scFvs referred to in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these scFvs or molecules, that immunospecifically bind to B Lymphocyte Stimulator, preferably the soluble and membrane-bound forms of B Lymphocyte Stimulator, are also encompassed by the invention, as are nucleic acid molecules encoding these scFvs, molecules, fragments and/or variants.

The present invention provides antibodies (including molecules comprising, or alternatively consisting of, antibody

fragments or variants thereof) that immunospecifically bind to a polypeptide or a polypeptide fragment of B Lymphocyte Stimulator. In particular, the invention provides antibodies corresponding to the scFvs referred to in Table 1, such scFvs may routinely be "converted" to immunoglobulin molecules by inserting, for example, the nucleotide sequences encoding the VH and/or VL domains of the scFv into an expression vector containing the constant domain sequences and engineered to direct the expression of the immunoglobulin molecule, as described in more detail in Example 20, *infra*.

In one embodiment, the invention provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) wherein said antibodies comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one of the VH domains contained in the sequences referred to in Table 1. The present invention also provides antibodies that immunospecifically bind to a polypeptide, or polypeptide fragment of B Lymphocyte Stimulator, wherein said antibodies comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one, two, three, or more of the VH CDRs contained in the sequences referred to in Table 1. Molecules comprising, or alternatively consisting of, these antibodies, or antibody fragments or variants thereof, that immunospecifically bind to B Lymphocyte Stimulator or a B Lymphocyte Stimulator fragment are also encompassed by the invention, as are nucleic acid molecules encoding these antibodies, molecules, fragments and/or variants.

In one embodiment of the present invention, antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind B Lymphocyte Stimulator, comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VH CDR referred to in Table 1. In particular, the invention provides antibodies that immunospecifically bind B Lymphocyte Stimulator, comprising, or alternatively consisting of, a polypeptide having the amino acid sequence of a VH CDR1 contained in SEQ ID NOS:1-46, 321-329, 1563-1569, or 1881-1885 as disclosed in Table 1. In another embodiment, antibodies that immunospecifically bind B Lymphocyte Stimulator, comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VH CDR2 contained in SEQ ID NOS:1-46, 321-329, 1563-1569, or 1881-1885 as disclosed in Table 1. In a preferred embodiment, antibodies that immunospecifically bind B Lymphocyte Stimulator, comprise, or alternatively consist of a polypeptide having the amino acid sequence of a VH CDR3 contained in SEQ ID NOS:1-46, 321-329, 1563-1569, or 1881-1885 as disclosed in Table 1. In yet another embodiment, antibodies that immunospecifically bind B Lymphocyte Stimulator, comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VH CDR1 contained in SEQ ID NOS:834-872, 1570-1595, or 1886-1908 as disclosed in Table 1; a VH CDR2 contained in SEQ ID NOS: SEQ ID NOS: SEQ ID NOS:834-872, 1570-1595, or 1886-1908; and/or a VH CDR3 contained in SEQ ID NOS: SEQ ID NOS:834-872, 1570-1595, or 1886-1908 as disclosed in Table 1. Preferably, antibodies of the invention comprise, or alternatively consist of, VH CDRs that are derived from the same scFv as disclosed in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies that immunospecifically bind to B Lymphocyte Stimulator are also encompassed by the invention, as are nucleic acid molecules encoding these antibodies, molecules, fragments or variants.

The present invention provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants) that immunospecifically bind to a polypeptide, or polypeptide fragment of B Lymphocyte Stimulator. In particular, the invention provides antibodies wherein said antibodies comprise, or alternatively consist of, a VL domain having an amino acid sequence of any one of the VL domains referred to in Table 1. The present invention also provides antibodies that immunospecifically bind to a polypeptide or polypeptide fragment of B Lymphocyte Stimulator, wherein said antibodies comprise, or alternatively consist of, a VL CDR having an amino acid sequence of any one, two, three, or more of the VL CDRs contained in the sequences referred to in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies that immunospecifically bind to B Lymphocyte Stimulator are also encompassed by the invention, as are nucleic acid molecules encoding these antibodies, molecules, fragments or variants.

In one embodiment of the present invention, antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind B Lymphocyte Stimulator, comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VL CDR referred to in Table 1. In particular, the invention provides antibodies that immunospecifically bind B Lymphocyte Stimulator, comprising, or alternatively consisting of, a polypeptide having the amino acid sequence of a VL CDR1 contained in SEQ ID NOS:1-46, 321-329, 1563-1569, or 1881-1885 as disclosed in Table 1. In another embodiment, antibodies that immunospecifically bind B Lymphocyte Stimulator comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VL CDR2 contained in SEQ ID NOS:1-46, 321-329, 1563-1569, or 1881-1885 as disclosed in Table 1. In a preferred embodiment, antibodies comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VL CDR3 contained in SEQ ID NOS: 1-46, 321-329, 1563-1569, or 1881-1885 disclosed in Table 1. In yet another embodiment, antibodies that immunospecifically bind B Lymphocyte Stimulator comprise, or alternatively consist of: a polypeptide having the amino acid sequence of a VL CDR1 contained in SEQ ID NOS: 834-872, 1570-1595, or 1886-1908 as disclosed in Table 1; a VL CDR2 SEQ ID NOS:834-872, 1570-1595, or 1886-1908 as disclosed in Table 1; and a VL CDR3 contained SEQ ID NOS:834-872, 1570-1595, or 1886-1908 as disclosed in Table 1. Preferably, antibodies of the invention comprise, or alternatively consist of, VL CDRs that are derived from the same scFv as disclosed in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies, that immunospecifically bind to B Lymphocyte Stimulator are also encompassed by the invention, as are nucleic acid molecules encoding these antibodies, molecules, fragments or variants.

The present invention also provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to a polypeptide or a polypeptide fragment of B Lymphocyte Stimulator, wherein said antibodies comprise, or alternatively consist of, a VH domain of one of the scFvs referred to in Table 1, or other VL domain. The present invention further provides antibodies (including molecules comprising, or alternatively consist of, antibody fragments or variants thereof) that immunospecifically bind to a polypeptide or a polypeptide fragment of B Lymphocyte

Stimulator, wherein said antibodies comprise, or alternatively consist of, a VL domain of one of the scFvs referred to in Table 1 combined with a VH domain of one of the scFvs referred to in Table 1, or other VH domain. In a preferred embodiment, antibodies that immunospecifically bind to a polypeptide or a polypeptide fragment of B Lymphocyte Stimulator, comprise, or alternatively consist of, a polypeptide having the amino acid sequence of a VH domain contained SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1 and a VL domain contained in contained SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1. In a further preferred embodiment, the antibodies of the invention comprise, or alternatively consist of, a VH and a VL domain from the same scFv as disclosed in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies, that immunospecifically bind to B Lymphocyte Stimulator are also encompassed by the invention, as are nucleic acid molecules encoding these antibodies, molecules, fragments or variants.

The present invention also provides antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants) that immunospecifically bind to a polypeptide or polypeptide fragment of B Lymphocyte Stimulator, wherein said antibodies comprise, or alternatively consist of, one, two, three, or more VH CDRs and one, two, three or more VL CDRs, as referred to in Table 1. In particular, the invention provides for antibodies that immunospecifically bind to a polypeptide or polypeptide fragment of B Lymphocyte Stimulator, wherein said antibodies comprise, or alternatively consist of, a VH CDR1 and a VL CDR1, a VH CDR1 and a VL CDR2, a VH CDR1 and a VL CDR3, a VH CDR2 and a VL CDR1, VH CDR2 and VL CDR2, a VH CDR2 and a VL CDR3, a VH CDR3 and a VH CDR1, a VH CDR3 and a VL CDR2, a VH CDR3 and a VL CDR3, or any combination thereof, of the VH CDRs and VL CDRs referred to in Table 1. In a preferred embodiment, one or more of these combinations are from the same scFv as disclosed in Table 1. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies, that immunospecifically bind to B Lymphocyte Stimulator are also encompassed by the invention, as are nucleic acid molecules encoding these antibodies, molecules, fragments or variants.

In a preferred embodiment the invention provides antibodies wherein the VH CDRX (where X=1, 2, or 3) and VL CDRY (where Y=1, 2, or 3) are from scFvs with the same specificity (i.e., from scFvs that bind soluble B Lymphocyte Stimulator, from scFvs that bind membrane-bound B Lymphocyte Stimulator, or from scFvs that bind both soluble and membrane-bound B Lymphocyte Stimulator. Molecules comprising, or alternatively consisting of, fragments or variants of these antibodies, that immunospecifically bind to B Lymphocyte Stimulator are also encompassed by the invention, as are nucleic acid molecules encoding these antibodies, molecules, fragments or variants.

The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. As such, the term "antibody" encompasses not only whole antibody molecules, but also antibody fragments, as well as variants (including derivatives) of antibodies and antibody fragments. Antibodies of the invention include, but are not limited to, monoclonal, multispecific, human or chimeric antibodies, single chain antibodies, single chain Fvs (scFvs), Fab fragments, F(ab')₂ fragments, Fd frag-

ments, disulfide-linked Fvs (sdFvs), antidiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA, and IgA₂) or subclass of immunoglobulin molecule. The antibodies of the present invention also include molecules comprising, or alternatively consisting of, a polypeptide having an amino acid sequence of a portion of an amino acid sequence contained SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908. Preferably, an antibody of the invention comprises, or alternatively consists of, a polypeptide having an amino acid sequence of a VH domain, VH CDR, VL domain, or VL CDR of any one those contained in the sequences referred to in Table 1. Antibodies of the invention also include molecules comprising, or alternatively consisting of, fragments or variants of the above antibodies that immunospecifically bind B Lymphocyte Stimulator.

Most preferably the antibodies of the present invention are whole antibodies or antibody fragments that immunospecifically bind human B Lymphocyte Stimulator. Antibody fragments of the invention that immunospecifically bind human B Lymphocyte Stimulator include, but are not limited to, Fab, Fab' and F(ab')₂, Fd fragments, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFvs), fragments comprising, or alternatively consisting of, either a VL or VH domain, and epitope binding fragments of any of the above.

B Lymphocyte Stimulator-binding antibody fragments, including single-chain antibodies, may comprise, or alternatively consist of, the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. In a preferred embodiment, the antibodies of the invention comprise, or alternatively consist of, a polypeptide that immunospecifically binds to B Lymphocyte Stimulator, said polypeptides comprise, or alternatively consist of, one, two, three, four, five, six or more CDRs referred to in Table 1, preferably a polypeptide having an amino acid sequence of a VH CDR3 and/or a VL CDR3 of contained SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1. Most preferably, antibodies of the invention comprise, or alternatively consist of, one, two, three, four, five, six or more CDRs from the same scFv, as referred to in Table 1. The antibodies of the invention may be from any animal origin, including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken. Most preferably, the antibodies are human antibodies. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries and xenomice or other organisms that have been genetically engineered to produce human antibodies. For a detailed discussion of a few of the technologies for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Pat. Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598; and Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995), which are incorporated by reference herein in their entirety. Human antibodies or "humanized" chimeric monoclonal antibodies can be produced using

techniques described herein or otherwise known in the art. For example, methods for producing chimeric antibodies are known in the art. See, for review the following references which are hereby incorporated in their entirety: Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Cabilly et al., U.S. Pat. No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., *Nature* 312:643 (1984); Neuberger et al., *Nature* 314:268 (1985). In addition, companies such as Abgenix, Inc. (Freemont, Calif.) and Genpharm (San Jose, Calif.) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

The antibodies of the present invention may be monovalent, bivalent, trivalent or multivalent. For example, monovalent scFvs can be multimerized either chemically or by association with another protein or substance. An scFv that is fused to a hexahistidine tag or a Flag tag can be multimerized using Ni-NTA agarose (Qiagen) or using anti-Flag antibodies (Stratagene, Inc.).

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a B Lymphocyte Stimulator polypeptide, or fragment thereof, or may be specific for both a B Lymphocyte Stimulator polypeptide, or fragment thereof, and a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., *J. Immunol.* 147:60-69 (1991); U.S. Pat. Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., *J. Immunol.* 148:1547-1553 (1992).

The antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may bind immunospecifically to murine B Lymphocyte Stimulator (e.g., a polypeptide having the amino acid sequence of human B Lymphocyte Stimulator (SEQ ID NOS:3228 and/or 3229) or B Lymphocyte Stimulator expressed on human monocytes; murine B Lymphocyte Stimulator (SEQ ID NOS:3230 and/or 3231) or B Lymphocyte Stimulator expressed on murine monocytes; rat B Lymphocyte Stimulator (either the soluble forms as given in SEQ ID NOS:3232, 3233, 3234 and/or 3235 or in a membrane associated form, e.g., on the surface of rat monocytes); or monkey B Lymphocyte Stimulator (e.g., the monkey B Lymphocyte Stimulator polypeptides of SEQ ID NOS:3236 and/or 3237, the soluble form of monkey B Lymphocyte Stimulator, or B Lymphocyte Stimulator expressed on monkey monocytes), preferably the antibodies of the invention bind immunospecifically to human B Lymphocyte Stimulator. Preferably, the antibodies of the invention bind immunospecifically to human and monkey B Lymphocyte Stimulator. Also preferably, the antibodies of the invention bind immunospecifically to human B Lymphocyte Stimulator and murine B Lymphocyte Stimulator. More preferably, antibodies of the invention, bind immunospecifically and with higher affinity to human B Lymphocyte Stimulator than to murine B Lymphocyte Stimulator.

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described

herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, antibodies of the present invention cross react with APRIL (SEQ ID NO:3239; GenBank Accession No. AF046888; J. Exp. Med. 188(6):1185-1190; PCT International Publication WO97/33902). In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under hybridization conditions (as described herein).

In preferred embodiments, the antibodies of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), immunospecifically bind to B Lymphocyte Stimulator and do not cross-react with any other antigens. In more preferred embodiments, the antibodies of the invention immunospecifically bind to B Lymphocyte Stimulator and do not cross-react with TRAIL, APRIL, Endokine-alpha, TNF-alpha, TNF-beta, Fas-L or LIGHT.

The present invention also provides for a nucleic acid molecule, generally

isolated, encoding an antibody of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof). In one embodiment, a nucleic acid molecule of the invention encodes an antibody comprising, or alternatively consisting of, a VH domain having an amino acid sequence of any one of the VH domains referred to in Table 1. In another embodiment, a nucleic acid molecule of the present invention encodes an antibody comprising, or alternatively consisting of, a VH CDR1 having an amino acid sequence of any one of the VH CDR1s referred to in Table 1. In another embodiment, a nucleic acid molecule of the present invention encodes an antibody comprising, or alternatively consisting of, a VH CDR2 having an amino acid sequence of any one of the VH CDR2s referred to in Table 1. In yet another embodiment, a nucleic acid molecule of the present invention encodes an antibody comprising, or alternatively consisting of, a VH CDR3 having an amino acid sequence of any one of the VH CDR3s referred to in Table 1. Nucleic acid molecules encoding antibodies that immunospecifically bind B Lymphocyte Stimulator and comprise, or alternatively consist of, fragments or variants of the VH domains and/or VH CDRs are also encompassed by the invention.

In another embodiment, a nucleic acid molecule of the invention encodes an antibody (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), comprising, or alternatively consisting of, a VL domain having an amino acid sequence of any one of the VL domains referred to in Table 1. In another embodiment, a nucleic acid molecule of the present invention encodes an antibody comprising, or alternatively consisting of, a VL CDR1 having amino acid sequence of any one of the VL CDR1s referred to in Table 1. In another embodi-

ment, a nucleic acid molecule of the present invention encodes an antibody comprising, or alternatively consisting of, a VL CDR2 having an amino acid sequence of any one of the VL CDR2s referred to in Table 1. In yet another embodiment, a nucleic acid molecule of the present invention encodes an antibody comprising, or alternatively consisting of, a VL CDR3 having an amino acid sequence of any one of the VL CDR3s referred to in Table 1. Nucleic acid encoding antibodies that immunospecifically bind B Lymphocyte Stimulator and comprise, or alternatively consist of, fragments or variants of the VL domains and/or VLCDR(s) are also encompassed by the invention.

In another embodiment, a nucleic acid molecule of the invention encodes an antibody (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), comprising, or alternatively consisting of, a VH domain having an amino acid sequence of any one of the VH domains referred to in Table 1 and a VL domain having an amino acid sequence of any one of the VL domains referred to in Table 1. In another embodiment, a nucleic acid molecule of the invention encodes an antibody comprising, or alternatively consisting of, a VH CDR1, a VL CDR1, a VH CDR2, a VL CDR2, a VH CDR3, a VL CDR3, or any combination thereof having an amino acid sequence referred to in Table 1. Nucleic acid encoding antibodies that immunospecifically bind B Lymphocyte Stimulator and comprise, or alternatively consist of, fragments or variants of the VL and/or domains and/or VHCDR(s) and/or VLCDR(s) are also encompassed by the invention.

The present invention also provides antibodies that comprise, or alternatively consist of, variants (including derivatives) of the VH domains, VH CDRs, VL domains, and VL CDRs described herein, which antibodies immunospecifically bind to B Lymphocyte Stimulator. Standard techniques known to those of skill in the art can be used to introduce mutations in the nucleotide sequence encoding a molecule of the invention, including, for example, site-directed mutagenesis and PCR-mediated mutagenesis which result in amino acid substitutions. Preferably, the variants (including derivatives) encode less than 50 amino acid substitutions, less than 40 amino acid substitutions, less than 30 amino acid substitutions, less than 25 amino acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2 amino acid substitutions relative to the reference VH domain, VHCDR1, VHCDR2, VHCDR3, VL domain, VLCDR1, VLCDR2, or VLCDR3. In specific embodiments, the variants encode substitutions of VHCDR3. In a preferred embodiment, the variants have conservative amino acid substitutions at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a side chain with a similar charge. Families of amino acid residues having side chains with similar charges have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence,

such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity (e.g., the ability to bind B Lymphocyte Stimulator). Following mutagenesis, the encoded protein may routinely be expressed and the functional and/or biological activity of the encoded protein, (e.g., ability to immunospecifically bind B Lymphocyte Stimulator) can be determined using techniques described herein or by routinely modifying techniques known in the art.

The antibodies of the invention include derivatives (i.e., variants) that are modified, e.g., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not affect the ability of the antibody to immunospecifically bind to B Lymphocyte Stimulator. For example, but not by way of limitation, derivatives of the invention include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

In a specific embodiment, an antibody of the invention (including a molecule comprising, or alternatively consisting of, an antibody fragment or variant thereof), that immunospecifically binds B Lymphocyte Stimulator, comprises, or alternatively consists of, an amino acid sequence encoded by a nucleotide sequence that hybridizes to a nucleotide sequence that is complementary to that encoding one of the VH or VL domains referred to in Table 1 under stringent conditions, e.g., hybridization to filter-bound DNA in 6x sodium chloride/sodium citrate (SSC) at about 45° C. followed by one or more washes in 0.2xSSC/0.1% SDS at about 50–65° C., under highly stringent conditions, e.g., hybridization to filter-bound nucleic acid in 6xSSC at about 45° C. followed by one or more washes in 0.1xSSC/0.2% SDS at about 68° C., or under other stringent hybridization conditions which are known to those of skill in the art (see, for example, Ausubel, F. M. et al., eds., 1989, *Current Protocols in Molecular Biology*, Vol. 1, Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York at pages 6.3.1–6.3.6 and 2.10.3). In another embodiment, an antibody of the invention that immunospecifically binds to B Lymphocyte Stimulator, comprises, or alternatively consists of, an amino acid sequence encoded by a nucleotide sequence that hybridizes to a nucleotide sequence that is complementary to that encoding one of the VH CDRs or VL CDRs referred to in Table 1 under stringent conditions, e.g., hybridization under conditions as described above, or under other stringent hybridization conditions which are known to those of skill in the art. In another embodiment, an antibody of the invention that immunospecifically binds to B Lymphocyte Stimulator, comprises, or alternatively consists of, an amino acid sequence encoded by a nucleotide sequence that hybridizes to a nucleotide sequence that is complementary to that encoding one of the VH CDR3s referred to in Table 1 under stringent conditions e.g., hybridization under conditions as described above, or under other stringent hybridization conditions which are known to those of skill in the art. Nucleic acid molecules encoding these antibodies are also encompassed by the invention.

In another embodiment, an antibody (including a molecule comprising, or alternatively consisting of, an antibody fragment or variant thereof), that immunospecifically binds

to B Lymphocyte Stimulator comprises, or alternatively consists of, a polypeptide having an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical, to any one of the VH domains referred to in Table 1. In another embodiment, an antibody of the invention that immunospecifically binds to B Lymphocyte Stimulator comprises, or alternatively consists of, a polypeptide having an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical, to any one of the VH CDRs referred to in Table 1. In another embodiment, an antibody of the invention that immunospecifically binds to B Lymphocyte Stimulator comprises, or alternatively consists of, a polypeptide having an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to any one of the VH CDR3s referred to in Table 1. Nucleic acid molecules encoding these antibodies are also encompassed by the invention.

In another embodiment, an antibody of the invention (including a molecule comprising, or alternatively consisting of, an antibody fragment or variant thereof), that immunospecifically binds to B Lymphocyte Stimulator comprises, or alternatively consists of, a polypeptide having an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical, to any one of the VL domains referred to in Table 1. In another embodiment, an antibody of the invention that immunospecifically binds to B Lymphocyte Stimulator comprises, or alternatively consists of, a polypeptide having an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical, to any one of the VL CDRs referred to in Table 1. In another embodiment, an antibody of the invention that immunospecifically binds to B Lymphocyte Stimulator comprises, or alternatively consists of, a polypeptide having an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical, to any one of the VL CDR3s referred to in Table 1. Nucleic acid molecules encoding these antibodies are also encompassed by the invention.

Antibodies of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may also be described or specified in terms of their binding affinity for to B Lymphocyte Stimulator polypeptides or fragments or variants of B Lymphocyte Stimulator polypeptides (e.g., to the soluble form of B Lymphocyte Stimulator and/or membrane-bound form of B Lymphocyte Stimulator). In specific embodiments, antibodies of the invention bind B Lymphocyte Stimulator polypeptides, or fragments or variants thereof, with a dissociation constant or K_D of less than or equal to 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, or 10^{-5} M. More preferably, antibodies of the invention bind B Lymphocyte Stimulator polypeptides or fragments or variants thereof with a dissociation constant or K_D less than or equal to 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M,

or 10^{-8} M. Even more preferably, antibodies of the invention bind B Lymphocyte Stimulator polypeptides or fragments or variants thereof with a dissociation constant or K_D less than or equal to 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, or 10^{-15} M. The invention encompasses antibodies that bind B Lymphocyte Stimulator polypeptides with a dissociation constant or K_D that is within any one of the ranges that are between each of the individual recited values.

In specific embodiments, antibodies of the invention bind B Lymphocyte Stimulator polypeptides or fragments or variants thereof with an off rate (k_{off}) of less than or equal to $5 \times 10^{-2} \text{ sec}^{-1}$, 10^{-2} sec^{-1} , $5 \times 10^{-3} \text{ sec}^{-1}$ or 10^{-3} sec^{-1} . More preferably, antibodies of the invention bind B Lymphocyte Stimulator polypeptides or fragments or variants thereof with an off rate (k_{off}) less than or equal to $5 \times 10^{-4} \text{ sec}^{-1}$, 10^{-4} sec^{-1} , $5 \times 10^{-5} \text{ sec}^{-1}$, or 10^{-5} sec^{-1} , $5 \times 10^{-6} \text{ sec}^{-1}$, 10^{-6} sec^{-1} , $5 \times 10^{-7} \text{ sec}^{-1}$ or 10^{-7} sec^{-1} . The invention encompasses antibodies that bind B Lymphocyte Stimulator polypeptides with an off rate (k_{off}) that is within any one of the ranges that are between each of the individual recited values.

In other embodiments, antibodies of the invention bind B Lymphocyte Stimulator polypeptides or fragments or variants thereof with an on rate (k_{on}) of greater than or equal to $10^3 \text{ M}^{-1} \text{ sec}^{-1}$, $5 \times 10^3 \text{ M}^{-1} \text{ sec}^{-1}$, $10^4 \text{ M}^{-1} \text{ sec}^{-1}$ or $5 \times 10^4 \text{ M}^{-1} \text{ sec}^{-1}$. More preferably, antibodies of the invention bind B Lymphocyte Stimulator polypeptides or fragments or variants thereof with an on rate (k_{on}) greater than or equal to $10^5 \text{ M}^{-1} \text{ sec}^{-1}$, $5 \times 10^5 \text{ M}^{-1} \text{ sec}^{-1}$, $10^6 \text{ M}^{-1} \text{ sec}^{-1}$, or $5 \times 10^6 \text{ M}^{-1} \text{ sec}^{-1}$ or $10^7 \text{ M}^{-1} \text{ sec}^{-1}$. The invention encompasses antibodies that bind B Lymphocyte Stimulator polypeptides with on rate (k_{on}) that is within any one of the ranges that are between each of the individual recited values.

The invention also encompasses antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that have one or more of the same biological characteristics as one or more of the antibodies described herein. By "biological characteristics" is meant, the in vitro or in vivo activities or properties of the antibodies, such as, for example, the ability to bind to B Lymphocyte Stimulator (e.g., the soluble form of B Lymphocyte Stimulator, the membrane-bound form of B Lymphocyte Stimulator, the soluble form and membrane-bound form of B Lymphocyte Stimulator), and/or an antigenic and/or epitope region of B Lymphocyte Stimulator), the ability to substantially block B Lymphocyte Stimulator/B Lymphocyte Stimulator receptor (e.g., TACI—GenBank accession number AAC51790 and/or BCMA—GenBank accession number NP_001183) binding, or the ability to block B Lymphocyte Stimulator mediated biological activity (e.g., stimulation of B cell proliferation and immunoglobulin production). Optionally, the antibodies of the invention will bind to the same epitope as at least one of the antibodies specifically referred to herein. Such epitope binding can be routinely determined using assays known in the art.

The present invention also provides for antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), that neutralize B Lymphocyte Stimulator or a fragment thereof, said antibodies comprising, or alternatively consisting of, a portion (i.e., a VH domain, VL domain, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, or VL CDR3) of an scFv referred to in Table 1, more preferably having an amino acid sequence contained in SEQ ID NOS:834–872, 1570–1595, or 1886–1908, and even more preferably having an amino acid sequence contained in SEQ ID NOS:1–46, 321–329,

1563–1569, or 1881–1885 as disclosed in Table 1, or a fragment or variant thereof. By an antibody that "neutralizes B Lymphocyte Stimulator or a fragment thereof" is meant an antibody that diminishes or abolishes the ability of B Lymphocyte Stimulator to bind to its receptor (e.g., TACI and BCMA) to stimulate B cell proliferation, to stimulate immunoglobulin secretion by B cells, and/or to stimulate the B Lymphocyte Stimulator receptor signalling cascade. In one embodiment, an antibody that neutralizes B Lymphocyte Stimulator or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH domain contained in SEQ ID NOS:1–46, 321–329, 834–872, 1563–1595, or 1881–1908 as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that neutralizes B Lymphocyte Stimulator or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL domain contained in SEQ ID NOS:1–46, 321–329, 834–872, 1563–1595, or 1881–1908 as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that neutralizes B Lymphocyte Stimulator or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH CDR domain in SEQ ID NOS:1–46, 321–329, 834–872, 1563–1595, or 1881–1908 as disclosed in Table 1, or a fragment or variant thereof. In a preferred embodiment, an antibody that neutralizes B Lymphocyte Stimulator or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH CDR3 contained in SEQ ID NOS:1–46, 321–329, 834–872, 1563–1595, or 1881–1908 as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that neutralizes B Lymphocyte Stimulator or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL CDR domain contained in SEQ ID NOS:1–46, 321–329, 834–872, 1563–1595, or 1881–1908 as disclosed in Table 1, or a fragment or variant thereof. In another preferred embodiment, an antibody that neutralizes B Lymphocyte Stimulator or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL CDR3 contained in SEQ ID NOS:1–46, 321–329, 834–872, 1563–1595, or 1881–1908 as disclosed in Table 1, or a fragment or variant thereof. Nucleic acid molecules encoding these antibodies are also encompassed by the invention.

The present invention also provides for antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), that inhibit (i.e., diminish or abolish) B Lymphocyte Stimulator mediated B cell proliferation as determined by any method known in the art such as, for example, the assays described in Examples 21 and 22, *infra*, said antibodies comprising, or alternatively consisting of, a portion (e.g., a VH domain, VL domain, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, or VL CDR3) of an scFv having an amino acid sequence SEQ ID NOS:834–872, 1570–1595, 1886–1908, and even more preferably having an amino acid sequence SEQ ID NOS:1–46, 321–329, 1563–1569, 1881–1885 as disclosed in Table 1 or a fragment or variant thereof. In one embodiment, an antibody that inhibits B Lymphocyte Stimulator mediated B cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH domain contained in SEQ ID NOS:1–46, 321–329, 834–872, 1563–1595, or 1881–1908, as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that inhibits B Lymphocyte Stimulator mediated B

cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL domain contained in SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1, or a fragment or variant thereof. In a preferred embodiment, an antibody that inhibits B Lymphocyte Stimulator mediated B cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH CDR3 contained in SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1, or a fragment or variant thereof. In another preferred embodiment, an antibody that inhibits B Lymphocyte Stimulator mediated B cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL CDR3 contained in SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1, or a fragment or variant thereof. Nucleic acid molecules encoding these antibodies are also encompassed by the invention.

The present invention also provides for antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), that enhance the activity of B Lymphocyte Stimulator or a fragment thereof, said antibodies comprising, or alternatively consisting of, a portion (i.e., a VH domain, VL domain, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, or VL CDR3) of an scFv having an amino acid sequence SEQ ID NOS: 834-872, 1570-1595, or 1886-1908, and preferably having an amino acid sequence of SEQ ID NOS:1-46, 321-329, 1563-1569, or 1881-1885, as disclosed in Table 1, or a fragment or variant thereof. By an antibody that "enhances the activity of B Lymphocyte Stimulator or a fragment thereof" is meant an antibody increases the ability of B Lymphocyte Stimulator to bind to its receptor (e.g., TACI or BCMA), to stimulate B cell proliferation, to stimulate immunoglobulin secretion by B cells, and/or to stimulate the B Lymphocyte Stimulator receptor signalling cascade. In one embodiment, an antibody that enhances the activity of B Lymphocyte Stimulator or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH domain contained in SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that enhances the activity of B Lymphocyte Stimulator or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL domain contained in SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that enhances the activity of B Lymphocyte Stimulator or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH CDR domain contained in SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1, or a fragment or variant thereof. In a preferred embodiment, an antibody that enhances the activity of B Lymphocyte Stimulator or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH CDR3 contained in SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that enhances B Lymphocyte Stimulator or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL CDR domain contained in SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1,

or a fragment or variant thereof. In another preferred embodiment, an antibody that enhances the activity of B Lymphocyte Stimulator or a fragment thereof, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL CDR3 contained in SEQ ID NOS: 1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1, or a fragment or variant thereof. Nucleic acid molecules encoding these antibodies are also encompassed by the invention.

The present invention also provides for antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), that stimulate B Lymphocyte Stimulator mediated B cell proliferation as determined by any method known in the art, such as, for example, the assays described in Examples 21 and 22, *infra*, said antibodies comprising, or alternatively consisting of, a portion (e.g., a VH domain, VL domain, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, or VL CDR3) of an scFv having an amino acid sequence of SEQ ID NOS: 834-872, 1570-1595, or 1886-1908, and even more preferably having an amino acid sequence of SEQ ID NOS: 1-46, 321-329, 1563-1569, or 1881-1885 as disclosed in Table 1 or a fragment or variant thereof. In one embodiment, an antibody that stimulates B Lymphocyte Stimulator mediated B cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH domain contained in SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1, or a fragment or variant thereof. In another embodiment, an antibody that stimulates B Lymphocyte Stimulator mediated B cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL domain contained in SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1, or a fragment or variant thereof. In a preferred embodiment, an antibody that stimulates B Lymphocyte Stimulator mediated B cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VH CDR3 contained in SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1, or a fragment or variant thereof. In another preferred embodiment, an antibody that stimulates B Lymphocyte Stimulator mediated B cell proliferation, comprises, or alternatively consists of, a polypeptide having the amino acid sequence of a VL CDR3 contained in SEQ ID NOS:1-46, 321-329, 834-872, 1563-1595, or 1881-1908 as disclosed in Table 1, or a fragment or variant thereof. Nucleic acid molecules encoding these antibodies are also encompassed by the invention.

The present invention also provides for fusion proteins comprising, or alternatively consisting of, an antibody (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), that immunospecifically binds to B Lymphocyte Stimulator, and a heterologous polypeptide. Preferably, the heterologous polypeptide to which the antibody is fused to is useful for B-cell function or is useful to target the antibody to B-cells. In an alternative preferred embodiment, the heterologous polypeptide to which the antibody is fused to is useful for monocyte cell function or is useful to target the antibody to a monocyte. In another embodiment, the heterologous polypeptide to which the antibody is fused is albumin (including but not limited to recombinant human serum albumin or fragments or variants thereof (see, e.g., U.S. Pat. No. 5,876,969, issued Mar. 2, 1999, EP Patent 0 413 622, and U.S. Pat. No. 5,766,883, issued Jun. 16, 1998, herein incorporated by reference in their entirety)). In a preferred embodiment, antibodies of the

present invention (including fragments or variants thereof) are fused with the mature form of human serum albumin (i.e., amino acids 1–585 of human serum albumin as shown in FIGS. 1 and 2 of EP Patent 0 322 094) which is herein incorporated by reference in its entirety. In another preferred embodiment, antibodies of the present invention (including fragments or variants thereof) are fused with polypeptide fragments comprising, or alternatively consisting of, amino acid residues 1-x of human serum albumin, where x is an integer from 1 to 585 and the albumin fragment has human serum albumin activity. In another preferred embodiment, antibodies of the present invention (including fragments or variants thereof) are fused with polypeptide fragments comprising, or alternatively consisting of, amino acid residues 1-z of human serum albumin, where z is an integer from 369 to 419, as described in U.S. Pat. No. 5,766,883 herein incorporated by reference in its entirety. Antibodies of the present invention (including fragments or variants thereof) may be fused to either the N- or C-terminal end of the heterologous protein (e.g., immunoglobulin Fc polypeptide or human serum albumin polypeptide).

In one embodiment, a fusion protein of the invention comprises, or alternatively consists of, a polypeptide having the amino acid sequence of any one or more of the VH domains referred to in Table 1 or the amino acid sequence of any one or more of the VL domains referred to in Table 1 or fragments or variants thereof, and a heterologous polypeptide sequence. In another embodiment, a fusion protein of the present invention comprises, or alternatively consists of, a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs referred to in Table 1, or the amino acid sequence of any one, two, three, or more of the VL CDRs referred to in Table 1, or fragments or variants thereof, and a heterologous polypeptide sequence. In a preferred embodiment, the fusion protein comprises, or alternatively consists of, a polypeptide having the amino acid sequence of, a VH CDR3 referred to in Table 1, or fragment or variant thereof, and a heterologous polypeptide sequence, which fusion protein immunospecifically binds to B Lymphocyte Stimulator. In another embodiment, a fusion protein comprises, or alternatively consists of a polypeptide having the amino acid sequence of at least one VH domain referred to in Table 1 and the amino acid sequence of at least one VL domain referred to in Table 1 or fragments or variants thereof, and a heterologous polypeptide sequence. Preferably, the VH and VL domains of the fusion protein correspond to the same scFv referred to in Table 1. In yet another embodiment, a fusion protein of the invention comprises, or alternatively consists of a polypeptide having the amino acid sequence of any one, two, three or more of the VH CDRs referred to in Table 1 and the amino acid sequence of any one, two, three or more of the VL CDRs referred to in Table 1, or fragments or variants thereof, and a heterologous polypeptide sequence. Preferably, two, three, four, five, six, or more of the VHCDR(s) or VLCDR(s) correspond to the same scFv referred to in Table 1. Nucleic acid molecules encoding these fusion proteins are also encompassed by the invention.

The present invention also provides: antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), that immunospecifically bind to the soluble form of B Lymphocyte Stimulator; antibodies that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator; and antibodies that immunospecifically bind to both the soluble form and membrane-bound form of B Lymphocyte Stimulator.

In one embodiment of the present invention, antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to the soluble form of B Lymphocyte Stimulator, comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one or more of the VH domains contained in SEQ ID NOS:1563–1880 as disclosed in Table 1 and/or the amino acid sequence of any one or more of the VL domains contained in SEQ ID NOS: 1563–1880 as disclosed in Table 1, or fragment(s) or variant(s) (including derivative) thereof. Preferably, the VH and VL domains of the antibody correspond to the same scFv as disclosed in Table 1. In another embodiment, antibodies that immunospecifically bind to the soluble form of B Lymphocyte Stimulator are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs contained in SEQ ID NOS: 1563–1880 as disclosed in Table 1 and/or the amino acid sequence of any one, two, three, or more of the VL CDRs contained in SEQ ID NOS: 1563–1880 as disclosed in Table 1, or fragment(s) or variant(s) thereof. Preferably, two, three, four, five, six or more of the VH and VL CDRs of the antibody correspond to the same scFv as disclosed in Table 1. In a preferred embodiment, antibodies that immunospecifically bind to the soluble form of B Lymphocyte Stimulator are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one or more of the VH CDR3s contained in SEQ ID NOS: 1563–1880 as disclosed in Table 1 and/or the amino acid sequence of any one or more of the VL CDR3s contained in SEQ ID NOS: 1563–1880 as disclosed in Table 1, or fragment(s) or variant(s) thereof. Preferably, the VHCDR3 and VLCDR3 of the antibody correspond to the same scFv, as disclosed in Table 1. Nucleic acid molecules encoding these antibodies are also encompassed by the invention.

In another embodiment of the present invention, antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one or more of the VH domains contained in SEQ ID NOS: 1881–2128 as disclosed in Table 1 and/or the amino acid sequence of any one or more of the VL domains contained in SEQ ID NOS: 1881–2128 as disclosed in Table 1, or a fragment or variant thereof. Preferably, the VH and VL domains of the antibody correspond to the same scFv as disclosed in Table 1. In another embodiment, antibodies that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs contained in SEQ ID NOS: 1881–2128 as disclosed in Table 1 and/or the amino acid sequence of any one, two, three, or more of the VL CDRs contained in SEQ ID NOS: 1881–2128 as disclosed in Table 1, or fragment(s) or variant(s) thereof. Preferably, two, three, four, five, six or more of the VH and VL CDRs of the antibody correspond to the same scFv as disclosed in Table 1. In a preferred embodiment, antibodies that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one or more of the VH CDR3s contained in SEQ ID NOS: 1881–2128 as disclosed in Table 1 and/or the amino acid sequence of any one or more of the VL CDR3s contained in

SEQ ID NOS: 1881–2128 as disclosed in Table 1, or fragment(s) or variant(s) thereof. Preferably, the VHCDR3 and VLCDR3 of the antibody correspond to the same scFv, as disclosed in Table 1. Nucleic acid molecules encoding these antibodies are also encompassed by the invention.

In another embodiment of the present invention, antibodies (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to the soluble form and membrane-bound form of B Lymphocyte Stimulator, are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one or more of the VH domains contained in SEQ ID NOS: 1–1562 as disclosed in Table 1 and/or the amino acid sequence of any one or more of the VL domains contained in SEQ ID NOS: 1–1562 as disclosed in Table 1, or a fragment or variant thereof. Preferably, the VH and VL domains of the antibody correspond to the same scFv as disclosed in Table 1. In another embodiment, antibodies that immunospecifically bind to the soluble form and membrane-bound form of B Lymphocyte Stimulator are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one, two, three, or more of the VH CDRs contained in SEQ ID NOS: 1–1562 as disclosed in Table 1 and/or the amino acid sequence of any one, two, three, or more of the VL CDRs contained in SEQ ID NOS: 1–1562 as disclosed in Table 1, or fragment(s) or variant(s) thereof. Preferably, two, three, four, five, six or more of the VH and VL CDRs of the antibody correspond to the same scFv as disclosed in Table 1. In a preferred embodiment, antibodies that immunospecifically bind to the soluble form and membrane-bound form of B Lymphocyte Stimulator are provided that comprise, or alternatively consist of, a polypeptide having the amino acid sequence of any one or more of the VH CDR3s contained in SEQ ID NOS: 1–1562, disclosed in Table 1 and/or the amino acid sequence of any one or more of the VL CDR3s contained in SEQ ID NOS: 1–1562, disclosed in Table 1, or fragment(s) or variant(s) thereof. Preferably, the VHCDR3 and VLCDR3 of the antibody correspond to the same scFv, as disclosed in Table 1.

The present invention also provides for mixtures of antibodies (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to B Lymphocyte Stimulator, wherein the mixture has at least one, two, three, four, five or more different antibodies of the invention. In particular, the invention provides for mixtures of different antibodies that immunospecifically bind to the soluble form of B Lymphocyte Stimulator, the membrane-bound form of B Lymphocyte Stimulator, and/or both the membrane-bound form and soluble form of B Lymphocyte Stimulator. In specific embodiments, the invention provides mixtures of at least 2, preferably at least 4, at least 6, at least 8, at least 10, at least 12, at least 15, at least 20, or at least 25 different antibodies that immunospecifically bind to B Lymphocyte Stimulator, wherein at least 1, at least 2, at least 4, at least 6, or at least 10, antibodies of the mixture is an antibody of the invention. In a specific embodiment, each antibody of the mixture is an antibody of the invention.

The present invention also provides for panels of antibodies (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to B Lymphocyte Stimulator, wherein the panel has at least one, two, three, four, five or more different antibodies of the invention. In particular, the invention provides for panels of different antibodies that immunospecifically bind to the soluble form

of B Lymphocyte Stimulator, the membrane-bound form of B Lymphocyte Stimulator, and/or both the membrane-bound form and soluble form of B Lymphocyte Stimulator. In specific embodiments, the invention provides for panels of antibodies that have different affinities for B Lymphocyte Stimulator, different specificities for B Lymphocyte Stimulator, or different dissociation rates. The invention provides panels of at least 10, preferably at least 25, at least 50, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500, at least 550, at least 600, at least 650, at least 700, at least 750, at least 800, at least 850, at least 900, at least 950, or at least 1000, antibodies. Panels of antibodies can be used, for example, in 96 well plates for assays such as ELISAs.

The present invention further provides for compositions comprising, one or more antibodies (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants of the invention). In one embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH domains contained in SEQ ID NOS:1563–1880 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDR1s contained in SEQ ID NOS:1563–1880 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDR2s contained in SEQ ID NOS:1563–1880 as disclosed in Table 1, or a variant thereof. In a preferred embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDR3s contained in SEQ ID NOS:1563–1880, as disclosed in Table 1 or a variant thereof.

The present invention further provides for compositions comprising, one or more antibodies (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants of the invention). In one embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH domains contained in SEQ ID NOS:1881–2128 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDR1s contained in SEQ ID NOS:1881–2128 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDR2s contained in SEQ ID NOS:1881–2128 as disclosed in Table 1, or a variant thereof. In a preferred embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid

sequence of any one or more of the VH CDR3s contained in SEQ ID NOS:1881–2128 as disclosed in Table 1 or a variant thereof.

The present invention further provides for compositions comprising, one or more antibodies (including scFvs, or molecules comprising, or alternatively consisting of antibody fragments or variants of the invention). In one embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH domains contained in SEQ ID NOS:1–1562 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDR1s contained in SEQ ID NOS:1–1562 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDR2s contained in SEQ ID NOS:1–1562 as disclosed in Table 1, or a variant thereof. In a preferred embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH CDR3s contained in SEQ ID NOS:1–1562 as disclosed in Table 1 or a variant thereof.

Other embodiments of the present invention providing for compositions comprising, one or more antibodies (including scFvs and other molecules comprising, or alternatively consisting of antibody fragments or variants of the invention) are listed below. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL domains contained in SEQ ID NOS:1563–1880 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR1s contained in SEQ ID NOS:1563–1880 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR2s contained in SEQ ID NOS:1563–1880 as disclosed in Table 1, or a variant thereof. In a preferred embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR3s contained in SEQ ID NOS:1563–1880 as disclosed in Table 1, or a variant thereof.

Other embodiments of the present invention providing for compositions comprising, one or more antibodies (including scFvs and other molecules comprising, or alternatively consisting of antibody fragments or variants of the invention) are listed below. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively

consist of, a polypeptide having an amino acid sequence of any one or more of the VL domains contained in SEQ ID NOS:1881–2128 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR1s contained in SEQ ID NOS:1881–2128 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR2s SEQ ID NOS:1881–2128 as disclosed in Table 1, or a variant thereof. In a preferred embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR3s contained in SEQ ID NOS:1881–2128 as disclosed in Table 1, or a variant thereof.

Other embodiments of the present invention providing for compositions comprising, one or more antibodies (including scFvs and other molecules comprising, or alternatively consisting of antibody fragments or variants of the invention) are listed below. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL domains contained in SEQ ID NOS:1–1562 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR1s contained in SEQ ID NOS:1–1562 as disclosed in Table 1, or a variant thereof. In another embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR2s SEQ ID NOS:1–1562 as disclosed in Table 1, or a variant thereof. In a preferred embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VL CDR3s contained in SEQ ID NOS:1–1562 as disclosed in Table 1, or a variant thereof.

In a preferred embodiment, a composition of the present invention comprises, one, two, three, four, five, or more antibodies that comprise, or alternatively consist of, a polypeptide having an amino acid sequence of any one or more of the VH domains disclosed in Table 1, or a variant thereof, and an amino acid sequence of any one or more of the VL domains disclosed in Table 1, or a variant thereof wherein the VH and VL domains are from scFvs with the same specificity (i.e., from scFvs that bind soluble B Lymphocyte Stimulator (SEQ ID NOS:1563–1880), from scFvs that bind membrane-bound B Lymphocyte Stimulator (SEQ ID NOS:1881–2128), or from scFvs that bind both soluble and membrane-bound B Lymphocyte Stimulator (SEQ ID NOS:1–1562). In a preferred embodiment the invention provides antibodies wherein the VH CDRX (where X=1,2, or 3) and VL CDRY (where Y=1,2, or 3) are from scFvs with the same specificity (i.e., from scFvs that bind soluble B Lymphocyte

Stimulator (SEQ ID NOS:1563–1880), from scFvs that bind membrane-bound B Lymphocyte Stimulator (SEQ ID NOS: 1881–2128), or from scFvs that bind both soluble and membrane-bound B Lymphocyte Stimulator (SEQ ID NOS: 1–1562). In yet another embodiment, a composition of the present invention comprises one or more fusion proteins.

As discussed in more detail below, a composition of the invention may be used either alone or in combination with other compositions. The antibodies (including scFvs and other molecules comprising, or alternatively consisting of antibody fragments or variants of the present invention) may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Pat. No. 5,314,995; and EP 396,387.

Antibodies of the present invention (including scFvs and other molecules comprising, or alternatively consisting of antibody fragments or variants of the present invention) may be used, for example, but not limited to, to purify and detect B Lymphocyte Stimulator, and to target the polypeptides of the present invention to cells expressing membrane-bound B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of B Lymphocyte Stimulator in biological samples. See, e.g., Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

Methods Producing Antibodies

The antibodies of the invention (including scFvs and other molecules comprising, or alternatively consisting of antibody fragments or variants of the invention) can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

The single chain Fvs disclosed in Table 1 were generated using phage display methods known in the art. Furthermore, other scFvs that immunospecifically bind B Lymphocyte Stimulator may be generated using phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In particular, DNA sequences encoding VH and VL domains are amplified from animal cDNA libraries (e.g., human or murine cDNA libraries of lymphoid tissues) or synthetic cDNA libraries. The DNA encoding the VH and VL domains are joined together by an scFv linker by PCR and cloned into a phagemid vector (e.g., p CANTAB 6 or pComb 3 HSS). The vector is electroporated in *E. coli* and the *E. coli* is infected with helper phage. Phage used in these methods are typically filamentous phage including fd and M13 and the VH and VL domains are usually recombinantly fused to either the phage gene III or gene VIII. Phage expressing an antigen binding domain that binds to an antigen of interest (i.e., B Lymphocyte Stimulator or a fragment thereof) can be selected or identified with antigen,

e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Examples of phage display methods that can be used to make the antibodies of the present invention include, but are not limited to, those disclosed in Brinkman et al., *J. Immunol. Methods* 182:41–50 (1995); Ames et al., *J. Immunol. Methods* 184:177–186 (1995); Kettleborough et al., *Eur. J. Immunol.* 24:952–958 (1994); Persic et al., *Gene* 187 9–18 (1997); Burton et al., *Advances in Immunology* 57:191–280(1994); PCT application No. PCT/GB91/O1134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; WO97/13844; and U.S. Pat. Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described below. Techniques to recombinantly produce Fab, Fab' and F(ab')₂ fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques* 12(6):864–869 (1992); Sawai et al., *AJRI* 34:26–34 (1995); and Better et al., *Science* 240:1041–1043 (1988) (said references incorporated by reference in their entireties).

To generate whole antibodies, PCR primers including VH or VL nucleotide sequences, a restriction site, and a flanking sequence to protect the restriction site can be used to amplify the VH or VL sequences in scFv clones. Utilizing cloning techniques known to those of skill in the art, the PCR amplified VH domains can be cloned into vectors expressing a VH constant region, e.g., the human gamma 4 constant region, and the PCR amplified VL domains can be cloned into vectors expressing a VL constant region, e.g., human kappa or lambda constant regions. Preferably, the vectors for expressing the VH or VL domains comprise a promoter suitable to direct expression of the heavy and light chains in the chosen expression system, a secretion signal, a cloning site for the immunoglobulin variable domain, immunoglobulin constant domains, and a selection marker such as neomycin. The VH and VL domains may also be cloned into one vector expressing the necessary constant regions. The heavy chain conversion vectors and light chain conversion vectors are then co-transfected into cell lines to generate stable or transient cell lines that express full-length antibodies, e.g., IgG, using techniques known to those of skill in the art.

Cell lines that express antibodies that comprise the VH and VL domains of scFvs of the invention have been deposited with the American Type Culture Collection ("ATCCTM") on the dates listed in Table 2 and given the ATCCTM Deposit Numbers identified in Table 2. The American Type Culture Collection is located at 10801 University Boulevard, Manassas, Va. 20110-2209, USA. The ATCCTM deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

Cell Line	Corresponding scFv	SEQ ID NO:	ATCC Deposit Number	ATCC Deposit Date
NSO-B11-15	1050B11-15	24	PTA-3238	Mar. 27, 2001
NSO-anti-BLyS-6D08-18	1006D08	2	PTA-3239	Mar. 27, 2001
NSO- anti-BLyS-116A01-60	1116A01	327	PTA-3240	Mar. 27, 2001
IO26C04K	IO26C04-K	1563	PTA-3241	Mar. 27, 2001
IO50A12	IO50A12	12	PTA-3242	Mar. 27, 2001
IO50-B11	IO50B11	9	PTA-3243	Mar. 27, 2001

Accordingly, in one embodiment, the invention provides antibodies that comprise the VH and VL domains of scFvs of the invention.

In a preferred embodiment, an antibody of the invention is the antibody expressed by cell line NSO-B11-15.

In a preferred embodiment, an antibody of the invention is the antibody expressed by cell line NSO-anti-BLyS-6D08-18.

In a preferred embodiment, an antibody of the invention is the antibody expressed by cell line NSO-anti-BLyS-116A01-60.

In a preferred embodiment, an antibody of the invention is the antibody expressed by cell line IO26C04K.

In a preferred embodiment, an antibody of the invention is the antibody expressed by cell line IO50A12.

In a preferred embodiment, an antibody of the invention is the antibody expressed by cell line NSO-B11.

In other preferred embodiments, the invention provides antibodies that competitively inhibit binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a B Lymphocyte Stimulator polypeptide. In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a B Lymphocyte Stimulator polypeptide by between 1% and 10% in a competitive inhibition assay. In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a B Lymphocyte Stimulator polypeptide by between 1% and 10% in a competitive inhibition assay.

In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a B Lymphocyte Stimulator polypeptide by at least 10% and up to 20% in a competitive inhibition assay.

In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a B Lymphocyte Stimulator polypeptide by at least 20% and up to 30% in a competitive inhibition assay.

In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or

variant of an scFv referred to in Table 1 to a B Lymphocyte Stimulator polypeptide by at least 30% and up to 40% in a competitive inhibition assay.

In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a B Lymphocyte Stimulator polypeptide by at least 40% and up to 50% in a competitive inhibition assay.

In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a B Lymphocyte Stimulator polypeptide by at least 50% and up to 60% in a competitive inhibition assay.

In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a B Lymphocyte Stimulator polypeptide by at least 60% and up to 70% in a competitive inhibition assay.

In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a B Lymphocyte Stimulator polypeptide by at least 70% and up to 80% in a competitive inhibition assay.

In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a B Lymphocyte Stimulator polypeptide by at least 80% and up to 90% in a competitive inhibition assay.

In preferred embodiments, the invention provides antibodies that which reduce the binding of an antibody comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to a B Lymphocyte Stimulator polypeptide by at least 90% and up to 100% in a competitive inhibition assay.

In other preferred embodiments, the invention provides antibodies that competitively inhibit binding of the antibody produced by the cell line having ATCC™ deposit number PTA-3238 to a B Lymphocyte Stimulator polypeptide.

In other preferred embodiments, the invention provides antibodies that competitively inhibit binding of the antibody produced by the cell line having ATCC™ deposit number PTA-3239 to a B Lymphocyte Stimulator polypeptide.

In other preferred embodiments, the invention provides antibodies that competitively inhibit binding of the antibody produced by the cell line having ATCC™ deposit number PTA-3240 to a B Lymphocyte Stimulator polypeptide.

In other preferred embodiments, the invention provides antibodies that competitively inhibit binding of the antibody produced by the cell line having ATCC™ deposit number PTA-3241 to a B Lymphocyte Stimulator polypeptide.

In other preferred embodiments, the invention provides antibodies that competitively inhibit binding of the antibody produced by the cell line having ATCC™ deposit number PTA-3242 to a B Lymphocyte Stimulator polypeptide.

In other preferred embodiments, the invention provides antibodies that competitively inhibit binding of the antibody produced by the cell line having ATCC™ deposit number PTA-3243 to a B Lymphocyte Stimulator polypeptide.

For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use human or chimeric antibodies. Completely human antibodies are particularly desirable for therapeutic treatment of human patients. See also, U.S. Pat. Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety. In a specific embodiment, antibodies of the present invention comprise one or more VH and VL domains corresponding to the human scFvs of the invention and framework regions from another immunoglobulin molecule, preferably a human immunoglobulin molecule. In a specific embodiment, antibodies of the present invention comprise one or more CDRs corresponding to the human scFvs of the invention and framework regions from another immunoglobulin molecule, preferably a human immunoglobulin molecule. In other embodiments, an antibody of the present invention comprises one, two, three, four, five, six or more VL CDRs or VH CDRs corresponding to one or more of the human scFvs referred to in Table 1, or fragments or variants thereof, and framework regions (and, optionally CDRs not derived from the scFvs in Table 1) from a human immunoglobulin molecule. In a preferred embodiment, an antibody of the present invention comprises a VH CDR3, VL CDR3, or both, corresponding to the same scFv, or different scFvs referred to in Table 1, or fragments or variants thereof, and framework regions from a human immunoglobulin.

A chimeric antibody is a molecule in which different portions of the antibody are derived from different immunoglobulin molecules such as antibodies having a variable region derived from a human antibody and a non-human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Gillies et al., *J. Immunol. Methods* 125:191–202 (1989); U.S. Pat. Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Chimeric antibodies comprising one or more CDRs from human species and framework regions from a non-human immunoglobulin molecule (e.g., framework regions from a canine or feline immunoglobulin molecule) can be produced using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Pat. Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, *Molecular Immunology* 28(4/5):489–498 (1991); Studnicka et al., *Protein Engineering* 7(6):805–814 (1994); Roguska et al., *PNAS* 91:969–973 (1994)), and chain shuffling (U.S. Pat. No. 5,565,332). In a preferred embodiment,

chimeric antibodies comprise a human CDR3 having an amino acid sequence of any one of the VH CDR3s or VL CDR3s referred to in Table 1, or a variant thereof, and non-human framework regions or human framework regions different from those of the frameworks in the corresponding scFv disclosed in Table 1. Often, framework residues in the framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Pat. No. 5,585,089; Riechmann et al., *Nature* 332:323 (1988), which are incorporated herein by reference in their entirety.)

Further, the antibodies of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that “mimic” B Lymphocyte Stimulator polypeptides using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, *FASEB J.* 7(5):437–444 (1993); and Nissinoff, *J. Immunol.* 147(8):2429–2438 (1991)). For example, antibodies of the invention which bind to B Lymphocyte Stimulator and competitively inhibit the binding of B Lymphocyte Stimulator to its receptor (as determined by assays well known in the art such as, for example, that disclosed, *infra*) can be used to generate anti-idiotypes that “mimic” a B Lymphocyte Stimulator ligand/receptor-binding domain and, as a consequence, bind to and neutralize B Lymphocyte Stimulator receptors (e.g., TACI, BCMA, and TR20). Such neutralizing anti-idiotypes (including molecules comprising, or alternatively consisting of, antibody fragments or variants, such as Fab fragments of such anti-idiotypes) can be used in therapeutic regimens to neutralize B Lymphocyte Stimulator. For example, such anti-idiotypic antibodies can be used to bind B Lymphocyte Stimulator ligands/receptors, and thereby block B Lymphocyte Stimulator mediated biological activity. Alternatively, anti-idiotypes that “mimic” a B Lymphocyte Stimulator binding domain may bind to B Lymphocyte Stimulator receptor(s) and induce B Lymphocyte Stimulator receptor mediated signalling (e.g., activation of nuclear factor of activated T cells (NF-AT), nuclear factor-kappa B (NF-kappa B), and/or AP-1). Such agonistic anti-idiotypes (including agonistic Fab fragments of these anti-idiotypes) can be used in therapeutic regimens to induce or enhance B Lymphocyte Stimulator receptor mediated signalling. For example, such anti-idiotypic antibodies can be used to bind B Lymphocyte Stimulator ligands/receptors, and thereby stimulate B Lymphocyte Stimulator mediated biological activity (e.g., B cell proliferation and/or immunoglobulin production).

Once an antibody molecule of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) has been chemically synthesized or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, or more generally, a protein molecule, such as, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. Further, the antibodies of the present invention may be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

Polynucleotides Encoding an Antibody

The invention provides polynucleotides comprising, or alternatively consisting of, a nucleotide sequence encoding an antibody of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof). The invention also encompasses polynucleotides that hybridize under high stringency, or alternatively, under intermediate or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides complementary to nucleic acids having a polynucleotide sequence that encodes an antibody of the invention or a fragment or variant thereof.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. Since the amino acid sequences of the scFv antibodies and VH domains, VL domains and CDRs thereof, are known (as described in Table 1), nucleotide sequences encoding these antibodies can be determined using methods well known in the art, i.e., the nucleotide codons known to encode the particular amino acids are assembled in such a way to generate a nucleic acid that encodes the antibody, of the invention. Such a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., *BioTechniques* 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence of the antibody (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, one or more of the VH and VL domains referred to in Table 1, or fragments or variants thereof, is inserted within framework regions using recom-

binant DNA techniques known in the art. In a specific embodiment, one, two, three, four, five, six, or more of the CDRs referred to in Table 1, or fragments or variants thereof, is inserted within framework regions using recombinant DNA techniques known in the art. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., *J. Mol. Biol.* 278: 457-479 (1998) for a listing of human framework regions, the contents of which are hereby incorporated by reference in its entirety). Preferably, the polynucleotides generated by the combination of the framework regions and CDRs encode an antibody (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that specifically binds to B Lymphocyte Stimulator. Preferably, as discussed supra, polynucleotides encoding variants of antibodies or antibody fragments having one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules, or antibody fragments or variants, lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and fall within the ordinary skill of the art.

Recombinant Expression of an Antibody

Recombinant expression of an antibody of the invention (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof (e.g., a heavy or light chain of an antibody of the invention or a portion thereof or a single chain antibody of the invention)), requires construction of an expression vector(s) containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule (e.g., a whole antibody, a heavy or light chain of an antibody, or portion thereof (preferably, but not necessarily, containing the heavy or light chain variable domain)), of the invention has been obtained, the vector(s) for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention (e.g., a whole antibody, a heavy or light chain of an antibody, a heavy or light chain variable domain of an antibody, or a portion thereof, or a heavy or light chain CDR, a single chain Fv, or fragments or variants thereof), operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Pat. No. 5,122,464, the contents of each of which are hereby incorporated by reference in its entirety) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy chain, the entire light chain, or both the entire heavy and light chains.

The expression vector(s) is(are) transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing polynucleotide(s) encoding an antibody of the invention (e.g., whole antibody, a heavy or light chain thereof, or portion thereof, or a single chain antibody of the invention, or a fragment or variant thereof), operably linked to a heterologous promoter. In preferred embodiments, for the expression of entire antibody molecules, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention *in situ*. These include, but are not limited to, microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited to, the *E. coli* expression vector pUR278 (Ruther et al., *EMBO J.* 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, *Nucleic Acids Res.* 13:3101-3109 (1985); Van Heeke & Schuster, *J. Biol. Chem.* 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified

from lysed cells by adsorption and binding to matrix glutathione agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) may be used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. Antibody coding sequences may be cloned individually into non-essential regions (for example, the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example, the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts (e.g., see Logan & Shenk, *Proc. Natl. Acad. Sci. USA* 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see, e.g., Bittner et al., *Methods in Enzymol.* 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to, CHO, VERY, BHK, Hela, COS, NSO, MDCK, 293, 3T3, W138, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched

media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compositions that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to, the herpes simplex virus thymidine kinase (Wigler et al., *Cell* 11:223 (1977)), hypoxanthineguanine phosphoribosyltransferase (Szybalska & Szybalski, *Proc. Natl. Acad. Sci. USA* 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., *Cell* 22:8 17 (1980)) genes can be employed in tk-, hgp^rt- or apr^rt-cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., *Natl. Acad. Sci. USA* 77:357 (1980); O'Hare et al., *Proc. Natl. Acad. Sci. USA* 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, *Proc. Natl. Acad. Sci. USA* 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 (*Clinical Pharmacy* 12:488-505; Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); TIB TECH 11(5):155-215 (May, 1993)); and hyg^r, which confers resistance to hygromycin (Santerre et al., *Gene* 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); Krieglner, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds.), *Current Protocols in Human Genetics*, John Wiley & Sons, NY (1994); Colberre-Garapin et al., *J. Mol. Biol.* 150:1 (1981), which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning*, Vol. 3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the coding sequence of the antibody, production of the antibody will also increase (Crouse et al., *Mol. Cell. Biol.* 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain is preferably placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, *Nature* 322:52 (1986); Kohler, *Proc. Natl. Acad.*

Sci. USA 77:2 197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by recombinant expression, it may be purified by any method known in the art for purification of an immunoglobulin molecule, or more generally, for purification of a protein, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. Further, the antibodies of the present invention may be fused to heterologous polypeptide sequences described herein or otherwise known in the art to facilitate purification.

Antibody Characterization

Antibodies of the present invention (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may be characterized in a variety of ways. In particular, antibodies and related molecules of the invention may be assayed for the ability to immunospecifically bind to B Lymphocyte Stimulator or a fragment of B Lymphocyte Stimulator (e.g., to the soluble form or the membrane-bound form of B Lymphocyte Stimulator) using techniques described herein or routinely modifying techniques known in the art. B Lymphocyte Stimulator or B Lymphocyte Stimulator fragments that may be immunospecifically bound by the compositions of the invention include, but are not limited to, human B Lymphocyte Stimulator (SEQ ID NOS:3228 and/or 3229) or B Lymphocyte Stimulator expressed on human monocytes; murine B Lymphocyte Stimulator (SEQ ID NOS:3230 and/or 3231) or B Lymphocyte Stimulator expressed on murine monocytes; rat B Lymphocyte Stimulator (either the soluble forms as given in SEQ ID NOS:3232, 3233, 3234 and/or 3235 or in a membrane associated form, e.g., on the surface of rat monocytes); or monkey B Lymphocyte Stimulator (e.g., the monkey B Lymphocyte Stimulator polypeptides of SEQ ID NOS:3236 and/or 3237, the soluble form of monkey B Lymphocyte Stimulator, or B Lymphocyte Stimulator expressed on monkey monocytes) or fragments thereof. Preferably compositions of the invention bind human B Lymphocyte Stimulator (SEQ ID NOS:3228 and/or 3229) or fragments thereof. Assays for the ability of the antibodies of the invention to immunospecifically bind B Lymphocyte Stimulator or a fragment of B Lymphocyte Stimulator may be performed in solution (e.g., Houghten, *Bio/Techniques* 13:412-421(1992)), on beads (e.g., Lam, *Nature* 354:82-84 (1991)), on chips (e.g., Fodor, *Nature* 364:555-556 (1993)), on bacteria (e.g., U.S. Pat. No. 5,223,409), on spores (e.g., U.S. Pat. Nos. 5,571,698; 5,403,484; and 5,223,409), on plasmids (e.g., Cull et al., *Proc. Natl. Acad. Sci. USA* 89:1865-1869 (1992)) or on phage (e.g., Scott and Smith, *Science* 249:386-390 (1990); Devlin, *Science* 249:404-406 (1990); Cwirla et al., *Proc. Natl. Acad. Sci. USA* 87:6378-6382 (1990); and Felici, *J. Mol. Biol.* 222:301-310 (1991)) (each of these references is incorporated herein in its entirety by reference). Antibodies that have been identified to immunospecifically bind to B Lymphocyte Stimulator or a fragment of B Lymphocyte Stimulator can then be assayed for their specificity and affinity for B Lymphocyte Stimulator or a fragment of B Lymphocyte Stimulator using or routinely modifying techniques described herein or otherwise known in the art.

The antibodies of the invention may be assayed for immunospecific binding to B Lymphocyte Stimulator and

cross-reactivity with other antigens by any method known in the art. In particular, the ability of an antibody to immunospecifically bind to the soluble form or membrane-bound form of B Lymphocyte Stimulator and the specificity of the antibody, fragment, or variant for B Lymphocyte Stimulator polypeptide from a particular species (e.g., murine, monkey or human, preferably human) may be determined using or routinely modifying techniques described herein or otherwise known in art.

Immunoassays which can be used to analyze immunospecific binding and cross-reactivity include, but are not limited to, competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, and protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, *Current Protocols in Molecular Biology*, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1 to 4 hours) at 40 degrees C., adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 40 degrees C., washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, *Current Protocols in Molecular Biology*, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%–20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., ^{32}P or ^{125}I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion

regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, *Current Protocols in Molecular Biology*, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96-well microtiter plate with the antigen, washing away antigen that did not bind the wells, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the wells and incubating for a period of time, washing away unbound antibodies or non-specifically bound antibodies, and detecting the presence of the antibodies specifically bound to the antigen coating the well. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, the detectable molecule could be the antigen conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase). One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, *Current Protocols in Molecular Biology*, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

The binding affinity of an antibody (including an scFv or other molecule comprising, or alternatively consisting of, antibody fragments or variants thereof) to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., ^3H or ^{125}I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of the present invention for B Lymphocyte Stimulator and the binding off-rates can be determined from the data by Scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, B Lymphocyte Stimulator is incubated with an antibody of the present invention conjugated to a labeled compound (e.g., ^3H or ^{125}I) in the presence of increasing amounts of an unlabeled second anti-B Lymphocyte Stimulator antibody.

In a preferred embodiment, BIAcore kinetic analysis is used to determine the binding on and off rates of antibodies (including an scFv or other molecule comprising, or alternatively consisting of, antibody fragments or variants thereof) to B Lymphocyte Stimulator, or fragments of B Lymphocyte Stimulator. BIAcore kinetic analysis comprises analyzing the binding and dissociation of B Lymphocyte Stimulator from chips with immobilized antibodies on their surface as described in detail in Examples 6, 12, 17 and 18, *infra*.

The antibodies of the invention (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) can also be assayed for their ability to inhibit, increase, or not significantly alter, the binding of B Lymphocyte Stimulator to a B Lymphocyte Stimulator receptor (e.g., TACI and BCMA) using techniques known to those of skill in the art. For example, cells expressing a receptor for B Lymphocyte Stimulator (e.g., IM9, REH, ARH-77 cells, Namalwa, and RPMI-8226 B cell tumor lines as well as peripheral CD20+ B cells) can be contacted with B Lymphocyte Stimulator in the presence or absence of an antibody, and the ability of the antibody to

inhibit, increase, or not significantly alter, B Lymphocyte Stimulator binding to the cells can be measured. B Lymphocyte Stimulator binding to cells can be measured by, for example, flow cytometry or a scintillation assay. B Lymphocyte Stimulator or the antibody can be labeled with a detectable compound such as a radioactive label (e.g., ^{32}P , ^{35}S , and ^{125}I) or a fluorescent label (e.g., fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine) to enable detection of an interaction between B Lymphocyte Stimulator and a B Lymphocyte Stimulator receptor and/or B Lymphocyte Stimulator and an antibody of the invention. Alternatively, the ability of antibodies of the invention to inhibit, increase, or not significantly alter, B Lymphocyte Stimulator binding to a B Lymphocyte Stimulator receptor can be determined in cell-free assays. For example, native or recombinant B Lymphocyte Stimulator (e.g., that having the amino acid sequence of amino acids 134–285 of SEQ ID NO:3228) or a fragment thereof can be contacted with an antibody and the ability of the antibody to inhibit, increase, or not significantly alter, B Lymphocyte Stimulator from binding to a B Lymphocyte Stimulator receptor can be determined. Preferably, the antibody is immobilized on a solid support and B Lymphocyte Stimulator or a B Lymphocyte Stimulator fragment is labeled with a detectable compound. Alternatively, B Lymphocyte Stimulator or a B Lymphocyte Stimulator fragment is immobilized on a solid support and the antibody is labeled with a detectable compound. B Lymphocyte Stimulator may be partially or completely purified (e.g., partially or completely free of other polypeptides) or part of a cell lysate. Further, the B Lymphocyte Stimulator polypeptide may be a fusion protein comprising B Lymphocyte Stimulator or a biologically active portion thereof and a domain such as an Immunoglobulin Fc or glutathione-S-transferase. For example, amino acid residues 1–154 of TACI (GenBank accession number AAC51790), or 1–48 of BCMA (GenBank accession number NP_001183) may be fused to the Fc region of an IgG molecule and used in a cell free assay to determine the ability of antibodies of the invention to inhibit, increase, or not significantly alter, B Lymphocyte Stimulator binding to a B Lymphocyte Stimulator receptor. Alternatively, B Lymphocyte Stimulator can be biotinylated using techniques well known to those of skill in the art (e.g., biotinylation kit, Pierce Chemicals; Rockford, Ill.).

The antibodies of the invention (including scFvs or other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), can also be assayed for their ability to inhibit, stimulate, or not significantly alter, B Lymphocyte Stimulator-induced B-cell proliferation using techniques known to those of skill in the art. For example, B-cell proliferation can be assayed by ^3H -thymidine incorporation assays and trypan blue cell counts (see, e.g., Moore et al., *Science* 285: 260–263 (1999)). Further, the antibodies of the invention, or fragments or variants thereof, can be assayed for their ability to block, stimulate, or not significantly alter, B Lymphocyte Stimulator-induced activation of cellular signaling molecules and transcription factors such as calcium-modulator and cyclophilin ligand (“CAML”), calcineurin, nuclear factor of activated T cells transcription factor (“NF-AT”), nuclear factor-kappa B (“NF-kappa B”), and AP-1 using techniques known to those of skill in the art (see, e.g., von Bulow and Bram, *Science* 278:138–141 (1997)). For example, NF-AT activity can be determined by electromobility gel shift assays, by detecting the expression of a protein known to be regulated by NF-AT (e.g., IL-2 expression), by detecting the induction of a reporter gene

(e.g., an NF-AT regulatory element operably linked to a nucleic acid encoding a detectable marker such as luciferase, beta-galactosidase or chloramphenicol acetyltransferase (CAT)), or by detecting a cellular response (e.g., cellular differentiation, or cell proliferation).

The antibodies of the invention, or fragments or variants thereof can also be assayed for their ability to neutralize, enhance, or not significantly alter, B Lymphocyte Stimulator activity. For example, antibodies or fragments or variants thereof, may be routinely tested for their ability to inhibit B Lymphocyte Stimulator from binding to cells expressing the receptor for B Lymphocyte Stimulator (see Example 3, *infra*).

Selection and Screening for Antibodies that Immunospecifically Bind to Soluble B Lymphocyte Stimulator

Antibodies of the invention (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may be screened in a variety of assays to identify those antibodies that immunospecifically bind to the soluble form of B Lymphocyte Stimulator. In one particular assay, antibodies that bind to the biotinylated soluble form of B Lymphocyte Stimulator in solution are captured on streptavidin coated magnetic beads. This assay may be relatively applied to identify antibodies of the invention that neutralize and/or bind to B Lymphocyte Stimulator. Additionally, antibodies may be assayed in neutralization assays described herein or otherwise known in the art (see Example 3, *infra*). For example, antibodies may be tested for their ability to inhibit soluble B Lymphocyte Stimulator (e.g., biotinylated B Lymphocyte Stimulator) from binding to IM9 cells. In this assay, labeled soluble B Lymphocyte Stimulator (e.g., biotinylated B Lymphocyte Stimulator) is incubated with candidate anti-B Lymphocyte Stimulator antibodies to allow for the formation of B Lymphocyte Stimulator-anti-B Lymphocyte Stimulator antibody complexes. Following incubation, an aliquot of the B Lymphocyte Stimulator-anti-B Lymphocyte Stimulator antibody sample is added to IM9 cells. The binding of soluble B Lymphocyte Stimulator may be determined using techniques known in the art. For example, the binding of biotinylated B Lymphocyte Stimulator to IM9 cells may be detected using a fluorimeter following the addition of streptavidin-delfia. Biotinylated B Lymphocyte Stimulator, if it is not bound by antibodies that neutralize B Lymphocyte Stimulator, binds to the cells is detected. Thus, an antibody that decreases the amount of bio-B Lymphocyte Stimulator that binds to IM-9 cells (relative to a control sample in which the B Lymphocyte Stimulator had been preincubated with an irrelevant antibody or no antibody at all) is identified as one that binds to and neutralizes the soluble form of B Lymphocyte Stimulator. In another assay, antibodies are screened using ELISAs for those antibodies that bind to biotinylated soluble B Lymphocyte Stimulator, but do not bind membrane-bound B Lymphocyte Stimulator, such as, for example, B Lymphocyte Stimulator on membranes from U937 cells (see Examples 2 and 9, *infra*). In these assays, soluble B Lymphocyte Stimulator (e.g., biotinylated B Lymphocyte Stimulator) and membrane-bound B Lymphocyte Stimulator (e.g., on U937 membranes) are incubated in separate samples with the same antibodies and those antibodies that bind to the soluble B Lymphocyte Stimulator (biotinylated B Lymphocyte Stimulator), but not membrane-bound B Lymphocyte Stimulator (e.g., on U937 membranes) are captured and identified.

Antibodies of the invention (including scFvs and other molecules comprising, or alternatively consisting of, anti-

body fragments or variants thereof) may be tested to identify those antibodies that do not cross-react with APRIL, endokine-alpha, VEGI, TRAIL, TNF-alpha, TNF-beta, Fas-L, LIGHT, and PBS (see Example 4, *infra*). Antibodies may also be tested for their affinity for B Lymphocyte Stimulator using, for example, BIAcore analysis (see Examples 6, 12, 17 and 18 *infra*). Antibodies may also be tested for their ability to stimulate, inhibit, or not alter, B Lymphocyte Stimulator-induced immunoglobulin production and/or B-cell proliferation using techniques known to those of skill in the art. For example, human B-cells, B Lymphocyte Stimulator and antibodies may be incubated together in 96 well plates and ³H-thymidine incorporation may be measured using a scintillation counter.

Selection and Screening for Antibodies that Immunospecifically Bind to Membrane-Bound B Lymphocyte Stimulator

Antibodies of the invention (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may be screened in a variety of assays to identify those antibodies that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator. In one particular assay, antibodies that bind to B Lymphocyte Stimulator on U937 membranes or immobilized histidine-tagged B Lymphocyte Stimulator are captured. Other cell lines that express B Lymphocyte Stimulator that might be useful for testing antibody binding to membrane-bound form of B Lymphocyte Stimulator include, K-562, HL-60 and THP-1 cells. In another assay, antibodies are screened using ELISAs for those antibodies (or antibody fragments or variants) that bind to B Lymphocyte Stimulator on U937 membranes or to histidine-tagged B Lymphocyte Stimulator. In this assay, antibodies are added to 96 well plates coated with U937 membranes or histidine-tagged B Lymphocyte Stimulator and those antibodies or antibody fragments or variants that bind to the U937 membranes or histidine-tagged B Lymphocyte Stimulator are captured. In another assay, antibodies are screened using ELISAs for those antibodies (or antibody fragments or variants thereof) that do not bind to biotinylated B Lymphocyte Stimulator (soluble B Lymphocyte Stimulator) but bind to membrane-bound B Lymphocyte Stimulator, such as, for example, that on membranes from U937 cells (see Example 2, *infra*). In these assays, soluble B Lymphocyte Stimulator (e.g., biotinylated B Lymphocyte Stimulator) and membrane-bound B Lymphocyte Stimulator (e.g., on U937 membranes) are incubated in separate samples with the same antibodies (or antibody fragments or variants) and those antibodies (or antibody fragments or variants) that do not bind to the soluble B Lymphocyte Stimulator (biotinylated B Lymphocyte Stimulator), but bind the membrane-bound B Lymphocyte Stimulator (e.g., on U937 membranes) are captured and identified. In other assays, antibodies are screened using ELISAs to determine which of the antibodies (or antibody fragments or variants) that bind to histidine-tagged B Lymphocyte Stimulator or membranes from U937 cells do not cross-react with APRIL, endokine-alpha, VEGI, TRAIL, TNF-alpha, TNF-beta, Fas-L, LIGHT, and PBS (See Example 4, *infra*). ELISAs can also be used to determine which of the antibodies (or antibody fragments or variants) that bind to histidine-tagged B Lymphocyte Stimulator or membranes from U937 cells bind to B Lymphocyte Stimulator in the presence of TNF-alpha (see Example 4, *infra*). Antibodies or fragments or variants thereof that immunospecifically bind to the membrane-bound form of B Lymphocyte Stimulator may also be tested for their affinity

for histidine-tagged B Lymphocyte Stimulator using high-throughput BIAcore analysis (see Example 14, *infra*).

Additionally, antibodies of the invention may be screened against cells engineered to express an "uncleavable" form of B Lymphocyte Stimulator in order to determine their specificity for the membrane-bound form of B Lymphocyte Stimulator. Mutations in B Lymphocyte Stimulator which may achieve this result include, but are not limited to, the mutation or deletion of amino acid residues Lys-132 and/or Arg-133 of the B Lymphocyte Stimulator sequence shown in SEQ ID NO:3228. A typical mutagenesis might include mutation of one or both of residues Lys-132 or Arg-133 to alanine residues. Cells expressing such an "uncleavable" form of B Lymphocyte Stimulator provide a profound reagent to use in assaying the ability of antibodies to bind the membrane-bound form of B Lymphocyte Stimulator.

Selection and Screening for Antibodies that Immunospecifically Bind to Soluble and Membrane-Bound B Lymphocyte Stimulator

Antibodies of the invention (including scFvs and other molecules comprising, or alternately consisting of, antibody fragments or variants) may be screened in a variety of assays to identify those antibodies or antibody fragments or variants that immunospecifically bind to the soluble form and membrane-bound form of B Lymphocyte Stimulator. In one particular assay, antibodies that bind to immobilized B Lymphocyte Stimulator are captured. In another assay, antibodies are screened using ELISAs for those antibodies (or antibody fragments or variants) that inhibit the binding of soluble B Lymphocyte Stimulator (e.g. soluble bio-B Lymphocyte Stimulator) to IM-9 cells as described *supra*. In other assays, antibodies are screened using ELISAs for those antibodies that bind to membranes from U937 cells. Additionally, further ELISA assays may be performed using techniques known in the art to determine which antibodies do not cross-react with APRIL, endokine-alpha, VEGI, TRAIL, TNF-alpha, TNF-beta, Fas-L, LIGHT, and PBS, or those antibodies that bind to B Lymphocyte Stimulator in the presence of TNF-alpha (see Example 4 *infra*). Antibodies may be assayed in neutralization assays using techniques described herein or otherwise known in the art. Antibodies that immunospecifically bind to the soluble and membrane-bound forms of B Lymphocyte Stimulator may also be tested for their affinity for B Lymphocyte Stimulator using high-throughput BIAcore analysis.

Antibody Conjugates

The present invention encompasses antibodies (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), recombinantly fused or chemically conjugated (including both covalent and non-covalent conjugations) to a heterologous polypeptide (or portion thereof, preferably at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100 amino acids of the polypeptide) to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. For example, antibodies of the invention may be used to target heterologous polypeptides to particular cell types (e.g., cells of monocytic lineage and B-cells), either *in vitro* or *in vivo*, by fusing or conjugating the heterologous polypeptides to antibodies of the invention that are specific for particular cell surface antigens (e.g., membrane-bound B Lymphocyte Stimulator on cells of monocytic lineage) or which bind antigens that bind particular cell surface receptors (e.g., TACI and/or BCMA located on B cells). Antibodies fused or conjugated to

heterologous polypeptides may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., *supra*, and PCT publication WO 93/2 1232; EP 439,095; Naramura et al., *Immunol. Lett.* 39:91-99 (1994); U.S. Pat. No. 5,474,981; Gillies et al., *PNAS* 89:1428-1432 (1992); Fell et al., *J. Immunol.* 146:2446-2452 (1991), which are incorporated by reference in their entirety.

In one embodiment, a fusion protein comprises a polypeptide having an amino acid sequence of any one of the VH domains referred to in Table 1, and a heterologous polypeptide. In another embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VH CDR1s referred to in Table 1, and a heterologous polypeptide. In another embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VH CDR2s referred to in Table 1, and a heterologous polypeptide. In a preferred embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VH CDR3s referred to in Table 1 (i.e., SEQ ID NOS:2129-3227), and a heterologous polypeptide.

In another embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VL domains referred to in Table 1, and a heterologous polypeptide. In another embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VL CDR1s referred to in Table 1, and a heterologous polypeptide. In yet another embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VL CDR2s referred to in Table 1, and a heterologous polypeptide. In a preferred embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VL CDR3s referred to in Table 1, and a heterologous polypeptide.

In another embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of any one of the VH domains referred to in Table 1, and one or more VL domains referred to in Table 1, and a heterologous polypeptide. In another embodiment, a fusion protein of the present invention comprises a polypeptide having the amino acid sequence of any one of the VH CDRs referred to in Table 1, and any one of the VL CDRs referred to in Table 1, and a heterologous polypeptide.

The present invention further includes compositions comprising, or alternatively consisting of, heterologous polypeptides fused or conjugated to antibody fragments. For example, the heterologous polypeptides may be fused or conjugated to a Fab fragment, Fd fragment, Fv fragment, F(ab)₂ fragment, or a portion thereof. Methods for fusing or conjugating polypeptides to antibody portions are known in the art. See, e.g., U.S. Pat. Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., *Proc. Natl. Acad. Sci. USA* 88: 10535-10539 (1991); Zheng et al., *J. Immunol.* 154:5590-5600 (1995); and Vil et al., *Proc. Natl. Acad. Sci. USA* 89:11337-11341 (1992) (said references incorporated by reference in their entirety).

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of antibodies (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), such methods can be used to generate antibodies with altered

activity (e.g., antibodies with higher affinities and lower dissociation rates). See, generally, U.S. Pat. Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., *Curr. Opin. Biotechnol.* 8:724-33 (1997); Harayama, *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, et al., *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo and Blasco, *Biotechniques* 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, polynucleotides encoding antibodies of the invention may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more portions of a polynucleotide encoding an antibody which portions immunospecifically bind to B Lymphocyte Stimulator may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

Moreover, the antibodies of the present invention (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), can be fused to marker sequences, such as a polypeptides to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine polypeptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, Calif., 91311), among others, many of which are commercially available. As described in Gentz et al., *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the hemagglutinin "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., *Cell* 37:767 (1984)) and the "flag" tag (DYKDDDDK, (SEQ ID No: 3238) Stratagene, La Jolla, Calif.).

The present invention further encompasses antibodies (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor or prognose the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include, but are not limited to, various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Pat. No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include, but are not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include, but are not limited to, streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include, but are not limited to, umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes, but is not limited to, luminol; examples of bioluminescent materials include, but are not limited to, luciferase, luciferin, and aequorin; and examples

of suitable radioactive material include, but are not limited to, iodine (^{131}I , ^{125}I , ^{123}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium ($^{115\text{m}}\text{In}$, $^{113\text{m}}\text{In}$, ^{112}In , ^{111}In), and technetium ($^{99\text{m}}\text{Tc}$, $^{99\text{m}}\text{Tc}$), thallium (^{201}Tl), gallium (^{68}Ga , ^{67}Ga), palladium (^{103}Pd), molybdenum (^{99}Mo), xenon (^{133}Xe), fluorine (^{18}F), ^{153}Sm , ^{177}Lu , ^{159}Gd , ^{149}Pm , ^{140}La , ^{175}Yb , ^{166}Ho , ^{90}Y , ^{47}Sc , ^{186}Re , ^{188}Re , ^{142}Pr , ^{105}Ph , ^{97}Ru , ^{68}Ge , ^{57}Co , ^{65}Zn , ^{85}Sr , ^{32}P , ^{153}Gd , ^{169}Yb , ^{51}Cr , ^{54}Mn , ^{75}Se , ^{113}Sn , and ^{117}In .

Further, an antibody of the invention (including an scFv or other molecule comprising, or alternatively consisting of, antibody fragments or variants thereof), may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytotoxic agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, ^{213}Bi . In specific embodiments, antibodies of the invention are attached to macrocyclic chelators useful for conjugating radiometal ions, including but not limited to, ^{111}In , ^{177}Lu , ^{90}Y , ^{166}Ho , and ^{153}Sm , to polypeptides. In preferred embodiments, the radiometal ion associated with the macrocyclic chelators attached to antibodies of the invention is ^{111}In . In preferred embodiments, the radiometal ion associated with the macrocyclic chelators attached to antibodies of the invention is ^{90}Y . In specific embodiments, the macrocyclic chelator is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA). In other specific embodiments, the DOTA is attached to the antibody of the invention via a linker molecule. Examples of linker molecules useful for conjugating DOTA to a polypeptide are commonly known in the art—see, for example, DeNardo et al., *Clin Cancer Res.* 4(10):2483–90, 1998; Peterson et al., *Bioconjug. Chem.* 10(4):553–7, 1999; and Zimmerman et al., *Nucl. Med. Biol.* 26(8):943–50, 1999 which are hereby incorporated by reference in their entirety.

A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells and includes such molecules as small molecule toxins and enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof. Examples include, but are not limited to, paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide (VP-16), teniposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, thymidine kinase, endonuclease, RNase, and puromycin and fragments, variants or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cisdichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine), impropulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, altretamine, triethylenemelamine, triethylenephosphoramidate, triethylenethiophosphoramidate trimethylolomelamine, chlornaphazine, cholophosphamide, estramustine, ifosfamide, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, chlorozotocin, fotemustine, nimustine, ranimustine, aclacinomysins, azaserine, cactinomycin, calicheamicin, carabycin, carminomycin, carzinophilin, chromomycins, detorubicin, 6-diazo-5-oxo-L-norleucine, epiru-

bicin, esorubicin, idarubicin, marcellomycin, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, quelamycin, rodorubicin, streptonigrin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, pteropterin, trimetrexate, fludarabine, thiamiprine, ancitabine, azacitidine, 6-azauridine, carmofur, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, frolic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, amscarine, bestabucil, bisantrene, edatraxate, defofamine, dernecolcine, diaziquone, elformithine, elliptinium acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, mitoguanzone, mopidamol, nitracrine, pentostatin, phenamet, pirarubicin, podophyllinic acid, 2-ethylhydrazide, procarbazine, PSKO, razoxane, sizofiran, spirogermanium, tenuazonic acid, triaziquone, 2, 2', 2''-trichlorotriethylamine, urethan, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, arabinoside ("Ara-C"), taxoids, e.g. paclitaxel (TAXOL", Bristol-Myers Squibb Oncology, Princeton, N.J.) doxetaxel (TAXOTERE", Rh6ne-Poulenc Rorer, Antony, France), gemcitabine, ifosfamide, vinorelbine, navelbine, novantrone, teniposide, aminopterin, xeloda, ibandronate, CPT-I 1, topoisomerase inhibitor RFS 2000, difluoromethylomithine (DMFO), retinoic acid, esperamicins, capecitabine, and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included in this definition are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4 hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, toremifene (Fareston), and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin, and pharmaceutically acceptable salts, acids or derivatives of any of the above.

Techniques known in the art may be applied to label antibodies of the invention. Such techniques include, but are not limited to, the use of bifunctional conjugating agents (see e.g., U.S. Pat. Nos. 5,756,065; 5,714,631; 5,696,239; 5,652,361; 5,505,931; 5,489,425; 5,435,990; 5,428,139; 5,342,604; 5,274,119; 4,994,560; and 5,808,003; the contents of each of which are hereby incorporated by reference in its entirety) and direct coupling reactions (e.g., Bolton-Hunter and Chloramine-T reaction).

The antibodies of the invention which are conjugates can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, but are not limited to, for example, a toxin such as abrin, ricin A, alpha toxin, pseudomonas exotoxin, or diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin; a protein such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF-alpha, TNF-beta, AIM I (see, International Publication No. WO 97/33899), AIM II (see, International Publication No. WO 97/34911), Fas Ligand (Takahashi et al., *Int. Immunol.*, 6:1567–1574 (1994)), VEGF (see, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-

6), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), or other growth factors.

Antibodies of the invention (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating a therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

Alternatively, an antibody of the invention can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Pat. No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody of the invention (including an scFv or other molecule comprising, or alternatively consisting of, an antibody fragment or variant thereof), with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

Use of Antibodies for Epitope Mapping

The present invention provides antibodies (including scFvs and other molecules comprising, or alternatively consisting of, antibody fragments or variants thereof), that can be used to identify epitopes of B Lymphocyte Stimulator. In particular, the antibodies of the present invention can be used to identify epitopes of human B Lymphocyte Stimulator (SEQ ID NOS:3228 and/or 3229) or B Lymphocyte Stimulator expressed on human monocytes; murine B Lymphocyte Stimulator (SEQ ID NOS:3230 and/or 3231) or B Lymphocyte Stimulator expressed on murine monocytes; rat B Lymphocyte Stimulator (either the soluble forms as given in SEQ ID NOS:3232, 3233, 3234 and/or 3235 or in a membrane associated form, e.g., on the surface of rat monocytes); or monkey B Lymphocyte Stimulator (e.g., the monkey B Lymphocyte Stimulator polypeptides of SEQ ID NOS:3236 and/or 3237, the soluble form of monkey B Lymphocyte Stimulator, or B Lymphocyte Stimulator expressed on monkey monocytes) using techniques described herein or otherwise known in the art. Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, *Proc. Natl. Acad. Sci. USA* 82:5131-5135 (1985), further described in U.S. Pat. No. 4,631,211.)

Diagnostic Uses of Antibodies

Labeled antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody frag-

ments or variants thereof) which specifically bind to B Lymphocyte Stimulator can be used for diagnostic purposes to detect, diagnose, prognose, or monitor diseases and/or disorders associated with the aberrant expression and/or activity of B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor. The invention provides for the detection of aberrant expression of B Lymphocyte Stimulator comprising: (a) assaying the expression of B Lymphocyte Stimulator in a biological sample from an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard level of B Lymphocyte Stimulator, e.g., in normal biological samples, whereby an increase or decrease in the assayed level of B Lymphocyte Stimulator compared to the standard level of B Lymphocyte Stimulator is indicative of aberrant expression.

By "biological sample" is intended any fluids and/or cells obtained from an individual, body fluid, body tissue, body cell, cell line, tissue culture, or other source which may contain B Lymphocyte Stimulator protein or mRNA. Body fluids include, but are not limited to, sera, plasma, urine, synovial fluid, spinal fluid, saliva, and mucous. Tissues samples may be taken from virtually any tissue in the body. Tissue samples may also be obtained from autopsy material. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The invention also provides for the detection of aberrant expression of B Lymphocyte Stimulator receptor comprising (a) assaying the expression of B Lymphocyte Stimulator receptor in a biological sample from an individual using one or more antibodies or fragments or variants thereof that immunospecifically binds only to soluble B Lymphocyte Stimulator, but does not inhibit B Lymphocyte Stimulator /B Lymphocyte Stimulator receptor binding. Such an antibody, by way of an example that is not to be construed as limiting, would be one that is able to capture a biotinylated B Lymphocyte Stimulator from solution (see Example 8), but that would not prevent B Lymphocyte Stimulator from binding to IM-9 cells (see Example 3). and (b) comparing the level of B Lymphocyte Stimulator receptor with a standard level of B Lymphocyte Stimulator receptor, e.g., in normal tissue or cell samples, whereby an increase or decrease in the assayed level of B Lymphocyte Stimulator receptor compared to the standard level of B Lymphocyte Stimulator receptor is indicative of aberrant expression.

Antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) which specifically bind to B Lymphocyte Stimulator can be used for diagnostic purposes to detect, diagnose, prognose, or monitor autoimmune disorders and/or immunodeficiencies, and/or diseases or conditions associated therewith. The invention provides for the detection of aberrant expression of B Lymphocyte Stimulator comprising: (a) assaying the expression of B Lymphocyte Stimulator in a biological sample from an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard level of B Lymphocyte Stimulator, e.g., in normal biological samples, whereby an increase or decrease in the assayed level of B Lymphocyte Stimulator compared to the standard level of B Lymphocyte Stimulator is indicative of an autoimmune disorder or disease and/or an immunodeficiency. In specific embodiments, an increase in the assayed level of B Lymphocyte

Stimulator is indicative of an autoimmune disorder or disease. In other specific embodiments, a decrease in the assayed level of B Lymphocyte Stimulator is indicative of an immunodeficiency.

Antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) which specifically bind to B Lymphocyte Stimulator but, do not inhibit B Lymphocyte Stimulator/B Lymphocyte Stimulator receptor binding can be used for diagnostic purposes to detect, diagnose, prognose, or monitor autoimmune disorders and/or immunodeficiencies, and/or diseases or conditions associated therewith. The invention provides for the detection of aberrant expression of B Lymphocyte Stimulator receptor comprising: (a) assaying the expression of B Lymphocyte Stimulator receptor in a biological sample from an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator receptor with a standard level of B Lymphocyte Stimulator receptor, e.g., in normal biological samples, whereby an increase or decrease in the assayed level of B Lymphocyte Stimulator receptor compared to the standard level of B Lymphocyte Stimulator receptor is indicative of an autoimmune disorder or disease and/or an immunodeficiency. In specific embodiments, an increase in the assayed level of B Lymphocyte Stimulator receptor is indicative of an autoimmune disorder or disease. In other specific embodiments, a decrease in the assayed level of B Lymphocyte Stimulator receptor is indicative of an immunodeficiency.

Autoimmune disorders, diseases, or conditions that may be detected, diagnosed, prognosed, or monitored using the antibodies of the invention include, but are not limited to, autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, autoimmune neutropenia, autoimmunocytopenia, hemolytic anemia, antiphospholipid syndrome, dermatitis, gluten-sensitive enteropathy, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis (e.g., IgA nephropathy), Multiple Sclerosis, Neuritis, Uveitis Ophthalmia, Polyendocrinopathies, Purpura (e.g., Henoch-Schoenlein purpura), Reiter's Disease, Stiff-Man Syndrome, Autoimmune Pulmonary Inflammation, myocarditis, IgA glomerulonephritis, dense deposit disease, rheumatic heart disease, Guillain-Barre Syndrome, diabetes mellitus (e.g., Type I diabetes mellitus or insulin dependent diabetes mellitus), juvenile onset diabetes, and autoimmune inflammatory eye, autoimmune thyroiditis, hypothyroidism (i.e., Hashimoto's thyroiditis, systemic lupus erythematosus, discoid lupus, Goodpasture's syndrome, Pemphigus, Receptor autoimmunities such as, for example, (a) Graves' Disease, (b) Myasthenia Gravis, and (c) insulin resistance, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, rheumatoid arthritis, scleroderma with anti-collagen antibodies, mixed connective tissue disease, polymyositis/dermatomyositis, pernicious anemia (Addison's disease), idiopathic Addison's disease, infertility, glomerulonephritis such as primary glomerulonephritis and IgA nephropathy, bullous pemphigoid, Sjögren's syndrome, diabetes mellitus, and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis), chronic active hepatitis, primary biliary cirrhosis, other endocrine gland failure, vitiligo, vasculitis, post-MI, cardiotomy syndrome, urticaria, atopic dermatitis, asthma, inflammatory myopathies, and other inflammatory, granulomatous, degenerative, and atrophic disorders and other disorders such as inflammatory skin diseases including psoria-

sis and sclerosis, responses associated with inflammatory bowel disease (such as Crohn's disease and ulcerative colitis), respiratory distress syndrome (including adult respiratory distress syndrome, ARDS), meningitis, encephalitis, colitis, allergic conditions such as eczema and other conditions involving infiltration of T cells and chronic inflammatory responses, atherosclerosis, leukocyte adhesion deficiency, Reynaud's syndrome, and immune responses associated with acute and delayed hypersensitivity mediated by cytokines and T-lymphocytes typically found in tuberculosis, sarcoidosis, granulomatosis and diseases involving leukocyte diapedesis, central nervous system (CNS) inflammatory disorder, multiple organ injury syndrome, antigen-antibody complex mediated diseases, anti-glomerular basement membrane disease, Lambert-Eaton myasthenic syndrome, Beheet disease, giant cell arteritis, immune complex nephritis, IgA nephropathy, IgM polyneuropathies or autoimmune thrombocytopenia etc.

In specific embodiments, the present invention encompasses methods and compositions for detecting, diagnosing and/or prognosing diseases or disorders associated with hypergammaglobulinemia (e.g., AIDS, autoimmune diseases, and some immunodeficiencies). In other specific embodiments, the present invention encompasses methods and compositions for detecting, diagnosing and/or prognosing diseases or disorders associated with hypogammaglobulinemia (e.g., an immunodeficiency).

Immunodeficiencies that may be detected, diagnosed, prognosed, or monitored using the antibodies of the invention include, but are not limited to, severe combined immunodeficiency (SCID)-X linked, SCID-autosomal, adenosine deaminase deficiency (ADA deficiency), X-linked agammaglobulinemia (XLA), Bruton's disease, congenital agammaglobulinemia, X-linked infantile agammaglobulinemia, acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, transient hypogammaglobulinemia of infancy, unspecified hypogammaglobulinemia, agammaglobulinemia, common variable immunodeficiency (CVID) (acquired), Wiskott-Aldrich Syndrome (WAS), X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, selective IgA deficiency, IgG subclass deficiency (with or without IgA deficiency), antibody deficiency with normal or elevated Igs, immunodeficiency with thymoma, Ig heavy chain deletions, kappa chain deficiency, B cell lymphoproliferative disorder (BLPD), selective IgM immunodeficiency, recessive agammaglobulinemia (Swiss type), reticular dysgenesis, neonatal neutropenia, severe congenital leukopenia, thymic aplasia/aplasia or dysplasia with immunodeficiency, ataxia-telangiectasia, short limbed dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof syndrome-combined immunodeficiency with Igs, purine nucleoside phosphorylase deficiency (PNP), MHC Class II deficiency (Bare Lymphocyte Syndrome) and severe combined immunodeficiency.

Elevated levels of soluble B Lymphocyte Stimulator have been observed in the serum of patients with Systemic Lupus Erythematosus (SLE). In comparing the sera of 150 SLE patients with that of 38 control individuals, it was found that most of the SLE patients had more than 5 ng/ml of serum B Lymphocyte Stimulator, more than 30% of SLE patients had levels greater than 10 ng/ml, and approximately 10% of SLE patients had serum B Lymphocyte Stimulator levels greater than 20 ng/ml. In contrast, the majority of normal controls had B Lymphocyte Stimulator levels less than 5 ng/ml, and less than 10% had levels higher than 10 ng/ml. The elevated

levels of B Lymphocyte Stimulator protein in sera is present in the soluble form and has biologic activity as assayed by the ability to stimulate anti-IgM treated B cells in vitro. SLE patients with more than 15 ng/ml serum B Lymphocyte Stimulator were also found to have elevated levels of anti-dsDNA antibodies compared to both normal controls and SLE patients with less than 5 ng/ml of serum B Lymphocyte Stimulator. (unpublished data).

In addition the serum of two subgroups of patients which were positive for anti-nuclear antibodies (ANA+) but did not meet the formal requirements of the American College of Rheumatology (ACR) for classification of SLE were analyzed for B Lymphocyte Stimulator levels. The first subgroup of sera was ANA+ sera that came from patients who did not present with the clinical impression of SLE. This group had only slightly elevated levels of B Lymphocyte Stimulator (~9 ng/ml B Lymphocyte Stimulator). The second subgroup however, which was ANA+ sera from patients who presented with the clinical impression of SLE, had significantly increased B Lymphocyte Stimulator levels (~15 ng/ml). These results suggest that an elevated level of B Lymphocyte Stimulator precedes the formal fulfillment of the ACR criteria. The ACR criteria are described in Tan, E. M., et al, *Arthritis and Rheumatism* 25:1271-1277 (1982).

Thus in specific embodiments, antibodies of the invention which specifically bind to B Lymphocyte Stimulator can be used for diagnostic purposes to detect, diagnose, prognose, or monitor Systemic Lupus Erythematosus or conditions associated therewith. The invention provides for the detection of aberrant expression of B Lymphocyte Stimulator comprising: (a) assaying the expression of B Lymphocyte Stimulator in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard level of B Lymphocyte Stimulator, e.g., in normal biological samples, whereby an increase in the assayed level of B Lymphocyte Stimulator compared to the standard level of B Lymphocyte Stimulator is indicative of SLE.

In other specific embodiments, antibodies of the invention which specifically bind to B Lymphocyte Stimulator can be used for diagnostic purposes to detect, diagnose, prognose, or monitor IgA nephropathy or conditions associated therewith. The invention provides for the detection of aberrant expression of B Lymphocyte Stimulator comprising: (a) assaying the expression of B Lymphocyte Stimulator in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard level of B Lymphocyte Stimulator, e.g., in normal biological samples, whereby an increase in the assayed level of B Lymphocyte Stimulator compared to the standard level of B Lymphocyte Stimulator is indicative of IgA nephropathy.

In other specific embodiments, antibodies of the invention which specifically bind to B Lymphocyte Stimulator can be used for diagnostic purposes to detect, diagnose, prognose, or monitor Sjögren's Syndrome or conditions associated therewith. The invention provides for the detection of aberrant expression of B Lymphocyte Stimulator comprising: (a) assaying the expression of B Lymphocyte Stimulator in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard level of B Lymphocyte Stimulator, e.g., in normal biological samples, whereby an increase in the assayed level of B Lymphocyte Stimulator

compared to the standard level of B Lymphocyte Stimulator is indicative of Sjögren's Syndrome.

In other specific embodiments, antibodies of the invention which specifically bind to B Lymphocyte Stimulator can be used for diagnostic purposes to detect, diagnose, prognose, or monitor HIV infection or conditions associated therewith (e.g. AIDS). The invention provides for the detection of aberrant expression of B Lymphocyte Stimulator comprising: (a) assaying the expression of B Lymphocyte Stimulator in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard level of B Lymphocyte Stimulator, e.g., in normal biological samples, whereby an increase in the assayed level of B Lymphocyte Stimulator compared to the standard level of B Lymphocyte Stimulator is indicative of HIV infection.

In other specific embodiments, antibodies of the invention which specifically bind to B Lymphocyte Stimulator can be used for diagnostic purposes to detect, diagnose, prognose, or monitor Myasthenia Gravis or conditions associated therewith. The invention provides for the detection of aberrant expression of B Lymphocyte Stimulator comprising: (a) assaying the expression of B Lymphocyte Stimulator in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard level of B Lymphocyte Stimulator, e.g., in normal biological samples, whereby an increase in the assayed level of B Lymphocyte Stimulator compared to the standard level of B Lymphocyte Stimulator is indicative of Myasthenia Gravis.

In other specific embodiments, antibodies of the invention which specifically bind to B Lymphocyte Stimulator can be used for diagnostic purposes to detect, diagnose, prognose, or monitor idiopathic thrombocytopenic purpura (ITP) or conditions associated therewith. The invention provides for the detection of aberrant expression of B Lymphocyte Stimulator comprising: (a) assaying the expression of B Lymphocyte Stimulator in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard level of B Lymphocyte Stimulator, e.g., in normal biological samples, whereby an increase in the assayed level of B Lymphocyte Stimulator compared to the standard level of B Lymphocyte Stimulator is indicative of idiopathic thrombocytopenic purpura (ITP).

In other specific embodiments, antibodies of the invention which specifically bind to B Lymphocyte Stimulator can be used for diagnostic purposes to detect, diagnose, prognose, or monitor hemolytic anemia or conditions associated therewith. The invention provides for the detection of aberrant expression of B Lymphocyte Stimulator comprising: (a) assaying the expression of B Lymphocyte Stimulator in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard level of B Lymphocyte Stimulator, e.g., in normal biological samples, whereby an increase in the assayed level of B Lymphocyte Stimulator compared to the standard level of B Lymphocyte Stimulator is indicative of hemolytic anemia.

In other specific embodiments, antibodies of the invention which specifically bind to B Lymphocyte Stimulator can be used for diagnostic purposes to detect, diagnose, prognose, or monitor thyroiditis or conditions associated therewith.

The invention provides for the detection of aberrant expression of B Lymphocyte Stimulator comprising: (a) assaying the expression of B Lymphocyte Stimulator in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard level of B Lymphocyte Stimulator, e.g., in normal biological samples, whereby an increase in the assayed level of B Lymphocyte Stimulator compared to the standard level of B Lymphocyte Stimulator is indicative of thyroiditis.

In other specific embodiments, antibodies of the invention which specifically bind to B Lymphocyte Stimulator can be used for diagnostic purposes to detect, diagnose, prognose, or monitor Goodpasture's syndrome or conditions associated therewith. The invention provides for the detection of aberrant expression of B Lymphocyte Stimulator comprising: (a) assaying the expression of B Lymphocyte Stimulator in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard level of B Lymphocyte Stimulator, e.g., in normal biological samples, whereby an increase in the assayed level of B Lymphocyte Stimulator compared to the standard level of B Lymphocyte Stimulator is indicative of Goodpasture's syndrome.

In other specific embodiments, antibodies of the invention which specifically bind to B Lymphocyte Stimulator can be used for diagnostic purposes to detect, diagnose, prognose, or monitor multiple sclerosis or conditions associated therewith. The invention provides for the detection of aberrant expression of B Lymphocyte Stimulator comprising: (a) assaying the expression of B Lymphocyte Stimulator in a biological sample of an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard level of B Lymphocyte Stimulator, e.g., in normal biological samples, whereby an increase in the assayed level of B Lymphocyte Stimulator compared to the standard level of B Lymphocyte Stimulator is indicative of multiple sclerosis.

In additional embodiments, antibodies of the invention which specifically bind to B Lymphocyte Stimulator can be used for diagnostic purposes to detect, diagnose, prognose, or monitor Rheumatoid Arthritis. The invention provides for the detection of aberrant expression of B Lymphocyte Stimulator comprising: (a) assaying the expression of B Lymphocyte Stimulator in a biological sample (e.g., serum and synovial fluid) of an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard level of B Lymphocyte Stimulator, e.g., in normal biological samples, whereby an increase in the assayed level of B Lymphocyte Stimulator compared to the standard level of B Lymphocyte Stimulator is indicative of Rheumatoid arthritis.

In additional embodiments, antibodies of the invention which specifically bind to B Lymphocyte Stimulator can be used for diagnostic purposes to detect, diagnose, prognose, or monitor an immune-based rheumatologic disease, (e.g., SLE, rheumatoid arthritis, CREST syndrome (a variant of scleroderma characterized by calcinosis, Raynaud's phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia.), Seronegative spondyloarthropathy (SpA), Polymyositis/dermatomyositis, Microscopic polyangiitis, Hepatitis C-associated arthritis, Takayasu's arteritis, and undifferentiated connective tissue disorder). The invention

provides for the detection of aberrant expression of B Lymphocyte Stimulator comprising: (a) assaying the expression of B Lymphocyte Stimulator in a biological sample (e.g., serum and synovial fluid) of an individual using one or more antibodies of the invention that immunospecifically binds to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard level of B Lymphocyte Stimulator, e.g., in normal biological samples, whereby an increase in the assayed level of B Lymphocyte Stimulator compared to the standard level of B Lymphocyte Stimulator is indicative of monitor an immune-based rheumatologic disease.

It has been observed, that serum B Lymphocyte Stimulator levels inversely correlate with nephrotic range proteinuria (>3 gm proteinuria in a 24 hour urine collection) using a sample of 71 SLE patients ($p=0.019$). Proteinuria was determined in 71 SLE patients within one month of phlebotomy for serum B Lymphocyte Stimulator determination. Serum B Lymphocyte Stimulator was classified as low, normal, or high based on the 5th through 95th percentiles for normal controls. Nephrotic-range proteinuria was inversely correlated with serum Neutrokin- α levels. Thus, in specific embodiments, serum levels of B Lymphocyte Stimulator (determined using one or more antibodies of the present invention) in individuals diagnosed with an immune based rheumatologic disease (e.g., SLE, rheumatoid arthritis, CREST syndrome (a variant of scleroderma characterized by calcinosis, Raynaud's phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia.), seronegative spondyloarthropathy (SpA), polymyositis/dermatomyositis, microscopic polyangiitis, hepatitis C-associated arthritis, Takayasu's arteritis, and undifferentiated connective tissue disorder) may be used to determine, diagnose, prognose, or monitor the severity of certain aspects or symptoms of the disease, such as nephrotic-range proteinuria.

In another specific embodiment, antibodies of the invention are used to diagnose, prognose, treat, or prevent conditions associated with CVID, including, but not limited to, conditions associated with acute and recurring infections (e.g., pneumonia, bronchitis, sinusitis, otitis media, sepsis, meningitis, septic arthritis, and osteomyelitis), chronic lung disease, autoimmunity, granulomatous disease, lymphoma, cancers (e.g., cancers of the breast, stomach, colon, mouth, prostate, lung, vagina, ovary, skin, and melanin forming cells (i.e. melanoma), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, and ulcerative proctitis), malabsorption, Hodgkin's disease, and Waldenstrom's macroglobulinemia).

The invention provides a diagnostic assay for diagnosing or prognosing a disease or disorder, comprising: (a) assaying for the level of B Lymphocyte Stimulator in a biological sample of an individual using one or more antibodies of the invention that immunospecifically bind to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard B Lymphocyte Stimulator level, e.g., in a biological sample from a patient without the disease or disorder, whereby an increase or decrease in the assayed B Lymphocyte Stimulator level compared to the standard level of B Lymphocyte Stimulator is indicative of a particular disease or disorder. With respect to cancer, the presence of a relatively high amount of B Lymphocyte Stimulator in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to

employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

In specific embodiments, the presence of a relatively high amount of membrane-bound B Lymphocyte Stimulator in a biological sample is indicative of monocytic cell related leukemias or lymphomas, such as, for example acute myelogenous leukemia and/or the severity thereof.

In other specific embodiments, the presence of a relatively high amount of B Lymphocyte Stimulator receptor in a biological sample (as determined using antibodies of the invention that bind to soluble B Lymphocyte Stimulator, but do not inhibit B Lymphocyte Stimulator/B Lymphocyte Stimulator receptor binding) is indicative of B cell related leukemias or lymphomas (e.g., chronic lymphocytic leukemia, multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's disease), and/or the severity thereof.

In specific embodiments, the invention provides a diagnostic assay for diagnosing or prognosing Systemic Lupus Erythematosus, comprising: (a) assaying for the level of B Lymphocyte Stimulator in a biological sample of an individual using one or more antibodies of the invention that immunospecifically bind to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard B Lymphocyte Stimulator level, e.g., in a biological sample from a patient without Systemic Lupus Erythematosus, whereby an increase in the assayed B Lymphocyte Stimulator level compared to the standard level of B Lymphocyte Stimulator is indicative of Systemic Lupus Erythematosus.

In specific embodiments, the invention provides a diagnostic assay for diagnosing or prognosing a Rheumatoid Arthritis, comprising: (a) assaying for the level of B Lymphocyte Stimulator in a biological sample of an individual using one or more antibodies of the invention that immunospecifically bind to B Lymphocyte Stimulator; and (b) comparing the level of B Lymphocyte Stimulator with a standard B Lymphocyte Stimulator level, e.g., in a biological sample from a patient without Rheumatoid Arthritis, whereby an increase or decrease in the assayed B Lymphocyte Stimulator level compared to the standard level of B Lymphocyte Stimulator is indicative of Rheumatoid Arthritis.

The invention provides a diagnostic assay for diagnosing or prognosing a disease or disorder, comprising: (a) assaying for the level of B Lymphocyte Stimulator receptor in cells or a tissue sample of an individual using one or more antibodies of the invention that immunospecifically binds only to soluble B Lymphocyte Stimulator, but does not neutralize B Lymphocyte Stimulator/B Lymphocyte Stimulator receptor binding; and (b) comparing the level of B Lymphocyte Stimulator receptor with a standard B Lymphocyte Stimulator receptor level, e.g., in a tissue sample from a patient without the disease or disorder, whereby an increase or decrease in the assayed B Lymphocyte Stimulator receptor level compared to the standard level of B Lymphocyte Stimulator receptor is indicative of a particular disease or disorder. With respect to cancer, the presence of a relatively high amount of B Lymphocyte Stimulator receptor in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) can be used to assay protein levels in a biological sample using classical immunohistological methods as described herein or as known to those of skill in the art (e.g., see Jalkanen, et al., *J. Cell. Biol.* 101:976-985 (1985); Jalkanen, et al., *J. Cell. Biol.* 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, alkaline phosphatase, and horseradish peroxidase; radioisotopes, such as iodine (^{121}I , ^{123}I , ^{125}I , ^{131}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{111}In , ^{112}In , $^{113\text{m}}\text{In}$, $^{115\text{m}}\text{In}$), technetium ($^{99\text{Tc}}$, $^{99\text{mTc}}$), thallium (^{201}Tl), gallium (^{68}Ga , ^{67}Ga), palladium (^{103}Pd), molybdenum (^{99}Mo), xenon (^{133}Xe), fluorine (^{18}F), ^{153}Sm , ^{177}Lu , ^{159}Gd , ^{149}Pm , ^{140}La , ^{175}Yb , ^{166}Ho , ^{90}Y , ^{47}Sc , ^{188}Re , $^{188\text{m}}\text{Re}$, ^{142}Pr , ^{105}Rh , and ^{97}Ru ; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled antibody of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically binds to B Lymphocyte Stimulator; b) waiting for a time interval following the administering for permitting the labeled antibody to preferentially concentrate at sites in the subject where B Lymphocyte Stimulator is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled antibody in the subject, such that detection of labeled antibody or fragment thereof above the background level and above or below the level observed in a person without the disease or disorder indicates that the subject has a particular disease or disorder associated with aberrant expression of B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{Tc}}$. The labeled antibody will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S. W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in *Tumor Imaging: The Radiochemical Detection of Cancer*, S. W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In

another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disorder, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Pat. No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

Immunophenotyping

The antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may be utilized for immunophenotyping of cell lines and biological samples by their B Lymphocyte Stimulator expression or B Lymphocyte Stimulator receptor expression. Various techniques can be utilized using antibodies, fragments, or variants of the invention to screen for cellular populations (i.e., immune cells, particularly monocytic cells or B-cells) expressing B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor, and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (see, e.g., U.S. Pat. No. 5,985,660; and Morrison et al., *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e., minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

In one embodiment, antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) are used to identify cells of monocytic or B cell origin.

Therapeutic Uses of Antibodies

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention and nucleic acids encoding antibodies (and anti-idiotypic antibodies) of the invention as described

herein. The antibodies of the invention can be used to treat, ameliorate or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of B Lymphocyte Stimulator or B Lymphocyte Stimulator receptor, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant B Lymphocyte Stimulator expression and/or activity or aberrant B Lymphocyte Stimulator receptor expression and/or activity includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

Antibodies of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that function as agonists or antagonists of B Lymphocyte Stimulator, preferably of B Lymphocyte Stimulator-induced signal transduction, can be administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant B Lymphocyte Stimulator expression, lack of B Lymphocyte Stimulator function, aberrant B Lymphocyte Stimulator receptor expression, or lack of B Lymphocyte Stimulator receptor function. For example, antibodies of the invention which disrupt the interaction between B Lymphocyte Stimulator and its receptor may be administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant B Lymphocyte Stimulator expression, excessive B Lymphocyte Stimulator function, aberrant B Lymphocyte Stimulator receptor expression, or excessive of B Lymphocyte Stimulator receptor function. Antibodies of the invention which do not prevent B Lymphocyte Stimulator from binding its receptor but inhibit or downregulate B Lymphocyte Stimulator-induced signal transduction can be administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant B Lymphocyte Stimulator expression, excessive B Lymphocyte Stimulator function, aberrant B Lymphocyte Stimulator receptor expression, or excessive B Lymphocyte Stimulator receptor function. In particular, antibodies of the present invention which prevent B Lymphocyte Stimulator-induced signal transduction by specifically recognizing the unbound B Lymphocyte Stimulator, receptor-bound B Lymphocyte Stimulator or both unbound and receptor-bound B Lymphocyte Stimulator can be administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant B Lymphocyte Stimulator expression, excessive B Lymphocyte Stimulator function, aberrant B Lymphocyte Stimulator receptor expression, or excessive B Lymphocyte Stimulator receptor function. The ability of an antibody of the invention to inhibit or downregulate B Lymphocyte Stimulator-induced signal transduction may be determined by techniques described herein or otherwise known in the art. For example, B Lymphocyte Stimulator-induced receptor activation and the activation of signaling molecules can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or a signaling molecule by immunoprecipitation followed by western blot analysis (for example, as described herein).

In a specific embodiment, an antibody of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that inhibits or downregulates B Lymphocyte Stimulator activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%,

at least 25%, at least 20%, or at least 10% relative to B Lymphocyte Stimulator activity in absence of the antibody is administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant B Lymphocyte Stimulator expression, excessive B Lymphocyte Stimulator function, aberrant B Lymphocyte Stimulator receptor expression, or excessive B Lymphocyte Stimulator receptor function. In another embodiment, a combination of antibodies, a combination of antibody fragments, a combination of antibody variants, or a combination of antibodies, antibody fragments, and/or variants that inhibit or downregulate B Lymphocyte Stimulator activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, or at least 10% relative to B Lymphocyte Stimulator activity in absence of said antibodies, antibody fragments, and/or antibody variants are administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant B Lymphocyte Stimulator expression, excessive B Lymphocyte Stimulator function, aberrant B Lymphocyte Stimulator receptor expression, or excessive B Lymphocyte Stimulator receptor function.

Further, antibodies of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) which activate B Lymphocyte Stimulator-induced signal transduction can be administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant B Lymphocyte Stimulator expression, lack of B Lymphocyte Stimulator function, aberrant B Lymphocyte Stimulator receptor expression, or lack of B Lymphocyte Stimulator receptor function. These antibodies may potentiate or activate either all or a subset of the biological activities of B Lymphocyte Stimulator-mediated receptor activation, for example, by inducing multimerization of B Lymphocyte Stimulator and/or multimerization of the receptor. The antibodies of the invention may be administered with or without being pre-complexed with B Lymphocyte Stimulator. In a specific embodiment, an antibody of the present invention that increases B Lymphocyte Stimulator activity by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% relative to B Lymphocyte Stimulator activity in absence of the antibody is administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant B Lymphocyte Stimulator expression, lack of B Lymphocyte Stimulator function, aberrant B Lymphocyte Stimulator receptor expression, or lack of B Lymphocyte Stimulator receptor function. In another embodiment, a combination of antibodies, a combination of antibody fragments, a combination of antibody variants, or a combination of antibodies, antibody fragments and/or antibody variants that increase B Lymphocyte Stimulator activity by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% relative to B Lymphocyte Stimulator activity in absence of the said antibodies or antibody fragments and/or antibody variants is administered to an animal to treat, prevent or ameliorate a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or lack of B Lymphocyte Stimulator function or aberrant B

Lymphocyte Stimulator receptor expression or lack of B Lymphocyte Stimulator receptor function.

One or more antibodies of the present invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to B Lymphocyte Stimulator may be used locally or systemically in the body as a therapeutic. The antibodies of this invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may also be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy, anti-tumor agents, anti-angiogenesis and anti-inflammatory agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments, or variants, (e.g., derivatives), or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) that immunospecifically bind to B Lymphocyte Stimulator, or polynucleotides encoding antibodies that immunospecifically bind to B Lymphocyte Stimulator, for both immunoassays directed to and therapy of disorders related to B Lymphocyte Stimulator polynucleotides or polypeptides, including fragments thereof. Such antibodies will preferably have an affinity for B Lymphocyte Stimulator and/or B Lymphocyte Stimulator fragments. Preferred binding affinities include those with a dissociation constant or K_D less than or equal to 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, or 10^{-5} M. More preferably, antibodies of the invention bind B Lymphocyte Stimulator polypeptides or fragments or variants thereof with a dissociation constant or K_D less than or equal to 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, or 10^{-8} M. Even more preferably, antibodies of the invention bind B Lymphocyte Stimulator polypeptides or fragments or variants thereof with a dissociation constant or K_D less than or equal to 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, or 10^{-15} M. The invention encompasses antibodies that bind B Lymphocyte Stimulator polypeptides with a dissociation constant or K_D that is within any one of the ranges that are between each of the individual recited values.

In a preferred embodiment, antibodies of the invention neutralize B Lymphocyte Stimulator activity. In another preferred embodiment, antibodies of the invention inhibit B cell proliferation.

In a preferred embodiment, antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) inhibit or reduce binding of the soluble form of B Lymphocyte Stimulator to a B Lymphocyte Stimulator receptor. In another preferred embodiment antibodies of the invention inhibit or reduce B cell proliferation induced by the soluble form of B Lymphocyte Stimulator. In another preferred embodiment anti-

bodies of the invention inhibit or reduce immunoglobulin production induced by the soluble form of B Lymphocyte Stimulator.

In a preferred embodiment, antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) inhibit or reduce binding of membrane-bound B Lymphocyte Stimulator to a B Lymphocyte Stimulator receptor. In another preferred embodiment, antibodies of the invention inhibit or reduce B cell proliferation induced by the membrane-bound form of B Lymphocyte Stimulator. In another preferred embodiment, antibodies of the invention inhibit or reduce immunoglobulin production induced by the membrane bound form of B Lymphocyte Stimulator.

In a preferred embodiment, antibodies of the invention (including molecules comprising, or alternatively consisting of, antibody fragments or variants thereof) inhibit or reduce binding of both the soluble and membrane-bound forms of B Lymphocyte Stimulator to a B Lymphocyte Stimulator receptor. In another preferred embodiment, antibodies of the invention inhibit or reduce B cell proliferation induced by either or both forms of B Lymphocyte Stimulator. In another preferred embodiment, antibodies of the invention inhibit or reduce immunoglobulin production induced by either or both forms of B Lymphocyte Stimulator.

In one embodiment, the invention provides a method of delivering antibody conjugates of the invention to targeted cells, such as, for example, monocytic cells expressing the membrane-bound form of B Lymphocyte Stimulator, or B cells expressing a B Lymphocyte Stimulator receptor.

In one embodiment, the invention provides a method for the specific delivery of antibodies and antibody conjugates of the invention to cells by administering molecules of the invention that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering antibodies or antibody conjugates of the invention (e.g., antibodies conjugated with radioisotopes, toxins, or cytotoxic prodrugs). In a specific embodiment, the invention provides a method for the specific destruction of cells of monocytic lineage (e.g., monocytic cell related leukemias or lymphomas, such as, for example acute myelogenous leukemia) by administering antibodies or antibody conjugates of the invention (e.g., antibodies conjugated with radioisotopes, toxins, or cytotoxic prodrugs) that immunospecifically bind the membrane-bound form of B Lymphocyte Stimulator. In another specific embodiment, the invention provides a method for the specific destruction of cells of B cell lineage (e.g., B cell related leukemias or lymphomas (e.g., chronic lymphocytic leukemia, multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's disease) by administering antibodies or antibody conjugates of the invention (e.g., antibodies conjugated with radioisotopes, toxins, or cytotoxic prodrugs) that bind soluble B Lymphocyte Stimulator, but do not inhibit B Lymphocyte Stimulator binding to a B Lymphocyte Stimulator receptor on B cells.

In another preferred embodiment antibodies of the invention (including antibody fragments and variants) promote or enhance B cell proliferation induced by the soluble form of

B Lymphocyte Stimulator. In another preferred embodiment, antibodies of the invention (including antibody fragments and variants) promote or enhance B cell proliferation induced by the membrane or soluble form of APRIL. In another preferred embodiment antibodies of the invention (including antibody fragments and variants) increase or enhance immunoglobulin production induced by the soluble form of B Lymphocyte Stimulator. In another preferred embodiment antibodies of the invention (including antibody fragments and variants) increase or enhance immunoglobulin production in response to T cell dependent immunogens. In another preferred embodiment antibodies of the invention (including antibody fragments and variants, and anti-antibody antibodies) increase or enhance immunoglobulin production in response to T cell independent immunogens.

In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate immune disorders. Immune disorders include, but are not limited to, autoimmune disorders (e.g., arthritis, graft rejection, Hashimoto's thyroiditis, insulin-dependent diabetes, lupus, idiopathic thrombocytopenic purpura, systemic lupus erythematosus and multiple sclerosis), elective IgA deficiency, ataxia-telangiectasia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome, idiopathic hyper-eosinophilic syndrome, monocytic leukemoid reaction, monocytic leukocytosis, monocytic leukopenia, monocytopenia, monocytosis, and graft or transplant rejection.

As discussed herein, antibodies and antibody compositions of the invention, may be used to treat, prevent, ameliorate, diagnose or prognose various immune system-related disorders and/or conditions associated with these disorders, in mammals, preferably humans. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of antibody and antibody compositions of the invention that can inhibit an immune response, particularly the proliferation of B cells and/or the production of immunoglobulins, may be an effective therapy in treating and/or preventing autoimmune disorders. Thus, in preferred embodiments, antibodies and antibody compositions of the invention are used to treat, prevent, ameliorate, diagnose and/or prognose an autoimmune disorder, or condition(s) associated with such disorder.

Autoimmune disorders and conditions associated with these disorders that may be treated, prevented, ameliorated, diagnosed and/or prognosed with the therapeutic and pharmaceutical compositions of the invention include, but are not limited to, autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, autoimmune neutropenia, autoimmune cytopenia, hemolytic anemia, antiphospholipid syndrome, dermatitis, gluten-sensitive enteropathy, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis (e.g., IgA nephropathy), Multiple Sclerosis, Neuritis, Uveitis Ophthalmia, Polyendocrinopathies, Purpura (e.g., Henoch-Schoenlein purpura), Reiter's Disease, Stiff-Man Syndrome, Autoimmune Pulmonary Inflammation, myocarditis, IgA glomerulonephritis, dense deposit disease, rheumatic heart disease, Guillain-Barre

Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Additional autoimmune disorders and conditions associated with these disorders that may be treated, prevented, ameliorated, diagnosed and/or prognosed with the therapeutic and pharmaceutical compositions of the invention include, but are not limited to, autoimmune thyroiditis, hypothyroidism (i.e., Hashimoto's thyroiditis) (often characterized, e.g., by cell-mediated and humoral thyroid cytotoxicity), systemic lupus erythematosus (often characterized, e.g., by circulating and locally generated immune complexes), discoid lupus, Goodpasture's syndrome (often characterized, e.g., by anti-basement membrane antibodies), Pemphigus (often characterized, e.g., by epidermal acantholytic antibodies), Receptor autoimmunities such as, for example, (a) Graves' Disease (often characterized, e.g., by TSH receptor antibodies), (b) Myasthenia Gravis (often characterized, e.g., by acetylcholine receptor antibodies), and (c) insulin resistance (often characterized, e.g., by insulin receptor antibodies), autoimmune hemolytic anemia (often characterized, e.g., by phagocytosis of antibody-sensitized RBCs), autoimmune thrombocytopenic purpura (often characterized, e.g., by phagocytosis of antibody-sensitized platelets).

Additional autoimmune disorders and conditions associated with these disorders that may be treated, prevented, ameliorated, diagnosed and/or prognosed with the therapeutic and pharmaceutical compositions of the invention include, but are not limited to, rheumatoid arthritis (often characterized, e.g., by immune complexes in joints), scleroderma with anti-collagen antibodies (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed connective tissue disease (often characterized, e.g., by antibodies to extractable nuclear antigens (e.g., ribonucleoprotein)), polymyositis/dermatomyositis (often characterized, e.g., by nonhistone ANA), pernicious anemia (often characterized, e.g., by antiparietal cell, microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often characterized, e.g., by humoral and cell-mediated adrenal cytotoxicity, infertility (often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often characterized, e.g., by glomerular basement membrane antibodies or immune complexes) such as primary glomerulonephritis and IgA nephropathy, bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjögren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes mellitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies), chronic active hepatitis (often characterized, e.g., by smooth muscle antibodies), primary biliary cirrhosis (often characterized, e.g., by mitochondrial antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by myocardial antibodies), cardiomyopathy (often characterized, e.g., by myocardial antibodies), urticaria (often characterized, e.g., by IgG and IgM antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma (often characterized, e.g., by IgG and IgM antibodies to IgE), inflammatory myopathies, and many other inflammatory, granulomatous, degenerative, and atrophic disorders.

In a preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, a member of the group: autoimmune hemolytic anemia, as primary glomerulonephritis, IgA glomerulonephritis, Goodpasture's syndrome, idiopathic thrombocytopenia, Multiple Sclerosis, Myasthenia Gravis, Pemphigus, polymyositis/dermatomyositis, relapsing polychondritis, rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus, Uveitis, vasculitis, and primary biliary cirrhosis.

In another preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, an immune based-rheumatologic disease, such as, for example, SLE, rheumatoid arthritis, CREST syndrome (a variant of scleroderma characterized by calcinosis, Raynaud's phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia.), Seronegative spondyloarthritis (SpA), polymyositis/dermatomyositis, microscopic polyangiitis, hepatitis C-associated arthritis, Takayasu's arteritis, and undifferentiated connective tissue disorder.

In a specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, rheumatoid arthritis and/or medical conditions associated therewith.

For example, an antibody, or antibodies, of the present invention are used to treat patients with clinical diagnosis of rheumatoid arthritis (RA). The patient treated preferably will not have a B cell malignancy. Moreover, the patient is optionally further treated with any one or more agents employed for treating RA such as salicylate; nonsteroidal anti-inflammatory drugs such as indomethacin, phenylbutazone, phenylacetic acid derivatives (e.g. ibuprofen and fenoprofen), naphthalene acetic acids (naproxen), pyrrolealkanoic acid (tometin), indoleacetic acids (sulindac), halogenated anthranilic acid (meclofenamate sodium), piroxicam, zomepirac and diflunisal; antimalarials such as chloroquine; gold salts; penicillamine; or immunosuppressive agents such as methotrexate or corticosteroids in dosages known for such drugs or reduced dosages. Preferably however, the patient is only treated with an antibody, or antibodies, of the present invention. Antibodies of the present invention are administered to the RA patient according to a dosing schedule as described infra, which may be readily determined by one of ordinary skill in the art. The primary response is determined by the Paulus index (Paulus et al. *Arthritis Rheum.* 33:477-484 (1990)), i.e. improvement in morning stiffness, number of painful and inflamed joints, erythrocyte sedimentation (ESR), and at least a 2-point improvement on a 5-point scale of disease severity assessed by patient and by physician. Administration of an antibody, or antibodies, of the present invention will alleviate one or more of the symptoms of RA in the patient treated as described above.

In a specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, lupus and/or medical conditions associated therewith. Lupus-associated conditions that may be treated, prevented, ameliorated, prognosed and/or diagnosed with the antibodies and antibody compositions of the invention include, but are not limited to, hematologic disorders (e.g., hemolytic anemia, leukopenia, lymphopenia, and thrombocytopenia), immunologic disorders (e.g., anti-DNA antibodies, and anti-Sm antibodies), rashes, photosensitivity, oral ulcers, arthritis, fever, fatigue, weight loss, serositis (e.g., pleuritis (pleurisy)), renal disorders (e.g., nephritis), neurological disorder

ders (e.g., seizures, peripheral neuropathy, CNS related disorders), gastrointestinal disorders, Raynaud phenomenon, and pericarditis. In a preferred embodiment, therapeutic and pharmaceutical compositions of the invention are used to treat, prevent, ameliorate, diagnose, or prognose, renal disorders associated with systemic lupus erythematosus. In a most preferred embodiment, therapeutic and pharmaceutical compositions of the invention are used to treat, prevent, ameliorate, diagnose, or prognose, nephritis associated with systemic lupus erythematosus. In another most preferred embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate lupus or glomerular nephritis.

In a further specific embodiment, antibodies of the invention are used to treat, inhibit, prognose, diagnose or prevent hemolytic anemia. For example, patients diagnosed with autoimmune hemolytic anemia (AIHA), e.g., cryoglobulinemia or Coombs positive anemia, are treated with an antibody, or antibodies, of the present invention. AIHA is an acquired hemolytic anemia due to auto-antibodies that react with the patient's red blood cells. The patient treated preferably will not have a B cell malignancy. Further adjunct therapies (such as glucocorticoids, prednisone, azathioprine, cyclophosphamide, vinca-laden platelets or Danazol) may be combined with the antibody therapy, but preferably the patient is treated with an antibody, or antibodies, of the present invention as a single-agent throughout the course of therapy. Antibodies of the present invention are administered to the hemolytic anemia patient according to a dosing schedule as described infra, which may be readily determined by one of ordinary skill in the art. Overall response rate is determined based upon an improvement in blood counts, decreased requirement for transfusions, improved hemoglobin levels and/or a decrease in the evidence of hemolysis as determined by standard chemical parameters. Administration of an antibody, or antibodies of the present invention will improve any one or more of the symptoms of hemolytic anemia in the patient treated as described above. For example, the patient treated as described above will show an increase in hemoglobin and an improvement in chemical parameters of hemolysis or return to normal as measured by serum lactic dehydrogenase and/or bilirubin.

In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, Sjögren's Syndrome and/or medical conditions associated therewith.

In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, HIV infection and/or medical conditions associated therewith (e.g. AIDS).

In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, Myasthenia gravis and/or medical conditions associated therewith.

In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, IgA nephropathy and/or medical conditions associated therewith.

In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, hemolytic anemia and/or medical conditions associated therewith.

In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, thyroiditis and/or medical conditions associated therewith.

In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, Goodpasture's Syndrome and/or medical conditions associated therewith.

In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, multiple sclerosis and/or medical conditions associated therewith.

In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, chronic lymphocytic leukemia (CLL) and/or medical conditions associated therewith.

In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, multiple myeloma and/or medical conditions associated therewith.

In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, Non-Hodgkin's lymphoma and/or medical conditions associated therewith.

In another specific preferred embodiment, therapeutic and pharmaceutical compositions of the invention, are used to treat, prevent, ameliorate, diagnose or prognose, Hodgkin's disease and/or medical conditions associated therewith.

In another specific embodiment, antibodies of the invention are used to treat, inhibit, prognose, diagnose or prevent adult immune thrombocytopenic purpura. Adult immune thrombocytopenic purpura (ITP) is a relatively rare hematologic disorder that constitutes the most common of the immune-mediated cytopenias. The disease typically presents with severe thrombocytopenia that may be associated with acute hemorrhage in the presence of normal to increased megakaryocytes in the bone marrow. Most patients with ITP have an IgG antibody directed against target antigens on the outer surface of the platelet membrane, resulting in platelet sequestration in the spleen and accelerated reticuloendothelial destruction of platelets (Bussell, J. B. *Hematol. Oncol. Clin. North Am.* (4):179 (1990)). A number of therapeutic interventions have been shown to be effective in the treatment of ITP. Steroids are generally considered first-line therapy, after which most patients are candidates for intravenous immunoglobulin (IVIG), splenectomy, or other medical therapies including vincristine or immunosuppressive/cytotoxic agents. Up to 80% of patients with ITP initially respond to a course of steroids, but far fewer have complete and lasting remissions. Splenectomy has been recommended as standard second-line therapy for steroid failures, and leads to prolonged remission in nearly 60% of cases yet may result in reduced immunity to infection. Splenectomy is a major surgical procedure that may be associated with substantial morbidity (15%) and mortality (2%). IVIG has also been used as second line medical therapy, although only a small proportion of adult patients with ITP achieve remission. Therapeutic options that would interfere with the production of autoantibodies by activated B cells without the associated morbidities that occur with corticosteroids and/or splenectomy would provide an important treatment approach for a proportion of patients with ITP. Patients with clinical diagnosis of ITP are treated with an antibody, or antibodies of the present invention, optionally in combination with steroid therapy. The patient treated will not have a B cell malignancy. Antibodies of the present invention are administered to the RA patient according to a dosing schedule as described infra, which may be readily

determined by one of ordinary skill in the art. Overall patient response rate is determined based upon a platelet count determined on two consecutive occasions two weeks apart following treatments as described above. See, George et al. "Idiopathic Thrombocytopenic Purpura: A Practice Guideline Developed by Explicit Methods for The American Society of Hematology", *Blood* 88:3-40 (1996), expressly incorporated herein by reference.

In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate an IgE-mediated allergic reaction or histamine-mediated allergic reaction. Examples of allergic reactions include, but are not limited to, asthma, rhinitis, eczema, chronic urticaria, and atopic dermatitis. In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent, or ameliorate anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility. In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate or modulate inflammation or an inflammatory disorder. Examples of chronic and acute inflammatory disorders that may be treated prevented or ameliorated with the therapeutic and pharmaceutical compositions of the invention include, but are not limited to, chronic prostatitis, granulomatous prostatitis and malacoplakia, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, Crohn's disease, inflammatory bowel disease, chronic and acute inflammatory pulmonary diseases, bacterial infection, psoriasis, septicemia, cerebral malaria, arthritis, gastroenteritis, and glomerular nephritis.

In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate ischemia and arteriosclerosis. Examples of such disorders include, but are not limited to, reperfusion damage (e.g., in the heart and/or brain) and cardiac hypertrophy.

Therapeutic or pharmaceutical compositions of the invention, may also be administered to modulate blood clotting and to treat or prevent blood clotting disorders, such as, for example, antibody-mediated thrombosis (i.e., antiphospholipid antibody syndrome (APS)). For example, therapeutic or pharmaceutical compositions of the invention, may inhibit the proliferation and differentiation of cells involved in producing anticardiolipin antibodies. These compositions of the invention can be used to treat, prevent, ameliorate, diagnose, and/or prognose thrombotic related events including, but not limited to, stroke (and recurrent stroke), heart attack, deep vein thrombosis, pulmonary embolism, myocardial infarction, coronary artery disease (e.g., antibody-mediated coronary artery disease), thrombosis, graft reocclusion following cardiovascular surgery (e.g., coronary arterial bypass grafts, recurrent fetal loss, and recurrent cardiovascular thromboembolic events).

Therapeutic or pharmaceutical compositions of the invention, may also be administered to treat, prevent, or ameliorate organ rejection or graft-versus-host disease (GVHD) and/or conditions associated therewith. Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of antibodies of the invention, that

inhibit an immune response, may be an effective therapy in preventing organ rejection or GVHD.

In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate a disease or disorder diseases associated with increased apoptosis including, but not limited to, AIDS, neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration), myelodysplastic syndromes (such as aplastic anemia), ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia. In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate bone marrow failure, for example, aplastic anemia and myelodysplastic syndrome.

In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate growth, progression, and/or metastases of malignancies and proliferative disorders associated with increased cell survival, or the inhibition of apoptosis. Examples of such disorders, include, but are not limited to, leukemia (e.g., acute leukemia such as acute lymphocytic leukemia and acute myelocytic leukemia), neoplasms, tumors (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma), heavy chain disease, metastases, or any disease or disorder characterized by uncontrolled cell growth.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used to treat or prevent a disorder characterized by hypergammaglobulinemia (e.g., AIDS, autoimmune diseases, and some immunodeficiencies).

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used to treat or prevent a disorder characterized by deficient serum immunoglobulin production, recurrent infections, and/or immune system dysfunction. Moreover, therapeutic or pharmaceutical compositions of the invention may be used to treat or prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL, recurrent bronchi-

tis, sinusitis, otitis media, conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes zoster), and/or *pneumocystis carinii*.

Therapeutic or pharmaceutical compositions of the invention of the invention thereof, may be used to diagnose, prognose, treat or prevent one or more of the following diseases or disorders, or conditions associated therewith: primary immunodeficiencies, immune-mediated thrombocytopenia, Kawasaki syndrome, bone marrow transplant (e.g., recent bone marrow transplant in adults or children), chronic B-cell lymphocytic leukemia, HIV infection (e.g., adult or pediatric HIV infection), chronic inflammatory demyelinating polyneuropathy, and post-transfusion purpura.

Additionally, therapeutic or pharmaceutical compositions of the invention may be used to diagnose, prognose, treat or prevent one or more of the following diseases, disorders, or conditions associated therewith, Guillain-Barre syndrome, anemia (e.g., anemia associated with parvovirus B19, patients with stable multiple myeloma who are at high risk for infection (e.g., recurrent infection), autoimmune hemolytic anemia (e.g., warm-type autoimmune hemolytic anemia), thrombocytopenia (e.g., neonatal thrombocytopenia), and immune-mediated neutropenia), transplantation (e.g., cytomegalovirus (CMV)-negative recipients of CMV-positive organs), hypogammaglobulinemia (e.g., hypogammaglobulinemic neonates with risk factor for infection or morbidity), epilepsy (e.g., intractable epilepsy), systemic vasculitic syndromes, myasthenia gravis (e.g., decompensation in myasthenia gravis), dermatomyositis, and polymyositis.

Additional preferred embodiments of the invention include, but are not limited to, the use of therapeutic or pharmaceutical compositions of the invention in the following applications:

Administration to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response. In a specific nonexclusive embodiment, therapeutic or pharmaceutical compositions of the invention are administered to boost the immune system to produce increased quantities of IgG. In another specific nonexclusive embodiment, antibodies of the invention are administered to boost the immune system to produce increased quantities of IgA. In another specific nonexclusive embodiment, antibodies of the invention are administered to boost the immune system to produce increased quantities of IgM.

Administration to an animal (including, but not limited to, those listed above, and also including transgenic animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. WO98/24893, WO/9634096, WO/9633735, and WO/9110741).

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a vaccine adjuvant that enhances immune responsiveness to specific antigen. In a specific embodiment, the vaccine is an antibody described herein. In another specific embodiment, the vaccine adjuvant is a polynucleotide described herein (e.g., an antibody polynucleotide genetic vaccine adjuvant). As discussed herein, therapeutic or pharmaceutical compositions of the

invention may be administered using techniques known in the art, including but not limited to, liposomal delivery, recombinant vector delivery, injection of naked DNA, and gene gun delivery.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an adjuvant to enhance tumor-specific immune responses.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an adjuvant, include, but are not limited to, virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: HIV/AIDS, Respiratory syncytial virus, Dengue, Rotavirus, Japanese B encephalitis, Influenza A and B, Parainfluenza, Measles, Cytomegalovirus, Rabies, Junin, Chikungunya, Rift Valley fever, Herpes simplex, and yellow fever. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to the HIV gp120 antigen.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as an adjuvant, include bacteria or fungus and bacteria or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: *Vibrio cholerae*, *Mycobacterium leprae*, *Salmonella typhi*, *Salmonella paratyphi*, *Neisseria meningitidis*, *Streptococcus pneumoniae*, Group B streptococcus, *Shigella* spp., Enterotoxigenic *Escherichia coli*, Enterohemorrhagic *E. coli*, *Borrelia burgdorferi*, and *Plasmodium* (malaria).

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an adjuvant to enhance anti-parasitic immune responses. Anti-parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to *Plasmodium* (malaria).

In a specific embodiment, compositions of the invention may be administered to patients as vaccine adjuvants. In a further specific embodiment, compositions of the invention may be administered as vaccine adjuvants to patients suffering from an immune-deficiency. In a further specific

embodiment, compositions of the invention may be administered as vaccine adjuvants to patients suffering from HIV.

In a specific embodiment, compositions of the invention may be used to increase or enhance antigen-specific antibody responses to standard and experimental vaccines. In a specific embodiment, compositions of the invention may be used to enhance seroconversion in patients treated with standard and experimental vaccines. In another specific embodiment, compositions of the invention may be used to increase the repertoire of antibodies recognizing unique epitopes in response to standard and experimental vaccination.

In a preferred embodiment, antibodies of the invention (including antibody fragments and variants, and anti-antibody antibodies) increase or enhance antigen-specific antibody responses to standard and experimental vaccines by regulating binding of the soluble form of B Lymphocyte Stimulator to a B Lymphocyte Stimulator receptor (e.g., BCMA and TACI). In another preferred embodiment, antibodies of the invention (including antibody fragments and variants, and anti-antibody antibodies) increase or enhance antigen-specific antibody responses to standard and experimental vaccines by regulating binding of the soluble form of APRIL to an APRIL receptor (e.g., BCMA and TACI).

In a preferred embodiment, antibodies of the invention (including antibody fragments and variants, and anti-antibody antibodies) increase or enhance seroconversion in patients treated with standard and experimental vaccines by regulating binding of the soluble form of B Lymphocyte Stimulator to B Lymphocyte Stimulator receptor (e.g., BCMA and TACI). In another preferred embodiment, antibodies of the invention (including antibody fragments and variants, and anti-antibody antibodies) increase or enhance seroconversion in patients treated with standard and experimental vaccines by regulating binding of the soluble form of APRIL to an APRIL receptor (e.g., BCMA and TACI).

In a preferred embodiment, antibodies of the invention (including antibody fragments and variants, and anti-antibody antibodies) increase or enhance the repertoire of antibodies recognizing unique epitopes in response to standard and experimental vaccination by regulating binding of the soluble form of B Lymphocyte Stimulator to a B Lymphocyte Stimulator receptor (e.g., BCMA and TACI). In another preferred embodiment, antibodies of the invention (including antibody fragments and variants, and anti-antibody antibodies) increase or enhance the repertoire of antibodies recognizing unique epitopes in response to standard and experimental vaccination by regulating binding of the soluble form of APRIL to an APRIL receptor (e.g., BCMA and TACI).

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a stimulator of B cell responsiveness to pathogens.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent that elevates the immune status of an individual prior to their receipt of immunosuppressive therapies.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent to induce higher affinity antibodies.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent to increase serum immunoglobulin concentrations.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent to accelerate recovery of immunocompromised individuals.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent to boost immunoresponsiveness among aged populations.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an immune system enhancer prior to, during, or after bone marrow transplant and/or other transplants (e.g., allogeneic or xenogeneic organ transplantation). With respect to transplantation, compositions of the invention may be administered prior to, concomitant with, and/or after transplantation. In a specific embodiment, compositions of the invention are administered after transplantation, prior to the beginning of recovery of T-cell populations. In another specific embodiment, compositions of the invention are first administered after transplantation after the beginning of recovery of T cell populations, but prior to full recovery of B cell populations.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete splenectomy. B cell immunodeficiencies that may be ameliorated or treated by administering the antibodies and/or compositions of the invention include, but are not limited to, severe combined immunodeficiency (SCID)-X linked, SCID-autosomal, adenosine deaminase deficiency (ADA deficiency), X-linked agammaglobulinemia (XLA), Bruton's disease, congenital agammaglobulinemia, X-linked infantile agammaglobulinemia, acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, transient hypogammaglobulinemia of infancy, unspecified hypogammaglobulinemia, agammaglobulinemia, common variable immunodeficiency (CVID) (acquired), Wiskott-Aldrich Syndrome (WAS), X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, selective IgA deficiency, IgG subclass deficiency (with or without IgA deficiency), antibody deficiency with normal or elevated Igs, immunodeficiency with thymoma, Ig heavy chain deletions, kappa chain deficiency, B cell lymphoproliferative disorder (BLPD), selective IgM immunodeficiency, recessive agammaglobulinemia (Swiss type), reticular dysgenesis, neonatal neutropenia, severe congenital leukopenia, thymic aplasia/aplasia or dysplasia with immunodeficiency, ataxia-telangiectasia, short limbed dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof syndrome-combined immunodeficiency with Igs, purine nucleoside phosphorylase deficiency (PNP), MHC Class II deficiency (Bare Lymphocyte Syndrome) and severe combined immunodeficiency.

In a specific embodiment, antibodies and/or compositions of the invention are administered to treat or ameliorate selective IgA deficiency.

In another specific embodiment, antibodies and/or compositions of the invention are administered to treat or ameliorate ataxia-telangiectasia.

In another specific embodiment antibodies and/or compositions of the invention are administered to treat or ameliorate common variable immunodeficiency.

In another specific embodiment, antibodies and/or compositions of the invention are administered to treat or ameliorate X-linked agammaglobulinemia.

In another specific embodiment, antibodies and/or compositions of the invention are administered to treat or ameliorate severe combined immunodeficiency (SCID).

In another specific embodiment, antibodies and/or compositions of the invention are administered to treat or ameliorate Wiskott-Aldrich syndrome.

In another specific embodiment, antibodies and/or compositions of the invention are administered to treat or ameliorate X-linked Ig deficiency with hyper IgM.

As an agent to boost immunoresponsiveness among individuals having an acquired loss of B cell function. Conditions resulting in an acquired loss of B cell function that may be ameliorated or treated by administering antibodies and/or compositions of the invention include, but are not limited to, HIV Infection, AIDS, bone marrow transplant, and B cell chronic lymphocytic leukemia (CLL).

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent to boost immunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune deficiency that may be ameliorated or treated by administering antibodies and/or compositions of the invention include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, recovery from surgery.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a regulator of antigen presentation by monocytes, dendritic cells, T cells and/or B-cells. In one embodiment, antibody polypeptides or polynucleotides enhance antigen presentation or antagonize antigen presentation in vitro or in vivo. Moreover, in related embodiments, this enhancement or antagonization of antigen presentation may be useful in anti-tumor treatment or to modulate the immune system.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a mediator of mucosal immune responses. The expression of B Lymphocyte Stimulator on monocytes, the expression of B Lymphocyte Stimulator receptor on B cells, and the responsiveness of B cells to B Lymphocyte Stimulator suggests that it may be involved in exchange of signals between B cells and monocytes or their differentiated progeny. This activity is in many ways analogous to the CD40-CD154 signalling between B cells and T cells. Anti-B Lymphocyte Stimulator antibodies and compositions of the invention may therefore be good regulators of T cell independent immune responses to environmental pathogens. In particular, the unconventional B cell populations (CD5+) that are associated with mucosal sites and responsible for much of the innate immunity in humans may respond to antibodies or compositions of the invention thereby enhancing or inhibiting individual's immune status.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an agent to direct an individual's immune system towards development of a humoral response (i.e. TH2) as opposed to a TH1 cellular response.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to virtually all anti-neoplastic regimens. If these cells were forced to proliferate more rapidly, their susceptibility profile would likely change.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a monocyte cell specific binding protein to which specific activators or

inhibitors of cell growth may be attached. The result would be to focus the activity of such activators or inhibitors onto normal, diseased, or neoplastic B cell populations.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a B cell specific binding protein to which specific activators or inhibitors of cell growth may be attached. The result would be to focus the activity of such activators or inhibitors onto normal, diseased, or neoplastic B cell populations.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a means of detecting monocytic cells by virtue of its specificity. This application may require labeling the protein with biotin or other agents (e.g., as described herein) to afford a means of detection.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a means of detecting B-lineage cells by virtue of its specificity. This application may require labeling the protein with biotin or other agents (e.g., as described herein) to afford a means of detection.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or Common Variable immunodeficiency.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as part of a monocyte selection device the function of which is to isolate monocytes from a heterogeneous mixture of cell types. Antibodies of the invention could be coupled to a solid support to which monocytes would then specifically bind. Unbound cells would be washed out and the bound cells subsequently eluted. A non-limiting use of this selection would be to allow purging of tumor cells from, for example, bone marrow or peripheral blood prior to transplant.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as part of a B cell selection device the function of which is to isolate B cells from a heterogeneous mixture of cell types. Antibodies of the invention (that do not inhibit B Lymphocyte Stimulator/B Lymphocyte Stimulator Receptor interaction) binding soluble B Lymphocyte Stimulator could be coupled to a solid support to which B cells would then specifically bind. Unbound cells would be washed out and the bound cells subsequently eluted. A non-limiting use of this selection would be to allow purging of tumor cells from, for example, bone marrow or peripheral blood prior to transplant.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic defect.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a gene-based therapy for genetically inherited disorders resulting in immuno-incompetence such as observed among SCID patients.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as an antigen for the generation of antibodies to inhibit or enhance B Lymphocyte Stimulator mediated responses.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a means of activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as *Leishmania*.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as pretreatment of

bone marrow samples prior to transplant. Such treatment would increase B cell representation and thus accelerate recovery.

In a specific embodiment, therapeutic or pharmaceutical compositions of the invention are used as a means of regulating secreted cytokines that are elicited by B Lymphocyte Stimulator and/or B Lymphocyte Stimulator receptor.

Antibody polypeptides or polynucleotides of the invention may be used to modulate IgE concentrations in vitro or in vivo.

Additionally, antibody polypeptides or polynucleotides of the invention may be used to treat, prevent, and/or diagnose IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema.

In a specific embodiment, antibody polypeptides or polynucleotides of the invention, are administered to treat, prevent, diagnose, and/or ameliorate selective IgA deficiency.

In another specific embodiment antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate ataxia-telangiectasia.

In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate common variable immunodeficiency.

In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate X-linked agammaglobulinemia.

In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate severe combined immunodeficiency (SCID).

In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate Wiskott-Aldrich syndrome.

In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate X-linked Ig deficiency with hyper IgM. In a specific embodiment antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate X-linked Ig deficiency with hyper IgM.

In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, and/or diagnose chronic myelogenous leukemia, acute myelogenous leukemia, leukemia, histiocytic leukemia, monocytic leukemia (e.g., acute monocytic leukemia), leukemic reticulosis, Shilling Type monocytic leukemia, and/or other leukemias derived from monocytes and/or monocytic cells and/or tissues.

In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate monocytic leukemoid reaction, as seen, for example, with tuberculosis.

In another specific embodiment, antibody polypeptides or polynucleotides of the invention are administered to treat, prevent, diagnose, and/or ameliorate monocytic leukocytosis, monocytic leukopenia, monocytopenia, and/or monocytosis.

In a specific embodiment, antibody polypeptides or polynucleotides of the invention are used to treat, prevent, detect, and/or diagnose monocyte disorders and/or diseases, and/or conditions associated therewith.

In a specific embodiment, antibody polypeptides or polynucleotides of the invention are used to treat, prevent, detect, and/or diagnose primary B lymphocyte disorders and/or diseases, and/or conditions associated therewith. In one embodiment, such primary B lymphocyte disorders, diseases, and/or conditions are characterized by a complete or partial loss of humoral immunity. Primary B lymphocyte disorders, diseases, and/or conditions associated therewith that are characterized by a complete or partial loss of humoral immunity and that may be prevented, treated, detected and/or diagnosed with compositions of the invention include, but are not limited to, X-Linked Agammaglobulinemia (XLA), severe combined immunodeficiency disease (SCID), and selective IgA deficiency.

In a preferred embodiment antibody polypeptides or polynucleotides of the invention are used to treat, prevent, and/or diagnose diseases or disorders affecting or conditions associated with any one or more of the various mucous membranes of the body. Such diseases or disorders include, but are not limited to, for example, mucositis, mucoclasia, mucocolitis, mucocutaneous leishmaniasis (such as, for example, American leishmaniasis, leishmaniasis americana, nasopharyngeal leishmaniasis, and New World leishmaniasis), mucocutaneous lymph node syndrome (for example, Kawasaki disease), mucoenteritis, mucoepidermoid carcinoma, mucoepidermoid tumor, mucoepithelial dysplasia, mucoid adenocarcinoma, mucoid degeneration, myxoid degeneration; myxomatous degeneration; myxomatosis, mucoid medial degeneration (for example, cystic medial necrosis), mucopolipidosis (including, for example, mucopolipidosis I, mucopolipidosis II, mucopolipidosis III, and mucopolipidosis IV), mucolysis disorders, mucomembranous enteritis, mucoenteritis, mucopolysaccharidosis (such as, for example, type I mucopolysaccharidosis (i.e., Hurler's syndrome), type IS mucopolysaccharidosis (i.e., Scheie's syndrome or type V mucopolysaccharidosis), type II mucopolysaccharidosis (i.e., Hunter's syndrome), type III mucopolysaccharidosis (i.e., Sanfilippo's syndrome), type IV mucopolysaccharidosis (i.e., Morquio's syndrome), type VI mucopolysaccharidosis (i.e., Maroteaux-Lamy syndrome), type VII mucopolysaccharidosis (i.e., mucopolysaccharidosis due to beta-glucuronidase deficiency), and mucosulfatidosis), mucopolysacchariduria, mucopurulent conjunctivitis, mucopus, mucormycosis (i.e., zygomycosis), mucosal disease (i.e., bovine virus diarrhea), mucous colitis (such as, for example, mucocolitis and myxomembranous colitis), and mucoviscidosis (such as, for example, cystic fibrosis, cystic fibrosis of the pancreas, Clarke-Hadfield syndrome, fibrocystic disease of the pancreas, mucoviscidosis, and viscidosis). In a highly preferred embodiment, antibody polypeptides or polynucleotides of the invention are used to treat, prevent, and/or diagnose mucositis, especially as associated with chemotherapy.

In a preferred embodiment, antibody polypeptides or polynucleotides of the invention are used to treat, prevent, and/or diagnose diseases or disorders affecting or conditions associated with sinusitis.

An additional condition, disease or symptom that can be treated, prevented, and/or diagnosed by antibody polypeptides or polynucleotides of the invention is osteomyelitis.

An additional condition, disease or symptom that can be treated, prevented, and/or diagnosed by antibody polypeptides or polynucleotides of the invention is endocarditis.

All of the above described applications as they may apply to veterinary medicine.

Antibody polypeptides or polynucleotides of the invention may be used to treat, prevent, and/or diagnose diseases

and disorders of the pulmonary system (e.g., bronchi such as, for example, sinopulmonary and bronchial infections and conditions associated with such diseases and disorders and other respiratory diseases and disorders. In specific embodiments, such diseases and disorders include, but are not limited to, bronchial adenoma, bronchial asthma, pneumonia (such as, e.g., bronchial pneumonia, bronchopneumonia, and tuberculous bronchopneumonia), chronic obstructive pulmonary disease (COPD), bronchial polyps, bronchiectasia (such as, e.g., bronchiectasia sicca, cylindrical bronchiectasis, and saccular bronchiectasis), bronchiolar adenocarcinoma, bronchiolar carcinoma, bronchiolitis (such as, e.g., exudative bronchiolitis, bronchiolitis fibrosa obliterans, and proliferative bronchiolitis), bronchiolo-alveolar carcinoma, bronchitic asthma, bronchitis (such as, e.g., asthmatic bronchitis, Castellani's bronchitis, chronic bronchitis, croupous bronchitis, fibrinous bronchitis, hemorrhagic bronchitis, infectious avian bronchitis, obliterative bronchitis, plastic bronchitis, pseudomembranous bronchitis, putrid bronchitis, and verminous bronchitis), bronchocentric granulomatosis, bronchoedema, bronchoesophageal fistula, bronchogenic carcinoma, bronchogenic cyst, bronchiolithiasis, bronchomalacia, bronchomycosis (such as, e.g., bronchopulmonary aspergillosis), bronchopulmonary spirochetosis, hemorrhagic bronchitis, bronchorrhea, bronchospasm, bronchostaxis, bronchostenosis, Biot's respiration, bronchial respiration, Kussmaul respiration, Kussmaul-Kien respiration, respiratory acidosis, respiratory alkalosis, respiratory distress syndrome of the newborn, respiratory insufficiency, respiratory scleroma, respiratory syncytial virus, and the like.

In a specific embodiment, antibody polypeptides or polynucleotides of the invention are used to treat, prevent, and/or diagnose chronic obstructive pulmonary disease (COPD).

In another embodiment, antibody polypeptides or polynucleotides of the invention are used to treat, prevent, and/or diagnose fibroses and conditions associated with fibroses, including, but not limited to, cystic fibrosis (including such fibroses as cystic fibrosis of the pancreas, Clarke-Hadfield syndrome, fibrocystic disease of the pancreas, mucoviscidosis, and viscidosis), endomyocardial fibrosis, idiopathic retroperitoneal fibrosis, leptomeningeal fibrosis, mediastinal fibrosis, nodular subepidermal fibrosis, pericentral fibrosis, perimuscular fibrosis, pipestem fibrosis, replacement fibrosis, subadventitial fibrosis, and Symmers' clay pipestem fibrosis.

In another embodiment, therapeutic or pharmaceutical compositions of the invention are administered to an animal to treat, prevent or ameliorate infectious diseases. Infectious diseases include diseases associated with yeast, fungal, viral and bacterial infections. Viruses causing viral infections which can be treated or prevented in accordance with this invention include, but are not limited to, retroviruses (e.g., human T-cell lymphotropic virus (HTLV) types I and II and human immunodeficiency virus (HIV)), herpes viruses (e.g., herpes simplex virus (HSV) types I and II, Epstein-Barr virus, HHV6-HHV8, and cytomegalovirus), arenaviruses (e.g., lassa fever virus), paramyxoviruses (e.g., morbillivirus virus, human respiratory syncytial virus, mumps, and pneumovirus), adenoviruses, bunyaviruses (e.g., hantavirus), coronaviruses, filoviruses (e.g., Ebola virus), flaviviruses (e.g., hepatitis C virus (HCV), yellow fever virus, and Japanese encephalitis virus), hepadnaviruses (e.g., hepatitis B viruses (HBV)), orthomyxoviruses (e.g., influenza viruses A, B and C), papovaviruses (e.g., papillomaviruses), picornaviruses (e.g., rhinoviruses, enteroviruses and hepatitis A viruses), poxviruses, reoviruses (e.g., rotaviruses), togaviruses (e.g.,

rubella virus), rhabdoviruses (e.g., rabies virus). Microbial pathogens causing bacterial infections include, but are not limited to, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Neisseria gonorrhoea*, *Neisseria meningitidis*, *Corynebacterium diphtheriae*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium tetani*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella ozaenae*, *Klebsiella rhinoscleromatis*, *Staphylococcus aureus*, *Vibrio cholerae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Campylobacter* (Vibrio) fetus, *Campylobacter jejuni*, *Aeromonas hydrophila*, *Bacillus cereus*, *Edwardsiella tarda*, *Yersinia enterocolitica*, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Salmonella typhimurium*, *Treponema pallidum*, *Treponema pertenuis*, *Treponema carateneum*, *Borrelia vincentii*, *Borrelia burgdorferi*, *Leptospira icterohemorrhagiae*, *Mycobacterium tuberculosis*, *Toxoplasma gondii*, *Pneumocystis carinii*, *Francisella tularensis*, *Brucella abortus*, *Brucella suis*, *Brucella melitensis*, *Mycoplasma* spp., *Rickettsia prowazeki*, *Rickettsia tsutsugumushi*, *Chlamydia* spp., and *Helicobacter pylori*.

Gene Therapy

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of B Lymphocyte Stimulator and/or its receptor, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., *Clinical Pharmacy* 12:488-505 (1993); Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, *TIBTECH* 11(5): 155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); and Kriegler, *Gene Transfer and Expression*, A Laboratory Manual, Stockton Press, NY (1990).

In a preferred aspect, a composition of the invention comprises, or alternatively consists of, nucleic acids encoding an antibody, said nucleic acids being part of an expression vector that expresses the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acids have promoters, preferably heterologous promoters, operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); Zijlstra et al., *Nature* 342: 435-438 (1989). In specific embodiments, the expressed antibody molecule is an scFv; alternatively, the nucleic acid

sequences include sequences encoding both the heavy and light chains, or fragments or variants thereof, of an antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Pat. No. 4,980, 286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); Zijlstra et al., *Nature* 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention or fragments or variants thereof are used. For example, a retroviral vector can be used (see Miller et al., *Meth. Enzymol.* 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr 1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., *J. Clin. Invest.* 93:644-651 (1994); Klein et al., *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable

of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143-155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Pat. No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen et al., *Meth. Enzymol.* 217:618-644 (1993); *Clin. Pharma. Ther.* 29:69-92m (1985)) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody or fragment thereof are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can

be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

Demonstration of Therapeutic or Prophylactic Utility of a Composition

The compounds of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays which can be used to determine whether administration of a specific antibody or composition of the present invention is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered an antibody or composition of the present invention, and the effect of such an antibody or composition of the present invention upon the tissue sample is observed. In various specific embodiments, in vitro assays can be carried out with representative cells of cell types involved in a patient's disorder, to determine if an antibody or composition of the present invention has a desired effect upon such cell types. Preferably, the antibodies or compositions of the invention are also tested in in vitro assays and animal model systems prior to administration to humans.

Antibodies or compositions of the present invention for use in therapy can be tested for their toxicity in suitable animal model systems, including but not limited to rats, mice, chicken, cows, monkeys, and rabbits. For in vivo testing of an antibody or composition's toxicity any animal model system known in the art may be used.

Efficacy in treating or preventing viral infection may be demonstrated by detecting the ability of an antibody or composition of the invention to inhibit the replication of the virus, to inhibit transmission or prevent the virus from establishing itself in its host, or to prevent, ameliorate or alleviate the symptoms of disease a progression. The treatment is considered therapeutic if there is, for example, a reduction in viral load, amelioration of one or more symptoms, or a decrease in mortality and/or morbidity following administration of an antibody or composition of the invention.

Antibodies or compositions of the invention can be tested for the ability to induce the expression of cytokines such as IFN- γ , by contacting cells, preferably human cells, with an antibody or composition of the invention or a control antibody or control composition and determining the ability of the antibody or composition of the invention to induce one or more cytokines. Techniques known to those of skill in the art can be used to measure the level of expression of cytokines. For example, the level of expression of cytokines can be measured by analyzing the level of RNA of cytokines by, for example, RT-PCR and Northern blot analysis, and by analyzing the level of cytokines by, for example, immunoprecipitation followed by western blot analysis and ELISA. In a preferred embodiment, a compound of the invention is tested for its ability to induce the expression of IFN- γ .

Antibodies or compositions of the invention can be tested for their ability to modulate the biological activity of

immune cells by contacting immune cells, preferably human immune cells (e.g., T-cells, B-cells, and Natural Killer cells), with an antibody or composition of the invention or a control compound and determining the ability of the antibody or composition of the invention to modulate (i.e., increase or decrease) the biological activity of immune cells. The ability of an antibody or composition of the invention to modulate the biological activity of immune cells can be assessed by detecting the expression of antigens, detecting the proliferation of immune cells (i.e., B-cell proliferation), detecting the activation of signaling molecules, detecting the effector function of immune cells, or detecting the differentiation of immune cells. Techniques known to those of skill in the art can be used for measuring these activities. For example, cellular proliferation can be assayed by ^3H -thymidine incorporation assays and trypan blue cell counts. Antigen expression can be assayed, for example, by immunoassays including, but not limited to, competitive and non-competitive assay systems using techniques such as western blots, immunohistochemistry radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays and FACS analysis. The activation of signaling molecules can be assayed, for example, by kinase assays and electrophoretic shift assays (EMSAs). In a preferred embodiment, the ability of an antibody or composition of the invention to induce B-cell proliferation is measured. In another preferred embodiment, the ability of an antibody or composition of the invention to modulate immunoglobulin expression is measured.

Antibodies or compositions of the invention can be tested for their ability to reduce tumor formation in in vitro, ex vivo and in vivo assays. Antibodies or compositions of the invention can also be tested for their ability to inhibit viral replication or reduce viral load in in vitro and in vivo assays. Antibodies or compositions of the invention can also be tested for their ability to reduce bacterial numbers in in vitro and in vivo assays known to those of skill in the art. Antibodies or compositions of the invention can also be tested for their ability to alleviate one or more symptoms associated with cancer, an immune disorder (e.g., an inflammatory disease), a neurological disorder or an infectious disease. Antibodies or compositions of the invention can also be tested for their ability to decrease the time course of the infectious disease. Further, antibodies or compositions of the invention can be tested for their ability to increase the survival period of animals suffering from disease or disorder, including cancer, an immune disorder or an infectious disease. Techniques known to those of skill in the art can be used to analyze the function of the antibodies or compositions of the invention in vivo.

Therapeutic/Prophylactic Compositions and Administration

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of antibody (or fragment or variant thereof) or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, an antibody or fragment or variant thereof is substantially purified (i.e., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to, animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably a human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer antibody or fragment or variant thereof of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the antibody or antibody fragment, receptor-mediated endocytosis (see, e.g., Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the composition can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*).

In yet another embodiment, the composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Rev. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Press, Boca Raton, Fla. (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the composition of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Pat. No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see e.g., Joliet et al., *Proc. Natl. Acad. Sci. USA* 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of an antibody or a fragment thereof, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin. Such compositions will contain a therapeutically effective amount of the antibody or fragment thereof, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized

powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The amount of the composition of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of therapeutic or pharmaceutical compositions of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The antibodies and antibody compositions of the invention may be administered alone or in combination with other adjuvants. Adjuvants that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, antibody and antibody compositions of the invention are administered in combination with alum. In another specific embodiment, antibody and antibody compositions of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, Adju Vax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, *haemophilus influenzae* B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow

fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis, and/or PNEUMOVAX-23™. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

In another specific embodiment, antibody and antibody compositions of the invention are used in combination with PNEUMOVAX-23™ to treat, prevent, and/or diagnose infection and/or any disease, disorder, and/or condition associated therewith. In one embodiment, antibody and antibody compositions of the invention are used in combination with PNEUMOVAX-23™ to treat, prevent, and/or diagnose any Gram positive bacterial infection and/or any disease, disorder, and/or condition associated therewith. In another embodiment, antibody and antibody compositions of the invention are used in combination with PNEUMOVAX-23™ to treat, prevent, and/or diagnose infection and/or any disease, disorder, and/or condition associated with one or more members of the genus *Enterococcus* and/or the genus *Streptococcus*. In another embodiment, antibody and antibody compositions of the invention are used in any combination with PNEUMOVAX-23™ to treat, prevent, and/or diagnose infection and/or any disease, disorder, and/or condition associated with one or more members of the Group B streptococci. In another embodiment, antibody and antibody compositions of the invention are used in combination with PNEUMOVAX-23™ to treat, prevent, and/or diagnose infection and/or any disease, disorder, and/or condition associated with *Streptococcus pneumoniae*.

The antibody and antibody compositions of the invention may be administered alone or in combination with other therapeutic agents, including but not limited to, chemotherapeutic agents, antibiotics, antivirals, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents and cytokines. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

In one embodiment, the antibody and antibody compositions of the invention are administered in combination with other members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), TRAIL, AIM-II (International Publication No. WO 97/34911), APRIL (J. Exp. Med. 188(6):1185-1190 (1998)), endokine-alpha (International Publication No. WO 98/07880), Neutrokin-alpha (International Application Publication No. WO 98/18921), OPG, OX40, and nerve

growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

In a preferred embodiment, the antibody and antibody compositions of the invention are administered in combination with CD40 ligand (CD40L), a soluble form of CD40L (e.g., AVREND™), biologically active fragments, variants, or derivatives of CD40L, anti-CD40 antibodies (e.g., agonistic or antagonistic antibodies), and/or anti-CD40 antibodies (e.g., agonistic or antagonistic antibodies).

In an additional embodiment, the antibody and antibody compositions of the invention are administered alone or in combination with an anti-angiogenic agent(s). Anti-angiogenic agents that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, Angiostatin (Entremed, Rockville, Md.), Tropolin-1 (Boston Life Sciences, Boston, Mass.), anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel (Taxol), Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, VEGI, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include, but are not limited to, platelet factor 4; protamine sulphate; sulphated chitin

derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP-PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2 (3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; (Takeuchi et al., Agents Actions 36:312-316, 1992); and metalloproteinase inhibitors such as BB94.

Additional anti-angiogenic factors that may also be utilized within the context of the present invention include Thalidomide, (Celgene, Warren, N.J.); Angiostatic steroid; AGM-1470 (H. Brem and J. Folkman *J. Pediatr. Surg.* 28:445-51 (1993)); an integrin alpha v beta 3 antagonist (C. Storgard et al., *J. Clin. Invest.* 103:47-54 (1999)); carboxyaminoimidazole; Carboxyamidotriazole (CAI) (National Cancer Institute, Bethesda, Md.); Conbretastatin A-4 (CA4P) (OXIGENE, Boston, Mass.); Squalamine (Magain Pharmaceuticals, Plymouth Meeting, Pa.); TNP-470, (Tap Pharmaceuticals, Deerfield, Ill.); ZD-0101 AstraZeneca (London, UK); APRA (CT2584); Benefin, Byrostatin-1 (SC339555); CGP-41251 (PKC 412); CM101; Dextrazoxane (ICRF187); DMXAA; Endostatin; Flavopridiol; Genestein; GTE; ImmTher; Iressa (ZD1839); Octreotide (Somatostatin); Panretin; Penacillamine; Photopoint; PI-88; Prinomastat (AG-3340) Purytin; Suradista (FCE26644); Tamoxifen (Nolvadex); Tazarotene; Tetrathiomolybdate; Xeloda (Capecitabine); and 5-Fluorouracil.

Anti-angiogenic agents that may be administered in combination with the compounds of the invention may work through a variety of mechanisms including, but not limited to, inhibiting proteolysis of the extracellular matrix, blocking the function of endothelial cell-extracellular matrix adhesion molecules, by antagonizing the function of angiogenesis inducers such as growth factors, and inhibiting integrin receptors expressed on proliferating endothelial cells. Examples of anti-angiogenic inhibitors that interfere with extracellular matrix proteolysis and which may be administered in combination with the antibody and antibody compositions of the invention include, but are not limited to, AG-3340 (Agouron, La Jolla, Calif.), BAY-12-9566 (Bayer, West Haven, Conn.), BMS-275291 (Bristol Myers Squibb, Princeton, N.J.), CGS-27032A (Novartis, East Hanover, N.J.), Marimastat (British Biotech, Oxford, UK), and Metastat (Aeterna, St-Foy, Quebec). Examples of anti-angiogenic inhibitors that act by blocking the function of endothelial cell-extracellular matrix adhesion molecules and which may be administered in combination with the antibody and antibody compositions of the invention include, but are not limited to, EMD-121974 (Merck KgaA Darmstadt, Germany) and Vitaxin (Ixsys, La Jolla, Calif./Medimmune, Gaithersburg, Md.). Examples of anti-angiogenic agents that act by directly antagonizing or inhibiting angiogenesis inducers and which may be administered in combi-

nation with the antibody and antibody compositions of the invention include, but are not limited to, Angiozyme (Ribozyme, Boulder, Colo.), Anti-VEGF antibody (Genentech, S. San Francisco, Calif.), PTK-787/ZK-225846 (Novartis, Basel, Switzerland), SU-101 (Sugen, S. San Francisco, Calif.), SU-5416 (Sugen/Pharmacia Upjohn, Bridgewater, N.J.), and SU-6668 (Sugen). Other anti-angiogenic agents act to indirectly inhibit angiogenesis. Examples of indirect inhibitors of angiogenesis which may be administered in combination with the antibody and antibody compositions of the invention include, but are not limited to, IM-862 (Cytran, Kirkland, Wash.), Interferon-alpha, IL-12 (Roche, Nutley, N.J.), and Pentosan polysulfate (Georgetown University, Washington, D.C.).

In particular embodiments, the use of antibody and antibody compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of an autoimmune disease, such as for example, an autoimmune disease described herein.

In a particular embodiment, the use of antibody and antibody compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of arthritis. In a more particular embodiment, the use of antibody and antibody compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of rheumatoid arthritis.

In another embodiment, antibody and antibody compositions of the invention are administered in combination with an anticoagulant. Anticoagulants that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, heparin, warfarin, and aspirin. In a specific embodiment, antibody and antibody compositions of the invention are administered in combination with heparin and/or warfarin. In another specific embodiment, antibody and antibody compositions of the invention are administered in combination with warfarin. In another specific embodiment, antibody and antibody compositions of the invention are administered in combination with warfarin and aspirin. In another specific embodiment, antibody and antibody compositions of the invention are administered in combination with heparin. In another specific embodiment, antibody and antibody compositions of the invention are administered in combination with heparin and aspirin.

In another embodiment, antibody and antibody compositions of the invention are administered in combination with an agent that suppresses the production of anticardiolipin antibodies. In specific embodiments, the polynucleotides of the invention are administered in combination with an agent that blocks and/or reduces the ability of anticardiolipin antibodies to bind phospholipid-binding plasma protein beta 2-glycoprotein I (b2GPI).

In certain embodiments, antibody and antibody compositions of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination with the antibody and antibody compositions of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the antibody and antibody

compositions of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the antibody and antibody compositions of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with antibody and antibody compositions of the invention to treat, prevent, and/or diagnose AIDS and/or to treat, prevent, and/or diagnose HIV infection.

In other embodiments, antibody and antibody compositions of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the antibody and antibody compositions of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, antibody and antibody compositions of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat, prevent, and/or diagnose an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, antibody and antibody compositions of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat, prevent, and/or diagnose an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, antibody and antibody compositions of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat, prevent, and/or diagnose an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, antibody and antibody compositions of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat, prevent, and/or diagnose an opportunistic cytomegalovirus infection. In another specific embodiment, antibody and antibody compositions of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat, prevent, and/or diagnose an opportunistic fungal infection. In another specific embodiment, antibody and antibody compositions of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat, prevent, and/or diagnose an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, antibody and antibody compositions of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat, prevent, and/or diagnose an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, antibody and antibody compositions of the invention are used in any combination with

LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat, prevent, and/or diagnose an opportunistic bacterial infection.

In a further embodiment, the antibody and antibody compositions of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In a further embodiment, the antibody and antibody compositions of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, amoxicillin, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamethoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the antibody and antibody compositions of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs cyclophosphamide, cyclophosphamide IV, methylprednisolone, prednisolone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, antibody and antibody compositions of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™ (cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucocorticosteroids, and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In a preferred embodiment, the antibody and antibody compositions of the invention are administered in combination with steroid therapy. Steroids that may be administered in combination with the antibody and antibody compositions of the invention, include, but are not limited to, oral corticosteroids, prednisone, and methylprednisolone (e.g., IV methylprednisolone). In a specific embodiment, antibody and antibody compositions of the invention are administered in combination with prednisone. In a further specific embodiment, the antibody and antibody compositions of the invention are administered in combination with prednisone and an immunosuppressive agent. Immunosuppressive agents that may be administered with the antibody and antibody compositions of the invention and prednisone are those described herein, and include, but are not limited to, azathioprine, cyclophosphamide, and cyclophosphamide IV. In another specific embodiment, antibody and antibody compositions of the invention are administered in combination with methylprednisolone. In a further specific embodiment, the antibody and antibody compositions of the invention are administered in combination with methylprednisolone and an immunosuppressive agent. Immunosuppressive agents that may be administered with the antibody and antibody compositions of the invention and methylprednisolone are those described herein, and include, but are not limited to, azathioprine, cyclophosphamide, and cyclophosphamide IV.

In a preferred embodiment, the antibody and antibody compositions of the invention are administered in combination with an antimalarial. Antimalarials that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, hydroxychloroquine, chloroquine, and/or quinacrine.

In a preferred embodiment, the antibody and antibody compositions of the invention are administered in combination with an NSAID.

In a nonexclusive embodiment, the antibody and antibody compositions of the invention are administered in combination with one, two, three, four, five, ten, or more of the following drugs: NRD-101 (Hoechst Marion Roussel), diclofenac (Dimethaid), oxaprozin potassium (Monsanto), mecamermin (Chiron), T-614 (Toyama), pemetrexed disodium (Eli Lilly), atreleuton (Abbott), valdecoxib (Monsanto), eltenac (Byk Gulden), campath, AGM-1470 (Takeda), CDP-571 (Celltech Chiroscience), CM-101 (CarboMed), ML-3000 (Merckle), CB-2431 (KS Biomedix), CBF-BS2 (KS Biomedix), IL-1Ra gene therapy (Valentis), JTE-522 (Japan Tobacco), paclitaxel (Angiotech), DW-166HC (Dong Wha), darbufelone mesylate (Warner-Lambert), soluble TNF receptor 1 (synergen; Amgen), IPR-6001 (Institute for Pharmaceutical Research), trocade (Hoffman-La Roche), EF-5 (Scotia Pharmaceuticals), BIIL-284 (Boehringer Ingelheim), BIIF-1149 (Boehringer Ingelheim), Leuko Vax (Inflammatics), MK-663 (Merck), ST-1482 (Sigma-Tau), and butixocort propionate (WarnerLambert).

In a preferred embodiment, the antibody and antibody compositions of the invention are administered in combination with one, two, three, four, five or more of the following drugs: methotrexate, sulfasalazine, sodium aurothiomalate, auranofin, cyclosporine, penicillamine, azathioprine, an antimalarial drug (e.g., as described herein), cyclophosphamide, chlorambucil, gold, ENBREL™ (Etanercept), anti-TNF antibody, LJP 394 (La Jolla Pharmaceutical Company, San Diego, Calif.) and prednisolone.

In a more preferred embodiment, the antibody and antibody compositions of the invention are administered in combination with an antimalarial, methotrexate, anti-TNF antibody, ENBREL™ and/or sulfasalazine. In one embodiment, the antibody and antibody compositions of the invention are administered in combination with methotrexate. In another embodiment, the antibody and antibody compositions of the invention are administered in combination with anti-TNF antibody. In another embodiment, the antibody and antibody compositions of the invention are administered in combination with methotrexate and anti-TNF antibody. In another embodiment, the antibody and antibody compositions of the invention are administered in combination with sulfasalazine. In another specific embodiment, the antibody and antibody compositions of the invention are administered in combination with methotrexate, anti-TNF antibody, and sulfasalazine. In another embodiment, the antibody and antibody compositions of the invention are administered in combination with ENBREL™. In another embodiment, the antibody and antibody compositions of the invention are administered in combination with ENBREL™ and methotrexate. In another embodiment, the antibody and antibody compositions of the invention are administered in combination with ENBREL™, methotrexate and sulfasalazine. In another embodiment, the antibody and antibody compositions of the invention are administered in combination with ENBREL™, methotrexate and sulfasalazine. In other embodiments, one or more antimalarials is combined with one of the above-recited combinations. In a specific embodiment, the antibody and antibody compositions of the inven-

tion are administered in combination with an antimalarial (e.g., hydroxychloroquine), ENBREL™, methotrexate and sulfasalazine. In another specific embodiment, the antibody and antibody compositions of the invention are administered in combination with an antimalarial (e.g., hydroxychloroquine), sulfasalazine, anti-TNF antibody, and methotrexate.

In an additional embodiment, antibody and antibody compositions of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the antibody and antibody compositions of the invention include, but not limited to, GAMMART™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™. In a specific embodiment, antibody and antibody compositions of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

CD40 ligand (CD40L), a soluble form of CD40L (e.g., AVREND™), biologically active fragments, variants, or derivatives of CD40L, anti-CD40L antibodies (e.g., agonistic or antagonistic antibodies), and/or anti-CD40 antibodies (e.g., agonistic or antagonistic antibodies).

In an additional embodiment, the antibody and antibody compositions of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzylamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephallen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

In a specific embodiment, antibody and antibody compositions of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, antibody and antibody compositions of the invention are administered in combination

with Rituximab. In a further embodiment, antibody and antibody compositions of the invention are administered with Rituximab and CHOP, or Rituximab and any combination of the components of CHOP.

In an additional embodiment, the antibody and antibody compositions of the invention are administered in combination with cytokines. Cytokines that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, GM-CSF, G-CSF, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-alpha, IFN-beta, IFN-gamma, TNF-alpha, and TNF-beta. In preferred embodiments, antibody and antibody compositions of the invention are administered with B Lymphocyte Stimulator (e.g., amino acids 134-285 of SEQ ID NO:3228). In another embodiment, antibody and antibody compositions of the invention may be administered with any interleukin, including, but not limited to, IL-1 alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, and IL-22. In preferred embodiments, the antibody and antibody compositions of the invention are administered in combination with IL4 and IL10.

In one embodiment, the antibody and antibody compositions of the invention are administered in combination with one or more chemokines. In specific embodiments, the antibody and antibody compositions of the invention are administered in combination with an α (C×C) chemokine selected from the group consisting of gamma-interferon inducible protein-10 (γ IP-10), interleukin-8 (IL-8), platelet factor-4 (PF4), neutrophil activating protein (NAP-2), GRO- α , GRO- β , GRO- γ , neutrophil-activating peptide (ENA-78), granulocyte chemoattractant protein-2 (GCP-2), and stromal cell-derived factor-1 (SDF-1, or pre-B cell stimulatory factor (PBSF)); and/or a β (CC) chemokine selected from the group consisting of: RANTES (regulated on activation, normal T expressed and secreted), macrophage inflammatory protein-1 alpha (MIP-1 α), macrophage inflammatory protein-1 beta (MIP-1 β), monocyte chemotactic protein-1 (MCP-1), monocyte chemotactic protein-2 (MCP-2), monocyte chemotactic protein-3 (MCP-3), monocyte chemotactic protein-4 (MCP-4) macrophage inflammatory protein-1 gamma (MIP-1 γ), macrophage inflammatory protein-3 alpha (MIP-3 α), macrophage inflammatory protein-3 beta (MIP-3 β), macrophage inflammatory protein-4 (MIP-4/DC-CK-1/ PARC), eotaxin, Exodus, and I-309; and/or the γ (C) chemokine, lymphotactin.

In another embodiment, the antibody and antibody compositions of the invention are administered with chemokine beta-8, chemokine beta-1, and/or macrophage inflammatory protein-4. In a preferred embodiment, the antibody and antibody compositions of the invention are administered with chemokine beta-8.

In an additional embodiment, the antibody and antibody compositions of the invention are administered in combination with an IL-4 antagonist. IL-4 antagonists that may be administered with the antibody and antibody compositions of the invention include, but are not limited to: soluble IL-4 receptor polypeptides, multimeric forms of soluble IL-4 receptor polypeptides; anti-IL-4 receptor antibodies that bind the IL-4 receptor without transducing the biological signal elicited by IL-4, anti-IL4 antibodies that block binding of IL-4 to one or more IL-4 receptors, and muteins of IL-4 that bind IL-4 receptors but do not transduce the biological signal elicited by IL-4. Preferably, the antibodies employed according to this method are monoclonal antibodies (including antibody fragments, such as, for example, those described herein).

The invention also encompasses combining the polynucleotides and/or polypeptides of the invention (and/or agonists or antagonists thereof) with other proposed or conventional hematopoietic therapies. Thus, for example, the polynucleotides and/or polypeptides of the invention (and/or agonists or antagonists thereof) can be combined with compounds that singly exhibit erythropoietic stimulatory effects, such as erythropoietin, testosterone, progenitor cell stimulators, insulin-like growth factor, prostaglandins, serotonin, cyclic AMP, prolactin, and triiodothyronine. Also encompassed are combinations of the antibody and antibody compositions of the invention with compounds generally used to treat aplastic anemia, such as, for example, methenolene, stanozolol, and nandrolone; to treat iron-deficiency anemia, such as, for example, iron preparations; to treat malignant anemia, such as, for example, vitamin B₁₂ and/or folic acid; and to treat hemolytic anemia, such as, for example, adrenocortical steroids, e.g., corticoids. See e.g., Resegotti et al., *Panminerva Medica*, 23:243-248 (1981); Kurtz, *FEBS Letters*, 14a:105-108 (1982); McGonigle et al., *Kidney Int.*, 25:437-444 (1984); and Pavlovic-Kantera, *Expt. Hematol.*, 8(supp. 8) 283-291 (1980), the contents of each of which are hereby incorporated by reference in their entirety.

Compounds that enhance the effects of or synergize with erythropoietin are also useful as adjuvants herein, and include but are not limited to, adrenergic agonists, thyroid hormones, androgens, hepatic erythropoietic factors, erythropoietins, and erythrocytogens. See for e.g., Dunn, "Current Concepts in Erythropoiesis", John Wiley and Sons (Chichester, England, 1983); Kalmani, *Kidney Int.*, 22:383-391 (1982); Shahidi, *New Eng. J. Med.*, 289:72-80 (1973); Urabe et al., *J. Exp. Med.*, 149:1314-1325 (1979); Billat et al., *Expt. Hematol.*, 10:133-140 (1982); Naughton et al., *Acta Haemat.*, 69:171-179 (1983); Cognote et al. in abstract 364, *Proceedings 7th Intl. Cong. of Endocrinology* (Quebec City, Quebec, Jul. 1-7, 1984); and Rothman et al., 1982, *J. Surg. Oncol.*, 20:105-108 (1982). Methods for stimulating hematopoiesis comprise administering a hematopoietically effective amount (i.e., an amount which effects the formation of blood cells) of a pharmaceutical composition containing polynucleotides and/or polypeptides of the invention (and/or agonists or antagonists thereof) to a patient. The polynucleotides and/or polypeptides of the invention and/or agonists or antagonists thereof is administered to the patient by any suitable technique, including but not limited to, parenteral, sublingual, topical, intrapulmonary and intranasal, and those techniques further discussed herein. The pharmaceutical composition optionally contains one or more members of the group consisting of erythropoietin, testosterone, progenitor cell stimulators, insulin-like growth factor, prostaglandins, serotonin, cyclic AMP, prolactin, triiodothyronine, methenolene, stanozolol, and nandrolone, iron preparations, vitamin B₁₂, folic acid and/or adrenocortical steroids.

In an additional embodiment, the antibody and antibody compositions of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIN™) and NEUPOGEN™ (FILGRASTIN™).

In an additional embodiment, the antibody and antibody compositions of the invention are administered in combina-

tion with fibroblast growth factors. Fibroblast growth factors that may be administered with the antibody and antibody compositions of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

Additionally, the antibody and antibody compositions of the invention may be administered alone or in combination with other therapeutic regimens, including but not limited to, radiation therapy. Such combinatorial therapy may be administered sequentially and/or concomitantly.

Kits

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In an alternative embodiment, a kit comprises an antibody fragment that immunospecifically binds to B Lymphocyte Stimulator. In a specific embodiment, the kits of the present invention contain a substantially isolated B Lymphocyte Stimulator polypeptide as a control. Preferably, the kits of the present invention further comprise a control antibody which does not react with B Lymphocyte Stimulator. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to B Lymphocyte Stimulator (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized B Lymphocyte Stimulator. The B Lymphocyte Stimulator provided in the kit may also be attached to a solid support. In a more specific embodiment the detecting means of the above-described kit includes a solid support to which B Lymphocyte Stimulator is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to B Lymphocyte Stimulator can be detected by binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with B Lymphocyte Stimulator, and means for detecting the binding of B Lymphocyte Stimulator to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound B Lymphocyte

Stimulator obtained by the methods of the present invention. After B Lymphocyte Stimulator binds to a specific antibody, the unbound serum components are removed by washing, reporter-labeled anti-human antibody is added, unbound anti-human antibody is removed by washing, and a reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-B Lymphocyte Stimulator antibody on the solid support. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate.

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant B Lymphocyte Stimulator, and a reporter-labeled anti-human antibody for detecting surface-bound anti-B Lymphocyte Stimulator antibody.

In specific embodiments, the present invention encompasses a single chain Fv (scFv) having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the present invention encompasses a single chain Fv (scFv) having an amino acid sequence of one of SEQ ID NOS: 1 to 46, 321 to 329, 1563 to 1595, and 1881 to 1908.

In specific embodiments, the present invention encompasses a single chain Fv (scFv) having an amino acid sequence of one of SEQ ID NOS: 1563 to 1880.

In specific embodiments, the present invention encompasses a single chain Fv (scFv) having an amino acid sequence of one of SEQ ID NOS: 1881 to 2128.

In specific embodiments, the present invention encompasses a single chain Fv (scFv) having an amino acid sequence of one of SEQ ID NOS: 1 to 1562.

In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator.

In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 46, 321 to 329, 1563 to 1595, and 1881 to 1908.

In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1881 to 2128, and in which said antibody or fragment thereof immunospecifically binds to the membrane-bound form of B Lymphocyte Stimulator.

In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VH

domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1563 to 1880, and in which said antibody or fragment thereof immunospecifically binds to the soluble form of B Lymphocyte Stimulator.

In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator.

In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 46, 321 to 329, 1563 to 1595, and 1881 to 1908.

In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1881 to 2128, and in which said antibody or fragment thereof immunospecifically binds to the membrane-bound form of B Lymphocyte Stimulator.

In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1563 to 1880, and in which said antibody or fragment thereof immunospecifically binds to the soluble form of B Lymphocyte Stimulator.

In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator and which also comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator and which also comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, and in which said VL and said VH domains are derived from the same scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the present invention encompasses an antibody or fragment thereof comprising an amino acid sequence of one of SEQ ID NOS: 2129 to 3227 wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator.

In specific embodiments, the antibody or fragment thereof of the invention is a whole immunoglobulin molecule.

In specific embodiments, the antibody or fragment thereof of the invention is a Fab fragment.

In specific embodiments, the antibody or fragment thereof of the invention is a Fv fragment.

In specific embodiments, the present invention encompasses a chimeric protein comprising the antibody or fragment thereof of the invention covalently linked to a heterologous polypeptide.

In specific embodiments, the present invention encompasses a composition comprising two or more types of antibodies or fragments or variants thereof, each of which

type immunospecifically binds to B Lymphocyte Stimulator, and each of which type of antibody or fragment thereof comprises a VH domain from a different scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the present invention encompasses a composition comprising two or more types of antibodies or fragments or variants thereof, each of which type immunospecifically binds to B Lymphocyte Stimulator, and each of which type of antibody or fragment thereof comprises a VL domain from a different scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the present invention encompasses a composition comprising two or more types of antibodies or fragments or variants thereof, each of which type immunospecifically binds to B Lymphocyte Stimulator, and each of which type of antibody or fragment thereof comprises a VL domain from a different scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128 and wherein each type of antibody or fragment thereof further comprises a VH domain from a different scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the present invention encompasses a composition comprising two or more types of antibodies or fragments or variants thereof, each of which type immunospecifically binds to B Lymphocyte Stimulator, and each of which type of antibody or fragment thereof comprises a VH CDR3 having an amino acid sequence of one of SEQ ID NOS: 3129 to 3227.

In specific embodiments, the present invention encompasses a panel of two or more types of antibodies or fragments or variants thereof, each of which type immunospecifically binds to B Lymphocyte Stimulator, and each of which type of antibody or fragment thereof comprises a VH domain from a different scFv having an amino acid sequence of one of SEQ ID NO: 1 to 2128.

In specific embodiments, the present invention encompasses a panel of two or more types of antibodies or fragments or variants thereof, each of which type immunospecifically binds to B Lymphocyte Stimulator, and each of which type of antibody or fragment thereof comprises a VL domain from a different scFv having an amino acid sequence of one of SEQ ID NO: 1 to 2128.

In specific embodiments, the present invention encompasses a panel of two or more types of antibodies or fragments or variants thereof, each of which type immunospecifically binds to B Lymphocyte Stimulator, and each of which type of antibody or fragment thereof comprises a VL domain from a different scFv having an amino acid sequence of one of SEQ ID NO: 1 to 2128 and wherein each type of antibody or fragment further comprises a VH domain from a different scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the present invention encompasses a panel of two or more antibodies or fragments or variants thereof, each of which type immunospecifically binds to B Lymphocyte Stimulator, and each of which type of antibody or fragment thereof comprises a VHCDR3 from a different scFv having an amino acid sequence of one of SEQ ID NOS: 2129 to 3227.

In specific embodiments, the antibodies or fragments thereof of the antibody panel of the invention, are each in a well of a 96 well plate.

In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator.

In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 46, 321 to 329, 1563 to 1595, and 1881 to 1908, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator.

In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1881 to 1908, wherein the antibody of fragment thereof immunospecifically binds the membrane-bound form of B Lymphocyte Stimulator.

In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1563 to 1569, wherein said antibody of fragment thereof immunospecifically binds the soluble form of B Lymphocyte Stimulator. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed.

In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or

fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed.

In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 46, 321 to 329, 1563 to 1595, and 1881 to 1908, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed.

In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1881 to 2128, wherein the antibody or fragment thereof immunospecifically binds the membrane-bound form of B Lymphocyte Stimulator. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed.

In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1563 to 1880, wherein said antibody or fragment thereof immunospecifically binds the soluble form of B Lymphocyte Stimulator. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors.

Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed.

In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator and which also comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed.

In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator and which also comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128 and in which said VL domain and said VH domain are derived from the same scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-described nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed.

In specific embodiments, the present invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof comprising a VHCDR3 from an scFv having an amino acid sequence of one of SEQ ID NOS: 2129 to 3227, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator. The present invention also encompasses vectors comprising the isolated nucleic acid molecule described above, including vectors comprising a nucleotide sequence which regulates the expression of the antibody or fragment thereof encoded by the above-de-

scribed nucleic acid molecule. Additionally the present invention also encompasses host cells, including mammalian host cells, comprising the above-described nucleic acid molecule which is operably linked to a heterologous promoter, as well as host cells, including mammalian host cells, comprising the above-described vectors. Additionally, the present invention also provides a method for producing an antibody or fragment thereof comprising culturing the above-described host cells under conditions in which the nucleic acid molecule is expressed.

In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to B Lymphocyte Stimulator, said antibody or fragment thereof comprising an amino acid sequence of a VH domain encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence encoding a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to B Lymphocyte Stimulator, said antibody or fragment thereof comprising an amino acid sequence of a VL domain encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence encoding a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to B Lymphocyte Stimulator, said antibody or fragment thereof comprising an amino acid sequence of a VH domain encoded by a nucleotide sequence that hybridizes under highly stringent conditions to a nucleotide sequence encoding a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to B Lymphocyte Stimulator, said antibody or fragment thereof comprising an amino acid sequence of a VL domain encoded by a nucleotide sequence that hybridizes under highly stringent conditions to a nucleotide sequence encoding a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to B Lymphocyte Stimulator, said antibody or fragment thereof comprising an amino acid sequence of a CDR encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence encoding a CDR from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to B Lymphocyte Stimulator, said antibody or fragment thereof comprising an amino acid sequence of a CDR encoded by a nucleotide sequence that hybridizes under highly stringent conditions to a nucleotide sequence encoding a CDR from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to B Lymphocyte Stimulator, said antibody or fragment thereof comprising an amino acid sequence of a VH CDR3 encoded by a nucleotide sequence that hybridizes

under stringent conditions to a nucleotide sequence encoding a VH CDR3 having an amino acid sequence of one of SEQ ID NOS: 2129 to 3227.

In specific embodiments, the present invention provides an antibody or fragment thereof that immunospecifically binds to B Lymphocyte Stimulator, said antibody or fragment thereof comprising an amino acid sequence of a VH CDR3 encoded by a nucleotide sequence that hybridizes under highly stringent conditions to a nucleotide sequence encoding a VH CDR3 having an amino acid sequence of one of SEQ ID NOS: 2129 to 3227.

In specific embodiments, the present invention provides a method for detecting of aberrant expression of B Lymphocyte Stimulator, comprising:

assaying the level of B Lymphocyte Stimulator expression in cells or a tissue sample of an individual using one or more antibodies or fragments or variants thereof that immunospecifically bind B Lymphocyte Stimulator; and

comparing the level of B Lymphocyte Stimulator assayed in the cells or a tissue sample with a standard level of B Lymphocyte Stimulator or a level of B Lymphocyte Stimulator in cells or a tissue sample from an individual without aberrant B Lymphocyte Stimulator expression, wherein an increase or decrease in the assayed level of B Lymphocyte Stimulator or level in cells or a tissue sample from an individual without aberrant B Lymphocyte Stimulator expression compared to the standard level of B Lymphocyte Stimulator is indicative of aberrant expression.

In specific embodiments, the present invention provides a method for diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or activity, comprising:

administering to a subject an effective amount of a labeled antibody or fragment thereof that immunospecifically binds to B Lymphocyte Stimulator;

waiting for a time interval following the administering for permitting the labeled antibody or fragment thereof to preferentially concentrate at sites in the subject where B Lymphocyte Stimulator is expressed;

determining background level; and

detecting the labeled antibody or fragment thereof in the subject, such that detection of labeled antibody or fragment thereof above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of B Lymphocyte Stimulator.

In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above comprises a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128.

In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above comprises a VH CDR3 having an amino acid sequence of one of SEQ ID NOS: 2129 to 3227.

In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above is conjugated to a diagnostic agent.

In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above is conjugated to a diagnostic agent wherein the diagnostic

agent is horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase.

In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above is conjugated to a diagnostic agent wherein the diagnostic agent is fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin.

In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above is conjugated to a diagnostic agent wherein the diagnostic agent is ^{125}I , ^{131}I , ^{111}In , ^{90}Y or ^{99}Tc .

In specific embodiments, the antibody or fragment thereof utilized in the two methods described immediately above is conjugated to a diagnostic agent wherein the diagnostic agent is luciferase, luciferin or aequorin.

A pharmaceutical composition comprising at least one antibody or fragment thereof of comprising a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator and a pharmaceutically acceptable carrier.

A pharmaceutical composition comprising at least one antibody or fragment thereof of comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator and a pharmaceutically acceptable carrier.

A pharmaceutical composition comprising at least one antibody or fragment thereof of comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator and which also comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128 and a pharmaceutically acceptable carrier.

A pharmaceutical composition comprising at least one antibody or fragment thereof of comprising an amino acid sequence of one of SEQ ID NOS: 2129 to 3227 wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator and a pharmaceutically acceptable carrier.

A method of treating, preventing or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or activity, comprising administering to an animal in need thereof the pharmaceutical composition comprising at least one antibody or fragment thereof of comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator and which also comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128 and a pharmaceutically acceptable carrier in an amount effective to treat, prevent or ameliorate the disease or disorder. This method may be used to treat an infectious disorder, cancer, and/or an autoimmune disease such as lupus or glomerular nephritis.

A method of treating, preventing or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or activity, comprising administering to an animal in need thereof the pharmaceutical composition comprising at least one antibody or fragment thereof of comprising a VL domain from an scFv having an amino acid

sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator and a pharmaceutically acceptable carrier in an amount effective to treat, prevent or ameliorate the disease or disorder. This method may be used to treat an infectious disorder, cancer, and/or an autoimmune disease such as lupus or glomerular nephritis.

A method of treating, preventing or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or activity, comprising administering to an animal in need thereof the pharmaceutical composition comprising at least one antibody or fragment thereof of comprising a VL domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128, wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator and which also comprises a VH domain from an scFv having an amino acid sequence of one of SEQ ID NOS: 1 to 2128 and a pharmaceutically acceptable carrier in an amount effective to treat, prevent or ameliorate the disease or disorder. This method may be used to treat an infectious disorder, cancer, and/or an autoimmune disease such as lupus or glomerular nephritis.

A method of treating, preventing or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or activity, comprising administering to an animal in need thereof the pharmaceutical composition of comprising at least one antibody or fragment thereof of comprising an amino acid sequence of one of SEQ ID NOS: 2129 to 3227 wherein said antibody or fragment thereof immunospecifically binds B Lymphocyte Stimulator and a pharmaceutically acceptable carrier in an amount effective to treat, prevent or ameliorate the disease or disorder. This method may be used to treat an infectious disorder, cancer, and/or an autoimmune disease such as lupus or glomerular nephritis.

This method may be used to treat an infectious disorder, cancer, and/or an autoimmune disease such as lupus or glomerular nephritis.

EXAMPLES

Abbreviations

0.2 M Tris-HCl, 0.5 mM EDTA, 0.5 M sucrose (TES)

1-ethyl-3-[3-dimethylaminopropyl]carbo diimide hydrochloride (EDC)

2TY supplemented with 100 µg/ml ampicillin and 2% glucose (2TYAG)

2TY supplemented with 100 µg/ml ampicillin and 50 µg/ml kanamycin (2TYAK)

3,3',5,5'-Tetramethyl Benzidine (TMB)

50% inhibitory concentration (IC_{50})

6×PBS containing 18% Marvel blocking solution (6×MPBS)

Absorbance (A)

Bovine serum albumin (BSA)

Enzyme linked immunosorbent assay (ELISA)

Foetal calf serum (FCS)

Heavy chain variable (V_H)

191

Hepes buffered saline (HBS)
 Horseradish peroxidase (HRP)
 Immobilised Metal Affinity Chromatography (IMAC)
 Isopropyl β -D-thiogalactopyranoside (IPTG)
 Light chain variable (V_L)
 Multiplicity of infection (MOI)
 N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid] (Hepes)
 Nanomolar (nM)
 N-Hydroxysuccinimide (NHS)
 PBS containing 3% Marvel (MPBS)
 Phosphate Buffered Saline (PBS)
 Phosphate Buffered Saline+0.1% (v/v) Tween 20 (PBST)
 Picomolar (pM)
 Single chain fragment variable (scFv)
 Tumour Necrosis Factor-alpha (TNF- α)
 Tumour Necrosis Factor-beta (TNF- β)
 TNF-related apoptosis inducing ligand (TRAIL)

Definitions:

In the following section "immobilized B Lymphocyte Stimulator" refers to a soluble form of B Lymphocyte Stimulator or biotinylated B Lymphocyte Stimulator coated on a plastic assay plate (e.g., a 96 well plate), but does not refer to histidine tagged B Lymphocyte Stimulator coated on a plastic assay plate.; "biotinylated B Lymphocyte Stimulator" is a soluble form of B Lymphocyte Stimulator except when used to coat an ELISA plate, in which case it would be "immobilized B Lymphocyte Stimulator." Membrane bound forms of B Lymphocyte Stimulator include, but are not limited to, U937 and P388 plasma membranes.

Example 1

Antibodies Immunospecifically Binding to Soluble and Membrane-Bound B Lymphocyte Stimulator

A library of phage was screened in an assay to identify those phage displaying scFvs that immunospecifically bind to the soluble and membrane-bound forms of B Lymphocyte Stimulator. Phage displaying scFvs that bound to immobilized B Lymphocyte Stimulator were identified after panning on immobilized B Lymphocyte Stimulator and assessment by ELISA for binding to immobilized B Lymphocyte Stimulator. The B Lymphocyte Stimulator that was immobilized on plates for these assays was purified from supernatants of Sf9 cells infected with a baculovirus expression construct as described in Moore et al., Science 285:260-263 which is hereby incorporated by reference in its entirety. Each of the identified scFvs were then sequenced. Certain sequences were isolated multiple times, thus a panel (panel 1) containing one member of each unique sequences was generated and further characterized for their ability to immunospecifically bind to the soluble and membrane-bound forms of B Lymphocyte Stimulator.

The derived amino acid sequences of these scFvs are shown in Table 1 above. The individual V_H and V_L segments of the scFvs were aligned to the known human germline sequences in V-BASE (Tomlinson et al, which can accessed

192

on the United Kingdom Medical Research Council (MRC) Centre for Protein Engineering website) and the closest germline identified.

Example 2

Specificity of scFvs for B Lymphocyte Stimulator and Membrane-Bound B Lymphocyte Stimulator

The specificity of each of the scFvs for both B Lymphocyte Stimulator and membrane-bound B Lymphocyte Stimulator was determined by phage ELISA. B Lymphocyte Stimulator was immobilised onto plastic as a purified soluble form of the protein or as a membrane-bound form present on plasma membrane preparations from the human macrophage-like cell line, U937.

Maintenance of U937 Cells

U937 cells are a human monocyte-like, histiocytic lymphoma cell line known to express B Lymphocyte Stimulator on their plasma membranes. They were maintained in RPMI-1640 supplemented with 4 mM L-glutamine, 10% FCS, 10 U penicillin, 100 g/ml streptomycin (all reagents from Sigma). The cells were thawed from frozen stock and are either used for plasma membrane preparation, or split 1:5, after 2 days in culture when the cell density reaches 1×10^6 /ml.

Preparation of U937 Plasma Membranes

To prepare plasma membranes, 1×10^9 U937 cells were harvested from their culture medium by centrifugation at 1000 rpm at 4° C. for 5 minutes in a benchtop centrifuge. The cells were resuspended in 40 ml 12 mM Tris, pH 7.5, 250 mM sucrose and placed on ice. The cells are then lysed using a hand-held electric homogenizer (Labortechnik IKA Ultra-Turrax) for four, one minute, bursts. To check that cell lysis had occurred, 10 μ l cell lysate was added to 10 μ l Trypan blue and the cell lysate was examined under a microscope. After confirming lysis, the homogenate was centrifuged at 270xg, for 10 minutes at 4° C. to pellet the nuclear fraction and the supernatant was retained. The supernatant was centrifuged at 8000xg, 10 mins, 4° C., to pellet the mitochondrial and lysosomal fractions and the supernatant was retained. The supernatant was then centrifuged at 100000xg, 60 mins, 4° C. to pellet the plasma membrane enriched fraction. The supernatant was discarded and the plasma membrane pellet was resuspended in 1 ml PBS and stored at -70° C. The protein concentration of the plasma membrane fraction was determined using a protein quantification kit (Biorad). Typical yields were between 5 and 10 mg of plasma membranes.

Phage ELISA

To determine the specificity of each of the unique scFvs, a phage ELISA was performed for each scFv against human B Lymphocyte Stimulator, U937 plasma membranes, TNF α (R&D Systems, Minneapolis, Minn.), BSA and uncoated well. Individual *E. coli* colonies containing a phagemid representing one of the unique scFvs from panel 1 were inoculated into 96-well plates containing 100 μ l 2TYAG medium per well. Plates were incubated at 37° C. for 4 hours, shaking. M13KO7 helper phage was added to each well to a MOI of 10 and the plates were incubated for a further 1 hour at 37° C. The plates were centrifuged in a benchtop centrifuge at 2000 rpm for 10 minutes. The supernatant was removed and cell pellets were resuspended in 100 μ l 2TYAK and incubated at 30° C. overnight, shaking. The next day, plates were centrifuged at 2000 rpm for 10 min and

the 100 μ l phage-containing supernatant from each well carefully transferred into a fresh 96-well plate. Twenty μ l of 6 \times MPBS was added to each well, and incubated at room temperature for 1 hour to pre-block the phage prior to ELISA.

Flexible 96-well plates (Falcon) were coated overnight at 4° C. with human B Lymphocyte Stimulator (1 μ g/ml) in PBS, U937 plasma membranes (10 μ g/ml) in PBS, TNF α (1 μ g/ml) in PBS, BSA (1 μ g/ml) in PBS, or PBS. After coating, the solutions were removed from the wells, and the plates were blocked for 1 hour at room temperature in MPBS. The plates were washed 3 times with PBS and then 50 μ l of pre-blocked phage was added to each well. The plates were incubated at room temperature for 1 hour and then washed with 3 changes of PBST followed by 3 changes of PBS. To each well, 50 μ l of an anti-gene VIII-HRP conjugate (Pharmacia) at a 1 to 5000 dilution in MPBS was added and the plates incubated at room temperature for 1 hour. Each plate was washed three times with PBST followed by three times with PBS. Then 50 μ l of an HRP-labelled anti-mouse polymer (DAKO EnVision) diluted 1/50 in 3% MPBS was added and incubated for 1 hour at room temperature. Each plate was then washed three times with PBST followed by three times with PBS. Fifty μ l of TMB substrate was then added to each well, and incubated at room temperature for 30 minutes or until colour development. The reaction was stopped by the addition of 25 μ l of 0.5 M H₂SO₄. The signal generated was measured by reading the absorbance at 450 nm (A₄₅₀) using a microtiter plate reader (Bio-Rad 3550).

The results for 3 clones (I006E07, I008D05 and I016F04) are shown in FIG. 1. All 3 scFvs recognize immobilized B Lymphocyte Stimulator and U937 plasma membranes but do not recognize TNF α , BSA or an uncoated well (PBS only). These results indicate that these scFvs specifically recognize immobilized B Lymphocyte Stimulator and membrane-bound B Lymphocyte Stimulator.

Example 3

Inhibition in an In Vitro Receptor Binding Assay by Phage ScFvs

All of the unique phage scFvs in panel 1 were assessed for their ability to inhibit soluble B Lymphocyte Stimulator binding to its cognate receptor on IM9 cells.

Biotinylation of B Lymphocyte Stimulator

One hundred μ g of either human or mouse B Lymphocyte Stimulator was dialysed overnight at 4° C. against 50 mM sodium bicarbonate (sodium hydrogen carbonate) pH8.5 using a slide-a-lyzer cassette (Pierce). The next day, NHS-biotin (Pierce) was dissolved in DMSO to 13.3 mg/ml. This was then added to the B Lymphocyte Stimulator at a molar ratio of 20:1 biotin:B Lymphocyte Stimulator, mixed and incubated on ice for 2 hours. The biotinylated B Lymphocyte Stimulator was then dialysed back into sterile PBS (Sigma) using a slide-a-lyzer cassette overnight at 4° C. The biological activity of the biotinylated B Lymphocyte Stimulator was confirmed using the receptor binding inhibition assay (see below).

Maintenance of IM9 Cells

IM9 cells are a human B lymphocyte cell line. They were maintained in RPMI-1640 supplemented with 4 mM L-glutamine, 10% FCS, 10 U penicillin, 100 g/ml streptomycin (all reagents from Sigma). The cells are thawed from frozen stock and can be used in assays after 5 days in culture when they reach a density of 4–8 \times 10⁵/ml.

Receptor Binding Inhibition Assay

Individual *E. coli* colonies containing a phagemid representing one of the unique scFvs from panel 1 were inoculated into 96-well plates containing 100 μ l 2TYAG medium per well. Plates were incubated at 37° C. for 4 hours, shaking. M13KO7 helper phage was added to each well to a MOI of 10 and the plates were incubated for a further 1 hour at 37° C. The plates were centrifuged in a benchtop centrifuge at 2000 rpm for 10 minutes. The supernatant was removed and cell pellets were resuspended in 100 μ l 2TYAK and incubated at 30° C. overnight, shaking. The next day, plates were centrifuged at 2000 rpm for 10 min and the 100 μ l phage-containing supernatant from each well carefully transferred into a fresh 96-well plate. Phage were diluted 1 in 2 in MPBS prior to use.

Flat-bottomed 96-well plates (Costar) were coated with 100 μ l per well of a 1:10 dilution of poly-L-lysine (Sigma) in PBS for 1 hour at room temperature. The plates were then washed twice with water, allowed to air-dry and placed at 4° C. overnight. One hundred μ l of IM9 cells (at 10⁶/ml in RPMI-1640 culture medium) were then added to each well. Plates were then centrifuged at 3200 rpm for 5 mins to pellet the cells. The media was carefully aspirated and 200 μ l of MPBS added to each well. The plates were then allowed to block for 1 hour at room temperature.

To a separate 96-well plate 10 μ l of biotinylated B Lymphocyte Stimulator (at 162.5 ng/ml) in MPBS was added to each well to give a final concentration of 25 ng/ml. Fifty-five μ l of each appropriate phage supernatant was added to each well and the final volume in each well was 65 μ l. Plates were then incubated at room temperature for 30 minutes.

The IM9 coated plates were washed twice in PBS, tapped dry and immediately 50 μ l of the phage/biotinylated-B Lymphocyte Stimulator mix was added and incubated at room temperature for 1 hour. Plates were washed three times in PBST and three times in PBS, tapped dry and 50 μ l of streptavidin-Delfia (Wallac) was added to each well at 1:1000 dilution in the Manufacturer's assay buffer. The plates were then incubated at room temperature for 1 hour and washed six times in Delfia wash solution (Wallac). After tapping the plates dry, 100 μ l per well of Delfia enhancement solution (Wallac) was added. The plates were gently tapped to encourage micelle formation, incubated at room temperature for 10 minutes, and fluorescence read on a Wallac 1420 workstation at 6520 nM.

Results for 3 phage scFvs (I001C09, I018D07 and I016H07) that inhibited the binding of biotinylated B Lymphocyte Stimulator are shown in FIG. 2. Maximal binding of biotinylated B Lymphocyte Stimulator to its receptor (bio-B Lymphocyte Stimulator only), the background signal in the absence of biotinylated B Lymphocyte Stimulator (no bio-B Lymphocyte Stimulator), and results with an irrelevant (i.e., does not recognize B Lymphocyte Stimulator) phage antibody are also shown. All 3 phage scFvs inhibited biotinylated B Lymphocyte Stimulator binding to its receptor on IM9 cells, identifying these scFvs as scFvs that bind the soluble form of B Lymphocyte Stimulator. These scFvs also bind to U937 membranes, thus they also bind the membrane bound form of B Lymphocyte Stimulator.

Forty-eight of the scFvs from panel 1 that demonstrated the greatest inhibition as phage particles in this assay were chosen for further study. These 48 scFvs are listed in Table 3.

TABLE 3

scFvs that Inhibit the Binding of Biotinylated-BLyS to its Receptor				
Antibody	Antibody	Antibody	Antibody	Antibody
I008C02	I029D07	I008C03	I008C12	I028A06
I022E02	I061E07	I007H08	I061H01	I031C03
I018C02	I006D07	I008A11	I006D08	I031F02
I008B01	I017D10	I061D02	I026E03	I031F09
I016F04	I007B03	I008A09	I027A07	I031G11
I016E05	I018C10	I007F11	I016H07	I050A07
I0018H08	I001C09	I037E07	I021B05	I050A12
I018H09	I018D07	I037E12	I031G10	I050B11
	I029F11	I016F02	I031G08	I051C04
	I022D01		I031C07	I003F12
			I012A06	

Example 4

Specificity of Anti-B Lymphocyte Stimulator Antibodies

The specificity of the 48 scFvs listed in Table 3 for human and murine B Lymphocyte Stimulator was determined using phage ELISA.

Phage ELISA

To determine the specificity of the 48 scFvs, a phage ELISA was performed against human and mouse B Lymphocyte Stimulator, and a panel of related and unrelated human antigens: Fas ligand, TRAIL, TNF α , TNF β , and PBS. The: Fas ligand, TRAIL, TNF α , and TNF β antigens were obtained from R&D Systems, Minneapolis, Minn. Individual *E. coli* colonies containing phagemid were inoculated into 5 ml 2YTAG and incubated at 37° C. for 4 hours, shaking. M13K07 helper phage (Pharmacia) was added to each tube to a MOI of 10 and incubated for 30 minutes at 37° C. for 1 hour, the first 30 minutes static and the final 30 minutes with gentle shaking. Cells were pelleted by centrifugation at 3,500 rpm for 10 minutes and the supernatant discarded. Cell pellets were resuspended in 5 ml 2TYAK and incubated at 30° C. overnight with shaking. The next day, the cells were pelleted by centrifugation at 3,500 rpm for 10 minutes. The phage-containing supernatant (5 ml) was carefully transferred to a fresh tube, 1 ml of 6MPBS was added, and the tube was incubated at room temperature for 1 hour to pre-block the phage prior to ELISA.

All antigens were coated at 1 μ g/ml. ELISAs were performed essentially as described in Example 2. The only exception to this being the detection of phage antibody binding to mouse B Lymphocyte Stimulator where the step involving incubation with the HRP-labelled anti-mouse polymer was omitted. Binding to mouse B Lymphocyte Stimulator was detected with TMB as in Section Example 2.

All 48 scFvs are specific for immobilized human B Lymphocyte Stimulator and 43 out of the 48 scFvs cross-react with immobilized mouse B Lymphocyte Stimulator but not with any other unrelated or related antigen tested. I008C03, I007F11, I037E07, I037E12, and I016H07 did not bind murine B Lymphocyte Stimulator. Results for two scFvs, I022D01 and I031F02, are shown in FIG. 3. Both these scFvs specifically recognize human and mouse B Lymphocyte Stimulator but not any other unrelated or related antigen tested.

Example 5

Specificity for the Membrane-Bound Form of B Lymphocyte Stimulator

The specificity of 48 scFvs for membrane-bound B Lymphocyte Stimulator was determined by the phage ELISA described in Example 2. B Lymphocyte Stimulator was immobilised onto plastic as a membrane-bound form present on plasma membranes preparations from the human macrophage-like cell line, U937. This cell line is known to express the membrane-bound form of human B Lymphocyte Stimulator.

To demonstrate that this binding is specific for membrane-bound B Lymphocyte Stimulator, a competition ELISA was developed to determine if the ELISA signal for an individual antibody on U937's could be competed out by pre-incubation with either B Lymphocyte Stimulator or TNF α . An anti-B Lymphocyte Stimulator antibody that also recognizes membrane-bound B Lymphocyte Stimulator would be expected to demonstrate a signal reduction with free B Lymphocyte Stimulator but not free TNF α .

Competition ELISA

Individual *E. coli* colonies containing phagemid for each of the 48 scFvs listed in Table 3 were inoculated into 5 ml 2YTAG and incubated at 37° C. for 4 hours, shaking. M13K07 helper phage (Pharmacia) was added to each tube to a MOI of 10 and incubated for 30 minutes at 37° C. for 1 hour, the first 30 minutes static and the final 30 minutes with gentle shaking. Cells were pelleted by centrifugation at 3,500 rpm for 10 minutes and the supernatant discarded. Cell pellets were resuspended in 5 ml 2TYAK and incubated at 30° C. overnight with shaking. The next day, the cells were pelleted by centrifugation at 3,500 rpm for 10 minutes. The phage-containing supernatants (5 ml) were carefully transferred to a fresh tube.

For each of the 48 scFvs listed in Table 3, two aliquots of 20 μ l 6xMPBS were pipetted into separate wells of a 96-well plate (Greiner). The first aliquot was supplemented with B Lymphocyte Stimulator to a final concentration of 0.5 μ g/ml. The second aliquot was supplemented with TNF- α to a final concentration of 0.5 μ g/ml. Each experiment was performed in triplicate. One hundred μ l of each phage supernatant was then added to each aliquot and mixed by pipetting up and down. The phage were incubated (\pm competing antigen) at room temperature for 1 hour.

Flexible 96-well plates (Falcon) were coated overnight at 4° C. with 50 μ l of 10 μ g/ml U937 plasma membranes. After coating, the plates were washed 3 times with PBS and blocked for 1 hour at room temperature with 200 μ l MPBS. The plates were washed 3 times with PBS and 50 μ l of phage (\pm competing antigen) was added to each appropriate well. The plates were incubated at room temperature for 1 hour and then washed with 3 changes of PBST followed by 3 changes of PBS. To each well, 50 μ l of a mouse anti-gene VIII-HRP conjugate (Pharmacia) at a 1:5000 dilution in MPBS was added and the plates incubated at room temperature for 1 hour. Each plate was washed three times with PBST followed by three times with PBS. Then 50 μ l of an HRP-labelled anti-mouse polymer (DAKO EnVision) diluted 1:50 in 3% MPBS was added and incubated for 1 hour at room temperature. Each plate was then washed three times with PBST followed by three times with PBS. Fifty μ l of TMB substrate was then added to each well, and incubated at room temperature for 30 to 60 minutes or until color development. The reaction was stopped by the addition of 25

μl of 0.5 M H_2SO_4 . The signal generated was measured by reading the absorbance at 450 nm (A_{450}) using a microtiter plate reader (Bio-Rad 3550).

All 48 scFvs bind to U937 plasma membrane preparations. This signal could be competed out by pre-incubation of the phage antibody with B Lymphocyte Stimulator but not by pre-incubation with $\text{TNF-}\alpha$. This indicates that the 48 scFvs specifically recognize membrane-bound B Lymphocyte Stimulator as well as soluble B Lymphocyte Stimulator. Typical results are exemplified by scFvs I031F09, I050A12 and I051C04 and are shown in FIG. 4. All 3 scFvs demonstrate binding to U937 plasma membranes. This binding was specifically competed out with B Lymphocyte Stimulator but did not compete with $\text{TNF-}\alpha$, demonstrating specific recognition of membrane-bound B Lymphocyte Stimulator.

Example 6

scFv Off-Rate Determinations

All off-rate determinations were performed on BIAcore 2000 machines, using the BIAcore 2000 Control Software and evaluated using the BIAevaluation 3.0 software.

Preparation of a Low Density B Lymphocyte Stimulator Surface

A 500 RU surface was prepared for kinetic studies with purified scFvs. A low density B Lymphocyte Stimulator surface (500 RU B Lymphocyte Stimulator coupled) was prepared in flow cell 2 by amine coupling to a CM5 chip. A new CM5 chip was inserted into the BIAcore and a sensorgram initiated with HBS buffer at a flow rate of 5 $\mu\text{l}/\text{min}$. The NHS and EDC coupling solutions (BIAcore) were mixed according to manufacturer's instructions and 30 μl injected over the CM5 surface. Fifty μl of B Lymphocyte Stimulator at 1 $\mu\text{g}/\text{ml}$ in 10 mM sodium acetate buffer, pH4, was then injected followed by 30 μl of ethanolamine-HCl solution (BIAcore). The flow rate was then adjusted to 20 $\mu\text{l}/\text{min}$ and 10 μl of 4M guanidine hydrochloride in HBS injected over the surface. This strips the surface of non-covalently bound B Lymphocyte Stimulator.

Measurement of scFv Off-Rate Kinetics on the Low Density Surfaces

The chip containing the low density B Lymphocyte Stimulator surface was inserted in to the BIAcore. A dilution series of purified scFvs was prepared in HBS, typically 50 $\mu\text{g}/\text{ml}$ doubling dilutions down to 1.5 $\mu\text{g}/\text{ml}$. The dilution series was then injected sequentially over the low density B Lymphocyte Stimulator surface (and blank control) using the following program:

```

MAIN
FLOWCELL 1,2,3,4
APROG      genab      r1d1      ab1
APROG      genab      r1d2      ab2
APROG      genab      r1d3      ab3
APROG      genab      r1d4      ab4
APROG      genab      r1d5      ab5
APROG      genab      r1d6      ab6
APPEND CONTINUE
END
DEFINE APROG genab
PARAM %Abpos %Abld
FLOW      20
KINJECT    %Abpos 200 80

```

-continued

INJECT	r1c6 10!guanidine hydrochloride regeneration step
EXTRACLEAN	
END	

Bound scFvs were removed by injecting 10 μl 4M GuHCl in HBS over the surface between scFv samples.

The binding curves for individual scFvs were analyzed using the BIAevaluation software to determine antibody off-rates. Kinetic analysis for a typical scFv antibody, I003C02, is shown in FIG. 5. I003C02 has a $K_{off} = 6 \times 10^{-3} \text{ s}^{-1}$.

Example 7

Inhibition in an In Vitro Receptor Binding Assay by scFv Antibodies

The 48 scFvs listed in Table 3 were purified and assessed for their ability to inhibit B Lymphocyte Stimulator binding to its receptor on IM9 cells.

Purification of scFv

To determine the inhibitory potency of anti-B Lymphocyte Stimulator scFv, scFv's were first prepared by IMAC. 2TYAG (5 ml) was inoculated with a single colony and grown overnight at 30° C., shaking. This overnight culture was then used to inoculate 500 ml of 2TY containing 100 $\mu\text{g}/\text{ml}$ ampicillin and 0.1% Glucose, and grown at 30° C., shaking, until an A_{600} of 1.0 was attained. IPTG was added to 1 mM and the culture was grown for a further 3.5 hours at 30° C.

Cells were harvested by centrifugation at 5,000 rpm, and resuspended in 10 ml of TES. A further 15 ml of a 1:5 dilution (in water) of TES was added, and the cell suspension incubated on a turning wheel at 4° C. for 30 minutes. This causes osmotic shock and yields a periplasmic extract containing the scFv. Residual cells and debris were pelleted by centrifugation at 9,000 rpm for 20 minutes at 4° C. The supernatant was transferred to a new tube, and 50 μl of 1 M MgCl_2 added. Two ml of a Ni-NTA agarose (Qiagen), pre-washed with buffer (50 mM sodium phosphate, pH 8, 300 mM NaCl) together with a protease inhibitor tablet (Boehringer Mannheim) were then added to the periplasmic extract. The preparation was incubated, rotating, overnight at 4° C. The Ni-NTA was pelleted by centrifugation at 2,000 rpm for 5 minutes, and the supernatant was aspirated. The agarose beads were washed 3 times with 50 ml wash buffer, centrifuging to collect the agarose in between each wash. Ten ml of wash buffer was added after the final wash, and the slurry was loaded on to a polyprop column (BioRad). Two ml elution buffer (50 mM NaPi (sodium phosphate), pH 8, 300 mM NaCl, 250 mM imidazole) was added to the drained agarose, and the eluate was collected. IMAC purified scFv was buffer exchanged in to PBS by use of a Nap 5 column (Pharmacia) according to the manufacturer's instructions. The A_{280} was read and the protein concentration determined using a molar extinction coefficient of 1 mg/ml protein= A_{280} 1.4. Purified scFv was stored in 500 μl aliquots at -70° C.

Receptor Binding Inhibition Assay

Flat-bottomed 96-well plates (Costar) were coated with 100 μl per well of a 1:10 dilution of poly-L-lysine (Sigma) in PBS for 1 hour at room temperature. The plates were then washed twice with water, allowed to air-dry and placed at 4°

C. overnight. One hundred μ l of IM9 cells (at 10^6 /ml in RPMI-1640) were then added to each well. Plates were then centrifuged at 3200 rpm for 5 mins to pellet the cells. The media was carefully aspirated and 200 μ l of MPBS added to each well. The plates were then left to block for 1 hour at room temperature.

To a separate 96-well plate, titrate test scFvs in MPBS, in triplicate, over a concentration range from 10 μ g/ml down to 0.001 μ g/ml were added. The final volume of test scFv in each well was 55 μ l. Competition with unlabelled B Lymphocyte Stimulator was also included in every assay as a control. Unlabelled B Lymphocyte Stimulator, in MPBS, was typically titrated in triplicate, over a concentration range from 1 μ g/ml down to 0.001 μ g/ml. 10 μ l of biotinylated-B Lymphocyte Stimulator (at 162.5 ng/ml) in MPBS was added to each well to give a final concentration of 25 ng/ml. Plates were then incubated at room temperature for 30 minutes.

The IM9 coated plates was washed twice in PBS, tapped dry and immediately 50 μ l of the scFv/biotinylated-B Lymphocyte Stimulator mix was added and incubated at room temperature for 1 hour. Plates were washed three times in PBST and three times in PBS, tapped dry and 50 μ l per well added of streptavidin-Delfia (Wallac) at 1:1000 dilution in the Manufacturer's assay buffer. The plates were then incubated at room temperature for 1 hour and washed six times in Delfia wash solution (Wallac). After tapping the plates dry, 100 μ l per well of Delfia enhancement solution (Wallac) was added. The plates were gently tapped to encourage micelle formation, incubated at room temperature for 10 minutes, and fluorescence read on a Wallac 1420 workstation at 6520 nM.

Typical titration curves for two scFv antibodies, I007F11 and I050A07, are shown in FIG. 6. Unlabelled B Lymphocyte Stimulator competed for binding to its receptor with an IC_{50} value of 0.8 nM. The IC_{50} values for I007F11 and I050A07 are 7.9 nM and 17.1 nM, respectively. The assay was performed in triplicate and standard error bars are shown. The 9 scFvs that demonstrated the greatest inhibition as scFv are listed in Table 4. This data also confirms that these 9 scFvs recognize the soluble form of B Lymphocyte Stimulator.

TABLE 4

ScFvs that demonstrated greatest potency in BLyS Receptor Binding Inhibition Assay
ScFv Antibody
I017D10
I022D01
I008A11
I006D08
I031F02
I050A12
I050B11
I051C04
I003F12S

Example 8

Antibodies Recognizing a Soluble Form of B Lymphocyte Stimulator

A library of phage was screened in an assay to identify those phage displaying scFvs that immunospecifically bind to the soluble but not the membrane-bound forms of B Lymphocyte Stimulator.

A phage library was screened for the ability to bind to biotinylated B Lymphocyte Stimulator. The phage were exposed to biotinylated B Lymphocyte Stimulator, allowed an interval of time to bind the biotinylated B Lymphocyte Stimulator. Phage binding bio-B Lymphocyte Stimulator were then isolated by capture on streptavidin coated magnetic beads.

The phage identified in the screen above (capture of Bio-B Lymphocyte Stimulator from solution) were then screened by ELISA for their ability to bind immobilized B Lymphocyte Stimulator. The scFv expressed by phage that bound immobilized B Lymphocyte Stimulator were then cloned and sequenced. Again, several sequences were identified multiple times, thus a panel (panel 2) consisting of on example of each phage expressing a unique scFv was then characterized further.

The derived amino acid sequences of these scFvs are shown in Table 1 above. The individual V_H and V_L segments of the scFvs were aligned to the known human germline sequences in V-BASE (Tomlinson et al, which can accessed on the United Kingdom Medical Research Council (MRC) Centre for Protein Engineering website) and the closest germline identified.

Example 9

Specificity For Soluble B Lymphocyte Stimulator

The scFvs were isolated from a library of phage based on their ability to bind a soluble form of B Lymphocyte Stimulator. Briefly, phage were preincubated with biotinylated B Lymphocyte Stimulator in solution. Phage that bound to this biotinylated B Lymphocyte Stimulator were then isolated using streptavidin coated magnetic beads.

The specificity of each of the unique scFvs for B Lymphocyte Stimulator and for the membrane-bound form of B Lymphocyte Stimulator, was determined by phage ELISA. B Lymphocyte Stimulator was immobilised onto plastic as a purified soluble form of the protein or as a membrane-bound form present on plasma membrane preparations from the human macrophage-like cell line, U937. Maintenance of U937 cells and plasma membrane preparations were performed as detailed in Example 2.

Phage ELISA

To determine the specificity of each of the scFvs, a phage ELISA was performed for each antibody against human B Lymphocyte Stimulator, U937 plasma membranes, TNF α , BSA and an uncoated well. Antigen coating conditions were as described in Example 2, apart from human B Lymphocyte Stimulator. B Lymphocyte Stimulator was first biotinylated (as described in Example 3) and coated at 1 μ g/ml onto streptavidin coated plates (Reacti-Bind, Pierce) for 30 mins at room temperature. The plates were then washed, blocked and the phage ELISA performed as detailed in Example 2.

The results for 3 clones (I074B12, I075F12 and I075A02) that bind the soluble but not the membrane-bound form of B Lymphocyte Stimulator are shown in FIG. 7. As a control, a phage antibody that recognizes TNF α , is also shown in FIG. 7. There is a small non-specific background signal on the U937 plasma membranes that is evident with both the anti-B Lymphocyte Stimulator scFvs as well as the anti-TNF α control. All 3 anti-B Lymphocyte Stimulator scFvs recognize B Lymphocyte Stimulator but not U937 plasma membranes, TNF α , BSA or an uncoated well (PBS only). This indicates that the scFvs do not bind the membrane-bound form of B Lymphocyte Stimulator. Further, The fact

201

that these scFvs were isolated on the basis of their ability to bind soluble biotinylated B Lymphocyte Stimulator indicates that they bind the soluble form of B Lymphocyte Stimulator. Further confirmation of these scFvs' specificity for B Lymphocyte Stimulator is provided in Example 10.

Example 10

Inhibition in an In Vitro Receptor Binding Assay by Phage scFvs

All of the unique phage scFvs from panel 2 were assessed for their ability to inhibit B Lymphocyte Stimulator binding to its cognate receptor on IM9 cells. The biotinylation of B Lymphocyte Stimulator, maintenance of IM9 cells and receptor binding inhibition assay were performed as described in Example 3.

Results for two phage scFvs, I0025B09 and I026C04 are shown in FIG. 8. Maximal binding of biotinylated B Lymphocyte Stimulator to its receptor (bio-B Lymphocyte Stimulator only), the background signal in the absence of biotinylated B Lymphocyte Stimulator (no bio-B Lymphocyte Stimulator), and results with an irrelevant (i.e. does not recognize B Lymphocyte Stimulator) phage antibody are also shown. Both phage scFvs inhibited biotinylated B Lymphocyte Stimulator binding to its receptor on IM9 cells. 33 of the unique scFvs from panel 2 were identified for further study. These 33 scFvs demonstrated the greatest inhibition as phage particles in this assay and are listed in Table 5.

TABLE 5

Identification of 33 phage scFvs to free BLYS that demonstrates the most significant inhibition of biotinylated-BLYS binding to its receptor

Antibody	Antibody	Antibody	Antibody
I026C04	I074B12	I073F04	I065D04
I003C06	I075A02	I078D08	I068C08
I025B09	I068B08	I078D02	I068F03
I027B12	I068B04	I075G01	I069B07
I025B06	I068C06	I071B03	
I030A10	I075F12	I072B09	
I002A01R	I065D08	I078H08	
I002A01K	I065F08	I064C04	
I026C04R	I067B10	I064C07	
I026C04K	I067F05		

Example 11

Specificity of Anti-B Lymphocyte Stimulator scFvs

The specificity of the 33 scFvs (listed in Table 5) for immobilized human and murine B Lymphocyte Stimulator was determined using phage ELISA.

Phage ELISA

To determine the specificity of the 33 scFvs, a phage ELISA was performed as described in Example 4 against human and mouse B Lymphocyte Stimulator, and a panel of related human antigens: TRAIL, LIGHT, TNF α , TNF β , and an uncoated well (PBS only).

Typical results for two scFvs, I067F05 and I078D02 are shown in FIG. 9. A control antibody that specifically recognizes TNF α is also shown. Both anti-B Lymphocyte Stimulator scFvs specifically recognize immobilized human and mouse B Lymphocyte Stimulator but not any other antigen tested.

202

All 33 scFvs are specific for human B Lymphocyte Stimulator. 14/33 cross-react with mouse B Lymphocyte Stimulator but not with any other unrelated or related antigen tested.

Example 12

scFv Off-Rate Determinations

Off-rate determinations, preparation of a low density B Lymphocyte Stimulator surface and kinetic measurements were as detailed in Example 6.

The binding curves for individual scFvs were analysed using the BIAevaluation software to determine antibody off-rates. Kinetic analysis for a typical scFv antibody, I002A01, is shown in FIG. 10. I002A01 has a $K_{off}=9 \times 10^{-4} \text{ s}^{-1}$.

Example 13

Inhibition in an In Vitro Receptor Binding Assay by scFv Antibodies

The 33 scFvs identified in Table 5 were prepared as purified scFvs and assessed for their ability to inhibit B Lymphocyte Stimulator binding to its receptor on IM9 cells. The scFvs were purified and analysed in the receptor binding inhibition assay as described in Example 6.1.8.

Typical titration curves for two scFvs, I0068C06 and I074B12, are shown in FIG. 11. Unlabelled B Lymphocyte Stimulator competed for binding to its receptor with an inhibitory constant 50 (IC_{50}) value of 0.66 nM. The IC_{50} values for I0068C06 and I074B12 are 61 nM and 13 nM, respectively. The assay was performed in triplicate and standard error bars are shown. The 7 scFvs that demonstrated the greatest inhibition as scFv are listed in Table 6.

TABLE 6

Identification of 7 scFvs to free BLYS that demonstrate the most significant inhibition of biotinylated-BLYS binding to its receptor as purified scFv's.

Antibody
I002A01-R
I002A01-K
I026C04-R
I026C04-K
I068C06
I075F12
I067B10

Example 14

ScFvs Recognizing Membrane-Bound B Lymphocyte Stimulator

A library of phage was screened in an assay to identify those phage displaying scFvs that immunospecifically bind to the membrane-bound but not the soluble form of B Lymphocyte Stimulator.

As a starting point, a library of phage expressing scFv antibodies were panned on immobilized HIS-tagged B Lymphocyte Stimulator. Phage isolated by panning were then screened for the ability to bind to HIS-tagged B Lymphocyte Stimulator. HIS-tagged B Lymphocyte Stimulator was obtained by expressing amino acids 71-285 of SEQ ID

203

NO:3228 using the pQE9 vector (Qiagen Inc., Valencia, Calif.) in *E. coli* and purifying the expressed protein. This phage clones identified by this screen were then sequenced. After sequencing, A panel (panel 3) of phage each expressing a unique scFv that bound HIS-tagged B Lymphocyte Stimulator was generated and further characterized.

The derived amino acid sequences of the unique scFvs from panel 3 are shown in Table 1 above. The individual V_H and V_L segments of the scFvs were aligned to the known human germline sequences in V-BASE (Tomlinson et al, which can accessed on the United Kingdom Medical Research Council (MRC) Centre for Protein Engineering website) and the closest germline identified.

Example 15

Recognition of Membrane-Bound B Lymphocyte Stimulator

The specificity of each of the unique scFvs for both the membrane-bound form of B Lymphocyte Stimulator as well as for the soluble form of B Lymphocyte Stimulator, was determined by phage ELISA.

B Lymphocyte Stimulator was immobilised onto plastic either directly as a purified soluble form of the protein or biotinylated and coated on a streptavidin plate as in Example 9. Binding to HIS-tagged B Lymphocyte Stimulator was used as a primary screen for scFv's that would bind the membrane-bound form of B Lymphocyte Stimulator (see below). The membrane-bound form of B Lymphocyte Stimulator was presented as plasma membranes preparations from the human macrophage-like cell line, U937 or the murine cell line P388.

Mouse monoclonal antibodies have been raised against His-tagged B Lymphocyte Stimulator according to standard procedures. Characterization of these mouse monoclonal antibodies revealed that they specifically recognized both His-tagged B Lymphocyte Stimulator and the membrane-bound form of B Lymphocyte Stimulator on U937 cells, but not soluble B Lymphocyte Stimulator. Therefore, specific recognition of His-tagged B Lymphocyte Stimulator was used as supporting evidence for the recognition of the membrane-bound form of B Lymphocyte Stimulator by phage and scFv antibodies.

Phage ELISA

To determine the specificity of each of the scFvs, a phage ELISA was performed for each antibody against His-tagged human B Lymphocyte Stimulator, U937 plasma membranes, TNF α , BSA and an uncoated well. Antigen coating conditions were as described in 2. apart from human B Lymphocyte Stimulator. B Lymphocyte Stimulator was first biotinylated (as described in Example 3) and coated at 1 μ g/ml onto streptavidin coated plates (Reacti-Bind, Pierce) for 30 mins at room temperature. The plates were then washed, blocked and the phage ELISA performed as detailed in Example 2.

The results for 3 clones, I079C01, I081C10 and I082A02, and a control phage antibody that recognizes TNF α , are shown in FIG. 12. All 3 scFvs recognize U937 plasma membranes (U937) and His-tagged B Lymphocyte Stimulator (HIS-B Lymphocyte Stimulator) but not, biotinylated B Lymphocyte Stimulator (bio-B Lymphocyte Stimulator) or an uncoated well (PBS). This indicates that the scFvs recognize the membrane-bound form of B Lymphocyte Stimulator.

204

Example 16

Specificity for Membrane-Bound B Lymphocyte Stimulator

The specificity of the scFvs for only the membrane-bound form of B Lymphocyte Stimulator, and not for the soluble form, was confirmed using a competition ELISA. This assay assesses the ability of test phage scFvs to bind to the membrane-bound form of B Lymphocyte Stimulator on U937 plasma membranes in the presence of different forms of competing B Lymphocyte Stimulator. Competing B Lymphocyte Stimulator was either the His-tagged form of B Lymphocyte Stimulator or soluble B Lymphocyte Stimulator. ScFvs specific for the membrane-bound B Lymphocyte Stimulator would be expected to be competed out by pre-incubation with His-tagged B Lymphocyte Stimulator but not by pre-incubation with soluble B Lymphocyte Stimulator.

Maintenance of U937 cells and plasma membrane preparations were performed as detailed in Example 2.

Competition ELISA

U937 plasma membranes (50 μ l per well) were coated at 10 μ g/ml in PBS onto Falcon 96-well plates overnight at 4° C.

Individual *E. coli* colonies containing a phagemid representing one of the unique scFvs from the panel 3 were inoculated into 50 ml tubes (Falcon) containing 5 ml 2TYAG medium. Tubes were incubated at 37° C. for 4 hours, shaking. M13KO7 helper phage was added to each tube to an MOI of 10 and the tubes were incubated for a further 1 hour at 37° C. The tubes were centrifuged in a benchtop centrifuge at 3500 rpm for 10 minutes. The supernatant was removed and cell pellets were resuspended in 5 ml 2TYAK and incubated at 30° C. overnight, shaking. The next day, tubes were centrifuged at 3500 rpm for 10 min and the phage-containing supernatant carefully transferred into a fresh tube.

For each test phage antibody, 3 aliquots of 20 μ l 18% marvel/6 \times PBS were transferred into separate wells of a 96-well plate. The first aliquot was supplemented with His-tagged B Lymphocyte Stimulator to a final concentration of 60 μ g/ml. The second aliquot was supplemented with soluble B Lymphocyte Stimulator to a final concentration of 60 μ g/ml. The third aliquot was not supplemented with any competing antigen. One hundred μ l of phage supernatant was then added to each aliquot and left to block at room temperature for 1 hour.

The antigen-coated plates were washed once with PBS before the addition of 200 μ l/well 3% marvel/PBS. These plates were left to block at 37° C. for 1 hour and were then washed once with PBS. Duplicate samples of 50 μ l pre-blocked phage (above) were added to the antigen-coated plates and left at room temperature for 1 hour. Plates were washed 3 \times with PBS/0.1% Tween 20, then 3 \times with PBS. Fifty μ l/well mouse anti-M13 HRP (Pharmacia) at 1/5000 in 3% Marvel/PBS was added and left for 1 hour at room temperature. Plates were washed 3 times with PBS/0.1% Tween 20, then 3 times with PBS. Fifty μ l/well HRP-labelled anti-mouse Envision polymer (DAKO) at 1/50 in 3% marvel/PBS was added and left for 1 hour at RT. Plates were washed 3 times with PBS/0.1% Tween 20, then 3 times with PBS. Next, 50 μ l/well of TMB (Sigma) was added and plates left to develop for 30 to 60 minutes. When sufficient color has developed, 25 μ l/well 0.5M H₂SO₄ was added to

stop the reaction. The plates were read at 450 nm on a microtiter plate reader (Bio-Rad 3550).

The results for 3 clones, I079B04, I079F08 and I080B01, and a control phage antibody that recognizes TNF α , are shown in FIG. 13. All 3 scFvs recognize U937 plasma membranes (U937). This binding is competed out to background levels (i.e. comparable to the signal observed with the anti-TNF α phage antibody) in the presence of His-tagged B Lymphocyte Stimulator (HIS-B Lymphocyte Stimulator) but not biotinylated B Lymphocyte Stimulator (bio-B Lymphocyte Stimulator). This confirms that the scFvs specifically recognize the membrane-bound form but not the soluble form of B Lymphocyte Stimulator.

Example 17

High Throughput BIAcore Screen to Identify High Affinity scFvs

This is a 96-well screen where the test samples (scFvs) are derived from 1 ml periplasmic extracts of individual antibody expressing clones. Potentially higher affinity scFvs are then identified principally as those giving a large number of total RU's bound to a HIS-B Lymphocyte Stimulator surface in BIAcore. This method of ranking does assume approximately equal yields of scFv from each clone. Since this is not always the case, some scFvs may also be identified that simply express high levels of scFv. These can be discriminated from those of higher affinity by further characterization of the scFvs (see Example 18).

Preparation of ScFv from 1 ml *E. coli* Cultures

Individual *E. coli* colonies containing a phagemid representing one of the unique scFvs from panel 3 were inoculated into 96-well plates containing 100 μ l 2TYAG medium per well. Eight wells on each plate were reserved for positive and negative control samples. The plate was grown overnight at 30° C. with shaking at 120 rpm.

Next day, 1 ml of 2TYAG+345 mM sucrose was added to each well of an autoclaved 96 deep well plate (Beckman). Twenty μ l of each overnight culture was resuspended and transferred to the appropriate well of the deep well plate. The plate was grown for approximately 3.5 hours at 30° C. with shaking at 250 rpm (or until the OD₆₀₀=0.6). Fifty μ l of 1M IPTG was added to 5 ml 2TY and 10 μ l of this was added to each well. The plate was grown overnight at 30° C. with shaking at 250 rpm.

Plates were kept at 4° C. for the remainder of the procedure. The overnight plate (above) was centrifuged at 3500 rpm for 10 minutes at 4° C. to pellet the cells. The supernatant was decanted and each pellet resuspended in 100 μ l TES (0.2M Tris HCl pH8.0, 0.5 mM EDTA, 0.5M sucrose) and transferred to a fresh 96 well plate. This plate was incubated on ice for 30 minutes and then centrifuged for 10 minutes at 3500 rpm at 4° C. to pellet the cell debris. During centrifugation, 15 μ l of freshly made protease inhibitors cocktail (Roche, 1 tablet dissolved in 1.5 ml water) was added to each well of a fresh 96 well plate. Supernatants from the centrifuged plate were then transferred to the plate containing the protease inhibitors. The plate was centrifuged at 3500 rpm for 10 minutes at 4° C. and the supernatant was transferred to a further 96-well plate. This step was repeated at least once more or until there was no sign of any cell debris following centrifugation. Finally, the plate was covered in foil to prevent evaporation of samples during the BIAcore run.

Generation of a High Density HIS-B Lymphocyte Stimulator Surface

All BIAcore analysis was performed on BIAcore 2000 machines, using the BIAcore 2000 control software and evaluated using the BIAevaluation 3.0 software. A high density His-tagged B Lymphocyte Stimulator surface (>1000 RU HIS-B Lymphocyte Stimulator coupled) was prepared in flow cell 2 by amine coupling to a CM5 chip. A new CM5 chip was inserted into the BIAcore and a sensorgram started over flow cell 2 with HBS buffer at a flow rate of 5 μ l/min. The NHS and EDC solution were mixed 1:1 before injecting 30 μ l over the CM5 surface. Fifty μ l HIS-B Lymphocyte Stimulator (at 10 μ g/ml in Sodium acetate buffer, pH4) was injected and allowed to couple to the surface. Thirty μ l of ethanolamine-HCl solution was then injected to block free NHS esters. Prior to using the chip, 10 μ l of 4M Guanidine hydrochloride in HBS was injected over the surface to strip the surface of non-covalently bound B Lymphocyte Stimulator. A blank surface (no HIS-B Lymphocyte Stimulator) was also prepared over flow cell 1 so that non-specific binding effects can be subtracted from the HIS-B Lymphocyte Stimulator binding curves.

Typically, a 5000 RU His-tagged B Lymphocyte Stimulator surface was generated in this way and used for 96-well analysis of scFvs isolated from the periplasm of *E. coli*.

BIAcore Analysis

The 96-well plate containing periplasmic scFvs was secured inside the BIAcore. Two ml of 4M Guanidine hydrochloride in HBS was placed in a rack inside the BIAcore for regeneration of the HIS-B Lymphocyte Stimulator surface between samples. The sensorgram was run over flow cells 1 and 2 at a flow rate of 20 μ l/minute. The following method was run:

MAIN

FLOWCELL 1,2,3,4

LOOP cycle STEP

APROG inj % pos

ENDLOOP

APPEND CONTINUE

END

DEFINE LOOP cycle

LPARAM % pos

r1a1

r1b1

r1c1

r1d1

r1e1

r1f1 etc (all wells listed until r1h12)

END

DEFINE APROG inj

PARAM % pos

FLOW 20

KINJECT % pos 35 30 !scfv injection

QUICKINJECT r2f3 10 !regeneration

EXTRACLEAN

END

When the run had finished, the sensorgram data for flow cell 1 was subtracted from the data for flow cell 2 for each sample using the BIAevaluation software. The clones were compared with one another principally by overall RU change as the scFv dissociates from the surface. In addition a few scFvs were identified as having potentially slower off-rates. An example of the dissociation section of a typical sensorgram for 8 scFvs is shown in FIG. 14. An anti-TNF α antibody that does not recognize B Lymphocyte Stimulator was included as a control. Of the 8 scFvs exemplified, I079F06 was identified for further study due to the relatively high numbers of RU's bound to the surface.

ScFvs were identified principally if they demonstrated a RU change of over 1200, a few were also identified as having potentially slower than typical off-rates. A total of 28 clones were chosen on these criteria and are listed in Table 7.

TABLE 7

Identification of 28 antibodies to membrane-bound BLyS that demonstrate the most significant RU changes by BIAcore	
Antibody	Antibody
I079C01	I084C04
I082H08	I080E05
I079E02	I083B12
I079B05	I082G01
I079F06	I082G02
I079F06	I082C03
I079F11	I082A05
I079B12	I082D07
I080B01	I082B08
I080G09	I084A01
I099D03	I084B02
I080D03	I080A08
I080A03	I084C11
I083G03	
I080G07	

Example 18

scFv Affinity Determinations

The affinity (K_D) of the 28 scFvs was determined using the BIAcore.

Low Density HIS-B Lymphocyte Stimulator Surface for Kinetic Studies

500 RU surfaces were used for kinetic studies of purified scFv binding to HIS-B Lymphocyte Stimulator. The method to prepare these surfaces was identical to the method described in Example 17, only smaller volumes of HIS-B Lymphocyte Stimulator were injected.

Measurement of scFv Binding Kinetics

The chip containing the low density HIS-B Lymphocyte Stimulator surface was inserted into the BIAcore. A dilution series for each of the 28 purified scFvs (prepared as in Example 6) were diluted in HBS (typically starting with 50 μ g/ml scFv and double diluting down to 1.5 μ g/ml). The dilution series was then injected sequentially over the blank control (flow cell 1) and low density HIS-B Lymphocyte Stimulator surface (flow cell 2) using the following program:

```

MAIN
FLOWCELL 1,2,3,4
APROG      genab      r1d1      ab1
APROG      genab      r1d2      ab2
APROG      genab      r1d3      ab3
APROG      genab      r1d4      ab4
APROG      genab      r1d5      ab5
APROG      genab      r1d6      ab6
APPEND CONTINUE
END
DEFINE APROG genab
PARAM %Abpos %Abld
FLOW      20
KINJECT    %Abpos 200 80
INJECT     r2f3 10
EXTRACLEAN
END

```

Bound scFv were removed by injecting 10 μ l of 4M Guanidine hydrochloride in HBS (location r2f3 in the above program) over the surface between samples. Binding curves for individual scFv were analysed using the BIAevaluation software to determine antibody on- and off-rates.

A typical example of the binding curves generated for the scFv antibody I082C03 is shown in FIG. 15. The off-rate for this clone was calculated as $2 \times 10^{-3} \text{ s}^{-1}$. The affinity of I082C03 was calculated as 20 nM, assuming 100% activity of the scFv. The 5 scFvs with the highest affinities as scFvs are given in Table 8.

TABLE 8

Identification of 5 antibodies to membrane-bound BLyS that have the highest affinities as scFvs	
Antibody	Affinity (K_D)
I079F11	5 nM
I079E02	10 nM
I082G02	6 nM
I082H08	1 nM
I099D03	4 nM

Example 19

Recognition of Mouse Membrane-Bound B Lymphocyte Stimulator

The ability of the 5 scFvs listed in Table 8 to also recognize murine membrane-bound B Lymphocyte Stimulator was determined using a competition ELISA. This assay assesses the ability of test phage scFvs to bind to the membrane-bound form of B Lymphocyte Stimulator on the murine cell line, P388, plasma membranes in the presence of different forms of competing human B Lymphocyte Stimulator. Competing B Lymphocyte Stimulator was either presented as the His-tagged form of B Lymphocyte Stimulator, or soluble B Lymphocyte Stimulator. ScFvs that recognize mouse membrane-bound B Lymphocyte Stimulator would give an ELISA signal on the P388 plasma membranes that is competed out by pre-incubation with HIS-tagged B Lymphocyte Stimulator but not by pre-incubation with soluble B Lymphocyte Stimulator.

Maintenance of P388.D1 Cells and Preparation of Plasma Membranes

P388.D1 cells are a mouse monocyte-macrophage like cell line. They were cultured in L-15 medium supplemented

with 2 mM L-glutamine, 10% CS, 10 U penicillin, 100 g/ml streptomycin (all reagents from Sigma). Cells were split 1:4 every 3–4 days to maintain a cell density of $2-8 \times 10^5$ per ml. A fresh aliquot of cells was thawed from liquid nitrogen every 6 weeks. Plasma membrane fractions were prepared as described in Example 2.

Competition ELISA

P388 plasma membranes (50 μ l per well) were coated at 10 μ g/ml in PBS onto Falcon 96-well plates overnight at 4° C. The method is otherwise essentially as described Example 16.

The results for 3 clones, I079E02, I082H08 and I099D03 are shown in FIG. 16. All 3 scFvs recognize P388 plasma membranes. This binding is competed out in the presence of HIS-tagged B Lymphocyte Stimulator (HIS-B Lymphocyte Stimulator) but not in the presence of biotinylated B Lymphocyte Stimulator (bio-B Lymphocyte Stimulator). This confirms that these scFvs also recognize the membrane-bound form but not the soluble form of mouse B Lymphocyte Stimulator.

Example 20

Conversion of scFvs to IgG1 Format

The VH domain and the VL domains of scFvs that we wished to convert into IgG molecules were cloned into vectors containing the nucleotide sequences of the appropriate heavy (human IgG1) or light chain (human kappa or human lambda) constant regions such that a complete heavy or light chain molecule could be expressed from these vectors when transfected into an appropriate host cell. Further, when cloned heavy and light chains are both expressed in one cell line (from either one or two vectors), they can assemble into a complete functional antibody molecule that is secreted into the cell culture medium. Methods for converting scFvs into conventional antibody molecules are well known within the art.

Generation of NS0 Cell Lines Expressing Anti-B Lymphocyte Stimulator Antibodies (IgG1)

Plasmids containing the heavy and light chains were separately linearized using the Pvu I restriction enzyme. The linearized DNAs were purified by phenol-chloroform extraction followed by ethanol precipitation and then resuspended in H₂O. NS0 cells (10^7) from a growing culture were electroporated (0.25 kV and 975 μ F) in PBS with 12.5 μ g linearized heavy chain plasmid DNA and 37.5 μ g linearized light chain DNA. The cells were washed in 20 ml non-selective medium (10% FCS in DMEM supplemented with 6 mM glutamine, amino acids and penicillin/streptomycin) and then transferred in 12.5 ml medium into a T75 cm² flask and incubated overnight at 37° C., 5% CO₂/air. The day after transfection the cells were resuspended in selective medium containing 1 mg/ml geneticin and dispensed into 5x96-well plates at 200 μ l/well. After 18 days at 37° C. (5% CO₂/air) the colony supernatants were screened by an ELISA that detects assembled human IgG in order to identify colonies expressing IgG. Approximately twenty positive colonies were expanded and adapted to growth in serum-free, selective medium. Duplicate T25 cm² flasks were set up. Cells from one flask were frozen down as a stock and cells in the second flask were grown to saturation. The productivity of

the saturated cultures was assessed by ELISA. The highest producing cell lines were then selected for large-scale anti-body production.

The above procedure is exemplified for the I006D08 anti-B Lymphocyte Stimulator antibody constructs. Following electroporation and selection of NS0 cells, supernatants from ninety-three wells each containing a single colony were screened by ELISA to detect assembled IgG1, antibody. Twenty-seven of the supernatants were identified as containing IgG. The colonies from 24 of the positive wells were transferred to 1 ml selective medium in a 24-well plate and allowed to grow for 2 days. The 1 ml cultures of cells were then added to 4 ml selective medium containing reduced serum (0.5% FCS) in a T25 cm² flask. When the cultures reached confluency 1 ml cells were diluted in 4 ml selective, serum-free medium in a T25 cm² flask. At confluency this subculture regime was repeated again. Finally 1 ml cells from the culture containing 0.1% FCS was diluted with 9 ml serum-free, selective medium and divided into 2xT25 cm² to form the saturated and stock cultures. The stock cultures were frozen down and stored in liquid nitrogen once the cultures were confluent. The saturation culture was grown until the viability of the culture was <10%. Twenty-three out of the 24 colonies originally expanded were successfully adapted to growth in serum-free medium. The productivity of these serum-free adapted cell lines ranged from 0.3 to 17 μ g/ml by ELISA quantification of the saturated, 5 ml serum-free cultures. The I006D08-32 cell line produced 17 μ g/ml.

Large-Scale IgG Production

The highest-producing cell lines were revived from frozen stocks and then expanded to 400 ml in selective, serum-free medium in 2 liter roller bottles. The cells were grown at 37° C. and rolled at 4 rpm with the headspace being re-equilibrated with 5% CO₂/air every 2–3 days. Finally the culture was expanded to a 4 liter volume by the addition of serum-free medium without selection (400 ml per 2 liter roller bottle). The cultures were then grown to saturation.

This procedure is exemplified by the production of I006D08 antibody from the I006D08-32 cell line. The frozen stock of I006D08-32 was revived into a T25 cm² containing 5 ml serum-free medium containing 1 mg/ml geneticin and grown at 37° C. in 5% CO₂/air incubator. After two days growth the culture was diluted with 7.5 ml fresh medium and transferred to a T75 cm² flask. After a further three days in the incubator the cells were transferred to 130 ml selective medium and transferred to a 2 liter roller bottle. After three days growth the cells were diluted with 500 ml selective medium and split into 2x2 liter roller bottles. After another 2 days 100 ml fresh selective medium was added to each roller. Finally the next day the culture was expanded to a total volume of 4 liters with non-selective medium and divided into 10x2 liter roller bottles. After three days the medium was supplemented with 6 mM glutamine. The cells were grown for 17 days from the final subculture into a 4 liter volume. The cells grew up to 3×10^6 cells/ml before viability declined to $<0.2 \times 10^6$ cells/ml. At this low viability the culture supernatants were harvested. ELISA analysis indicated that the culture supernatant contained 33 μ g/ml IgG. Hence, the 4 liter culture contained 132 mg IgG.

IgG Purification

The purification of the IgG from the fermentation broth is performed using a combination of conventional techniques

211

commonly used for antibody production. Typically the culture harvest is clarified to remove cells and cellular debris prior to starting the purification scheme. This would normally be achieved using either centrifugation or filtration of the harvest. Following clarification, the antibody would typically be captured and significantly purified using affinity chromatography on Protein A Sepharose. The antibody is bound to Protein A Sepharose at basic pH and, following washing of the matrix, is eluted by a reduction of the pH. Further purification of the antibody is then achieved by gel filtration. As well as removing components with different molecular weights from the antibody this step can also be used to buffer exchange into the desired final formulation buffer.

Purification of I006D08 IgG1

The harvest was clarified by sequential filtration through 0.5 μm and 0.22 μm filters. Clarified harvest was then applied to a column of recombinant Protein A Sepharose equilibrated at pH 8.0 and washed with the equilibration buffer. I006D08 antibody was eluted from the Protein A Sepharose by application of a buffer at pH 3.5. The collected antibody containing eluate was then neutralized to pH 7.4 by the addition of pH 8.0 buffer. The neutralized eluate was concentrated by ultrafiltration using a 30 KDa cut off membrane. Concentrated material was then purified by Sephacryl S300HR gel filtration using phosphate buffered saline as the mobile phase. The final monomeric IgG1 fraction from the gel filtration column was then concentrated to the desired formulation concentration by ultrafiltration using a 30 KDa cut off membrane. The final product was filtered through a 0.22 μm filter.

Example 21

Antibody Neutralization of Murine Splenocyte Proliferation as Measured by 3HdT Incorporation

To determine if an antibody inhibited B Lymphocyte Stimulator mediated B cell proliferation, a splenocyte proliferation assay was performed. Briefly, murine splenocytes were isolated by flushing spleen with complete medium using a 25 g needle and 10 ml of complete medium (RPMI 1640 with 10% FBS containing 100 U/ml penicillin, 100 $\mu\text{g}/\text{ml}$ streptomycin, 4 mM glutamine, $5 \times 10^{-5}\text{M}$ β -mercaptoethanol). The cells were passed through a 100 micron nylon filter to remove cell clumps. The cell suspension was then ficolled at $400 \times g$ for 25 minutes at room temperature (one 15 ml conical tube/spleen; 3 ml ficol, 10 ml cell suspension/spleen; Ficoll 1083 from Sigma). The recovered cells were washed 3 times in complete medium and counted. Recovered cells were then diluted to a concentration of $3 \times 10^6/\text{ml}$ in complete medium containing a $3 \times$ concentration of SAC ($3 \times = 1:33,333$ dilution of stock) (*Staph. aureus* Cowan strain; Calbiochem).

For each antibody, 50 microliters of antibody dilutions at 30 $\mu\text{g}/\text{ml}$, 3.0 $\mu\text{g}/\text{ml}$, and 0.3 $\mu\text{g}/\text{ml}$ concentrations were aliquotted into individual wells of a 96 well plate in triplicate. Suitable positive controls, such as, for example monoclonal antibody 15C10, were also used. Medium containing no antibody (and human isotype controls (purchased commercially) when necessary) were used as negative controls.

B Lymphocyte Stimulator protein was diluted in complete medium to concentrations of 300 ng/ml, 90 ng/ml and 30 ng/ml. 50 microliters of each of the B Lymphocyte Stimu-

212

lator dilutions were then added to the antibody dilution series in the plates. The plate containing the antibody and B Lymphocyte Stimulator dilutions are then incubated for 30 minutes at 37°C ., 5% CO_2 , after which 50 microliters of the splenocyte cell suspension containing SAC was added to all wells. The plates were then incubated for 72 hours (37°C ., 5% CO_2).

After 72 hours, each well was supplemented with 50 μl of complete medium containing 0.5 μCi of ^3H -thymidine (6.7 Ci/mM; Amersham) and cells were incubated for an additional 20–24 hours at (37°C ., 5% CO_2). Following incubation cells were harvested using a Tomtec Cell Harvester and filters counted in a TopCount Scintillation counter (Packard).

Example 22

Human B cell Proliferation Assay for In Vitro Screening of B Lymphocyte Stimulator Antagonist Molecules

The bioassay for assessing the effects of putative B Lymphocyte Stimulator antagonists was performed in triplicate in 96 well format by mixing equal volumes of B Lymphocyte Stimulator, responder cells, and putative antagonist each of which is prepared as a $3 \times$ stock reagent.

B-lymphocytes were purified from human tonsil by MACS (anti-CD3 depletion), washed, and resuspended in complete medium (CM) (RPMI 1640 with 10% FBS containing 100 U/ml penicillin, 100 $\mu\text{g}/\text{ml}$ streptomycin, 4 mM glutamine, $5 \times 10^{-5}\text{M}$ β -mercaptoethanol) at a concentration of 3×10^6 cells/mL. *Staphylococcus aureus*, Cowan I (SAC, CalBiochem) was added to cells at $3 \times$ concentration ($3 \times = 1:33,333$ dilution of stock).

Meanwhile, eight serial dilutions (3-fold) of potential antagonist were prepared in CM such that the diluted antagonists are at $3 \times$ the final concentrations to be tested in the assay. Antibodies are routinely tested starting at a final concentration of 10 $\mu\text{g}/\text{mL}$ and going down to about 1.5 ng/mL.

Human rB Lymphocyte Stimulator was prepared in CM to $3 \times$ concentration ($3 \times = 300$ ng/mL, 30 ng/mL, and 3 ng/mL) in CM. Potential inhibitors were routinely tested at several concentrations of B Lymphocyte Stimulator to avoid false negatives due to unexpectedly low affinity or antagonist concentration.

Fifty microliters of diluted antagonist and 50 μL of diluted B Lymphocyte Stimulator were added to the putative antagonist dilution series.

Cells were then incubated for 72 hours (37°C ., 5% CO_2) in a fully humidified chamber. After 72 hrs., the cells were supplemented with 0.5 $\mu\text{Ci}/\text{well}$ ^3H -thymidine (6.7 Ci/mmol) and incubated for an additional 24 hours. Plates were harvested using a Tomtec Cell Harvester and filters counted in a TopCount Scintillation counter (Packard).

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in this application is incorporated in their entireties herein by reference. Further, the sequences disclosed herein are also disclosed in U.S. Provisional Application 60/212,210 filed Jun. 16, 2000 the contents of which are incorporated in their entireties herein by reference.

scFvs that Immunospecifically Bind to BlyS

Clone ID	scFv SEQ ID NO	AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	CDR1	AAs of VH CDR2	CDR3	VH CDR3 Sequence (SEQ ID NO)
1003F12S 1006GD08 1008A11 1017D10 1022D01 1031F02 1050A12 1051C04 1050B11 1050B11-01 1050B11-02 1050B11-03 1050B11-04 1050B11-05 1050B11-06 1050B11-07 1050B11-08 1050B11-09 1050B11-10 1050B11-11 1050B11-12 1050B11-13 1050B11-14 1050B11-15 1050B11-16 1050B11-17 1050B11-18 1050B11-19 1050B11-20 1050B11-21 1050B11-22 1050B11-23 1050B11-24 1050B11-25 1050B11-26 1050B11-27 1050B11-28 1093D03 1093D09 1093C08 1097D11 1101A04 1101B01 1102A02 1102E01 1102G06	1	138-248	160-173	22 189-195	228-237	1-122	26-35	50-66	99-111	HDDDVLTGYVEES (SEQ ID NO: 2130)
	2	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPHYGMNV (SEQ ID NO: 2133)
	3	144-254	166-179	195-201	234-243	1-128	26-37	52-69	102-117	DRYDILTYGYVGMNV (SEQ ID NO: 2129)
	4	148-255	169-179	195-201	234-244	1-132	26-35	50-66	99-121	VQMSSEYDLLTGINVPFYFDY (SEQ ID NO: 2132)
	5	142-249	160-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGSYVGMNV (SEQ ID NO: 2135)
	6	137-251	163-173	189-195	228-240	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)
	7	140-250	164-174	190-196	229-239	1-124	26-35	50-66	99-113	APYDILLTHYHFYFDY (SEQ ID NO: 2134)
	8	145-256	168-181	197-203	236-245	1-129	26-35	50-66	99-118	AATTSQKHKNYAYFYGMNV (SEQ ID NO: 2131)
	9	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PYDILTSYVFQYFDH (SEQ ID NO: 2137)
	10	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQVWA (SEQ ID NO: 2143)
	11	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQVWA (SEQ ID NO: 2143)
	12	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQVWA (SEQ ID NO: 2143)
	13	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQVWA (SEQ ID NO: 2143)
	14	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQVWA (SEQ ID NO: 2143)
	15	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQVWA (SEQ ID NO: 2143)
	16	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2141)
	17	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQVWA (SEQ ID NO: 2142)
	18	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQVWA (SEQ ID NO: 2140)
	19	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2144)
	20	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQVWA (SEQ ID NO: 2140)
	21	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQVWA (SEQ ID NO: 2140)
	22	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2137)
	23	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQVWA (SEQ ID NO: 2137)
	24	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQVWA (SEQ ID NO: 2143)
	25	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQVWA (SEQ ID NO: 2143)
	26	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2144)
	27	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2139)
	28	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2139)
	29	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2139)
	30	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2138)
	31	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2138)
	32	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2138)
	33	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2139)
	34	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2144)
	35	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2139)
	36	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2138)
	37	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2137)
	38	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLTGYLS (SEQ ID NO: 2145)
	39	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2137)
	40	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQVWA (SEQ ID NO: 2143)
	41	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2139)
	42	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2137)
	43	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2137)
	44	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2137)
	45	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2144)
	46	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFQYFDH (SEQ ID NO: 2141)

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
I087A07	47	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLPVTP (SEQ ID NO: 2227)	
I087A08	48	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVCRPHF (SEQ ID NO: 2238)	
I087A09	49	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVRCPPV (SEQ ID NO: 2272)	
I087B02	50	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVFRPDL (SEQ ID NO: 2281)	
I087B03	51	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVKSMT (SEQ ID NO: 2305)	
I087B04	52	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVFLYC (SEQ ID NO: 2292)	
I087B05	53	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVVPST (SEQ ID NO: 2270)	
I087B06	54	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVGHGL (SEQ ID NO: 2282)	
I087B08	55	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVPCPPR (SEQ ID NO: 2261)	
I087B09	56	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVCYPPA (SEQ ID NO: 2240)	
I087C02	57	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVPLLS (SEQ ID NO: 2224)	
I087C05	58	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVALYRL (SEQ ID NO: 2234)	
I087C06	59	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVRAFS (SEQ ID NO: 2271)	
I087C07	60	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVCTVP (SEQ ID NO: 2319)	
I087C08	61	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVWPSFES (SEQ ID NO: 2277)	
I087D01	62	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVTPRGY (SEQ ID NO: 2275)	
I087D02	63	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVSSLS (SEQ ID NO: 2213)	
I087D03	64	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVPLPLC (SEQ ID NO: 2263)	
I087D05	65	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVPPSFL (SEQ ID NO: 2266)	
I087D07	66	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVPTSTI (SEQ ID NO: 2269)	
I087D09	67	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVISCWA (SEQ ID NO: 2299)	
I087E04	68	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVSALEPP (SEQ ID NO: 2274)	
I087E05	69	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVGRHLF (SEQ ID NO: 2236)	
I087E10	70	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVVSFSL (SEQ ID NO: 2307)	
I087F02	71	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVMGVTPS (SEQ ID NO: 2322)	
I087F04	72	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLRFPVL (SEQ ID NO: 2326)	
I087F05	73	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVPSVGG (SEQ ID NO: 2267)	
I087F07	74	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVPPTRH (SEQ ID NO: 2286)	
I087F08	75	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVLRSD (SEQ ID NO: 2243)	
I087F09	76	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVPLPP (SEQ ID NO: 2310)	
I087G05	77	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVLRCLV (SEQ ID NO: 2239)	
I087G06	78	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVHPSRS (SEQ ID NO: 2285)	
I087G07	79	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLRPLPQ (SEQ ID NO: 2241)	
I087G09	80	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVGPYGT (SEQ ID NO: 2284)	
I087G10	81	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVTPCT (SEQ ID NO: 2276)	
I087H02	82	137-244	160-170	186-192	225-233	1-121	26-35	50-66	99-110	ASYLTSSSLDN (SEQ ID NO: 2265)	
I088A01	83	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVIFLPL (SEQ ID NO: 2290)	
I088A03	84	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLIHYPH (SEQ ID NO: 2335)	
I088A04	85	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILINVFHYAS (SEQ ID NO: 2323)	
I088A08	86	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILINVILYLYH (SEQ ID NO: 2295)	
I088A09	87	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVILYFH (SEQ ID NO: 2137)	
I088A10	88	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)	
I088A11	89	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLMYFPH (SEQ ID NO: 2220)	
I088A12	90	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFYPL (SEQ ID NO: 2325)	
I088B01	91	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)	
I088B02	92	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFDYAS (SEQ ID NO: 2244)	
I088B03	93	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVIFLPL (SEQ ID NO: 2290)	

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunoselectively Bind to BLyS										AAs of VH CDR3	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	AAs of VH CDR1	AAs of VH CDR2								
I088B05	94	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088B06	95	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2324)									
I088B07	96	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088B08	97	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088B09	98	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2303)									
I088B10	99	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088B12	100	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVLFQYFDH (SEQ ID NO: 2223)									
I088C01	101	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2317)									
I088C03	102	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088C09	103	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088C12	104	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088D01	105	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088D03	106	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2215)									
I088D04	107	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVLFQYFDH (SEQ ID NO: 2225)									
I088D07	108	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088D08	109	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088D11	110	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088E01	111	138-248	163-174	190-196	229-237	1-122	23-32	47-63	96-111	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088E02	112	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2216)									
I088E03	113	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088E04	114	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088E08	115	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088E10	116	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088E11	117	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088F07	118	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088G02	119	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088G03	120	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088G07	121	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2260)									
I088G09	122	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2264)									
I088G10	123	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2301)									
I088H05	124	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I088H07	125	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I092A03	126	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2258)									
I092A05	127	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I092A06	128	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I092A08	129	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2283)									
I092A10	130	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I092A11	131	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I092B01	132	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I092B02	133	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I092B04	134	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I092B05	135	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I092B10	136	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I092B12	137	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I092C01	138	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I092C02	139	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)									
I092C07	140	140-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVLFQYFDH (SEQ ID NO: 2328)									

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLYS										AAs of VH CDR3	AAs of VH CDR1	AAs of VH CDR2	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH CDR3	AAs of VH CDR1	AAs of VH CDR2	VH CDR3 Sequence (SEQ ID NO)
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2										
1092C08	141	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYYSI (SEQ ID NO: 2254)											
1092C12	142	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092D01	143	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFKYYTD (SEQ ID NO: 2226)											
1092D07	144	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092D09	145	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFMHAYPL (SEQ ID NO: 2255)											
1092D10	146	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2256)											
1092D11	147	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092E01	148	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2230)											
1092E03	149	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2248)											
1092E04	150	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092E07	151	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2327)											
1092E10	152	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092E11	153	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092E11	154	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092E11	155	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092E11	156	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092E11	157	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092E11	158	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092E11	159	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092E11	160	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092E11	161	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092E11	162	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092E11	163	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1092E11	164	137-244	160-170	186-192	225-233	1-121	26-35	50-66	99-110	ASYLSTSSSLDN (SEQ ID NO: 2265)											
1093A06	165	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2334)											
1093A09	166	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2268)											
1093A11	167	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1093A12	168	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1093B02	169	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1093B05	170	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1093B06	171	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1093B09	172	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1093B12	173	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2289)											
1093C02	174	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1093C03	175	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2332)											
1093C05	176	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1093D05	177	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2295)											
1093D08	178	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2245)											
1093D10	179	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2273)											
1093D12	180	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											
1093E01	181	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2302)											
1093E02	182	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2297)											
1093E05	183	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2283)											
1093E08	184	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2321)											
1093E10	185	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2246)											
1093F01	186	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2251)											
1093F03	187	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVFGYFDH (SEQ ID NO: 2137)											

scFvs that Immunospecifically Bind to BLYS

Clone ID	seqFv	SEQ ID NO	AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
1093F05	188	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1093F08	189	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1093F11	190	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYLFHFPL (SEQ ID NO: 2333)		
1093G07	191	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYLVQYVL (SEQ ID NO: 2237)		
1093G11	192	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1093G12	193	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1093H06	194	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094A08	195	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDY (SEQ ID NO: 2280)		
1094B07	196	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYLPVWVS (SEQ ID NO: 2228)		
1094B08	197	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094B12	198	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094C11	199	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094C12	200	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094D06	201	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYIEYVPV (SEQ ID NO: 2288)		
1094D07	202	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094D08	203	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYLVHLP (SEQ ID NO: 2314)		
1094D09	204	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094D10	205	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094D11	206	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFHEYVPV (SEQ ID NO: 2218)		
1094E04	207	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094E08	208	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094F04	209	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094F05	210	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094F10	211	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094F11	212	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094F12	213	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094G06	214	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSVYFQYFDH (SEQ ID NO: 2137)		
1094G10	215	141-251	16									

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS					AAs of VH CDR1	AAs of VL CDR1	AAs of VH CDR2	AAs of VL CDR2	AAs of VH CDR3	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH								
I095F09	235	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVIGFYPV (SEQ ID NO: 2291)				
I095G06	236	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I095G09	237	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVMDYFSV (SEQ ID NO: 2253)				
I095G11	238	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096A01	239	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096A10	240	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLPFYAL (SEQ ID NO: 2222)				
I096B01	241	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096B03	242	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096C01	243	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLPYLTH (SEQ ID NO: 2229)				
I096C06	244	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096C09	245	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096D01	246	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096D02	247	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096D05	248	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096D06	249	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096D09	250	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096E02	251	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096E06	252	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096E11	253	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096F02	254	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096G01	255	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096G02	256	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096G05	257	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096G07	258	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096G09	259	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096G12	260	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I096H01	261	137-244	160-170	186-192	225-233	1-121	26-35	50-66	99-110	ASYLTSYVLEFFSH (SEQ ID NO: 2315)				
I097A04	262	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097A06	263	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097A09	264	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097B02	265	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097B09	266	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097B10	267	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097B11	268	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097C05	269	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097C09	270	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097C11	271	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097D05	272	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097D06	273	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097E01	274	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097E04	275	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097E08	276	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097E09	277	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097E09	278	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097G10	279	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				
I097H02	280	137-244	160-170	186-192	225-233	1-121	26-35	50-66	99-110	ASYLTSYVQYFDH (SEQ ID NO: 2265)				
I098A04	281	141-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQYFDH (SEQ ID NO: 2137)				

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scfvs that Immunospecifically Bind to BlyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	Sequence (SEQ ID NO)	
		scfvs that Immunospecifically Bind to BlyS									
		AAs of VH CDR3 Sequence (SEQ ID NO)									
		99-114									
I098A05	282	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I098B08	283	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I098C01	284	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I098C04	285	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I098F11	286	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I098F12	287	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I098G02	288	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I098G12	289	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I098H05	290	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I101A01	291	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I101B04	292	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I101B06	293	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I101D04	294	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I101D07	295	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I101E09	296	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I101E12	297	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I101G02	298	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I102C03	300	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I102E09	301	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I102F02	302	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I102G08	303	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I102G09	304	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I106A09	305	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I106B02	306	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I106B06	307	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I106C07	308	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I106E05	309	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I106E12	310	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I106G03	312	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I109B06	313	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I109D12	314	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I109E12	315	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I109G06	316	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I109H04	317	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I110B03	318	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I112D09	319	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I112F10	320	141-251	166-177	193-199	232-240	1-125	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-114		
I089F12	321	139-249	163-173	189-195	228-238	1-123	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-112		
I105E12	322	139-249	163-173	189-195	228-238	1-123	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-112		
I108D08	323	139-249	163-173	189-195	228-238	1-123	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-112		
I108E06	324	139-249	163-173	189-195	228-238	1-123	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-112		
I113E07	325	139-249	163-173	189-195	228-238	1-123	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-112		
I114G05	326	139-249	163-173	189-195	228-238	1-123	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-112		
I116A01	327	139-249	163-173	189-195	228-238	1-123	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-112		
I116A09	328	139-249	163-173	189-195	228-238	1-123	50-66	PFYDILTSYVLFQYFDH (SEQ ID NO: 2137)	99-112		

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BlyS										AAs of VH CDR2	AAs of VH CDR3	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	AAs of VH CDR1	AAs of VH CDR2									
I116C11	329	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPHHFDL (SEQ ID NO: 2147)										
I085A01	330	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPHDHLF (SEQ ID NO: 2602)										
I085A02	331	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFSDPLGF (SEQ ID NO: 2639)										
I085A03	332	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPHPLSF (SEQ ID NO: 2561)										
I085A04	333	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPLAPLF (SEQ ID NO: 2550)										
I085A05	334	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFSDPLSL (SEQ ID NO: 2659)										
I085A06	335	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFSPAPLSF (SEQ ID NO: 2611)										
I085A07	336	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFSPAPLSF (SEQ ID NO: 2611)										
I085A09	337	138-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRDILLFNDALS (SEQ ID NO: 2632)										
I085A10	338	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-111	SRDILLFSPAPLSF (SEQ ID NO: 2609)										
I085A11	339	138-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRDILLFPHDPLF (SEQ ID NO: 2663)										
I085B01	340	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFQSPLYP (SEQ ID NO: 2466)										
I085B02	341	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPHSSLYF (SEQ ID NO: 2392)										
I085B03	342	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPYDPLF (SEQ ID NO: 2638)										
I085B04	343	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPHAPLYF (SEQ ID NO: 2589)										
I085B05	344	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPHAPLSF (SEQ ID NO: 2573)										
I085B06	345	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPLSPF (SEQ ID NO: 2574)										
I085B07	346	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPDFMAP (SEQ ID NO: 2433)										
I085B10	347	138-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRDILLFPHSPLY (SEQ ID NO: 2470)										
I085B12	348	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPQDPLSP (SEQ ID NO: 2372)										
I085C02	349	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPDPLLS (SEQ ID NO: 2430)										
I085C03	350	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPHGPLI (SEQ ID NO: 2400)										
I085C05	351	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPGPLIF (SEQ ID NO: 2491)										
I085C06	352	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPTAALSF (SEQ ID NO: 2341)										
I085C07	353	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFHTPLRF (SEQ ID NO: 2375)										
I085C09	354	138-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRDILLFPHSPLI (SEQ ID NO: 2468)										
I085C10	355	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFSPPLIF (SEQ ID NO: 2471)										
I085C12	356	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFSPHPLF (SEQ ID NO: 2680)										
I085D01	357	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPRLLF (SEQ ID NO: 2548)										
I085D02	358	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFSPQYDLF (SEQ ID NO: 2523)										
I085D03	359	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFSPPLIF (SEQ ID NO: 2713)										
I085D04	360	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFSPPLIF (SEQ ID NO: 2646)										
I085D06	361	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFSPPLIF (SEQ ID NO: 2488)										
I085D07	362	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFSPAPLIF (SEQ ID NO: 2694)										
I085D09	363	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPHSVLSF (SEQ ID NO: 2477)										
I085D10	364	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFQTPPLF (SEQ ID NO: 2467)										
I085D11	365	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPHSPLHF (SEQ ID NO: 2563)										
I085D12	366	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPHAPLAP (SEQ ID NO: 2510)										
I085E01	367	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPHHTLRF (SEQ ID NO: 2495)										
I085E02	368	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPYAVLHF (SEQ ID NO: 2620)										
I085E07	370	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPTSPLR (SEQ ID NO: 2575)										
I085E08	371	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFSDALS (SEQ ID NO: 2568)										
I085E09	372	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPNAPLDF (SEQ ID NO: 2603)										
I085E10	373	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFPHDPPRF (SEQ ID NO: 2628)										
I085E11	374	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFSPPLRF (SEQ ID NO: 2668)										
I085E12	375	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILLFSSPLSN (SEQ ID NO: 2716)										
										SRDILLFPHPLTIP (SEQ ID NO: 2431)										

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunoselectively Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VH CDR1	AAs of VH CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
I085F01	376	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPRSPLLF (SEQ ID NO: 2551)	
I085F02	377	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPTSPQL (SEQ ID NO: 2376)	
I085F03	378	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPYTPLLF (SEQ ID NO: 2682)	
I085F04	379	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPSPPLAF (SEQ ID NO: 2707)	
I085F05	380	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLPYF (SEQ ID NO: 2706)	
I085F06	381	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFAHLLF (SEQ ID NO: 2586)	
I085F07	382	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAGPLRF (SEQ ID NO: 2410)	
I085F09	383	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPAFFV (SEQ ID NO: 2439)	
I085F10	384	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFSDSGFA (SEQ ID NO: 2662)	
I085F11	385	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPSSYLEF (SEQ ID NO: 2339)	
I085F12	386	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLII (SEQ ID NO: 2558)	
I085G01	387	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFSPALHP (SEQ ID NO: 2605)	
I085G02	388	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPNAPLL (SEQ ID NO: 2613)	
I085G03	389	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAAPLLF (SEQ ID NO: 2403)	
I085G04	390	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFSPALDP (SEQ ID NO: 2601)	
I085G07	391	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPNAVLDI (SEQ ID NO: 2629)	
I085G08	392	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPSEPLF (SEQ ID NO: 2664)	
I085G09	393	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPSSVLP (SEQ ID NO: 2338)	
I085G10	394	138-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRDLLFPAPLQ (SEQ ID NO: 2354)	
I085G11	395	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLAP (SEQ ID NO: 2445)	
I085G12	396	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPSSPLHP (SEQ ID NO: 2576)	
I085H10	397	142-249	163-173	189-195	228-238	1-123	26-35	50-66	99-115	DGYDILGTYSYGYGMDV (SEQ ID NO: 2135)	
I086A03	398	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFSPMLTF (SEQ ID NO: 2695)	
I086A04	399	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPHSLHP (SEQ ID NO: 2438)	
I086A05	400	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPHAPLH (SEQ ID NO: 2569)	
I086A07	401	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDAALRF (SEQ ID NO: 2421)	
I086A09	402	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPSSHLSF (SEQ ID NO: 2704)	
I086A10	403	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAPLSS (SEQ ID NO: 2624)	
I086A11	404	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAPLTP (SEQ ID NO: 2577)	
I086B02	405	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPYDPLHS (SEQ ID NO: 2635)	
I086B03	406	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPHFPLHP (SEQ ID NO: 2348)	
I086B03	407	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAHPLF (SEQ ID NO: 2412)	
I086B05	408	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFEPPII (SEQ ID NO: 2457)	
I086B06	409	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAPLNP (SEQ ID NO: 2364)	
I086B07	410	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPSSPLTF (SEQ ID NO: 2720)	
I086B09	411	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPTSPLSF (SEQ ID NO: 2579)	
I086B10	412	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDIDGLSS (SEQ ID NO: 2428)	
I086B11	413	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPIPLCF (SEQ ID NO: 2530)	
I086C03	414	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPTAPLYG (SEQ ID NO: 2535)	
I086C05	415	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPHHSLTF (SEQ ID NO: 2427)	
I086C07	416	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPQGPLRF (SEQ ID NO: 2440)	
I086C08	417	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAAPLAF (SEQ ID NO: 2401)	
I086C09	418	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPHPLLF (SEQ ID NO: 2350)	
I086C10	419	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPTPEPLF (SEQ ID NO: 2541)	
I086C11	420	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLSF (SEQ ID NO: 2432)	
I086C12	421	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDLSLF (SEQ ID NO: 2622)	
I086D01	422	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFSPAPLTP (SEQ ID NO: 2630)	

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLys										AAs of VH CDR3	AAs of VH CDR2	AAs of VH CDR1	AAs of VH	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VL	AAs of VL CDR1						
I086D04	423	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRLLFFPYAPLYD (SEQ ID NO: 2697)							
I086D05	424	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPSPLSF (SEQ ID NO: 2461)							
I086D06	425	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPTAPLDL (SEQ ID NO: 2379)							
I086D07	426	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPHTLTF (SEQ ID NO: 2365)							
I086D08	427	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPHTLTF (SEQ ID NO: 2473)							
I086D09	428	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPNHPMP (SEQ ID NO: 2665)							
I086D10	429	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPSSLEF (SEQ ID NO: 2587)							
I086D11	430	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPNAPLHP (SEQ ID NO: 2610)							
I086D12	431	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPRAHLRF (SEQ ID NO: 2469)							
I086E02	432	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPYDPLHF (SEQ ID NO: 2621)							
I086E03	433	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDHALQS (SEQ ID NO: 2598)							
I086E05	434	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPRTPLTF (SEQ ID NO: 2567)							
I086E07	435	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAAHLSF (SEQ ID NO: 2398)							
I086E08	436	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAPLTF (SEQ ID NO: 2490)							
I086E09	437	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFSLAP (SEQ ID NO: 2464)							
I086E10	438	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAPLRF (SEQ ID NO: 2367)							
I086E12	439	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAPLRF (SEQ ID NO: 2522)							
I086F02	440	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPSPPLRI (SEQ ID NO: 2714)							
I086F05	441	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPTPLQF (SEQ ID NO: 2540)							
I086F08	442	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPSPPLSA (SEQ ID NO: 2643)							
I086F09	443	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPYNTPIF (SEQ ID NO: 2653)							
I086F11	444	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAPLDF (SEQ ID NO: 2489)							
I086G03	445	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAPLDF (SEQ ID NO: 2513)							
I086G04	446	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLLI (SEQ ID NO: 2454)							
I086G05	447	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLLI (SEQ ID NO: 2537)							
I086G06	448	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAPLTF (SEQ ID NO: 2407)							
I086G07	449	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAPLTF (SEQ ID NO: 2448)							
I086G09	450	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPAPLTF (SEQ ID NO: 2385)							
I086G10	451	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPADSLF (SEQ ID NO: 2391)							
I086H05	452	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPYSPPLTH (SEQ ID NO: 2679)							
I089A01	453	138-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRDLLFPDPLI (SEQ ID NO: 2612)							
I089A03	454	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2590)							
I089A06	455	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPHTPLHF (SEQ ID NO: 2485)							
I089A07	456	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2539)							
I089A08	457	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2539)							
I089A10	458	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2682)							
I089A11	459	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2436)							
I089B01	460	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2572)							
I089B02	461	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2450)							
I089B03	462	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2528)							
I089B04	463	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2556)							
I089B05	464	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2712)							
I089B06	465	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2596)							
I089B07	466	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2374)							
I089B08	467	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2405)							
I089B09	468	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2384)							
I089B10	469	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLI (SEQ ID NO: 2571)							

scFvs that Immunospecifically Bind to BLYS

Clone ID	scFv SEQ ID NO	AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	scFvs that Immunospecifically Bind to BLyS	
										Sequence (SEQ ID NO)	Seq ID NO
1089B11	470	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPNSPLFP (SEQ ID NO: 2388)	2388
1089C01	471	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPHYGMDV (SEQ ID NO: 2133)	2133
1089C02	472	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPRSPPLF (SEQ ID NO: 2551)	2551
1089C03	473	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPYHPPLF (SEQ ID NO: 2532)	2532
1089C05	474	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSSALRF (SEQ ID NO: 2722)	2722
1089C06	475	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSPYLSF (SEQ ID NO: 2701)	2701
1089C07	476	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFQAPLFD (SEQ ID NO: 2683)	2683
1089C09	477	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPHAPFTF (SEQ ID NO: 2507)	2507
1089D01	478	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPHAPLVL (SEQ ID NO: 2581)	2581
1089D02	479	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPHYGMDV (SEQ ID NO: 2133)	2133
1089D03	480	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPHYPLLF (SEQ ID NO: 2344)	2344
1089D04	481	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSSPLSP (SEQ ID NO: 2717)	2717
1089D05	482	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPHAPLFT (SEQ ID NO: 2546)	2546
1089D07	483	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFNDPLLI (SEQ ID NO: 2634)	2634
1089D08	484	138-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRDLLFFPHAPLQ (SEQ ID NO: 2554)	2554
1089D09	485	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSHAFHE (SEQ ID NO: 2677)	2677
1089D11	486	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFNHPLYP (SEQ ID NO: 2663)	2663
1089E01	487	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPYSPLFP (SEQ ID NO: 2657)	2657
1089E02	488	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFQDPLHP (SEQ ID NO: 2346)	2346
1089E03	489	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFDPAPLFP (SEQ ID NO: 2423)	2423
1089E04	490	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFHSPLLI (SEQ ID NO: 2453)	2453
1089E06	491	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFGSPLLF (SEQ ID NO: 2491)	2491
1089E09	492	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSPPLTF (SEQ ID NO: 2718)	2718
1089E10	493	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFTPQLSF (SEQ ID NO: 2566)	2566
1089F01	494	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPLPLF (SEQ ID NO: 2380)	2380
1089F03	495	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPYSPLLF (SEQ ID NO: 2580)	2580
1089F04	496	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFHSPRLI (SEQ ID NO: 2459)	2459
1089F05	497	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPRAPLFP (SEQ ID NO: 2490)	2490
1089F06	498	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPRPLTF (SEQ ID NO: 2567)	2567
1089F08	499	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSPAPLTF (SEQ ID NO: 2626)	2626
1089F09	500	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSAPLTF (SEQ ID NO: 2721)	2721
1089F10	501	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSHPLLF (SEQ ID NO: 2687)	2687
1089F11	502	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPNQPLSF (SEQ ID NO: 2667)	2667
1089G01	503	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPLEPMHF (SEQ ID NO: 2565)	2565
1089G02	504	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSAPLTF (SEQ ID NO: 2626)	2626
1089G03	505	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSAPLTF (SEQ ID NO: 2721)	2721
1089G05	506	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSAPLTF (SEQ ID NO: 2687)	2687
1089G06	507	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPRPLTF (SEQ ID NO: 2721)	2721
1089G07	508	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSAPLTF (SEQ ID NO: 2389)	2389
1089G08	509	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSAPLTF (SEQ ID NO: 2514)	2514
1089G11	510	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSAPLTF (SEQ ID NO: 2597)	2597
1089H11	511	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSAPLTF (SEQ ID NO: 2688)	2688
1089H12	512	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILFTGYSYVGMDV (SEQ ID NO: 2135)	2135
1089H13	513	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSAPLTF (SEQ ID NO: 2416)	2416
1089A03	514	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPNSTLSF (SEQ ID NO: 2678)	2678
1089A04	515	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFDAPLTF (SEQ ID NO: 2426)	2426
1089A05	516	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPHEPLII (SEQ ID NO: 2648)	2648

scFvs that Immunospecifically Bind to BLYS

Clone ID	seqFv	SEQ ID NO	AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
I090A06	517	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFTPTPLSF (SEQ ID NO: 2600)	
I090A07	518	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFTPEPLV (SEQ ID NO: 2479)	
I090A08	519	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFTPTPLHF (SEQ ID NO: 2584)	
I090B01	520	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDPLTF (SEQ ID NO: 2627)	
I090B03	521	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPQAPLTF (SEQ ID NO: 2705)	
I090B04	522	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPHAPLEA (SEQ ID NO: 2520)	
I090B05	523	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDHPPLF (SEQ ID NO: 2520)	
I090B06	524	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPRAPLRF (SEQ ID NO: 2496)	
I090B08	525	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPRAPLRF (SEQ ID NO: 2542)	
I090B11	526	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPTPLTF (SEQ ID NO: 2474)	
I090B12	527	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPQHPPLSF (SEQ ID NO: 2452)	
I090C01	528	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSAPLTF (SEQ ID NO: 2591)	
I090C02	529	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFQAPLTF (SEQ ID NO: 2702)	
I090C03	530	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPRAPLRF (SEQ ID NO: 2493)	
I090C05	531	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPRAPLRF (SEQ ID NO: 2567)	
I090C06	532	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPHAPLDF (SEQ ID NO: 2538)	
I090C07	533	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPHAGFDS (SEQ ID NO: 2498)	
I090C08	534	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPSPLSF (SEQ ID NO: 2676)	
I090C10	535	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFGRLTF (SEQ ID NO: 2358)	
I090D02	536	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPAEHLTF (SEQ ID NO: 2408)	
I090D03	537	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPTAPLRF (SEQ ID NO: 2351)	
I090D04	538	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPHEPLTA (SEQ ID NO: 2654)	
I090D05	539	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFHAPLFE (SEQ ID NO: 2529)	
I090D06	540	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPRAPLDF (SEQ ID NO: 2367)	
I090D07	541	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPGTLRF (SEQ ID NO: 2462)	
I090D08	542	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSSPLVF (SEQ ID NO: 2723)	
I090D09	543	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPRDPLAF (SEQ ID NO: 2505)	
I090D12	544	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFTPSPLSF (SEQ ID NO: 2579)	
I090E04	545	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFHAPLTL (SEQ ID NO: 2552)	
I090E05	546	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSAPISF (SEQ ID NO: 2588)	
I090E06	547	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFQGPLSF (SEQ ID NO: 2443)	
I090E07	548	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPGSLPH (SEQ ID NO: 2484)	
I090E09	549	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSDPLSF (SEQ ID NO: 2647)	
I090E11	550	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPHDXGLAP (SEQ ID NO: 2700)	
I090E12	551	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFTPSPLTF (SEQ ID NO: 2582)	
I090F01	552	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFNGPLHP (SEQ ID NO: 2649)	
I090F02	553	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFQAPLSF (SEQ ID NO: 2696)	
I090F03	554	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFTPAPLSF (SEQ ID NO: 2526)	
I090F04	555	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPTPLQF (SEQ ID NO: 2460)	
I090F05	556	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFDPLPHF (SEQ ID NO: 2359)	
I090F06	557	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSEPLQL (SEQ ID NO: 2666)	
I090F07	558	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFEPALRF (SEQ ID NO: 2451)	
I090F08	559	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPLHLF (SEQ ID NO: 2570)	
I090F09	560	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFHYPLLF (SEQ ID NO: 2344)	
I090F10	561	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFPRDPLRI (SEQ ID NO: 2527)	
I090F11	562	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFSNPLTF (SEQ ID NO: 2698)	
I090G01	563	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFFTPALEI (SEQ ID NO: 2347)	

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
I09G002	564	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2395)	
I09G004	565	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2633)	
I09G005	566	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2472)	
I09G006	567	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2656)	
I09G007	568	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2480)	
I09G008	569	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2492)	
I09G009	570	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2356)	
I09G010	571	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2343)	
I09G012	572	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2669)	
I09A02	573	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2724)	
I09A03	574	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2592)	
I09A06	575	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2594)	
I09A11	576	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2441)	
I09B01	577	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2585)	
I09B02	578	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2361)	
I09B04	579	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2395)	
I09B05	580	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2475)	
I09B07	581	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2626)	
I09B10	582	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2342)	
I09B11	583	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2444)	
I09B12	584	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2690)	
I09C02	585	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2414)	
I09C03	586	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2378)	
I09C04	587	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2531)	
I09C05	588	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2583)	
I09C06	589	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2344)	
I09C09	590	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2415)	
I09C11	591	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2650)	
I09C12	592	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2618)	
I09D01	593	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2672)	
I09D02	594	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2673)	
I09D04	595	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2443)	
I09D05	596	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2650)	
I09D06	597	138-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRDLLFPDRPQF (SEQ ID NO: 2456)	
I09D07	598	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2645)	
I09D09	599	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2719)	
I09E01	600	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2425)	
I09E02	601	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2689)	
I09E03	602	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2352)	
I09E04	603	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2547)	
I09E06	604	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2576)	
I09E07	605	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2661)	
I09E08	606	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2607)	
I09E09	607	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2361)	
I09E10	608	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2711)	
I09F01	609	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2486)	
I09F03	610	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPDRPQF (SEQ ID NO: 2599)	

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
I091F05	611	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPLAHP (SEQ ID NO: 2553)	
I091F06	612	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHDPLGF (SEQ ID NO: 2353)	
I091F07	613	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHYGMVDV (SEQ ID NO: 2133)	
I091F08	614	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHQSPPLIF (SEQ ID NO: 2458)	
I091F09	615	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHSHLSE (SEQ ID NO: 2354)	
I091F10	616	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHSPDLF (SEQ ID NO: 2444)	
I091F11	617	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHSPSP (SEQ ID NO: 2549)	
I091F12	618	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHYGMVDV (SEQ ID NO: 2133)	
I091G01	619	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNAALYP (SEQ ID NO: 2386)	
I091G03	620	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLFG (SEQ ID NO: 2355)	
I091G04	621	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHGAPLSP (SEQ ID NO: 2478)	
I091G05	622	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	ARDLLFLPHAAPIWP (SEQ ID NO: 2397)	
I091G06	623	138-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I091G07	624	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I091G09	625	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I091G10	626	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I091G11	627	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I091G12	628	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04A01	629	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04A07	630	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04A08	631	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04A09	632	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04A10	633	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04A11	634	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04B02	635	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04B04	636	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04B09	637	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04B11	638	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04C01	640	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04C04	641	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04C05	642	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04C06	643	138-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04C07	644	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04C09	645	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04D01	646	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04D02	647	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04D03	648	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04D04	649	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04D07	650	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04D08	651	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04D09	652	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04E01	653	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04E02	654	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04E03	655	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04E05	656	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	
I04E05	657	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFLPHNDPLR (SEQ ID NO: 2637)	

TABLE 1-continued

Clone ID	scfv SEQ ID NO	scfvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VH	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
I104E11	658	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFYPAPLSF (SEQ ID NO: 2385)	
I104E12	659	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPASP (SEQ ID NO: 2364)	
I104F02	660	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPHDPLSP (SEQ ID NO: 2616)	
I104F03	661	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPRDPLRF (SEQ ID NO: 2360)	
I104F04	662	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPGDPLDF (SEQ ID NO: 2481)	
I104F05	663	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPHGPLTF (SEQ ID NO: 2402)	
I104F06	664	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPHAPLSF (SEQ ID NO: 2573)	
I104F07	665	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFSPSPLIL (SEQ ID NO: 2465)	
I104F10	666	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPNSPLSP (SEQ ID NO: 2362)	
I104F11	667	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPQDPLVF (SEQ ID NO: 2708)	
I104F12	668	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPKAPLVE (SEQ ID NO: 2544)	
I104G04	669	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPHAPLRF (SEQ ID NO: 2559)	
I104G05	670	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPRAPLAP (SEQ ID NO: 2476)	
I104G09	671	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPTAPLNF (SEQ ID NO: 2518)	
I104G11	672	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRHLLFPQGPLSF (SEQ ID NO: 2482)	
I105A02	673	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPHPLNP (SEQ ID NO: 2494)	
I105A03	674	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPHSFDL (SEQ ID NO: 2147)	
I105A04	675	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPQAPLYP (SEQ ID NO: 2378)	
I105A08	676	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPAPLAP (SEQ ID NO: 2487)	
I105A09	677	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFRSPLSF (SEQ ID NO: 2557)	
I105A11	678	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFSHSFDI (SEQ ID NO: 2692)	
I105B04	679	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPSPHP (SEQ ID NO: 2658)	
I105B05	680	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPSPLSF (SEQ ID NO: 2676)	
I105B07	681	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPHSFDL (SEQ ID NO: 2147)	
I105B08	682	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPHSFDL (SEQ ID NO: 2147)	
I105B10	683	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPASP (SEQ ID NO: 2364)	
I105B11	684	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPHEPLSP (SEQ ID NO: 2651)	
I105C05	685	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPAPLAP (SEQ ID NO: 2560)	
I105C02	686	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPAPLAP (SEQ ID NO: 2472)	
I105C03	687	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFSPLSF (SEQ ID NO: 2715)	
I105C06	688	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPAPLDF (SEQ ID NO: 2367)	
I105C08	689	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPAPLDF (SEQ ID NO: 2367)	
I105C12	690	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPQHGFD (SEQ ID NO: 2446)	
I105D04	692	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPRDPLRF (SEQ ID NO: 2360)	
I105D06	693	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPRDPLRF (SEQ ID NO: 2368)	
I105D08	694	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPAPLAP (SEQ ID NO: 2608)	
I105D09	695	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPAPLAP (SEQ ID NO: 2619)	
I105D10	696	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPHEPLSP (SEQ ID NO: 2640)	
I105D11	697	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPAPLAP (SEQ ID NO: 2519)	
I105E01	698	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPAPLAP (SEQ ID NO: 2519)	
I105E06	699	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPHSFDL (SEQ ID NO: 2422)	
I105E11	700	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPQHGFD (SEQ ID NO: 2133)	
I105F03	701	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPHHPLSP (SEQ ID NO: 2675)	
I105F06	702	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPAPLAP (SEQ ID NO: 2409)	
I105F07	703	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPAPLAP (SEQ ID NO: 2691)	
I105F09	704	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDILFFPAPLAP (SEQ ID NO: 2340)	
										SRDILFFPAPLAP (SEQ ID NO: 2344)	

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
I103F12	705	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFTYPLVF (SEQ ID NO: 2604)	
I105G03	706	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPAPLHP (SEQ ID NO: 2370)	
I105G08	707	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2366)	
I105G09	708	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPASPLNP (SEQ ID NO: 2364)	
I105G10	709	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I105G11	710	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107A01	711	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107A03	712	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107A06	713	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107A07	714	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107A09	715	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107A12	716	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107B02	717	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107B04	718	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107B05	719	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107C01	720	137-247	161-171	187-193	226-236	1-121	24-33	48-64	97-110	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107C02	721	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107C04	722	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107C06	723	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107C08	724	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107C10	725	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107D01	726	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107D04	727	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107D07	728	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107D12	729	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107E01	730	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107E05	731	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107E07	732	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107E09	733	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107F01	734	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107F05	735	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107F09	736	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107F10	737	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107G01	738	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107G05	739	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107H02	740	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107H06	741	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107H09	742	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I107H10	743	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I108A12	744	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I108B03	745	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I108B04	746	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I108C09	747	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I108C11	748	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I108D10	749	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I108D11	750	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	
I108D12	751	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLFPKHPVF (SEQ ID NO: 2364)	

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS					AAs of VL	AAs of VL CDR1	AAs of VH CDR2	AAs of VH CDR3	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
		VL	VL CDR1	VL CDR2	VL CDR3	VH								
I108E01	752	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHHSFDL (SEQ ID NO: 2147)				
I108E03	753	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPKHPLRF (SEQ ID NO: 2393)				
I108E05	754	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2533)				
I108E07	755	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2533)				
I108E08	756	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2369)				
I108E09	757	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2344)				
I108E10	758	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2623)				
I108E11	759	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2509)				
I108F10	760	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2516)				
I108F12	761	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2371)				
I108G01	762	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2508)				
I108G02	763	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2360)				
I108G07	764	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2476)				
I108G10	765	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2429)				
I108G11	766	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2377)				
I108G12	767	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2615)				
I108H01	768	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2147)				
I108H02	769	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2364)				
I108H06	770	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2691)				
I108H08	771	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2147)				
I11A06	772	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2449)				
I11B12	773	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2147)				
I11C01	774	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2147)				
I11D06	775	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2515)				
I11E04	776	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2147)				
I11E10	777	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2691)				
I11E11	778	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2344)				
I11E12	779	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2150)				
I11F07	780	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2501)				
I11G02	781	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2534)				
I11H10	782	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2703)				
I11A04	783	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2352)				
I11A12	784	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2411)				
I11B06	785	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2434)				
I11C06	786	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2406)				
I11G04	787	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2344)				
I11G05	788	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2344)				
I11G10	789	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2517)				
I11G11	790	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2413)				
I11H06	791	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2344)				
I11H07	792	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2147)				
I11H09	793	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2525)				
I11C04	794	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2406)				
I11C12	795	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2691)				
I11D04	796	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2133)				
I11D06	797	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2147)				
I11D10	798	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLFPFHAPLPF (SEQ ID NO: 2521)				

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunoselectively Bind to BLyS						AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH					
I114E01	799	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPQELSP (SEQ ID NO: 2435)		
I114E02	800	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPQESFL (SEQ ID NO: 2437)		
I114E03	801	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPKAPLTF (SEQ ID NO: 2382)		
I114E11	802	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFL (SEQ ID NO: 2383)		
I114H01	803	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2147)		
I114H06	804	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2404)		
I115A02	805	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2147)		
I115A07	806	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2684)		
I115B10	807	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2344)		
I115C05	808	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2147)		
I115C06	809	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2501)		
I115C08	810	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2150)		
I115C12	811	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2147)		
I115D07	812	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2424)		
I115E09	813	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2344)		
I115F06	814	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2418)		
I115F07	815	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2685)		
I115F12	816	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2686)		
I115G04	817	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2150)		
I115G05	818	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2418)		
I115G08	819	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2344)		
I115H04	820	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2631)		
I115H07	821	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2503)		
I115H09	822	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2344)		
I116A07	823	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2418)		
I116B01	824	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2642)		
I116B12	825	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2147)		
I116C06	826	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2418)		
I116D07	827	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2344)		
I116E02	828	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2147)		
I116E04	829	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2418)		
I116F02	830	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2150)		
I116F11	831	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2344)		
I116G05	832	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLLPDHSFDL (SEQ ID NO: 2699)		
I001C09	833	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	DGSDILTYIDNMDV (SEQ ID NO: 2154)		
I006D07	834	143-250	164-174	190-196	229-239	1-127	26-35	50-66	99-112	SHYDILTYIDNMDV (SEQ ID NO: 2166)		
I007B03	835	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-112	DGSDILTYIDNMDV (SEQ ID NO: 2166)		
I007F11	836	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-112	DGSDILTYIDNMDV (SEQ ID NO: 2129)		
I007H08	837	140-250	162-171	191-197	230-239	1-124	26-35	50-66	99-112	DGSDILTYIDNMDV (SEQ ID NO: 2160)		
I008A09	838	144-254	166-179	195-201	236-245	1-128	26-35	50-66	99-112	DGSDILTYIDNMDV (SEQ ID NO: 2160)		
I008B01	839	146-256	168-181	197-203	236-245	1-128	26-35	50-66	99-112	DGSDILTYIDNMDV (SEQ ID NO: 2129)		
I008C02	840	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-112	ATYDILTYIDNMDV (SEQ ID NO: 2153)		
I008C03	841	145-255	167-180	196-202	235-244	1-129	26-35	50-66	99-112	ATYDILTYIDNMDV (SEQ ID NO: 2167)		
I008C12	842	143-250	164-174	190-196	229-239	1-127	26-35	50-66	99-112	HVRDYLTYIDNMDV (SEQ ID NO: 2171)		
I012A06	843	146-256	168-181	197-203	236-245	1-130	26-35	50-66	99-112	ENPTYDILTYIDNMDV (SEQ ID NO: 2155)		
I016E05	844	145-254	169-179	195-201	234-243	1-129	26-35	50-66	99-112	GRWDYDILTYIDNMDV (SEQ ID NO: 2162)		
	845	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-112	ATYDILTYIDNMDV (SEQ ID NO: 2153)		

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
I01GF02	846	135-245	157-170	1-119	26-35	186-192	225-234	1-119	50-66	99-108	GMGDHYGMDV (SEQ ID NO: 2161)
I01GF04	847	141-251	163-176	1-125	26-35	192-198	231-240	1-125	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)
I01GH07	848	141-248	162-172	1-125	26-35	188-194	227-237	1-125	50-66	99-114	GYHDLTYSYNNWFDP (SEQ ID NO: 2163)
I01HC02	849	141-251	163-176	1-125	26-35	192-198	231-240	1-125	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)
I01HC10	850	143-250	164-174	1-127	26-35	190-196	229-239	1-127	50-66	99-116	DGSYDLITGYIDNYMDV (SEQ ID NO: 2154)
I01HD07	851	143-250	164-174	1-127	26-35	190-196	229-239	1-127	50-66	99-116	DGSYDLITGYIDNYMDV (SEQ ID NO: 2154)
I01HD08	852	141-251	163-176	1-125	26-35	192-198	231-240	1-125	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)
I01HD09	853	141-251	163-176	1-125	26-35	192-198	231-240	1-125	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)
I02IB05	854	143-253	165-178	1-127	24-33	194-200	233-242	1-127	48-64	97-116	EGGNYDLITGYIGNGAFDI (SEQ ID NO: 2158)
I02IE02	855	141-251	163-176	1-125	26-35	192-198	231-240	1-125	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2157)
I02IE03	856	141-251	165-175	1-125	26-35	191-197	230-240	1-125	50-66	99-114	TDYDLITGYPMGYFDP (SEQ ID NO: 2173)
I02IA07	857	144-255	167-179	1-128	26-35	195-201	234-244	1-128	50-66	99-117	GGYDLITGYFGLGVYDY (SEQ ID NO: 2170)
I02IA06	858	142-253	164-176	1-126	26-35	192-198	231-242	1-126	50-66	99-115	GGYDLITGLYYGMDV (SEQ ID NO: 2156)
I029D07	859	141-250	163-176	1-125	26-35	192-198	231-239	1-125	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)
I029F11	860	143-253	165-177	1-127	26-35	193-199	232-242	1-127	50-66	99-116	DGSYDLITGYIDNYMDV (SEQ ID NO: 2154)
I031C03	861	137-248	160-172	1-121	26-35	188-194	227-237	1-121	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)
I031C07	862	147-258	170-183	1-131	26-35	199-205	238-247	1-131	50-66	99-120	SSPRWYDALTGDSYSHSAMDV (SEQ ID NO: 2169)
I031F09	863	143-255	167-179	1-127	26-35	195-201	234-244	1-127	50-66	99-116	DEGRDLITGYWPNFFDS (SEQ ID NO: 2168)
I031G08	864	147-259	170-182	1-131	26-35	198-204	237-248	1-131	50-66	99-120	SSPKWYDALTGDSYSHSAMDV (SEQ ID NO: 2159)
I031G10	865	147-258	170-182	1-127	26-35	198-204	237-247	1-127	50-66	99-116	DEGRDLITGYWPNFFDS (SEQ ID NO: 2168)
I031G11	866	143-255	167-179	1-124	26-35	195-201	234-244	1-124	50-66	99-113	DGIDILVPAALMDV (SEQ ID NO: 2160)
I037E07	867	140-250	162-175	1-124	26-35	191-197	230-239	1-124	50-66	104-118	DGIDILVPAALMDV (SEQ ID NO: 2160)
I037E12	868	140-250	162-175	1-124	26-35	191-197	230-239	1-124	50-66	104-118	DGIDILVPAALMDV (SEQ ID NO: 2160)
I050A07	869	145-257	168-181	1-129	26-40	197-203	236-246	1-129	55-71	102-117	DRYDLITGYSGDGF (SEQ ID NO: 2129)
I061E07	870	144-254	166-179	1-128	26-37	195-201	234-243	1-128	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)
I061H01	871	141-251	163-175	1-128	26-35	191-197	230-240	1-128	50-66	101-119	FNPTDILTGYIGYFQH (SEQ ID NO: 2155)
I001A03	872	146-256	168-181	1-130	26-35	197-203	236-245	1-130	50-66	99-117	ERHYDILTGYQTGYGMDV (SEQ ID NO: 2784)
I001A10	873	144-254	166-179	1-128	26-35	192-198	231-240	1-128	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)
I001A07	874	141-251	163-176	1-125	26-35	192-198	231-240	1-125	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)
I001A08	875	141-251	163-176	1-125	26-35	192-198	231-240	1-125	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)
I001A12	876	141-251	163-176	1-125	26-35	192-198	231-240	1-125	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)
I001B02	877	141-248	162-172	1-121	26-35	188-194	227-237	1-121	50-66	99-110	DRETKVGYGMDV (SEQ ID NO: 2945)
I001B07	878	137-247	159-171	1-121	26-35	187-193	226-236	1-121	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)
I001C06	879	141-251	163-176	1-125	26-35	192-198	231-240	1-125	50-66	99-114	EGGNYDLITGYIGNGAFDI (SEQ ID NO: 2158)
I001C08	880	143-253	165-178	1-127	24-33	194-200	233-242	1-127	48-64	97-116	EGSYDILTGYVGVGRMDV (SEQ ID NO: 2171)
I001C12	881	144-254	166-179	1-128	26-35	195-201	234-243	1-128	50-66	99-117	EGSYDILTGYVGVGRMDV (SEQ ID NO: 2171)
I001D08	882	141-251	163-176	1-125	26-35	192-198	231-240	1-125	50-66	98-113	DSYDILTGYRGYFDY (SEQ ID NO: 2745)
I001D12	883	140-250	162-175	1-124	26-35	191-197	230-239	1-124	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)
I001E05	884	141-251	163-176	1-125	26-35	192-198	231-240	1-125	50-66	99-114	EGGNYDLITGYIGNGAFDI (SEQ ID NO: 2158)
I001E07	885	143-253	165-178	1-125	26-35	194-200	233-242	1-125	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)
I001E09	886	141-251	163-176	1-125	26-35	192-198	231-240	1-125	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)
I001H05	887	141-251	163-176	1-125	26-35	192-198	231-240	1-125	50-66	99-114	ERHYDILTGYQTGYGMDV (SEQ ID NO: 2784)
I001H08	888	144-254	166-179	1-128	26-35	195-201	234-243	1-128	50-66	99-117	ERHYDILTGYQTGYGMDV (SEQ ID NO: 2784)
I003A01	889	141-251	163-176	1-125	26-35	192-198	231-240	1-125	50-66	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)
I003A06	890	140-251	163-176	1-124	26-34	192-198	231-240	1-124	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)
I003A07	891	140-251	163-176	1-124	26-34	192-198	231-240	1-124	49-65	99-115	DGYDILTGYSGYSGMDV (SEQ ID NO: 2135)
I003A07	892	142-249	163-173	1-126	26-35	189-195	228-238	1-126	50-66		

scFvs that Immunospecifically Bind to BLYS

Clone ID	scFv SEQ ID NO	AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
0003A10	893	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDILTGYYGGYFDY (SEQ ID NO: 2179)
0003B03	894	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)
0003B04	895	138-248	162-172	188-194	227-237	1-122	25-34	49-65	98-111	RYGDPFYYYMMNV (SEQ ID NO: 2755)
0003B09	896	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTGYSYGMDV (SEQ ID NO: 2174)
0003C01	897	140-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
0003C02	898	141-252	164-176	192-198	231-241	1-125	26-35	50-66	99-114	GDYDILTGPAECFQI (SEQ ID NO: 2854)
0003C03	899	141-250	164-174	190-196	229-239	1-125	26-35	50-66	99-114	GDYDILTGPAECFQI (SEQ ID NO: 2854)
0003C12	900	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDILTGYYGGYFDY (SEQ ID NO: 2179)
0003D04	901	139-250	162-174	190-196	229-239	1-125	26-35	50-66	99-112	RYGDPFYYYMMNV (SEQ ID NO: 2755)
0003E05	902	141-253	164-176	192-198	231-242	1-125	26-35	50-66	99-114	GDYDILTGPAECFQI (SEQ ID NO: 2854)
0003F01	903	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)
0003F02	904	139-251	162-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDPFYYYMMNV (SEQ ID NO: 2755)
0003G01	905	143-254	168-179	195-201	234-243	1-127	26-35	50-66	99-116	GTGYDILTGYYMGSADFQ (SEQ ID NO: 2800)
0003G05	906	143-255	166-179	195-201	234-244	1-127	26-35	50-66	99-116	GSGYDILTGYYTGSPLDY (SEQ ID NO: 2766)
0003G06	907	145-256	168-181	197-203	236-245	1-129	26-35	50-66	99-118	DRGNNYDILTGYYFHGGVDV (SEQ ID NO: 2914)
0003G11	908	144-251	165-175	191-197	230-240	1-128	26-35	50-66	99-117	DAQSYDILTGYSQYAFDI (SEQ ID NO: 2183)
0003H02	909	140-253	164-176	192-198	233-242	1-124	26-35	50-66	99-113	DNYDILTGYSRRFDP (SEQ ID NO: 2942)
0003H05	910	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)
0003H08	911	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTGYSYGMDV (SEQ ID NO: 2135)
0005A01	912	141-249	162-172	188-194	227-238	1-125	26-35	50-66	99-114	SHYDILTGLNYYWYFDL (SEQ ID NO: 2166)
0005A02	913	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	EGRDILTGYYYGGLDV (SEQ ID NO: 2893)
0005B01	914	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	SHYDILTGLNYYWYFDL (SEQ ID NO: 2166)
0005B09	915	137-247	159-172	188-194	227-236	1-121	26-35	50-65	98-110	TYDILTGREFDI (SEQ ID NO: 2866)
0005C01	916	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	SHYDILTGLNYYWYFDL (SEQ ID NO: 2166)
0005D02	917	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	DLRYDILTGTHDAFDI (SEQ ID NO: 2890)
0005D03	918	142-249	165-175	191-197	230-238	1-126	26-35	50-66	99-115	GAYYDILTGYPYGMDV (SEQ ID NO: 2860)
0005E01	919	142-249	165-175	191-197	230-238	1-126	26-35	50-66	99-115	GTYYDILTGYPHYGMDV (SEQ ID NO: 2860)
0005E08	920	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-115	SHYDILTGLNYYWYFDL (SEQ ID NO: 2774)
0005F01	921	140-248	164-174	190-196	229-238	1-124	26-35	50-66	99-113	DQHDILTGYYYGMDV (SEQ ID NO: 216

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunoselectively Bind to BLyS						AAs of VH	AAs of VH CDR2	AAs of VH CDR1	AAs of VH	AAs of VH CDR3	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1							
1007A01	940	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1007A08	941	139-249	161-174	190-196	229-238	1-123	26-35	50-66	99-114	SHYDILTGLNYYVFDY (SEQ ID NO: 2746)				
1007A11	942	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	ENYDPLTGYSGDGF (SEQ ID NO: 2772)				
1007A12	943	144-251	165-175	191-197	230-240	1-128	26-35	50-68	101-117	GIYDILTGYHWDGAFDI (SEQ ID NO: 2892)				
1007B04	944	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1007C04	945	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1007C08	946	142-249	163-173	189-195	228-238	1-126	26-35	50-65	98-115	IRLYCVSLTGYGYPGMD (SEQ ID NO: 2810)				
1007C12	947	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	TNYDILTGYGQVYD (SEQ ID NO: 2782)				
1007D07	948	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	QYYDILTGYNWFDP (SEQ ID NO: 2857)				
1007D08	949	144-251	165-175	191-197	230-240	1-128	26-35	50-66	101-117	GIYDILTGYHWDGAFDI (SEQ ID NO: 2872)				
1007E03	950	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1007E10	951	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	DFYDILTGYPLGGMDV (SEQ ID NO: 2741)				
1007E11	952	144-251	165-175	191-197	230-240	1-128	26-35	50-66	99-117	DLFYDILTGYSLTSGMDV (SEQ ID NO: 2923)				
1007F06	953	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1007F08	954	143-253	165-178	194-200	233-242	1-127	26-35	50-65	98-116	GRYDILTGYYYHHGMDV (SEQ ID NO: 2811)				
1007G07	955	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	SHYDILTGLNYYVFDL (SEQ ID NO: 2166)				
1007G09	956	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	DSGGDILTGYMPYFDY (SEQ ID NO: 2847)				
1007G10	957	142-249	163-173	189-195	228-238	1-126	26-35	50-65	98-115	VGLYDILTGYPSGMDV (SEQ ID NO: 2805)				
1007H11	958	147-257	169-182	198-204	237-246	1-131	26-35	50-68	101-120	SQAHYDILTGYLWSYGMDV (SEQ ID NO: 2875)				
1008A02	959	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ESYDILTGYRHYGMDL (SEQ ID NO: 2891)				
1008A05	960	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1008A06	961	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1008A07	962	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-115	DREYDILTGYLHAFDM (SEQ ID NO: 2960)				
1008A12	963	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-113	ENYDPLTGYGAFDI (SEQ ID NO: 2772)				
1008B02	964	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1008B04	965	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-116	DGSYDILTGYIDNYMDV (SEQ ID NO: 2154)				
1008B05	966	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-114	DHYDILTGYLWSYGMDV (SEQ ID NO: 2760)				
1008B06	967	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1008B07	968	141-251	163-176	192-198	231-240	1-124	24-33	48-64	97-113	GRYDILTGYKGPLDY (SEQ ID NO: 2902)				
1008B10	969	140-247	163-173	189-195	228-236	1-125	26-35	50-66	99-117	EGYDILTGYLWSYGMDV (SEQ ID NO: 2947)				
1008B11	970	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1008C06	971	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-114	GRYDILTGYKGPLDY (SEQ ID NO: 2753)				
1008C08	972	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-117	EGYDILTGYLWSYGMDV (SEQ ID NO: 2902)				
1008C09	973	149-259	171-183	199-205	238-248	1-133	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1008D01	974	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	GRYDILTGYLWSYGMDV (SEQ ID NO: 2753)				
1008D02	975	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	EGYDILTGYRDPYGM (SEQ ID NO: 2973)				
1008D03	976	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1008D04	977	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EVRYDILTGYLWSYGMDV (SEQ ID NO: 2751)				
1008D05	978	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1008D06	979	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1008D07	980	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	DRGYDILTGYRHHGMDV (SEQ ID NO: 2837)				
1008D08	981	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	DLFYDILTGYSLTSGMDV (SEQ ID NO: 2923)				
1008D12	982	144-251	165-175	191-197	230-240	1-128	26-35	50-66	99-117	EEGYDILTGYGPGYFDY (SEQ ID NO: 2974)				
1008E01	983	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1008E02	984	141-248	162-172	188-194	227-237	1-125	26-35	50-66	96-110	EGYDILTGYSKFLDY (SEQ ID NO: 2906)				
1008E03	985	137-247	159-172	188-194	227-236	1-121	20-31	46-63	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)				
1008E03	986	141-251	163-176	192-198	231-240	1-125	26-35	50-66						

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS										AAs of VH CDR2	AAs of VH CDR1	AAs of VH CDR3	AAs of VH CDR3	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	AAs of VH CDR3	AAs of VH CDR3						
I008E04	987	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSGFDGDI (SEQ ID NO: 2153)							
I008E08	988	141-252	163-175	191-197	230-241	1-125	26-35	50-66	99-114	SHYDILTGLNYYWFDL (SEQ ID NO: 2166)							
I008E09	989	143-253	163-178	194-200	233-242	1-127	26-35	50-66	99-116	ERADYDILTGYGYFYDMDV (SEQ ID NO: 2833)							
I008E12	990	141-251	163-176	192-198	231-240	1-125	26-37	52-67	100-114	FRYDILTSYYGYGMDV (SEQ ID NO: 2734)							
I008F03	991	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGFDGDI (SEQ ID NO: 2153)							
I008F06	992	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGFDGDI (SEQ ID NO: 2153)							
I008F07	993	143-250	164-174	190-196	229-239	1-127	26-35	50-65	98-116	GRYDILTGYYHHGMDV (SEQ ID NO: 2811)							
I008F08	994	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	GHYDILTGYYDYYGMDV (SEQ ID NO: 2844)							
I008F09	995	133-243	155-168	184-190	223-232	1-117	26-35	50-65	98-106	HDILTGFDY (SEQ ID NO: 2904)							
I008F10	996	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	SGYDILTGYYGMDV (SEQ ID NO: 2934)							
I008F11	997	144-251	165-175	191-197	230-240	1-128	26-35	50-68	101-117	APYDILTGYSYVYGMV (SEQ ID NO: 2968)							
I008G02	998	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGFDGDI (SEQ ID NO: 2153)							
I008G03	999	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	GDYDPLTGYSGFDGDI (SEQ ID NO: 2941)							
I008G04	1000	143-253	165-178	194-200	233-242	1-127	26-35	50-65	98-116	EGSYDILTGYYVGVGRMDV (SEQ ID NO: 2171)							
I008G05	1001	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	DGYDILTGFGYYGYGMDV (SEQ ID NO: 2899)							
I008G11	1002	136-246	158-171	187-193	226-235	1-120	26-35	50-66	99-109	AYYDILTGIDY (SEQ ID NO: 2966)							
I008G12	1003	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	DQYDILTGYYHHGMDV (SEQ ID NO: 2964)							
I008H02	1004	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	DQVLLMDHNTYMDV (SEQ ID NO: 2918)							
I008H03	1005	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	DQVLLMDHNTYMDV (SEQ ID NO: 2918)							
I008H06	1006	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	EGSYDILTGYYVGVGRMDV (SEQ ID NO: 2171)							
I008H09	1007	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	DQYDILTGYYHHGMDV (SEQ ID NO: 2964)							
I012B03	1008	141-248	163-175	192-198	231-240	1-124	26-34	49-65	98-113	TKYDILTGYYHHGMDV (SEQ ID NO: 2856)							
I012B06	1010	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)							
I012B10	1011	140-251	163-175	191-197	230-238	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)							
I012C03	1012	142-255	165-178	194-200	233-244	1-126	26-35	50-66	99-115	TDRLGAKDVTSRWGMV (SEQ ID NO: 2814)							
I012C06	1013	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)							
I012C09	1014	140-250	164-174	190-196	229-239	1-124	26-34	49-65	99-112	RYGDPFYYYMMNV (SEQ ID NO: 2755)							
I012D12	1015	145-256	168-180	196-202	235-245	1-129	26-35	50-66	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)							
I012E07	1016	140-252	164-176	192-198	231-241	1-124	26-34	49-65	99-112	RYGDPFYYYMMNV (SEQ ID NO: 2755)							
I012E08	1017	139-250	163-173	189-195	228-238	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)							
I012E09	1018	140-247	163-173	189-195	228-238	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)							
I012F05	1019	140-249	163-173	189-195	228-238	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)							
I012F12	1020	140-251	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)							
I012G05	1021	140-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)							
I012G10	1022	139-250	163-173	189-195	228-239	1-123	26-35	50-66	99-112	RYGDPFYYYMMNV (SEQ ID NO: 2755)							
I012H09	1023	139-251	162-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDPFYYYMMNV (SEQ ID NO: 2755)							
I012H10	1024	140-249	163-173	189-195	228-238	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)							
I013A10	1025	147-256	170-182	198-204	237-248	1-131	26-35	50-66	99-120	SSPKWYDALTGSSYHSAMDV (SEQ ID NO: 2159)							
I013A12	1026	147-256	171-181	197-203	236-245	1-131	26-35	50-66	99-120	SSPKWYDALTGSSYHSAMDV (SEQ ID NO: 2159)							
I013B04	1027	147-256	172-182	198-204	237-245	1-131	26-35	50-66	99-120	SSPKWYDALTGSSYHSAMDV (SEQ ID NO: 2165)							
I013B09	1028	147-257	171-181	197-203	236-246	1-131	26-35	50-66	99-120	SSPKWYDALTGSSYHSAMDV (SEQ ID NO: 2159)							
I013C02	1029	147-258	170-182	198-204	237-247	1-131	26-35	50-66	99-120	SSPKWYDALTGSSYHSAMDV (SEQ ID NO: 2159)							
I013C04	1030	137-249	161-173	189-195	228-238	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)							
I013D02	1031	137-248	160-173	189-195	228-237	1-121	26-35	50-66	99-120	SSPKWYDALTGSSYHSAMDV (SEQ ID NO: 2165)							
I013D03	1032	147-259	170-183	199-205	238-248	1-131	26-35	50-66	99-118	GLRHVTLFGTGRGHFMDV (SEQ ID NO: 2789)							
I013D10	1033	145-257	168-181	197-203	236-246	1-129	26-35	50-66									

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VH CDR1	AAs of VH CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
I013E02	1034	147-259	170-183	1-131	238-248	1-131	26-35	50-66	99-120	99-120	GRETDKVKPWRYYHYHMDV (SEQ ID NO: 2809)
I013E05	1035	137-249	162-173	1-121	228-238	1-121	26-35	50-66	99-110	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)
I013E09	1036	147-260	170-183	1-131	238-249	1-131	26-35	50-66	99-120	99-120	SSPKWYDALTGDSYHSAMDV (SEQ ID NO: 2165)
I013F03	1037	137-248	160-172	1-121	227-237	1-121	26-35	50-66	99-110	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)
I013F04	1038	147-258	170-182	1-121	237-247	1-121	26-35	50-66	99-120	99-120	SSPKWYDALTGDSYHSAMDV (SEQ ID NO: 2159)
I013F07	1039	145-260	170-185	1-129	240-249	1-129	26-35	50-66	99-118	99-118	AATTSQKHKYAYFYGMVDV (SEQ ID NO: 2131)
I013F09	1040	137-248	160-172	1-121	227-237	1-121	26-35	50-66	99-110	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)
I013F10	1041	147-259	170-183	1-131	238-248	1-131	26-35	50-66	99-120	99-120	SSPKWYDALTGDSYHSAMDV (SEQ ID NO: 2159)
I013H04	1042	147-258	170-182	1-131	237-247	1-131	26-35	50-66	99-120	99-120	SSPKWYDALTGDSYHSAMDV (SEQ ID NO: 2159)
I014A12	1043	147-259	170-183	1-131	238-248	1-131	26-35	50-66	99-120	99-120	GRETDKVKPWRYYHYHMDV (SEQ ID NO: 2809)
I014C06	1044	143-253	163-178	1-127	233-242	1-127	24-33	48-64	97-116	97-116	EGNYDILGYGNGAFDI (SEQ ID NO: 2158)
I014C10	1045	141-254	164-177	1-125	233-243	1-125	26-35	50-66	99-114	99-114	GDYDLTGPAECFI (SEQ ID NO: 2854)
I014C12	1046	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I014E06	1047	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I014F02	1048	140-252	164-176	1-124	231-241	1-124	26-34	49-65	98-113	98-113	ELGLSNGATGALDM (SEQ ID NO: 2174)
I016A08	1049	141-251	166-176	1-125	231-240	1-125	26-37	52-67	100-114	100-114	AGYDILTGYPYFDS (SEQ ID NO: 2757)
I016A09	1050	144-251	165-175	1-128	230-240	1-128	26-35	50-66	99-117	99-117	EVNRDILTRSYLAGPLDN (SEQ ID NO: 2751)
I016C02	1051	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I016C03	1052	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I016C05	1053	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I016C09	1054	148-255	169-179	1-132	234-244	1-132	26-35	50-66	99-121	99-121	VQMDSEYDILTGIVGPYFDY (SEQ ID NO: 2132)
I016C11	1055	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I016D10	1056	148-255	169-179	1-132	234-244	1-132	26-35	50-66	99-121	99-121	VQMDSEYDILTGIVGPYFDY (SEQ ID NO: 2132)
I016D11	1057	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I016E03	1058	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I016E04	1059	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I016F03	1060	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I016F11	1061	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I016G11	1062	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I016G01	1063	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I016G06	1064	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I016G12	1065	148-255	169-179	1-132	234-244	1-132	26-35	50-66	99-121	99-121	VQMDSEYDILTGIVGPYFDY (SEQ ID NO: 2132)
I016H10	1066	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I017A06	1067	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I017A07	1068	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I017A11	1069	140-253	162-175	1-124	233-242	1-124	25-34	49-65	98-113	98-113	ATYDPLTGYSFDFDI (SEQ ID NO: 2157)
I017E12	1070	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I017G03	1071	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I017G07	1072	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I017H01	1073	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I018A02	1074	141-251	163-176	1-128	234-243	1-128	26-35	50-66	99-117	99-117	EGSYDILGYVGVGRMDV (SEQ ID NO: 2171)
I018A04	1075	144-254	166-179	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I018A05	1076	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I018A11	1077	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I018B02	1078	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I018B08	1079	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)
I018C04	1080	141-251	163-176	1-125	231-240	1-125	26-35	50-66	99-114	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunoselectively Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
I018D02	1081	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGFEDI (SEQ ID NO: 2153)	
I018E06	1082	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGFEDI (SEQ ID NO: 2153)	
I018E08	1083	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGFEDI (SEQ ID NO: 2153)	
I018F04	1084	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGFEDI (SEQ ID NO: 2153)	
I018G06	1085	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGFEDI (SEQ ID NO: 2153)	
I018H07	1086	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGFEDI (SEQ ID NO: 2153)	
I019E05	1087	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	ERHYDILTYGTYGMDV (SEQ ID NO: 2784)	
I019F06	1088	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	ERHYDILTYGTYGMDV (SEQ ID NO: 2784)	
I019G12	1089	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNYDILTYGTYGMDV (SEQ ID NO: 2158)	
I020D01	1090	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	DRETKVGYGMDV (SEQ ID NO: 2945)	
I020D05	1091	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNYDILTYGTYGMDV (SEQ ID NO: 2158)	
I020E10	1092	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNYDILTYGTYGMDV (SEQ ID NO: 2158)	
I020G12	1093	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNYDILTYGTYGMDV (SEQ ID NO: 2158)	
I020H06	1094	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNYDILTYGTYGMDV (SEQ ID NO: 2158)	
I020H10	1095	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNYDILTYGTYGMDV (SEQ ID NO: 2158)	
I021A11	1096	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNYDILTYGTYGMDV (SEQ ID NO: 2158)	
I021B01	1097	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNYDILTYGTYGMDV (SEQ ID NO: 2158)	
I021C11	1098	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNYDILTYGTYGMDV (SEQ ID NO: 2158)	
I021D12	1099	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	DRETKVGYGMDV (SEQ ID NO: 2945)	
I021E10	1100	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNYDILTYGTYGMDV (SEQ ID NO: 2158)	
I022A08	1101	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNYDILTYGTYGMDV (SEQ ID NO: 2158)	
I022B01	1103	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGFEDI (SEQ ID NO: 2153)	
I022B10	1104	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	MEYDILTYGTYGMDV (SEQ ID NO: 2179)	
I022C02	1105	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGTYGMDV (SEQ ID NO: 2135)	
I022C04	1106	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGFEDI (SEQ ID NO: 2153)	
I022C08	1107	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGFEDI (SEQ ID NO: 2153)	
I022D06	1108	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGTYGMDV (SEQ ID NO: 2135)	
I022E08	1109	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGTYGMDV (SEQ ID NO: 2135)	
I022F01	1110	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGTYGMDV (SEQ ID NO: 2135)	
I022F04	1111	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGTYGMDV (SEQ ID NO: 2135)	
I022F12	1112	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	GDYDILTYGTYGMDV (SEQ ID NO: 2859)	
I022G11	1113	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGTYGMDV (SEQ ID NO: 2135)	
I023D01	1114	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGFEDI (SEQ ID NO: 2153)	
I023D04	1115	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGTYGMDV (SEQ ID NO: 2135)	
I024B04	1116	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	GDYDILTYGTYGMDV (SEQ ID NO: 2135)	
I024D01	1117	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGTYGMDV (SEQ ID NO: 2135)	
I024F06	1118	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGTYGMDV (SEQ ID NO: 2135)	
I024H01	1119	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGTYGMDV (SEQ ID NO: 2135)	
I024H07	1120	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGTYGMDV (SEQ ID NO: 2135)	
I025A01	1121	140-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGFEDI (SEQ ID NO: 2153)	
I025A04	1122	140-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGFEDI (SEQ ID NO: 2153)	
I025A07	1123	140-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGTYGMDV (SEQ ID NO: 2135)	
I025B01	1124	133-244	156-168	184-190	223-233	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)	
I025B10	1125	140-253	164-176	192-198	233-242	1-124	26-35	50-66	99-113	DNYDILTYGTYGMDV (SEQ ID NO: 2942)	
I025B12	1126	140-251	163-176	192-198	231-240	1-124	26-35	50-66	99-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
I025C07	1127	140-251	163-176	192-198	231-240	1-124	26-35	50-66	99-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
1025D11	1128	140-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1025E04	1129	142-252	164-176	192-198	231-241	1-126	26-35	50-66	99-115	PLGITAVRGAKTDAFGI (SEQ ID NO: 2929)	
1025E05	1130	140-251	163-175	192-198	230-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1025E07	1131	140-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1025F01	1132	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)	
1025F08	1133	139-251	162-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDPFYYYMNV (SEQ ID NO: 2755)	
1025F08	1134	137-248	160-172	188-194	227-237	1-121	26-35	50-66	99-110	GGSSQNFYGMVDV (SEQ ID NO: 2884)	
1025G03	1135	140-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1025G08	1136	140-254	163-176	192-198	231-243	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1025H02	1137	144-255	167-179	195-201	234-244	1-128	26-35	50-65	98-117	AGSGFHDILTYGKGGYFDY (SEQ ID NO: 2961)	
1026A01	1138	141-249	165-175	191-197	230-238	1-125	26-35	50-66	99-114	GSVYDILTYGKSGMGV (SEQ ID NO: 2733)	
1026B01	1139	143-254	166-178	194-200	233-243	1-127	26-35	50-66	99-116	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1026B06	1140	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1026C06	1141	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1026C10	1142	138-249	161-174	190-196	229-238	1-122	26-34	49-65	98-111	RYGDPFYYYMNV (SEQ ID NO: 2755)	
1026C11	1143	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)	
1026D09	1144	139-252	162-175	191-197	230-241	1-123	26-35	50-66	99-112	RYGDPFYYYMNV (SEQ ID NO: 2755)	
1026E06	1145	140-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1026E09	1146	140-251	163-175	191-197	230-240	1-124	26-35	50-66	99-113	GYDDILTYGIMALDY (SEQ ID NO: 2821)	
1026F01	1147	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1026F09	1148	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1026F12	1149	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1026G08	1150	140-256	163-176	192-202	237-245	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1026G10	1151	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1026G11	1152	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1026H02	1153	143-255	166-179	195-201	234-244	1-127	26-35	50-66	99-116	GTGYDILTYGMSAFDQ (SEQ ID NO: 2800)	
1026H06	1154	139-251	162-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDPFYYYMNV (SEQ ID NO: 2755)	
1026H10	1155	140-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1027A09	1156	144-255	167-179	195-201	234-244	1-128	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1027B02	1157	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1027B05	1158	139-250	162-174	190-196	229-239	1-123	26-35	50-66	99-112	RYGDPFYYYMNV (SEQ ID NO: 2755)	
1027C08	1159	140-250	163-176	192-198	230-239	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1027D02	1160	138-249	161-174	190-196	229-238	1-122	26-34	49-63	96-111	DPFGAVPGYYAMDV (SEQ ID NO: 2852)	
1027E03	1161	141-250	164-174	190-196	229-239	1-125	26-35	50-66	99-114	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1027E05	1162	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1027F04	1163	140-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1027F05	1164	144-252	167-176	192-198	231-241	1-128	26-35	50-66	99-117	GPWYDPLFPSSGRHYGLDV (SEQ ID NO: 2793)	
1027F05	1165	140-254	163-176	192-198	231-243	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1027F11	1166	140-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSIVGATTGALDM (SEQ ID NO: 2852)	
1027G06	1167	140-253	164-176	192-198	232-242	1-124	26-35	50-66	99-113	DNYDILTYGSRFP (SEQ ID NO: 2942)	
1027G07	1168	140-250	164-174	190-196	229-239	1-125	26-35	50-66	99-114	GDYDILTYGPAECFQI (SEQ ID NO: 2854)	
1027H03	1169	141-252	164-176	192-198	231-241	1-127	26-35	50-66	99-116	DMYDILTYGTYTGLAFDM (SEQ ID NO: 2880)	
1028A04	1170	143-250	164-174	190-196	229-239	1-125	26-35	50-66	99-114	VLNYDILTYGYYGMDV (SEQ ID NO: 2832)	
1028A07	1171	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)	
1028B08	1172	141-251	163-176	192-198	231-240	1-132	26-35	50-68	101-121	DFGYDILTYGYYGAFYAFDI (SEQ ID NO: 2861)	
1028B10	1173	148-258	170-183	199-205	238-247	1-126	26-37	52-69	102-115	GGHTCIPTCHMGG (SEQ ID NO: 2796)	
1028C01	1174	142-250	165-175	191-197	230-239	1-126	26-37	52-69	102-115		

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
1028C04	1175	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	DMYYDILTYTGLAFDM (SEQ ID NO: 2880)	
1028C08	1176	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDFGI (SEQ ID NO: 2153)	
1028D04	1177	140-247	163-173	189-195	228-236	1-124	26-35	50-65	98-113	ATQDILTYLSGMDV (SEQ ID NO: 2977)	
1028D05	1178	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	EHYDILTYSLGMDV (SEQ ID NO: 2907)	
1028D12	1179	143-250	164-174	190-196	229-239	1-127	26-35	50-66	99-116	DGYYDILTYSVYVGMV (SEQ ID NO: 2938)	
1028E06	1180	143-253	165-178	194-200	233-242	1-127	26-35	50-65	98-116	EGSYDILTYVYVGVGRMDV (SEQ ID NO: 2171)	
1028E07	1181	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSGDFGI (SEQ ID NO: 2153)	
1028E08	1182	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSGDFGI (SEQ ID NO: 2153)	
1028F06	1183	146-256	168-180	196-202	235-245	1-130	26-35	50-66	99-119	DDRRGYDILTYVYVGRSDFI (SEQ ID NO: 2901)	
1028F08	1184	134-244	156-169	185-191	224-233	1-118	26-35	50-66	99-107	DHIGGDDS (SEQ ID NO: 2954)	
1028G08	1185	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	VSGYNSGYFESYDMDV (SEQ ID NO: 2732)	
1028G09	1186	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EVRNYDILTYSLAGPLDN (SEQ ID NO: 2751)	
1028H02	1187	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDFGI (SEQ ID NO: 2153)	
1028H03	1188	142-249	165-175	191-197	230-238	1-126	26-37	52-69	102-115	SGEPCITLACNLGG (SEQ ID NO: 2797)	
1028H05	1189	148-256	169-179	195-201	234-245	1-132	26-35	50-66	99-121	DASEYDILTYLYLATGRNWDFP (SEQ ID NO: 2888)	
1028H06	1190	145-255	167-180	196-202	235-244	1-129	26-35	50-66	99-118	DSPYYDILTYVYVGMV (SEQ ID NO: 2843)	
1028H09	1191	140-250	162-175	191-197	230-239	1-124	26-35	50-68	101-113	EIDILTYGYMDV (SEQ ID NO: 2905)	
1029A10	1192	139-246	160-170	186-192	225-235	1-123	26-35	50-65	98-112	MNYDILTYVNWDFP (SEQ ID NO: 2786)	
1029A12	1193	137-247	159-171	187-193	226-236	1-121	26-35	50-68	101-110	RDILTYFYS (SEQ ID NO: 2933)	
1029B11	1194	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDFGI (SEQ ID NO: 2153)	
1029C08	1195	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EGSYDILTYVYVGVGRMDV (SEQ ID NO: 2171)	
1029F08	1196	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EVRNYDILTYSLAGPLDN (SEQ ID NO: 2751)	
1029G08	1197	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-114	GYDILTYVQSDAFDI (SEQ ID NO: 2927)	
1030A02	1199	142-253	165-177	188-194	232-242	1-126	26-35	50-66	99-115	TERGAKDVTARWGMV (SEQ ID NO: 2874)	
1030A03	1200	140-253	163-175	191-197	230-242	1-124	26-35	50-66	99-113	ENYDILTYVNWDFP (SEQ ID NO: 2737)	
1030A04	1201	140-252	163-176	192-198	231-241	1-124	26-35	50-66	99-113	ROYDILTYVGGDFY (SEQ ID NO: 2958)	
1030A05	1202	140-249	163-175	191-197	230-238	1-124	26-34	49-65	98-113	ELGSLV'GATTGALDM (SEQ ID NO: 2174)	
1030A09	1203	139-250	162-174	190-196	229-239	1-123	26-35	50-66	99-112	RYGDPFYVYVYVYVYVYV (SEQ ID NO: 2755)	
1030A12	1204	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	RYGDPFYVYVYVYVYVYV (SEQ ID NO: 2755)	
1030B06	1205	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	RYGDPFYVYVYVYVYVYV (SEQ ID NO: 2755)	
1030B08	1206	140-247	163-173	189-195	228-238	1-123	26-35	50-66	99-112	RYGDPFYVYVYVYVYVYV (SEQ ID NO: 2755)	
1030B10	1207	141-251	165-175	191-197	230-240	1-125	26-35	50-66	99-114	ELGHRGGYVYVSPYV (SEQ ID NO: 2838)	
1030C03	1208	139-252	162-175	191-197	230-241	1-123	26-35	50-66	99-112	RYGDPFYVYVYVYVYVYV (SEQ ID NO: 2755)	
1030C06	1209	146-256	169-182	198-204	237-245	1-130	26-35	50-66	101-119	DPGNYDILTYVYVYVYVYVYV (SEQ ID NO: 2935)	
1030C08	1210	133-244	156-168	184-190	223-233	1-117	26-35	50-66	99-106	SGPWDFP (SEQ ID NO: 2870)	
1030C09	1211	140-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGSLV'GATTGALDM (SEQ ID NO: 2174)	
1030C10	1212	140-250	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGSLV'GATTGALDM (SEQ ID NO: 2174)	
1030C11	1213	139-251	162-175	191-197	230-239	1-124	26-34	49-65	98-113	ELGSLV'GATTGALDM (SEQ ID NO: 2174)	
1030C12	1214	133-244	156-168	184-190	223-233	1-117	26-35	50-66	99-106	SGPWDFP (SEQ ID NO: 2870)	
1030D07	1215	139-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	RYGDPFYVYVYVYVYVYV (SEQ ID NO: 2755)	
1030D12	1216	140-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGSLV'GATTGALDM (SEQ ID NO: 2174)	
1030E02	1217	139-251	162-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDPFYVYVYVYVYVYV (SEQ ID NO: 2755)	
1030E05	1218	140-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGSLV'GATTGALDM (SEQ ID NO: 2174)	
1030E07	1219	140-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGSLV'GATTGALDM (SEQ ID NO: 2174)	
1030E08	1220	140-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGSLV'GATTGALDM (SEQ ID NO: 2174)	
1030E09	1221	140-252	163-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGSLV'GATTGALDM (SEQ ID NO: 2174)	

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
I030E10	1222	139-250	162-174	190-196	229-239	1-123	26-35	50-66	99-112	RYGDPFYYYMNV (SEQ ID NO: 2755)	
I030F02	1223	141-252	164-176	192-198	231-241	1-125	26-37	52-67	100-114	AGYDLITGPFYFDS (SEQ ID NO: 2757)	
I030F05	1224	140-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
I030F06	1225	139-251	162-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDPFYYYMNV (SEQ ID NO: 2755)	
I030F08	1226	140-254	163-176	192-198	231-243	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
I030F09	1227	140-253	164-176	192-198	231-242	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
I030F11	1228	139-250	162-174	190-196	229-239	1-123	26-35	50-66	99-112	RYGDPFYYYMNV (SEQ ID NO: 2755)	
I030F12	1229	140-251	163-175	191-197	230-240	1-124	26-35	50-66	99-113	DNYDLITGYSRRFDP (SEQ ID NO: 2942)	
I030G03	1230	140-256	163-176	192-202	237-245	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
I030G07	1231	139-251	162-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDPFYYYMNV (SEQ ID NO: 2755)	
I030G09	1232	140-251	164-174	190-196	229-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
I030H05	1233	145-255	168-181	197-203	236-244	1-129	26-35	50-66	99-118	DRGNYDLITGYYFHGVDV (SEQ ID NO: 2914)	
I030H06	1234	146-258	170-182	198-204	239-247	1-130	26-37	52-69	102-119	ATKSYDLITGYSRRFDP (SEQ ID NO: 2748)	
I030H10	1235	140-253	163-176	192-198	231-242	1-124	26-35	50-66	99-113	DNYDLITGYSRRFDP (SEQ ID NO: 2942)	
I030H11	1236	140-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
I031A01	1237	137-248	160-173	189-195	228-237	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)	
I031A03	1238	141-251	166-176	192-198	231-240	1-125	26-35	50-66	99-114	PYDPLTAVTFQVFN (SEQ ID NO: 2806)	
I031A08	1239	147-258	169-181	197-203	237-247	1-131	26-35	50-66	99-120	GREDITDKVPWDRYHYHYMDV (SEQ ID NO: 2809)	
I031A12	1240	146-257	169-181	197-203	236-246	1-130	26-35	50-66	99-119	GREDITDKVPWDRYHYHYMDV (SEQ ID NO: 2809)	
I031B03	1241	136-246	159-172	188-194	227-237	1-126	26-35	50-66	101-109	GILGHTSDS (SEQ ID NO: 2959)	
I031B06	1242	142-253	165-177	193-199	232-242	1-126	26-35	50-66	99-115	AKGYYDSSGASDFDV (SEQ ID NO: 2871)	
I031B07	1243	147-258	170-182	198-204	237-247	1-131	26-35	50-66	99-120	GREDITDKVPWDRYHYHYMDV (SEQ ID NO: 2809)	
I031B08	1244	147-260	171-183	199-205	238-249	1-131	26-35	50-66	99-120	SSPKWYDALTGHSYHSAMDV (SEQ ID NO: 2159)	
I031B09	1245	147-258	170-182	198-204	237-247	1-131	26-35	50-66	99-120	SNPKWYDALTGHSYHSAMDV (SEQ ID NO: 2840)	
I031B12	1246	137-248	160-172	188-194	227-237	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)	
I031C01	1247	147-259	170-183	199-205	238-248	1-131	26-35	50-66	99-120	GREDITDKVPWDRYHYHYMDV (SEQ ID NO: 2809)	
I031C02	1248	137-248	160-172	188-194	227-237	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)	
I031C04	1249	141-253	164-177	193-199	232-242	1-125	26-35	50-66	99-114	PYDPLTAVTFQVFN (SEQ ID NO: 2137)	
I031C08	1250	147-260	171-183	199-205	238-249	1-131	26-35	50-66	99-120	GYDSSAFRAFDI (SEQ ID NO: 2136)	
I031C11	1251	137-248	161-171	187-193	226-237	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)	
I031D01	1252	147-257	171-181	197-203	236-246	1-131	26-35	50-66	99-120	SGREDITDKVPWDRYHYHYMDV (SEQ ID NO: 2809)	
I031D04	1253	145-256	168-180	196-202	235-245	1-129	26-35	50-66	99-118	AATTSQKHNKYVYFYGMVDV (SEQ ID NO: 2131)	
I031D06	1254	137-248	160-172	188-194	227-237	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)	
I031D08	1255	147-258	170-182	198-204	237-247	1-131	26-35	50-66	99-120	GREDITDKVPWDRYHYHYMDV (SEQ ID NO: 2807)	
I031D09	1256	144-257	167-180	196-202	235-246	1-128	26-35	50-66	99-117	VRPKLRYFDWLSRHDADF (SEQ ID NO: 2820)	
I031D11	1257	137-247	161-171	187-193	226-236	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)	
I031D12	1258	147-256	171-181	197-203	236-245	1-131	26-35	50-66	99-120	SSPKWYDALTGHSYHSAMDV (SEQ ID NO: 2165)	
I031E01	1259	144-254	168-178	194-200	233-243	1-128	26-35	50-66	99-117	DKAHGFYGRDYVYFYGMVDV (SEQ ID NO: 2735)	
I031E05	1260	147-258	170-182	198-204	237-247	1-131	26-35	50-66	99-120	SSPKWYDALTGHSYHSAMDV (SEQ ID NO: 2159)	
I031E07	1261	147-257	171-181	197-203	236-246	1-131	26-35	50-66	99-120	SSPKWYDALTGHSYHSAMDV (SEQ ID NO: 2848)	
I031E09	1262	147-259	170-182	198-204	237-248	1-131	26-35	50-66	99-120	GREDITDKVPWDRYHYHYMDV (SEQ ID NO: 2159)	
I031E10	1263	147-259	170-183	199-205	238-248	1-131	26-35	50-66	99-120	GREDITDKVPWDRYHYHYMDV (SEQ ID NO: 2136)	
I031E11	1264	137-246	162-173	189-195	228-235	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)	
I031E12	1265	147-258	170-182	198-204	237-247	1-131	26-35	50-66	99-120	SSPKWYDALTGHSYHSAMDV (SEQ ID NO: 2165)	
I031F01	1266	147-258	170-182	198-204	237-247	1-131	26-35	50-66	99-120	SSPKWYDALTGHSYHSAMDV (SEQ ID NO: 2159)	
I031F04	1267	137-248	160-172	188-194	227-237	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)	
	1268	137-246	162-172	188-194	227-235	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)	

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS					AAs of VL CDR1	AAs of VH CDR1	AAs of VH CDR2	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR3	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH									
1031F06	1269	135-247	159-171	187-193	226-236	1-119	26-35	50-66	99-108	DTVRSGMDV (SEQ ID NO: 2804)					
1031F10	1270	147-259	170-183	199-205	238-248	1-131	26-35	50-66	99-120	GRDITDKVPWDRYHYHYMDV (SEQ ID NO: 2809)					
1031F11	1271	144-255	167-179	195-201	234-244	1-128	26-35	50-66	99-117	DKAHGEYGRDYHYHYMDV (SEQ ID NO: 2735)					
1031F12	1272	137-249	160-172	188-194	227-238	1-121	26-35	50-66	99-110	GVDSSAFRAFDI (SEQ ID NO: 2136)					
1031G01	1273	137-248	160-172	188-194	227-237	1-121	26-35	50-66	99-110	GVDSSAFRAFDI (SEQ ID NO: 2136)					
1031G03	1274	147-258	170-182	198-204	237-247	1-131	26-35	50-66	99-120	SSPPKWYDALIGHSSHSAMDV (SEQ ID NO: 2159)					
1031G05	1275	147-259	170-183	199-205	238-248	1-131	26-35	50-66	99-120	GRDITDKVPWDRYHYHYMDV (SEQ ID NO: 2809)					
1031G06	1276	147-258	170-182	198-204	237-247	1-131	26-35	50-66	99-120	GRDITDKVPWDRYHYHYMDV (SEQ ID NO: 2809)					
1031G07	1277	147-259	171-183	199-205	238-248	1-131	26-35	50-66	99-120	SSPPKWYDALIGHSSHSAMDV (SEQ ID NO: 2159)					
1031G09	1278	147-263	170-183	199-209	244-252	1-131	26-35	50-66	99-120	GRDITDKVPWDRYHYHYMDV (SEQ ID NO: 2809)					
1031G12	1279	145-256	168-180	196-202	235-245	1-129	26-35	50-66	99-118	GRDITDKVPWDRYHYHYMDV (SEQ ID NO: 2809)					
1031H01	1280	137-250	160-173	189-195	228-239	1-121	26-35	50-66	99-110	GRDITDKVPWDRYHYHYMDV (SEQ ID NO: 2809)					
1031H02	1281	142-255	165-178	194-200	233-244	1-126	26-35	50-66	99-118	AATISQKHKNKAYFYGMVDV (SEQ ID NO: 2131)					
1031H03	1282	147-260	170-183	199-205	238-249	1-131	26-35	50-66	99-115	GRDITDKVPWDRYHYHYMDV (SEQ ID NO: 2809)					
1031H06	1283	144-257	167-179	195-201	234-246	1-128	26-35	50-66	99-117	DKAHGEYGRDYHYHYMDV (SEQ ID NO: 2735)					
1031H09	1284	144-255	167-179	195-201	234-246	1-128	26-35	50-66	99-116	DKAHGEYGRDYHYHYMDV (SEQ ID NO: 2735)					
1031H10	1285	143-256	166-179	195-201	234-245	1-127	26-35	50-66	99-116	DRGYTGDRLVGGYFDF (SEQ ID NO: 2931)					
1031H11	1286	135-246	158-170	186-192	225-235	1-119	26-35	50-66	99-108	DTVRSGMDV (SEQ ID NO: 2804)					
1033A08	1287	144-254	166-179	195-201	234-243	1-128	26-37	52-69	102-117	DRYDILTYGYYGMDV (SEQ ID NO: 2129)					
1033B11	1288	144-254	166-179	195-201	234-243	1-128	26-37	52-69	102-117	DRYDILTYGYYGMDV (SEQ ID NO: 2129)					
1033C01	1289	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EVNRYDLITRSYLAGPLDN (SEQ ID NO: 2751)					
1033C08	1290	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	EMGYDILTYGYYGMDV (SEQ ID NO: 2862)					
1033D02	1291	138-245	161-171	187-193	226-234	1-122	26-35	50-66	99-111	GDYDILTYGYYGMDV (SEQ ID NO: 2781)					
1033D03	1292	141-251	163-172	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDFDI (SEQ ID NO: 2153)					
1033D11	1293	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-113	ATYDPLTGYSGDFDI (SEQ ID NO: 2153)					
1033D12	1294	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-117	GGPHYDILTYGYYMAVGFDI (SEQ ID NO: 2962)					
1033E01	1295	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-112	DIDARLAALDAFDI (SEQ ID NO: 2794)					
1033E06	1296	139-249	161-173	189-195	228-238	1-123	26-35	50-66	99-114	ATHDPLTGYSGDFDI (SEQ ID NO: 2780)					
1033E11	1297	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-115	HRSCSSTSCRNDAFDI (SEQ ID NO: 2770)					
1033E12	1298	143-253	163-177	193-199	232-242	1-127	26-35	50-66	99-112	EMGYDILTYGYYGMDV (SEQ ID NO: 2862)					
1033F03	1299	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-112	EGAADYLNQGVFQD (SEQ ID NO: 2768)					
1033F08	1300	139-246	160-170	186-192	225-235	1-129	26-35	50-66	99-118	QKVVYDILTYGYYGMDV (SEQ ID NO: 2767)					
1033F10	1301	145-256	167-179	195-201	234-245	1-128	26-35	50-66	99-117	EVNRYDLITRSYLAGPLDN (SEQ ID NO: 2751)					
1033F12	1302	144-254	166-179	195-201	234-243	1-118	26-35	50-66	99-107	DIDGGDS (SEQ ID NO: 2954)					
1033G01	1303	134-241	155-165	181-187	220-230	1-127	24-33	48-64	97-116	EGGYDILTYGYYGMDV (SEQ ID NO: 2158)					
1033G03	1304	142-253	165-178	194-200	233-242	1-127	24-33	48-64	99-115	PQGVTLVGAETDAFAI (SEQ ID NO: 2925)					
1033G08	1305	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-114	ATYDPLTGYSGDFDI (SEQ ID NO: 2153)					
1033H04	1306	141-248	162-172	188-194	227-237	1-125	26-35	49-65	98-113	ATYDPLTGYSGDFDI (SEQ ID NO: 2153)					
1037A05	1307	140-247	161-171	187-193	226-236	1-124	25-34	49-65	99-112	SRDLFLPHYGMVDV (SEQ ID NO: 2133)					
1037B03	1308	139-246	160-170	186-192	225-235	1-123	26-35	50-66	99-114	SHYDILTYGYYGMDV (SEQ ID NO: 2950)					
1037B04	1309	141-251	163-175	191-197	230-240	1-128	26-35	50-66	99-117	DPGYDILTYGYYGMDV (SEQ ID NO: 2922)					
1037C04	1310	142-252	164-177	193-199	232-241	1-126	26-35	50-65	98-115	EMGYDILTYGYYGMDV (SEQ ID NO: 2752)					
1037C06	1311	141-249	163-173	189-195	228-238	1-125	26-35	50-66	99-114	LYYDILTYGYYGMDV (SEQ ID NO: 2882)					
1037C08	1312	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	DGIDILTYGYYGMDV (SEQ ID NO: 2160)					
1037D11	1313	136-246	158-171	187-193	226-235	1-120	26-35	50-66	99-109	SQWLEHDFDI (SEQ ID NO: 2864)					
1037E06	1315	144-251	165-175	191-197	230-240	1-128	26-35	50-66	99-117	DRDYDILTYGYYGMDV (SEQ ID NO: 2928)					

TABLE 1-continued

Clone ID	seqV NO	seqV SEQ ID NO	scfvs that Immunospecifically Bind to BLyS					AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of CDR1	AAs of CDR2	AAs of CDR3	VH CDR3 Sequence (SEQ ID NO)
			AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH								
I037F04	1316		144-251	165-175	191-197	230-240	1-128	26-35	50-65	98-117	KQGDYDILTYGVLGYAFDI (SEQ ID NO: 2808)				
I037G01	1317		141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	SHYDILTRNLYWYFDL (SEQ ID NO: 2950)				
I037G03	1318		146-256	168-181	197-203	236-245	1-130	26-35	50-66	99-119	DLGSFYDILTALENYGMDV (SEQ ID NO: 2963)				
I037G10	1319		140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	DYVDILTKLPYGMVDV (SEQ ID NO: 2975)				
I042A07	1320		144-251	167-177	193-199	232-240	1-128	26-35	50-66	98-115	VSPSYDILTYGVLGYAFDI (SEQ ID NO: 2849)				
I042A10	1321		142-249	165-175	191-197	230-238	1-126	26-35	50-65	99-113	GRPYDILTYGYNWFDV (SEQ ID NO: 2801)				
I042B03	1322		140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-114	DIDDLTYGVLGMVDV (SEQ ID NO: 2924)				
I042B12	1323		141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-113	SHYDILTYGYNWYFDL (SEQ ID NO: 2166)				
I042D01	1324		136-246	158-171	187-193	226-235	1-120	26-35	50-66	99-109	QQWLPYDAFDI (SEQ ID NO: 2839)				
I042D03	1325		140-250	162-175	191-197	230-239	1-124	26-35	50-68	101-113	AYDYDILTYGFFDI (SEQ ID NO: 2873)				
I042D10	1326		142-252	164-177	193-199	232-241	1-126	26-35	50-65	98-115	ERADYDILTYGFFYGMVDV (SEQ ID NO: 2802)				
I042E10	1327		147-257	169-182	198-204	237-246	1-131	26-37	52-69	102-120	ERPYYDILTYGTYGMDV (SEQ ID NO: 2798)				
I042E11	1328		140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	DEYDILTKLQGMVDV (SEQ ID NO: 2883)				
I042F08	1329		142-252	164-177	193-199	233-241	1-126	26-37	52-67	100-115	GDYDILTYGVLGYAFDI (SEQ ID NO: 2738)				
I042G08	1330		140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	DGYDILTYGFGMDV (SEQ ID NO: 2976)				
I042G10	1331		141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	EHYDILTYGSLGMVDV (SEQ ID NO: 2907)				
I043A03	1332		141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	SHYDILTYGYNWYFDL (SEQ ID NO: 2166)				
I043B02	1333		143-253	165-178	194-200	233-242	1-127	26-35	50-65	98-116	GSLYDILTYGTYGNAFDI (SEQ ID NO: 2759)				
I043B03	1334		144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	DQYDILTYGTYGNAFDI (SEQ ID NO: 2759)				
I043B06	1335		142-249	163-173	189-195	228-238	1-126	26-35	50-65	98-115	GGYYDILTYGVLGYGMVDV (SEQ ID NO: 2809)				
I043B07	1336		141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTYGTFDGFDI (SEQ ID NO: 2153)				
I043B09	1337		143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	DQYDILTYGTYGNAFDI (SEQ ID NO: 2828)				
I043D11	1338		141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTYGTFDGFDI (SEQ ID NO: 2153)				
I043E05	1339		143-253	165-178	194-200	233-242	1-127	26-35	50-65	98-116	HVRDYDILTYGTYGNAFDI (SEQ ID NO: 2727)				
I043F01	1340		144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EVNRYDILTYGTYGNAFDI (SEQ ID NO: 2751)				
I043F04	1341		141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-116	TESNYDILTYGTYGNAFDI (SEQ ID NO: 2940)				
I043F12	1342		141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTYGTFDGFDI (SEQ ID NO: 2153)				
I043H07	1343		143-250	164-174	190-196	229-239	1-127	26-35	50-66	99-116	TESNYDILTYGTYGNAFDI (SEQ ID NO: 2153)				
I044A11	1344		141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTYGTFDGFDI (SEQ ID NO: 2153)				
I044B11	1345		144-251	165-175	191-197	230-240	1-125	26-35	50-66	99-116	TESNYDILTYGTYGNAFDI (SEQ ID NO: 2943)				
I044C09	1346		139-249	161-173	189-195	228-238	1-123	26-35	50-66	99-112	DSDARLAALDAFDI (SEQ ID NO: 2978)				
I044C10	1347		140-250	162-174	190-196	229-239	1-124	26-35	50-66	99-113	QGFGLPNYYYHMDV (SEQ ID NO: 2943)				
I044D03	1348		143-253	165-177	193-199	232-242	1-127	26-35	50-66	99-116	DKRYNSNWPYYDYGMVDV (SEQ ID NO: 2776)				
I044D09	1349		144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	DKQYDILTYGTYGNAFDI (SEQ ID NO: 2889)				
I044E07	1350		141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTYGTFDGFDI (SEQ ID NO: 2153)				
I044E11	1351		137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSSLVTYGTDV (SEQ ID NO: 2153)				
I044F07	1352		143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	SDDYDILTYGTYGNAFDI (SEQ ID NO: 2825)				
I044G02	1353		147-257	169-182	198-204	237-246	1-131	26-35	50-66	99-120	DGRLSYDILTYGTYGNAFDI (SEQ ID NO: 2758)				
I044G07	1354		141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTYGTFDGFDI (SEQ ID NO: 2153)				
I050A01	1355		149-259	171-184	200-206	239-248	1-133	26-35	50-66	99-122	DQNHPIYDILTYGTYGNAFDI (SEQ ID NO: 2845)				
I050B12	1356		144-251	165-175	191-197	230-240	1-128	26-35	50-66	99-117	EVNRYDILTYGTYGNAFDI (SEQ ID NO: 2751)				
I050C06	1357		141-253	164-177	193-199	232-242	1-125	26-35	50-66	99-114	DMGYDILTYGTYGNAFDI (SEQ ID NO: 2946)				
I050C08	1358		140-248	165-175	191-197	230-237	1-124	26-35	50-65	98-113	DYDVLTYGSLDGMVDV (SEQ ID NO: 2829)				
I050E11	1359		141-253	164-177	193-199	232-242	1-125	26-35	50-66	99-114	DHYDVLTYGSLQAFDV (SEQ ID NO: 2728)				
I050E11	1360		140-248	165-175	191-197	230-237	1-124	26-35	50-65	98-113	DHYDVLTYGSLQAFDV (SEQ ID NO: 2728)				
I050E11	1361		140-248	165-175	191-197	230-237	1-124	26-35	50-65	98-113	DHYDVLTYGSLQAFDV (SEQ ID NO: 2728)				
I050E11	1362		140-252	163-176	192-198	231-241	1-124	26-35	50-66	99-113	GHYDILTYGTYGNAFDI (SEQ ID NO: 2886)				

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS										AAs of VH CDR3	AAs of VH CDR1	AAs of VH CDR2	AAs of VL CDR2	AAs of VL CDR1	AAs of VL	VH CDR3 Sequence (SEQ ID NO)
		AA of VL	AA of VL CDR1	AA of VL CDR2	AA of VL CDR3	AA of VH	AA of VH CDR1	AA of VH CDR2	AA of VH CDR3	AA of VH CDR3								
I050E10	1363	137-248	160-172	188-194	227-237	1-121	26-35	50-66	99-110	DMKVVYKYALDV (SEQ ID NO: 2823)								
I050H08	1364	141-253	164-177	193-199	232-242	1-125	26-35	50-66	99-114	DLRYDLTGVDADF (SEQ ID NO: 2890)								
I051A04	1365	147-258	170-183	199-205	238-247	1-131	26-35	50-66	99-120	SSPKWYDALGHSSHSAMDV (SEQ ID NO: 2159)								
I051A08	1366	141-252	164-176	192-198	231-241	1-125	26-35	50-66	99-114	HRKARVVPVPGAMDV (SEQ ID NO: 2930)								
I051B08	1367	143-250	164-174	190-196	229-239	1-127	26-35	50-66	99-116	DGSRVLTGYIDNMDV (SEQ ID NO: 2154)								
I051C06	1368	142-253	165-177	193-199	232-242	1-126	26-36	51-67	100-115	RSNVVTTAPYDAFDL (SEQ ID NO: 2785)								
I051G12	1370	135-246	158-170	186-192	225-235	1-119	26-35	50-66	99-108	DVRSRGMDV (SEQ ID NO: 2804)								
I055A05	1371	143-250	164-174	190-196	229-239	1-127	26-35	50-66	99-116	DGSDYDLTGYYIDNMDV (SEQ ID NO: 2154)								
I055A11	1372	133-244	156-169	185-191	224-233	1-117	26-35	50-66	99-106	SGPGWFD (SEQ ID NO: 2870)								
I061A03	1373	140-251	163-176	192-198	231-240	1-124	26-34	50-66	99-113	ELGSLVGAITGALDM (SEQ ID NO: 2852)								
I061A04	1374	141-251	165-175	191-197	230-240	1-125	26-35	50-66	99-114	GDYDLTGPAECFQI (SEQ ID NO: 2854)								
I061A08	1375	140-253	164-176	192-198	233-242	1-124	26-35	50-66	99-113	DNYDLTGYSRRFDP (SEQ ID NO: 2942)								
I061A09	1376	140-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGSLVGAITGALDM (SEQ ID NO: 2174)								
I061A10	1377	140-249	163-173	189-195	228-238	1-124	26-34	49-65	98-113	ELGSLVGAITGALDM (SEQ ID NO: 2174)								
I061B07	1378	140-252	163-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGSLVGAITGALDM (SEQ ID NO: 2174)								
I061B09	1379	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNYDLTGYYIGNGAFDI (SEQ ID NO: 2158)								
I061B12	1380	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)								
I061C12	1381	138-248	160-173	189-195	228-237	1-122	26-35	50-66	99-111	TYDILTGYYHFDY (SEQ ID NO: 2788)								
I061D01	1382	137-247	159-172	188-194	227-236	1-121	26-35	50-66	101-110	PGFVIGNYDY (SEQ ID NO: 2749)								
I061D03	1383	140-247	161-171	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)								
I061D07	1384	140-248	162-172	188-194	227-237	1-125	26-35	50-66	99-113	AVLYSAGLGAFDI (SEQ ID NO: 2970)								
I061D09	1385	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	VSGYNSGYFESYDMDV (SEQ ID NO: 2732)								
I061D10	1386	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	LNLEKTVVRGFGYFDL (SEQ ID NO: 2952)								
I061E01	1387	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	DHYDLTGYYGMDV (SEQ ID NO: 2760)								
I061E05	1388	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	LNLEKTVVRGFGYFDL (SEQ ID NO: 2952)								
I061E09	1389	142-251	163-175	191-197	230-240	1-126	26-35	50-66	99-115	GGELVWFESDYGMDV (SEQ ID NO: 2787)								
I061E12	1390	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)								
I061F01	1391	133-240	154-164	180-186	219-229	1-117	26-35	50-66	99-106	SQRLFDS (SEQ ID NO: 2842)								
I061F09	1392	146-256	168-181	197-203	236-245	1-130	26-35	50-66	99-119	DRYDILTGYYIPGLDADF (SEQ ID NO: 2887)								
I061F10	1393	139-246	160-170	186-192	225-235	1-123	26-35	50-66	99-112	DSARLAALDAFDI (SEQ ID NO: 2978)								
I061F11	1394	145-252	166-176	192-198	231-241	1-129	26-35	50-66	99-118	EESYDILTGYYVHYGMDV (SEQ ID NO: 2743)								
I061G01	1395	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)								
I061G03	1396	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)								
I061G09	1397	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)								
I061G10	1398	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EVNRYDLTRSYLAGPLDN (SEQ ID NO: 2751)								
I061G11	1399	143-253	165-178	194-200	233-242	1-127	26-35	50-65	98-116	EGSYDILTGYYVGVGRMDV (SEQ ID NO: 2171)								
I061H05	1400	137-247	159-171	187-193	226-236	1-121	26-35	50-68	101-110	RDILTGYS (SEQ ID NO: 2933)								
I064A05	1401	142-252	164-177	193-199	232-241	1-126	26-37	52-67	100-115	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)								
I064A11	1402	142-249	163-173	189-195	228-238	1-126	26-35	50-68	101-115	DFYDLTGYYGMDV (SEQ ID NO: 2919)								
I064B01	1403	138-248	160-173	189-195	228-237	1-122	26-35	50-66	99-111	HSKEYNWNALDY (SEQ ID NO: 2750)								
I064B02	1404	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	TRMDVLTTRYSD (SEQ ID NO: 2754)								
I064B12	1405	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-111	AFEDYDLTGYYHDAFDI (SEQ ID NO: 2911)								
I064C06	1406	133-243	155-168	184-190	223-232	1-117	26-35	50-66	99-106	PSHYMDV (SEQ ID NO: 2740)								
I064D01	1407	145-255	167-180	196-202	235-244	1-129	26-35	50-66	99-118	VNADYDLTGPRDYGMDV (SEQ ID NO: 2819)								
I064D02	1408	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFDFDI (SEQ ID NO: 2153)								
I064D02	1409	146-256	168-181	197-203	236-245	1-130	26-35	50-66	99-119	EDATYDILTGYYMGSGMDV (SEQ ID NO: 2763)								

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
1064E01	1410	143-250	166-176	192-198	231-239	1-127	26-35	50-66	99-116	ETRYKTSPPNYYYMDV (SEQ ID NO: 2756)	
1064E02	1411	140-251	162-174	190-196	229-240	1-124	26-35	50-66	99-113	RDYDLTSGRFDV (SEQ ID NO: 2752)	
1064E03	1412	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	DGIYDLITLTYNGMDV (SEQ ID NO: 2775)	
1064E07	1413	140-250	162-175	191-197	230-239	1-124	26-35	50-65	98-113	GERDILTYLDGMDV (SEQ ID NO: 2948)	
1064E08	1414	140-250	162-174	190-196	229-239	1-124	26-35	50-66	99-113	ERGSYSGYSGAFDV (SEQ ID NO: 2898)	
1064F05	1415	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	ESGGYSGRDYNGMDV (SEQ ID NO: 2836)	
1064F08	1416	145-252	166-176	192-198	231-241	1-129	26-35	50-66	99-118	DRGVGYDLTGRTYYGMDV (SEQ ID NO: 2900)	
1064G06	1417	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGSFDFDI (SEQ ID NO: 2153)	
1065A12	1418	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	DVSGHDILGYSRYFDV (SEQ ID NO: 2795)	
1065C04	1419	139-249	161-173	189-195	228-238	1-123	26-35	50-66	99-112	GQKNYESSGYLEH (SEQ ID NO: 2916)	
1065C09	1420	140-250	162-174	190-196	229-239	1-124	26-35	50-66	99-113	GDYDLTGYSHEDY (SEQ ID NO: 2908)	
1065E02	1421	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	AVDYDLTGYSYFDY (SEQ ID NO: 2895)	
1065E04	1422	135-245	157-169	185-191	224-234	1-119	26-35	50-66	99-108	GMGDHYGMDV (SEQ ID NO: 2161)	
1065F03	1423	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSSLMYGTIDV (SEQ ID NO: 2773)	
1065G06	1424	135-242	156-166	182-188	221-231	1-119	26-35	50-66	99-108	GMGDHYGMDV (SEQ ID NO: 2161)	
1065G07	1425	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	GGNYDLTGYGAFDI (SEQ ID NO: 2824)	
1065G08	1426	139-246	160-170	186-192	225-235	1-123	26-35	50-66	99-112	SRDLLLPHYGMDV (SEQ ID NO: 2133)	
1065H06	1427	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	GVEYDLITGYNELGAFDI (SEQ ID NO: 2851)	
1066A03	1428	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	DGYDILITGYNQYGMV (SEQ ID NO: 2915)	
1066A08	1429	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	AGSSLMYGTIDV (SEQ ID NO: 2773)	
1066A09	1430	135-245	157-169	185-191	224-234	1-119	26-35	50-66	99-108	GMGDHYGMDV (SEQ ID NO: 2161)	
1066A10	1431	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	DRGYDILTGYGMDV (SEQ ID NO: 2876)	
1066A11	1432	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	EVRDYDLTGYISYMDV (SEQ ID NO: 2778)	
1066B02	1433	135-242	156-166	182-188	221-231	1-119	26-35	50-66	99-108	GMGDHYGMDV (SEQ ID NO: 2161)	
1066B08	1434	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSSLMYGTIDV (SEQ ID NO: 2773)	
1066B10	1435	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	GLYFEDTNYRHGDAFDI (SEQ ID NO: 2790)	
1066C02	1436	135-245	157-169	185-191	224-234	1-119	26-35	50-66	99-108	GMGDHYGMDV (SEQ ID NO: 2161)	
1066C11	1437	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGSFDFDI (SEQ ID NO: 2153)	
1066C12	1438	135-242	156-166	182-188	221-231	1-119	26-35	50-66	99-108	GMGDHYGMDV (SEQ ID NO: 2161)	
1066D06	1439	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	ENYDILTGYGAFDI (SEQ ID NO: 2772)	
1066D08	1440	138-248	160-173	189-195	228-237	1-122	26-35	50-66	99-111	HSKEYNNWYALDY (SEQ ID NO: 2754)	
1066D11	1441	144-254	166-179	195-201	228-237	1-128	26-35	50-66	99-117	ERSQDFLTGVDYRHPMDV (SEQ ID NO: 2956)	
1066D12	1442	139-249	161-174	190-196	229-238	1-123	26-35	50-66	99-112	EGAADYLNQYFQH (SEQ ID NO: 2815)	
1066E06	1443	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	AGSSLMYGTIDV (SEQ ID NO: 2161)	
1066E12	1444	135-242	156-166	182-188	221-231	1-119	26-35	50-66	99-108	GLYFEDTNYRHGDAFDI (SEQ ID NO: 2790)	
1066G05	1445	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	GLYFEDTNYRHGDAFDI (SEQ ID NO: 2791)	
1066G08	1446	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	VYDILTGHPTYGMDV (SEQ ID NO: 2872)	
1066G10	1447	144-254	166-178	194-200	233-243	1-128	26-35	50-68	101-117	GYDILTGHQDDAFDI (SEQ ID NO: 2885)	
1066G12	1448	143-254	165-177	193-199	232-243	1-127	26-35	50-66	99-116	ESTYDILTGSYHDYGLDV (SEQ ID NO: 2822)	
1066H04	1449	143-253	165-178	194-200	233-242	1-127	26-35	50-65	98-116	DRLHYDLTGHQDDAFDI (SEQ ID NO: 2885)	
1067A07	1450	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	VLNVDILTGYRDAFDM (SEQ ID NO: 2939)	
1067A11	1451	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-116	GMGDHYGMDV (SEQ ID NO: 2161)	
1067B08	1452	149-259	171-184	200-206	239-248	1-133	26-35	50-66	99-108	DRGASNYDILTYYPAGQVAFDI (SEQ ID NO: 2969)	
1067C08	1453	148-258	170-183	199-205	238-247	1-132	26-37	52-69	102-121	EGAHYDILTGHNYHYGMDV (SEQ ID NO: 2747)	
1067C09	1454	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	ETRYKTSPPNYYYMDV (SEQ ID NO: 2736)	
1067D07	1455	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	AGSSLMYGTIDV (SEQ ID NO: 2773)	

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
I067E01	1456	140-248	164-174	190-196	229-238	1-124	26-35	50-66	99-113	DQHDILGVYYGMDV (SEQ ID NO: 2921)	
I067E06	1457	135-245	157-169	185-191	224-234	1-119	26-35	50-66	99-108	GMGDHYGMDV (SEQ ID NO: 2161)	
I067E07	1458	150-260	172-184	200-206	239-249	1-134	26-35	50-67	100-123	DYPGSEYDILTYLFGYYGMDV (SEQ ID NO: 2926)	
I067E11	1459	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGSFDFDI (SEQ ID NO: 2153)	
I067G03	1460	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	ARRVGLGKNAFEI (SEQ ID NO: 2765)	
I067G05	1461	140-250	162-174	190-196	229-239	1-124	26-35	50-66	99-113	DQHDILGVYYGMDV (SEQ ID NO: 2894)	
I067G12	1462	141-252	163-176	192-198	231-241	1-125	26-35	50-66	99-114	ATYDPLTGSFDFDI (SEQ ID NO: 2153)	
I067H05	1463	146-256	168-180	196-202	235-245	1-130	26-35	50-68	101-119	EGTYDILTYPLGYFDY (SEQ ID NO: 2936)	
I067H06	1464	135-245	157-169	185-191	224-234	1-119	26-35	50-66	99-108	GMGDHYGMDV (SEQ ID NO: 2161)	
I068C09	1465	137-248	160-172	188-194	227-237	1-121	26-35	50-66	99-110	GGSSQNFYGMV (SEQ ID NO: 2884)	
I068G03	1466	143-254	166-178	194-200	233-243	1-127	26-35	50-66	99-116	GTGYDILTYMGSAFDQ (SEQ ID NO: 2800)	
I068G04	1467	142-252	165-178	194-200	233-241	1-126	26-35	50-66	99-115	GYYVWVAYGDVGYGFDV (SEQ ID NO: 2937)	
I068G07	1468	140-251	164-174	190-196	229-240	1-124	26-35	50-66	99-113	HDYYMTAAHYTYS (SEQ ID NO: 2909)	
I068G08	1469	143-254	166-178	194-200	233-243	1-127	26-35	50-66	99-116	GIGYDLITGYFTGSPLDY (SEQ ID NO: 2846)	
I070F07	1470	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	DFYDILTYHDAFDI (SEQ ID NO: 2910)	
I070G05	1471	140-250	162-175	191-197	230-239	1-124	26-35	50-68	101-113	DYDDILTYGSWDY (SEQ ID NO: 2867)	
I070H02	1472	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDILTYGGYFDY (SEQ ID NO: 2179)	
I071A01	1473	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	AAAYDPLTGSFDFDI (SEQ ID NO: 2783)	
I071A03	1474	143-250	164-174	190-196	229-239	1-127	26-35	50-66	99-116	DMHYDILTYTGLAFDM (SEQ ID NO: 2917)	
I071B08	1475	142-252	166-176	192-198	231-241	1-126	27-36	51-67	100-115	GGYDILTYPAEFFHP (SEQ ID NO: 2764)	
I071E01	1476	138-248	160-173	189-195	228-237	1-122	26-35	50-66	99-111	DFGVIGDYRFDY (SEQ ID NO: 2777)	
I071F11	1477	135-245	157-169	185-191	224-234	1-119	26-35	50-66	99-108	SSNPVYGLDV (SEQ ID NO: 2957)	
I071G11	1478	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGSFDFDI (SEQ ID NO: 2153)	
I071H08	1479	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGSFDFDI (SEQ ID NO: 2153)	
I074A02	1480	141-250	164-174	190-196	229-239	1-125	26-35	50-66	99-114	DDRLITNYLEYFQH (SEQ ID NO: 2868)	
I074D10	1481	147-259	170-182	198-204	237-248	1-131	26-35	50-66	99-120	DKTLGQIVLVAAYYDGMV (SEQ ID NO: 2165)	
I074E01	1483	144-255	168-178	194-200	233-242	1-128	26-35	50-66	99-117	LGRSRDLITGYHFNNMDV (SEQ ID NO: 2776)	
I074E02	1484	140-250	164-174	190-196	229-239	1-124	26-35	50-66	99-113	DYDILTGSLYFDS (SEQ ID NO: 2803)	
I074E08	1485	143-259	166-179	195-205	240-248	1-127	26-35	50-66	99-116	GTGYDILTYMGSAFDQ (SEQ ID NO: 2800)	
I074F12	1486	140-250	164-174	190-196	229-239	1-124	26-35	50-66	99-113	DRADILTYNDAFDI (SEQ ID NO: 2739)	
I074H06	1487	139-251	162-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDPFYYYMNV (SEQ ID NO: 2755)	
I074H07	1488	143-253	167-177	193-199	232-242	1-127	26-35	50-66	99-116	GTGYDILTYMGSAFDQ (SEQ ID NO: 2800)	
I075A07	1490	143-253	167-177	193-199	233-243	1-126	26-35	50-66	99-115	VSNLITGWGGYNNWFDQ (SEQ ID NO: 2955)	
I075B04	1491	133-244	156-168	184-190	223-233	1-117	26-35	50-66	99-106	DQGRYDL (SEQ ID NO: 2175)	
I075B06	1493	140-252	163-175	191-197	230-241	1-124	26-34	49-65	99-103	DQGRYDL (SEQ ID NO: 2175)	
I075B08	1494	143-257	166-179	195-201	234-246	1-127	26-35	50-66	99-116	GTGYDILTYMGSAFDQ (SEQ ID NO: 2800)	
I075B09	1495	141-252	164-176	192-198	231-241	1-125	26-35	50-66	99-116	TYDILTYGYAEYFQH (SEQ ID NO: 2932)	
I075B12	1496	140-251	163-176	192-198	231-240	1-124	26-35	50-66	99-113	SDYDILTYGWVPAV (SEQ ID NO: 2812)	
I075C01	1497	147-259	170-183	199-205	238-248	1-131	26-35	50-66	99-120	GRETDKVKPDRHYHYMDV (SEQ ID NO: 2835)	
I075D05	1498	133-244	156-168	184-190	223-233	1-117	26-35	50-66	99-106	DQGRYDL (SEQ ID NO: 2175)	
I075D07	1499	143-253	168-179	195-201	234-242	1-127	26-35	50-66	99-116	GTGYDILTYMGSAFDQ (SEQ ID NO: 2897)	
I075D08	1501	140-251	163-175	191-197	230-240	1-124	26-35	49-65	99-114	SYDILTYGYHTPLDY (SEQ ID NO: 2853)	
									98-113	ELGSIVGATTGALDM (SEQ ID NO: 2174)	

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
I075E01	1502	143-253	167-177	193-199	232-242	1-127	26-35	50-66	99-116	GTGYDLTGYMGSADFQ (SEQ ID NO: 2800)	
I075E03	1503	148-261	172-184	200-206	239-250	1-132	28-37	52-68	101-121	GGGYDLTGYSPYLYGLDV (SEQ ID NO: 2865)	
I075E04	1504	143-255	166-179	195-201	234-244	1-127	26-35	50-66	99-116	GRGYDLTGYFTGSPLDY (SEQ ID NO: 2881)	
I075E05	1505	140-252	163-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
I075E10	1506	140-252	163-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
I075E11	1507	133-244	156-168	184-190	223-233	1-117	26-35	50-66	99-106	SGPGWDFP (SEQ ID NO: 2870)	
I075E12	1508	142-254	165-178	194-200	233-243	1-126	26-35	50-66	99-115	TRFGAKDVTARWGMDF (SEQ ID NO: 2979)	
I075F02	1509	144-253	168-178	194-200	233-242	1-128	26-35	50-66	99-117	EQGYDLTGYPEGWDFP (SEQ ID NO: 2834)	
I075F04	1510	141-251	164-176	192-198	231-240	1-125	26-37	52-67	100-114	AGYDLTGYPPYFDS (SEQ ID NO: 2757)	
I075F06	1511	144-254	168-178	194-200	233-243	1-128	26-35	50-66	99-117	GRNYDLTGYNENGLDY (SEQ ID NO: 2830)	
I075F07	1512	140-251	163-175	191-197	230-240	1-124	26-35	50-66	99-113	ENYDSLTYGYNFYDY (SEQ ID NO: 2971)	
I075F08	1513	133-244	156-168	184-190	223-233	1-117	26-35	50-66	99-106	DQRKAQDI (SEQ ID NO: 2779)	
I075F09	1514	145-257	169-181	197-203	236-246	1-129	26-35	50-66	99-118	LKAPYYDLTGYHLPKWFDT (SEQ ID NO: 2953)	
I075F10	1515	133-243	157-167	183-189	222-232	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)	
I075F11	1516	133-245	156-169	185-191	224-234	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)	
I075G05	1517	140-252	163-175	191-197	230-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
I075G07	1518	140-252	163-175	191-197	230-241	1-124	26-35	50-66	99-113	GRYDMLTRGGYFDY (SEQ ID NO: 2858)	
I075G08	1519	140-252	163-176	192-198	231-241	1-124	26-35	50-66	99-113	RQYDLTGYGGFDY (SEQ ID NO: 2958)	
I075G11	1520	141-253	164-177	193-199	232-242	1-125	26-35	50-66	99-114	TDYDLTGYPMGYFDP (SEQ ID NO: 2173)	
I075G12	1521	133-245	156-169	185-191	224-234	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)	
I075H02	1522	143-245	166-178	194-200	233-243	1-127	26-35	50-66	99-116	GTGYDLTGYMGSADFQ (SEQ ID NO: 2800)	
I075H03	1523	133-245	156-169	185-191	224-234	1-117	26-35	50-66	99-116	DQGRYLDL (SEQ ID NO: 2175)	
I075H06	1524	133-244	156-168	184-190	223-233	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)	
I075H08	1525	143-254	166-179	195-201	234-243	1-127	26-35	50-66	99-116	SGGYDLTGYFTGSPLDY (SEQ ID NO: 2766)	
I076A01	1526	142-253	166-176	192-198	231-242	1-126	26-35	50-66	99-115	DRRDDLTGYLYDAFDS (SEQ ID NO: 2878)	
I076A03	1527	135-247	159-171	187-193	226-236	1-119	26-35	50-68	101-108	GYPDAMQY (SEQ ID NO: 2951)	
I076A06	1528	133-245	156-168	184-190	223-234	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)	
I076A07	1529	139-250	162-174	190-196	229-239	1-123	26-35	50-66	99-112	DRRDILTGSNFGQD (SEQ ID NO: 2913)	
I076A08	1530	142-253	166-176	192-198	231-242	1-126	26-35	50-66	99-115	MGHYDLTGYRHYGMDF (SEQ ID NO: 2831)	
I076B01	1531	143-257	167-179	195-201	236-246	1-127	26-35	50-66	99-116	SGGYDLTGYFTGSPLDY (SEQ ID NO: 2766)	
I076B03	1532	133-245	156-169	185-191	224-234	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)	
I076B07	1533	133-243	157-167	183-189	222-232	1-117	26-35	50-66	99-114	PYYDPLATYTFYFGN (SEQ ID NO: 2806)	
I076B08	1534	141-252	166-177	193-199	232-241	1-125	26-35	50-66	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
I076C04	1535	140-250	164-174	190-196	229-239	1-124	26-34	49-65	99-113	GRYDMLTRGGYFDY (SEQ ID NO: 2858)	
I076D10	1536	140-251	163-175	191-197	230-240	1-124	26-35	50-66	99-114	LDYDLTGYPSGFDY (SEQ ID NO: 2799)	
I076D08	1537	141-252	164-176	192-198	231-241	1-125	26-35	50-66	100-113	RFYDLTGYSAFDS (SEQ ID NO: 2756)	
I076D11	1538	140-251	163-175	191-197	230-240	1-124	26-37	52-67	99-116	GTGYDLTGYMGSADFQ (SEQ ID NO: 2800)	
I076D12	1539	143-255	166-179	195-201	234-244	1-127	26-35	50-66	98-113	GTGYDLTGYMGSADFQ (SEQ ID NO: 2800)	
I076D13	1540	140-250	164-174	190-196	229-239	1-124	26-34	49-65	99-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
I076E04	1541	143-252	167-177	193-199	232-241	1-127	26-35	50-66	99-113	GTGYDLTGYMGSADFQ (SEQ ID NO: 2800)	
I076E07	1542	140-251	163-175	193-199	232-242	1-124	26-35	50-66	99-114	EYDVLTLGLFYMDV (SEQ ID NO: 2841)	
I076E09	1543	141-253	164-177	193-199	232-242	1-125	26-35	50-66	99-114	DRDLINYYLEYFQH (SEQ ID NO: 2868)	
I076F01	1544	143-254	166-179	195-201	234-243	1-127	26-35	50-66	99-116	GTGYDLTGYMGSADFQ (SEQ ID NO: 2800)	
I076F03	1545	143-253	166-178	194-199	232-242	1-127	26-35	50-66	99-113	GTGYDLTGYMGSADFQ (SEQ ID NO: 2800)	
I076F04	1546	140-251	163-175	191-197	230-240	1-124	26-36	51-66	99-113	GDYDLTGYLRKLDY (SEQ ID NO: 2742)	
I076F04	1547	133-245	157-169	185-191	224-234	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)	

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
1076F08	1548	140-250	164-174	190-196	229-239	1-124	26-36	51-66	99-113	VHYDILGYLWAFDI (SEQ ID NO: 2730)	
1076F10	1549	140-252	163-175	191-197	230-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1076G09	1550	133-245	156-168	184-190	223-234	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)	
1076G10	1551	140-251	163-175	191-197	230-240	1-124	26-35	50-66	99-113	GRYDMLTRGGYFDY (SEQ ID NO: 2858)	
1076G11	1552	143-259	166-179	195-205	240-248	1-127	26-35	50-66	99-116	GTGYDILTYMGSAFDQ (SEQ ID NO: 2800)	
1076G12	1553	146-257	169-181	197-203	236-246	1-130	26-35	50-66	99-119	NGYYDILGYLWDYYGMDV (SEQ ID NO: 2769)	
1076H02	1554	140-251	163-175	191-197	230-240	1-124	26-35	50-66	99-113	ENYDSLIGYNNYFDY (SEQ ID NO: 2971)	
1076H04	1555	141-251	165-175	191-197	230-240	1-125	26-35	50-66	99-114	THYDILTYGYSPLDY (SEQ ID NO: 2863)	
1076H05	1556	140-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1076H06	1557	140-252	163-176	192-198	231-241	1-124	26-35	50-66	99-113	VPYDILTYWGAFDV (SEQ ID NO: 2174)	
1076H09	1558	143-256	166-179	195-201	234-245	1-127	26-35	50-66	99-116	GSYDILTYGFTGSPDY (SEQ ID NO: 2766)	
1076H10	1559	143-256	166-179	195-201	234-245	1-127	26-35	50-66	99-116	GSYDILTYGFTGSPDY (SEQ ID NO: 2766)	
1077D06	1560	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	VYDILTYGYNLFDDY (SEQ ID NO: 2177)	
1078B04	1561	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	VYDILTYGYNLFDDY (SEQ ID NO: 2177)	
1078E10	1562	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	MEYDILTYGYYGYFDY (SEQ ID NO: 2179)	
1002A01-K	1563	141-250	164-174	190-196	229-239	1-125	26-35	50-66	99-114	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1002A01-R	1564	141-250	164-174	190-196	229-239	1-125	26-35	50-66	99-114	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1026C04-K	1565	141-250	164-176	192-198	231-239	1-125	26-35	50-66	99-114	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1026C04-R	1566	141-250	164-176	192-198	231-239	1-125	26-35	50-66	99-114	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1067B10	1567	149-259	171-183	199-205	238-248	1-133	26-35	50-66	99-122	DRGAPNDILTYGYPACGVAFDI (SEQ ID NO: 2176)	
1068C06	1568	133-244	156-169	185-191	224-233	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)	
1075F12	1569	133-244	156-168	184-190	223-233	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)	
1003C06	1570	140-249	163-173	189-195	228-238	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1025B06	1571	140-249	163-175	191-197	230-238	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1025B09	1572	140-249	163-175	191-197	230-238	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1026C04	1573	140-249	163-175	191-197	230-238	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1027B12	1574	141-250	164-174	190-196	229-239	1-125	26-34	49-65	99-114	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1030A10	1575	140-252	163-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1064C04	1576	147-257	169-182	198-204	237-246	1-131	26-35	50-66	99-120	DGRLSYDILTYGYYARDYYGMDD (SEQ ID NO: 2188)	
1064C07	1577	134-241	157-167	183-189	222-230	1-118	26-35	50-66	99-107	SEGTFEVD (SEQ ID NO: 2178)	
1065D04	1578	144-254	166-179	195-201	234-243	1-128	26-36	51-66	99-117	GKYYDILTYGYYRDNWFDP (SEQ ID NO: 2181)	
1065D08	1579	147-257	169-182	198-204	237-246	1-131	26-35	50-66	99-120	TPSSVYDILTYGYYHYFYMDV (SEQ ID NO: 2189)	
1063F08	1580	135-242	158-168	184-190	223-231	1-119	26-35	50-66	99-108	EKSAAGYFDY (SEQ ID NO: 2190)	
1067F05	1581	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	ENYDSLIGYGAFDI (SEQ ID NO: 2185)	
1068B04	1582	133-244	156-168	184-190	223-233	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)	
1068B08	1583	140-252	163-175	191-197	231-241	1-124	26-34	49-65	98-113	KLGLSVGATTGALDM (SEQ ID NO: 2186)	
1068C08	1584	142-254	165-178	194-200	233-243	1-126	26-35	50-66	99-115	EGMDFNSHHYYTMDA (SEQ ID NO: 2182)	
1068F03	1585	139-251	162-175	191-197	230-240	1-123	26-35	50-66	99-112	AGNEYGHTHPADY (SEQ ID NO: 2180)	
1069B07	1586	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	MEYDILTYGYYGYFDY (SEQ ID NO: 2179)	
1071B03	1587	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTYGSFDFDI (SEQ ID NO: 2153)	
1072B09	1588	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTYGSFDFDI (SEQ ID NO: 2153)	
1073F04	1589	136-246	158-171	187-193	226-235	1-120	26-35	50-66	99-109	SLATPLGMDV (SEQ ID NO: 2184)	
1074B12	1590	140-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1075A02	1591	140-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)	
1075G01	1592	140-251	164-174	190-196	229-240	1-124	26-35	50-66	99-113	DHFDILTYGFRLLDS (SEQ ID NO: 2187)	
1078D02	1593	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	VYDILTYGYNLFDDY (SEQ ID NO: 2177)	

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunoselectively Bind to BlyS										AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	AAs of VH CDR3	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	AAs of VH CDR3	AAs of VH CDR3						
1078D08	1594	144-251	165-175	191-197	230-240	1-128	26-35	50-66	99-117	DAQSYDILTGYSYAFDI (SEQ ID NO: 2183)							
1078H08	1595	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	VYDILTGYNLFDDY (SEQ ID NO: 2177)							
1064A03	1596	150-257	171-181	197-203	236-246	1-134	26-35	50-66	99-123	GPSTIVYDILGYPYPPYYMDV (SEQ ID NO: 3014)							
1064B03	1597	145-255	167-179	195-201	234-244	1-129	26-37	52-67	100-118	HVRDYDILGYYRGHYFDY (SEQ ID NO: 2167)							
1064B05	1598	140-250	162-174	190-196	229-239	1-124	26-35	50-66	99-113	ERGVVYTAGGDSFDL (SEQ ID NO: 2985)							
1064B11	1599	138-248	160-173	189-195	228-237	1-122	26-35	50-66	99-111	DRGFGLLSFFES (SEQ ID NO: 3033)							
1064C02	1600	146-256	168-180	196-202	235-245	1-130	26-35	50-66	99-119	DEYDILTGQAAPYYTGMDV (SEQ ID NO: 3068)							
1064C03	1601	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	ERGVVYTAGGDSFDL (SEQ ID NO: 2985)							
1064C11	1602	143-253	165-178	194-200	233-242	1-127	26-35	50-65	98-116	DVTYHDILTGAGHEAFDI (SEQ ID NO: 3055)							
1064C12	1603	148-255	171-181	197-203	236-244	1-132	26-37	52-69	102-121	ESGRYDILGYSGGGMDV (SEQ ID NO: 3012)							
1064D03	1604	146-256	168-181	197-203	236-245	1-130	26-35	50-66	99-119	DGANYDILGYYTTTYYGMDV (SEQ ID NO: 3072)							
1064D04	1605	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	RSYDILGYYTGMDV (SEQ ID NO: 3090)							
1064D06	1606	134-244	156-169	185-191	224-233	1-118	26-35	50-66	99-107	EGSSGYLVG (SEQ ID NO: 2981)							
1064E05	1607	146-256	168-180	196-202	235-245	1-130	26-37	52-67	100-119	KQRGDYDILGYSYGMMDV (SEQ ID NO: 3053)							
1064E06	1608	145-255	167-180	196-202	235-244	1-129	26-35	50-66	99-118	ERPGYDILGYPSSYGMMDV (SEQ ID NO: 3053)							
1064F07	1609	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSDFGDI (SEQ ID NO: 2153)							
1064F09	1610	147-257	169-181	197-203	236-246	1-131	26-35	50-66	99-120	DTLGYDILGYPYPPYYMDV (SEQ ID NO: 2988)							
1064F10	1611	143-253	165-177	193-199	232-242	1-127	22-31	46-62	95-116	DTLGYDILGYPYPPYYMDV (SEQ ID NO: 2988)							
1064F11	1612	142-252	164-177	193-199	232-241	1-126	26-35	50-65	98-115	GRHYDILGYYNEAFDI (SEQ ID NO: 3031)							
1064G01	1613	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	NYDYDILGYSYGMMDV (SEQ ID NO: 3077)							
1064G04	1614	133-243	155-167	183-189	222-232	1-117	26-35	50-66	99-106	DNSGTGY (SEQ ID NO: 3084)							
1064G08	1615	138-245	159-169	185-191	224-234	1-122	26-35	50-66	99-111	GGVYTAGRSYFDS (SEQ ID NO: 2990)							
1064G10	1616	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	SPNGDYSYAWGLE (SEQ ID NO: 3085)							
1064G11	1617	138-248	160-173	189-195	228-237	1-122	26-35	50-65	98-111	YFDGSGYYPVSFES (SEQ ID NO: 3064)							
1064H02	1618	139-249	161-173	189-195	228-238	1-123	26-37	52-67	100-116	VNYDILGGLGYFDY (SEQ ID NO: 3049)							
1064H03	1619	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-115	PLGTAVRGAKTDAFGI (SEQ ID NO: 2929)							
1064H04	1620	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-122	DRGASNYDILGYYAPQGVAFDI (SEQ ID NO: 2969)							
1064H06	1621	149-256	170-180	196-202	235-245	1-133	26-35	50-66	99-114	ATYDPLTGYSDFGDI (SEQ ID NO: 2153)							
1065A02	1622	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-117	DGGYDILGYSYGMMDV (SEQ ID NO: 2987)							
1065A04	1623	141-248	162-172	188-194	227-237	1-125	26-35	50-66	98-118	WATYYDILGRLKDHAGDI (SEQ ID NO: 3017)							
1065A06	1624	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-115	SPGDDILGYYKYFDY (SEQ ID NO: 3032)							
1065A07	1625	145-255	167-180	196-202	235-244	1-129	26-35	50-65	99-119	DAGESYDILGYYVIEGYMDV (SEQ ID NO: 2986)							
1065B01	1626	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-109	EGWSGLDLDY (SEQ ID NO: 3007)							
1065B05	1627	146-253	167-177	193-199	232-242	1-130	26-35	50-66	99-114	ATYDPLTGYSDFGDI (SEQ ID NO: 2153)							
1065B09	1628	139-249	161-174	190-196	229-238	1-123	26-35	50-66	99-112	EGAADYLNQYFQH (SEQ ID NO: 2815)							
1065B12	1629	136-246	158-170	186-192	225-235	1-120	26-35	50-66	99-109	EGWSGLDLDY (SEQ ID NO: 3007)							
1065C02	1630	141-253	163-175	191-197	230-242	1-125	26-35	50-66	99-114	ATYDPLTGYSDFGDI (SEQ ID NO: 2153)							
1065C06	1631	141-253	163-175	191-197	230-242	1-125	26-35	50-66	99-114	VSGNSGYFESYMDV (SEQ ID NO: 2732)							
1065C08	1632	141-250	163-176	192-198	231-239	1-125	26-35	50-66	99-110	QGGQYDPSPLDV (SEQ ID NO: 3002)							
1065C10	1633	142-252	159-172	188-194	227-236	1-121	26-35	50-66	99-115	DRDYDILGYSYGMMDV (SEQ ID NO: 3074)							
1065D01	1634	137-247	164-177	193-199	232-241	1-126	26-35	50-66	99-115	APLYDILGYYIGGNDY (SEQ ID NO: 3028)							
1065D03	1635	142-249	165-175	191-197	230-238	1-126	26-35	50-66	99-116	DKDYDILGYSYGMMDV (SEQ ID NO: 3040)							
1065D05	1636	143-252	165-178	194-200	233-242	1-127	26-35	50-66	99-115	DPNYDILGYYVAMDV (SEQ ID NO: 3062)							
1065D06	1637	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-112	EFQDILARGHGMDV (SEQ ID NO: 3027)							
1065E01	1638	139-246	160-170	186-192	225-235	1-123	26-35	50-66	99-110	AGSSLMTYGTDV (SEQ ID NO: 2773)							
1065E05	1639	137-244	158-168	184-190	223-233	1-121	26-35	50-66									

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunoselectively Bind to BLyS					AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	AAs of VH	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
		VL	VL CDR1	VL CDR2	VL CDR3	VL						
1063E06	1640	146-256	168-181	197-203	236-245	1-130	26-35	50-66	99-119	ARGSYDILTYRPGDGYFDY (SEQ ID NO: 3043)		
1063E08	1641	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	GLYFEDTNYRHGDAFDI (SEQ ID NO: 2790)		
1063E09	1642	145-255	167-179	195-201	234-244	1-129	26-35	50-65	98-118	ERSYYDILTYGSPRSKYGMVDV (SEQ ID NO: 3021)		
1063E12	1643	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTYGSEDFDI (SEQ ID NO: 2153)		
1063F04	1644	140-240	162-175	192-197	230-239	1-124	26-35	50-66	99-113	ERGVTAYGGDSFDL (SEQ ID NO: 2985)		
1063F05	1645	140-250	162-175	191-197	230-239	1-124	26-35	50-65	98-113	RYSDALTYGSLGAFDV (SEQ ID NO: 3018)		
1063F07	1646	145-252	166-176	192-198	231-241	1-129	26-38	53-69	102-118	GAYDYLTGYYPYGMVDV (SEQ ID NO: 2860)		
1063F09	1647	143-250	164-174	190-196	229-239	1-127	26-35	50-66	99-116	DYPIDVLTGRITKNWFDV (SEQ ID NO: 3013)		
1063F12	1648	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	DQVDRLLMQNYNMDA (SEQ ID NO: 3047)		
1065G01	1649	143-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTYGSEDFDI (SEQ ID NO: 2153)		
1065G09	1650	143-253	165-178	194-200	233-242	1-127	26-35	50-68	101-116	DAYDYLTGWVYGMVDV (SEQ ID NO: 3030)		
1065G10	1651	140-247	161-171	187-193	226-236	1-124	26-36	51-66	99-113	FRYDILTYGYVDMVDV (SEQ ID NO: 2983)		
1065H05	1652	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	EYDYLTGYSGAFDI (SEQ ID NO: 2984)		
1065H07	1653	138-248	160-173	189-195	228-237	1-122	26-35	50-66	99-111	TRMDVLTTRYSDV (SEQ ID NO: 2750)		
1066A05	1654	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSLMTYGTVDV (SEQ ID NO: 2773)		
1066A06	1655	139-246	160-170	186-192	225-235	1-123	26-35	50-66	99-112	EGAADYLNQGYTQH (SEQ ID NO: 2815)		
1066A12	1656	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	DIRVIGIQWGERGAFDM (SEQ ID NO: 3080)		
1066B05	1657	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTYGSEDFDI (SEQ ID NO: 2153)		
1066B11	1658	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	PLGTAVRGAKTDAFGI (SEQ ID NO: 2929)		
1066C06	1659	144-254	166-178	194-200	233-243	1-128	26-35	50-65	98-117	GRRYDILTYSLGRGEMDV (SEQ ID NO: 3009)		
1066C10	1660	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTYGSEDFDI (SEQ ID NO: 2153)		
1066D02	1661	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSLMTYGTVDV (SEQ ID NO: 3048)		
1066D07	1662	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	GPYDVLTYLSGNFDV (SEQ ID NO: 2992)		
1066E01	1663	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	OGGOYDPPFDV (SEQ ID NO: 3001)		
1066E03	1664	149-259	171-184	200-206	239-248	1-133	26-35	50-66	99-122	GEKARYDILTYSSAWGGYYMDV (SEQ ID NO: 3045)		
1066E04	1665	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	LNLEKTVIRGFGYFDL (SEQ ID NO: 3081)		
1066E05	1666	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	VGGYDILTYVLRGMDV (SEQ ID NO: 2997)		
1066E07	1667	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTYGSEDFDI (SEQ ID NO: 2153)		
1066E09	1668	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTYGSEDFDI (SEQ ID NO: 2153)		
1066F01	1669	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	SPYDILTYVYNGVDV (SEQ ID NO: 3058)		
1066F03	1670	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTYGSEDFDI (SEQ ID NO: 2153)		
1066F04	1671	141-251	163-175	191-197	230-240	1-125	26-35	50-66	99-114	VAAGARTLGYFGMDV (SEQ ID NO: 3071)		
1066F07	1672	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	DVSGHDILTYSYRYFDV (SEQ ID NO: 2795)		
1066F08	1673	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	SPMYDRLTGYPSPGYFDS (SEQ ID NO: 3036)		
1066F11	1674	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	GAYDYLTGYYPYGMVDV (SEQ ID NO: 2860)		
1066F12	1675	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	GPSSAGTITGLGSFDP (SEQ ID NO: 3005)		
1066G06	1676	143-250	164-174	190-196	229-239	1-117	26-35	50-66	99-116	ETRYTSSPPNYYYMDV (SEQ ID NO: 2736)		
1066G07	1677	133-242	155-168	184-190	223-232	1-119	26-30	45-61	94-106	DOFSVGGRHAFDL (SEQ ID NO: 3054)		
1066H02	1678	135-242	156-166	182-188	221-231	1-119	26-35	50-66	99-108	GMGDHYGMVDV (SEQ ID NO: 2161)		
1067A02	1679	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-110	ATYDPLTYGSEDFDI (SEQ ID NO: 2153)		
1067A03	1680	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSLMTYGTVDV (SEQ ID NO: 2773)		
1067A06	1681	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTYGSEDFDI (SEQ ID NO: 2153)		
1067A08	1682	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	AGSLMTYGTVDV (SEQ ID NO: 2773)		
1067A10	1683	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	ERGVTAYGGDSFDL (SEQ ID NO: 2985)		
1067B03	1684	142-253	164-177	193-199	232-242	1-126	26-35	50-66	99-115	PLGTAVRGAKTDAFGI (SEQ ID NO: 2929)		
1067B04	1685	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSLMTYGTVDV (SEQ ID NO: 2773)		

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunotopically Bind to BlyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
1067C03	1686	133-244	156-169	185-191	224-233	1-117	26-35	50-66	99-106	DWGHWFDP (SEQ ID NO: 2982)	
	1687	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	SGSLMTYGTDV (SEQ ID NO: 3015)	
	1688	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	EPYDILTYGSGYEDY (SEQ ID NO: 3041)	
1067C07	1689	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSLMTYGTDV (SEQ ID NO: 2773)	
1067C12	1690	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	TYDILTYGSGGAFDY (SEQ ID NO: 3024)	
1067D01	1691	136-246	158-171	187-193	226-235	1-120	26-35	50-66	99-109	GSRRGVTPDL (SEQ ID NO: 3020)	
1067D03	1692	137-244	158-168	184-190	223-233	1-121	26-35	50-66	99-110	AGSLMTYGTDV (SEQ ID NO: 2773)	
1067D05	1693	146-256	168-180	196-202	235-245	1-130	26-35	50-66	99-119	ECSSCARPPYQYMDV (SEQ ID NO: 2993)	
1067D06	1694	137-244	158-168	184-190	223-233	1-121	26-35	50-66	99-110	AGSLMTYGTDV (SEQ ID NO: 2773)	
1067D09	1695	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	GAYDILTYGYPYGMVDV (SEQ ID NO: 2860)	
1067D12	1696	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	QGGQYDSPLDV (SEQ ID NO: 3002)	
1067E02	1697	142-252	164-176	192-198	231-241	1-126	26-35	50-66	99-115	AGSLMTYGTDV (SEQ ID NO: 2860)	
1067E04	1698	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	DYRNYDILTHPPYGMVDV (SEQ ID NO: 2996)	
1067E05	1699	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	QHYDILTYGHHYGMVDV (SEQ ID NO: 3087)	
1067F01	1700	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-112	EGAADYLGQYFQH (SEQ ID NO: 2815)	
1067F03	1701	139-246	160-170	186-192	225-235	1-123	26-35	50-66	99-113	LGYYDILTYGRSDDY (SEQ ID NO: 3029)	
1067F04	1702	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-110	AGSLMAYGTDV (SEQ ID NO: 3016)	
1067F08	1704	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-113	ENYDELTYGSGAFDI (SEQ ID NO: 2772)	
1067F10	1705	140-248	163-176	192-198	231-240	1-125	26-35	50-66	99-114	AIYDPLTYGSEFEDI (SEQ ID NO: 2153)	
1067G01	1706	141-251	164-174	193-199	232-241	1-126	26-35	50-66	99-110	AGSLMTYGTDV (SEQ ID NO: 2773)	
1067G09	1707	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-117	GGLYDILTRPATDDAFDI (SEQ ID NO: 3035)	
1067H07	1708	144-251	165-175	191-197	230-240	1-128	26-35	50-66	99-115	TDRFGAKDVTARWGMVDV (SEQ ID NO: 2979)	
1068A07	1709	142-254	165-178	194-200	233-243	1-126	26-35	50-66	99-120	GREDTDKVPDRYHYGMVDV (SEQ ID NO: 2809)	
1068E08	1710	147-257	170-183	199-205	238-246	1-131	26-35	50-66	99-106	DOGRYLDL (SEQ ID NO: 2175)	
1068E11	1711	133-247	157-169	185-193	226-236	1-117	26-35	50-66	99-106	ELGLSIVGATTGALDM (SEQ ID NO: 2174)	
1068F04	1712	140-251	163-176	192-198	231-240	1-124	26-34	50-66	98-113	ELHREGGYWYSPYNV (SEQ ID NO: 2838)	
1068G05	1713	141-252	164-176	192-198	231-241	1-125	26-35	50-66	99-114	KNMGASAAADF (SEQ ID NO: 3042)	
1068G06	1714	135-245	159-169	185-191	224-234	1-119	26-35	50-66	98-108	RYGDPFYHYMYMV (SEQ ID NO: 2755)	
1068G11	1715	139-250	162-174	190-196	229-239	1-123	26-35	50-66	99-112	ESGSHYDLTLGLVAANGFDV (SEQ ID NO: 3044)	
1069A09	1716	146-258	169-182	198-204	237-247	1-130	26-35	50-66	99-119	MEYDILTYGSGYEDY (SEQ ID NO: 2179)	
1069A10	1717	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	MEYDILTYGSGYEDY (SEQ ID NO: 2179)	
1069B06	1718	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDILTYGSGYEDY (SEQ ID NO: 2179)	
1069B09	1719	141-248	164-174	190-196	229-238	1-123	26-35	50-66	99-112	PYYDILTYGSGYEDY (SEQ ID NO: 3026)	
1069B12	1720	139-249	161-174	188-194	227-237	1-125	26-35	50-66	99-114	MEYDILTYGSGYEDY (SEQ ID NO: 2179)	
1069C06	1721	141-248	162-172	190-196	229-239	1-127	26-35	50-66	99-116	VLPHYDILTYGSGYEDY (SEQ ID NO: 3000)	
1069C09	1722	143-250	164-174	190-196	229-238	1-127	26-35	50-66	99-116	VLPHYDILTYGSGYEDY (SEQ ID NO: 3000)	
1069D03	1723	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGSGYEDY (SEQ ID NO: 2135)	
1069E09	1724	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYDILTYGSGYEDY (SEQ ID NO: 2135)	
1069E11	1725	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-113	VYYDILTYGYNLEFDY (SEQ ID NO: 2177)	
1069F05	1726	140-247	161-171	188-194	227-237	1-125	26-35	50-66	99-114	MEYDILTYGSGYEDY (SEQ ID NO: 2179)	
1069F07	1727	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDILTYGSGYEDY (SEQ ID NO: 2179)	
1069F12	1728	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-113	GYYDILTYGSGYEDY (SEQ ID NO: 3051)	
1069G06	1729	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-115	DGYDILTYGSGYEDY (SEQ ID NO: 3059)	
1069G08	1730	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-118	DRLEYDILTYGSGYEDY (SEQ ID NO: 3039)	
	1731	145-252	166-176	192-198	231-241	1-129	26-35	50-66			

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunospecifically Bind to BLyS									
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)	
I069G11	1732	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDILTGYYGGYFDY (SEQ ID NO: 2179)	
I070A03	1733	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	MEYDILTGYYGGYFDY (SEQ ID NO: 2179)	
I070A09	1734	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDILTGYYGGYFDY (SEQ ID NO: 2179)	
I070B01	1735	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	SQSDYDILGYYGGYGM DV (SEQ ID NO: 3038)	
I070B05	1736	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	MEYDILTGYYGGYFDY (SEQ ID NO: 2179)	
I070D03	1737	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	MEYDILTGYYGGYFDY (SEQ ID NO: 2179)	
I070D04	1738	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	MEYDILSYGGYFDY (SEQ ID NO: 3034)	
I070E01	1739	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	SQSDYDILGYYGGYGM DV (SEQ ID NO: 3038)	
I070F01	1740	144-251	165-175	191-197	230-240	1-128	26-35	50-66	99-117	SQSDYDILGYYGGYGM DV (SEQ ID NO: 3067)	
I070G10	1741	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDILTGYYGGYFDY (SEQ ID NO: 2179)	
I071A06	1742	135-242	156-166	182-188	221-231	1-119	26-35	50-66	99-108	GMGDHYGM DV (SEQ ID NO: 2161)	
I071B02	1743	135-245	157-170	186-192	225-234	1-119	26-35	50-66	99-108	GMGDHYGM DV (SEQ ID NO: 2161)	
I071D02	1744	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGTSLMNYGTDV (SEQ ID NO: 3048)	
I071D08	1745	146-256	168-181	197-203	236-245	1-130	26-37	52-66	99-119	VPYYDTSGYLGYYGM DV (SEQ ID NO: 3010)	
I071F01	1746	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGTSLMNYGTDV (SEQ ID NO: 3048)	
I071G09	1747	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFGDFI (SEQ ID NO: 2153)	
I072A01	1748	139-249	161-174	190-196	229-238	1-123	26-35	50-66	99-112	SRDLLEPHYGM DV (SEQ ID NO: 2133)	
I072A09	1749	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFGDFI (SEQ ID NO: 2153)	
I072B02	1750	135-245	157-170	186-192	225-234	1-119	26-35	50-66	99-108	GMGDHYGM DV (SEQ ID NO: 2161)	
I072B10	1751	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSMLTYGTDV (SEQ ID NO: 2773)	
I072B11	1752	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFGDFI (SEQ ID NO: 2153)	
I072B12	1753	140-249	162-173	189-195	228-238	1-124	26-35	50-66	99-113	ENYDILTGYYGAFDI (SEQ ID NO: 2995)	
I072C05	1754	135-245	157-169	185-191	224-234	1-119	26-35	50-66	99-108	GMGDHYGM DV (SEQ ID NO: 2161)	
I072C10	1755	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSFGDFI (SEQ ID NO: 2153)	
I072D01	1756	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFGDFI (SEQ ID NO: 2153)	
I072D05	1757	135-245	157-169	185-191	224-234	1-119	26-35	50-66	99-108	GMGDHYGM DV (SEQ ID NO: 2161)	
I072E01	1758	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFGDFI (SEQ ID NO: 2153)	
I072E04	1759	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EGSYDILGYYVGVGRM DV (SEQ ID NO: 2171)	
I072E05	1760	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFGDFI (SEQ ID NO: 2153)	
I072E06	1761	135-242	156-166	182-188	221-231	1-119	26-35	50-66	99-108	GMGDHYGM DV (SEQ ID NO: 2161)	
I072F03	1762	135-242	156-166	182-188	221-231	1-119	26-35	50-66	99-108	GMGDHYGM DV (SEQ ID NO: 2161)	
I072F07	1763	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFGDFI (SEQ ID NO: 2153)	
I072F11	1764	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	DEYDILGLQGM DV (SEQ ID NO: 2883)	
I072G03	1765	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSFGDFI (SEQ ID NO: 2153)	
I072G04	1766	137-247	159-171	187-193	226-236	1-121	26-35	50-68	101-110	RDLTFYDS (SEQ ID NO: 2933)	
I072G05	1767	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	GYRNDWYGAFDI (SEQ ID NO: 3079)	
I072G09	1768	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFGDFI (SEQ ID NO: 2153)	
I072H03	1769	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFGDFI (SEQ ID NO: 2153)	
I072H07	1770	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGTSLMNYGMDV (SEQ ID NO: 3070)	
I073A02	1771	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-110	GPYDILGYYRDAFDI (SEQ ID NO: 2998)	
I073A03	1772	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	THYDILGYYTADAFDI (SEQ ID NO: 3019)	
I073A04	1773	148-258	170-183	199-205	238-247	1-132	26-35	50-66	99-121	VQMDSEYYDLTGNGVPPYFDY (SEQ ID NO: 2132)	
I073A05	1774	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFGDFI (SEQ ID NO: 2153)	
I073A06	1775	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFGDFI (SEQ ID NO: 2153)	
I073A09	1776	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSFGDFI (SEQ ID NO: 2153)	
I073A10	1777	146-253	167-177	193-199	232-242	1-130	26-35	50-66	99-119	GDFGDYDILGYYPPVYGM DV (SEQ ID NO: 3082)	

TABLE 1-continued

scfvs that Immunospecifically Bind to BLyS											
Clone ID	scFv SEQ ID NO	AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	Sequence (SEQ ID NO)	
I073A11	1778	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	SYVDLTGYTPFGMDV (SEQ ID NO: 3004)	
I073B02	1779	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	DLWYDILTYGYLDADF (SEQ ID NO: 2999)	
I073B05	1780	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	DLWYDILTYGYLDADF (SEQ ID NO: 2999)	
I073B06	1781	139-246	160-170	186-192	225-235	1-123	26-35	50-66	99-112	SRDLLFPHYGMDV (SEQ ID NO: 2133)	
I073B07	1782	138-248	160-173	189-195	228-237	1-122	26-35	50-66	99-111	TRMDVLTRYYSDF (SEQ ID NO: 2750)	
I073B08	1783	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073B11	1784	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073C01	1785	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	GYHDLTYSYNWDFP (SEQ ID NO: 3006)	
I073C02	1786	148-255	169-179	195-201	234-244	1-132	26-35	50-66	99-121	AQMDSEYVDLTGINVGPYFDY (SEQ ID NO: 3076)	
I073C04	1787	141-252	164-177	193-199	232-241	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073C07	1788	134-241	155-165	181-187	220-230	1-118	26-35	50-66	99-107	GMGDHYMDV (SEQ ID NO: 3008)	
I073C08	1789	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	EMGYDILTGYLNMDV (SEQ ID NO: 2862)	
I073C09	1790	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	QHYDILTYSGQEPDI (SEQ ID NO: 3022)	
I073C11	1791	146-256	168-181	197-203	236-245	1-130	26-35	50-68	101-119	FNPTYDILTYGYGFQFH (SEQ ID NO: 2155)	
I073C12	1792	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073D01	1793	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073D03	1794	135-245	157-169	185-191	224-234	1-119	26-35	50-66	99-108	GMGDHYGMDV (SEQ ID NO: 2161)	
I073D06	1795	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073D08	1796	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EVRNYDILTRSYLAGPLDN (SEQ ID NO: 2751)	
I073D10	1797	140-250	162-175	191-197	230-239	1-124	26-35	50-68	101-113	QYDILTYGELDI (SEQ ID NO: 3073)	
I073D11	1798	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073E01	1799	148-258	170-183	199-205	238-247	1-132	26-37	52-69	102-121	EGAHYDILTHGNYHYHYGMDV (SEQ ID NO: 2747)	
I073E02	1800	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073E03	1801	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSLDGF (SEQ ID NO: 3003)	
I073E05	1802	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	QHYDILTYSGQEPDI (SEQ ID NO: 3022)	
I073E06	1803	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073F01	1804	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	ENYDILTYGYGAFDI (SEQ ID NO: 2772)	
I073F02	1805	141-251	163-175	191-197	230-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073F02	1806	141-251	163-175	191-197	230-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073F03	1807	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073F05	1808	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073F07	1809	141-251	163-175	191-197	230-240	1-125	26-35	50-66	99-114	GEYDILTYPPYWFEL (SEQ ID NO: 3023)	
I073F09	1810	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073F11	1811	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073F12	1812	141-251	163-175	191-197	230-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073G03	1813	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	DGSYDILTYGYDNYMDV (SEQ ID NO: 2154)	
I073G04	1814	143-253	165-178	194-200	233-242	1-127	26-35	50-65	98-116	GEGYDILTYLRYGMDV (SEQ ID NO: 3037)	
I073G05	1815	135-245	157-169	185-191	224-234	1-119	26-35	50-66	99-108	GMGDHYGMDV (SEQ ID NO: 2161)	
I073G06	1816	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073G07	1817	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	GSYDILTGISGLMDV (SEQ ID NO: 3063)	
I073G08	1818	139-246	160-170	186-192	225-235	1-123	26-35	50-66	99-112	SRDLLFPHYGMDV (SEQ ID NO: 2133)	
I073G09	1819	145-255	167-180	196-202	235-244	1-129	26-35	50-66	99-118	DRGYDILTYGYIEPSGFDY (SEQ ID NO: 3061)	
I073G10	1820	135-245	157-170	186-192	225-234	1-119	26-35	50-66	99-108	PGFVIGNDY (SEQ ID NO: 2749)	
I073G12	1821	142-252	164-177	193-199	232-241	1-126	26-35	50-68	101-115	GGMRAREDYNYMDV (SEQ ID NO: 3083)	
I073H01	1822	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	
I073H03	1823	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSGDGF (SEQ ID NO: 2153)	

TABLE 1-continued

scFvs that Immunospecifically Bind to BlyS														
Clone ID	scFv SEQ ID NO	AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)				
1073H05	1824	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDFDI (SEQ ID NO: 2153)				
	1825	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDFDI (SEQ ID NO: 2153)				
	1826	138-245	159-169	185-191	224-234	1-122	26-35	50-66	99-111	TYVDILTYGYFDY (SEQ ID NO: 3056)				
	1827	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSGDFDI (SEQ ID NO: 2153)				
	1828	143-255	166-179	195-201	234-244	1-127	26-35	50-66	99-116	LPYDMLTGYVGGMDV (SEQ ID NO: 3050)				
	1829	143-255	167-177	193-199	232-242	1-127	26-35	50-66	99-116	AKPYTDFSRGSDADAFDV (SEQ ID NO: 3065)				
	1830	133-242	156-166	182-188	221-231	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)				
	1831	139-251	162-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDPFYVYVYMN (SEQ ID NO: 2755)				
	1832	140-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)				
	1833	141-251	165-175	191-197	230-240	1-125	26-35	50-66	99-114	GGYDILTYQPAEFHP (SEQ ID NO: 2764)				
	1834	133-246	156-169	185-191	224-235	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)				
	1835	143-253	167-177	193-199	232-242	1-127	26-35	50-66	99-116	DRYYDILTKGDYVYGMVDV (SEQ ID NO: 3060)				
	1836	150-262	173-186	202-208	241-251	1-134	26-35	50-66	99-123	VQGETYYDILTYGWPKRDLYGMDV (SEQ ID NO: 3069)				
	1074D08	1837	140-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGLSVVATTGALDM (SEQ ID NO: 2980)			
		1838	138-249	161-174	190-196	229-238	1-122	26-35	50-66	99-111	ESGEGDYTNPEGY (SEQ ID NO: 2991)			
		1839	133-245	156-169	185-191	224-234	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)			
1840		140-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)				
1841		146-258	169-182	198-204	237-247	1-130	26-35	50-68	101-119	DPGNYDILTYGYVYGMVDV (SEQ ID NO: 2935)				
1842		137-244	160-170	186-192	225-233	1-121	26-35	50-66	99-110	VRPHHHYEMAV (SEQ ID NO: 3075)				
1843		142-254	166-178	194-200	233-243	1-126	26-35	50-66	99-115	ESSITVNPYYFYGMVDV (SEQ ID NO: 3025)				
1844		133-242	158-168	184-190	223-231	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)				
1845		133-244	157-169	185-191	223-231	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)				
1846		143-254	166-178	194-200	233-243	1-127	26-35	50-66	99-116	SPEGDYQPLSSNNWLDLP (SEQ ID NO: 3011)				
1847		133-246	156-169	185-191	224-235	1-117	26-36	51-66	99-106	GKEGYNDN (SEQ ID NO: 3089)				
1848		143-253	167-177	193-199	232-242	1-127	26-35	50-66	99-116	GSGYDILTYFTGSPLDY (SEQ ID NO: 2766)				
1849		143-255	166-179	195-201	234-244	1-127	26-35	50-66	99-116	SPEGDYQPLSSNNWLDLP (SEQ ID NO: 3011)				
1850		142-253	165-177	193-199	232-242	1-126	26-35	50-66	99-115	MGHYDILTYGRHYGMVDV (SEQ ID NO: 2831)				
1851		138-250	162-174	190-196	229-239	1-122	26-35	50-66	99-111	GNVDILTYGPHDL (SEQ ID NO: 3086)				
1075H05		1852	141-252	164-176	192-198	231-241	1-125	26-35	50-66	99-114	SYVDILTYGHTPLDY (SEQ ID NO: 2853)			
	1853	143-253	167-177	193-199	232-242	1-127	26-35	50-66	99-116	GSGYDILTYFTGSPLDY (SEQ ID NO: 2766)				
	1854	141-254	164-177	193-199	232-243	1-125	26-35	50-66	99-114	DDRDILTYVLEYFQH (SEQ ID NO: 2868)				
	1855	143-256	166-178	194-200	233-245	1-127	26-35	50-66	99-116	GSGYDILTYFTGSPLDY (SEQ ID NO: 3057)				
	1856	140-249	164-174	190-196	229-238	1-124	26-35	50-66	99-113	GRYDILTYFTSFDY (SEQ ID NO: 3066)				
	1857	141-254	164-177	193-199	232-243	1-125	26-35	50-66	99-114	DDRDILTYVLEYFQH (SEQ ID NO: 2868)				
	1858	143-253	167-177	193-199	232-242	1-127	26-35	50-66	99-116	GTGYDILTYMGSAFDQ (SEQ ID NO: 2800)				
	1859	142-253	165-177	193-199	232-242	1-126	26-35	50-66	99-115	MGHYDILTYGRHYGMVDV (SEQ ID NO: 2831)				
	1860	133-245	156-168	184-190	223-234	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)				
	1861	140-252	163-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)				
	1862	143-255	166-179	195-201	234-244	1-127	26-35	50-66	99-116	GTGYDILTYMGSAFDQ (SEQ ID NO: 2800)				
	1863	133-243	157-167	183-189	222-232	1-117	26-35	50-66	99-106	DQGRYLDL (SEQ ID NO: 2175)				
	1864	133-245	156-169	185-191	224-234	1-117	26-36	51-66	99-106	RDVQGAPY (SEQ ID NO: 3088)				
	1865	143-254	166-178	194-200	233-243	1-127	26-35	50-66	99-116	VEGYDILTYGSFAFDI (SEQ ID NO: 3078)				
	1866	144-254	168-178	194-200	233-243	1-128	26-35	50-66	99-117	EQGYDILTYGPEGGWFDLP (SEQ ID NO: 2834)				
	1867	140-250	164-174	190-196	229-239	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)				
1868	147-257	169-182	198-204	237-246	1-131	26-37	52-69	102-120	DKSYDILTYGYVYGMVDV (SEQ ID NO: 3052)					

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunoselectively Bind to BLyS										VH CDR3 Sequence (SEQ ID NO)
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	AAAs of VH		
1077C10	1869	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	MEYDILTYGGYFDY (SEQ ID NO: 2179)		
1077D01	1870	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	MEYDILTYGGYFDY (SEQ ID NO: 2179)		
1077D04	1871	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDILTYGGYFDY (SEQ ID NO: 2179)		
1077D11	1872	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	MEYDILTYGGYFDY (SEQ ID NO: 2179)		
1077D12	1873	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	EKYDILTYGDAFDI (SEQ ID NO: 3046)		
1077E01	1874	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	EMGYDILTYGYNMVDV (SEQ ID NO: 2862)		
1077E03	1875	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	EMGYDILTYGYNMVDV (SEQ ID NO: 2862)		
1077E08	1876	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	MEYDILTYGGYFDY (SEQ ID NO: 2179)		
1077F05	1877	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDILTYGGYFDY (SEQ ID NO: 2179)		
1077G06	1878	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	MEYDILTYGGYFDY (SEQ ID NO: 2179)		
1077H02	1879	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	MEYDILTYGGYFDY (SEQ ID NO: 2179)		
1078B05	1880	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	ESHYDILTYGYNPSFDI (SEQ ID NO: 2994)		
1079E02	1881	137-244	160-170	186-192	225-233	1-121	26-35	50-66	99-110	DGSGYYDAFDI (SEQ ID NO: 2194)		
1079F11	1882	132-239	155-165	181-187	220-228	1-116	26-35	50-66	99-105	TGSGFDY (SEQ ID NO: 2192)		
1082G02	1883	136-243	159-169	185-191	224-232	1-120	26-35	50-66	99-109	DGYRTNDALDI (SEQ ID NO: 2191)		
1082H08	1884	131-242	154-167	183-189	222-231	1-115	26-35	50-66	99-104	DWDMVDV (SEQ ID NO: 2193)		
1099D03	1885	136-247	159-172	188-194	227-236	1-120	26-35	50-66	99-109	DNGGGTIGFDY (SEQ ID NO: 2195)		
1079B05	1886	130-240	152-165	181-187	220-229	1-114	26-35	50-66	99-103	FVLDY (SEQ ID NO: 2210)		
1079B12	1887	134-241	157-167	183-189	222-230	1-118	26-35	50-66	99-107	WTSSGAFDI (SEQ ID NO: 2205)		
1079C01	1888	131-241	153-166	182-188	221-230	1-115	26-35	50-66	99-104	DWDMVDV (SEQ ID NO: 2193)		
1079F06	1889	134-241	157-167	183-189	222-230	1-118	26-35	50-66	99-107	DNLHAAFDI (SEQ ID NO: 2202)		
1079F08	1890	138-248	160-172	188-194	227-237	1-122	26-35	50-66	99-111	YYHSSGDAFDI (SEQ ID NO: 2206)		
1080A03	1891	138-249	161-173	189-195	228-238	1-122	26-35	50-66	99-111	VGKAAAVDNFEY (SEQ ID NO: 2197)		
1080A08	1892	135-247	158-171	187-193	226-236	1-119	26-35	50-66	99-108	VHSTGYAFEN (SEQ ID NO: 2200)		
1080B01	1893	142-254	166-178	194-200	233-243	1-126	26-35	50-66	99-115	EYSGYHYVEGGSYAMDV (SEQ ID NO: 2201)		
1080D03	1894	138-249	161-173	189-195	228-238	1-122	26-35	50-66	99-111	VGKAAAVDNFEY (SEQ ID NO: 2197)		
1080E05	1895	141-253	164-177	193-199	232-242	1-125	26-35	50-66	99-114	EGGDAVDVAPYFDY (SEQ ID NO: 2204)		
1080G07	1896	136-245	161-172	188-194	227-234	1-120	26-35	50-66	99-109	EGPGYYGMDV (SEQ ID NO: 2209)		
1080G09	1897	136-249	159-172	188-194	227-238	1-120	26-35	50-66	99-109	DNGGGTIGFDY (SEQ ID NO: 2195)		
1082A05	1898	131-240	153-165	181-187	220-229	1-115	26-35	50-66	99-104	DLDFDY (SEQ ID NO: 2208)		
1082B08	1899	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	DLGIAGTYFDY (SEQ ID NO: 2207)		
1082C03	1900	138-245	161-171	187-193	226-234	1-122	26-35	50-66	99-111	DASRDIVLPLAI (SEQ ID NO: 2198)		
1082D07	1901	134-241	157-167	183-189	222-230	1-118	26-35	50-66	99-107	WTSSGAFDI (SEQ ID NO: 2205)		
1082G01	1902	138-245	161-171	187-193	226-234	1-122	26-35	50-66	99-111	DRSGWPNWYFDL (SEQ ID NO: 2212)		
1083B12	1903	137-247	161-171	187-193	226-236	1-121	26-35	50-66	99-110	ESGAGYYDDY (SEQ ID NO: 2196)		
1083G03	1904	138-249	161-173	189-195	228-238	1-122	26-35	50-66	99-111	VGKAAAVDNFEY (SEQ ID NO: 2197)		
1084A01	1905	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)		
1084B02	1906	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)		
1084C04	1907	131-238	152-162	178-184	217-227	1-115	25-34	49-65	98-104	NLWGLDY (SEQ ID NO: 2199)		
1084C11	1908	134-244	156-169	185-191	224-233	1-118	26-35	50-66	99-107	GNAWGAFDI (SEQ ID NO: 2211)		
1079A01	1909	134-243	156-168	184-190	223-232	1-118	26-35	50-66	99-107	EGVAAGEDI (SEQ ID NO: 3123)		
1079A03	1910	134-244	156-169	185-191	224-233	1-118	26-35	50-66	99-107	GGMWDWDFDY (SEQ ID NO: 3183)		
1079A04	1911	134-241	155-165	181-187	220-230	1-118	26-35	50-66	99-107	VDSSGYAYY (SEQ ID NO: 3213)		
1079A06	1912	133-240	154-164	180-186	219-229	1-117	26-35	50-66	99-106	DAAVTAEG (SEQ ID NO: 3142)		
1079A07	1913	136-246	158-170	186-192	225-235	1-120	26-35	50-66	99-109	GSNYPDAFDI (SEQ ID NO: 3112)		
1079A10	1914	148-255	169-179	195-201	234-244	1-132	26-35	50-68	101-121	LPPDLRYCDGGICPGFDWLGP (SEQ ID NO: 3163)		

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunoselectively Bind to BLYS					AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
		VL	VL CDR1	VL CDR2	VL CDR3	VH									
I079A11	1915	135-242	158-168	184-190	223-231	1-119	26-35	50-66	99-108	GPSYYYMAV (SEQ ID NO: 3114)					
I079B02	1916	134-243	156-168	184-190	223-232	1-118	26-35	50-66	99-107	EGVAAGEDY (SEQ ID NO: 3123)					
I079B03	1917	136-246	158-170	186-192	225-235	1-120	26-35	50-66	99-109	GSNYSPPAFDI (SEQ ID NO: 3112)					
I079B04	1918	130-240	152-165	181-187	220-229	1-114	26-35	50-66	99-103	LLSDY (SEQ ID NO: 3168)					
I079B07	1919	138-245	159-169	185-191	224-234	1-122	26-35	50-66	99-111	DLGSYFSRYFDY (SEQ ID NO: 3193)					
I079B09	1920	139-246	162-172	188-194	227-235	1-123	26-35	50-66	99-112	VEVEDIVGSAFDI (SEQ ID NO: 3128)					
I079C02	1921	144-251	167-177	193-199	232-240	1-128	26-35	50-66	99-117	VTLSYSSSGYYYGMDV (SEQ ID NO: 3145)					
I079C04	1922	132-239	155-165	181-187	220-228	1-116	26-35	50-66	99-105	GWRGVYD (SEQ ID NO: 3195)					
I079C05	1923	140-247	163-173	189-195	228-236	1-124	26-35	50-66	99-113	AGGNPRSGSLVYFDY (SEQ ID NO: 3225)					
I079C07	1924	137-244	158-168	184-190	223-233	1-121	26-35	50-66	99-110	GLDVYVYGLDV (SEQ ID NO: 3176)					
I079D01	1925	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EVRYVDLLTRSYLAGPLDN (SEQ ID NO: 2751)					
I079D02	1926	135-245	157-169	185-191	224-234	1-119	26-35	50-66	99-108	EIGWEGAFDI (SEQ ID NO: 3178)					
I079D04	1927	133-243	155-167	183-189	222-232	1-117	26-35	50-66	99-106	VRPGLMDV (SEQ ID NO: 3132)					
I079D06	1928	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	EAYTSSWAEFDF (SEQ ID NO: 3190)					
I079D07	1929	136-243	157-167	183-189	222-232	1-120	26-35	50-66	99-109	NITPLAMV'GDF (SEQ ID NO: 3146)					
I079D08	1930	130-240	152-165	181-187	220-229	1-114	26-35	50-66	99-103	LIEDF (SEQ ID NO: 3161)					
I079D09	1931	131-238	152-162	178-184	217-227	1-115	26-35	50-66	99-104	DSGSPD (SEQ ID NO: 3108)					
I079D11	1932	134-241	157-167	183-189	222-230	1-118	26-35	50-66	99-107	EGVAAGEDY (SEQ ID NO: 3123)					
I079E06	1933	136-244	158-168	184-190	223-233	1-120	26-35	50-66	99-109	EKRGSRRVFDI (SEQ ID NO: 3093)					
I079E08	1934	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	EAVASSWAEFDF (SEQ ID NO: 3189)					
I079E11	1935	136-243	159-169	185-191	224-232	1-120	26-35	50-66	99-109	PYSGSGYAFDI (SEQ ID NO: 3185)					
I079E12	1936	143-253	165-177	193-199	232-242	1-127	26-35	50-66	99-116	ARDYYDSSGYVPDAFDI (SEQ ID NO: 3107)					
I079F01	1937	133-241	154-164	180-186	219-230	1-117	26-35	50-66	99-106	GHFYGMDV (SEQ ID NO: 3098)					
I079F02	1938	148-253	169-179	195-201	234-242	1-132	26-35	50-68	101-121	LPDLRYGDGCMGSGFDWLGP (SEQ ID NO: 3219)					
I079F03	1939	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	ESLITEEYCGSDCY (SEQ ID NO: 3115)					
I079F04	1940	136-243	157-167	183-189	222-232	1-120	26-35	50-66	99-109	NSAPPAPMDV (SEQ ID NO: 3099)					
I079F09	1941	130-237	151-161	177-183	216-226	1-114	26-35	50-66	99-103	RYVDY (SEQ ID NO: 3139)					
I079F10	1942	136-243	157-167	183-189	222-232	1-120	26-35	50-66	99-109	NITPLAMV'GDF (SEQ ID NO: 3146)					
I079G02	1943	136-243	159-169	185-191	224-232	1-120	26-35	50-66	99-109	ADYSDNYMDV (SEQ ID NO: 3166)					
I079G05	1944	136-243	157-167	183-189	222-232	1-120	26-35	50-66	99-109	NITPLAMV'GDF (SEQ ID NO: 3146)					
I079G05	1945	136-243	159-169	185-191	224-234	1-120	26-35	50-66	99-109	FPLESYYMDV (SEQ ID NO: 3124)					
I079G06	1946	135-245	157-170	186-192	225-234	1-119	26-35	50-66	99-108	GNISFGRITLDY (SEQ ID NO: 3158)					
I079H05	1947	136-243	157-167	183-189	222-232	1-120	26-35	50-66	99-109	DVPPPDGYLEV (SEQ ID NO: 3192)					
I079H06	1948	134-241	157-167	183-189	222-230	1-118	26-35	50-66	99-107	ASYPVPFDY (SEQ ID NO: 3171)					
I080A01	1949	131-242	154-166	182-188	221-231	1-115	26-35	50-66	99-104	GGWLDD (SEQ ID NO: 3210)					
I080A02	1950	133-245	156-169	185-191	224-234	1-117	26-35	50-66	99-106	EHSSFDY (SEQ ID NO: 3111)					
I080A05	1951	141-253	164-177	193-199	232-242	1-125	26-35	50-66	99-114	EGEGDGYNVAPYFDY (SEQ ID NO: 3160)					
I080A06	1952	141-250	166-176	192-198	231-239	1-125	26-35	50-66	99-114	EAGGSGYHFSRFDY (SEQ ID NO: 3188)					
I080A07	1953	135-247	158-171	187-193	226-236	1-119	26-35	50-66	99-108	TGIWGYFDY (SEQ ID NO: 3175)					
I080A10	1954	141-252	164-176	192-198	231-241	1-125	26-35	50-66	99-114	DGNLNYDGSYDYGMDV (SEQ ID NO: 3140)					
I080B02	1955	138-248	162-174	188-194	227-237	1-122	26-35	50-66	99-111	LGRNYTSSWLDY (SEQ ID NO: 3181)					
I080B03	1956	138-249	161-173	189-195	228-238	1-122	26-35	50-66	99-111	VVGYSSTLGTIDY (SEQ ID NO: 3096)					
I080B05	1957	137-249	161-173	189-195	228-238	1-121	26-35	50-66	99-110	LGVARGREAFDI (SEQ ID NO: 3206)					
I080B06	1958	142-254	165-177	193-199	232-243	1-126	26-37	52-69	102-115	AVSPGYYYYMDV (SEQ ID NO: 3125)					
I080B07	1959	133-243	157-167	183-189	222-232	1-117	26-35	50-66	99-106	GRKPLFDY (SEQ ID NO: 3141)					
I080B08	1960	136-248	159-172	188-194	227-237	1-120	26-37	52-67	100-109	KQRREKYFDY (SEQ ID NO: 3100)					

TABLE 1-continued

scFvs that Immunospecifically Bind to BLyS												
scFv	SEQ ID NO	AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	CDR1	AAs of VH CDR2	AAs of VH CDR3	Sequence (SEQ ID NO)		
1080B09	1961	142-254	165-178	194-200	233-243	1-126	26-35	50-66	99-115	EKAHETTSGEADPFDI (SEQ ID NO: 3151)		
1080B10	1962	138-249	161-173	189-195	228-238	1-122	26-37	52-67	100-111	RPALRSWYFDL (SEQ ID NO: 3102)		
1080B11	1963	137-248	160-172	188-194	227-237	1-121	26-35	50-68	101-110	LHCTGGSCGF (SEQ ID NO: 3186)		
1080B12	1964	139-253	164-179	195-201	234-242	1-123	26-35	50-66	99-112	NPVYDSSGSEGFDDY (SEQ ID NO: 3109)		
1080C03	1965	138-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SGRQAYYYGMDV (SEQ ID NO: 3091)		
1080C06	1966	144-254	168-178	194-200	233-243	1-128	26-36	51-66	99-117	DYDGGSSYSGDDYYVMDV (SEQ ID NO: 3227)		
1080C07	1967	144-256	167-180	196-202	235-245	1-128	26-35	50-66	99-117	DSDLVVYPTAIQGRYYFDN (SEQ ID NO: 3227)		
1080C08	1968	137-249	160-173	189-195	228-238	1-121	26-35	50-66	99-110	GKRYSGWYFDI (SEQ ID NO: 3130)		
1080C10	1969	131-243	154-167	183-189	222-232	1-115	26-35	50-66	99-104	DTPLDP (SEQ ID NO: 3094)		
1080C11	1970	137-249	160-173	189-195	228-238	1-121	26-35	50-66	99-110	EGDPTDNDADFV (SEQ ID NO: 3155)		
1080C12	1971	138-249	161-173	189-195	228-238	1-122	26-35	50-66	99-111	DGPTYARPPYYLDH (SEQ ID NO: 3153)		
1080D01	1972	136-245	161-171	187-193	226-234	1-120	26-35	50-66	99-109	DGTYDWDGFDY (SEQ ID NO: 3220)		
1080D02	1973	141-254	164-177	193-199	232-243	1-125	26-35	50-66	99-114	ETFSHCSSGSCYPFDY (SEQ ID NO: 3212)		
1080D04	1974	138-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SGRQAYYYGMDV (SEQ ID NO: 3091)		
1080D05	1975	136-246	160-170	186-192	225-235	1-120	26-35	50-66	99-109	EFFGYVYLTDY (SEQ ID NO: 3165)		
1080D08	1976	137-248	160-172	188-194	227-237	1-121	26-35	50-68	101-110	LHCTGGSCGF (SEQ ID NO: 3186)		
1080D09	1977	138-250	161-174	190-196	229-239	1-122	26-35	50-66	99-111	VDTYDYMGAPEI (SEQ ID NO: 3187)		
1080D11	1978	135-247	158-171	187-193	226-236	1-119	26-35	50-66	99-108	VGNFYGYFEY (SEQ ID NO: 3196)		
1080D12	1979	135-245	159-169	185-191	224-234	1-119	26-35	50-68	101-108	SSRNGGDY (SEQ ID NO: 3214)		
1080E01	1980	136-246	160-170	186-192	225-235	1-120	26-35	50-66	99-109	DLRSVAGRFDY (SEQ ID NO: 3164)		
1080E04	1981	136-247	159-171	187-193	226-236	1-120	26-37	52-67	100-109	HDVYGDLDY (SEQ ID NO: 3211)		
1080E06	1982	137-248	160-172	188-194	227-237	1-121	26-35	50-68	101-110	LHCSGGSCGF (SEQ ID NO: 3221)		
1080E07	1983	142-254	165-178	194-200	233-243	1-126	26-35	50-66	99-115	EGSIVGAILTINDAFDI (SEQ ID NO: 3150)		
1080E08	1984	137-249	160-173	189-195	228-238	1-121	26-35	50-66	99-110	GKRYSGWYFDI (SEQ ID NO: 3130)		
1080E12	1985	130-242	154-166	182-188	221-231	1-114	26-35	50-66	99-103	DPFDY (SEQ ID NO: 3134)		
1080F04	1986	138-249	161-173	189-195	228-238	1-122	26-35	50-66	99-111	DGPTYARPPYYLDH (SEQ ID NO: 3153)		
1080F05	1987	142-253	165-177	193-199	232-242	1-126	26-35	50-66	99-115	ESSGTLGFESELPFDY (SEQ ID NO: 3203)		
1080F06	1988	138-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	LGRNYTSSWLDY (SEQ ID NO: 3181)		
1080F08	1989	130-240	154-164	180-186	219-229	1-114	26-35	50-66	99-103	NAFDY (SEQ ID NO: 3121)		
1080G03	1990	140-250	164-174	190-196	229-239	1-124	26-36	51-66	99-113	GRGYSSSSVYGMDF (SEQ ID NO: 3095)		
1080G04	1991	131-244	156-171	187-193	226-233	1-115	26-35	50-66	99-104	VHSSGS (SEQ ID NO: 3216)		
1080G10	1992	143-252	167-177	193-199	232-241	1-127	26-35	50-66	99-116	KRGDFGIVRLHHYVMDV (SEQ ID NO: 3136)		
1080G11	1993	136-247	159-171	187-193	226-236	1-120	26-37	52-67	100-109	HDVYGDLDY (SEQ ID NO: 3205)		
1080H01	1994	140-252	164-176	192-198	231-241	1-124	26-37	52-67	100-113	LRPDADYGDYGFY (SEQ ID NO: 3218)		
1080H02	1995	139-248	162-172	188-194	227-237	1-123	26-35	50-66	99-112	TSEGTYSQWDFDN (SEQ ID NO: 3204)		
1080H03	1996	135-246	158-170	186-192	225-235	1-119	26-35	50-66	99-108	EAGEVAADY (SEQ ID NO: 3180)		
1080H04	1997	137-249	160-173	189-195	228-238	1-121	26-35	50-66	99-110	GKRYSGWYFDI (SEQ ID NO: 3130)		
1080H05	1998	136-247	159-171	187-193	226-236	1-120	26-37	52-67	100-109	HDVYGDLDY (SEQ ID NO: 3205)		
1080H06	1999	137-249	160-173	189-195	228-238	1-121	26-35	50-66	99-110	GKRYSGWYFDY (SEQ ID NO: 3217)		
1080H07	2000	137-248	160-172	188-194	227-237	1-121	26-35	50-68	101-110	LHCTGGSCGF (SEQ ID NO: 3186)		
1080H08	2001	138-251	162-175	191-197	230-240	1-122	26-35	50-66	99-111	ERGRDGDYALDF (SEQ ID NO: 3148)		
1080H09	2002	139-249	163-173	189-195	228-238	1-123	26-36	51-66	99-112	RTPDHNGDSPPDY (SEQ ID NO: 3215)		
1081A01	2003	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	DTTDY (SEQ ID NO: 2203)		
1081A03	2004	135-245	157-170	186-192	225-234	1-119	26-35	50-66	99-108	ESLTGGAFDI (SEQ ID NO: 3117)		
1081A04	2005	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	DTTDY (SEQ ID NO: 2203)		
1081A06	2006	130-237	151-161	177-183	216-226	1-114	26-35	50-66	99-103	DTTDY (SEQ ID NO: 2203)		

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunoselectively Bind to BLyS										AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	AAs of VH CDR3	AAs of VH CDR3	AAs of VH CDR3		
I081A08	2007	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081A09	2008	134-241	155-165	181-187	220-230	1-118	26-35	50-66	99-107	99-107	99-107	GAGRYFDL (SEQ ID NO: 3118)	
I081A10	2009	133-243	155-168	184-190	223-232	1-117	26-35	50-66	99-106	99-106	99-106	GGDRAFDI (SEQ ID NO: 3119)	
I081B01	2010	130-236	151-161	177-183	216-225	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081B04	2011	134-244	156-169	185-191	224-233	1-118	26-35	50-66	99-107	99-107	99-107	GNAWGAFDI (SEQ ID NO: 2211)	
I081B05	2012	133-243	155-168	184-190	223-232	1-117	26-35	50-66	99-106	99-106	99-106	GGDRAFDI (SEQ ID NO: 3119)	
I081B06	2013	133-240	154-164	180-186	219-229	1-117	26-35	50-66	99-106	99-106	99-106	VKRYTFDY (SEQ ID NO: 3179)	
I081B07	2014	136-243	157-167	183-189	222-232	1-120	26-35	50-66	99-109	99-109	99-109	ELTGANDAFDI (SEQ ID NO: 3104)	
I081B08	2015	132-239	153-163	179-185	218-228	1-116	26-35	50-66	99-105	99-105	99-105	RRYALDY (SEQ ID NO: 2920)	
I081B09	2016	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081B10	2017	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081B11	2018	132-239	153-163	179-185	218-228	1-116	26-35	50-66	99-105	99-105	99-105	GEALYKD (SEQ ID NO: 3169)	
I081C07	2019	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081C08	2020	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081D04	2021	135-242	156-166	182-188	221-231	1-119	26-35	50-66	99-108	99-108	99-108	EDLTGDAFDI (SEQ ID NO: 3103)	
I081D06	2022	132-239	153-163	179-185	218-228	1-116	26-35	50-66	99-105	99-105	99-105	GDAYFDY (SEQ ID NO: 3147)	
I081D08	2023	132-239	153-163	179-185	218-228	1-116	26-35	50-66	99-105	99-105	99-105	GDAYFDY (SEQ ID NO: 3147)	
I081D09	2024	130-238	152-162	178-184	217-227	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081D10	2025	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081D11	2026	134-244	156-169	185-191	224-233	1-118	26-35	50-66	99-107	99-107	99-107	EGLLDAFDI (SEQ ID NO: 3200)	
I081D12	2027	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081E02	2028	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081E03	2029	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081E05	2030	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081E06	2031	134-241	155-165	181-187	220-230	1-118	26-35	50-66	99-107	99-107	99-107	VGYGKGDY (SEQ ID NO: 3137)	
I081E07	2032	134-241	155-165	181-187	220-230	1-118	26-35	50-66	99-107	99-107	99-107	GAGRYFDL (SEQ ID NO: 3118)	
I081E10	2033	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	99-115	99-115	GLAPVDGGMINDAFDI (SEQ ID NO: 3184)	
I081F01	2034	130-239	152-164	180-186	219-228	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081F04	2035	132-239	153-163	179-185	218-228	1-116	26-35	50-66	99-105	99-105	99-105	ERGNQAFDI (SEQ ID NO: 3156)	
I081F05	2036	130-237	151-161	177-183	216-226	1-114	26-35	50-66	99-103	99-103	99-103	RRYALDY (SEQ ID NO: 2920)	
I081F06	2037	134-244	156-169	185-191	224-233	1-118	26-35	50-66	99-107	99-107	99-107	DTTDY (SEQ ID NO: 2203)	
I081F07	2038	132-239	153-163	179-185	218-228	1-116	26-35	50-66	99-105	99-105	99-105	DTTDY (SEQ ID NO: 2203)	
I081F11	2039	130-237	151-161	177-183	216-226	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081G01	2040	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081G04	2041	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081G06	2042	135-245	157-170	186-192	225-234	1-119	26-35	50-66	99-108	99-108	99-108	SRSPYDAFDI (SEQ ID NO: 3097)	
I081G10	2043	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081H02	2044	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081H03	2045	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I081H04	2046	135-242	156-166	182-188	221-231	1-119	26-35	50-66	99-108	99-108	99-108	SNWGGDAFDI (SEQ ID NO: 3202)	
I081H06	2047	130-240	152-165	181-187	220-229	1-114	26-35	50-66	99-103	99-103	99-103	LAFDI (SEQ ID NO: 3174)	
I081H08	2048	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	99-103	99-103	DTTDY (SEQ ID NO: 2203)	
I082A02	2049	139-249	161-173	189-195	228-238	1-123	26-35	50-66	99-112	99-112	99-112	PAASSRGPKDAFDI (SEQ ID NO: 3129)	
I082A04	2050	130-240	152-165	181-187	220-229	1-114	26-35	50-66	99-103	99-103	99-103	LSGDS (SEQ ID NO: 3122)	
I082A08	2051	134-243	156-168	184-190	223-232	1-118	26-35	50-66	99-107	99-107	99-107	EGVAAAGEDY (SEQ ID NO: 3123)	
I082A11	2052	130-240	152-165	181-187	220-229	1-114	26-35	50-66	99-103	99-103	99-103	FVLDY (SEQ ID NO: 2210)	

scFvs that Immunospecifically Bind to BLYS

Clone ID	scFv	SEQ ID NO	AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	CDR1	AAs of VH CDR2	AAs of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
1082B06	2053	131-238	154-164	180-186	219-227	1-115	26-35	50-66	99-104	GNGKDV (SEQ ID NO: 3135)	
1082B09	2054	134-241	157-167	183-189	222-230	1-118	26-35	50-66	99-107	EGVAAGEDY (SEQ ID NO: 3123)	
1082B12	2055	131-241	153-166	182-188	221-230	1-115	26-35	50-66	99-104	DLDFFD (SEQ ID NO: 2208)	
1082C01	2056	136-243	157-167	183-189	222-232	1-120	26-35	50-66	99-109	VNDIVVDMV (SEQ ID NO: 3143)	
1082C05	2057	136-243	157-167	183-189	222-232	1-120	26-35	50-66	99-109	EKGSRVFDI (SEQ ID NO: 3093)	
1082C08	2058	137-244	158-168	184-190	223-233	1-121	26-35	50-66	99-110	LSNRNRLRLDY (SEQ ID NO: 3106)	
1082D02	2059	130-240	152-165	181-187	220-229	1-114	26-35	50-66	99-103	FVLDY (SEQ ID NO: 2210)	
1082E05	2060	134-241	155-165	181-187	220-230	1-118	26-35	50-66	99-107	TWAINTFDM (SEQ ID NO: 3152)	
1082E06	2061	130-240	152-165	181-187	220-229	1-114	26-35	50-66	99-103	FDLDY (SEQ ID NO: 3167)	
1082E07	2062	139-246	162-172	188-194	227-235	1-123	26-35	50-66	99-112	VEWEDIVVGSADF (SEQ ID NO: 3128)	
1082F11	2063	136-243	159-169	185-191	224-232	1-120	26-35	50-66	99-109	GGDMITVTIDY (SEQ ID NO: 3177)	
1082G07	2064	136-243	159-169	185-191	224-232	1-120	26-35	50-66	99-109	ADYSNDYYMDV (SEQ ID NO: 3166)	
1082G10	2065	134-249	160-173	189-195	228-238	1-118	26-35	50-66	99-107	EGVAAGEDY (SEQ ID NO: 3123)	
1083G11	2066	143-250	164-174	190-196	229-239	1-127	26-35	50-66	99-116	GPYYFDGSAYEGYFDY (SEQ ID NO: 3222)	
1082H04	2067	132-238	153-163	179-185	218-227	1-116	26-35	50-65	98-105	NMADAFEI (SEQ ID NO: 3223)	
1082H09	2068	139-246	160-170	186-192	225-235	1-123	26-35	50-66	99-112	PAASSRGPKDAFDI (SEQ ID NO: 3129)	
1083A06	2069	136-244	159-169	185-191	224-233	1-120	26-35	50-68	99-109	DSRPTNRAHY (SEQ ID NO: 3110)	
1083A09	2070	137-248	160-172	188-194	227-237	1-121	26-35	50-68	101-110	LHCTGGSCGF (SEQ ID NO: 3186)	
1083A11	2071	135-248	158-171	187-193	226-237	1-119	26-35	50-66	99-108	VRDSSAGFDY (SEQ ID NO: 3173)	
1083B03	2072	137-247	161-171	187-193	226-236	1-121	26-35	50-66	99-110	VLVQRQYRGMDL (SEQ ID NO: 3138)	
1083B05	2073	138-250	161-174	190-196	229-239	1-122	26-35	50-66	99-111	VDYTDYEMGAFDL (SEQ ID NO: 3172)	
1083B06	2074	138-250	161-174	190-196	229-239	1-122	26-35	50-66	99-111	DRLAAAGDAFDI (SEQ ID NO: 3194)	
1083B10	2075	137-246	162-172	188-194	227-235	1-121	26-35	50-66	99-110	DIYKNGYALFDS (SEQ ID NO: 3197)	
1083C01	2076	135-247	158-171	187-193	226-236	1-119	26-35	50-66	99-108	FGAGRLYDDY (SEQ ID NO: 3224)	
1083C02	2077	135-246	158-171	187-193	226-235	1-119	26-35	50-66	99-108	DNCGGTIGFDY (SEQ ID NO: 2195)	
1083C07	2078	136-249	159-172	188-194	227-238	1-120	26-35	50-66	99-109	DQGIETANDY (SEQ ID NO: 3207)	
1083C12	2079	135-246	158-171	187-193	226-235	1-119	26-35	50-66	99-108	DILPDYDFWNPNEDASSLDT (SEQ ID NO: 3133)	
1083D04	2080	145-256	168-181	197-203	236-245	1-129	26-35	50-66	99-118	DFQWVRGVFIAPNPYYGMDV (SEQ ID NO: 3154)	
1083D07	2081	148-262	173-188	204-210	233-243	1-132	26-35	50-66	99-121	DQMDGLVEAETTNWFDS (SEQ ID NO: 3126)	
1083D08	2082	142-254	165-178	194-200	233-243	1-126	26-35	52-69	102-119	ATKSYDILTRMYYYHMDV (SEQ ID NO: 2748)	
1083D10	2083	146-258	169-181	197-203	236-247	1-130	26-37	52-69			
1083D12	2084	132-242	156-166	182-188	221-231	1-116	26-35	50-66	99-105	DRTRMDV (SEQ ID NO: 3182)	
1083E02	2085	138-249	161-173	189-195	228-238	1-122	26-35	50-66	99-111	VGKAAAVDNFEY (SEQ ID NO: 2197)	
1083E03	2086	135-248	158-171	187-193	226-237	1-119	26-35	50-66	99-108	DEYNDAFDY (SEQ ID NO: 3105)	
1083E04	2087	143-255	166-179	195-201	234-244	1-127	26-35	50-66	99-110	DGDISPNNQNYAMD (SEQ ID NO: 3101)	
1083E08	2088	138-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	RGGTSENYSGMDV (SEQ ID NO: 3209)	
1083E12	2089	134-245	157-170	186-192	225-234	1-118	26-35	50-66	99-107	DYPHNAFDI (SEQ ID NO: 3127)	
1083F02	2090	145-258	168-181	197-203	236-247	1-129	26-35	50-66	99-118	DVDRSFRFSGGYYHYSMDV (SEQ ID NO: 3131)	
1083F04	2091	137-248	160-172	188-194	227-237	1-121	26-35	50-66	99-110	STLEVGATIDFY (SEQ ID NO: 3199)	
1083F06	2092	134-247	157-170	186-192	225-236	1-118	26-35	50-66	99-107	SDDWGAYHI (SEQ ID NO: 3198)	
1083F08	2093	138-250	161-174	190-196	229-239	1-122	26-35	50-66	99-111	ERGRDGDYALDF (SEQ ID NO: 3148)	
1083F11	2094	136-248	159-172	188-194	227-237	1-120	26-35	50-66	99-109	ELVGAPGDF (SEQ ID NO: 3191)	
1083G04	2095	138-250	161-174	190-196	229-239	1-122	26-35	50-66	99-111	VDYTDYEMGAFDL (SEQ ID NO: 3172)	
1083G05	2096	137-249	161-174	189-195	228-238	1-121	26-35	50-68	101-110	SVARGNFDY (SEQ ID NO: 3208)	
1083G06	2097	138-250	161-174	190-196	229-239	1-122	26-35	50-66	99-111	ERGRDGDYALDF (SEQ ID NO: 3148)	
1083G08	2098	141-253	164-177	193-199	232-242	1-125	26-35	50-66	99-114	EGGGDAYDVAPYYFDY (SEQ ID NO: 2204)	

TABLE 1-continued

Clone ID	scFv SEQ ID NO	scFvs that Immunoselectively Bind to BLyS							
		AAs of VL	AAs of VL CDR1	AAs of VL CDR2	AAs of VL CDR3	AAs of VH	AAs of VH CDR1	AAs of VH CDR2	
		VH CDR3 Sequence (SEQ ID NO)							
I083G09	2099	130-242	154-166	182-188	221-231	1-114	26-35	50-66	DPFDY (SEQ ID NO: 3134)
I083G11	2100	140-252	163-176	192-198	231-241	1-124	26-35	50-66	ALLGPSDFSYVDV (SEQ ID NO: 3159)
I083H04	2101	141-253	164-177	193-199	232-242	1-125	26-35	50-66	EGEGDGYNVAPYYFDY (SEQ ID NO: 3160)
I083H05	2102	133-243	157-167	183-189	222-232	1-117	26-35	50-66	TDYGGFDY (SEQ ID NO: 3092)
I083H07	2103	137-247	161-171	187-193	226-236	1-121	26-35	50-66	GGVGDGRGVDFP (SEQ ID NO: 3162)
I084A03	2104	130-237	153-163	179-185	218-226	1-114	26-35	50-66	DTTDY (SEQ ID NO: 2203)
I084A08	2105	130-240	152-164	180-186	219-229	1-114	26-35	50-66	DTTDDY (SEQ ID NO: 2203)
I084B08	2106	135-242	156-166	182-188	221-231	1-119	26-35	50-66	ESLTGDADF (SEQ ID NO: 3116)
I084C02	2107	136-243	157-167	183-189	222-232	1-120	26-35	50-66	SPLHESDAFDI (SEQ ID NO: 3120)
I084D03	2108	130-240	152-164	180-186	219-229	1-114	26-35	50-66	DTTDY (SEQ ID NO: 2203)
I084D05	2109	133-243	155-168	184-190	223-232	1-117	26-35	50-66	EVGGAFDI (SEQ ID NO: 3157)
I084E01	2110	130-237	153-163	179-185	218-226	1-114	26-35	50-66	DTTDY (SEQ ID NO: 2203)
I084E06	2111	130-237	153-163	179-185	218-226	1-114	26-35	50-66	DTTDY (SEQ ID NO: 2203)
I084E10	2112	130-237	151-161	177-183	216-226	1-114	26-35	50-66	DTTDY (SEQ ID NO: 2203)
I084E12	2113	130-240	152-164	180-186	219-229	1-114	26-35	50-66	DTTDY (SEQ ID NO: 2203)
I084F04	2114	130-237	153-163	179-185	218-226	1-114	26-35	50-66	ESLTGDADF (SEQ ID NO: 3116)
I084F07	2115	130-237	153-163	179-185	218-226	1-114	26-35	50-66	DTTDY (SEQ ID NO: 2203)
I084F12	2116	135-245	157-170	186-192	225-234	1-119	26-35	50-66	DTTDY (SEQ ID NO: 2203)
I084G12	2117	130-240	152-164	180-186	219-229	1-114	26-35	50-66	DTTDY (SEQ ID NO: 2203)
I084H02	2118	130-237	153-163	179-185	218-226	1-114	26-35	50-66	DTTDY (SEQ ID NO: 2203)
I084H05	2119	145-256	168-180	196-202	235-245	1-129	26-35	50-66	GAHYDRSPSHLSKYWFDL (SEQ ID NO: 3149)
I089B05	2120	138-249	161-173	189-195	228-238	1-122	26-35	50-66	VGIKAAAVDNFEY (SEQ ID NO: 2197)
I089G09	2121	138-248	162-172	188-194	227-237	1-122	26-35	50-66	LGKNTSSWSLDY (SEQ ID NO: 3181)
I089H01	2122	138-249	161-173	189-195	228-238	1-122	26-35	50-66	VGIKAAAVDNFEY (SEQ ID NO: 2197)
I089H06	2123	144-255	167-179	195-201	234-244	1-128	26-35	50-66	GGRYGYDGDGGYVDAFDI (SEQ ID NO: 3226)
I089H08	2124	136-247	159-172	188-194	227-236	1-120	26-35	50-66	DNGGGTIGFDY (SEQ ID NO: 2195)
I100A10	2125	140-251	163-175	191-197	230-240	1-124	26-35	50-66	VRQIADPPRSFFDP (SEQ ID NO: 3144)
I100B03	2126	136-247	159-172	188-194	227-236	1-120	26-35	50-66	DNGGGTIGFDY (SEQ ID NO: 2195)
I100B04	2127	136-247	159-172	188-194	227-236	1-120	26-35	50-66	DNGGGTIGFDY (SEQ ID NO: 2195)
I100C03	2128	140-251	163-175	191-197	230-240	1-124	26-35	50-66	VRQIADPPRSFFDP (SEQ ID NO: 3144)

SEQUENCE LISTING

The patent contains a lengthy "Sequence Listing" section. A copy of the "Sequence Listing" is available in electronic form from the USPTO web site (<http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US07138501B2>). An electronic copy of the "Sequence Listing" will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

What is claimed is:

1. An isolated antibody that immunospecifically binds B Lymphocyte Stimulator protein wherein said antibody comprises a first amino acid sequence at least 85% identical to amino acid residues 1-123 of SEQ ID NO:327 and a second amino acid sequence at least 85% identical to amino acid residues 141-249 of SEQ ID NO:327 and wherein said B Lymphocyte Stimulator protein is selected from the group consisting of:

- (a) a protein whose amino acid sequence consists of amino acid residues 1-285 of SEQ ID NO:3228;
- (b) a protein whose amino acid sequence consists of amino acid residues 134-285 of SEQ ID NO:3228; and
- (c) a trimer of the protein of (b).

2. The antibody of claim 1 wherein the first amino acid sequence is at least 95% identical to amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence is at least 95% identical to amino acid residues 141-249 of SEQ ID NO:327.

3. The antibody of claim 1 wherein the amino acid differences between the first amino acid sequence and amino acid residues 1-123 of SEQ ID NO:327 are in one or more of the CDR regions located at amino acid residues 26-35, 50-66 and 99-112 of SEQ ID NO: 327 and wherein the amino acid differences between the second amino acid sequence and amino acid residues 141-249 of SEQ ID NO: 327 are in one or more of the CDR regions located at amino acid residues 163-173, 189-195 and 228-238 of SEQ ID NO: 327.

4. An isolated antibody that immunospecifically binds B Lymphocyte Stimulator protein wherein said antibody comprises amino acid residues 1-123 of SEQ ID NO: 327 and amino acid residues 141-249 of SEQ ID NO: 327 and wherein said B Lymphocyte Stimulator protein is selected from the group consisting of:

- (a) a protein whose amino acid sequence consists of amino acid residues 1-285 of SEQ ID NO:3228;
- (b) a protein whose amino acid sequence consists of amino acid residues 134-285 of SEQ ID NO:3228; and
- (c) a trimer of the protein of (b).

5. The antibody of claim 1 wherein the antibody is selected from the group consisting of:

- (a) a whole immunoglobulin molecule;
- (b) an scFv;
- (c) a chimeric antibody;
- (d) a Fab fragment;
- (e) an Fab' fragment; and
- (f) an F(ab')₂.

6. The antibody of claim 1 wherein the antibody is a monoclonal antibody.

7. The antibody of claim 1 wherein the antibody is a human antibody.

8. The antibody of claim 1 which comprises a heavy chain immunoglobulin constant domain selected from the group consisting of:

- (a) a human IgM constant domain;
- (b) a human IgG1 constant domain;
- (c) a human IgG2 constant domain;
- (d) a human IgG3 constant domain;
- (e) a human IgG4 constant domain; and
- (f) a human IgA constant domain.

9. The antibody of claim 1 which comprises a light chain immunoglobulin constant domain selected from the group consisting of:

- (a) a human kappa constant domain; and
- (b) a human lambda constant domain.

10. The antibody of claim 1 wherein the antibody has a dissociation constant (K_D) less than or equal to 10^{-9} M.

11. The antibody of claim 1 wherein the antibody is coupled to a detectable label.

12. The antibody of claim 11 wherein the detectable label is a radioisotope, an enzyme, a fluorescent label, a luminescent label, bioluminescent label or biotin.

13. The antibody of claim 12 wherein the radioisotope is ¹²⁵I, ¹³¹I, ¹¹¹In, ⁹⁰Y, ^{99m}Tc, ¹⁷⁷Lu, ¹⁶⁶Ho, or ¹⁵³Sm.

14. The antibody of claim 1 wherein the antibody neutralizes said protein.

15. The antibody of claim 14 wherein the antibody diminishes the ability of said protein to bind to a receptor of said protein.

16. The antibody of claim 15 wherein the receptor is TACI.

17. The antibody of claim 15 wherein the receptor is BCMA.

18. The antibody of claim 14 wherein the antibody diminishes the ability of said protein to stimulate B cell proliferation.

19. The antibody of claim 14 wherein the antibody diminishes the ability of said protein to stimulate immunoglobulin secretion by B cells.

20. The antibody of claim 4 wherein the antibody is selected from the group consisting of:

- (a) a whole immunoglobulin molecule;
- (b) an scFv;
- (c) a chimeric antibody;
- (d) a Fab fragment;
- (e) an Fab' fragment; and
- (f) an F(ab')₂.

21. The antibody of claim 4 wherein the antibody is a monoclonal antibody.

22. The antibody of claim 4 wherein the antibody is a human antibody.

23. The antibody of claim 4 which comprises a heavy chain immunoglobulin constant domain selected from the group consisting of:

307

- (a) a human IgM constant domain;
- (b) a human IgG1 constant domain;
- (c) a human IgG2 constant domain;
- (d) a human IgG3 constant domain;
- (e) a human IgG4 constant domain; and
- (f) a human IgA constant domain.

24. The antibody of claim 4 which comprises a light chain immunoglobulin constant domain selected from the group consisting of:

- (a) a human kappa constant domain; and
- (b) a human lambda constant domain.

25. The antibody of claim 4 wherein the antibody is coupled to a detectable label.

26. The antibody of claim 25 wherein the detectable label is a radioisotope, an enzyme, a fluorescent label, a luminescent label, bioluminescent label or biotin.

27. The antibody of claim 26 wherein the radioisotope is ^{125}I , ^{131}I , ^{111}In , ^{90}Y , $^{99\text{m}}\text{Tc}$, ^{177}Lu , ^{166}Ho , or ^{153}Sm .

28. An antibody purified from the cell line contained in American Type Culture Collection Deposit Number PTA-3239.

29. An antibody purified from the cell line contained in American Type Culture Collection Deposit Number PTA-3240.

30. The antibody of claim 4 which comprises a human IgG1 heavy chain immunoglobulin constant domain and a human lambda light chain immunoglobulin constant domain.

308

31. The antibody of claim 4 wherein the antibody neutralizes said protein.

32. The antibody of claim 31 wherein the antibody diminishes the ability of said protein to bind to a receptor of said protein.

33. The antibody of claim 32 wherein the receptor is TACI.

34. The antibody of claim 32 wherein the receptor is BCMA.

35. The antibody of claim 31 wherein the antibody diminishes the ability of said protein to stimulate B cell proliferation.

36. The antibody of claim 31 wherein the antibody diminishes the ability of said protein to stimulate immunoglobulin secretion by B cells.

37. An isolated antibody that immunospecifically binds B Lymphocyte Stimulator protein wherein said antibody comprises amino acid residues 1-123 of SEQ ID NO:2 and amino acid residues 141-249 of SEQ ID NO:2 and wherein said B Lymphocyte Stimulator protein is selected from the group consisting of:

- (a) a protein whose amino acid sequence consists of amino acid residues 1-285 of SEQ ID NO:3228;
- (b) a protein whose amino acid sequence consists of amino acid residues 134-285 of SEQ ID NO:3228; and
- (c) a trimer of the protein of (b).

* * * * *

U.S. Patent No. 7,138,501

Application for Patent Term Extension

Attachment E

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,138,501 B2
APPLICATION NO. : 09/880748
DATED : November 21, 2006
INVENTOR(S) : Ruben et al.

Page 1 of 52

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Title:

Delete "ANTIBODIES THAT IMMUNOSPECIICALLY BIND TO BLYS"
and replace with --ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B
LYMPHOCYTE STIMULATOR PROTEIN--.

Title Page:


At INID (56) – Other Publications, delete "Kennell, D.E., Prog. Nucl. Acid Res.
Med. Biol, 11:259:301 1971."

In the Specification:

Replace Table 1, spanning pages 213-304 with the attached Table 1.

Signed and Sealed this

Sixth Day of March, 2007

A handwritten signature in black ink, reading "Jon W. Dudas". The signature is stylized, with a large, looped initial "J" and a distinct "D" for "Dudas".

JON W. DUDAS
Director of the United States Patent and Trademark Office

Table 1: scFvs that Immunospecifically Bind to B Lymphocyte Stimulator

Clone ID	scFv SEQ ID NO	AA of VL CDR1	AA of VL CDR2	AA of VL CDR3	AA of VH CDR1	AA of VH CDR2	AA of VH CDR3	VH CDR3 Sequence (SEQ ID NO)
10508128	1	138-248	189-195	228-237	1-122	26-35	99-111	HODDLVLGYTFS (SEQ ID NO: 2132)
10508129	2	141-249	189-195	228-238	1-123	26-35	99-112	SDALLTFHYGMGV (SEQ ID NO: 2133)
10508130	3	144-254	193-201	234-243	1-128	26-37	102-117	IRYDLTGYTYGMGV (SEQ ID NO: 2129)
10508131	4	148-255	193-201	234-244	1-132	26-35	99-121	VQMSSEYDLTGAVQYFEDY (SEQ ID NO: 2132)
10508132	5	142-249	189-195	228-238	1-126	26-35	99-115	DIYDELTGYTYGMGV (SEQ ID NO: 2135)
10508133	6	138-251	189-195	228-239	1-121	26-35	99-110	GYSASAFADI (SEQ ID NO: 2136)
10508134	7	142-250	190-196	228-239	1-124	26-35	99-113	AFYDLTHYHYFEDY (SEQ ID NO: 2134)
10508135	8	146-256	188-191	236-245	1-129	26-35	99-118	AATSKENKYAVYGMGV (SEQ ID NO: 2131)
10508136	9	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508137	10	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508138	11	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508139	12	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508140	13	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508141	14	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508142	15	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508143	16	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508144	17	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508145	18	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508146	19	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508147	20	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508148	21	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508149	22	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508150	23	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508151	24	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508152	25	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508153	26	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508154	27	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508155	28	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508156	29	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508157	30	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508158	31	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508159	32	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508160	33	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508161	34	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)
10508162	35	143-251	193-199	232-240	1-125	26-35	99-114	PFYDLTSYVQYFEDH (SEQ ID NO: 2137)

1050B1-127	36	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFOYEDH (SEQ ID NO: 2138)
1050B1-128	37	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2137)
1053D03	38	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVLGYVLS (SEQ ID NO: 2145)
1053D09	39	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2137)
1053G08	40	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFOYVVA (SEQ ID NO: 2143)
1097D11	41	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVQYTDH (SEQ ID NO: 2139)
1101A04	42	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2137)
1102A02	44	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2137)
1102E01	43	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2137)
1102G06	45	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2137)
1087A07	47	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087A08	48	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087A09	49	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087B02	50	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087E03	51	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087B04	52	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087B05	53	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087B06	54	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087B08	55	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087B09	56	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087C02	57	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087C03	58	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087C06	59	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087C07	60	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087C08	61	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087D01	62	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087D02	63	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087D03	64	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087D05	65	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087D07	66	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087D09	67	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087E04	68	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087E05	69	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087E10	70	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087F02	71	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087F04	72	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087F05	73	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087F07	74	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087F08	75	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087F09	76	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)
1087G05	77	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFDLILSYVFEQYTH (SEQ ID NO: 2144)

U.S. Patent

Nov. 21, 2006

Sheet 4 of 52

7,138,501 B2

1087C06	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVLFPS (SEQ ID NO: 2285)
1087C07	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPLPQ (SEQ ID NO: 2286)
1087C09	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVLFYGT (SEQ ID NO: 2287)
1087G10	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVLTPTCT (SEQ ID NO: 2276)
1087H02	137-244	160-170	186-192	225-233	1-121	26-35	50-66	99-110	ASYLTSSSLDN (SEQ ID NO: 2263)
1088A03	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2137)
1088A04	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2290)
1088A08	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088A09	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088A10	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088A11	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088A12	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088B02	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088B03	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088B05	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088B06	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088B07	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088B08	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088B09	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088B10	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088B12	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088C01	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088C03	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088C09	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088C12	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088C01	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088D03	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088D04	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088D07	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088D08	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088D11	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2235)
1088E01	140-248	163-174	190-196	229-237	1-122	23-32	47-63	96-111	PFYDILTSYVLFPL (SEQ ID NO: 2215)
1088E02	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2215)
1088E03	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2215)
1088E04	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2215)
1088E08	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2215)
1088E10	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2215)
1088E11	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2215)
1088F07	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2215)
1088G02	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFPL (SEQ ID NO: 2215)

1089C003	120	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1088C007	121	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVHYFYL (SEQ ID NO: 2266)
1088C009	122	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVPYYL (SEQ ID NO: 2264)
1088C010	123	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLFHDH (SEQ ID NO: 2301)
1088H005	124	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
108H007	125	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092A003	126	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092A005	127	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVHEHYDV (SEQ ID NO: 2248)
1092A006	128	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092A008	129	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVHEFLS (SEQ ID NO: 2283)
1092A10	130	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092A11	131	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092B001	132	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092B02	133	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092B04	134	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092B05	135	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092B08	136	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092C007	137	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092C01	138	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092C02	139	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092C03	140	142-250	165-176	192-198	231-239	1-124	26-35	50-66	99-113	PFYDILTSYVLAALIL (SEQ ID NO: 2328)
1092C12	141	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092D01	142	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092D07	143	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092E009	144	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVMARLP (SEQ ID NO: 2255)
1092D10	145	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092D11	146	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVHELYLV (SEQ ID NO: 2256)
1092E01	147	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092E03	148	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092E04	149	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092E07	150	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092E09	151	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092E10	152	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLYFYL (SEQ ID NO: 2327)
1092E11	153	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092F01	154	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092F02	155	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092F03	156	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092F07	157	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092F08	158	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092F11	159	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)
1092F12	160	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVLYATPD (SEQ ID NO: 2360)
1092G01	161	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDILTSYVQFYFDH (SEQ ID NO: 2137)

U.S. Patent

Nov. 21, 2006

Sheet 6 of 52

7,138,501 B2

1092G05	162	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1092G10	163	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1092H01	164	137-244	160-170	186-192	225-233	1-121	26-35	50-66	99-110	ASVLTSSSLIN (SEQ ID NO: 2265)
1093A06	165	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVLPYDHA (SEQ ID NO: 2334)
1093A09	166	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYFAH (SEQ ID NO: 2268)
1093A11	167	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093A12	168	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093B02	169	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093B05	170	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093B06	171	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093B09	172	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093B12	173	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093C02	174	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093C03	175	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093C05	176	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093D05	177	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093D08	178	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093D10	179	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093D12	180	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093E01	181	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093E02	182	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093E05	183	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093E08	184	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093E10	185	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093F01	186	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093F03	187	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093F05	188	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093F08	189	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093F11	190	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093G07	191	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093G11	192	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093G12	193	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1093H06	194	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1094A08	195	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1094B07	196	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1094B08	197	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1094B12	198	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1094C11	199	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1094C12	200	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1094D06	201	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1094D07	202	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)
1094D08	203	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	PFYDLTSYVQYEDH (SEQ ID NO: 2137)

I094D069	204	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I094D10	205	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I094D11	206	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFHYFPV (SEQ ID NO: 2137)
I094E04	207	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFHYFPV (SEQ ID NO: 2137)
I094E08	208	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVLKPSL (SEQ ID NO: 2311)
I094F04	209	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQEYFP (SEQ ID NO: 2252)
I094F05	210	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I094F10	211	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I094F11	212	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVWLWYYOD (SEQ ID NO: 2249)
I094F12	213	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFHYTPT (SEQ ID NO: 2296)
I094G06	214	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I094C10	215	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095A04	216	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095A12	217	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVLEFFPA (SEQ ID NO: 2312)
I095B04	218	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVLEFLPL (SEQ ID NO: 2387)
I095B09	219	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVHLHYSA (SEQ ID NO: 2317)
I095C02	221	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVLFYTIA (SEQ ID NO: 2331)
I095C05	222	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVHLVLEV (SEQ ID NO: 2337)
I095C07	223	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095C08	224	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095C09	225	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVFNHHYPT (SEQ ID NO: 2289)
I095D01	226	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095D02	227	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095D03	228	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVQLXERY (SEQ ID NO: 2325)
I095D05	229	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVYLQYDTI (SEQ ID NO: 2328)
I095D09	230	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095E01	231	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVLDYSSS (SEQ ID NO: 2309)
I095E03	232	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYEDH (SEQ ID NO: 2221)
I095E12	233	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVEFYFH (SEQ ID NO: 2157)
I095F06	234	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFHYFPV (SEQ ID NO: 2291)
I095F09	235	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFHYFPV (SEQ ID NO: 2291)
I095G06	236	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095G09	237	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095G11	238	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095G01	239	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095G10	240	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095G08	241	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095G03	242	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095G01	243	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095G06	244	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)
I095G09	245	143-251	166-177	193-199	232-240	1-125	26-35	58-66	99-114	PFDYDLTSLVVFQYFDDH (SEQ ID NO: 2137)

[illegible]

1098G02	288	163-231	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1098G12	289	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1098G03	290	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1101A01	291	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1101B04	292	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1101B06	293	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1101D04	294	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1101D07	295	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1101B09	296	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1101B12	297	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1101G02	298	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1101G11	299	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1102C05	300	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1102B09	301	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1102F02	302	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1102G04	303	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1102C09	304	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1106A09	305	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1106B02	306	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1106B06	307	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1106C07	308	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1106B05	309	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1106B12	310	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2146)
1106G01	311	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1106C03	312	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1109B05	313	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1109D12	314	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1109B12	315	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1109G06	316	143-251	166-177	193-199	232-240	1-125	26-35	50-66	99-114	FFYDILTSYVQYFDH (SEQ ID NO: 2137)
1110F104	317	143-251	166-177	193-199	23					

U.S. Patent

Nov. 21, 2006

Sheet 10 of 52

7,138,501 B2

1085A01	330	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTHDHLF (SEQ ID NO: 2602)
1085A02	331	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLGF (SEQ ID NO: 2639)
1085A03	332	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTHPLSF (SEQ ID NO: 2561)
1085A04	333	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FPLPLF (SEQ ID NO: 2550)
1085A05	334	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSL (SEQ ID NO: 2659)
1085A06	335	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2611)
1085A07	336	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2390)
1085A09	337	140-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRD111FSDPLSF (SEQ ID NO: 2632)
1085A10	338	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2609)
1085A11	339	140-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRD111FTHDPLF (SEQ ID NO: 2363)
1085B01	340	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2466)
1085B02	341	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2392)
1085B03	342	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2638)
1085B04	343	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2589)
1085B05	344	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2573)
1085B06	345	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2574)
1085B07	346	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2433)
1085B10	347	140-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRD111FSDPLSF (SEQ ID NO: 2470)
1085B12	348	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2372)
1085C02	349	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2430)
1085C03	350	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2400)
1085C05	351	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2491)
1085C06	352	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2341)
1085C07	353	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2375)
1085C09	354	140-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRD111FSDPLSF (SEQ ID NO: 2468)
1085C10	355	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2471)
1085C12	356	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2680)
1085D01	357	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2548)
1085D02	358	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2523)
1085D03	359	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2713)
1085D04	360	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2646)
1085D06	361	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2488)
1085D07	362	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2694)
1085D08	363	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2477)
1085D09	364	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2467)
1085D10	365	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2563)
1085D11	366	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2510)
1085D12	367	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2495)
1085E01	368	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2620)
1085E02	369	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2575)
1085E07	370	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2568)
1085E08	371	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FSDPLSF (SEQ ID NO: 2603)

U.S. Patent

Nov. 21, 2006

Sheet 11 of 52

7,138,501 B2

1085E09	372	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPHDPRF (SEQ ID NO: 2623)
1085E10	373	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSELPWP (SEQ ID NO: 2668)
1085E11	374	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSPFLN (SEQ ID NO: 2716)
1085E12	375	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPHPLTP (SEQ ID NO: 2431)
1085F01	376	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSPFLF (SEQ ID NO: 2351)
1085F02	377	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSPFLQ (SEQ ID NO: 2376)
1085F03	378	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPYTFLF (SEQ ID NO: 2682)
1085F05	380	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPHDPLF (SEQ ID NO: 2706)
1085F06	381	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSAPLRF (SEQ ID NO: 2586)
1085F07	382	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPAGPLRF (SEQ ID NO: 2410)
1085F09	383	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPDHATV (SEQ ID NO: 2439)
1085F10	384	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSSQFA (SEQ ID NO: 2662)
1085F11	385	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSSVLEF (SEQ ID NO: 2339)
1085F12	386	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFRDPLH (SEQ ID NO: 2358)
1085G01	387	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSAPLQ (SEQ ID NO: 2695)
1085G02	388	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPNAFLF (SEQ ID NO: 2613)
1085G03	389	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPNAFLQ (SEQ ID NO: 2403)
1085G04	390	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSAPLDF (SEQ ID NO: 2681)
1085G07	391	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPNAVLDI (SEQ ID NO: 2629)
1085G08	392	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSEPLF (SEQ ID NO: 2664)
1085G09	393	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSSVLP (SEQ ID NO: 2338)
1085G10	394	140-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRDLFFPHAFQ (SEQ ID NO: 2534)
1085G11	395	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPDSPLF (SEQ ID NO: 2445)
1085G12	396	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSSPLRP (SEQ ID NO: 2376)
1085H10	397	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	IXYYDLTGYSYYGMDV (SEQ ID NO: 2135)
1086A03	398	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSSMFLTF (SEQ ID NO: 2495)
1086A04	399	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPHSLRP (SEQ ID NO: 2438)
1086A05	400	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPHAPLSH (SEQ ID NO: 2569)
1086A07	401	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPDALRF (SEQ ID NO: 2621)
1086A09	402	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFSSHLSF (SEQ ID NO: 2704)
1086A10	403	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSPFLSS (SEQ ID NO: 2624)
1086A11	404	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPHALTP (SEQ ID NO: 2577)
1086A12	405	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPYDPLHS (SEQ ID NO: 2635)
1086A02	406	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPHPLRP (SEQ ID NO: 2348)
1086B03	407	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPHAFLLF (SEQ ID NO: 2412)
1086B05	408	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSEPLH (SEQ ID NO: 2457)
1086B06	409	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPASELP (SEQ ID NO: 2364)
1086B07	410	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSPFLYF (SEQ ID NO: 2720)
1086B09	411	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSPFLSF (SEQ ID NO: 2379)
1086B10	412	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPDKGLSS (SEQ ID NO: 2428)
1086B11	413	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSPFLCF (SEQ ID NO: 2530)

U.S. Patent

Nov. 21, 2006

Sheet 12 of 52

7,138,501 B2

1086C03	414	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTPALYQ (SEQ ID NO: 2535)
1086C05	415	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHSLFF (SEQ ID NO: 2427)
1086C07	416	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFQGLRF (SEQ ID NO: 2440)
1086C08	417	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFFAALAF (SEQ ID NO: 2401)
1086C09	418	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHPLLF (SEQ ID NO: 2350)
1086C10	419	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTFPLF (SEQ ID NO: 2544)
1086C11	420	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHDDLSF (SEQ ID NO: 2432)
1086C12	421	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFDLSLF (SEQ ID NO: 2622)
1086D01	422	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFSAPLF (SEQ ID NO: 2630)
1086D04	423	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFVAPLVD (SEQ ID NO: 2497)
1086D06	424	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086D07	425	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086D08	426	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086D09	427	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086D10	428	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086D11	429	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086D12	430	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086E02	431	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086E03	432	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086E05	433	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086E07	434	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086E09	435	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086E10	436	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086E11	437	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086E12	438	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086F02	439	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086F05	440	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086F08	441	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086F09	442	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086F11	443	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086G03	444	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086G04	445	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086G06	446	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086G07	447	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086G09	448	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086G10	449	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086G105	450	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086G105	451	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086G105	452	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086G105	453	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086G105	454	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)
1086G105	455	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHLTF (SEQ ID NO: 2365)

U.S. Patent

Nov. 21, 2006

Sheet 13 of 52

7,138,501 B2

1089A07	456	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFFDALVF (SEQ ID NO: 2539)
1089A08	457	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFFTYLLF (SEQ ID NO: 2682)
1089A10	458	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHQPLF (SEQ ID NO: 2436)
1089A11	459	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFRTYDF (SEQ ID NO: 2572)
1089B01	460	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHSPLF (SEQ ID NO: 2430)
1089B02	461	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHSIDL (SEQ ID NO: 2147)
1089B03	462	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTSPLQ (SEQ ID NO: 2528)
1089B04	463	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFTHPLF (SEQ ID NO: 2550)
1089B05	464	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFSSPLF (SEQ ID NO: 2712)
1089B06	465	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFMAPLSP (SEQ ID NO: 2596)
1089B07	466	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPYSGLDA (SEQ ID NO: 2374)
1089B08	467	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFFAATLSP (SEQ ID NO: 2405)
1089B09	468	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFFSPLF (SEQ ID NO: 2384)
1089B10	469	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFNSPLF (SEQ ID NO: 2388)
1089B11	470	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHYGMDV (SEQ ID NO: 2133)
1089C01	471	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSPLF (SEQ ID NO: 2531)
1089C02	472	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFFTYLLF (SEQ ID NO: 2571)
1089C03	473	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHYPLF (SEQ ID NO: 2532)
1089C05	474	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFSSALRF (SEQ ID NO: 2722)
1089C06	475	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFPSPLF (SEQ ID NO: 2701)
1089C07	476	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFQAPLED (SEQ ID NO: 2483)
1089C09	477	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPTF (SEQ ID NO: 2507)
1089D01	478	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLVL (SEQ ID NO: 2381)
1089D02	479	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHYGMDV (SEQ ID NO: 2133)
1089D03	480	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHYPLF (SEQ ID NO: 2344)
1089D04	481	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFSSPLF (SEQ ID NO: 2717)
1089D05	482	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLFT (SEQ ID NO: 2346)
1089D07	483	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLQ (SEQ ID NO: 2354)
1089D08	484	140-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRDLFFSHAPHB (SEQ ID NO: 2677)
1089D09	485	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLQ (SEQ ID NO: 2354)
1089D11	486	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLQ (SEQ ID NO: 2354)
1089E01	487	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLQ (SEQ ID NO: 2354)
1089E02	488	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLQ (SEQ ID NO: 2354)
1089E03	489	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLQ (SEQ ID NO: 2354)
1089E04	490	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLQ (SEQ ID NO: 2354)
1089E06	491	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLQ (SEQ ID NO: 2354)
1089E09	492	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLQ (SEQ ID NO: 2354)
1089E10	493	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLQ (SEQ ID NO: 2354)
1089E11	494	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLQ (SEQ ID NO: 2354)
1089F01	495	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLQ (SEQ ID NO: 2354)
1089F03	496	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLQ (SEQ ID NO: 2354)
1089F04	497	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLFFHAPLQ (SEQ ID NO: 2354)

U.S. Patent

Nov. 21, 2006

Sheet 14 of 52

7,138,501 B2

1089F05	498	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHPLR1 (SEQ ID NO: 2459)
1089F06	499	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2460)
1089F08	500	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHPL1F (SEQ ID NO: 2567)
1089F09	501	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPLAFLSF (SEQ ID NO: 2555)
1089F10	502	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHQPLSF (SEQ ID NO: 2467)
1089F11	503	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPLPMHF (SEQ ID NO: 2565)
1089G01	504	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPSAPL1F (SEQ ID NO: 2426)
1089G02	505	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPSHPL1F (SEQ ID NO: 2487)
1089G03	506	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHPL1F (SEQ ID NO: 2721)
1089G05	507	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFGSP1F (SEQ ID NO: 2389)
1089G06	508	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFTPPL1F (SEQ ID NO: 2514)
1089G07	509	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPSAPL1F (SEQ ID NO: 2597)
1089G08	510	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPSHPL1F (SEQ ID NO: 2488)
1089G11	511	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPSHPL1F (SEQ ID NO: 2671)
1089H10	512	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DOYDILIGYTYGMDV (SEQ ID NO: 2135)
1090A02	513	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFAPL1F (SEQ ID NO: 2416)
1090A03	514	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPNSL1F (SEQ ID NO: 2478)
1090A04	515	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFDAPL1F (SEQ ID NO: 2426)
1090A05	516	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFTPPL1F (SEQ ID NO: 2600)
1090A06	517	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFTPPL1F (SEQ ID NO: 2479)
1090A07	518	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFTPPL1F (SEQ ID NO: 2627)
1090A08	519	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFHPL1F (SEQ ID NO: 2705)
1090B01	520	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPLEA (SEQ ID NO: 2520)
1090B03	521	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2442)
1090B05	523	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2496)
1090B06	524	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2542)
1090B08	525	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2474)
1090B11	526	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2452)
1090B12	527	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2452)
1090C01	528	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2591)
1090C02	529	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2702)
1090C03	530	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2493)
1090C05	531	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2567)
1090C06	532	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2498)
1090C07	533	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2676)
1090C08	534	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2458)
1090C10	535	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2408)
1090D02	536	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2331)
1090D03	537	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2654)
1090D04	538	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2529)
1090D05	539	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1FFPHAPL1F (SEQ ID NO: 2529)

U.S. Patent

Nov. 21, 2006

Sheet 15 of 52

7,138,501 B2

1090D06	540	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2367)
1090D07	541	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2462)
1090D08	542	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2723)
1090D09	543	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2505)
1090D12	544	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2579)
1090E04	545	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2552)
1090E05	546	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2443)
1090E06	547	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2484)
1090E07	548	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2647)
1090E09	549	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2700)
1090E11	550	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2696)
1090E12	551	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2526)
1090F01	552	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2451)
1090F02	553	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2570)
1090F03	554	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2344)
1090F04	555	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2698)
1090F05	556	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2359)
1090F06	557	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2666)
1090F07	558	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2451)
1090F08	559	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2570)
1090F09	560	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2344)
1090F10	561	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2577)
1090F11	562	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2698)
1090G01	563	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2347)
1090G02	564	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2395)
1090G04	565	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2395)
1090G05	566	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2472)
1090G06	567	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2480)
1090G07	568	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2356)
1090G08	569	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2492)
1090G09	570	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2343)
1090G10	571	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2724)
1090G12	572	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2669)
1091A02	573	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2724)
1091A03	574	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2592)
1091A06	575	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2594)
1091A11	576	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2441)
1091B01	577	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2585)
1091B02	578	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2361)
1091B04	579	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2395)
1091B05	580	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2475)
1091B07	581	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD111FTRAPLDF (SEQ ID NO: 2626)

U.S. Patent

Nov. 21, 2006

Sheet 16 of 52

7,138,501 B2

1091B10	562	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2342)
1091B11	583	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2444)
1091B12	584	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2650)
1091C02	585	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2414)
1091C03	586	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2378)
1091C04	587	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2331)
1091C05	588	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2343)
1091C06	589	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2344)
1091C07	590	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2415)
1091C11	591	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2618)
1091C12	592	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2618)
1091D01	593	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2672)
1091D02	594	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2673)
1091D03	595	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2443)
1091D04	596	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2606)
1091D05	597	140-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRDLLEFTAPLAF (SEQ ID NO: 2456)
1091D06	598	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2643)
1091D07	599	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2719)
1091D08	600	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2425)
1091E01	601	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2689)
1091E02	602	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2352)
1091E03	603	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2597)
1091E04	604	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2576)
1091E07	605	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2661)
1091E08	606	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2607)
1091E09	607	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2361)
1091E10	608	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2711)
1091F01	609	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2456)
1091F03	610	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2599)
1091F05	611	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2553)
1091F06	612	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2553)
1091F07	613	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2133)
1091F08	614	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2458)
1091F09	615	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2334)
1091F10	616	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2444)
1091F11	617	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2549)
1091G01	618	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2386)
1091G03	619	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2355)
1091G04	620	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2478)
1091G05	621	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2397)
1091G06	622	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDLLEFTAPLAF (SEQ ID NO: 2397)
	623	140-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SRDLLEFTAPLAF (SEQ ID NO: 2637)

1091G07	624	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPTAPLDP (SEQ ID NO: 2345)
1091G09	625	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPTAPLFP (SEQ ID NO: 2349)
1091G10	626	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPDSFLYF (SEQ ID NO: 2660)
1091G11	627	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPQSPLTF (SEQ ID NO: 2389)
1091G12	628	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPYSHLEF (SEQ ID NO: 2655)
1104A01	629	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPQSPFLP (SEQ ID NO: 2455)
1104A07	630	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPQAPLFP (SEQ ID NO: 2689)
1104A08	631	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPYAPLTF (SEQ ID NO: 2617)
1104A09	632	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPQPHLHP (SEQ ID NO: 2506)
1104A10	633	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPHEPLCF (SEQ ID NO: 2636)
1104A11	634	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFSPAPLSF (SEQ ID NO: 2611)
1104A12	635	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPMAPIRF (SEQ ID NO: 2593)
1104B02	636	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFSPRSLF (SEQ ID NO: 2557)
1104B04	637	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFSPAPLYP (SEQ ID NO: 2387)
1104B11	639	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFRRDPLQF (SEQ ID NO: 2395)
1104C01	640	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPTAPLTF (SEQ ID NO: 2331)
1104C04	641	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPYSPLYP (SEQ ID NO: 2710)
1104C05	642	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPASPLIF (SEQ ID NO: 2417)
1104C06	643	140-248	162-172	188-194	228-238	1-122	26-35	50-66	99-111	SRD1LLFPHEPLF (SEQ ID NO: 2543)
1104C07	644	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPHPAPLE (SEQ ID NO: 2524)
1104C09	645	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPHPAPLHP (SEQ ID NO: 2370)
1104C11	646	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPHEPLF (SEQ ID NO: 2399)
1104D01	647	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPNHAIDL (SEQ ID NO: 2652)
1104D02	648	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPDWPPLYP (SEQ ID NO: 2483)
1104D03	649	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPHPLFL (SEQ ID NO: 2511)
1104D04	650	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPQAPLHP (SEQ ID NO: 2691)
1104D07	651	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPHPAMDLP (SEQ ID NO: 2595)
1104D08	652	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPRAPLTF (SEQ ID NO: 2500)
1104D09	653	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPHSPLEF (SEQ ID NO: 2447)
1104E01	654	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD1LLFPNDPLVL (SEQ ID NO: 264

U.S. Patent

Nov. 21, 2006

Sheet 18 of 52

7,138,501 B2

1104F10	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPNSPLSF (SEQ ID NO: 2362)
1104F11	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPQDPLVF (SEQ ID NO: 2706)
1104F12	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPKAPLVP (SEQ ID NO: 2544)
1104G04	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPHPAPLRF (SEQ ID NO: 2559)
1104G05	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPAPLAP (SEQ ID NO: 2476)
1104G09	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPAPLNF (SEQ ID NO: 2518)
1104G11	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPQGPLSF (SEQ ID NO: 2482)
1105A03	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPHPHFDL (SEQ ID NO: 2494)
1105A04	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPHPPLNF (SEQ ID NO: 2487)
1105A08	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPQAPLVP (SEQ ID NO: 2378)
1105A09	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPHPHFDL (SEQ ID NO: 2557)
1105A11	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPHPHFDL (SEQ ID NO: 2692)
1105B04	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPYHPLHP (SEQ ID NO: 2638)
1105B05	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPYHPLHP (SEQ ID NO: 2676)
1105B07	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPHPHFDL (SEQ ID NO: 2147)
1105B08	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPHPHFDL (SEQ ID NO: 2147)
1105B10	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPHPHFDL (SEQ ID NO: 2364)
1105B11	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPHPHFDL (SEQ ID NO: 2651)
1105B12	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPDPLII (SEQ ID NO: 2560)
1105C02	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPAPLAF (SEQ ID NO: 2472)
1105C03	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPSSPLSF (SEQ ID NO: 2715)
1105C06	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPHYGMDV (SEQ ID NO: 2133)
1105C08	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPAPLDF (SEQ ID NO: 2367)
1105D04	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPSPPLTF (SEQ ID NO: 2562)
1105D06	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPQHGDA (SEQ ID NO: 2446)
1105D08	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPDPLRF (SEQ ID NO: 2366)
1105D09	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPDPLSF (SEQ ID NO: 2366)
1105D10	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPYAPLAF (SEQ ID NO: 2608)
1105D11	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPYAPLAF (SEQ ID NO: 2619)
1105E01	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPSPALTF (SEQ ID NO: 2519)
1105E06	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPHPHFDL (SEQ ID NO: 2422)
1105E11	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPNSPLHP (SEQ ID NO: 2675)
1105F06	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPHPHFDL (SEQ ID NO: 2499)
1105F07	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPQAPLHP (SEQ ID NO: 2691)
1105F09	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPSPPLTF (SEQ ID NO: 2340)
1105F12	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPHYPLTF (SEQ ID NO: 2344)
1105G03	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPYPLVF (SEQ ID NO: 2604)
1105G08	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFPHPHFDL (SEQ ID NO: 2370)
									SRDL1LFPKHPPLVF (SEQ ID NO: 2366)

1105G09	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2366)
1105G10	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2419)
1105G11	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2614)
1107A01	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2361)
1107A03	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2369)
1107A07	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2371)
1107A09	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2369)
1107A12	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2366)
1107B02	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2366)
1107B04	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2363)
1107B05	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2363)
1107C01	139-247	161-171	187-193	226-236	1-121	24-33	48-64	97-110	SRD1L1FTASFLNP (SEQ ID NO: 2344)
1107C02	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2364)
1107C04	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2357)
1107C06	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2631)
1107C08	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2631)
1107C10	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2674)
1107D01	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2625)
1107D04	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2361)
1107D07	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2683)
1107D12	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2424)
1107E01	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2367)
1107E05	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2363)
1107E07	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2623)
1107E09	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2510)
1107F01	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2394)
1107F09	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2371)
1107F10	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2347)
1107G01	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2147)
1107G05	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2496)
1107H02	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2351)
1107H06	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2351)
1107H09	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2351)
1108A12	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2351)
1108B03	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2351)
1108B04	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2351)
1108C03	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2351)
1108C11	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2351)
1108D10	141-249	163-173	189-195	228-238	1-123	26-35	50-66	59-112	SRD1L1FTASFLNP (SEQ ID NO: 2351)

U.S. Patent

Nov. 21, 2006

Sheet 20 of 52

7,138,501 B2

1108D11	750	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2364)
1108D12	751	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2709)
1108E01	752	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2147)
1108E03	753	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2393)
1108E05	754	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2533)
1108E07	755	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2369)
1108E08	756	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2344)
1108E09	757	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2623)
1108E10	758	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2509)
1108E11	759	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2516)
1108F10	760	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2371)
1108F12	761	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2508)
1108G01	762	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2360)
1108G02	763	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2381)
1108G07	764	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2476)
1108G10	765	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2429)
1108G11	766	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2377)
1108G12	767	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2377)
1108H01	768	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2512)
1108H02	769	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2615)
1108H06	770	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2147)
1108H08	771	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2364)
1111A06	772	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2691)
1111B12	773	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2147)
1111C01	774	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2449)
1111D06	775	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2151)
1111E04	776	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2515)
1111E10	777	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2691)
1111E12	778	141-250	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2344)
1111F07	780	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2501)
1111G02	781	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2534)
1111H10	782	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2703)
1113A04	783	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2352)
1113A12	784	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2434)
1113B06	785	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2411)
1113C06	786	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2344)
1113G04	787	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2517)
1113G05	788	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2413)
1113G10	789	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2344)
1113G11	790	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2344)
1113H06	791	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRD11LFPASPLNP (SEQ ID NO: 2344)

U.S. Patent

Nov. 21, 2006

Sheet 21 of 52

7,138,501 B2

1113H07	792	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1113H09	793	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFHYTLLF (SEQ ID NO: 2525)
1114C04	794	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHGDA (SEQ ID NO: 2406)
1114C12	795	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFQAPLHP (SEQ ID NO: 2691)
1114D04	796	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFHYGMDY (SEQ ID NO: 2133)
1114D06	797	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1114E01	798	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFHYSLVL (SEQ ID NO: 2521)
1114E02	799	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFQEPYLP (SEQ ID NO: 2435)
1114E03	800	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFQESFSL (SEQ ID NO: 2437)
1114E04	801	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFKAPLTF (SEQ ID NO: 2382)
1114E05	802	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1114H06	803	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1114H09	804	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115A02	805	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115A07	806	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115B10	807	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115C05	808	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115C06	809	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115C08	810	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115C12	811	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115D07	812	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115E09	813	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115F06	814	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115F07	815	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115G04	816	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115H04	817	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115H05	818	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115H07	819	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115H08	820	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1115H09	821	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1116A07	822	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1116B01	823	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1116B12	824	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1116C06	825	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1116D07	826	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1116E02	827	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1116E04	828	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1116F02	829	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1116F11	830	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
1116G05	831	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
	832	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)
	833	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	SRDL1LFFPHHSEDL (SEQ ID NO: 2147)

U.S. Patent

Nov. 21, 2006

Sheet 22 of 52

7,138,501 B2

1001C09	164-174	198-196	229-239	1-127	26-35	58-66	99-116	DOSYDLTGYIENYMDV (SEQ ID NO: 2154)
1006D07	162-172	185-194	227-237	1-125	26-35	58-66	99-114	SHYDLTULANYVYFDL (SEQ ID NO: 2156)
1007B03	165-178	194-200	235-242	1-127	26-35	59-66	99-116	DOSYDLTGYIENYMDV (SEQ ID NO: 2154)
1007H11	162-175	191-197	234-239	1-124	26-35	58-66	99-113	DRYDLTVPALMDV (SEQ ID NO: 2160)
1007H08	166-179	193-201	234-243	1-124	26-37	52-69	102-117	DYDLTGYIENYMDV (SEQ ID NO: 2153)
1008A09	168-181	191-203	236-245	1-130	26-35	59-66	99-119	DREAYDLTGYIENYMDV (SEQ ID NO: 2153)
1008B01	163-176	192-198	231-240	1-125	26-35	59-66	99-114	ATYDLTGYIENYMDV (SEQ ID NO: 2153)
1008C02	167-180	196-203	235-244	1-129	26-37	52-67	100-118	RYDYDLTGYIENYMDV (SEQ ID NO: 2167)
1008C10	163-176	197-203	236-245	1-127	26-35	59-66	99-116	RYDYDLTGYIENYMDV (SEQ ID NO: 2171)
1008C12	168-181	197-203	236-245	1-130	26-35	59-66	101-119	RYDYDLTGYIENYMDV (SEQ ID NO: 2153)
1012A06	169-179	195-201	234-243	1-129	26-37	52-67	100-118	GRWYDLTGYIENYMDV (SEQ ID NO: 2162)
1016E05	163-176	192-198	231-240	1-125	26-35	59-66	99-114	ATYDLTGYIENYMDV (SEQ ID NO: 2153)
1016F02	157-170	186-192	235-244	1-119	26-35	59-66	99-108	GMCHYDMV (SEQ ID NO: 2161)
1016F04	163-176	192-198	231-240	1-125	26-35	59-66	99-114	ATYDLTGYIENYMDV (SEQ ID NO: 2153)
1016H07	162-172	188-194	227-237	1-125	26-35	59-66	99-114	GYDELTGYIENYMDV (SEQ ID NO: 2153)
1018C02	163-176	192-198	231-240	1-125	26-35	59-66	99-114	DYDLTGYIENYMDV (SEQ ID NO: 2153)
1018C10	164-174	190-196	229-239	1-127	26-35	59-66	99-116	DYDLTGYIENYMDV (SEQ ID NO: 2154)
1018D07	163-176	192-198	231-240	1-125	26-35	59-66	99-114	ATYDLTGYIENYMDV (SEQ ID NO: 2153)
1018H08	163-176	192-198	231-240	1-125	26-35	59-66	99-114	ATYDLTGYIENYMDV (SEQ ID NO: 2153)
1018H09	163-176	192-198	231-240	1-125	26-35	59-66	99-114	ATYDLTGYIENYMDV (SEQ ID NO: 2153)
1021E05	163-176	192-198	231-240	1-125	26-35	59-66	99-114	EGGYDLTGYIENYMDV (SEQ ID NO: 2158)
1022E02	163-176	192-198	231-240	1-125	26-35	59-66	99-114	ATYDLTGYIENYMDV (SEQ ID NO: 2157)
1026E03	165-175	191-197	230-240	1-125	26-35	59-66	99-114	TUYDLTGYIENYMDV (SEQ ID NO: 2173)
1027A07	167-179	195-201	234-244	1-126	26-35	59-66	99-117	GGYDLTGYIENYMDV (SEQ ID NO: 2170)
1028A05	164-176	192-198	231-242	1-126	26-35	59-66	99-115	GGYDLTGYIENYMDV (SEQ ID NO: 2156)
1029D07	163-176	192-198	231-240	1-125	26-35	59-66	99-114	ATYDLTGYIENYMDV (SEQ ID NO: 2153)
1029F11	163-176	192-198	231-240	1-125	26-35	59-66	99-116	DOSYDLTGYIENYMDV (SEQ ID NO: 2154)
1031C03	160-172	188-194	227-237	1-121	26-35	59-66	99-110	GYDSSARRAFDI (SEQ ID NO: 2156)
1031C07	170-183	199-205	238-247	1-131	26-35	59-66	99-120	SSPRWYDALTGSSYTHSAMDV (SEQ ID NO: 2169)
1031F09	167-179	195-201	234-244	1-127	26-35	59-66	99-116	DEGRDLTGYIENYMDV (SEQ ID NO: 2168)
1031G08	170-182	198-204	237-247	1-131	26-35	59-66	99-120	SSPRWYDALTGSSYTHSAMDV (SEQ ID NO: 2159)
1031G10	178-182	198-204	237-247	1-131	26-35	59-66	99-116	SSPRWYDALTGSSYTHSAMDV (SEQ ID NO: 2165)
1031G11	167-179	195-201	234-244	1-127	26-35	59-66	99-113	DEGRDLTGYIENYMDV (SEQ ID NO: 2168)
1037E07	162-175	191-197	230-239	1-124	26-35	59-66	99-113	DRYDLTVPALMDV (SEQ ID NO: 2160)
1037E12	162-175	191-197	230-239	1-124	26-35	59-66	99-113	DRYDLTVPALMDV (SEQ ID NO: 2160)
1030A07	168-181	197-203	236-246	1-128	26-40	55-71	104-118	QYNDPLTGYIENYMDV (SEQ ID NO: 2164)
1061D02	166-179	195-201	234-243	1-128	26-37	52-69	103-117	DRYDLTGYIENYMDV (SEQ ID NO: 2153)
1061E07	163-175	191-197	230-240	1-125	26-35	59-66	99-114	ATYDLTGYIENYMDV (SEQ ID NO: 2153)
1061E11	168-181	197-203	236-245	1-130	26-35	59-66	101-119	RYDYDLTGYIENYMDV (SEQ ID NO: 2153)
1061E13	166-179	195-201	234-243	1-128	26-35	59-66	99-117	RYDYDLTGYIENYMDV (SEQ ID NO: 2153)
1061A03	163-176	192-198	231-240	1-125	26-35	59-66	99-114	ATYDLTGYIENYMDV (SEQ ID NO: 2153)
1091A07	163-176	192-198	231-240	1-125	26-35	59-66	99-114	ATYDLTGYIENYMDV (SEQ ID NO: 2153)
1091A08	163-176	192-198	231-240	1-125	26-35	59-66	99-114	ATYDLTGYIENYMDV (SEQ ID NO: 2153)

U.S. Patent

Nov. 21, 2006

Sheet 23 of 52

7,138,501 B2

1001A10	876	141-251	165-176	191-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSDGFDX (SEQ ID NO: 2153)
1001A12	877	141-248	162-172	188-194	237-237	1-125	26-35	50-66	99-114	ATYDPLTGYSDGFDX (SEQ ID NO: 2153)
1001B02	878	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	DRETKVGYOMDY (SEQ ID NO: 2948)
1001B07	879	141-251	163-176	192-198	231-240	1-123	26-35	50-66	99-114	ATYDPLTGYSDGFDX (SEQ ID NO: 2153)
1001C06	880	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNYDLITGYVGNQAFDI (SEQ ID NO: 2156)
1001C08	881	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EGGNYDLITGYVGNQAFDI (SEQ ID NO: 2171)
1001C12	882	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSDGFDX (SEQ ID NO: 2153)
1001D08	883	140-250	162-175	191-197	230-239	1-124	26-35	50-65	98-113	DSYDLTGYRGVYEDY (SEQ ID NO: 2745)
1001D12	884	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSDGFDX (SEQ ID NO: 2153)
1001E05	885	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNYDLITGYVGNQAFDI (SEQ ID NO: 2158)
1001E07	886	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSDGFDX (SEQ ID NO: 2153)
1001C09	887	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSDGFDX (SEQ ID NO: 2153)
1001H05	888	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	ERHYVBLITGYVGYGMDV (SEQ ID NO: 2784)
1001H08	889	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSDGFDX (SEQ ID NO: 2153)
1003A01	890	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSVGAITGALDM (SEQ ID NO: 2852)
1003A06	891	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSVGAITGALDM (SEQ ID NO: 2852)
1003A07	892	142-249	163-172	188-194	227-237	1-125	26-35	50-66	99-114	DOYDILTGYSYGMDV (SEQ ID NO: 2135)
1003A18	893	141-248	162-172	189-195	228-238	1-126	26-35	50-66	99-115	DOYDILTGYSYGMDV (SEQ ID NO: 2135)
1003B03	894	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSVGAITGALDM (SEQ ID NO: 2852)
1003B04	895	140-248	162-172	188-194	227-237	1-122	25-34	49-65	98-111	RYDPPFYTYTMMNV (SEQ ID NO: 2755)
1003B09	896	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DOYDILTGYSYGMDV (SEQ ID NO: 2135)
1003C01	897	142-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGSSVGAITGALDM (SEQ ID NO: 2174)
1003C02	898	142-252	164-176	192-198	231-241	1-125	26-35	50-66	99-114	GDYDILTGYPAECFQ (SEQ ID NO: 2854)
1003C03	899	142-250	164-174	190-196	229-239	1-125	26-35	50-66	99-114	GDYDILTGYPAECFQ (SEQ ID NO: 2854)
1003C12	900	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDILTGYVGYTDMV (SEQ ID NO: 2179)
1003D04	901	140-250	164-176	192-198	231-242	1-125	26-35	50-66	99-114	RYDPPFYTYTMMNV (SEQ ID NO: 2755)
1003E05	902	142-253	164-176	192-198	231-242	1-125	26-35	50-66	99-114	RYDPPFYTYTMMNV (SEQ ID NO: 2755)
1003F01	903	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSVGAITGALDM (SEQ ID NO: 2852)
1003F02	904	140-251	162-175	191-197	230-240	1-123	26-35	50-66	99-112	RYDPPFYTYTMMNV (SEQ ID NO: 2755)
1003G01	905	145-254	168-179	195-201	234-243	1-127	26-35	50-66	99-116	GTGYDILTGYVGNQAFDI (SEQ ID NO: 2800)
1003G05	906	144-255	166-179	195-201	234-244	1-127	26-35	50-66	99-116	GTGYDILTGYVGNQAFDI (SEQ ID NO: 2766)
1003G06	907	146-256	168-181	197-203	236-245	1-129	26-35	50-66	99-118	DRGNYDILTGYVGNQAFDI (SEQ ID NO: 2183)
1003H11	908	144-251	165-175	191-197	230-240	1-124	26-35	50-66	99-113	DAQSYDILTGYVGNQAFDI (SEQ ID NO: 2183)
1003H02	909	142-253	164-176	192-198	233-242	1-124	26-35	50-66	99-113	DNYDILTGYVGNQAFDI (SEQ ID NO: 2942)
1003H05	910	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGSSVGAITGALDM (SEQ ID NO: 2852)
1003H08	911	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DOYDILTGYSYGMDV (SEQ ID NO: 2135)
1005A01	912	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	SHYDILTOLNYWYEDL (SEQ ID NO: 2166)
1005A02	913	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	SHYDILTOLNYWYEDL (SEQ ID NO: 2893)
1005B01	914	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	SHYDILTOLNYWYEDL (SEQ ID NO: 2166)
1005B09	915	137-247	159-172	188-194	227-236	1-121	26-35	50-65	98-110	TYDILTGYGFDX (SEQ ID NO: 2866)
1005C01	916	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	SHYDILTOLNYWYEDL (SEQ ID NO: 2166)
1005D02	917	141-251	163-176	192-198	231-243	1-125	26-35	50-66	99-114	DLRYDILTGYTHDAEDI (SEQ ID NO: 2890)

U.S. Patent

Nov. 21, 2006

Sheet 24 of 52

7,138,501 B2

1005D02	142-249	165-175	191-197	230-238	1-126	26-35	50-66	99-115	GAAYDLTGYYPGMDV (SEQ ID NO: 2860)
1005E01	142-249	165-175	191-197	230-238	1-126	26-35	50-66	99-115	GTYYDLTGYYHGMVD (SEQ ID NO: 2774)
1005E08	141-248	162-172	183-194	227-237	1-125	26-35	50-65	99-114	SHYDLTGYNWYEDL (SEQ ID NO: 2166)
1005F01	142-248	164-174	190-196	229-236	1-124	26-35	50-65	99-113	DQMDLTGYYGMDV (SEQ ID NO: 2021)
1005F02	144-251	167-177	193-199	232-240	1-128	26-35	50-66	99-117	VSPYDLTGYYLHAFDV (SEQ ID NO: 2849)
1005F04	137-247	159-172	188-194	227-236	1-121	26-35	50-65	99-110	TYDHLTGTFDI (SEQ ID NO: 2066)
1005F08	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	PSYDLTGYYLYDY (SEQ ID NO: 2850)
1005G01	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	DLRYDLTGYYHAFDI (SEQ ID NO: 2898)
1005G08	142-249	165-175	191-197	230-238	1-126	26-35	50-66	99-115	OAYDHLTGYYFGMDV (SEQ ID NO: 2860)
1005H02	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	GCYYDLTGYNWEDP (SEQ ID NO: 2857)
1005H01	139-246	160-170	186-192	225-235	1-123	26-35	50-66	99-112	SGDLTGYYGMDV (SEQ ID NO: 2133)
1005H09	143-253	165-177	193-199	232-242	1-127	26-35	50-66	99-116	GGYSSGWLGGPYNWEDP (SEQ ID NO: 2867)
1006B01	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	GDYDLTGYYFLDY (SEQ ID NO: 2792)
1006B07	143-250	165-178	194-200	233-242	1-127	26-35	50-68	101-116	NLFVWTLFYTYMDV (SEQ ID NO: 2365)
1006B02	142-253	164-176	192-198	231-239	1-127	26-35	50-66	99-116	ADYDLTGYYELTYGMDV (SEQ ID NO: 2762)
1006B07	142-253	164-176	192-198	231-242	1-126	26-35	50-66	99-115	MYDHLTGYYEDY (SEQ ID NO: 2879)
1006B07	143-253	165-177	193-199	232-242	1-127	26-35	50-66	99-116	VSRDLTGYYTYGMDV (SEQ ID NO: 2817)
1006G01	146-253	169-179	195-201	234-243	1-130	26-35	50-68	101-119	AGYYDLTGKRDYYGMDV (SEQ ID NO: 2967)
1006G04	132-239	153-163	179-185	218-228	1-116	26-35	50-66	99-105	RYALDY (SEQ ID NO: 2877)
1006H01	146-253	167-177	193-199	232-242	1-130	26-35	50-68	99-119	DRGSYDLTGYYTPHYTGMDV (SEQ ID NO: 2761)
1006H02	143-253	165-177	193-199	232-242	1-127	26-35	50-66	99-116	GGYSSGWLGGPYNWEDP (SEQ ID NO: 2867)
1007A01	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSFGDI (SEQ ID NO: 2153)
1007A08	139-249	161-174	190-196	229-238	1-123	26-35	50-66	99-114	SHYDLTGYNWYEDY (SEQ ID NO: 2746)
1007A11	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	ENYDLTGYYGAFDI (SEQ ID NO: 2772)
1007A12	144-251	165-175	191-197	230-240	1-128	26-35	50-68	101-117	GYDHLTGYYHWDGAFDI (SEQ ID NO: 2892)
1007B04	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSFGDI (SEQ ID NO: 2153)
1007C04	141-251	163-173	189-195	228-238	1-125	26-35	50-66	99-114	ATYDLTGYSFGDI (SEQ ID NO: 2153)
1007C12	142-249	163-173	189-195	228-238	1-125	26-35	50-66	99-115	IRLYCYSLTGYYFGMDV (SEQ ID NO: 2810)
1007D07	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	TRYDHLTGYYGVDY (SEQ ID NO: 2782)
1007D08	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	GCYYDLTGYNWEDP (SEQ ID NO: 2857)
1007D08	144-251	165-175	191-197	230-240	1-125	26-35	50-68	99-114	GYDHLTGYYHWDGAFDI (SEQ ID NO: 2872)
1007E10	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	DLFYDHLTGYYLSCMDV (SEQ ID NO: 2923)
1007E11	144-251	165-175	191-197	230-240	1-125	26-35	50-66	99-117	DYDHLTGYYPLGMDV (SEQ ID NO: 2741)
1007F06	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDLTGYSFGDI (SEQ ID NO: 2153)
1007F08	143-253	165-178	194-200	233-242	1-127	26-35	50-68	99-116	GRYDHLTGYYHYHGMVD (SEQ ID NO: 2811)
1007G07	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	SHYDLTGYNWYEDL (SEQ ID NO: 2166)
1007G09	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	DGQDLTGYYTFYEDY (SEQ ID NO: 2847)
1007G10	142-249	163-173	189-195	228-238	1-126	26-35	50-68	99-115	VGLYYDLTGYYFSGMDV (SEQ ID NO: 2803)
1007H07	147-257	169-182	198-204	237-246	1-131	26-35	50-68	101-129	SQAYDHLTGYYLWYSGMDV (SEQ ID NO: 2875)
1007H11	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ESYDLTGYYHYGMVDL (SEQ ID NO: 2891)

U.S. Patent

Nov. 21, 2006

Sheet 25 of 52

7,138,501 B2

1008A02	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008A05	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008A06	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008A07	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DREYDALLTGYVLAHADM (SEQ ID NO: 2060)
1008A12	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	ENYDELGTGYGAEDI (SEQ ID NO: 2772)
1008B02	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008B04	143-253	163-178	194-200	233-242	1-127	26-35	50-66	99-116	DQSYDILTYTNDYMDY (SEQ ID NO: 2154)
1008B05	141-244	162-172	188-194	227-237	1-125	26-35	50-66	99-114	DHYDILGTLYYNGMDV (SEQ ID NO: 2760)
1008B06	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008B10	141-248	162-173	189-195	228-236	1-124	24-33	48-64	97-113	GRYDILTYTKGELDY (SEQ ID NO: 2902)
1008B11	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	ATYDPLTGYSEDGEDI (SEQ ID NO: 2847)
1008C06	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	EGYDILTYVLYYHGMV (SEQ ID NO: 2753)
1008C08	149-259	171-183	199-205	238-248	1-133	26-35	50-66	99-122	GRGGEYDILTYGLSLDAEDI (SEQ ID NO: 2729)
1008C09	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	ETYDILTYVDRFYGMV (SEQ ID NO: 2972)
1008D01	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008D02	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EVRNYLLTSTYLACPLN (SEQ ID NO: 2751)
1008D03	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008D04	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008D05	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008D06	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	DQYDILTYVTRGEMDV (SEQ ID NO: 2837)
1008D07	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	DLPYDILTYVLTSGMDV (SEQ ID NO: 2923)
1008D08	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EGFYDILTYVYGYGYDY (SEQ ID NO: 2974)
1008E01	144-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008E02	137-247	159-172	185-194	227-236	1-121	20-31	46-63	96-110	EGYDILTYVSELDY (SEQ ID NO: 2986)
1008E03	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008E04	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008E08	141-252	163-175	191-197	230-241	1-125	26-35	50-66	99-114	SHYDILTYVYFYDMDV (SEQ ID NO: 2166)
1008E09	143-253	163-178	194-200	233-242	1-127	26-35	50-66	99-116	FRYDILTYVYFYDMDV (SEQ ID NO: 2734)
1008E12	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008F03	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008F06	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008F07	143-250	164-174	190-196	229-239	1-127	26-35	50-66	99-116	GRYDILTYVYHGMV (SEQ ID NO: 2811)
1008F08	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	GHYDILTYDDYVYGMV (SEQ ID NO: 2844)
1008F09	133-243	155-168	184-190	223-232	1-117	26-35	50-65	98-106	HMLTGEDY (SEQ ID NO: 2944)
1008F10	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	SGYDILTYVLYGMV (SEQ ID NO: 2924)
1008F11	144-251	163-175	191-197	230-240	1-125	26-35	50-66	99-117	AFYDILTYSDYVYGMV (SEQ ID NO: 2968)
1008G02	141-251	163-175	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1008G03	149-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	GDYDILTYVSEGYDY (SEQ ID NO: 2941)
1008G04	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	EGSYDILTYVYVYGMV (SEQ ID NO: 2171)
1008G05	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EGYDILTYGTFYVYVYGMV (SEQ ID NO: 2899)

U.S. Patent

Nov. 21, 2006

Sheet 27 of 52

7,138,501 B2

1014A12	1044	143-253	163-176	194-200	233-242	1-127	24-33	48-64	97-116	EGGYDLTGYKNGAFH (SEQ ID NO: 2158)
1014C06	1045	142-254	164-177	193-200	233-243	1-125	26-35	50-66	99-114	GDYDLTGYPAECFQ (SEQ ID NO: 2159)
1014C10	1046	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1014C12	1047	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1014E06	1048	142-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELSLVGAITIGALDM (SEQ ID NO: 2174)
1014F02	1049	143-251	166-176	192-198	231-240	1-125	26-37	52-67	100-117	AGYDLLHGVFFYDS (SEQ ID NO: 2177)
1016A08	1050	144-251	165-175	191-197	230-240	1-128	26-35	50-66	99-117	EVNVDLITSLYLAFLIN (SEQ ID NO: 2151)
1016A09	1051	141-251	165-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C02	1052	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C03	1053	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C09	1054	148-255	169-179	195-201	234-244	1-132	26-35	50-66	99-121	VQMDSEYDILLTGYNVGFYEDY (SEQ ID NO: 2132)
1016C11	1055	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1056	148-255	169-179	195-201	234-244	1-132	26-35	50-66	99-121	VQMDSEYDILLTGYNVGFYEDY (SEQ ID NO: 2132)
1016C11	1057	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1058	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1059	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1060	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1061	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1062	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1063	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1064	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1065	148-255	169-179	195-201	234-244	1-132	26-35	50-66	99-121	VQMDSEYDILLTGYNVGFYEDY (SEQ ID NO: 2132)
1016C11	1066	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1067	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1068	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1069	140-253	162-175	191-197	233-242	1-124	25-34	49-65	98-113	ATYDLTGYSEDFGH (SEQ ID NO: 2157)
1016C11	1070	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1071	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1072	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1073	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1074	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1075	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EGSYDLTGYVGVGRMEV (SEQ ID NO: 2171)
1016C11	1076	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1077	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1078	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1079	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1080	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1081	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1082	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1083	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1084	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)
1016C11	1085	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSEDFGH (SEQ ID NO: 2153)

U.S. Patent

Nov. 21, 2006

Sheet 29 of 52

7,138,501 B2

1025D11	142-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1025E04	142-252	164-176	192-198	231-241	1-126	26-35	50-66	99-113	ELGLAVRGAKTAPQI (SEQ ID NO: 2929)
1025E05	141-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1025E07	142-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1025E10	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSDGDFDI (SEQ ID NO: 2153)
1025F01	140-251	162-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDFYYYYMNV (SEQ ID NO: 2755)
1025F08	138-248	160-172	188-194	227-237	1-121	26-35	50-66	99-110	GGSSQNFYGMNDY (SEQ ID NO: 2884)
1025G03	142-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1025G08	141-254	163-176	192-198	231-243	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1025H02	145-255	167-179	195-201	234-244	1-128	26-35	50-66	98-117	AGCGRHDLTYTKGQYDY (SEQ ID NO: 2961)
1026A01	143-249	165-178	191-197	230-238	1-125	26-35	50-66	99-114	GSYDILTYPAECFQI (SEQ ID NO: 2854)
1026B06	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2852)
1026C06	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2852)
1026C10	143-249	161-174	190-196	229-238	1-122	26-34	49-65	96-111	RYGDFYYYYMNV (SEQ ID NO: 2755)
1026D09	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSDGDFDI (SEQ ID NO: 2153)
1026E04	142-252	164-176	192-198	231-241	1-123	26-35	50-66	99-112	RYGDFYYYYMNV (SEQ ID NO: 2755)
1026E06	141-251	163-175	191-197	230-240	1-124	26-35	50-66	99-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1026E09	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	GYDDLTYGTMALDY (SEQ ID NO: 2821)
1026F01	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2852)
1026F09	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2852)
1026H12	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2852)
1026G08	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2852)
1026G10	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2852)
1026H11	140-251	162-175	191-197	230-240	1-123	26-35	50-66	99-116	GTGYDLTYGTMGSAFDQ (SEQ ID NO: 2880)
1026H05	141-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1026H10	145-255	167-179	195-201	234-244	1-128	26-35	50-66	99-117	GYDYLTYGTFOLGYDY (SEQ ID NO: 2170)
1027A09	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2852)
1027B02	140-250	162-174	190-196	229-239	1-123	26-35	50-66	99-112	RYGDFYYYYMNV (SEQ ID NO: 2755)
1027B05	141-250	163-176	192-198	230-239	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2852)
1027C08	139-249	161-174	190-196	229-238	1-122	26-34	49-65	96-111	ELGLSVGATTGALDM (SEQ ID NO: 2852)
1027D02	142-250	164-174	190-196	229-239	1-125	26-35	50-66	99-114	DPFGAVPGYYVYAMDY (SEQ ID NO: 2826)
1027E03	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2852)
1027E05	142-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1027F04	145-252	167-176	192-198	231-241	1-128	26-35	50-66	99-117	QFWDYDLTFPPSGHYGLDY (SEQ ID NO: 2793)
1027F05	141-254	163-176	192-198	231-243	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1027F11	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2852)
1027G06	142-253	164-176	192-198	233-242	1-124	26-35	50-66	99-113	DTYDLTYGSRREFP (SEQ ID NO: 2942)
1027G07	142-250	164-174	190-196	229-239	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1027H03	142-252	164-176	192-198	231-241	1-125	26-35	50-66	99-114	GYDYLTYPAECFQI (SEQ ID NO: 2854)

U.S. Patent

Nov. 21, 2006

Sheet 30 of 52

7,138,501 B2

1028A04	143-250	164-174	190-196	229-239	1-127	26-35	50-66	99-116	DMYDILTYGTYGLAFDM (SEQ ID NO: 2880)
1028A07	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	VYNDLTYGTYGMDV (SEQ ID NO: 2882)
1028B08	141-251	163-176	192-198	231-240	1-123	26-35	50-66	99-114	ATYDPLTYGTYGMDV (SEQ ID NO: 2153)
1028B10	148-258	170-183	199-205	238-247	1-132	26-35	50-66	101-121	DFGYDILTYGTYGAFYAFIL (SEQ ID NO: 2861)
1028C01	142-250	165-173	191-197	230-239	1-126	26-37	52-69	102-115	GGHTCHFTGCBAG (SEQ ID NO: 2796)
1028C04	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	DMYDILTYGTYGLAFDM (SEQ ID NO: 2880)
1028C08	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTYGTYGMDV (SEQ ID NO: 2153)
1028D04	140-247	163-173	189-195	228-236	1-124	26-35	50-66	99-114	HYNDLTYGTYGMDV (SEQ ID NO: 2807)
1028D05	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	HYNDLTYGTYGMDV (SEQ ID NO: 2807)
1028E05	143-253	164-174	190-196	229-239	1-127	26-35	50-66	99-116	EGSYDILTYGTYGMDV (SEQ ID NO: 2938)
1028E07	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTYGTYGMDV (SEQ ID NO: 2153)
1028E08	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTYGTYGMDV (SEQ ID NO: 2153)
1028F06	146-256	168-180	196-202	234-245	1-130	26-35	50-66	99-119	DRRGYDILTYGTYGMDV (SEQ ID NO: 2901)
1028F08	134-244	156-169	185-191	224-233	1-118	26-35	50-66	99-107	DIXGDDDS (SEQ ID NO: 2944)
1028G08	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	VSYNSGYGTYGMDV (SEQ ID NO: 2792)
1028G09	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EVNRYDILTYGTYGMDV (SEQ ID NO: 2751)
1028G10	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTYGTYGMDV (SEQ ID NO: 2153)
1028H02	143-249	165-175	191-197	230-238	1-126	26-37	52-69	102-115	SGPCHTACNLGG (SEQ ID NO: 2797)
1028H03	148-256	169-179	195-201	234-244	1-129	26-35	50-66	99-118	DSPYDILTYGTYGMDV (SEQ ID NO: 2843)
1028H06	143-253	167-180	196-202	235-244	1-123	26-35	50-66	99-112	EDDILTYGTYGMDV (SEQ ID NO: 2905)
1028H10	137-247	159-171	187-193	226-236	1-121	26-35	50-66	101-110	EDDILTYGTYGMDV (SEQ ID NO: 2943)
1028H11	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTYGTYGMDV (SEQ ID NO: 2153)
1028H12	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EVNRYDILTYGTYGMDV (SEQ ID NO: 2751)
1028H13	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EVNRYDILTYGTYGMDV (SEQ ID NO: 2751)
1028H14	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	GYDILTYGTYGMDV (SEQ ID NO: 2927)
1028H15	143-253	165-177	193-199	232-242	1-126	26-35	50-66	99-115	TERFGADVTARWGMMDV (SEQ ID NO: 2874)
1028H16	141-251	163-175	191-197	230-242	1-124	26-35	50-66	99-113	EVNRYDILTYGTYGMDV (SEQ ID NO: 2751)
1028H17	141-252	163-176	192-198	231-241	1-124	26-35	50-66	99-113	EVNRYDILTYGTYGMDV (SEQ ID NO: 2751)
1028H18	141-249	163-175	191-197	230-238	1-124	26-34	49-65	99-112	RYGDPFYTYGMDV (SEQ ID NO: 2755)
1028H19	140-250	162-174	190-196	229-239	1-123	26-35	50-66	99-112	RYGDPFYTYGMDV (SEQ ID NO: 2755)
1028H20	141-249	163-173	189-195	228-238	1-123	26-35	50-66	99-112	RYGDPFYTYGMDV (SEQ ID NO: 2755)
1028H21	141-247	163-173	189-195	228-236	1-124	26-34	49-65	99-113	RYGDPFYTYGMDV (SEQ ID NO: 2755)
1028H22	143-251	165-175	191-197	230-241	1-123	26-35	50-66	99-112	RYGDPFYTYGMDV (SEQ ID NO: 2755)
1028H23	149-252	167-182	198-204	237-245	1-130	26-35	50-66	99-119	DRGYDILTYGTYGMDV (SEQ ID NO: 2935)
1028H24	147-256	169-182	198-204	237-245	1-117	26-35	50-66	99-106	SGPWFDP (SEQ ID NO: 2876)
1028H25	134-244	156-168	184-190	223-233	1-117	26-34	49-65	98-113	ELQSLVGTATGALDM (SEQ ID NO: 2174)
1028H26	141-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELQSLVGTATGALDM (SEQ ID NO: 2174)

U.S. Patent

Nov. 21, 2006

Sheet 31 of 52

7,138,501 B2

1030C10	1212	141-250	103-175	191-197	230-239	1-124	26-34	49-65	98-113	ELGLSVGATGALDM (SEQ ID NO: 2174)
1030C11	1213	140-251	102-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDFPYYVYVNV (SEQ ID NO: 2175)
1030C12	1214	134-244	106-168	184-196	228-233	1-117	26-35	50-66	99-112	RYGDFPYYVYVNV (SEQ ID NO: 2176)
1030D07	1215	134-244	103-173	189-195	228-238	1-123	26-35	50-66	99-112	RYGDFPYYVYVNV (SEQ ID NO: 2177)
1030D12	1216	141-251	103-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGLSVGATGALDM (SEQ ID NO: 2178)
1030E02	1217	140-251	102-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDFPYYVYVNV (SEQ ID NO: 2179)
1030E05	1218	142-252	104-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATGALDM (SEQ ID NO: 2180)
1030E07	1219	142-251	103-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGLSVGATGALDM (SEQ ID NO: 2181)
1030E08	1220	141-251	103-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDFPYYVYVNV (SEQ ID NO: 2182)
1030E09	1221	141-252	103-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATGALDM (SEQ ID NO: 2183)
1030E10	1222	140-250	102-174	190-196	229-239	1-123	26-35	50-66	99-112	RYGDFPYYVYVNV (SEQ ID NO: 2184)
1030E11	1223	142-252	104-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATGALDM (SEQ ID NO: 2185)
1030E12	1224	141-251	103-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDFPYYVYVNV (SEQ ID NO: 2186)
1030E13	1225	140-250	102-174	190-196	229-239	1-123	26-35	50-66	99-112	RYGDFPYYVYVNV (SEQ ID NO: 2187)
1030E14	1226	141-254	103-176	192-198	231-243	1-124	26-34	49-65	98-113	ELGLSVGATGALDM (SEQ ID NO: 2188)
1030E15	1227	142-253	104-176	192-198	231-242	1-124	26-34	49-65	98-113	ELGLSVGATGALDM (SEQ ID NO: 2189)
1030E16	1228	140-250	102-174	190-196	229-239	1-123	26-35	50-66	99-112	RYGDFPYYVYVNV (SEQ ID NO: 2190)
1030E17	1229	141-251	103-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGLSVGATGALDM (SEQ ID NO: 2191)
1030E18	1230	141-256	103-176	192-202	237-245	1-123	26-35	50-66	99-112	RYGDFPYYVYVNV (SEQ ID NO: 2192)
1030E19	1231	144-251	104-174	190-196	229-240	1-124	26-34	49-65	98-113	ELGLSVGATGALDM (SEQ ID NO: 2193)
1030E20	1232	142-251	103-175	191-197	230-240	1-123	26-35	50-66	99-112	RYGDFPYYVYVNV (SEQ ID NO: 2194)
1030E21	1233	146-253	104-181	197-203	236-244	1-129	26-37	52-69	102-119	ATKSYDLTGYTHHNV (SEQ ID NO: 2195)
1030E22	1234	148-248	104-182	198-204	239-247	1-130	26-37	52-69	102-119	ATKSYDLTGYTHHNV (SEQ ID NO: 2196)
1030E23	1235	141-253	103-176	192-198	231-242	1-124	26-35	50-66	99-112	RYGDFPYYVYVNV (SEQ ID NO: 2197)
1030E24	1236	142-252	104-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATGALDM (SEQ ID NO: 2198)
1030E25	1237	138-248	103-173	189-195	228-237	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2199)
1030E26	1238	143-251	105-176	192-198	231-240	1-123	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2200)
1030E27	1239	148-258	106-176	198-204	237-247	1-131	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2201)
1030E28	1240	147-257	105-172	197-203	236-246	1-130	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2202)
1030E29	1241	137-246	103-172	188-194	232-242	1-126	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2203)
1030E30	1242	143-253	105-177	193-199	232-242	1-126	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2204)
1030E31	1243	148-258	106-172	198-204	237-247	1-131	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2205)
1030E32	1244	149-260	107-183	199-205	238-248	1-131	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2206)
1030E33	1245	148-258	106-172	198-194	237-247	1-131	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2207)
1030E34	1246	138-248	105-172	188-194	232-242	1-126	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2208)
1030E35	1247	148-259	106-172	198-204	237-247	1-131	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2209)
1030E36	1248	138-248	105-172	188-194	232-242	1-126	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2210)
1030E37	1249	142-253	104-177	193-199	233-243	1-125	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2211)
1030E38	1250	149-260	107-183	199-205	238-248	1-131	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2212)
1030E39	1251	139-248	106-172	188-194	232-242	1-126	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2213)
1030E40	1252	145-257	105-172	188-194	232-242	1-126	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2214)
1030E41	1253	146-256	105-172	188-194	232-242	1-126	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2215)

U.S. Patent

Nov. 21, 2006

Sheet 32 of 52

7,138,501 B2

1031D04	1254	138-243	160-172	188-194	227-237	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)
1031D06	1255	148-258	170-182	198-204	237-247	1-131	26-35	50-66	99-120	GRGDTDKVKPWRDYHYHYMDV (SEQ ID NO: 2807)
1031D08	1256	145-257	167-180	196-202	235-245	1-128	26-35	50-66	99-117	VWPKLYFDWLSRDAFDA (SEQ ID NO: 2820)
1031D09	1257	139-247	161-171	187-193	226-236	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)
1031D11	1258	149-256	171-181	197-203	236-245	1-131	26-35	50-66	99-120	SSPKWYDALTGSSSYHSAMDV (SEQ ID NO: 2165)
1031D12	1259	146-254	168-178	194-200	233-243	1-128	26-35	50-66	99-117	DKAHGEYGRDYHYHYMDV (SEQ ID NO: 2735)
1031E01	1260	148-258	170-182	198-204	237-247	1-131	26-35	50-66	99-120	SSPKWYDALTGSSSYHSAMDV (SEQ ID NO: 2159)
1031E02	1261	149-257	171-181	197-203	236-246	1-131	26-35	50-66	99-120	SSPKWYDALTGSSSYHSAMDV (SEQ ID NO: 2848)
1031E07	1262	148-259	170-182	198-204	237-248	1-131	26-35	50-66	99-120	SSPKWYDALTGSSSYHSAMDV (SEQ ID NO: 2159)
1031E08	1263	148-259	170-182	198-204	237-247	1-131	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)
1031E10	1265	148-258	170-182	198-204	237-247	1-131	26-35	50-66	99-120	SSPKWYDALTGSSSYHSAMDV (SEQ ID NO: 2165)
1031E11	1266	148-258	170-182	198-204	237-247	1-131	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)
1031F01	1267	138-248	160-172	188-194	227-237	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)
1031F04	1268	139-246	162-172	188-194	227-235	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)
1031F06	1269	137-247	159-171	187-193	226-236	1-131	26-35	50-66	99-108	DTVRSGMDV (SEQ ID NO: 2804)
1031F10	1270	148-259	170-183	199-205	238-248	1-131	26-35	50-66	99-120	GRGDTDKVKPWRDYHYHYMDV (SEQ ID NO: 2809)
1031F11	1271	145-255	167-179	195-201	234-244	1-128	26-35	50-66	99-117	DKAHGEYGRDYHYHYMDV (SEQ ID NO: 2735)
1031F12	1272	138-248	160-172	188-194	227-237	1-121	26-35	50-66	99-110	GYDSSAFRAFDI (SEQ ID NO: 2136)
1031G01	1273	138-248	160-172	188-194	227-237	1-121	26-35	50-66	99-120	SSPKWYDALTGSSSYHSAMDV (SEQ ID NO: 2159)
1031G03	1274	148-258	170-182	198-204	237-247	1-131	26-35	50-66	99-120	GRGDTDKVKPWRDYHYHYMDV (SEQ ID NO: 2809)
1031G05	1275	148-259	170-183	199-205	238-248	1-131	26-35	50-66	99-120	SSPKWYDALTGSSSYHSAMDV (SEQ ID NO: 2816)
1031G06	1276	148-258	170-182	198-204	237-247	1-131	26-35	50-66	99-120	GRGDTDKVKPWRDYHYHYMDV (SEQ ID NO: 2809)
1031G07	1277	149-259	171-183	199-205	238-248	1-131	26-35	50-66	99-118	AATRKHNKYATFYMDV (SEQ ID NO: 2131)
1031G09	1278	146-263	170-183	199-209	244-252	1-131	26-35	50-66	99-115	AKGYTDSGASDVEDV (SEQ ID NO: 2871)
1031G12	1279	146-256	168-180	196-202	235-245	1-125	26-35	50-66	99-120	GRGDTDKVKPWRDYHYHYMDV (SEQ ID NO: 2809)
1031H01	1280	138-250	160-173	189-195	228-239	1-121	26-35	50-66	99-117	DKAHGEYGRDYHYHYMDV (SEQ ID NO: 2735)
1031H02	1281	143-255	165-178	194-200	233-244	1-125	26-35	50-66	99-117	DKAHGEYGRDYHYHYMDV (SEQ ID NO: 2735)
1031H03	1282	148-260	170-183	199-205	238-249	1-128	26-35	50-66	99-116	TRGYTGDRLVGGYFDF (SEQ ID NO: 2931)
1031H06	1283	145-257	167-179	195-201	234-244	1-128	26-35	50-66	99-108	DTVRSGMDV (SEQ ID NO: 2804)
1031H09	1284	145-255	167-179	195-201	234-244	1-127	26-35	50-66	102-117	DRYDLTGYYHYMDV (SEQ ID NO: 2129)
1031H10	1285	144-256	166-179	195-201	234-245	1-119	26-35	50-66	102-117	DRYDLTGYYHYMDV (SEQ ID NO: 2129)
1031H11	1286	136-246	158-170	186-192	225-235	1-128	26-37	52-69	99-117	BYRYDLTRESYLAGPLN (SEQ ID NO: 2751)
1033A08	1287	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-115	EMGYDLTGYYHYMDV (SEQ ID NO: 2862)
1033B11	1288	144-254	166-179	195-201	234-243	1-125	26-35	50-66	99-111	GYDLTGYYMDV (SEQ ID NO: 2781)
1033C01	1289	144-254	166-179	195-201	234-243	1-125	26-35	50-66	99-114	ATYDPLTGYSEDFDI (SEQ ID NO: 2153)
1033C08	1290	142-249	163-173	189-195	228-238	1-122	26-35	50-66	99-113	VERDILTGYYMDV (SEQ ID NO: 2869)
1033D02	1291	138-245	161-171	187-193	226-234	1-125	26-35	50-66		
1033D03	1292	141-251	163-176	192-198	231-240	1-125	26-35	50-66		
1033D05	1293	141-248	162-172	188-194	227-237	1-124	26-35	50-66		
1033D11	1294	140-247	161-171	187-193	226-236	1-128	26-35	50-66		
1033D12	1295	144-254	166-179	195-201	234-243	1-128	26-35	50-66		

U.S. Patent

Nov. 21, 2006

Sheet 33 of 52

7,138,501 B2

1033E01	1296	139-249	161-173	189-195	228-238	1-123	26-35	50-66	99-112	DIADRLAALDAFDI (SEQ ID NO: 2796)
1033E06	1297	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATHEDELTVSDFGFDI (SEQ ID NO: 2798)
1033E11	1298	143-253	165-177	193-199	233-242	1-127	26-35	50-66	99-115	HRSESSSTCRINDAFDI (SEQ ID NO: 2779)
1033E12	1299	142-249	163-173	189-193	228-238	1-126	26-35	50-66	99-116	EMAGYDLTGYYLNTYMDV (SEQ ID NO: 2862)
1033E03	1300	139-246	168-170	186-192	223-235	1-123	26-35	50-66	99-112	EGAADYLTNGQYFQD (SEQ ID NO: 2768)
1033E08	1301	145-256	167-179	195-201	234-245	1-129	26-35	50-66	99-118	OKVYDILTGYNVYYCYGMDV (SEQ ID NO: 2767)
1033E10	1302	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EYNYDILTESYLAGFDL (SEQ ID NO: 2751)
1033E12	1303	134-241	155-165	181-187	220-230	1-118	26-35	50-66	99-107	DIDIGDDDS (SEQ ID NO: 2954)
1033E01	1304	143-253	165-178	194-200	233-242	1-127	24-33	48-64	97-116	EGGNVDILTGYYGNGAFDI (SEQ ID NO: 2158)
1033E08	1305	142-249	163-173	189-193	228-238	1-126	26-35	50-66	99-115	PQGYTLVKGABTDAAFI (SEQ ID NO: 2925)
1033E08	1306	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDRLTGYSDFGFDI (SEQ ID NO: 2153)
1033E04	1307	140-247	161-171	187-193	226-236	1-124	25-34	49-65	98-113	ATYDRLTGYSDFGFDI (SEQ ID NO: 2153)
1033E05	1308	139-246	160-170	186-192	223-235	1-123	26-35	50-66	99-112	SRDLALTFHYGMDV (SEQ ID NO: 2153)
1033E03	1309	141-251	163-173	191-197	230-240	1-128	26-35	50-66	99-117	DFGYDILTGVEHYGMDV (SEQ ID NO: 2922)
1033E04	1310	144-251	167-177	193-199	232-240	1-128	26-35	50-66	98-115	ENGVDILTGQFYGMDV (SEQ ID NO: 2752)
1033E06	1311	142-252	164-177	193-195	232-241	1-125	26-35	50-66	99-114	LYDILTGTHWDAFDI (SEQ ID NO: 2882)
1033E06	1312	141-249	163-173	189-195	228-238	1-125	26-35	50-66	99-113	DIDILVPAALMDV (SEQ ID NO: 2160)
1033E08	1313	140-250	162-173	191-197	230-239	1-124	26-35	50-66	99-109	QSWLEHVDI (SEQ ID NO: 2864)
1033E11	1314	136-246	158-171	187-193	226-235	1-120	26-35	50-66	99-117	DRDYDILTRYYYGMDV (SEQ ID NO: 2928)
1033E04	1315	144-251	165-175	191-197	230-240	1-128	26-35	50-66	98-117	KQGEVDILTGVLGYAFDI (SEQ ID NO: 2808)
1033E01	1316	144-251	165-175	191-197	230-240	1-128	26-35	50-66	99-114	SHYDLTSLNWTYEDL (SEQ ID NO: 2959)
1033E03	1317	141-251	163-176	192-198	231-240	1-123	26-35	50-66	99-113	DLGSPYDILTALRLNYYGMDV (SEQ ID NO: 2915)
1033E03	1318	146-256	168-181	197-203	236-245	1-130	26-35	50-66	99-117	DYDILTKLPYGMADV (SEQ ID NO: 2849)
1033E10	1319	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-115	VSPYDILTGVLPHAFDI (SEQ ID NO: 2801)
1042A07	1320	144-251	167-177	193-199	232-240	1-128	26-35	50-66	99-113	DFRYDILTGYNVWTFDI (SEQ ID NO: 2824)
1042A10	1321	142-249	165-175	191-197	230-238	1-126	26-35	50-66	99-114	SHYDLTSLNWTYEDL (SEQ ID NO: 2166)
1042E03	1322	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-109	QQWLPYDAFI (SEQ ID NO: 2839)
1042E12	1323	141-244	162-172	188-194	227-237	1-125	26-35	50-66	98-113	AYDILTGFFDI (SEQ ID NO: 2873)
1042E01	1324	136-246	158-171	187-193	226-235	1-120	26-35	50-66	98-115	ERADYDILTGYYGMDV (SEQ ID NO: 2802)
1042D03	1325	140-250	162-175	191-197	230-239	1-124	26-35	50-66	102-128	DEYDILTLLQGMADV (SEQ ID NO: 2883)
1042D10	1326	142-252	164-177	193-199	232-241	1-136	26-35	50-66	99-114	GDYDILTGVLPHAFDI (SEQ ID NO: 2738)
1042E10	1327	147-257	169-182	198-204	237-246	1-131	28-37	52-69	99-113	DGYDILTGYYGMDV (SEQ ID NO: 2976)
1042E08	1328	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-114	SHYDLTSLNWTYEDL (SEQ ID NO: 2166)
1042F08	1329	142-252	164-177	193-199	232-241	1-126	26-35	50-66	98-116	GLYDILTGYHGNAFDI (SEQ ID NO: 2757)
1042F08	1330	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-117	DGYDILTGGFYYYGMDV (SEQ ID NO: 2899)
1042F08	1331	141-245	162-172	188-194	227-237	1-125	26-35	50-66	98-115	CGYDILTGYLYYYGMDV (SEQ ID NO: 2744)
1042G10	1332	141-251	163-176	192-198	231-240	1-127	26-35	50-66	99-114	ATYDILTGSDFGFDI (SEQ ID NO: 2153)
1042H03	1333	143-253	165-178	194-200	233-242	1-128	26-35	50-66	99-116	DQYDILTGVHEDYYMDV (SEQ ID NO: 2828)
1043A03	1334	144-254	166-179	195-201	234-243	1-128	26-35	50-66		
1043E02	1335	142-249	163-173	189-195	228-238	1-126	26-35	50-66		
1043E03	1336	141-251	163-176	192-198	231-240	1-125	26-35	50-66		
1043E06	1337	143-253	165-178	194-200	233-242	1-127	26-35	50-66		

U.S. Patent

Nov. 21, 2006

Sheet 37 of 52

7,138,501 B2

1067B06	135-245	157-169	185-191	224-234	1-119	26-35	30-66	99-108	GMGBHYGMDV (SEQ ID NO: 2161)
1068C08	138-248	160-172	188-194	227-237	1-121	26-35	30-66	99-110	GGSSNFYGMADV (SEQ ID NO: 2884)
1068C03	144-254	166-178	194-200	233-243	1-127	26-35	30-66	99-116	GTGYDLTGYTMGSADFQ (SEQ ID NO: 2809)
1068C04	143-252	165-178	194-200	233-241	1-126	26-35	30-66	99-115	GVVWVAYGDIYGYDGY (SEQ ID NO: 2937)
1068C07	142-251	164-174	190-196	229-240	1-124	26-35	30-66	99-113	HDVYMTAAHYVYDS (SEQ ID NO: 2999)
1068C08	144-254	166-178	194-200	233-243	1-127	26-35	30-66	99-116	GGYDLTGYYFSGELDY (SEQ ID NO: 2846)
1070B07	140-247	161-171	187-193	226-236	1-124	26-35	30-66	99-110	DFVRLTGTHDAFDI (SEQ ID NO: 2910)
1070C05	140-250	162-175	191-197	230-239	1-124	26-35	30-66	101-113	DVEDLTGYSWDY (SEQ ID NO: 2867)
1070B02	141-248	162-172	188-194	227-237	1-125	26-35	30-66	99-114	MEYDLTGYYGGYDY (SEQ ID NO: 2179)
1071A01	141-251	163-176	192-198	231-240	1-125	26-35	30-66	99-114	AAVYDLTGYSFDFDI (SEQ ID NO: 2783)
1071A03	143-253	164-174	190-196	229-239	1-127	26-35	30-66	99-116	DMHYDLTGYYTGLAEDM (SEQ ID NO: 2917)
1071B03	144-252	166-176	192-198	231-241	1-126	26-35	30-66	100-115	GGYDLTGYPANWHP (SEQ ID NO: 2764)
1071B01	138-243	159-173	189-195	228-237	1-122	26-35	30-66	99-111	DEGVGYDYDY (SEQ ID NO: 2777)
1071F11	135-245	157-168	185-191	224-234	1-119	26-35	30-66	99-108	SSNFVYGLDV (SEQ ID NO: 2957)
1071G11	141-251	163-176	192-198	231-240	1-125	26-35	30-66	99-114	ATYDFLTGYSDFDI (SEQ ID NO: 2153)
1071H08	141-251	163-176	192-198	231-240	1-125	26-35	30-66	99-114	ATYDFLTGYSDFDI (SEQ ID NO: 2153)
1074A02	142-250	164-174	190-196	229-239	1-125	26-35	30-66	99-114	DORLNTNYLYEYQHI (SEQ ID NO: 2868)
1074A08	146-253	168-178	194-200	233-244	1-131	26-35	30-66	99-120	SSPFKWDALTGNTSYHAMDY (SEQ ID NO: 2165)
1074B01	146-253	168-178	194-200	233-244	1-131	26-35	30-66	99-117	DKTLGDLQVLAAYYYDQMDV (SEQ ID NO: 2776)
1074B02	142-250	164-174	190-196	229-239	1-128	26-35	30-66	99-115	LGHTSRDLTGTHFYHMDV (SEQ ID NO: 2944)
1074B03	144-252	166-176	192-198	231-240	1-127	26-35	30-66	99-112	DDYDLTGSLYTFDS (SEQ ID NO: 2803)
1074B05	144-252	166-176	192-198	231-240	1-127	26-35	30-66	99-115	DRADILTGYNDAFDI (SEQ ID NO: 2739)
1074B07	143-254	167-177	193-199	232-242	1-124	26-35	30-66	99-112	RYGDFPYYTYTANV (SEQ ID NO: 2755)
1074B08	143-254	167-177	193-199	232-242	1-127	26-35	30-66	99-115	GTGYDLTGYYTMGSADFQ (SEQ ID NO: 2800)
1075A07	145-253	167-177	193-199	232-242	1-127	26-35	30-66	99-116	VSNELTGWGCYNWDFP (SEQ ID NO: 2955)
1075B01	142-250	164-174	190-196	229-239	1-127	26-35	30-66	99-106	GTGYDLTGYYTMGSADFQ (SEQ ID NO: 2800)
1075B04	134-247	156-168	183-191	224-236	1-117	26-35	30-66	99-106	DQGRVLDL (SEQ ID NO: 2175)
1075B05	141-252	163-175	191-197	230-241	1-124	26-34	49-65	98-113	ELGLSIVGATTGALDM (SEQ ID NO: 2174)
1075B06	142-252	164-176	192-198	231-241	1-127	26-35	30-66	99-116	GTGYDLTGYYTMGSADFQ (SEQ ID NO: 2800)
1075B08	142-252	164-176	192-198	231-241	1-125	26-35	30-66	99-114	TYDELTGYYAEYTFQH (SEQ ID NO: 2932)
1075B12	141-251	163-176	192-198	231-240	1-124	26-35	30-66	99-113	SDYDLTGYYWVWVAY (SEQ ID NO: 2812)
1075C01	148-259	170-183	199-205	238-248	1-131	26-35	30-66	99-120	GRBDTDLKVPWDRYFHTYMDV (SEQ ID NO: 2835)
1075C05	134-244	156-168	184-190	223-233	1-117	26-35	30-66	99-106	DQGRVLDL (SEQ ID NO: 2175)
1075D05	145-255	168-179	195-201	234-242	1-127	26-35	30-66	99-116	GTGYDLTGYYMGVYDFP (SEQ ID NO: 2897)
1075D07	142-252	164-176	192-198	231-241	1-125	26-35	30-66	99-114	SYDILTGYTHFLDY (SEQ ID NO: 2853)
1075D08	141-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGLSIVGATTGALDM (SEQ ID NO: 2174)
1075E01	145-253	167-177	193-199	232-242	1-127	26-35	30-66	99-116	GTGYDLTGYYTMGSADFQ (SEQ ID NO: 2800)
1075E03	150-261	172-184	200-206	239-250	1-127	26-37	52-68	101-121	GGGYDLTGYSFPLYYGLDY (SEQ ID NO: 2865)
1075E04	144-255	166-179	193-201	234-244	1-127	26-35	30-66	99-116	CRGYDLTGYPFGSLDY (SEQ ID NO: 2881)
1075E05	141-252	163-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSIVGATTGALDM (SEQ ID NO: 2174)

U.S. Patent

Nov. 21, 2006

Sheet 38 of 52

7,138,501 B2

1075E10	1406	141-252	163-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGSLVNGATTGALDM (SEQ ID NO: 2174)
1075E11	1507	134-244	156-168	184-190	223-233	1-117	26-35	50-66	99-106	SGQWEDP (SEQ ID NO: 2879)
1075E12	1508	143-254	165-178	194-200	233-243	1-126	26-35	50-66	99-115	TDKFGAKDVTARWGDV (SEQ ID NO: 2979)
1075E02	1509	146-253	168-178	194-200	233-242	1-128	26-35	50-66	99-117	EQYDILTOYFEGGWDF (SEQ ID NO: 2834)
1075E04	1510	142-251	164-176	192-198	231-240	1-125	26-37	52-67	100-114	AGYDILTGYPFFYDS (SEQ ID NO: 2757)
1075E06	1511	146-254	168-178	194-200	233-243	1-128	26-35	50-66	99-117	GRNYDFLTGYNFNLGLDY (SEQ ID NO: 2830)
1075E07	1512	141-251	163-175	191-197	230-240	1-124	26-35	50-66	99-113	ENYDILTOYNYEDY (SEQ ID NO: 2971)
1075E08	1513	134-244	156-168	184-190	223-233	1-117	26-35	50-66	99-106	DQKAAQH (SEQ ID NO: 2779)
1075E09	1514	147-257	169-181	197-203	236-246	1-129	26-35	50-66	99-118	LKAFYDILTGTHLPKWEDT (SEQ ID NO: 2953)
1075E10	1515	135-243	157-167	183-189	222-232	1-117	26-35	50-66	99-106	DQRYLDL (SEQ ID NO: 2173)
1075E11	1516	134-245	156-169	185-191	224-234	1-117	26-35	50-66	99-106	DQRYLDL (SEQ ID NO: 2175)
1075E05	1517	141-252	163-175	191-197	230-241	1-124	26-34	49-65	98-113	ELGSLVNGATTGALDM (SEQ ID NO: 2174)
1075E07	1518	141-252	163-175	191-197	230-241	1-124	26-35	50-66	99-113	GRYVDMLTRGGYEDY (SEQ ID NO: 2858)
1075E08	1519	141-252	163-176	192-198	231-241	1-124	26-35	50-66	99-113	QYDILTGYYGGEDY (SEQ ID NO: 2958)
1075E12	1520	142-253	164-177	193-199	232-242	1-125	26-35	50-66	99-114	TDYDILTGYPGWDF (SEQ ID NO: 2173)
1075E02	1521	134-245	156-169	185-191	224-234	1-117	26-35	50-66	99-106	DQRYLDL (SEQ ID NO: 2175)
1075E03	1522	134-245	156-169	185-191	224-234	1-117	26-35	50-66	99-116	GTGYDILTGYYMGSAFDQ (SEQ ID NO: 2808)
1075E06	1523	134-245	156-169	185-191	224-234	1-117	26-35	50-66	99-106	DQRYLDL (SEQ ID NO: 2175)
1075E08	1524	134-244	156-168	184-190	223-233	1-117	26-35	50-66	99-106	DQRYLDL (SEQ ID NO: 2175)
1075E08	1525	144-254	166-179	195-201	234-243	1-127	26-35	50-66	99-116	CGYDILTGYYTGSFLDY (SEQ ID NO: 2766)
1075E01	1526	144-253	166-176	192-198	231-242	1-126	26-35	50-66	99-115	DRRDDLTGVLVDAFDS (SEQ ID NO: 2878)
1075E03	1527	137-247	159-171	187-193	226-236	1-119	26-35	50-68	101-108	GYDTAMQY (SEQ ID NO: 2951)
1075E06	1528	134-245	156-168	184-190	223-234	1-117	26-35	50-66	99-106	DQRYLDL (SEQ ID NO: 2173)
1075E07	1529	140-250	162-174	180-196	229-239	1-123	26-35	50-66	99-112	DRDILTGSGNQD (SEQ ID NO: 2913)
1075E08	1530	144-253	166-176	192-198	231-242	1-126	26-35	50-66	99-115	MGYDILTGYYHYGMV (SEQ ID NO: 2831)
1075E01	1531	143-237	167-179	195-201	236-246	1-127	26-35	50-66	99-116	GSYDILTGYYTGSFLDY (SEQ ID NO: 2766)
1075E02	1532	134-245	156-169	185-191	224-234	1-117	26-35	50-66	99-106	DQRYLDL (SEQ ID NO: 2175)
1075E07	1533	135-243	157-167	183-189	222-232	1-117	26-35	50-66	99-106	DQRYLDL (SEQ ID NO: 2173)
1075E08	1534	143-252	166-177	193-199	232-241	1-125	26-35	50-66	99-114	FYDPLTAYTFQYQGN (SEQ ID NO: 2806)
1075E04	1535	142-250	164-174	190-196	229-239	1-124	26-34	49-65	98-113	ELGSLVNGATTGALDM (SEQ ID NO: 2174)
1075E01	1536	141-251	163-175	191-197	230-240	1-124	26-35	50-66	99-113	GRYVDMLTRGGYEDY (SEQ ID NO: 2858)
1075E08	1537	142-252	164-176	192-198	231-241	1-125	26-35	50-66	99-114	LDYDILTGYYSGEDY (SEQ ID NO: 2799)
1075E01	1538	141-251	163-175	191-197	230-240	1-124	26-37	52-67	100-113	RFYDILTGYSAFDS (SEQ ID NO: 2756)
1075E12	1539	144-255	166-179	195-201	234-244	1-127	26-35	50-66	99-116	GTGYDILTGYYMGSAFDQ (SEQ ID NO: 2800)
1075E04	1540	142-250	164-174	190-196	229-239	1-124	26-34	49-65	98-113	ELGSLVNGATTGALDM (SEQ ID NO: 2174)
1075E07	1541	145-252	167-177	193-199	232-241	1-127	26-35	50-66	99-116	GTGYDILTGYYMGSAFDQ (SEQ ID NO: 2800)
1075E08	1542	141-251	163-175	191-197	230-240	1-124	26-35	50-66	99-113	EYDVLTLGLPYTADV (SEQ ID NO: 2841)
1075E09	1543	143-253	164-177	193-199	232-242	1-125	26-35	50-66	99-114	DDRLTNVYLYEYFQH (SEQ ID NO: 2868)
1075E11	1544	144-254	166-179	195-201	234-243	1-127	26-35	50-66	99-116	GTGYDILTGYYMGSAFDQ (SEQ ID NO: 2800)
1075E01	1545	144-253	166-178	194-199	232-242	1-127	26-35	50-66	99-116	GTGYDILTGYYMGSAFDQ (SEQ ID NO: 2800)
1075E03	1546	141-251	163-175	191-197	230-240	1-124	26-36	51-66	99-113	GDYDVLTVGLRKLDY (SEQ ID NO: 2742)
1075E04	1547	135-246	157-169	185-191	224-234	1-117	26-35	50-66	99-106	DQRYLDL (SEQ ID NO: 2173)

U.S. Patent

Nov. 21, 2006

Sheet 39 of 52

7,138,501 B2

1076F08	1548	142-250	164-174	190-196	229-239	1-124	26-36	51-66	99-113	VHYDLTGYLWAFDI (SEQ ID NO: 2170)
1076F10	1549	141-252	163-173	191-197	230-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1076G09	1550	134-245	156-168	184-190	223-234	1-117	26-35	50-66	99-106	DQRYLDI (SEQ ID NO: 2175)
1076G10	1551	141-251	163-175	191-197	230-240	1-124	26-35	50-66	99-113	GRYDMLTRGQYFDY (SEQ ID NO: 2180)
1076G11	1552	144-259	166-179	195-205	240-248	1-127	26-35	50-66	99-116	GYDDELTYTANGSAPDQ (SEQ ID NO: 2180)
1076G12	1553	147-257	169-181	197-203	236-246	1-130	26-35	50-66	99-119	NGYDDELTYLWDYVYGMV (SEQ ID NO: 2180)
1076H02	1554	141-251	163-175	191-197	230-240	1-124	26-35	50-66	99-113	ENYDDELTYNYTFDY (SEQ ID NO: 2171)
1076H04	1555	143-251	165-175	191-197	230-240	1-125	26-35	50-66	99-114	THYDDELTYSHFDY (SEQ ID NO: 2186)
1076H05	1556	141-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1076H06	1557	141-252	163-176	192-198	231-241	1-124	26-35	50-66	99-113	VFDELTYTWGASDY (SEQ ID NO: 2187)
1076H08	1558	144-256	166-179	195-201	234-245	1-127	26-35	50-66	99-116	GSQYDDELTYTGSPLDY (SEQ ID NO: 2166)
1076H10	1559	144-256	166-179	195-201	234-245	1-127	26-35	50-66	99-116	QSOYDDELTYTGSPLDY (SEQ ID NO: 2166)
1077D06	1560	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	VYDDELTYNLFEDY (SEQ ID NO: 2177)
1078B04	1561	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	VYDDELTYNLFEDY (SEQ ID NO: 2177)
1078B10	1562	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	MEYDDELTYVSGQPDY (SEQ ID NO: 2179)
1078A01-K	1563	142-250	164-174	190-196	229-239	1-125	26-35	50-66	99-114	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1078A01-R	1564	142-250	164-174	190-196	229-239	1-125	26-35	50-66	99-114	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1078C04-K	1565	142-250	164-176	192-198	231-239	1-124	26-35	50-66	99-114	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1078C04-R	1566	142-250	164-176	192-198	231-239	1-125	26-35	50-66	99-114	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1078B10	1567	149-249	171-183	199-203	238-248	1-133	26-35	50-66	99-122	DRGAPNDLTYVAPAGVAFDI (SEQ ID NO: 2176)
1078C06	1568	134-244	156-169	185-191	224-233	1-117	26-35	50-66	99-106	DQRYLDI (SEQ ID NO: 2175)
1078B12	1569	134-244	156-168	184-190	223-233	1-117	26-35	50-66	99-106	DQRYLDI (SEQ ID NO: 2175)
1078B06	1570	141-249	163-173	189-195	228-238	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1078B06	1571	141-249	163-175	191-197	230-238	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1078B06	1572	141-249	163-175	191-197	230-238	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1078B06	1573	141-249	163-175	191-197	230-238	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1078B12	1574	142-250	163-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1078B12	1575	141-252	163-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2174)
1078B12	1576	147-257	169-182	194-204	237-246	1-131	26-35	50-66	99-120	DQRYLDI (SEQ ID NO: 2175)
1078B12	1577	134-241	157-167	183-189	222-230	1-118	26-35	50-66	99-107	SETIFDND (SEQ ID NO: 2178)
1078B12	1578	144-254	166-179	195-201	234-243	1-128	26-36	51-66	99-117	GRYDDELTYTNYTFDY (SEQ ID NO: 2181)
1078B12	1579	147-257	169-182	194-204	237-246	1-131	26-35	50-66	99-120	TPSSVYDDELTYTNYTFDY (SEQ ID NO: 2189)
1078B12	1580	135-242	158-168	184-190	223-231	1-119	26-35	50-66	99-108	ERSAATYFDY (SEQ ID NO: 2190)
1078B12	1581	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	ENYDDELTYTNYTFDY (SEQ ID NO: 2185)
1078B12	1582	134-244	156-163	184-190	223-233	1-117	26-35	50-66	99-106	DQRYLDI (SEQ ID NO: 2175)
1078B12	1583	141-252	163-175	191-197	231-241	1-124	26-34	49-65	98-113	ELGLSVGATTGALDM (SEQ ID NO: 2180)
1078B12	1584	143-254	165-178	194-206	233-243	1-126	26-35	50-66	99-115	EXMDFINSHRYTMDA (SEQ ID NO: 2182)
1078B12	1585	140-251	162-175	191-197	230-240	1-123	26-35	50-66	99-112	AGNYQHTREADY (SEQ ID NO: 2180)
1078B12	1586	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	MYDDELTYTNYTFDY (SEQ ID NO: 2179)
1078B12	1587	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDDELTYTNYTFDY (SEQ ID NO: 2153)
1078B12	1588	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDDELTYTNYTFDY (SEQ ID NO: 2153)
1078B12	1589	136-246	153-171	187-193	226-235	1-120	26-35	50-66	99-109	SLATRFQMDV (SEQ ID NO: 2184)

U.S. Patent

Nov. 21, 2006

Sheet 40 of 52

7,138,501 B2

1074B12	1590	142-252	164-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGLSTVGTGALDM (SEQ ID NO: 2174)
1075A02	1591	141-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELGLSTVGTGALDM (SEQ ID NO: 2174)
1075G01	1592	142-251	164-174	190-196	229-240	1-124	26-35	49-65	99-113	DVYDILTGYNRLDS (SEQ ID NO: 2187)
1078D02	1593	140-250	162-175	191-197	230-239	1-124	26-35	49-65	99-113	VYDILTGYNRLDS (SEQ ID NO: 2177)
1078E08	1594	144-251	165-175	191-197	230-240	1-128	26-35	49-65	99-117	DAQSYDILTGYSYAFDI (SEQ ID NO: 2183)
1078H08	1595	140-250	162-175	191-197	230-239	1-124	26-35	49-65	99-113	VYDILTGYNRLDS (SEQ ID NO: 2177)
1064A03	1596	150-257	171-181	197-203	236-246	1-134	26-35	50-66	99-123	HFSTYDILTGYYTTPYYTYMDV (SEQ ID NO: 3014)
1064B03	1597	145-255	167-179	195-201	234-244	1-129	26-37	52-67	100-118	HSRUYDILTGYYRGTTHDY (SEQ ID NO: 2167)
1064B05	1598	140-250	162-174	190-196	229-239	1-124	26-35	50-65	99-113	ERGVYTA YGGESEDL (SEQ ID NO: 2869)
1064B11	1599	138-248	160-173	189-195	228-237	1-122	26-35	50-65	99-111	DRGFGILSSFFES (SEQ ID NO: 3013)
1064C02	1600	146-256	168-180	196-202	235-245	1-130	26-35	50-65	99-119	DEYDILTGYPARTYYTOMEDY (SEQ ID NO: 3048)
1064C03	1601	140-250	162-175	191-197	230-239	1-124	26-35	50-65	99-113	ERGVYTA YGGESEDL (SEQ ID NO: 2869)
1064C11	1602	143-253	165-178	194-200	233-242	1-127	26-35	50-65	98-116	DVYDILTG YAGHEAETH (SEQ ID NO: 3055)
1064C12	1603	148-255	168-181	197-203	236-244	1-132	26-37	52-69	102-121	EXGANTDILTGYYTTPYYTYMDV (SEQ ID NO: 3012)
1064D04	1604	146-256	163-175	192-198	231-240	1-125	26-35	50-65	99-114	RSYDILTGYYTTPYYTYMDV (SEQ ID NO: 3050)
1064D06	1605	134-244	156-169	185-191	224-233	1-118	26-35	50-65	99-107	HSRUYTA YG (SEQ ID NO: 2981)
1064E05	1606	146-256	168-180	196-202	235-245	1-130	26-35	50-65	100-119	KORGVDILTG YQLOYAFDI (SEQ ID NO: 2886)
1064E07	1607	141-248	162-172	188-194	227-237	1-125	26-35	50-65	99-114	ERPVYDILTG YSSRYMDV (SEQ ID NO: 3051)
1064F09	1610	147-257	169-181	197-203	236-246	1-131	26-35	50-65	99-120	ATYDILTG YSHGEDI (SEQ ID NO: 2153)
1064F10	1611	143-253	165-177	194-199	232-242	1-127	26-31	46-62	98-116	DTLGYDILTG YPPPYTYMDV (SEQ ID NO: 2988)
1064F11	1612	142-252	164-177	193-199	232-241	1-126	26-35	50-65	98-115	CRHYDILTG YVNEAFDI (SEQ ID NO: 3031)
1064C01	1613	140-250	162-175	191-197	230-239	1-124	26-35	50-65	99-113	NYDVLTG YSYGMDV (SEQ ID NO: 3077)
1064C04	1614	135-243	155-167	183-189	222-232	1-117	26-35	50-65	99-106	INSYTYG (SEQ ID NO: 3034)
1064C08	1615	138-245	159-169	185-191	224-234	1-122	26-35	50-65	99-111	GGTYAGRSVYEDS (SEQ ID NO: 2990)
1064C10	1616	140-250	162-175	191-197	230-239	1-124	26-35	50-65	99-113	SPNGYSYFAWGLFY (SEQ ID NO: 3085)
1064C11	1617	138-248	160-173	189-195	228-237	1-122	26-35	50-65	98-111	YEDGSGYTPYSSY (SEQ ID NO: 3054)
1064C12	1618	139-249	163-178	194-200	233-242	1-127	26-37	52-67	100-112	VYDILTG YTYEDY (SEQ ID NO: 3049)
1064H04	1619	143-253	165-178	196-202	235-245	1-133	26-35	50-66	99-115	FLGSAVRGAKTDAFGI (SEQ ID NO: 2929)
1064H06	1620	147-249	163-173	189-195	228-238	1-126	26-35	50-66	99-122	DRGASNYDILTG YTAQGVAFDI (SEQ ID NO: 2963)
1065A02	1621	149-256	170-180	196-202	235-245	1-133	26-35	50-66	99-114	ATYDILTG YSHGEDI (SEQ ID NO: 2153)
1065A04	1622	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDILTG YSHGEDI (SEQ ID NO: 2153)
1065A06	1623	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDILTG YSHGEDI (SEQ ID NO: 2153)
1065A07	1624	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDILTG YSHGEDI (SEQ ID NO: 2153)
1065B01	1625	144-254	167-180	196-202	235-244	1-128	26-35	50-66	99-117	DGGVDILTG YTYMDV (SEQ ID NO: 2987)
1065B05	1626	145-255	167-177	193-199	232-241	1-126	26-35	50-66	98-118	WATYDILTG YLKHGEDI (SEQ ID NO: 3017)
1065B09	1627	142-252	164-177	193-199	232-242	1-130	26-35	50-66	99-115	SPGDDILTG YTYTYEDY (SEQ ID NO: 3032)
1065B12	1628	146-253	167-177	193-199	232-242	1-130	26-35	50-66	99-119	DAGESYDILTG YTYMDV (SEQ ID NO: 2986)
1065C02	1629	139-249	161-174	190-196	229-236	1-123	26-35	50-66	99-112	EQAAVDILTG YTYMDV (SEQ ID NO: 2815)
1065C06	1630	136-246	158-170	186-192	225-235	1-120	26-35	50-66	99-109	EQSVSGLDLDY (SEQ ID NO: 3007)
	1631	141-253	163-175	191-197	230-242	1-125	26-35	50-66	99-114	ATYDILTG YSHGEDI (SEQ ID NO: 2153)

U.S. Patent

Nov. 21, 2006

Sheet 41 of 52

7,138,501 B2

1632	141-250	163-176	192-198	231-239	1-125	26-35	50-66	99-114	VSGVNSGYFESYDMGV (SEQ ID NO: 2732)
1633	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	QGGQYDSPLDV (SEQ ID NO: 3062)
1634	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	DEDYDLTDYNYGMGV (SEQ ID NO: 3074)
1635	140-249	165-175	191-197	230-238	1-126	26-35	50-66	99-115	APYDLYTGYGGNDY (SEQ ID NO: 3028)
1636	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	DKDYDLTGTYVDELDY (SEQ ID NO: 3040)
1637	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	DEVDLDTYTYAMGV (SEQ ID NO: 3062)
1638	139-246	160-170	186-192	225-235	1-123	26-35	50-66	99-112	EPKDLARHGMDY (SEQ ID NO: 3027)
1639	137-244	158-168	184-190	223-233	1-121	26-35	50-66	99-110	AGSSLATYGV (SEQ ID NO: 2773)
1640	146-256	168-181	197-203	236-245	1-130	26-35	50-66	99-119	AGSYDLYTGYRFGDGYFDY (SEQ ID NO: 3043)
1641	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	GLYEDTYNYRUCDAEDY (SEQ ID NO: 2790)
1642	145-255	167-179	195-201	234-244	1-129	26-35	50-63	98-118	ERSYDLYTGYSGYCMGV (SEQ ID NO: 3021)
1643	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTYGSGDGFY (SEQ ID NO: 2153)
1644	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	ERGVVTA YGGSFYL (SEQ ID NO: 2885)
1645	145-253	165-176	192-198	231-241	1-129	26-38	53-69	98-113	RYEDALTYGSLGADV (SEQ ID NO: 3013)
1647	143-250	164-174	190-196	229-239	1-127	26-35	50-66	99-116	GLAYDLYTGYTYGMDY (SEQ ID NO: 2860)
1648	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	DYEDVLTGRTKRWDP (SEQ ID NO: 3015)
1649	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	DQYDRLAMQYNYMDA (SEQ ID NO: 3047)
1650	143-253	165-178	194-200	233-242	1-127	26-35	50-68	101-116	ATYDPLTYGSGDGFY (SEQ ID NO: 2153)
1651	140-247	161-171	187-193	226-236	1-124	26-36	51-66	99-113	DAYDYLTYGYYGMDY (SEQ ID NO: 3030)
1652	140-247	161-171	187-193	226-236	1-124	26-36	51-66	99-113	RYEDLTYGYDMGV (SEQ ID NO: 2863)
1653	138-248	160-173	189-195	228-237	1-122	26-35	50-66	99-111	TRMDVLTGYSDH (SEQ ID NO: 2750)
1654	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSSLATYGV (SEQ ID NO: 2773)
1655	139-246	163-176	192-198	231-240	1-125	26-35	50-66	99-114	EGADYLNQGVFGH (SEQ ID NO: 2815)
1656	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	DTYVGLQWEGAFDM (SEQ ID NO: 3080)
1657	141-248	162-172	188-194	227-237	1-123	26-35	50-66	99-114	ATYDPLTYGSGDGFY (SEQ ID NO: 2153)
1658	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	PLGTAVRGAKTDARFI (SEQ ID NO: 2829)
1659	144-254	166-178	194-200	233-243	1-128	26-35	50-63	98-117	GRYYDLYTGYSLGSGMDY (SEQ ID NO: 3059)
1660	141-248	162-172	188-194	227-237	1-123	26-35	50-66	99-114	ATYDPLTYGSGDGFY (SEQ ID NO: 2153)
1661	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGTSLAMVGV (SEQ ID NO: 3048)
1662	141-248	162-172	188-194	227-237	1-123	26-35	50-66	99-114	QPYDLYTGYSLGSGMDY (SEQ ID NO: 2892)
1663	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	QGGQYDSRFDY (SEQ ID NO: 3061)
1664	140-259	171-184	203-206	239-248	1-133	26-35	50-66	99-122	GECAAYDLYTGYSAWGGYAMGV (SEQ ID NO: 3045)
1665	141-248	162-172	188-194	227-237	1-123	26-35	50-66	99-114	LNLEKTVRGHGYFDL (SEQ ID NO: 3081)
1666	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	VGGYDLYTGYLRGMDY (SEQ ID NO: 2997)
1667	141-248	162-172	188-194	227-237	1-123	26-35	50-66	99-114	ATYDPLTYGSGDGFY (SEQ ID NO: 2153)
1668	141-248	162-172	188-194	227-237	1-123	26-35	50-66	99-114	ATYDPLTYGSGDGFY (SEQ ID NO: 2153)
1669	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	SPYDLYTGYVYMGVDY (SEQ ID NO: 3038)
1670	141-248	162-172	188-194	227-237	1-125	26-35	53-66	99-114	ATYDPLTYGSGDGFY (SEQ ID NO: 2153)
1671	141-251	163-175	191-197	230-240	1-123	26-35	50-66	99-114	VAAAGARTLGYFGMDY (SEQ ID NO: 3071)
1672	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	DVSGHDILTYGYSYRFDV (SEQ ID NO: 2795)
1673	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	SPNYDLYTGYFSGYFDS (SEQ ID NO: 3056)

U.S. Patent

Nov. 21, 2006

Sheet 42 of 52

7,138,501 B2

1066F11	142-252	164-177	153-199	232-241	1-126	26-35	50-66	99-115	QAYYDLKYYVYVGMV (SEQ ID NO: 2860)
1066F12	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	QFSSAGTTLGHSFDP (SEQ ID NO: 3005)
1066G06	143-254	164-174	190-196	229-239	1-127	26-35	50-66	99-116	ETKESVSSPPYNYTAMDV (SEQ ID NO: 2736)
1066G07	133-243	155-168	184-190	223-232	1-117	26-30	45-61	94-106	DQFVSGRHADEL (SEQ ID NO: 3054)
1066H02	135-243	156-166	182-188	221-231	1-119	26-35	50-66	99-108	GMGDHYOMDV (SEQ ID NO: 2161)
1067A02	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDLTGVSDFD (SEQ ID NO: 2153)
1067A03	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSLMTYGTDV (SEQ ID NO: 2773)
1067A06	141-248	163-173	188-194	227-237	1-125	26-35	50-66	99-114	ATYDLTGVSDFD (SEQ ID NO: 2153)
1067A08	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	AGSLMTYGTDV (SEQ ID NO: 2773)
1067A10	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	EGGVVTA VGGDSFDL (SEQ ID NO: 2985)
1067B03	142-253	164-177	193-199	232-242	1-126	26-35	50-66	99-115	FLGTAVRQAKTDAFCI (SEQ ID NO: 2929)
1067B04	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSLMTYGTDV (SEQ ID NO: 2773)
1067C03	134-244	156-169	185-191	224-233	1-117	26-35	50-66	99-106	DWGRWDFP (SEQ ID NO: 2932)
1067C05	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	SGSLMTYGTDV (SEQ ID NO: 3015)
1067C07	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	EPYDLTGYSYEDY (SEQ ID NO: 3041)
1067C10	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSLMTYGTDV (SEQ ID NO: 2773)
1067C12	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	TYDILTGYSGGAFDY (SEQ ID NO: 3024)
1067D01	136-246	158-171	187-193	226-235	1-120	26-34	50-64	99-109	GSEVRGVTPDL (SEQ ID NO: 3028)
1067D03	137-244	158-168	184-190	223-233	1-121	26-35	50-66	99-110	AGSLMTYGTDV (SEQ ID NO: 2773)
1067D05	146-256	168-180	196-202	235-245	1-130	26-35	50-66	99-119	ECSSSCARQHFYVYVMDV (SEQ ID NO: 2993)
1067D06	137-244	158-168	184-190	223-233	1-121	26-35	50-66	99-110	AGSLMTYGTDV (SEQ ID NO: 2773)
1067D09	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	GAYYDLTGYPYGMV (SEQ ID NO: 2860)
1067D12	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	QGGQVDSFPLDV (SEQ ID NO: 3002)
1067E02	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSLMTYGTDV (SEQ ID NO: 2773)
1067E04	142-252	164-176	192-198	231-241	1-125	26-35	50-66	99-115	GAYYDLTGYPYGMV (SEQ ID NO: 2860)
1067E05	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	DYRNVDLTGHPYVYGMV (SEQ ID NO: 2906)
1067F01	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	QFVLDLTVGSQEPDI (SEQ ID NO: 3022)
1067F03	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	DQYVLDLTVGHYVYVGMV (SEQ ID NO: 3087)
1067F04	139-246	160-178	186-192	225-235	1-123	26-35	50-66	99-112	EGAADYNGQVFOH (SEQ ID NO: 2815)
1067F08	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	LQYVLDLTVGSYEDY (SEQ ID NO: 3029)
1067F10	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGSLMTYGTDV (SEQ ID NO: 3016)
1067F11	140-248	163-176	192-198	231-240	1-124	26-35	50-66	99-113	BNYDLTGYSYEDY (SEQ ID NO: 2772)
1067G01	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSYEDY (SEQ ID NO: 2153)
1067G09	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	AGSLMTYGTDV (SEQ ID NO: 2773)
1067H07	144-251	165-175	191-197	230-240	1-128	26-35	50-66	99-117	GGLYDLTGKFAITDDAFDI (SEQ ID NO: 3035)
1068A07	143-254	165-178	194-200	233-243	1-126	26-35	50-66	99-115	TDREKADVTARWGMV (SEQ ID NO: 2978)
1068E05	148-257	170-183	199-205	238-246	1-131	26-35	50-66	99-120	GREDDKVPWDRYYHYVMDV (SEQ ID NO: 2809)
1068E08	135-247	157-169	185-193	226-236	1-117	26-35	50-66	99-106	DQKRYDL (SEQ ID NO: 2173)
1068E11	141-251	163-176	192-198	231-240	1-124	26-34	49-65	98-113	ELGLSVQATTTGALDM (SEQ ID NO: 2174)
1068F04	142-252	164-176	192-198	231-241	1-125	26-35	50-66	99-114	ELGHRGGYVTSFTNV (SEQ ID NO: 2838)
1068G05	137-245	159-169	185-191	224-234	1-119	26-35	50-66	98-108	KRMGASAAADF (SEQ ID NO: 3042)
1068G06	140-250	162-174	190-196	229-239	1-123	26-35	50-66	99-112	RYDFFYYVYVMDV (SEQ ID NO: 2755)

U.S. Patent

Nov. 21, 2006

Sheet 43 of 52

7,138,501 B2

1068G11	1716	147-258	169-182	198-204	237-247	1-130	26-35	50-66	99-119	BRKRYHLLTGLVAAAGFDV (SEQ ID NO: 3044)
1069A09	1717	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	MEYDLTGYYGGYEDV (SEQ ID NO: 2179)
1069A10	1718	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDLTGYYGGYEDV (SEQ ID NO: 2179)
1069B06	1719	143-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	MEYDLTGYYGGYEDV (SEQ ID NO: 2179)
1069B09	1720	139-249	161-174	190-196	229-238	1-123	26-35	50-66	99-112	PYDLTGYPARDI (SEQ ID NO: 3026)
1069B12	1721	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDLTGYYGGYEDV (SEQ ID NO: 2179)
1069C06	1722	143-250	164-174	190-196	229-239	1-127	26-35	50-66	99-116	VLPHYDLTGYSQNWDFP (SEQ ID NO: 3000)
1069C09	1723	143-250	164-174	190-196	229-239	1-127	26-35	50-66	99-116	VLPHYDLTGYSQNWDFP (SEQ ID NO: 3000)
1069D03	1724	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DOYDLTGYSYGGYEDV (SEQ ID NO: 2153)
1069D09	1725	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DOYDLTGYSYGGYEDV (SEQ ID NO: 2153)
1069E11	1726	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	VYDLTGYNLFEDV (SEQ ID NO: 2177)
1069F05	1727	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDLTGYYGGYEDV (SEQ ID NO: 2179)
1069F07	1728	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDLTGYYGGYEDV (SEQ ID NO: 2179)
1069F12	1729	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	QYDLTGYYDAFDI (SEQ ID NO: 3051)
1069G06	1730	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	DGYYDLTGYSYGGYEDV (SEQ ID NO: 3050)
1069G11	1731	142-252	166-176	192-198	231-241	1-129	26-35	50-66	99-118	DRLEYDLTGYYGGYEDV (SEQ ID NO: 3050)
1070A03	1732	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDLTGYYGGYEDV (SEQ ID NO: 2179)
1070A09	1733	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	MEYDLTGYYGGYEDV (SEQ ID NO: 2179)
1070B01	1734	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDLTGYYGGYEDV (SEQ ID NO: 2179)
1070B03	1735	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	SQSDYDLTGYYGGYEDV (SEQ ID NO: 3038)
1070B05	1736	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	MEYDLTGYYGGYEDV (SEQ ID NO: 2179)
1070B08	1737	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	MEYDLTGYYGGYEDV (SEQ ID NO: 2179)
1070B09	1738	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	MEYDLTGYYGGYEDV (SEQ ID NO: 2179)
1070C04	1739	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	SQSDYDLTGYYGGYEDV (SEQ ID NO: 3038)
1070C10	1740	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDLTGYYGGYEDV (SEQ ID NO: 2179)
1071A06	1741	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	MEYDLTGYYGGYEDV (SEQ ID NO: 2179)
1071B02	1742	135-242	156-166	182-188	221-231	1-119	26-35	50-66	99-108	QMGDHYGMDV (SEQ ID NO: 2161)
1071B02	1743	135-245	157-170	185-192	223-234	1-119	26-35	50-66	99-108	QMGDHYGMDV (SEQ ID NO: 2161)
1071D02	1744	137-247	159-172	186-194	227-236	1-121	26-35	50-66	99-110	AGTSLMAYGMDV (SEQ ID NO: 2161)
1071D08	1745	146-255	168-181	197-203	236-245	1-130	26-37	52-66	99-119	VFYDYLIGGVLGEYYGGYEDV (SEQ ID NO: 3048)
1071F01	1746	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGTSLMAYGMDV (SEQ ID NO: 2161)
1071G09	1747	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSYGGYEDV (SEQ ID NO: 2153)
1072A01	1748	130-249	161-174	190-196	229-238	1-123	26-35	50-66	99-112	SRDILLPHYGGYEDV (SEQ ID NO: 2153)
1072A09	1749	141-251	163-176	192-198	231-240	1-123	26-35	50-66	99-114	ATYDLTGYSYGGYEDV (SEQ ID NO: 2153)
1072B02	1750	135-245	157-170	185-192	223-234	1-119	26-35	50-66	99-108	QMGDHYGMDV (SEQ ID NO: 2161)
1072B10	1751	137-247	159-172	188-194	227-236	1-121	26-35	50-66	99-110	AGTSLMAYGMDV (SEQ ID NO: 2161)
1072B11	1752	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSYGGYEDV (SEQ ID NO: 2153)
1072B12	1753	140-249	162-173	189-195	228-238	1-124	26-35	50-66	99-113	ENYDYLIGYYGAFDI (SEQ ID NO: 2595)
1072C05	1754	135-245	157-169	185-191	224-234	1-119	26-35	50-66	99-108	QMGDHYGMDV (SEQ ID NO: 2161)
1072C10	1755	141-248	162-172	188-194	227-237	1-123	26-35	50-66	99-114	ATYDLTGYSYGGYEDV (SEQ ID NO: 2153)
1072D01	1756	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDLTGYSYGGYEDV (SEQ ID NO: 2153)
1072D05	1757	135-245	157-169	185-191	224-234	1-119	26-35	50-66	99-108	QMGDHYGMDV (SEQ ID NO: 2161)

U.S. Patent

Nov. 21, 2006

Sheet 44 of 52

7,138,501 B2

1072E01	1738	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072E04	1739	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	ESYDILAGYVVGEMDV (SEQ ID NO: 2171)
1072E05	1760	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072E06	1761	135-242	156-165	182-188	221-231	1-119	26-35	50-66	99-108	GMGRHYGMDV (SEQ ID NO: 2161)
1072E03	1762	135-242	156-166	182-188	221-231	1-119	26-35	50-66	99-108	GMGRHYGMDV (SEQ ID NO: 2161)
1072F07	1763	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072F11	1764	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	DEYDILTGLLQEMDV (SEQ ID NO: 2883)
1072G03	1765	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072G04	1766	137-247	159-171	187-193	226-236	1-121	26-35	50-66	101-110	RDYDPLTGYSEDGEDI (SEQ ID NO: 2913)
1072G05	1767	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	GYRNDWYGAPEI (SEQ ID NO: 3079)
1072G09	1768	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072H03	1769	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072H07	1770	137-247	159-172	186-194	227-236	1-121	26-35	50-66	99-110	AGSLAMNYGMDV (SEQ ID NO: 3070)
1072A02	1771	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	GFYDILTGYTRDAFEI (SEQ ID NO: 2998)
1072A03	1772	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	THYDILTGYTTADAPEI (SEQ ID NO: 3019)
1072A04	1773	143-258	170-183	198-205	238-247	1-132	26-35	50-66	99-121	VQMSSEYDILLTGNNVGPYVEDY (SEQ ID NO: 2137)
1072A05	1774	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072A06	1775	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072A08	1776	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072A10	1777	146-253	167-177	193-199	233-243	1-130	26-35	50-66	99-119	GMGRHYGMDV (SEQ ID NO: 3082)
1072A11	1778	141-248	164-174	190-196	229-237	1-125	26-35	50-66	99-114	SYDILTGYTPFGMDV (SEQ ID NO: 3004)
1072B02	1779	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	ELAYDILTGYTLDADAPEI (SEQ ID NO: 2999)
1072B03	1780	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	ELAYDILTGYTLDADAPEI (SEQ ID NO: 2999)
1072B06	1781	139-246	160-173	186-192	225-235	1-123	26-35	50-66	99-112	DLWYDILTGYTLDADAPEI (SEQ ID NO: 2999)
1072B07	1782	138-248	160-173	186-192	225-235	1-123	26-35	50-66	99-112	DLWYDILTGYTLDADAPEI (SEQ ID NO: 2133)
1072B08	1783	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072B11	1784	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072C01	1785	141-248	163-176	192-198	231-240	1-125	26-35	50-66	99-114	GYHDILTSINTVWTFE (SEQ ID NO: 3066)
1072C02	1786	148-255	169-179	194-201	234-244	1-132	26-35	50-66	99-121	ACMSSEYDILLTGNNVGPYTFDY (SEQ ID NO: 3073)
1072C04	1787	142-252	164-177	198-199	232-241	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072C07	1788	134-241	155-165	181-187	220-230	1-118	26-35	50-66	99-107	GMGRHYGMDV (SEQ ID NO: 3038)
1072C08	1789	142-252	164-177	198-199	232-241	1-126	26-35	50-66	99-115	EMGYDILTGYTLYNMDV (SEQ ID NO: 2862)
1072C11	1790	141-248	162-172	188-194	227-237	1-125	26-35	50-66	99-114	QHYDILTGYSEDGEDI (SEQ ID NO: 3022)
1072C12	1791	146-256	168-181	197-203	236-245	1-139	26-35	50-66	101-119	FRYDILTGYVAGGVFQH (SEQ ID NO: 2155)
1072D01	1792	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072D03	1794	135-245	157-169	185-191	224-234	1-119	26-35	50-66	99-108	GMGRHYGMDV (SEQ ID NO: 2161)
1072D06	1795	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072D08	1796	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	EVNSYDILTRSYLACHLDN (SEQ ID NO: 2751)
1072D10	1797	140-250	162-175	191-197	230-239	1-124	26-35	50-66	101-113	QYDILTGYSELDI (SEQ ID NO: 3072)
1072D11	1798	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATYDPLTGYSEDGEDI (SEQ ID NO: 2153)
1072E01	1799	148-258	170-183	199-205	238-247	1-132	26-37	52-69	102-121	EGAHYDILTGHNNYHYGMDV (SEQ ID NO: 2747)

U.S. Patent

Nov. 21, 2006

Sheet 45 of 52

7,138,501 B2

1073E02	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATTYDLTGYSDGEDI (SEQ ID NO: 2155)
1073E03	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATTYDLTGYSLDGEDH (SEQ ID NO: 3069)
1073E05	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	QRYDLTGYSDGEDH (SEQ ID NO: 3022)
1073E06	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	QRYDLTGYSDGEDH (SEQ ID NO: 3022)
1073E08	140-250	162-175	191-197	230-239	1-124	26-35	50-66	99-113	ENTYDLTGYTGAFDI (SEQ ID NO: 2172)
1073F01	141-251	163-175	191-197	230-240	1-125	26-35	50-66	99-114	ATTYDLTGYSDGEDDI (SEQ ID NO: 2153)
1073F02	141-251	163-175	191-197	230-240	1-125	26-35	50-66	99-114	ATTYDLTGYSDGEDDI (SEQ ID NO: 2153)
1073F03	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATTYDLTGYSDGEDDI (SEQ ID NO: 2153)
1073F05	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATTYDLTGYSDGEDDI (SEQ ID NO: 2153)
1073F07	141-251	163-175	191-197	230-240	1-124	26-35	50-66	99-114	QRYDLTGYTYWYFL (SEQ ID NO: 3023)
1073F09	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATTYDLTGYSDGEDDI (SEQ ID NO: 2153)
1073F11	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATTYDLTGYSDGEDDI (SEQ ID NO: 2153)
1073F12	141-251	163-175	191-197	230-240	1-125	26-35	50-66	99-114	ATTYDLTGYSDGEDDI (SEQ ID NO: 2153)
1073G03	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	DGSDYDLTGYLYGVGMV (SEQ ID NO: 2154)
1073G04	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	DGSDYDLTGYLYGVGMV (SEQ ID NO: 2154)
1073G06	141-248	162-172	188-194	227-237	1-123	26-35	50-66	99-114	ATTYDLTGYSDGEDH (SEQ ID NO: 2153)
1073G07	142-249	163-173	189-195	228-238	1-126	26-35	50-66	99-115	GSYDLTGYSDGEDH (SEQ ID NO: 3063)
1073G09	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	DGSDYDLTGYLYGVGMV (SEQ ID NO: 2154)
1073G10	143-253	165-178	194-200	233-242	1-127	26-35	50-66	99-116	DGSDYDLTGYLYGVGMV (SEQ ID NO: 2154)
1073G12	142-252	164-177	193-199	232-241	1-126	26-35	50-66	99-115	GGMARABEDYVYVMDV (SEQ ID NO: 3083)
1073H01	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATTYDLTGYSDGEDDI (SEQ ID NO: 2153)
1073H03	141-248	162-172	188-194	227-237	1-123	26-35	50-66	99-114	ATTYDLTGYSDGEDDI (SEQ ID NO: 2153)
1073H05	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATTYDLTGYSDGEDDI (SEQ ID NO: 2153)
1073H06	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATTYDLTGYSDGEDDI (SEQ ID NO: 2153)
1073H07	143-245	159-169	185-191	224-234	1-122	26-35	50-66	99-114	TYVDELTYVYVY (SEQ ID NO: 3056)
1073H08	141-251	163-176	192-198	231-240	1-125	26-35	50-66	99-114	ATTYDLTGYSDGEDDI (SEQ ID NO: 2153)
1074A05	144-253	166-179	195-201	234-244	1-127	26-35	50-66	99-116	LPYDMLTGYVGGGMV (SEQ ID NO: 3050)
1074A06	144-253	166-179	195-201	234-244	1-127	26-35	50-66	99-116	LPYDMLTGYVGGGMV (SEQ ID NO: 3050)
1074B05	143-242	156-166	182-188	221-231	1-117	26-35	50-66	99-106	DQGRYDL (SEQ ID NO: 2175)
1074B11	140-251	162-175	191-197	230-240	1-123	26-35	50-66	99-112	RYCEFFYYTYVYVY (SEQ ID NO: 2155)
1074C07	141-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELCELVGATGALDM (SEQ ID NO: 2174)
1074D03	143-251	165-175	191-197	230-240	1-125	26-35	50-66	99-114	GOYDLTQYVAFHFH (SEQ ID NO: 2164)
1074D04	143-251	165-175	191-197	230-240	1-125	26-35	50-66	99-114	GOYDLTQYVAFHFH (SEQ ID NO: 2164)
1074D05	143-253	167-177	193-199	232-242	1-127	26-35	50-66	99-116	DRYDLTKGYYVGMV (SEQ ID NO: 3060)
1074D07	141-262	173-186	202-208	241-251	1-134	26-35	50-66	99-123	VQBYTYDLTGYVGFKDLVGMV (SEQ ID NO: 3069)
1074D08	141-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELCELVGATGALDM (SEQ ID NO: 2174)
1074G11	139-249	161-174	190-196	229-238	1-122	26-35	50-66	99-111	ESEGGDYVNFQY (SEQ ID NO: 2991)
1074E03	134-245	156-169	185-191	224-234	1-117	26-35	50-66	98-106	DQGRYDL (SEQ ID NO: 2175)
1074E07	141-251	163-175	191-197	230-240	1-124	26-34	49-65	98-113	ELCELVGATGALDM (SEQ ID NO: 2174)
1074E09	147-258	169-182	198-204	237-247	1-130	26-35	50-68	101-119	DFGNYDLTGYVYVGMV (SEQ ID NO: 2935)

1842	138-244	168-170	186-192	225-233	1-121	26-35	50-56	99-110	VTLFPHRYFMAY (SEQ ID NO: 3075)
1843	144-254	168-178	194-200	233-243	1-126	26-35	50-56	99-115	ESSHVNRYTYGMNDY (SEQ ID NO: 3025)
1844	135-244	158-168	184-190	223-231	1-117	26-35	50-56	99-106	DQRYLYDL (SEQ ID NO: 2175)
1845	135-244	157-169	184-191	224-233	1-117	26-35	50-56	99-106	DQRYLYDL (SEQ ID NO: 2175)
1846	144-254	166-178	194-200	233-243	1-127	26-35	50-56	99-116	SPRDYQPLSSNRYMWDY (SEQ ID NO: 3011)
1847	134-246	155-169	185-191	224-235	1-117	26-36	51-56	99-106	QREKIVDN (SEQ ID NO: 3085)
1848	145-255	167-177	193-199	232-242	1-127	26-35	50-56	99-116	SGGYDLATGYTGSFLDY (SEQ ID NO: 2766)
1849	144-253	166-179	193-201	234-244	1-122	26-35	50-56	99-116	SPRDYQPLSSNRYMWDY (SEQ ID NO: 3011)
1850	143-253	165-177	193-199	232-242	1-126	26-35	50-56	99-115	MGRYDLTGTYRYGMNDY (SEQ ID NO: 2831)
1851	140-230	162-174	192-239	229-239	1-122	26-35	50-56	99-111	GNVYDLTGYPHDL (SEQ ID NO: 3046)
1852	142-252	164-176	192-198	231-241	1-125	26-35	50-56	99-114	SYRYDLTGTYTFLDY (SEQ ID NO: 2883)
1853	145-253	167-177	193-199	232-242	1-127	26-35	50-56	99-116	SGGYDLATGYTGSFLDY (SEQ ID NO: 2766)
1854	142-254	164-177	193-199	232-243	1-125	26-35	50-56	99-114	DDRLTNTYLYEYFH (SEQ ID NO: 2868)
1855	144-246	164-178	194-200	233-245	1-127	26-35	50-56	99-116	SGGYDLATGYTGSFLDY (SEQ ID NO: 3037)
1856	142-249	164-174	190-196	229-238	1-124	26-35	50-56	99-113	GRYDLTGTYTSDY (SEQ ID NO: 3066)
1857	142-244	164-177	193-199	232-243	1-125	26-35	50-56	99-114	DDRLTNTYLYEYFH (SEQ ID NO: 2868)
1858	145-253	167-177	193-199	232-242	1-127	26-35	50-56	99-116	GTGYDLTGTYMGSATDQ (SEQ ID NO: 2800)
1859	143-243	165-177	193-199	232-242	1-126	26-35	50-56	99-105	MGRYDLTGTYRYGMNDY (SEQ ID NO: 2831)
1860	134-243	156-168	184-190	223-234	1-117	26-35	50-56	99-106	DQRYLYDL (SEQ ID NO: 2175)
1861	141-252	163-176	192-198	231-241	1-124	26-34	49-65	98-113	ELGSHVQATGALDN (SEQ ID NO: 2174)
1862	144-245	166-179	195-203	234-244	1-127	26-35	50-56	99-116	GTGYDLTGTYMGSATDQ (SEQ ID NO: 2800)
1863	135-243	157-167	183-189	222-232	1-117	26-35	50-56	99-106	DQRYLYDL (SEQ ID NO: 2175)
1864	134-244	156-169	185-191	224-234	1-117	26-36	51-56	99-106	RIVQAPY (SEQ ID NO: 3088)
1865	144-254	166-178	194-200	233-243	1-127	26-35	50-56	99-116	VEGYDLTGYSFADFL (SEQ ID NO: 3078)
1866	146-250	164-178	194-200	233-243	1-128	26-35	50-56	99-117	EQGYDLTGTYREGWADP (SEQ ID NO: 2834)
1867	142-250	164-174	190-196	229-239	1-124	26-34	49-65	98-113	ELGSHVQATGALDN (SEQ ID NO: 2174)
1868	147-257	169-182	198-204	237-246	1-131	26-37	52-69	102-128	DESYDLTGTYVYGMNDY (SEQ ID NO: 3052)
1869	141-251	163-176	192-198	231-240	1-125	26-35	50-56	99-114	MEYDLTGTYGTYFDY (SEQ ID NO: 2179)
1870	141-251	163-176	192-198	231-240	1-125	26-35	50-56	99-114	MEYDLTGTYGTYFDY (SEQ ID NO: 2179)
1871	141-248	162-172	188-194	227-237	1-123	26-33	49-66	99-114	MEYDLTGTYGTYFDY (SEQ ID NO: 2179)
1872	141-251	163-176	192-198	231-240	1-125	26-35	50-56	99-114	MEYDLTGTYGTYFDY (SEQ ID NO: 2179)
1873	140-247	161-171	187-193	226-236	1-124	26-35	50-56	99-113	MEYDLTGTYGTYFDY (SEQ ID NO: 2179)
1874	142-252	164-177	193-199	232-241	1-126	26-35	50-56		

U.S. Patent

Nov. 21, 2006

Sheet 47 of 52

7,138,501 B2

10321308	132-242	154-167	183-189	222-231	1-115	26-35	50-66	99-104	DWDMDV (SEQ ID NO: 2193)
1039D03	137-247	159-172	188-194	227-236	1-120	26-35	50-66	99-106	DNCOTIGEDY (SEQ ID NO: 2195)
1079B05	130-240	152-165	181-187	220-229	1-114	26-35	50-66	99-103	FVLDY (SEQ ID NO: 2210)
1079B12	134-241	157-167	183-189	222-230	1-118	26-35	50-66	99-107	WTSSGAFDI (SEQ ID NO: 2205)
1079C01	131-241	153-166	182-188	221-230	1-115	26-35	50-66	99-104	DWDMDV (SEQ ID NO: 2193)
1079B06	134-241	157-167	183-189	222-230	1-118	26-35	50-66	99-107	DNLHAAFDI (SEQ ID NO: 2202)
1079B08	138-248	160-172	188-194	227-237	1-122	26-35	50-66	99-111	YVYHSGSDAFDI (SEQ ID NO: 2206)
1080A03	139-249	161-173	189-195	228-238	1-122	26-35	50-66	99-111	VCHLAAVDNEY (SEQ ID NO: 2197)
1080B01	136-247	158-171	187-193	226-236	1-119	26-35	50-66	99-106	YVYHSGSDAFDI (SEQ ID NO: 2206)
1080A08	144-254	166-178	194-200	233-243	1-126	26-35	50-66	99-113	EYSGYVYVGGYAMDV (SEQ ID NO: 2204)
1080B03	139-249	161-173	189-195	228-238	1-122	26-35	50-66	99-111	VCHLAAVDNEY (SEQ ID NO: 2197)
1080B05	142-253	164-177	193-199	232-242	1-123	26-35	50-66	99-114	EGCGDAYVAVPYEDY (SEQ ID NO: 2204)
1080B07	138-245	161-172	188-194	227-234	1-120	26-35	50-66	99-109	EGCGYVYGMVDV (SEQ ID NO: 2208)
1080C09	137-249	159-172	184-194	227-238	1-120	26-35	50-66	99-109	ENRGOTIGEDY (SEQ ID NO: 2198)
1082A05	131-240	153-165	181-187	220-229	1-115	26-35	50-66	99-104	DLDEY (SEQ ID NO: 2208)
1082B08	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	DLGAGTVEDY (SEQ ID NO: 2207)
1082C03	138-245	161-171	187-193	226-234	1-122	26-35	50-66	99-111	DASRDIVLFLAI (SEQ ID NO: 2198)
1082D07	134-241	157-167	183-189	222-230	1-118	26-35	50-66	99-107	WTSSGAFDI (SEQ ID NO: 2205)
1082G01	138-245	161-171	187-193	226-236	1-122	26-35	50-66	99-111	YVYHSGSDAFDI (SEQ ID NO: 2206)
1083B12	139-247	161-171	187-193	226-236	1-121	26-35	50-66	99-110	ESGAGUYVYDDY (SEQ ID NO: 2196)
1083G03	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)
1084A01	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)
1084B02	131-238	152-162	178-184	217-227	1-115	26-35	50-66	99-104	NLWGLDY (SEQ ID NO: 2199)
1084C04	134-244	156-168	184-190	223-232	1-118	26-35	50-66	99-107	GNAAWGAEDI (SEQ ID NO: 2211)
1084C11	134-241	155-165	181-187	220-230	1-118	26-35	50-66	99-107	EGVAAAGHDY (SEQ ID NO: 3123)
1079A03	133-248	154-164	188-186	219-229	1-117	26-35	50-66	99-106	DAAVTAHO (SEQ ID NO: 3142)
1079A06	136-246	158-170	186-192	225-235	1-120	26-35	50-66	99-109	GSNYSPDADI (SEQ ID NO: 3112)
1079A07	135-242	157-168	185-191	224-234	1-119	26-35	50-66	99-108	GSNYSPDADI (SEQ ID NO: 3112)
1079A10	136-245	158-168	184-190	223-231	1-118	26-35	50-66	99-107	GSNYSPDADI (SEQ ID NO: 3112)
1079A11	135-242	157-168	184-190	223-232	1-118	26-35	50-66	99-109	GSNYSPDADI (SEQ ID NO: 3112)
1079B02	134-243	156-168	184-190	223-232	1-118	26-35	50-66	99-109	GSNYSPDADI (SEQ ID NO: 3112)
1079B03	130-240	152-165	181-187	220-229	1-114	26-35	50-66	99-103	LLSDY (SEQ ID NO: 3168)
1079B04	138-243	159-169	185-191	224-234	1-122	26-35	50-66	99-111	VEWEDVVGSAEDI (SEQ ID NO: 3128)
1079B09	139-246	162-172	188-194	227-235	1-123	26-35	50-66	99-112	VTSYSSSGGYVYGMVDV (SEQ ID NO: 3145)
1079C02	144-251	167-177	191-199	232-240	1-128	26-35	50-66	99-117	GWRGVY (SEQ ID NO: 3195)
1079C04	132-239	155-165	181-187	228-238	1-116	26-35	50-66	99-105	AGNPFSGSLVYEDY (SEQ ID NO: 3225)
1079C05	140-247	163-173	189-195	228-236	1-124	26-35	50-66	99-113	GLDYVYHGLDV (SEQ ID NO: 3176)
1079C07	137-244	158-168	184-190	223-233	1-121	26-35	50-66	99-110	EVRYVILLTRSYLAGPLDN (SEQ ID NO: 2761)
1079D01	144-254	166-179	195-201	234-243	1-128	26-35	50-66	99-117	

U.S. Patent

Nov. 21, 2006

Sheet 48 of 52

7,138,501 B2

1073D02	1926	135-243	157-163	185-191	224-234	1-119	26-35	50-66	99-102	ELWEGAFDI (SEQ ID NO: 3178)
1073D04	1927	133-243	155-167	183-189	222-232	1-117	26-35	50-66	99-106	VEPLNDV (SEQ ID NO: 3152)
1073D06	1928	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	EATSSWABDF (SEQ ID NO: 3190)
1073D07	1929	136-243	157-167	183-189	222-232	1-120	26-35	50-66	99-103	NITPLAMVGRF (SEQ ID NO: 3146)
1073D08	1930	130-246	152-165	181-187	220-229	1-114	26-35	50-66	99-103	LIEDF (SEQ ID NO: 3161)
1073D09	1931	131-238	152-162	178-184	217-227	1-115	26-35	50-66	99-104	DSGSPD (SEQ ID NO: 3108)
1073D11	1932	134-241	157-167	183-189	222-230	1-118	26-35	50-66	99-107	EGVAAGEDY (SEQ ID NO: 3123)
1073D06	1933	136-244	158-168	184-190	223-233	1-120	26-35	50-66	99-109	ENRGRVVDI (SEQ ID NO: 3093)
1073D08	1934	137-247	159-171	187-193	226-236	1-121	26-35	50-66	99-110	EAYASWABDF (SEQ ID NO: 3189)
1073D11	1935	136-243	159-169	185-191	224-232	1-120	26-35	50-66	99-109	PGSSTYAFDI (SEQ ID NO: 3185)
1073D12	1936	143-253	165-177	193-199	232-242	1-127	26-35	50-66	99-116	ARDYDSSTYTFDAFI (SEQ ID NO: 3107)
1073D01	1937	133-241	154-164	180-186	219-230	1-117	26-35	50-66	99-106	GFYGMVDY (SEQ ID NO: 3094)
1073D02	1938	148-253	169-179	195-201	234-242	1-132	26-35	50-68	101-121	LPPLLYCDSGMCSDWLCF (SEQ ID NO: 3219)
1073D04	1939	140-247	161-171	187-193	226-236	1-124	26-35	50-66	99-113	ESLTLTYCGSDY (SEQ ID NO: 3115)
1073D04	1940	136-243	157-167	183-189	222-232	1-120	26-35	50-66	99-109	NSAPAPSMVDY (SEQ ID NO: 3095)
1073D09	1941	130-237	151-161	177-183	216-226	1-114	26-35	50-66	99-103	RYVDY (SEQ ID NO: 3139)
1073D10	1942	136-243	157-167	183-189	222-232	1-120	26-35	50-66	99-109	NITPLAMVGRF (SEQ ID NO: 3146)
1073D12	1943	136-243	155-169	185-191	224-232	1-120	26-35	50-66	99-109	ADYNDYNDY (SEQ ID NO: 3166)
1073D05	1944	136-243	157-167	183-189	222-232	1-120	26-35	50-66	99-109	NITPLAMVGRF (SEQ ID NO: 3146)
1073D06	1945	136-243	157-167	183-189	222-232	1-120	26-35	50-66	99-109	FFLESYVYADY (SEQ ID NO: 3124)
1073D06	1946	135-243	157-167	183-189	222-232	1-119	26-35	50-66	99-108	GNRPORTLDY (SEQ ID NO: 3158)
1073D03	1947	136-243	157-167	183-189	222-232	1-119	26-35	50-66	99-109	DVPPDGMVLY (SEQ ID NO: 3192)
1073D03	1948	134-241	157-167	183-189	222-230	1-118	26-35	50-66	99-107	ASYVFDY (SEQ ID NO: 3171)
1073D01	1949	132-242	154-166	182-188	221-231	1-115	26-35	50-66	99-104	GGWLDI (SEQ ID NO: 3210)
1073D02	1950	134-243	156-169	185-191	224-234	1-117	26-35	50-66	99-106	HESSFDY (SEQ ID NO: 3111)
1073D03	1951	142-253	164-177	193-199	232-242	1-125	26-35	50-66	99-114	EGEDGYNVAPYFDY (SEQ ID NO: 3160)
1073D07	1952	143-250	166-176	192-198	231-239	1-125	26-35	50-66	99-114	EACGSYHFFPDY (SEQ ID NO: 3188)
1073D10	1953	136-247	158-171	187-193	226-236	1-119	26-35	50-66	99-108	YGTWGYFDY (SEQ ID NO: 3175)
1073D10	1954	142-252	164-176	192-198	231-241	1-123	26-35	50-66	99-114	DGMLNDGSDY (SEQ ID NO: 3140)
1073D03	1955	140-248	162-172	194-194	227-237	1-122	26-35	50-66	99-111	LGHNYSWSLDY (SEQ ID NO: 3181)
1073D06	1956	139-249	161-173	189-195	228-238	1-122	26-35	50-66	99-111	VVGYSSTLDY (SEQ ID NO: 3096)
1073D07	1957	139-249	161-173	189-195	228-238	1-121	26-35	50-66	99-110	LGVARKEAFDI (SEQ ID NO: 3206)
1073D06	1958	143-254	165-177	193-199	232-243	1-126	26-37	52-69	102-115	AVRSPYVYVYMDY (SEQ ID NO: 3125)
1073D08	1959	135-243	157-167	183-189	222-232	1-117	26-35	50-66	99-106	GRKPLDY (SEQ ID NO: 3141)
1073D08	1960	137-248	159-172	185-194	227-237	1-120	26-37	52-67	100-109	KQREKYPDY (SEQ ID NO: 3109)
1073D09	1961	143-254	165-178	194-200	233-243	1-126	26-35	50-66	99-115	EKARETSGEADPDI (SEQ ID NO: 3151)
1073D10	1962	138-249	161-173	189-195	228-238	1-122	26-37	52-67	100-111	REALSLAWYFDI (SEQ ID NO: 3102)
1073D11	1963	138-248	160-172	188-194	227-237	1-121	26-35	50-68	101-110	LECTGSCQCF (SEQ ID NO: 3136)
1073D12	1964	141-253	164-173	195-201	234-242	1-123	26-35	50-66	99-112	NFYVDSSEFDY (SEQ ID NO: 3105)
1073D03	1965	140-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SEQA VYVYVYMDY (SEQ ID NO: 3091)
1073D06	1966	146-254	168-178	194-200	238-243	1-128	26-36	51-66	99-117	DYDGSYSYSGDYVYVYMDY (SEQ ID NO: 3227)
1073D07	1967	145-256	167-180	196-202	235-245	1-128	26-35	50-66	99-117	INDLVVFTAQGRYVTDN (SEQ ID NO: 3113)

U.S. Patent

Nov. 21, 2006

Sheet 49 of 52

7,138,501 B2

1080C08	136-249	160-173	189-195	228-238	1-121	26-35	50-66	99-110	GKRYSGWYFDL (SEQ ID NO: 3130)
1080C10	132-243	154-167	185-189	222-232	1-115	26-35	50-66	99-104	DTFLDP (SEQ ID NO: 3094)
1080C11	138-249	160-173	189-195	228-238	1-121	26-35	50-66	99-110	EGDFTDNEAFDY (SEQ ID NO: 3155)
1080C12	139-249	161-173	189-195	228-238	1-122	26-35	50-66	99-111	DQFTYARPYLDH (SEQ ID NO: 3153)
1080C21	138-249	161-171	187-193	226-234	1-120	26-35	50-66	99-109	DGTKYDWGHDY (SEQ ID NO: 3220)
1080C22	142-254	164-177	193-199	232-243	1-125	26-35	50-66	99-114	HTSHCSGSCYFDY (SEQ ID NO: 3212)
1080C24	140-248	162-172	188-194	227-237	1-122	26-35	50-66	99-111	SGRQATYYTOMDY (SEQ ID NO: 3091)
1080C25	138-244	160-170	186-192	225-235	1-120	26-35	50-66	99-109	EPFGVYLYDY (SEQ ID NO: 3165)
1080C26	138-248	160-172	188-194	227-237	1-121	26-35	50-66	101-110	LHCTGSCGF (SEQ ID NO: 3186)
1080C27	139-250	161-174	190-196	229-239	1-122	26-35	50-66	99-111	VDYIDYEMGAFDI (SEQ ID NO: 3187)
1080C11	136-247	158-171	187-193	226-236	1-119	26-35	50-66	99-108	VONGVYFHY (SEQ ID NO: 3156)
1080C12	137-245	159-169	185-191	224-234	1-119	26-35	50-66	101-108	SSRNGGDY (SEQ ID NO: 3214)
1080E01	138-246	160-170	186-192	225-235	1-120	26-35	50-66	99-109	DI.SRVACRFDY (SEQ ID NO: 3164)
1080E04	137-247	159-171	187-193	226-236	1-120	26-37	52-67	100-109	HDVYGDLEFDY (SEQ ID NO: 3211)
1080E06	138-248	160-172	188-194	227-237	1-121	26-35	50-66	101-110	LHCTGSCGF (SEQ ID NO: 3221)
1080E07	143-254	165-178	194-200	233-243	1-126	26-35	50-66	99-115	EGSTVGALTINDAFDI (SEQ ID NO: 3150)
1080E08	138-249	160-173	189-195	228-238	1-121	26-35	50-66	99-110	GKRYSGWYFDI (SEQ ID NO: 3130)
1080E09	137-247	159-171	187-193	226-236	1-120	26-35	50-66	99-109	DEFDY (SEQ ID NO: 3154)
1080E12	143-253	163-177	193-199	232-242	1-126	26-35	50-66	99-111	DQFTYARPYLDH (SEQ ID NO: 3153)
1080F04	139-249	161-173	189-195	228-238	1-122	26-35	50-66	99-113	ESSGTLGERSLEFDY (SEQ ID NO: 3203)
1080F05	143-253	163-177	193-199	232-242	1-122	26-35	50-66	99-110	LGRNYTSSWLDY (SEQ ID NO: 3181)
1080F06	140-248	162-172	188-194	227-237	1-114	26-35	50-66	99-103	NAPDY (SEQ ID NO: 3121)
1080F08	132-240	154-164	180-186	219-229	1-114	26-35	50-66	99-113	GKRYSSSSVYGMADI (SEQ ID NO: 3095)
1080G03	143-250	164-174	190-196	229-239	1-124	26-36	51-66	99-104	VESSOS (SEQ ID NO: 3216)
1080G04	133-244	156-171	187-193	226-236	1-115	26-35	50-66	99-116	KRGDFVRLHHYGMADY (SEQ ID NO: 3136)
1080G10	145-252	167-177	193-199	232-241	1-127	26-35	50-66	100-109	HDVYGDLEFDY (SEQ ID NO: 3205)
1080H01	137-247	159-171	187-193	226-236	1-120	26-37	52-67	100-113	LHPADYGDYGFY (SEQ ID NO: 3218)
1080H02	142-252	164-176	192-198	231-241	1-124	26-37	52-67	99-112	TSRGTGYQWDFDN (SEQ ID NO: 3204)
1080H03	140-248	162-172	188-194	227-237	1-123	26-35	50-66	99-108	EAGEVAANDY (SEQ ID NO: 3180)
1080H04	136-246	158-170	186-192	225-235	1-119	26-35	50-66	99-110	GKRYSGWYFDI (SEQ ID NO: 3130)
1080H05	138-249	160-173	189-195	228-238	1-121	26-35	50-66	100-109	HDVYGDLEFDY (SEQ ID NO: 3205)
1080H06	137-247	159-171	187-193	226-236	1-120	26-37	52-67	99-110	GKRYSGWYFDY (SEQ ID NO: 3217)
1080H07	138-248	160-172	188-194	227-237	1-121	26-35	50-66	101-110	LHCTGSCGF (SEQ ID NO: 3186)
1080H08	140-251	162-175	191-197	230-240	1-122	26-35	50-66	99-111	ERGRDGDYALDY (SEQ ID NO: 3148)
1080H09	141-249	163-173	189-195	228-238	1-123	26-36	51-66	99-112	KTFDENGDSKPFY (SEQ ID NO: 3215)
1081A01	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	DTTDY (SEQ ID NO: 2203)
1081A03	135-245	157-170	186-192	225-234	1-119	26-35	50-66	99-108	ESLIGQAFDI (SEQ ID NO: 3117)
1081A04	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	DTTDY (SEQ ID NO: 2203)
1081A06	130-237	151-161	177-183	216-226	1-114	26-35	50-66	99-103	DTTDY (SEQ ID NO: 2203)
1081A08	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	DTTDY (SEQ ID NO: 2203)
1081A09	134-241	155-165	181-187	220-230	1-118	26-35	50-66	99-107	GAGSRVFDL (SEQ ID NO: 3118)
1081A10	133-243	155-168	184-190	223-232	1-117	26-35	50-66	99-106	GCDRAFDI (SEQ ID NO: 3119)

U.S. Patent

Nov. 21, 2006

Sheet 50 of 52

7,138,501 B2

1081E01	130-236	151-161	177-183	216-225	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081E04	134-244	156-169	185-191	224-233	1-118	26-35	53-66	99-107	GNAYWGAFTI (SEQ ID NO: 2241)
1081E05	133-243	155-168	184-190	223-232	1-117	26-35	53-66	99-106	GGDEAFDI (SEQ ID NO: 3119)
1081E06	133-248	154-164	180-186	219-229	1-117	26-35	53-66	99-106	VKEYTFDI (SEQ ID NO: 3179)
1081E07	136-243	157-167	183-189	221-232	1-120	26-35	53-66	99-105	ELTGANDAFTI (SEQ ID NO: 3164)
1081E08	132-239	153-163	179-185	218-228	1-116	26-35	53-66	99-103	RRYALDY (SEQ ID NO: 2910)
1081E09	130-240	152-164	180-186	219-229	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081E10	130-237	153-163	179-185	218-226	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081E11	132-239	153-163	179-185	218-228	1-116	26-35	53-66	99-103	OFALYXD (SEQ ID NO: 3169)
1081E07	130-237	153-163	179-185	218-226	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081E08	130-237	153-163	179-185	218-226	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081E09	132-239	153-163	179-185	218-228	1-116	26-35	53-66	99-103	BDLTGDAFTI (SEQ ID NO: 3103)
1081E10	130-238	152-162	178-184	217-227	1-114	26-35	53-66	99-103	GDAYFDY (SEQ ID NO: 3147)
1081E11	130-240	152-164	180-186	219-229	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081D11	134-244	156-169	185-191	224-233	1-118	26-35	53-66	99-107	EGLLDAFTI (SEQ ID NO: 3200)
1081D12	130-237	153-163	179-185	218-226	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081E02	130-237	153-163	179-185	218-226	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081E03	130-248	152-164	180-186	219-229	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081E05	130-240	152-164	180-186	219-229	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081E06	134-241	155-165	181-187	220-230	1-118	26-35	53-66	99-107	VGYGKGDY (SEQ ID NO: 3137)
1081E10	142-249	163-173	189-195	228-238	1-126	26-35	53-66	99-115	GACSRVFDL (SEQ ID NO: 3118)
1081E07	130-237	153-163	179-185	218-226	1-116	26-35	53-66	99-103	GLAPVDGQATNDAYDI (SEQ ID NO: 3184)
1081E04	130-237	153-163	179-185	218-226	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081E05	130-237	153-163	179-185	218-226	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081E06	134-244	156-169	185-191	224-233	1-118	26-35	53-66	99-107	ERGNQAFDI (SEQ ID NO: 3156)
1081E07	132-239	153-163	179-185	218-228	1-116	26-35	53-66	99-103	RRYALDY (SEQ ID NO: 2920)
1081E11	130-237	153-163	179-185	218-226	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081G01	130-237	153-163	179-185	218-226	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081G04	130-240	152-164	180-186	219-229	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081G06	135-245	157-170	186-192	225-234	1-119	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081G10	130-237	153-163	179-185	218-226	1-114	26-35	53-66	99-103	SRGPTDAFTI (SEQ ID NO: 3097)
1081H02	130-240	152-164	180-186	219-229	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081H03	130-240	152-164	180-186	219-229	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1081H04	135-242	156-166	182-188	221-231	1-119	26-35	53-66	99-108	SNWGGJAFDI (SEQ ID NO: 3202)
1081H06	130-240	152-165	181-187	220-229	1-114	26-35	53-66	99-103	LAFDI (SEQ ID NO: 3174)
1081H08	130-240	152-164	180-186	219-229	1-114	26-35	53-66	99-103	DTTIDY (SEQ ID NO: 2203)
1082A02	139-249	161-173	189-195	228-238	1-123	26-35	53-66	99-112	PAASSRGPDADFI (SEQ ID NO: 3129)
1082A04	130-240	152-165	181-187	220-229	1-114	26-35	53-66	99-103	LSCDS (SEQ ID NO: 3122)
1082A08	134-243	156-168	184-190	223-232	1-118	26-35	53-66	99-107	EGVAAGEDY (SEQ ID NO: 3123)

U.S. Patent

Nov. 21, 2006

Sheet 51 of 52

7,138,501 B2

1082A11	2052	130-240	152-163	181-187	220-229	1-114	26-35	30-66	99-103	FVLDT (SEQ ID NO: 2210)
1082B06	2053	131-238	154-164	180-186	219-227	1-115	26-35	30-66	99-104	GNCKLDV (SEQ ID NO: 3153)
1082B09	2054	134-241	157-167	183-189	222-230	1-118	26-35	30-66	99-107	BOVAAAGHDY (SEQ ID NO: 3123)
1082B12	2055	131-241	153-166	182-188	221-230	1-115	26-35	30-66	99-104	DLDEYD (SEQ ID NO: 2208)
1082C01	2056	136-243	157-167	183-189	222-232	1-120	26-35	30-66	99-109	VNDVYVDMNDY (SEQ ID NO: 3143)
1082C05	2057	136-243	157-167	183-189	222-232	1-120	26-35	30-66	99-109	HEKGSRRVEDI (SEQ ID NO: 3093)
1082C08	2058	137-244	158-168	184-190	223-233	1-121	26-35	30-66	99-110	LSNRNENRLDYL (SEQ ID NO: 3106)
1082C08	2059	130-240	152-163	181-187	220-229	1-114	26-35	30-66	99-103	FVLDT (SEQ ID NO: 2210)
1082E05	2060	134-241	155-165	181-187	220-230	1-118	26-35	30-66	99-107	TWAINTEMA (SEQ ID NO: 3152)
1082E06	2061	130-240	152-163	181-187	220-229	1-114	26-35	30-66	99-103	FVLDT (SEQ ID NO: 3167)
1082E07	2062	139-246	162-172	188-194	227-235	1-123	26-35	30-66	99-112	VEVEDIVVQSAPDI (SEQ ID NO: 3128)
1082F11	2063	136-243	159-169	185-191	224-232	1-120	26-35	30-66	99-109	GGMATVYMDY (SEQ ID NO: 3177)
1082G07	2064	136-243	159-169	185-191	224-232	1-120	26-35	30-66	99-109	ADYNDYVMDY (SEQ ID NO: 3166)
1082G10	2065	138-249	160-173	189-195	228-238	1-118	26-35	30-66	99-107	BOVAAAGHDY (SEQ ID NO: 3123)
1082G11	2066	143-250	164-174	190-196	229-239	1-127	26-35	30-66	99-116	GRYTFDGSAYEGYTDY (SEQ ID NO: 3223)
1082H04	2067	132-238	153-163	179-185	218-227	1-116	26-35	30-65	98-103	MNADAFHI (SEQ ID NO: 3223)
1082H09	2068	139-246	160-170	186-192	225-235	1-123	26-35	30-66	99-112	PAASSRUPKDAFDI (SEQ ID NO: 3129)
1083A06	2069	137-244	159-169	183-191	224-233	1-120	26-35	30-66	99-109	DSRPTNRLAFHY (SEQ ID NO: 3116)
1083A09	2070	138-248	160-172	188-194	227-237	1-121	26-35	30-68	101-110	LECTGUSCOF (SEQ ID NO: 3189)
1083A11	2071	136-248	158-171	187-193	226-237	1-119	26-35	30-66	99-108	VRDESACFDY (SEQ ID NO: 3173)
1083D03	2072	139-247	161-171	187-193	226-236	1-121	26-35	30-66	99-110	VLYRQGYRGMGL (SEQ ID NO: 3138)
1083E05	2073	139-250	161-174	190-196	229-239	1-122	26-35	30-66	99-111	VDTYDYMGAFDL (SEQ ID NO: 3172)
1083E06	2074	139-250	161-174	190-196	229-239	1-122	26-35	30-66	99-111	DLTAAAGDAFDI (SEQ ID NO: 3194)
1083E10	2075	139-246	162-172	188-194	227-235	1-121	26-35	30-66	99-110	DLTKNGYALFDS (SEQ ID NO: 3197)
1083C01	2076	136-247	158-171	187-193	226-236	1-119	26-35	30-66	99-108	DEYSSLYMDY (SEQ ID NO: 3281)
1083C02	2077	136-246	158-171	187-193	226-235	1-119	26-35	30-66	99-108	FGAGRLYDDY (SEQ ID NO: 3224)
1083C07	2078	137-249	159-172	188-194	227-238	1-120	26-35	30-66	99-109	DNQGGTIGEDY (SEQ ID NO: 2193)
1083C12	2079	136-246	158-171	187-193	226-235	1-119	26-35	30-66	99-108	DQRTIANDY (SEQ ID NO: 3207)
1083D04	2080	146-256	168-181	197-203	236-245	1-129	26-35	30-66	99-118	DLPFYDFWPNEDASSLIT (SEQ ID NO: 3133)
1083D07	2081	150-262	173-188	204-210	243-251	1-132	26-35	30-66	99-121	DLPFYDFWPNEDASSLIT (SEQ ID NO: 3154)
1083D08	2082	143-254	165-178	194-200	233-243	1-126	26-35	30-66	99-115	DADKGLVBAITINWEDS (SEQ ID NO: 3126)
1083D10	2083	147-258	169-181	197-203	236-247	1-130	26-37	32-69	102-119	ATKSTYDLTRAYTYRMDY (SEQ ID NO: 2748)
1083D12	2084	134-242	156-166	182-188	221-231	1-116	26-35	30-65	99-105	DRTRMDY (SEQ ID NO: 3132)
1083E02	2085	139-249	161-173	189-195	228-238	1-122	26-35	30-66	99-111	VQKAAAVDNFEY (SEQ ID NO: 2197)
1083E03	2086	136-248	158-171	187-193	226-237	1-119	26-35	30-66	99-108	DEYNDADY (SEQ ID NO: 3105)
1083E04	2087	144-255	166-179	195-201	234-244	1-127	26-35	30-66	99-115	DODDESRNNQNTYAMD (SEQ ID NO: 3101)
1083E08	2088	140-248	162-172	188-194	227-237	1-122	26-35	30-66	99-111	RQGINNSYGMEDY (SEQ ID NO: 3239)
1083E12	2089	135-245	157-170	186-192	225-234	1-118	26-35	30-66	99-107	DYTHRAFDI (SEQ ID NO: 3127)
1083F02	2090	146-258	168-181	197-203	236-247	1-129	26-35	30-66	99-118	DVRSDFWSSGGYHYSGMDY (SEQ ID NO: 3131)
1083F04	2091	138-248	160-172	188-194	227-237	1-121	26-35	30-66	99-110	STLEVQATDFDY (SEQ ID NO: 3199)
1083F06	2092	135-247	157-170	186-192	225-236	1-118	26-35	30-66	99-107	SEDDWGAYHI (SEQ ID NO: 3198)
1083F08	2093	139-250	161-174	190-196	229-239	1-122	26-35	30-66	99-111	ERGGHDDYALDF (SEQ ID NO: 3148)

U.S. Patent

Nov. 21, 2006

Sheet 52 of 52

7,138,501 B2

1083F11	2094	137-248	159-172	188-194	227-237	1-120	26-35	59-66	99-109	ELYGAGGQFDP (SEQ ID NO: 3191)
1083G04	2095	139-250	161-174	190-196	229-239	1-122	26-35	59-66	99-111	VDYTDYEMQAFDL (SEQ ID NO: 3172)
1083G05	2096	139-249	161-173	189-195	228-238	1-121	26-35	50-68	101-110	SVAGRGWEDY (SEQ ID NO: 3208)
1083G06	2097	139-250	161-174	190-196	229-239	1-122	26-35	50-66	99-111	ERGRDGDYALDF (SEQ ID NO: 3148)
1083G08	2098	142-253	164-177	193-199	232-242	1-125	26-35	50-66	99-114	EGGGDAYDVAPTYEDY (SEQ ID NO: 2284)
1083G09	2099	132-242	154-166	182-188	221-231	1-114	26-35	50-66	99-103	DPEDY (SEQ ID NO: 3134)
1083G11	2100	141-252	163-176	192-198	231-241	1-124	26-35	50-66	99-113	ALLGLPSDSYTYDV (SEQ ID NO: 3159)
1083H04	2101	142-253	164-177	193-199	232-242	1-125	26-35	50-66	99-114	EGEGGYNVAPTYEDY (SEQ ID NO: 3160)
1083H05	2102	135-243	157-167	183-189	221-232	1-117	26-35	50-66	99-106	TDYGRHEDY (SEQ ID NO: 3092)
1083H07	2103	139-247	161-171	187-193	226-236	1-121	26-35	50-66	99-110	CGVGDSRGVTFDP (SEQ ID NO: 3162)
1084A03	2104	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)
1084A06	2105	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)
1084B08	2106	135-242	156-166	182-188	221-231	1-119	26-35	50-66	99-108	ESLGGDAFDI (SEQ ID NO: 3116)
1084C02	2107	136-243	157-167	183-189	222-232	1-120	26-35	50-66	99-109	SPLPSDAFDI (SEQ ID NO: 3120)
1084D03	2108	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)
1084D05	2109	133-243	155-168	184-190	223-232	1-117	26-35	50-66	99-106	EVGGAFDI (SEQ ID NO: 3157)
1084E01	2110	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)
1084E06	2111	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)
1084E10	2112	130-237	151-161	177-183	216-226	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)
1084H12	2113	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)
1084F04	2114	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)
1084F07	2115	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)
1084F12	2116	135-245	157-170	186-192	225-234	1-119	26-35	50-66	99-108	ESLGGDAFDI (SEQ ID NO: 3116)
1084G12	2117	130-240	152-164	180-186	219-229	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)
1084H02	2118	130-237	153-163	179-185	218-226	1-114	26-35	50-66	99-103	DTTIDY (SEQ ID NO: 2203)
1090B05	2119	146-256	168-180	196-202	235-245	1-129	26-35	50-66	99-118	GAHYDPSFHLKSYWVFDL (SEQ ID NO: 3149)
1099G09	2120	139-249	161-173	189-195	228-238	1-122	26-35	50-66	99-111	VGKAAAADNFEY (SEQ ID NO: 2197)
1099H01	2121	140-248	162-172	188-194	227-237	1-123	26-35	50-66	99-111	VGRNTSSWSLDY (SEQ ID NO: 3181)
1099H06	2122	139-249	161-173	189-195	228-238	1-122	26-35	50-66	99-111	VGKAAAADNFEY (SEQ ID NO: 2197)
1099H08	2123	145-255	167-179	195-201	234-244	1-128	26-35	50-66	99-117	GGRYGTYYDGTOTVDADF (SEQ ID NO: 3226)
1100A01	2124	137-247	159-172	186-194	227-236	1-120	26-35	50-66	99-109	DNGGTYGFDY (SEQ ID NO: 2195)
1100A10	2125	141-251	163-175	191-197	230-240	1-124	26-35	50-66	99-113	VRQQLADPPSFDF (SEQ ID NO: 3144)
1100B03	2126	137-247	159-172	188-194	227-236	1-120	26-35	50-66	99-109	DNGGTYGFDY (SEQ ID NO: 2195)
1100B04	2127	137-247	159-172	188-194	227-236	1-120	26-35	50-66	99-109	DNGGTYGFDY (SEQ ID NO: 2195)
1100C03	2128	141-251	163-175	191-197	230-240	1-124	26-35	50-66	99-113	VRQQLADPPSFDF (SEQ ID NO: 3144)

Attachment F



Customer No 000000

ISTMT

DATE PRINTED
11/10/2010

HUMAN GENOME SCIENCES INC.
INTELLECTUAL PROPERTY DEPT.
14200 SHADY GROVE ROAD
ROCKVILLE MD 20850

MAINTENANCE FEE STATEMENT

According to the records of the U.S. Patent and Trademark Office (USPTO), the maintenance fee and any necessary surcharge have been timely paid for the patent listed below. The "PYMT DATE" column indicates the payment date (i.e., the date the payment was filed).

The payment shown below is subject to actual collection. If the payment is refused or charged back by a financial institution, the payment will be void and the maintenance fee and any necessary surcharge unpaid.

Direct any questions about this statement to: Mail Stop M Correspondence, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT NUMBER	FEE AMT	SUR CHARGE	PYMT DATE	U.S. APPLICATION NUMBER	PATENT ISSUE DATE	APPL. FILING DATE	PAYMENT YEAR	SMALL ENTITY?	ATTY DKT NUMBER
7,138,501	\$980.00	\$0.00	05/21/10	09/880,748	11/21/06	06/15/01	04	NO	2H PF523 (P1)

Attachment G



DEPARTMENT OF HEALTH & HUMAN SERVICES

RA # <u>575</u> (Master)

OCT 30 2001

Food and Drug Administration
1401 Rockville Pike
Rockville MD 20852-1448

Our Reference: BB-IND 9970

Human Genome Sciences, Incorporated
Attention: Sally D. Bolmer, Ph.D.
Vice President, Regulatory Affairs
9410 Key West Avenue
Rockville, MD 20850

Dear Dr. Bolmer:

We have reviewed the October 4, and 17, 2001, submissions to your **Investigational New Drug Application (IND)** for "Human Monoclonal Antibody IgG1 (HG5) to B Lymphocyte Stimulator (BLyS)."

As discussed during the October 23, 2001, telephone conversation between you and Dr. Jeffrey Siegel of this office, you have satisfactorily addressed the issues raised in our letter of October 11, 2001. The clinical hold has been removed and your proposed study may proceed.

You are responsible for compliance with the Federal Food, Drug, and Cosmetic Act, and the Code of Federal Regulations (CFR). Progress reports are required at intervals not exceeding one year and are due within 60 days of the anniversary of the date that the IND went into effect [21 CFR 312.33]. Any unexpected, fatal or immediately life-threatening reaction associated with use of this product must be reported to this Division by telephone or facsimile transmission no later than seven calendar days after initial receipt of the information. All serious, unexpected adverse experiences, as well as results from animal studies that suggest significant clinical risk, must be reported, in writing, to this Division and to all investigators within fifteen calendar days after initial receipt of this information [21 CFR 312.32].

If you have any questions, please contact the Regulatory Project Manager, Dr. Craig Doty, at (301) 827-5101.

Sincerely yours,



Glen D. Jones, Ph.D.

Director

Division of Application Review and Policy

Office of Therapeutics

Research and Review



Center for Biologics

Evaluation and Research

**DEPARTMENT OF
HEALTH & HUMAN SERVICES**

Public Health Service
Food and Drug Administration (HFM-99)
Center for Biologics Evaluation and Research
1401 Rockville Pike
Rockville MD 20852-1448

Official Business
Penalty for Private Use \$300



Attachment H

BENLYSTA Clinical Trial Summary

Trial	Phase	Patient Population	Study Initiated¹	Study Completed²
<u>IV Controlled Trials in SLE</u>				
LBSL01	1	SLE	February 2002	March 2003
LBSL02	2	Active SLE	October 2003	June 2006
BLISS 52	3	Active SLE	May 2007	May 2009
BLISS 76	3	Active SLE	February 2007	March 2010
<u>IV Long-term Continuation Trials in SLE</u>				
LBSL99	2	Active SLE	May 2005	Ongoing
HGS1066-C1066	3	Active SLE	August 2008	Ongoing
HGS1006-1074	3	Active SLE	June 2008	Ongoing
<u>SC Trials in SLE</u>				
HGS1066-1058	1	Healthy Volunteers	September 2007	January 2008
HGS1006-1070	2	Active SLE	October 2008	Ongoing
<u>RA Trials</u>				
LBRA01	2	RA	December 2003	December 2005
LBRA99	2	RA	January 2005	November 2009
HGS1006-C1089	2	RA	September 2009	Ongoing

¹ Date that the first subject was randomized

² Date of the last subject's final visit